id,obj_cls,name,recommendation,drug_id,source,summary_markdown,text_markdown,raw
PA166104997,Guideline Annotation,Annotation of CPIC Guideline for abacavir and HLA-B,t,PA448004,Clinical Pharmacogenetics Implementation Consortium,"<p>In individuals with the HLA-B*57:01 variant allele (&quot;HLA-B*57:01-positive&quot;), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"" target=""_blank"">CPIC&reg; guideline for abacavir and HLA-B</a>.</p>
<h3 id=""may-2014-update"">May 2014 Update</h3>
<p><em>Accepted article preview online 21 February 2014; Advance online publication 12 March 2014</em></p>
<p>The <a rel=""noopener noreferrer"" href=""http://www.nature.com/clpt/journal/v95/n5/full/clpt201438a.html"" target=""_blank"">2014 update of CPIC guidelines</a> regarding abacavir has been published in <em>Clinical Pharmacology and Therapeutics</em>. Literature published between April 2011-November 2013 was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>.</p>
<ul>
<li>These guidelines are applicable to:
<ul>
<li>HIV Patients</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/abacavir/2014/24561393.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing: 2014 Update </a>.</li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/abacavir/2014/24561393-supplement.pdf"" target=""_blank"">2014 supplement</a>.</li>
</ul>
</li>
</ul>
<h3 id=""april-2012"">April 2012</h3>
<p><em>Advance online publication February 2012</em></p>
<ul>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/abacavir/2012/22378157.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/abacavir/2012/22378157-supplement.pdf"" target=""_blank"">2012 supplement</a>.</li>
</ul>
</li>
</ul>
<p>Excerpt from the abacavir dosing guidelines:</p>
<blockquote class=""blockquote"">
<p>We agree with others* that <em>HLA-B*57:01</em> screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are <em>HLA-B*57:01</em>-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk.</p>
</blockquote>
<p>*[Articles:<a href=""/pmid/18826546"">18826546</a>, <a href=""/pmid/19640227"">19640227</a>, <a href=""/pmid/21174626"">21174626</a>, <a href=""/pmid/21412232"">21412232</a>] <a rel=""noopener noreferrer"" href=""http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf"" target=""_blank"">Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF) </a></p>
<h3 id=""table-1-recommended-therapeutic-use-of-abacavir-based-on-hla-b-genotype"">Table 1: Recommended therapeutic use of abacavir based on <em>HLA-B</em> genotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2012 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for abacavir therapy</th><th>Classification of recommendation for abacavir therapy <sup>a</sup></th></tr>
</thead>
<tbody>
<tr><td>Very low risk of hypersensitivity (constitutes ~94% <sup>b</sup> of patients)</td><td>Absence of <em>*57:01</em> alleles (reported as &quot;negative&quot; on a genotyping test)</td><td>*X/*X <sup>c</sup></td><td>Low or reduced risk of abacavir hypersensitivity</td><td>Use abacavir per standard dosing guidelines</td><td>Strong</td></tr>
<tr><td>High risk of hypersensitivity (~6% of patients)</td><td>Presence of at least one <em>*57:01</em> allele (reported as &quot;positive&quot; on a genotyping test)</td><td><em>*57:01</em>/*X <sup>c</sup> <em>*57:01/*57:01</em></td><td>Significantly increased risk of abacavir hypersensitivity</td><td>Abacavir is not recommended</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> Rating scheme described in the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf"">2012 Supplement</a></p>
<p><sup>b</sup> See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf"">2012 Supplement</a> for estimates of genotype frequencies among different ethnic/geographic groups</p>
<p><sup>c</sup> *X = any <em>HLA-B</em> genotype other than <em>*57:01</em>.</p>
<p><em>HLA-B</em> = human leukocyte antigen B</p>
<p><strong>Listen to an interview with the lead author:</strong> <a rel=""noopener noreferrer"" href=""http://www.theaidsreader.com/display/article/1145619/2064707"" target=""_blank"">podcast</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104997"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104997"",""name"":""Annotation of CPIC Guideline for abacavir and HLA-B"",""cancerGenome"":false,""descriptiveVideoId"":""-ho-Se249_8"",""guidelineGenes"":[{""id"":1.449561708E9,""alleles"":[{""id"":1.449561709E9,""_label"":""*57:01:01"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165956565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165956565"",""symbol"":""HLA-B*57:01:01"",""name"":""*57:01:01""}},{""id"":1.44956171E9,""_label"":""Other"",""allele"":""Other"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558334"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558334E9,""resource"":""Allele Function"",""term"":""Absence"",""termId"":""haplotypeTags:1445558334""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}}],""history"":[{""id"":1.183699748E9,""date"":""2012-02-29T00:00:00-08:00"",""type"":""Update"",""version"":0.0},{""id"":1.183847536E9,""date"":""2014-02-28T00:00:00-08:00"",""description"":""CPIC update to guidelines published"",""type"":""Update"",""version"":0.0},{""id"":1.184512476E9,""date"":""2014-08-05T00:00:00-07:00"",""description"":""updated pubication date for update to May 2014"",""type"":""Update"",""version"":1.0},{""id"":1.184782525E9,""date"":""2014-09-30T00:00:00-07:00"",""description"":""Supplement was missing figures; complete supplement with figures added"",""type"":""Correction"",""version"":1.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15070904"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5070904E7,""resourceId"":""24561393"",""title"":""Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994233"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3994233"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279728E9,""resource"":""PubMed Central"",""resourceId"":""PMC3994233"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994233""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/24561393"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279727E9,""resource"":""PubMed"",""resourceId"":""24561393"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/24561393""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2014.38"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279729E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2014.38"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2014.38""}]},{""@id"":""https://pharmgkb.org/literature/14962778"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.4962778E7,""resourceId"":""22378157"",""title"":""Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374459"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3374459"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449267214E9,""resource"":""PubMed Central"",""resourceId"":""PMC3374459"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374459""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/22378157"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":8.27848488E8,""resource"":""PubMed"",""resourceId"":""22378157"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/22378157""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.355"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449267215E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.355"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.355""}]},{""@id"":""https://pharmgkb.org/literature/15100923"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100923E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"",""title"":""CPIC® Guideline for Abacavir and HLA-B – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983436E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448004"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448004"",""name"":""abacavir""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982036E9,""html"":""\u003cp\u003eIn individuals with the HLA-B*57:01 variant allele (\u0026quot;HLA-B*57:01-positive\u0026quot;), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982035E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for abacavir and HLA-B\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2014-update\""\u003eMay 2014 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online 21 February 2014; Advance online publication 12 March 2014\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.nature.com/clpt/journal/v95/n5/full/clpt201438a.html\"" target\u003d\""_blank\""\u003e2014 update of CPIC guidelines\u003c/a\u003e regarding abacavir has been published in \u003cem\u003eClinical Pharmacology and Therapeutics\u003c/em\u003e. Literature published between April 2011-November 2013 was reviewed and there is \u003cstrong\u003eno new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current\u003c/strong\u003e.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003eHIV Patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/abacavir/2014/24561393.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for \u003cem\u003eHLA-B\u003c/em\u003e Genotype and Abacavir Dosing: 2014 Update \u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/abacavir/2014/24561393-supplement.pdf\"" target\u003d\""_blank\""\u003e2014 supplement\u003c/a\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""april-2012\""\u003eApril 2012\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication February 2012\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/abacavir/2012/22378157.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for \u003cem\u003eHLA-B\u003c/em\u003e Genotype and Abacavir Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/abacavir/2012/22378157-supplement.pdf\"" target\u003d\""_blank\""\u003e2012 supplement\u003c/a\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eExcerpt from the abacavir dosing guidelines:\u003c/p\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003eWe agree with others* that \u003cem\u003eHLA-B*57:01\u003c/em\u003e screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are \u003cem\u003eHLA-B*57:01\u003c/em\u003e-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk.\u003c/p\u003e\n\u003c/blockquote\u003e\n\u003cp\u003e*[Articles:\u003ca href\u003d\""/pmid/18826546\""\u003e18826546\u003c/a\u003e, \u003ca href\u003d\""/pmid/19640227\""\u003e19640227\u003c/a\u003e, \u003ca href\u003d\""/pmid/21174626\""\u003e21174626\u003c/a\u003e, \u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e] \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\"" target\u003d\""_blank\""\u003eGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF) \u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""table-1-recommended-therapeutic-use-of-abacavir-based-on-hla-b-genotype\""\u003eTable 1: Recommended therapeutic use of abacavir based on \u003cem\u003eHLA-B\u003c/em\u003e genotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2012 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications for phenotypic measures\u003c/th\u003e\u003cth\u003eRecommendations for abacavir therapy\u003c/th\u003e\u003cth\u003eClassification of recommendation for abacavir therapy \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eVery low risk of hypersensitivity (constitutes ~94% \u003csup\u003eb\u003c/sup\u003e of patients)\u003c/td\u003e\u003ctd\u003eAbsence of \u003cem\u003e*57:01\u003c/em\u003e alleles (reported as \u0026quot;negative\u0026quot; on a genotyping test)\u003c/td\u003e\u003ctd\u003e*X/*X \u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eLow or reduced risk of abacavir hypersensitivity\u003c/td\u003e\u003ctd\u003eUse abacavir per standard dosing guidelines\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eHigh risk of hypersensitivity (~6% of patients)\u003c/td\u003e\u003ctd\u003ePresence of at least one \u003cem\u003e*57:01\u003c/em\u003e allele (reported as \u0026quot;positive\u0026quot; on a genotyping test)\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*57:01\u003c/em\u003e/*X \u003csup\u003ec\u003c/sup\u003e \u003cem\u003e*57:01/*57:01\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eSignificantly increased risk of abacavir hypersensitivity\u003c/td\u003e\u003ctd\u003eAbacavir is not recommended\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Rating scheme described in the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf\""\u003e2012 Supplement\u003c/a\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e See the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf\""\u003e2012 Supplement\u003c/a\u003e for estimates of genotype frequencies among different ethnic/geographic groups\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e *X \u003d any \u003cem\u003eHLA-B\u003c/em\u003e genotype other than \u003cem\u003e*57:01\u003c/em\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eHLA-B\u003c/em\u003e \u003d human leukocyte antigen B\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eListen to an interview with the lead author:\u003c/strong\u003e \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.theaidsreader.com/display/article/1145619/2064707\"" target\u003d\""_blank\""\u003epodcast\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983436E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/""}]},""status"":""success""}"
PA166104991,Guideline Annotation,Annotation of DPWG Guideline for abacavir and HLA-B,t,PA448004,Dutch Pharmacogenetics Working Group,"<p>Avoid abacavir for patients who have the HLA-B*57:01 allele (patients who are &quot;HLA-B*57:01-positive&quot;).</p>
","<h3 id=""august-2019-update"">August 2019 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 recommends avoiding abacavir.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>HLA-B*5701</td><td>abacavir</td><td>HLA-B*5701-positive patients have a strongly increased risk of a hypersensitivity reaction to abacavir. 48% of the HLA-B*5701-positive patients develop a severe and potentially life-threatening hypersensitivity reaction to abacavir</td><td>Abacavir is contra-indicated for HLA-B*5701-positive patients.<br/>1. Avoid abacavir.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002356.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 and give the same recommendation as in 2011.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>HLA-B*5701</td><td>abacavir</td><td>HLA-B*5701-positive patients have a strongly increased risk of a hypersensitivity reaction to abacavir.</td><td>Abacavir is contra-indicated for HLA-B*5701-positive patients.<br/>1. Advise the prescriber to prescribe an alternative according to the current guidelines.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002356.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 [Article:<a href=""/pmid/21412232"">21412232</a>]. They conclude that an alternate drug should be selected for patients who are HLA-B*57:01 positive.</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>HLA-B*57:01</td><td>Select alternative drug</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x109/l; leucopenia &lt; 1.0x109/l; thrombocytopenia &lt; 25x109/l; life-threatening complications from diarrhea.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods</a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104991"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104991"",""name"":""Annotation of DPWG Guideline for abacavir and HLA-B"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704435E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414978E9,""date"":""2019-05-23T11:11:09.217-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450815696E9,""date"":""2019-09-25T14:04:52.813-07:00"",""description"":""Changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45095626E9,""date"":""2020-01-31T13:13:12.226-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450962482E9,""date"":""2020-02-10T08:05:42.502-08:00"",""description"":""Fixed links to 2018 and 2019 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448004"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448004"",""name"":""abacavir""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982006E9,""html"":""\u003cp\u003eAvoid abacavir for patients who have the HLA-B*57:01 allele (patients who are \u0026quot;HLA-B*57:01-positive\u0026quot;).\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982005E9,""html"":""\u003ch3 id\u003d\""august-2019-update\""\u003eAugust 2019 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 recommends avoiding abacavir.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eHLA-B*5701\u003c/td\u003e\u003ctd\u003eabacavir\u003c/td\u003e\u003ctd\u003eHLA-B*5701-positive patients have a strongly increased risk of a hypersensitivity reaction to abacavir. 48% of the HLA-B*5701-positive patients develop a severe and potentially life-threatening hypersensitivity reaction to abacavir\u003c/td\u003e\u003ctd\u003eAbacavir is contra-indicated for HLA-B*5701-positive patients.\u003cbr/\u003e1. Avoid abacavir.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002356.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 and give the same recommendation as in 2011.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eHLA-B*5701\u003c/td\u003e\u003ctd\u003eabacavir\u003c/td\u003e\u003ctd\u003eHLA-B*5701-positive patients have a strongly increased risk of a hypersensitivity reaction to abacavir.\u003c/td\u003e\u003ctd\u003eAbacavir is contra-indicated for HLA-B*5701-positive patients.\u003cbr/\u003e1. Advise the prescriber to prescribe an alternative according to the current guidelines.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002356.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for abacavir based on HLA-B*57:01 [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e]. They conclude that an alternate drug should be selected for patients who are HLA-B*57:01 positive.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eHLA-B*57:01\u003c/td\u003e\u003ctd\u003eSelect alternative drug\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia \u0026lt; 0.5x109/l; leucopenia \u0026lt; 1.0x109/l; thrombocytopenia \u0026lt; 25x109/l; life-threatening complications from diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods\u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104938,Guideline Annotation,Annotation of DPWG Guideline for acenocoumarol and VKORC1,t,PA452632,Dutch Pharmacogenetics Working Group,"<p>Patients with the VKORC1 -1639 (<a href=""/variant/PA166155091"">rs9923231</a>) AA genotype should be given 50% of the standard initial dose of acenocoumarol and undergo more frequent INR monitoring. There are no recommendation for patients with the VKORC1 -1639 AG genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for acenocoumarol based on VKORC1 genotype. They recommend that patients with the VKORC1 -1639 (<a href=""/variant/PA166155091"">rs9923231</a>) AA genotype receive 50% of the standard initial dose and undergo more frequent INR monitoring.</p>
<p>No action is needed for patients with the VKORC1 -1639 AG genotype.</p>
<p>The annotation of the DPWG guideline for acenocoumarol and CYP2C9 can be found <a href=""https://www.pharmgkb.org/guidelineAnnotation/PA166104979"">here</a>.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>VKORC1 <a href=""/variant/PA166155091"">rs9923231</a> AA</td><td>acenocoumarol</td><td>An INR &gt;= 6, resulting in an increased risk of bleeding, occurs in 8-12% of these patients during the first weeks of treatment with standard regulation by the Anticoagulation Clinic. The genetic variation increases the sensitivity to acenocoumarol.</td><td>Monitoring by the ANTICOAGULATION CLINIC (National INR Monitoring Service): recommend to use 50% of the standard initial dose. OTHERWISE: recommend to use 50% of the standard initial dose and recommend more frequent monitoring of the INR .The initial dose and the maintenance dose can be calculated using an algorithm. However, for patients with two or more VKORC1 and/or CYP2C9 variations, the algorithm used in EU-PACT (see footnote for a link to a calculation tool in the form of an Excel file <sup>1</sup>) did not result in a significant reduction in the incidence of INRs above the target range when compared to an algorithm without genetic information. We are therefore unable to recommend the use of this algorithm at this time. A (non-validated) algorithm has been prescribed for children that should result in a better prediction of the maintenance dose for AA than the current guideline used by the Anticoagulation Clinic [Article:<a href=""/pmid/29935043"">29935043</a>].</td></tr>
<tr><td>VKORC1 <a href=""/variant/PA166155091"">rs9923231</a> AG</td><td>acenocoumarol</td><td>The genetic variation results in a reduction of the required dose, but with the current practice of initiating or reviewing treatment this results in little or no increased risk of bleeding or excessive anticoagulation.</td><td>NO action is needed for this gene-drug interaction</td></tr>
</tbody>
</table>
<p><sup>1</sup> <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics</a></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001910.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for acenocoumarol based on VKORC1 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They found that VKORC1 genotype contributes to dose variability.  However, they make no dosing recommendations at this time &quot;because of strict international normalized ratio monitoring by the Dutch Thrombosis Service.&quot;</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>VKORC1 <a href=""/variant/PA166155096"">rs9934438</a> AG</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms ); INR increase &lt; 4.5; Kinetic effect (S).</td></tr>
<tr><td>VKORC1 <a href=""/variant/PA166155096"">rs9934438</a> AA</td><td>Check INR more frequently.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms ); INR increase &lt; 4.5; Kinetic effect (S).</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104938"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104938"",""name"":""Annotation of DPWG Guideline for acenocoumarol and VKORC1"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704439E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414934E9,""date"":""2019-05-23T09:47:45.439-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450815699E9,""date"":""2019-09-25T14:08:17.635-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45082042E9,""date"":""2019-10-01T21:24:32.055-07:00"",""description"":""Fixed a typo from \""INR\u003d6\"" to \""INR\u003e\u003d6\"""",""type"":""Update"",""version"":0.0},{""id"":1.450956261E9,""date"":""2020-01-31T13:15:36.617-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.4509625E9,""date"":""2020-02-10T08:14:59.027-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0},{""id"":1.45096404E9,""date"":""2020-02-11T09:37:39.834-08:00"",""description"":""Fixed link to algorithms"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/variant/PA166155091"",""@context"":""https://api.pharmgkb.org/jsonld/variant.jsonld"",""objCls"":""Variant"",""id"":""PA166155091"",""symbol"":""rs9923231"",""name"":""rs9923231""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA452632"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA452632"",""name"":""acenocoumarol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA133787052"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA133787052"",""symbol"":""VKORC1"",""name"":""vitamin K epoxide reductase complex subunit 1""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981854E9,""html"":""\u003cp\u003ePatients with the VKORC1 -1639 (\u003ca href\u003d\""/variant/PA166155091\""\u003ers9923231\u003c/a\u003e) AA genotype should be given 50% of the standard initial dose of acenocoumarol and undergo more frequent INR monitoring. There are no recommendation for patients with the VKORC1 -1639 AG genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981853E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for acenocoumarol based on VKORC1 genotype. They recommend that patients with the VKORC1 -1639 (\u003ca href\u003d\""/variant/PA166155091\""\u003ers9923231\u003c/a\u003e) AA genotype receive 50% of the standard initial dose and undergo more frequent INR monitoring.\u003c/p\u003e\n\u003cp\u003eNo action is needed for patients with the VKORC1 -1639 AG genotype.\u003c/p\u003e\n\u003cp\u003eThe annotation of the DPWG guideline for acenocoumarol and CYP2C9 can be found \u003ca href\u003d\""https://www.pharmgkb.org/guidelineAnnotation/PA166104979\""\u003ehere\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 \u003ca href\u003d\""/variant/PA166155091\""\u003ers9923231\u003c/a\u003e AA\u003c/td\u003e\u003ctd\u003eacenocoumarol\u003c/td\u003e\u003ctd\u003eAn INR \u0026gt;\u003d 6, resulting in an increased risk of bleeding, occurs in 8-12% of these patients during the first weeks of treatment with standard regulation by the Anticoagulation Clinic. The genetic variation increases the sensitivity to acenocoumarol.\u003c/td\u003e\u003ctd\u003eMonitoring by the ANTICOAGULATION CLINIC (National INR Monitoring Service): recommend to use 50% of the standard initial dose. OTHERWISE: recommend to use 50% of the standard initial dose and recommend more frequent monitoring of the INR .The initial dose and the maintenance dose can be calculated using an algorithm. However, for patients with two or more VKORC1 and/or CYP2C9 variations, the algorithm used in EU-PACT (see footnote for a link to a calculation tool in the form of an Excel file \u003csup\u003e1\u003c/sup\u003e) did not result in a significant reduction in the incidence of INRs above the target range when compared to an algorithm without genetic information. We are therefore unable to recommend the use of this algorithm at this time. A (non-validated) algorithm has been prescribed for children that should result in a better prediction of the maintenance dose for AA than the current guideline used by the Anticoagulation Clinic [Article:\u003ca href\u003d\""/pmid/29935043\""\u003e29935043\u003c/a\u003e].\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 \u003ca href\u003d\""/variant/PA166155091\""\u003ers9923231\u003c/a\u003e AG\u003c/td\u003e\u003ctd\u003eacenocoumarol\u003c/td\u003e\u003ctd\u003eThe genetic variation results in a reduction of the required dose, but with the current practice of initiating or reviewing treatment this results in little or no increased risk of bleeding or excessive anticoagulation.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003e1\u003c/sup\u003e \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003ehttps://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\u003c/a\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001910.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for acenocoumarol based on VKORC1 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They found that VKORC1 genotype contributes to dose variability.  However, they make no dosing recommendations at this time \u0026quot;because of strict international normalized ratio monitoring by the Dutch Thrombosis Service.\u0026quot;\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 \u003ca href\u003d\""/variant/PA166155096\""\u003ers9934438\u003c/a\u003e AG\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms , \u0026lt;470 ms ); INR increase \u0026lt; 4.5; Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 \u003ca href\u003d\""/variant/PA166155096\""\u003ers9934438\u003c/a\u003e AA\u003c/td\u003e\u003ctd\u003eCheck INR more frequently.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms , \u0026lt;470 ms ); INR increase \u0026lt; 4.5; Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104979,Guideline Annotation,Annotation of DPWG Guideline for acenocoumarol and CYP2C9,f,PA452632,Dutch Pharmacogenetics Working Group,"<p>There are currently no recommendations for acenocoumarol dosing based on CYP2C9 genotypes.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for acenocoumarol based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p>The annotation of the DPWG guideline for acenocoumarol and VKORC1 can be found <a href=""https://www.pharmgkb.org/guidelineAnnotation/PA166104938"">here</a>.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001868.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for acenocoumarol based on CYP2C9 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>CYP2C9 *1/*2</td><td>Check INR more frequently after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt;4.5. Kinetic effect (S)</td></tr>
<tr><td>CYP2C9 *2/*2</td><td>Check INR more frequently after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt;4.5. Kinetic effect (S)</td></tr>
<tr><td>CYP2C9 *1/*3</td><td>Check INR more frequently after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>CYP2C9 *2/*3</td><td>Check INR more frequently after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt;4.5. Kinetic effect (S)</td></tr>
<tr><td>CYP2C9 *3/*3</td><td>Check INR more frequently during dose titration and after initiating or discontinuing NSAIDs</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt;4.5. Kinetic effect (S)</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/acenocoumarol_CYP2C9_271111.pdf"">Acenocoumarol CYP2C9 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104979"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104979"",""name"":""Annotation of DPWG Guideline for acenocoumarol and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704436E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414926E9,""date"":""2019-05-23T08:54:07.271-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820419E9,""date"":""2019-09-25T00:00:00-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450956221E9,""date"":""2020-01-31T13:16:09.847-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450962485E9,""date"":""2020-02-10T08:20:58.467-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/haplotype/PA165816543"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816543"",""symbol"":""CYP2C9*2"",""name"":""*2""},{""@id"":""https://pharmgkb.org/haplotype/PA165816544"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816544"",""symbol"":""CYP2C9*3"",""name"":""*3""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA452632"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA452632"",""name"":""acenocoumarol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981944E9,""html"":""\u003cp\u003eThere are currently no recommendations for acenocoumarol dosing based on CYP2C9 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981943E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for acenocoumarol based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThe annotation of the DPWG guideline for acenocoumarol and VKORC1 can be found \u003ca href\u003d\""https://www.pharmgkb.org/guidelineAnnotation/PA166104938\""\u003ehere\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001868.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for acenocoumarol based on CYP2C9 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*2\u003c/td\u003e\u003ctd\u003eCheck INR more frequently after initiating or discontinuing NSAIDs\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms females, \u0026lt;470 ms males); INR increase \u0026lt;4.5. Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*2\u003c/td\u003e\u003ctd\u003eCheck INR more frequently after initiating or discontinuing NSAIDs\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms females, \u0026lt;470 ms males); INR increase \u0026lt;4.5. Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*3\u003c/td\u003e\u003ctd\u003eCheck INR more frequently after initiating or discontinuing NSAIDs\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026gt; 3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia  \u0026gt; 75x10\u003csup\u003e9\u003c/sup\u003e/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*3\u003c/td\u003e\u003ctd\u003eCheck INR more frequently after initiating or discontinuing NSAIDs\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms females, \u0026lt;470 ms males); INR increase \u0026lt;4.5. Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *3/*3\u003c/td\u003e\u003ctd\u003eCheck INR more frequently during dose titration and after initiating or discontinuing NSAIDs\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms females, \u0026lt;470 ms males); INR increase \u0026lt;4.5. Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/acenocoumarol_CYP2C9_271111.pdf\""\u003eAcenocoumarol CYP2C9 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166105003,Guideline Annotation,Annotation of CPIC Guideline for allopurinol and HLA-B,t,PA448320,Clinical Pharmacogenetics Implementation Consortium,"<p>Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (&quot;HLA-B*58:01-positive&quot;) due to significantly increased risk of allopurinol-induced SCAR.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"" target=""_blank"">CPIC&reg; guideline for allopurinol and HLA-B</a>.</p>
<h3 id=""january-2016-update"">January 2016 Update</h3>
<p><em>Accepted article preview online June 2015</em></p>
<p>The 2015 update of CPIC guidelines regarding allopurinol has been published in <em>Clinical Pharmacology and Therapeutics</em>.  Recent literature was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>.</p>
<ul>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/allopurinol/2015/26094938.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update </a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/allopurinol/2015/26094938-supplement.pdf"" target=""_blank"">2015 supplement</a>.</li>
</ul>
</li>
</ul>
<h3 id=""february-2013"">February 2013</h3>
<p><em>Advanced online publication December 2012</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</li>
<li>These guidelines are applicable to:
<ul>
<li>adults</li>
</ul>
</li>
<li>Excerpt from the 2013 allopurinol dosing guidelines:
<ul>
<li>&quot;Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/allopurinol/2013/23232549.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing </a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/allopurinol/2013/23232549-supplement.pdf"" target=""_blank"">2013 supplement</a>.</li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-allopurinol-based-on-hla-b-genotype"">Table 1: Recommended dosing of allopurinol based on <em>HLA-B</em> genotype</h3>
<table class=""table"">
<thead>
<tr><th>Likely Phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for allopurinol therapy</th><th>Classification of recommendation for allopurinol therapy</th></tr>
</thead>
<tbody>
<tr><td>Low or reduced risk of allopurinol SCAR</td><td>Absence of <em>*58:01</em> alleles (reported as &quot;negative&quot; on a genotyping test)</td><td>*X/*X <sup>a</sup></td><td>Low or reduced risk of allopurinol SCAR</td><td>Use allopurinol per standard dosing guidelines</td><td>Strong</td></tr>
<tr><td>Significantly increased risk of allopurinol SCAR</td><td>Presence of at least one <em>*58:01</em> allele (reported as &quot;positive&quot; on a genotyping test)</td><td><em>*58:01</em>/*X <sup>a</sup> <em>*58:01/*58:01</em></td><td>Significantly increased risk of allopurinol SCAR</td><td>Allopurinol is contraindicated</td><td>Strong</td></tr>
</tbody>
</table>
<p><em>Adapted from Table 2 of the 2013 Guideline Manuscript</em></p>
<p><sup>a</sup> *X = any <em>HLA-B</em> genotype other than <em>*58:01</em>.</p>
<p><em>HLA-B</em> = human leukocyte antigen B</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166105003"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166105003"",""name"":""Annotation of CPIC Guideline for allopurinol and HLA-B"",""cancerGenome"":false,""descriptiveVideoId"":""8LF_sTtUCXY"",""guidelineGenes"":[{""id"":1.449560778E9,""alleles"":[{""id"":1.449560779E9,""_label"":""Other"",""allele"":""Other"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558334"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558334E9,""resource"":""Allele Function"",""term"":""Absence"",""termId"":""haplotypeTags:1445558334""}},{""id"":1.44956078E9,""_label"":""*58:01"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165987831"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165987831"",""symbol"":""HLA-B*58:01"",""name"":""*58:01""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}}],""history"":[{""id"":1.183699762E9,""date"":""2012-10-17T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.444841843E9,""date"":""2015-06-11T15:10:54.200-07:00"",""description"":""Published update"",""type"":""Update"",""version"":0.0},{""id"":1.44484185E9,""date"":""2015-06-12T08:50:16.155-07:00"",""type"":""Update"",""version"":0.0},{""id"":1.450042999E9,""date"":""2018-11-19T14:34:36.346-08:00"",""description"":""Updated link to new guideline video"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15090607"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5090607E7,""resourceId"":""26094938"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675696"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4675696"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449286509E9,""resource"":""PubMed Central"",""resourceId"":""PMC4675696"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675696""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/26094938"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449286508E9,""resource"":""PubMed"",""resourceId"":""26094938"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/26094938""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.161"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44928651E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.161"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.161""}]},{""@id"":""https://pharmgkb.org/literature/15033427"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5033427E7,""resourceId"":""23232549"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3564416"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449274192E9,""resource"":""PubMed Central"",""resourceId"":""PMC3564416"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23232549"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449274191E9,""resource"":""PubMed"",""resourceId"":""23232549"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23232549""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2012.209"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449274193E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2012.209"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2012.209""}]},{""@id"":""https://pharmgkb.org/literature/15100908"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100908E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"",""title"":""CPIC® Guideline for Allopurinol and HLA-B – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44798344E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448320"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448320"",""name"":""allopurinol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.44798195E9,""html"":""\u003cp\u003eAllopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (\u0026quot;HLA-B*58:01-positive\u0026quot;) due to significantly increased risk of allopurinol-induced SCAR.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981949E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for allopurinol and HLA-B\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""january-2016-update\""\u003eJanuary 2016 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online June 2015\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThe 2015 update of CPIC guidelines regarding allopurinol has been published in \u003cem\u003eClinical Pharmacology and Therapeutics\u003c/em\u003e.  Recent literature was reviewed and there is \u003cstrong\u003eno new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current\u003c/strong\u003e.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/allopurinol/2015/26094938.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update \u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/allopurinol/2015/26094938-supplement.pdf\"" target\u003d\""_blank\""\u003e2015 supplement\u003c/a\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""february-2013\""\u003eFebruary 2013\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvanced online publication December 2012\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003eadults\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2013 allopurinol dosing guidelines:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/allopurinol/2013/23232549.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing \u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/allopurinol/2013/23232549-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-allopurinol-based-on-hla-b-genotype\""\u003eTable 1: Recommended dosing of allopurinol based on \u003cem\u003eHLA-B\u003c/em\u003e genotype\u003c/h3\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely Phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications for phenotypic measures\u003c/th\u003e\u003cth\u003eRecommendations for allopurinol therapy\u003c/th\u003e\u003cth\u003eClassification of recommendation for allopurinol therapy\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eLow or reduced risk of allopurinol SCAR\u003c/td\u003e\u003ctd\u003eAbsence of \u003cem\u003e*58:01\u003c/em\u003e alleles (reported as \u0026quot;negative\u0026quot; on a genotyping test)\u003c/td\u003e\u003ctd\u003e*X/*X \u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eLow or reduced risk of allopurinol SCAR\u003c/td\u003e\u003ctd\u003eUse allopurinol per standard dosing guidelines\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eSignificantly increased risk of allopurinol SCAR\u003c/td\u003e\u003ctd\u003ePresence of at least one \u003cem\u003e*58:01\u003c/em\u003e allele (reported as \u0026quot;positive\u0026quot; on a genotyping test)\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*58:01\u003c/em\u003e/*X \u003csup\u003ea\u003c/sup\u003e \u003cem\u003e*58:01/*58:01\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eSignificantly increased risk of allopurinol SCAR\u003c/td\u003e\u003ctd\u003eAllopurinol is contraindicated\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Table 2 of the 2013 Guideline Manuscript\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e *X \u003d any \u003cem\u003eHLA-B\u003c/em\u003e genotype other than \u003cem\u003e*58:01\u003c/em\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eHLA-B\u003c/em\u003e \u003d human leukocyte antigen B\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44798344E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/""}]},""status"":""success""}"
PA166104993,Guideline Annotation,Annotation of PRO Guideline for allopurinol and HLA-B,t,PA448320,Professional Society,"<p>HLA-B*58:01-positive individuals (those with the HLA-B*58:01 variant allele) should be prescribed an alternative drug to allopurinol.</p>
","<p>The <strong>American College of Rheumatology</strong> guidelines for the management of gout include the following statement about pharmacogenomic testing for HLA-B*58:01 and allopurinol:</p>
<blockquote class=""blockquote"">
<p>Those with HLA-B*5801 and of Korean descent with stage 3 or worse CKD (HLA-B*5801 allele frequency ~12%), or of Han Chinese or Thai extraction irrespective of renal function (HLA-B*5801 allele frequency ~6-8%), have been highlighted in the literature as prime examples of subjects at high risk for AHS, marked by HLA-B*5801 hazard ratios of several hundred.  Such high-risk individuals were recommended to be prescribed an alternative to allopurinol if HLA-B*5801 positive.</p>
</blockquote>
<p>excerpted from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/GuidelinesHLABallopurinolACR.pdf"">2012 American College of Rheumatology Guidelines for the Management of Gout. Part1</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104993"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104993"",""name"":""Annotation of PRO Guideline for allopurinol and HLA-B"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.183704559E9,""date"":""2012-10-01T00:00:00-07:00"",""type"":""Create"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15065128"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5065128E7,""resourceId"":""23024028"",""title"":""2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683400"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3683400"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44927817E9,""resource"":""PubMed Central"",""resourceId"":""PMC3683400"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683400""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23024028"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449278169E9,""resource"":""PubMed"",""resourceId"":""23024028"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23024028""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/acr.21772"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449278171E9,""resource"":""DOI"",""resourceId"":""10.1002/acr.21772"",""_url"":""http://dx.doi.org/10.1002%2Facr.21772""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448320"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448320"",""name"":""allopurinol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Professional Society"",""summaryMarkdown"":{""id"":1.447982018E9,""html"":""\u003cp\u003eHLA-B*58:01-positive individuals (those with the HLA-B*58:01 variant allele) should be prescribed an alternative drug to allopurinol.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982017E9,""html"":""\u003cp\u003eThe \u003cstrong\u003eAmerican College of Rheumatology\u003c/strong\u003e guidelines for the management of gout include the following statement about pharmacogenomic testing for HLA-B*58:01 and allopurinol:\u003c/p\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003eThose with HLA-B*5801 and of Korean descent with stage 3 or worse CKD (HLA-B*5801 allele frequency ~12%), or of Han Chinese or Thai extraction irrespective of renal function (HLA-B*5801 allele frequency ~6-8%), have been highlighted in the literature as prime examples of subjects at high risk for AHS, marked by HLA-B*5801 hazard ratios of several hundred.  Such high-risk individuals were recommended to be prescribed an alternative to allopurinol if HLA-B*5801 positive.\u003c/p\u003e\n\u003c/blockquote\u003e\n\u003cp\u003eexcerpted from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/GuidelinesHLABallopurinolACR.pdf\""\u003e2012 American College of Rheumatology Guidelines for the Management of Gout. Part1\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182815,Guideline Annotation,Annotation of DPWG Guideline for amiodarone and CYP2D6,f,PA448383,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for amiodarone based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for amiodarone based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002543.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182815"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182815"",""name"":""Annotation of DPWG Guideline for amiodarone and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414995E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.450815698E9,""date"":""2019-09-25T14:06:51.536-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.4508157E9,""date"":""2019-09-25T14:09:05.773-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45096252E9,""date"":""2020-02-10T08:27:44.595-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448383"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448383"",""name"":""amiodarone""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414993E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for amiodarone based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414994E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for amiodarone based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002543.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166105006,Guideline Annotation,"Annotation of CPIC Guideline for amitriptyline and CYP2C19,CYP2D6",t,PA448385,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.</li>
</ul>
</li>
</ul>
<h3 id=""december-2016-update"">December 2016 Update</h3>
<p><em>Advance online publication December 2016.</em></p>
<ul>
<li>The 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">(CPIC)</a>.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.</li>
<li>Excerpt from the 2016 dosing guideline update:
<ul>
<li>&quot;There is substantial evidence linking <em>CYP2D6</em> and <em>CYP2C19</em> genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have <em>CYP2D6</em> or <em>CYP2C19</em> genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.&quot;</li>
<li>&quot; There are scarce studies focusing solely on <em>CYP2D6</em> or <em>CYP2C19</em> genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.&quot;</li>
</ul>
</li>
<li>The guideline includes dosing recommendation for amitriptyline based on:
<ul>
<li>CYP2D6 phenotype (<a href=""#table-1-dosing-recommendations-for-amitriptyline-based-on-cyp2d6-phenotype"">Table 1 below</a>)</li>
<li>CYP2C19 phenotype (<a href=""#table-2-dosing-recommendations-for-amitriptyline-based-on-cyp2c19-phenotype"">Table 2 below</a>)</li>
<li>combinations of CYP2D6 and CYP2C19 phenotypes (<a href=""#table-3-dosing-recommendations-for-amitriptyline-based-on-both-cyp2d6-and-cyp2c19-phenotype"">Table 3 below</a>)</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf"" target=""_blank"">2016 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 Gene-specific Information Tables</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c19RefMaterials"">CYP2C19 Gene-specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/Amitriptyline_Drug_Resource_Mappings.xlsx"" target=""_blank"">Amitriptyline Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/Amitriptyline_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Amitriptyline Pre and Post Test Alerts and Flow Chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-amitriptyline-based-on-cyp2d6-phenotype"">Table 1: Dosing recommendations for amitriptyline based on CYP2D6 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Activity score</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic Recommendations<sup>a, b</sup></th><th>Classification of recommendation for amitriptyline and nortriptyline<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 Ultrarapid metabolizer (~1-20% of patients)<sup>d</sup></td><td>&gt;2.0</td><td>An individual carrying more than two copies of functional alleles</td><td>*1/*1xN, *1/*2xN</td><td>Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.</td><td>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Strong</td></tr>
<tr><td>CYP2D6 Normal metabolizer (~72-88% of patients)<sup>d</sup></td><td>1.0-2.0<sup>f</sup></td><td>An individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0</td><td>*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5</td><td>Normal metabolism of TCAs.</td><td>Initiate therapy with recommended starting dose.<sup>g</sup></td><td>Strong</td></tr>
<tr><td>CYP2D6 Intermediate metabolizer (~1-13% of patients)<sup>d</sup></td><td>0.5</td><td>An individual carrying one decreased and one no function allele</td><td>*4/*41, *5/*9, *4/*10</td><td>Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Consider 25% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Moderate</td></tr>
<tr><td>CYP2D6 Poor metabolizer (~1-10% of patients)<sup>d</sup></td><td>0</td><td>An individual carrying only no function alleles</td><td>*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6</td><td>Greatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider 50% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement.</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
<p><sup>g</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<h3 id=""table-2-dosing-recommendations-for-amitriptyline-based-on-cyp2c19-phenotype"">Table 2: Dosing recommendations for amitriptyline based on CYP2C19 phenotype:</h3>
<p><em>Adapted from Tables 1 and 3 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic recommendations<sup>a,b</sup></th><th>Classification of recommendations for amitriptyline<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 Ultrarapid metabolizer (~2-5% of patients)<sup>d</sup></td><td>An individual carrying two increased function alleles</td><td>*17/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Rapid metabolizer (~2-30% of patients)<sup>d</sup></td><td>An individual carrying one normal and one increased function allele</td><td>*1/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Normal metabolizer (~35-50% of patients)<sup>d</sup></td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism of tertiary amines.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Strong</td></tr>
<tr><td>CYP2C19 Intermediate metabolizer (~18-45% of patients)<sup>d</sup></td><td>An individual carrying one normal and one no function allele or one no and one increased function allele</td><td>*1/*2, *1/*3, *2/*17<sup>g</sup></td><td>Reduced metabolism of tertiary amines compared to normal metabolizers.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Strong</td></tr>
<tr><td>CYP2C19 Poor metabolizer (~2-15% of patients)<sup>d</sup></td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>For tertiary amines, consider a 50% reduction of the recommended starting dose.<sup>f</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Moderate</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement.</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<p><sup>g</sup> The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.</p>
<h3 id=""table-3-dosing-recommendations-for-amitriptyline-based-on-both-cyp2d6-and-cyp2c19-phenotype"">Table 3: Dosing recommendations for amitriptyline based on both CYP2D6 and CYP2C19 phenotype:</h3>
<p><em>Adapted from Table 4 of the 2016 guideline update. <sup>a,b</sup></em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype</th><th>CYP2D6 Ultrarapid metabolizer</th><th>CYP2D6 Normal metabolizer</th><th>CYP2D6 Intermediate metabolizer</th><th>CYP2D6 Poor metabolizer</th></tr>
</thead>
<tbody>
<tr><td><strong>CYP2C19 Ultrarapid or Rapid metabolizer</strong></td><td>Avoid amitriptyline use.<sup>c</sup> Classification of recommendation<sup>d</sup>: Optional</td><td>Consider alternative drug not metabolized by CYP2C19.<sup>c, e</sup> Classification of recommendation<sup>d</sup>: Optional</td><td>Consider alternative drug not metabolized by CYP2C19.<sup>c, e</sup> Classification of recommendation<sup>d</sup>: Optional</td><td>Avoid amitriptyline use.<sup>c</sup> Classification of recommendation<sup>d</sup>: Optional</td></tr>
<tr><td><strong>CYP2C19 Normal metabolizer</strong></td><td>Avoid amitriptyline use. If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers).<sup>f, g</sup> Classification of recommendation<sup>d</sup>: Strong</td><td>Initiate therapy with recommended starting dose. <sup>h</sup> Classification of recommendation<sup>d</sup>: Strong</td><td>Consider 25% reduction of recommended starting dose. <sup>f, h</sup> Classification of recommendation<sup>d</sup>: Moderate</td><td>Avoid amitriptyline use. If amitriptyline is warranted, consider 50% reduction of recommended starting dose. <sup>f, h</sup> Classification of recommendation<sup>d</sup>: Strong</td></tr>
<tr><td><strong>CYP2C19 Intermediate metabolizer</strong></td><td>Avoid amitriptyline use.<sup>c</sup> Classification of recommendation<sup>d</sup>: Optional</td><td>Initiate therapy with recommended starting dose. <sup>h</sup> Classification of recommendation<sup>d</sup>: Strong</td><td>Consider 25% reduction of recommended starting dose. <sup>f, h</sup> Classification of recommendation<sup>d</sup>: Optional</td><td>Avoid amitriptyline use. If amitriptyline is warranted, consider 50% reduction of recommended starting dose.<sup>f, h</sup> Classification of recommendation<sup>d</sup>: Optional</td></tr>
<tr><td><strong>CYP2C19 Poor metabolizer</strong></td><td>Avoid amitriptyline use.<sup>c</sup> Classification of recommendation<sup>d</sup>: Optional</td><td>Avoid amitriptyline use.<sup>c</sup>  If amitriptyline is warranted, consider  a 50% reduction of recommended starting dose. <sup>f, h</sup> Classification of recommendation<sup>d</sup>: Moderate</td><td>Avoid amitriptyline use.<sup>c</sup> Classification of recommendation<sup>d</sup>: Optional</td><td>Avoid amitriptyline use.<sup>c</sup> Classification of recommendation<sup>d</sup>: Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>b</sup> The dosing recommendations are based on studies focusing on amitriptyline. Because tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply these guidelines to other tertiary amines including clomipramine, doxepin, imipramine and trimipramine (the classification of this recommendation is optional).</p>
<p><sup>c</sup> If amitriptyline is warranted, utilize therapeutic drug monitoring<sup>f</sup> to guide dose adjustment.</p>
<p><sup>d</sup> The rating scheme for the recommendation classification is described in the Supplement.</p>
<p><sup>e</sup> TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.</p>
<p><sup>f</sup> Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>
<p><sup>g</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>h</sup> Patients may receive an initial low dose of TCAs, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<h3 id=""may-2013"">May 2013</h3>
<p><em>Advance online publication January 2013.</em></p>
<ul>
<li>
<p>Guidelines regarding the use of pharmacogenomic tests in dosing of amitriptyline and nortriptyline have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">(CPIC)</a>.</p>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">2013 supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-CYP2D6%20frequency%20table%20legend%20(R2).pdf"" target=""_blank"">CYP2D6 frequency table legend (R2)</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-CYP2D6%20frequency%20table%20(R2).xlsx"" target=""_blank"">CYP2D6 frequency table (R2)</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166105006"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166105006"",""name"":""Annotation of CPIC Guideline for amitriptyline and CYP2C19,CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[{""id"":1.449562036E9,""alleles"":[{""id"":1.449562037E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.449562038E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980634"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980634"",""symbol"":""CYP2C19*1"",""name"":""*1""}},{""id"":1.449562039E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980635"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980635"",""symbol"":""CYP2C19*2"",""name"":""*2""}},{""id"":1.44956204E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980636"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980636"",""symbol"":""CYP2C19*3"",""name"":""*3""}},{""id"":1.449562043E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980638"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980638"",""symbol"":""CYP2C19*5"",""name"":""*5""}},{""id"":1.449562044E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816522"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816522"",""symbol"":""CYP2C19*6"",""name"":""*6""}},{""id"":1.449562045E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816523"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816523"",""symbol"":""CYP2C19*7"",""name"":""*7""}},{""id"":1.449562046E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816524"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816524"",""symbol"":""CYP2C19*8"",""name"":""*8""}},{""id"":1.449562047E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816525"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816525"",""symbol"":""CYP2C19*9"",""name"":""*9""}},{""id"":1.449562048E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816526"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816526"",""symbol"":""CYP2C19*10"",""name"":""*10""}},{""id"":1.449562049E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816527"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816527"",""symbol"":""CYP2C19*11"",""name"":""*11""}},{""id"":1.44956205E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816528"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816528"",""symbol"":""CYP2C19*12"",""name"":""*12""}},{""id"":1.449562051E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816529"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816529"",""symbol"":""CYP2C19*13"",""name"":""*13""}},{""id"":1.449562052E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816530"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816530"",""symbol"":""CYP2C19*14"",""name"":""*14""}},{""id"":1.449562053E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816531"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816531"",""symbol"":""CYP2C19*15"",""name"":""*15""}},{""id"":1.449562054E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816532"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816532"",""symbol"":""CYP2C19*16"",""name"":""*16""}},{""id"":1.449562055E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816533"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816533"",""symbol"":""CYP2C19*17"",""name"":""*17""}},{""id"":1.449562056E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816534"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816534"",""symbol"":""CYP2C19*18"",""name"":""*18""}},{""id"":1.449562057E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816535"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816535"",""symbol"":""CYP2C19*19"",""name"":""*19""}},{""id"":1.449562058E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816536"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816536"",""symbol"":""CYP2C19*22"",""name"":""*22""}},{""id"":1.449562059E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816537"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816537"",""symbol"":""CYP2C19*23"",""name"":""*23""}},{""id"":1.44956206E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816538"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816538"",""symbol"":""CYP2C19*24"",""name"":""*24""}},{""id"":1.449562061E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816539"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816539"",""symbol"":""CYP2C19*25"",""name"":""*25""}},{""id"":1.449562062E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816540"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816540"",""symbol"":""CYP2C19*26"",""name"":""*26""}},{""id"":1.449562064E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115675"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115675"",""symbol"":""CYP2C19*28"",""name"":""*28""}},{""id"":1.449562065E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123292"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123292"",""symbol"":""CYP2C19*29"",""name"":""*29""}},{""id"":1.449562066E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123293"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123293"",""symbol"":""CYP2C19*30"",""name"":""*30""}},{""id"":1.449562067E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123294"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123294"",""symbol"":""CYP2C19*31"",""name"":""*31""}},{""id"":1.449562068E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123295"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123295"",""symbol"":""CYP2C19*32"",""name"":""*32""}},{""id"":1.449562069E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123296"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123296"",""symbol"":""CYP2C19*33"",""name"":""*33""}},{""id"":1.44956207E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115676"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115676"",""symbol"":""CYP2C19*34"",""name"":""*34""}},{""id"":1.449562071E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128094"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128094"",""symbol"":""CYP2C19*35"",""name"":""*35""}},{""id"":1.450805217E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980637"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980637"",""symbol"":""CYP2C19*4"",""name"":""*4""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}},{""id"":1.449561916E9,""alleles"":[{""id"":1.449561917E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.449561918E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449561919E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.44956192E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449561921E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449561922E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449561923E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449561924E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449561925E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449561926E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449561927E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449561928E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449561929E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.44956193E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449561931E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449561932E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449561933E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.449561934E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449561935E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449561936E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.449561939E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.44956194E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449561941E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449561942E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449561943E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449561944E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449561945E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449561946E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449561947E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449561948E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449561949E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.44956195E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449561951E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449561952E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449561953E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449561954E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449561955E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449561956E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449561957E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449561958E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449561959E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.44956196E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449561961E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449561962E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449561963E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449561964E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449561965E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449561966E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449561967E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449561968E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449561969E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.44956197E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449561971E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449561972E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449561973E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449561974E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449561975E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449561976E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449561977E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449561978E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449561979E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.44956198E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449561981E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449561982E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449561983E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449561984E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449561985E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449561986E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449561987E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449561988E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449561989E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.44956199E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449561991E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449561992E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449561993E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449561994E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449561995E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449561996E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449561997E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449561998E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449561999E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449562E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449562001E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449562002E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449562003E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449562004E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449562005E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449562006E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449562007E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449562008E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449562009E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.44956201E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449562011E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449562012E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449562013E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449562014E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449562015E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449562016E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449562017E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449562018E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449562019E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.44956202E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449562021E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449562022E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449562023E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449562024E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449562025E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449562026E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449562027E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449562028E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449562029E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.44956203E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449562031E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449562032E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449562033E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449562034E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.449562035E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.45004278E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042781E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824548E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.183699763E9,""date"":""2013-01-16T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.448526122E9,""date"":""2016-12-14T13:47:34.827-08:00"",""description"":""2016 TCA CPIC guideline update"",""type"":""Update"",""version"":0.0},{""id"":1.450042782E9,""date"":""2018-11-15T20:13:32.640-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824533E9,""date"":""2019-10-24T18:29:34.841-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098242"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098242E7,""resourceId"":""27997040"",""title"":""Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5478479"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293321E9,""resource"":""PubMed Central"",""resourceId"":""PMC5478479"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/27997040"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44929332E9,""resource"":""PubMed"",""resourceId"":""27997040"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/27997040""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.597"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293322E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.597"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.597""}]},{""@id"":""https://pharmgkb.org/literature/15051926"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051926E7,""resourceId"":""23486447"",""title"":""Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3689226"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275357E9,""resource"":""PubMed Central"",""resourceId"":""PMC3689226"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23486447"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275356E9,""resource"":""PubMed"",""resourceId"":""23486447"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23486447""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.2"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275358E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.2"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.2""}]},{""@id"":""https://pharmgkb.org/literature/15100907"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100907E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448385"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448385"",""name"":""amitriptyline""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""},{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982032E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982031E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2016-update\""\u003eDecember 2016 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication December 2016.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2016 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;There is substantial evidence linking \u003cem\u003eCYP2D6\u003c/em\u003e and \u003cem\u003eCYP2C19\u003c/em\u003e genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot; There are scarce studies focusing solely on \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eThe guideline includes dosing recommendation for amitriptyline based on:\n\u003cul\u003e\n\u003cli\u003eCYP2D6 phenotype (\u003ca href\u003d\""#table-1-dosing-recommendations-for-amitriptyline-based-on-cyp2d6-phenotype\""\u003eTable 1 below\u003c/a\u003e)\u003c/li\u003e\n\u003cli\u003eCYP2C19 phenotype (\u003ca href\u003d\""#table-2-dosing-recommendations-for-amitriptyline-based-on-cyp2c19-phenotype\""\u003eTable 2 below\u003c/a\u003e)\u003c/li\u003e\n\u003cli\u003ecombinations of CYP2D6 and CYP2C19 phenotypes (\u003ca href\u003d\""#table-3-dosing-recommendations-for-amitriptyline-based-on-both-cyp2d6-and-cyp2c19-phenotype\""\u003eTable 3 below\u003c/a\u003e)\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf\"" target\u003d\""_blank\""\u003e2016 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c19RefMaterials\""\u003eCYP2C19 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/Amitriptyline_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eAmitriptyline Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/Amitriptyline_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eAmitriptyline Pre and Post Test Alerts and Flow Chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-amitriptyline-based-on-cyp2d6-phenotype\""\u003eTable 1: Dosing recommendations for amitriptyline based on CYP2D6 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003csup\u003ea, b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendation for amitriptyline and nortriptyline\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Ultrarapid metabolizer (~1-20% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying more than two copies of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN\u003c/td\u003e\u003ctd\u003eIncreased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Normal metabolizer (~72-88% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.0-2.0\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5\u003c/td\u003e\u003ctd\u003eNormal metabolism of TCAs.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Intermediate metabolizer (~1-13% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*41, *5/*9, *4/*10\u003c/td\u003e\u003ctd\u003eReduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Poor metabolizer (~1-10% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no function alleles\u003c/td\u003e\u003ctd\u003e*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider 50% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003ch3 id\u003d\""table-2-dosing-recommendations-for-amitriptyline-based-on-cyp2c19-phenotype\""\u003eTable 2: Dosing recommendations for amitriptyline based on CYP2C19 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ea,b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations for amitriptyline\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Ultrarapid metabolizer (~2-5% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles\u003c/td\u003e\u003ctd\u003e*17/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Rapid metabolizer (~2-30% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Normal metabolizer (~35-50% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism of tertiary amines.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Intermediate metabolizer (~18-45% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one no function allele or one no and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3, *2/*17\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eReduced metabolism of tertiary amines compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Poor metabolizer (~2-15% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eFor tertiary amines, consider a 50% reduction of the recommended starting dose.\u003csup\u003ef\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.\u003c/p\u003e\n\u003ch3 id\u003d\""table-3-dosing-recommendations-for-amitriptyline-based-on-both-cyp2d6-and-cyp2c19-phenotype\""\u003eTable 3: Dosing recommendations for amitriptyline based on both CYP2D6 and CYP2C19 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Table 4 of the 2016 guideline update. \u003csup\u003ea,b\u003c/sup\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003c/th\u003e\u003cth\u003eCYP2D6 Ultrarapid metabolizer\u003c/th\u003e\u003cth\u003eCYP2D6 Normal metabolizer\u003c/th\u003e\u003cth\u003eCYP2D6 Intermediate metabolizer\u003c/th\u003e\u003cth\u003eCYP2D6 Poor metabolizer\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cstrong\u003eCYP2C19 Ultrarapid or Rapid metabolizer\u003c/strong\u003e\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use.\u003csup\u003ec\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003ctd\u003eConsider alternative drug not metabolized by CYP2C19.\u003csup\u003ec, e\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003ctd\u003eConsider alternative drug not metabolized by CYP2C19.\u003csup\u003ec, e\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use.\u003csup\u003ec\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cstrong\u003eCYP2C19 Normal metabolizer\u003c/strong\u003e\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use. If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers).\u003csup\u003ef, g\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Strong\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. \u003csup\u003eh\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Strong\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting dose. \u003csup\u003ef, h\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Moderate\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use. If amitriptyline is warranted, consider 50% reduction of recommended starting dose. \u003csup\u003ef, h\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Strong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cstrong\u003eCYP2C19 Intermediate metabolizer\u003c/strong\u003e\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use.\u003csup\u003ec\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. \u003csup\u003eh\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Strong\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting dose. \u003csup\u003ef, h\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use. If amitriptyline is warranted, consider 50% reduction of recommended starting dose.\u003csup\u003ef, h\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cstrong\u003eCYP2C19 Poor metabolizer\u003c/strong\u003e\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use.\u003csup\u003ec\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use.\u003csup\u003ec\u003c/sup\u003e  If amitriptyline is warranted, consider  a 50% reduction of recommended starting dose. \u003csup\u003ef, h\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Moderate\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use.\u003csup\u003ec\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003ctd\u003eAvoid amitriptyline use.\u003csup\u003ec\u003c/sup\u003e Classification of recommendation\u003csup\u003ed\u003c/sup\u003e: Optional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e The dosing recommendations are based on studies focusing on amitriptyline. Because tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply these guidelines to other tertiary amines including clomipramine, doxepin, imipramine and trimipramine (the classification of this recommendation is optional).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e If amitriptyline is warranted, utilize therapeutic drug monitoring\u003csup\u003ef\u003c/sup\u003e to guide dose adjustment.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e The rating scheme for the recommendation classification is described in the Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eh\u003c/sup\u003e Patients may receive an initial low dose of TCAs, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2013\""\u003eMay 2013\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication January 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in dosing of amitriptyline and nortriptyline have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-CYP2D6%20frequency%20table%20legend%20(R2).pdf\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table legend (R2)\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-CYP2D6%20frequency%20table%20(R2).xlsx\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table (R2)\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166104982,Guideline Annotation,Annotation of DPWG Guideline for amitriptyline and CYP2D6,t,PA448385,Dutch Pharmacogenetics Working Group,"<p>The Dutch Pharmacogenetics Working Group Guideline for amitriptyline recommends decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.</p>
","<h3 id=""august-2019-update"">August 2019 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for amitriptyline based on CYP2D6 genotypes. They recommend decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers with plasma concentration monitoring, and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>amitriptyline</td><td>The risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased.  The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites.</td><td>1. increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites.  Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.<br/>2. if a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</td></tr>
<tr><td>CYP2D6 IM</td><td>amitriptyline</td><td>The risk of side effects is increased, because the gene variation leads to higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline.</td><td>Use 75% of the standard dose and monitor the efficacy and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose</td></tr>
<tr><td>CYP2D6 PM</td><td>amitriptyline</td><td>In theory risk of side effects is increased, because the genetic variation results in higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline.</td><td>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the mainenance dose</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001920.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for amitriptyline based on CYP2D6 genotype. They recommend to choose an alternative antidepressant if possible and in case an alternative is not an option to increase the dose for UM and decreased the dose for IM and PM together with plasma concentrations monitoring.</p>
<p><em>Wording in table taken from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines 2018 November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>amitriptyline</td><td>The genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause a decrease in the plasma concentrations of amitriptyline and its active metabolite nortriptyline and increased plasma concentrations of the active metabolites E-10-OH- amitriptyline and E-10-OH-nortriptyline.</td><td>1. Choose an alternative if possible. Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.<br/>2. If an alternative is not an option: increase the dose to 1.25 times the standard dose, monitor the plasma concentrations and be alert to potential therapy failure due to decreased amitriptyline plus nortriptyline plasma concentrations and to increased plasma concentrations of the potentially cardiotoxic, active hydroxy metabolites.</td></tr>
<tr><td>CYP2D6 IM</td><td>amitriptyline</td><td>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause an increase in the plasma concentrations of amitriptyline and its active metabolite nortriptyline and decreased plasma concentrations of the active metabolites E-10-OH- amitriptyline and E-10-OH-nortriptyline.</td><td>1. Choose an alternative if possible. Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.<br/>2. If an alternative is not an option: use 60% of the standard dose and monitor the plasma concentrations of amitriptyline and nortriptyline. As side effects are related to nortriptyline plasma concentrations and the efficacy to amitriptyline plus nortriptyline plasma concentrations, which are influenced to a lesser extent by CYP2D6, it is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, but the efficacy is maintained.</td></tr>
<tr><td>CYP2D6 PM</td><td>amitriptyline</td><td>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause an increase in the plasma concentrations of amitriptyline and its active metabolite nortriptyline and decreased plasma concentrations of the active metabolites E-10-OH- amitriptyline and E-10-OH-nortriptyline.</td><td>1. Choose an alternative if possible. Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.<br/>2. If an alternative is not an option: use 50% of the standard dose and monitor the plasma concentrations of amitriptyline and nortriptyline. As side effects are related to nortriptyline plasma concentrations and the efficacy to amitriptyline plus nortriptyline plasma concentrations, which are influenced to a lesser extent by CYP2D6, it is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, but the efficacy is maintained.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001920.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for amitriptyline based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend selecting an alternative drug or reducing the initial dose for patients carrying intermediate metabolizer alleles and selecting alternative drugs or monitor amitypityline and nortriptyline plasma concentration for patients carrying the poor metabolizer or ultrarapid metabolizer alleles.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Insufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., citalopram, sertraline) or monitor amitriptyline and nortriptyline plasma concentration.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5; Kinetic effect (S)</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Reduce dose by 25% and monitor plasma concentration or select alternative drug (e.g., citalopram, sertraline).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Insufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., citalopram,sertraline) or monitor (E-10-hydroxy)amitriptyline plasma concentration.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/Amitriptyline_CYP2D6.pdf"">Amitriptyline CYP2D6 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104982"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104982"",""name"":""Annotation of DPWG Guideline for amitriptyline and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704441E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415075E9,""date"":""2019-05-23T16:42:29.319-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450815701E9,""date"":""2019-09-25T14:28:22.748-07:00"",""description"":""Changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450956262E9,""date"":""2020-01-31T13:16:57.212-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096254E9,""date"":""2020-02-10T08:52:24.501-08:00"",""description"":""Fixed links to 2018 and 2019 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448385"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448385"",""name"":""amitriptyline""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.44798196E9,""html"":""\u003cp\u003eThe Dutch Pharmacogenetics Working Group Guideline for amitriptyline recommends decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981959E9,""html"":""\u003ch3 id\u003d\""august-2019-update\""\u003eAugust 2019 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for amitriptyline based on CYP2D6 genotypes. They recommend decreasing the dose for CYP2D6 intermediate and CYP2D6 poor metabolizers with plasma concentration monitoring, and increasing the dose or using an alternative drug for CYP2D6 ultra-rapid metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eamitriptyline\u003c/td\u003e\u003ctd\u003eThe risk of ineffectiveness is increased and the risk of cardiotoxic side effects may be increased.  The gene variation leads to increased conversion of amitriptyline and the active metabolite nortriptyline to less active and inactive metabolites.\u003c/td\u003e\u003ctd\u003e1. increase the dose to 1.4 times the standard dose, monitor the effect and side effects or the plasma concentrations and be alert to increased plasma concentrations of the cardiotoxic Z-10-hydroxy metabolites.  Plasma concentrations of Z-hydroxy nortriptyine or Z-hydroxy amitriptyline higher than 40 ng/mL are considered toxic.\u003cbr/\u003e2. if a dose increase is not desirable due to the cardiotoxic hydroxy metabolite: avoid amitriptyline. Anti-depressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eamitriptyline\u003c/td\u003e\u003ctd\u003eThe risk of side effects is increased, because the gene variation leads to higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline.\u003c/td\u003e\u003ctd\u003eUse 75% of the standard dose and monitor the efficacy and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the maintenance dose\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eamitriptyline\u003c/td\u003e\u003ctd\u003eIn theory risk of side effects is increased, because the genetic variation results in higher plasma concentrations of the active metabolite nortriptyline and to a lesser extent of amitriptyline.\u003c/td\u003e\u003ctd\u003eUse 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of amitriptyline and nortriptyline to adjust the mainenance dose\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001920.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for amitriptyline based on CYP2D6 genotype. They recommend to choose an alternative antidepressant if possible and in case an alternative is not an option to increase the dose for UM and decreased the dose for IM and PM together with plasma concentrations monitoring.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines 2018 November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eamitriptyline\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause a decrease in the plasma concentrations of amitriptyline and its active metabolite nortriptyline and increased plasma concentrations of the active metabolites E-10-OH- amitriptyline and E-10-OH-nortriptyline.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative if possible. Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\u003cbr/\u003e2. If an alternative is not an option: increase the dose to 1.25 times the standard dose, monitor the plasma concentrations and be alert to potential therapy failure due to decreased amitriptyline plus nortriptyline plasma concentrations and to increased plasma concentrations of the potentially cardiotoxic, active hydroxy metabolites.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eamitriptyline\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause an increase in the plasma concentrations of amitriptyline and its active metabolite nortriptyline and decreased plasma concentrations of the active metabolites E-10-OH- amitriptyline and E-10-OH-nortriptyline.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative if possible. Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\u003cbr/\u003e2. If an alternative is not an option: use 60% of the standard dose and monitor the plasma concentrations of amitriptyline and nortriptyline. As side effects are related to nortriptyline plasma concentrations and the efficacy to amitriptyline plus nortriptyline plasma concentrations, which are influenced to a lesser extent by CYP2D6, it is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, but the efficacy is maintained.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eamitriptyline\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause an increase in the plasma concentrations of amitriptyline and its active metabolite nortriptyline and decreased plasma concentrations of the active metabolites E-10-OH- amitriptyline and E-10-OH-nortriptyline.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative if possible. Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\u003cbr/\u003e2. If an alternative is not an option: use 50% of the standard dose and monitor the plasma concentrations of amitriptyline and nortriptyline. As side effects are related to nortriptyline plasma concentrations and the efficacy to amitriptyline plus nortriptyline plasma concentrations, which are influenced to a lesser extent by CYP2D6, it is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, but the efficacy is maintained.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001920.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for amitriptyline based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend selecting an alternative drug or reducing the initial dose for patients carrying intermediate metabolizer alleles and selecting alternative drugs or monitor amitypityline and nortriptyline plasma concentration for patients carrying the poor metabolizer or ultrarapid metabolizer alleles.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., citalopram, sertraline) or monitor amitriptyline and nortriptyline plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5; Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eReduce dose by 25% and monitor plasma concentration or select alternative drug (e.g., citalopram, sertraline).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., citalopram,sertraline) or monitor (E-10-hydroxy)amitriptyline plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/Amitriptyline_CYP2D6.pdf\""\u003eAmitriptyline CYP2D6 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104948,Guideline Annotation,Annotation of CPIC Guideline for clopidogrel and CYP2C19,t,PA449053,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy (e.g., prasugrel, ticagrelor) for CYP2C19 poor or intermediate metabolizers if there is no contraindication.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for clopidogrel and CYP2C19</a>.</p>
<h3 id=""september-2013-update"">September 2013 Update</h3>
<p><em>Advance online publication May 2013.</em></p>
<ul>
<li>The 2013 update of CPIC guidelines regarding clopidogrel have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>. Literature published between 1966 to January 2013 was reviewed. The updated therapeutic recommendations are more focused to patients with acute coronary syndromes undergoing percutaneous coronary intervention (ACS/PCI) than the original guideline, with additional updates involve refined recommendations for variant and novel <em>CYP2C19</em> alleles beyond *2.</li>
<li>At the time of the development of this recommendation, there are no data available on the possible role of CYP2C19 in clopidogrel response in pediatric patient populations; however, there is no reason to suspect that CYP2C19 variant alleles would affect clopidogrel metabolism differently in children as compared with adults.</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/clopidogrel/2013/23698643.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/clopidogrel/2013/23698643-supplement.pdf"" target=""_blank"">2013 supplement</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-antiplatelet-therapy-recommendations-based-on-cyp2c19-status-when-considering-clopidogrel-for-acs-patients-undergoing-pci"">Table 1: Antiplatelet therapy recommendations based on CYP2C19 status when considering clopidogrel for ACS patients undergoing PCI</h3>
<p><em>Adapted from Tables 1 and 2 of the 2013 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for clopidogrel</th><th>Therapeutic recommendations</th><th>Classification of recommendations</th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer (UM) (~5-30% of patients)</td><td>An individual carrying two increased activity alleles (*17) or one functional allele (*1) plus one increased activity allele (*17)</td><td>*1/*17, *17/*17</td><td>Increased platelet inhibition; decreased residual platelet aggregation <sup>1</sup></td><td>Clopidogrel - label recommended dosage and administration</td><td>Strong</td></tr>
<tr><td>Extensive metabolizer (EM) (~35-50% of patients)</td><td>An individual carrying two functional (*1) alleles</td><td>*1/*1</td><td>Normal platelet inhibition; normal residual platelet aggregation</td><td>Clopidogrel - label recommended dosage and administration</td><td>Strong</td></tr>
<tr><td>Intermediate metabolizer (IM) (~18-45% of patients)</td><td>An individual carrying one functional allele (*1) plus one loss-of-function allele (*2-*8) or one loss-of-function allele (*2-*8) plus one increased activity allele (*17) <sup>2</sup></td><td>*1/*2, *1/*3, *2/*17</td><td>Reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events</td><td>Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor</td><td>Moderate</td></tr>
<tr><td>Poor metabolizer (PM) (~2-15% of patients)</td><td>An individual carrying two loss-of-function alleles (*2-*8)</td><td>*2/*2, *2/*3, *3/*3</td><td>Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events</td><td>Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>1</sup> The CYP2C19*17 allele (<a href=""/variant/PA166154147"">rs12248560</a>) may be associated with increased risk of bleeding.</p>
<p><sup>2</sup> The predicted metabolizer phenotype for *2-*8/*17 genotypes are provisional classifications. The currently available evidence indicates that the *17 gain-of-function allele is unable to completely compensate for the *2 loss-of-function allele [Article:<a href=""/pmid/20492469"">20492469</a>]; however, this data has not been consistently replicated and is therefore a provisional classification (Table S5).</p>
<p>An important caveat for all genotyping tests is that the &quot;wild-type&quot; (*1) status is reported if all other alleles that are measured are absent.  Some genotype tests do not interrogate the rare loss of function alleles and therefore, if present, they may be erroneously reported as &quot;wild type&quot;. Furthermore, in human DNA, it is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer altered enzyme function in an individual, and thus lead to the rare possibility of a loss-of-function allele being erroneously called as &quot;wild-type&quot; (*1). The guidelines do not focus on demographic and other clinical variables, such as adherence to therapy, age, diabetes mellitus, obesity, smoking, and concomitant use of other drugs that may influence clopidogrel efficacy and clinical decision making.</p>
<p><strong>The American Society of Health-System Pharmacists (ASHP) has endorsed the Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.</strong></p>
<h3 id=""august-2011"">August 2011</h3>
<p><em>Advance online publication June 2011.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for clopidogrel were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/clopidogrel/2011/21716271.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/clopidogrel/2011/21716271-supplement.pdf"" target=""_blank"">2011 supplement</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104948"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104948"",""name"":""Annotation of CPIC Guideline for clopidogrel and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":""P_2Z61Rf-R8"",""guidelineGenes"":[{""id"":1.449561711E9,""alleles"":[{""id"":1.449561712E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980634"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980634"",""symbol"":""CYP2C19*1"",""name"":""*1""}},{""id"":1.449561713E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980635"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980635"",""symbol"":""CYP2C19*2"",""name"":""*2""}},{""id"":1.449561714E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980636"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980636"",""symbol"":""CYP2C19*3"",""name"":""*3""}},{""id"":1.449561717E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980638"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980638"",""symbol"":""CYP2C19*5"",""name"":""*5""}},{""id"":1.449561718E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816522"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816522"",""symbol"":""CYP2C19*6"",""name"":""*6""}},{""id"":1.449561719E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816523"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816523"",""symbol"":""CYP2C19*7"",""name"":""*7""}},{""id"":1.44956172E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816524"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816524"",""symbol"":""CYP2C19*8"",""name"":""*8""}},{""id"":1.449561721E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816533"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816533"",""symbol"":""CYP2C19*17"",""name"":""*17""}},{""id"":1.450805218E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980637"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980637"",""symbol"":""CYP2C19*4"",""name"":""*4""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}}],""history"":[{""id"":1.18369977E9,""date"":""2011-06-22T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.183699757E9,""date"":""2013-05-22T00:00:00-07:00"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15058235"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5058235E7,""resourceId"":""23698643"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748366"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3748366"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449276503E9,""resource"":""PubMed Central"",""resourceId"":""PMC3748366"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748366""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23698643"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449276502E9,""resource"":""PubMed"",""resourceId"":""23698643"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23698643""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.105"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449276504E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.105"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.105""}]},{""@id"":""https://pharmgkb.org/literature/8231172"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":8231172.0,""resourceId"":""21716271"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234301"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3234301"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44925064E9,""resource"":""PubMed Central"",""resourceId"":""PMC3234301"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234301""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/21716271"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":8.2769289E8,""resource"":""PubMed"",""resourceId"":""21716271"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21716271""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.132"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449250641E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.132"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.132""}]},{""@id"":""https://pharmgkb.org/literature/15100915"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100915E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"",""title"":""CPIC® Guideline for Clopidogrel and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44798349E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449053"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449053"",""name"":""clopidogrel""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447981866E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy (e.g., prasugrel, ticagrelor) for CYP2C19 poor or intermediate metabolizers if there is no contraindication.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981865E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for clopidogrel and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""september-2013-update\""\u003eSeptember 2013 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication May 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2013 update of CPIC guidelines regarding clopidogrel have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e. Literature published between 1966 to January 2013 was reviewed. The updated therapeutic recommendations are more focused to patients with acute coronary syndromes undergoing percutaneous coronary intervention (ACS/PCI) than the original guideline, with additional updates involve refined recommendations for variant and novel \u003cem\u003eCYP2C19\u003c/em\u003e alleles beyond *2.\u003c/li\u003e\n\u003cli\u003eAt the time of the development of this recommendation, there are no data available on the possible role of CYP2C19 in clopidogrel response in pediatric patient populations; however, there is no reason to suspect that CYP2C19 variant alleles would affect clopidogrel metabolism differently in children as compared with adults.\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/clopidogrel/2013/23698643.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/clopidogrel/2013/23698643-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-antiplatelet-therapy-recommendations-based-on-cyp2c19-status-when-considering-clopidogrel-for-acs-patients-undergoing-pci\""\u003eTable 1: Antiplatelet therapy recommendations based on CYP2C19 status when considering clopidogrel for ACS patients undergoing PCI\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2013 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications for clopidogrel\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer (UM) (~5-30% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased activity alleles (*17) or one functional allele (*1) plus one increased activity allele (*17)\u003c/td\u003e\u003ctd\u003e*1/*17, *17/*17\u003c/td\u003e\u003ctd\u003eIncreased platelet inhibition; decreased residual platelet aggregation \u003csup\u003e1\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eClopidogrel - label recommended dosage and administration\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eExtensive metabolizer (EM) (~35-50% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying two functional (*1) alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal platelet inhibition; normal residual platelet aggregation\u003c/td\u003e\u003ctd\u003eClopidogrel - label recommended dosage and administration\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer (IM) (~18-45% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying one functional allele (*1) plus one loss-of-function allele (*2-*8) or one loss-of-function allele (*2-*8) plus one increased activity allele (*17) \u003csup\u003e2\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3, *2/*17\u003c/td\u003e\u003ctd\u003eReduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events\u003c/td\u003e\u003ctd\u003eAlternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizer (PM) (~2-15% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying two loss-of-function alleles (*2-*8)\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eSignificantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events\u003c/td\u003e\u003ctd\u003eAlternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003e1\u003c/sup\u003e The CYP2C19*17 allele (\u003ca href\u003d\""/variant/PA166154147\""\u003ers12248560\u003c/a\u003e) may be associated with increased risk of bleeding.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e2\u003c/sup\u003e The predicted metabolizer phenotype for *2-*8/*17 genotypes are provisional classifications. The currently available evidence indicates that the *17 gain-of-function allele is unable to completely compensate for the *2 loss-of-function allele [Article:\u003ca href\u003d\""/pmid/20492469\""\u003e20492469\u003c/a\u003e]; however, this data has not been consistently replicated and is therefore a provisional classification (Table S5).\u003c/p\u003e\n\u003cp\u003eAn important caveat for all genotyping tests is that the \u0026quot;wild-type\u0026quot; (*1) status is reported if all other alleles that are measured are absent.  Some genotype tests do not interrogate the rare loss of function alleles and therefore, if present, they may be erroneously reported as \u0026quot;wild type\u0026quot;. Furthermore, in human DNA, it is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation may confer altered enzyme function in an individual, and thus lead to the rare possibility of a loss-of-function allele being erroneously called as \u0026quot;wild-type\u0026quot; (*1). The guidelines do not focus on demographic and other clinical variables, such as adherence to therapy, age, diabetes mellitus, obesity, smoking, and concomitant use of other drugs that may influence clopidogrel efficacy and clinical decision making.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eThe American Society of Health-System Pharmacists (ASHP) has endorsed the Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.\u003c/strong\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""august-2011\""\u003eAugust 2011\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication June 2011.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for clopidogrel were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/clopidogrel/2011/21716271.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/clopidogrel/2011/21716271-supplement.pdf\"" target\u003d\""_blank\""\u003e2011 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44798349E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/""}]},""status"":""success""}"
PA166104994,Guideline Annotation,Annotation of DPWG Guideline for doxepin and CYP2D6,t,PA449409,Dutch Pharmacogenetics Working Group,"<p>The Dutch Pharmacogenetics Working Group Guideline for doxepin recommends dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for doxepin based on CYP2D6 genotype. They recommend dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>doxepin</td><td>The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites.</td><td>Double the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic. If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</td></tr>
<tr><td>CYP2D6 IM</td><td>doxepin</td><td>The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin.</td><td>Use 80% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</td></tr>
<tr><td>CYP2D6 PM</td><td>doxepin</td><td>The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin.</td><td>Use 40% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002016.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for doxepin based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend lower dose for patients carrying the poor metabolizer (PM) alleles and intermediate metabolizer alleles and alternative drug for patients carrying the ultrarapid metabolizer (UM) allleles.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Reduce dose by 60%. Adjust maintenance dose in response to (nor)doxepin plasma concentration</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Reduce dose by 20%. Adjust maintenance dose in response to (nor)doxepin plasma concentration.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5 Kinetic effect (S)</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Select alternative drug (citalopram, sertraline) or increase dose by 100%. Adjust maintenance dose in response to (nor)doxepin plasma concentration.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5 Kinetic effect (S).</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods</a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104994"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104994"",""name"":""Annotation of DPWG Guideline for doxepin and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704462E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415095E9,""date"":""2019-05-23T20:53:50.845-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820793E9,""date"":""2019-10-06T23:19:47.375-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956361E9,""date"":""2020-01-31T13:27:11.803-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096286E9,""date"":""2020-02-10T11:22:54.014-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449409"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449409"",""name"":""doxepin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.44798202E9,""html"":""\u003cp\u003eThe Dutch Pharmacogenetics Working Group Guideline for doxepin recommends dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982019E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for doxepin based on CYP2D6 genotype. They recommend dose changes and to monitor the effect and side effects or the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid doxepin in UM.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003edoxepin\u003c/td\u003e\u003ctd\u003eThe risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of doxepin and the active metabolite nordoxepin and an increase in the plasma concentrations of the potentially cardiotoxic hydroxy metabolites.\u003c/td\u003e\u003ctd\u003eDouble the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic. If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid doxepin. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003edoxepin\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin.\u003c/td\u003e\u003ctd\u003eUse 80% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003edoxepin\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of doxepin and the active metabolite nordoxepin.\u003c/td\u003e\u003ctd\u003eUse 40% of the standard dose and monitor the effect and side effects or the plasma concentrations of doxepin and nordoxepin in order to set the maintenance dose. The therapeutic range is 100-250 ng/mL for the sum of doxepin and nordoxepin plasma concentrations. Values higher than 400 ng/mL are considered toxic.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002016.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for doxepin based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend lower dose for patients carrying the poor metabolizer (PM) alleles and intermediate metabolizer alleles and alternative drug for patients carrying the ultrarapid metabolizer (UM) allleles.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eReduce dose by 60%. Adjust maintenance dose in response to (nor)doxepin plasma concentration\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eReduce dose by 20%. Adjust maintenance dose in response to (nor)doxepin plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5 Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eSelect alternative drug (citalopram, sertraline) or increase dose by 100%. Adjust maintenance dose in response to (nor)doxepin plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5 Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods\u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166184526,Guideline Annotation,Annotation of DPWG Guideline for amitriptyline and CYP2C19,f,PA448385,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for amitriptyline based on CYP2C19 genotype.</p>
","<h3 id=""august-2019-guideline"">August 2019 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for amitriptyline based on CYP2C19 genotype. They conclude that NO action is required for this gene-drug interaction, (see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>).</p>
<p>For CYP2C19 IM and PM, the gene variation has an effect on the exposure to amitriptyline, but not on the exposure to amitriptyline + the active metabolite nortriptyline, which determines the effect and side effects. For CYP2C19 UM, the gene variation decreases the exposure to amitriptyline and increases the exposure to the active metabolite nortriptyline, but there is no evidence to indicate that this results in an increase in side effects or a decrease in efficacy. A higher dose is required to achieve the therapeutic range of amitriptyline+nortriptyline, but the therapeutic range of nortriptyline is achieved at the lower dose.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0007026.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166184526"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166184526"",""name"":""Annotation of DPWG Guideline for amitriptyline and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450820764E9,""date"":""2019-10-06T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450820765E9,""date"":""2019-10-06T00:00:00-07:00"",""description"":""August 2019 guideline"",""type"":""Create"",""version"":0.0},{""id"":1.450962521E9,""date"":""2020-02-10T08:45:00.519-08:00"",""description"":""Fixed links to 2019 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448385"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448385"",""name"":""amitriptyline""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450820762E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for amitriptyline based on CYP2C19 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450820763E9,""html"":""\u003ch3 id\u003d\""august-2019-guideline\""\u003eAugust 2019 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for amitriptyline based on CYP2C19 genotype. They conclude that NO action is required for this gene-drug interaction, (see the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eFor CYP2C19 IM and PM, the gene variation has an effect on the exposure to amitriptyline, but not on the exposure to amitriptyline + the active metabolite nortriptyline, which determines the effect and side effects. For CYP2C19 UM, the gene variation decreases the exposure to amitriptyline and increases the exposure to the active metabolite nortriptyline, but there is no evidence to indicate that this results in an increase in side effects or a decrease in efficacy. A higher dose is required to achieve the therapeutic range of amitriptyline+nortriptyline, but the therapeutic range of nortriptyline is achieved at the lower dose.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0007026.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104937,Guideline Annotation,Annotation of DPWG Guideline for aripiprazole and CYP2D6,t,PA10026,Dutch Pharmacogenetics Working Group,"<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for aripiprazole based on CYP2D6 genotype. They recommend reducing maximum dose of aripiprazole for CYP2D6 poor metabolizer (PM).</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>aripiprazole</td><td>-</td><td>NO action is needed for this gene-drug interaction. The genetic variation decreases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is no evidence that this increases the risk of reduced effectiveness.</td></tr>
<tr><td>CYP2D6 IM</td><td>aripiprazole</td><td>-</td><td>NO action is needed for this gene-drug interaction.The genetic variation increases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is insufficient evidence that this increases the risk of side effects.</td></tr>
<tr><td>CYP2D6 PM</td><td>aripiprazole</td><td>The risk of side effects is increased. The genetic variation leads to an increase in the sum of the plasma concentrations of aripiprazole and the active metabolite.</td><td>Administer no more than 10 mg/day or 300 mg/month (67-75% of the standard maximum dose of aripiprazole).</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001543.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for aripiprazole based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Reduce maximum dose to 10 mg/day (67% of the maximum recommended daily dose).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>No recommendations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5; Kinetic effect (S)</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>No recommendations.</td><td>--</td><td>--</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/aripiprazole_CYP2D6_271111.pdf"">Aripiprazole CYP2D6 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104937"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104937"",""name"":""Annotation of DPWG Guideline for aripiprazole and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704443E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415078E9,""date"":""2019-05-23T17:15:21.564-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820766E9,""date"":""2019-10-06T21:23:26.334-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956222E9,""date"":""2020-01-31T13:17:30.920-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096258E9,""date"":""2020-02-10T08:56:52.239-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10026"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10026"",""name"":""aripiprazole""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981884E9,""html"":""\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981883E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for aripiprazole based on CYP2D6 genotype. They recommend reducing maximum dose of aripiprazole for CYP2D6 poor metabolizer (PM).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003earipiprazole\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction. The genetic variation decreases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is no evidence that this increases the risk of reduced effectiveness.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003earipiprazole\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.The genetic variation increases the plasma concentration of the sum of aripiprazole and the active metabolite dehydroaripiprazole to a limited degree. There is insufficient evidence that this increases the risk of side effects.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003earipiprazole\u003c/td\u003e\u003ctd\u003eThe risk of side effects is increased. The genetic variation leads to an increase in the sum of the plasma concentrations of aripiprazole and the active metabolite.\u003c/td\u003e\u003ctd\u003eAdminister no more than 10 mg/day or 300 mg/month (67-75% of the standard maximum dose of aripiprazole).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001543.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for aripiprazole based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eReduce maximum dose to 10 mg/day (67% of the maximum recommended daily dose).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eNo recommendations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5; Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eNo recommendations.\u003c/td\u003e\u003ctd\u003e--\u003c/td\u003e\u003ctd\u003e--\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/aripiprazole_CYP2D6_271111.pdf\""\u003eAripiprazole CYP2D6 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166128738,Guideline Annotation,Annotation of CPIC Guideline for atazanavir and UGT1A1,t,PA10251,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC dosing guideline recommends considering advising individuals who carry two decreased function <em>UGT1A1</em> alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function <em>UGT1A1</em> alleles, respectively.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"" target=""_blank"">CPIC&reg; guideline for atazanavir and UGT1A1</a>.</p>
<h3 id=""april-2016"">April 2016</h3>
<p><em>Advance online publication September 2015</em></p>
<ul>
<li>
<p>Guidelines regarding the use of pharmacogenomic tests in determining whether atazanavir treatment should be undertaken have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</p>
</li>
<li>
<p>These guidelines are applicable to:</p>
<ul>
<li>Adults</li>
<li>At the time of this writing there are no pediatric data regarding associations between <em>UGT1A1</em> genotypes and likelihood of bilirubin-related discontinuation of atazanavir. However, <em>UGT1A1</em> genotypes are expected to affect atazanavir-related hyperbilirubinemia similarly in adults and children. Therefore, recommendations for adults may be directly adapted to pediatric patients.</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Atazanavir and <em>UGT1A1</em> Prescribing</a>.</li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955-supplement.pdf"" target=""_blank"">2015 Supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955-UGT1A1_allele_frequency.xlsx"" target=""_blank"">UGT1A1 Allele Frequencies</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-therapeutic-use-of-atazanavir-based-on-ugt1a1-genotype"">Table 1: Recommended therapeutic use of atazanavir based on <em>UGT1A1</em> genotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2015 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for atazanavir therapy</th><th>Classification of recommendation for atazanavir therapy</th></tr>
</thead>
<tbody>
<tr><td>Extensive Metabolizer</td><td>An individual carrying 2 reference <sup>b</sup> function and/or increased function alleles; or individuals of genotype CC at <a href=""/variant/PA166155607"">rs887829</a></td><td>*1/*1; *1/*36; *36/*36; <a href=""/variant/PA166155607"">rs887829</a> CC</td><td>Reference <sup>c</sup> UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.</td><td>There is no need to avoid prescribing of atazanavir based on <em>UGT1A1</em> genetic test result.</td><td>Strong</td></tr>
<tr><td>Intermediate Metabolizer</td><td>An individual carrying one reference <sup>b</sup> function (*1) <sup>c</sup> or increased function allele (*36) plus one decreased function allele (*6, *28, *37). Alternatively identified by heterozygosity for <a href=""/variant/PA166155607"">rs887829</a> C/T.</td><td>*1/*28; *1/*37; *36/*28; *36/*37; <a href=""/variant/PA166155607"">rs887829</a> C/T, *1/*6</td><td>Somewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir.</td><td>There is no need to avoid prescribing of atazanavir based on <em>UGT1A1</em> genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely</td><td>Strong</td></tr>
<tr><td>Poor Metabolizer</td><td>An individual carrying two decreased function alleles (*6, *28, *37). Alternatively identified by homozygosity for <a href=""/variant/PA166155607"">rs887829</a> T/T (*80/*80)</td><td>*28/*28; *28/*37; *37/*37; <a href=""/variant/PA166155607"">rs887829</a> T/T (*80/*80), *6/*6 <sup>a</sup></td><td>Markedly decreased UGT1A1 activity; high likelihood of bilirubin-related discontinuation of atazanavir.</td><td>Consider an alternative agent particularly where jaundice would be of concern to the patient.</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> Homozygosity for UGT1A1*6, which occurs almost exclusively in individuals of Asian descent, is associated with Gilbert syndrome. However, at this time, it is unclear if patients with this diplotype are at increased risk of severe atazanavir-associated hyperbilirubinemia.</p>
<p><sup>b</sup> “reference” function refers to the UGT1A1 alleles to which other alleles are compared.</p>
<p><sup>c</sup> The reference function *1 allele is a fully functional refers to the <a href=""/variant/PA166159020"">rs8175347</a> TA6 allele.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166128738"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166128738"",""name"":""Annotation of CPIC Guideline for atazanavir and UGT1A1"",""cancerGenome"":false,""descriptiveVideoId"":""PPOa3z0wIYo"",""guidelineGenes"":[{""id"":1.449560756E9,""alleles"":[{""id"":1.449560757E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558337"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558337E9,""resource"":""Allele Function"",""term"":""Extensive Metabolizer"",""termId"":""haplotypeTags:1445558337""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115841"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115841"",""symbol"":""UGT1A1*1"",""name"":""*1""}},{""id"":1.449560758E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558339"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558339E9,""resource"":""Allele Function"",""term"":""Poor Metabolizer"",""termId"":""haplotypeTags:1445558339""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115842"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115842"",""symbol"":""UGT1A1*28"",""name"":""*28""}},{""id"":1.449560759E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558337"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558337E9,""resource"":""Allele Function"",""term"":""Extensive Metabolizer"",""termId"":""haplotypeTags:1445558337""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115843"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115843"",""symbol"":""UGT1A1*36"",""name"":""*36""}},{""id"":1.44956076E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558339"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558339E9,""resource"":""Allele Function"",""term"":""Poor Metabolizer"",""termId"":""haplotypeTags:1445558339""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115844"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115844"",""symbol"":""UGT1A1*37"",""name"":""*37""}},{""id"":1.449560761E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115845"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115845"",""symbol"":""UGT1A1*60"",""name"":""*60""}},{""id"":1.449560762E9,""_label"":""*80"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558339"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558339E9,""resource"":""Allele Function"",""term"":""Poor Metabolizer"",""termId"":""haplotypeTags:1445558339""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115850"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115850"",""symbol"":""UGT1A1*80"",""name"":""*80""}},{""id"":1.449560763E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558339"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558339E9,""resource"":""Allele Function"",""term"":""Poor Metabolizer"",""termId"":""haplotypeTags:1445558339""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115858"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115858"",""symbol"":""UGT1A1*6"",""name"":""*6""}},{""id"":1.449560764E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115865"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115865"",""symbol"":""UGT1A1*27"",""name"":""*27""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA420"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA420"",""symbol"":""UGT1A1"",""name"":""UDP glucuronosyltransferase 1 family, polypeptide A1""}}],""history"":[{""id"":1.446898242E9,""date"":""2015-09-18T00:00:00-07:00"",""type"":""Create"",""version"":1.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15093021"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5093021E7,""resourceId"":""26417955"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785051"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4785051"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449290642E9,""resource"":""PubMed Central"",""resourceId"":""PMC4785051"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785051""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/26417955"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449290641E9,""resource"":""PubMed"",""resourceId"":""26417955"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/26417955""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.269"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449290643E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.269"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.269""}]},{""@id"":""https://pharmgkb.org/literature/15100914"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100914E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"",""title"":""CPIC® Guideline for Atazanavir and UGT1A1 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983449E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10251"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10251"",""name"":""atazanavir""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA420"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA420"",""symbol"":""UGT1A1"",""name"":""UDP glucuronosyltransferase 1 family, polypeptide A1""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982423E9,""html"":""\u003cp\u003eThe CPIC dosing guideline recommends considering advising individuals who carry two decreased function \u003cem\u003eUGT1A1\u003c/em\u003e alleles about a substantial likelihood of developing jaundice, which may cause non-adherence. The dosing guideline recommends that alternative agents be considered if the risk of non-adherence due to jaundice is high. The risk of discontinuation is low and very low for individuals carrying one, or no decreased function \u003cem\u003eUGT1A1\u003c/em\u003e alleles, respectively.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982422E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for atazanavir and UGT1A1\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""april-2016\""\u003eApril 2016\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication September 2015\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in determining whether atazanavir treatment should be undertaken have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThese guidelines are applicable to:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdults\u003c/li\u003e\n\u003cli\u003eAt the time of this writing there are no pediatric data regarding associations between \u003cem\u003eUGT1A1\u003c/em\u003e genotypes and likelihood of bilirubin-related discontinuation of atazanavir. However, \u003cem\u003eUGT1A1\u003c/em\u003e genotypes are expected to affect atazanavir-related hyperbilirubinemia similarly in adults and children. Therefore, recommendations for adults may be directly adapted to pediatric patients.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Atazanavir and \u003cem\u003eUGT1A1\u003c/em\u003e Prescribing\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955-supplement.pdf\"" target\u003d\""_blank\""\u003e2015 Supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/atazanavir/2015/26417955-UGT1A1_allele_frequency.xlsx\"" target\u003d\""_blank\""\u003eUGT1A1 Allele Frequencies\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-therapeutic-use-of-atazanavir-based-on-ugt1a1-genotype\""\u003eTable 1: Recommended therapeutic use of atazanavir based on \u003cem\u003eUGT1A1\u003c/em\u003e genotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2015 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications for phenotypic measures\u003c/th\u003e\u003cth\u003eRecommendations for atazanavir therapy\u003c/th\u003e\u003cth\u003eClassification of recommendation for atazanavir therapy\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eExtensive Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying 2 reference \u003csup\u003eb\u003c/sup\u003e function and/or increased function alleles; or individuals of genotype CC at \u003ca href\u003d\""/variant/PA166155607\""\u003ers887829\u003c/a\u003e\u003c/td\u003e\u003ctd\u003e*1/*1; *1/*36; *36/*36; \u003ca href\u003d\""/variant/PA166155607\""\u003ers887829\u003c/a\u003e CC\u003c/td\u003e\u003ctd\u003eReference \u003csup\u003ec\u003c/sup\u003e UGT1A1 activity; very low likelihood of bilirubin-related discontinuation of atazanavir.\u003c/td\u003e\u003ctd\u003eThere is no need to avoid prescribing of atazanavir based on \u003cem\u003eUGT1A1\u003c/em\u003e genetic test result.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one reference \u003csup\u003eb\u003c/sup\u003e function (*1) \u003csup\u003ec\u003c/sup\u003e or increased function allele (*36) plus one decreased function allele (*6, *28, *37). Alternatively identified by heterozygosity for \u003ca href\u003d\""/variant/PA166155607\""\u003ers887829\u003c/a\u003e C/T.\u003c/td\u003e\u003ctd\u003e*1/*28; *1/*37; *36/*28; *36/*37; \u003ca href\u003d\""/variant/PA166155607\""\u003ers887829\u003c/a\u003e C/T, *1/*6\u003c/td\u003e\u003ctd\u003eSomewhat decreased UGT1A1 activity; low likelihood of bilirubin-related discontinuation of atazanavir.\u003c/td\u003e\u003ctd\u003eThere is no need to avoid prescribing of atazanavir based on \u003cem\u003eUGT1A1\u003c/em\u003e genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient’s genotype makes this unlikely\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two decreased function alleles (*6, *28, *37). Alternatively identified by homozygosity for \u003ca href\u003d\""/variant/PA166155607\""\u003ers887829\u003c/a\u003e T/T (*80/*80)\u003c/td\u003e\u003ctd\u003e*28/*28; *28/*37; *37/*37; \u003ca href\u003d\""/variant/PA166155607\""\u003ers887829\u003c/a\u003e T/T (*80/*80), *6/*6 \u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eMarkedly decreased UGT1A1 activity; high likelihood of bilirubin-related discontinuation of atazanavir.\u003c/td\u003e\u003ctd\u003eConsider an alternative agent particularly where jaundice would be of concern to the patient.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Homozygosity for UGT1A1*6, which occurs almost exclusively in individuals of Asian descent, is associated with Gilbert syndrome. However, at this time, it is unclear if patients with this diplotype are at increased risk of severe atazanavir-associated hyperbilirubinemia.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e “reference” function refers to the UGT1A1 alleles to which other alleles are compared.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The reference function *1 allele is a fully functional refers to the \u003ca href\u003d\""/variant/PA166159020\""\u003ers8175347\u003c/a\u003e TA6 allele.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983449E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/""}]},""status"":""success""}"
PA166182822,Guideline Annotation,Annotation of DPWG Guideline for atenolol and CYP2D6,f,PA448499,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for atenolol based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atenolol based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002453.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182822"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182822"",""name"":""Annotation of DPWG Guideline for atenolol and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415082E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.450820767E9,""date"":""2019-10-06T21:28:41.452-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.4509626E9,""date"":""2020-02-10T09:34:52.409-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448499"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448499"",""name"":""atenolol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.45041508E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for atenolol based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415081E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atenolol based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002453.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166181885,Guideline Annotation,Annotation of CPIC Guideline for atomoxetine and CYP2D6,t,PA134688071,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy.</p>
","<p>This annotation is based on the CPIC&reg; guideline for <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"" target=""_blank"">atomoxetine and CYP2D6</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table, Atomoxetine pre- and post-test alerts and flow chart (access tables below):</p>
<ul>
<li>Activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The current guideline has a specific recommendation for AS of 1 (no CYP2D6*10 allele present); thus, the current published recommendations for normal and intermediate metabolizer will remain unchanged.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The recommendations for ultrarapid and normal metabolizers are the same so this change does not impact the recommended prescribing recommendations. The recommendations for the activity score of 1 (with a CYP2D6*10 allele present) and 0.5 are the same so the current published recommendations for this diplotype will remain unchanged.</li>
</ul>
</li>
</ul>
<h3 id=""february-2018"">February 2018</h3>
<p><em>Advance online publication February 2019</em></p>
<ul>
<li>The CPIC guidelines regarding the use of pharmacogenomic tests in dosing of atomoxetine have been published in <em>Clinical Pharmacology and Therapeutics</em> by the Clinical Pharmacogenetics Implementation Consortium (CPIC).</li>
<li>These guidelines are applicable to:
<ul>
<li>pediatric patients</li>
<li>adult patients</li>
</ul>
</li>
<li>Excerpts from the 2019 dosing guideline:
<ul>
<li>&quot;CYP2D6 genetic variation has a profound effect on atomoxetine pharmacokinetics. .... Atomoxetine exposure (AUC) is, on average, 10-fold higher in CYP2D6 PMs compared to non-PMs. .... Individuals with two CYP2D6*10 alleles had higher atomoxetine exposure (5-fold higher peak concentration) when compared to individuals with at least one normal function allele.&quot;</li>
<li>&quot;The most well studied pharmacokinetic parameter for atomoxetine relates plasma drug concentrations that approximate the Cmax of the parent compound to reduction of ADHD symptoms. Given this evidence, the therapeutic recommendation for each CYP2D6 phenotype class also includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure (i.e. exposure check). These target reference values are from the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology [Article:<a href=""/pmid/29493375"">29493375</a>], and are meant to guide the clinician in the event that patient response to atomoxetine is inadequate.&quot;</li>
<li>&quot;Data from both in vitro and in vivo studies (supplemental table 1), as well as consensus recommendations were used in formulating the guidance.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/atomoxetine/2019/30801677.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Atomoxetine Therapy</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/atomoxetine/2019/30801677-supplement.pdf"" target=""_blank"">2019 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">Gene-specific Information Tables for CYP2D6</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/atomoxetine/Atomoxetine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Atomoxetine drug resource mapping</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/atomoxetine/atomoxetine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Atomoxetine pre- and post-test alerts and flow chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-atomoxetine-by-cyp2d6-genotype-phenotype-for-children"">Table 1: Recommended dosing of atomoxetine by CYP2D6 genotype/phenotype for children.</h3>
<p><em>Adapted from Tables 1 and 2 of the 2019 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype<sup>a</sup></th><th>Activity Score</th><th>Genotype</th><th>Examples of genotypes<sup>b</sup></th><th>Implications</th><th>Therapeutic recommendations</th><th>Classification of recommendations<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td><em>CYP2D6</em> Ultrarapid Metabolizer</td><td>&gt;2</td><td>An individual carrying duplications of functional alleles</td><td>*1/*1xN, *1/*2xN, *2/*2xN<sup>d</sup></td><td>Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.</td><td>Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.<sup>e,f</sup></td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Normal metabolizer</td><td>1.5 and 2</td><td>An individual carrying two normal function alleles or one normal function and one decreased function allele</td><td>*1/*1, *1/*2, *1/*9, *1/*41, *2/*2</td><td>Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.</td><td>Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days.   If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.<sup>e,f</sup></td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Normal metabolizer or Intermediate metabolizer (controversy remains)<sup>g</sup></td><td>1 (no *10 allele present)<sup>h</sup></td><td>An individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased atomoxetine metabolism compared to those with an AS of 1.5 or 2.</td><td>*1/*4, *1/*5, *41/*41</td><td>Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Normal metabolizers may be at an increased risk of increased discontinuation as compared to poor metabolizers.</td><td>Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.<sup>e,f</sup></td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Normal metabolizer or Intermediate metabolizer (controversy remains)<sup>g</sup></td><td>1 (*10 allele present)<sup>h</sup></td><td>An individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased atomoxetine metabolism compared to those with an AS of 1.5 or 2.</td><td>*10/*10, *10/*41</td><td>Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of increased discontinuation as compared to poor metabolizers.</td><td>Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing.  If response is inadequate and concentration is &lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.<sup>e,f</sup> If unacceptable side effects are present at any time, consider a reduction in dose.</td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Intermediate metabolizer</td><td>0.5</td><td>An individual carrying one decreased function and one no function allele</td><td>*4/*10,*4/*41, *5/*9</td><td>Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers.</td><td>Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing.  If response is inadequate and concentration is &lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.<sup>e,f</sup> If unacceptable side effects are present at any time, consider a reduction in dose.</td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Poor metabolizer</td><td>0</td><td>An individual carrying only no functional alleles</td><td>*3/*4,*4/*4, *5/*5, *5/*6</td><td>Significantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may increase the occurrence of treatment-emergent side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers.</td><td>Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 h after dosing.  If response is inadequate and concentration is &lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.<sup>e,f</sup> If unacceptable side effects are present at any time, consider a reduction in dose.</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> See the CYP2D6 Frequency Table for race-specific allele and phenotype frequencies <a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 tables</a>.<br />
<sup>b</sup> Assignment of allele function and citations for allele function can be found in the CYP2D6 Allele Definition Table and CYP2D6 Allele Functionality Table. For a complete list of CYP2D6 diplotypes and resulting phenotypes, see the CYP2D6 Genotype to Phenotype Table <a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 tables</a>. Note that genotypes with an activity score of 1 are classified as NMs in the online CYP2D6 genotype to phenotype table.<br />
<sup>c</sup> Rating scheme described in Supplement.<br />
<sup>d</sup> Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.<br />
<sup>e</sup> Therapeutic range of 200 to 1000 ng/ml has been proposed [Article:<a href=""/pmid/29493375"">29493375</a>].<br />
<sup>f</sup> Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response.  Available information suggests that clinical response is greater in PMs compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose.  Furthermore, modest improvement in response, defined as reduction in ADHD-RS, is observed at peak concentrations greater than 400 ng/ml.<br />
<sup>g</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories. A group of CYP2D6 experts are currently working to standardize the CYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly.<br />
<sup>h</sup> CPIC has general classified patients with activity score of 1 as “normal metabolizer.” However, in the case of atomoxetine, prescribing recommendations for those with an AS of 1.0 are allele-dependent, based on the presence of the CYP2D6*10 allele.</p>
<h3 id=""table-2-recommended-dosing-of-atomoxetine-by-cyp2d6-genotype-phenotype-for-adults"">Table 2: Recommended dosing of atomoxetine by CYP2D6 genotype/phenotype for adults.</h3>
<p><em>Adapted from Tables 1 and 3 of the 2019 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype<sup>a</sup></th><th>Activity Score</th><th>Genotype</th><th>Examples of genotypes<sup>b</sup></th><th>Implications</th><th>Therapeutic recommendations</th><th>Classification of recommendations<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td><em>CYP2D6</em> Ultrarapid Metabolizer</td><td>&gt;2</td><td>An individual carrying duplications of functional alleles</td><td>*1/*1xN, *1/*2xN, *2/*2xN<sup>d</sup></td><td>Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.</td><td>Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.<sup>e,f</sup> Dosages greater than 100 mg/day may be needed to achieve target concentrations.<sup>g</sup></td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Normal metabolizer</td><td>1.5 and 2</td><td>An individual carrying two normal function alleles or one normal function and one decreased function allele</td><td>*1/*1, *1/*2, *1/*9, *1/*41, *2/*2</td><td>Normal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.</td><td>Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.<sup>e,f</sup> Dosages greater than 100 mg/day may be needed to achieve target concentrations.<sup>g</sup></td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Normal metabolizer or Intermediate metabolizer (controversy remains)<sup>h</sup></td><td>1 (no *10 allele present)<sup>i</sup></td><td>An individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased atomoxetine metabolism compared to those with an AS of 1.5 or 2.</td><td>*1/*4, *1/*5, *41/*41</td><td>Possibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Normal metabolizers may be at an increased risk of increased discontinuation as compared to poor metabolizers.</td><td>Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If &lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.<sup>e,f</sup> Dosages greater than 100 mg/day may be needed to achieve target concentrations.<sup>g</sup></td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Normal metabolizer or Intermediate metabolizer (controversy remains)<sup>h</sup></td><td>1 (*10 allele present)<sup>i</sup></td><td>An individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased atomoxetine metabolism compared to those with an AS of 1.5 or 2.</td><td>*10/*10, *10/*41</td><td>Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of increased discontinuation as compared to poor metabolizers.</td><td>Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is &lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.<sup>e,f</sup> If unacceptable side effects are present at any time, consider a reduction in dose.</td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Intermediate metabolizer</td><td>0.5</td><td>An individual carrying one decreased function and one no function allele</td><td>*4/*10,*4/*41, *5/*9</td><td>Decreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers.</td><td>Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is &lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.<sup>e,f</sup> If unacceptable side effects are present at any time, consider a reduction in dose.</td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Poor metabolizer</td><td>0</td><td>An individual carrying only no functional alleles</td><td>*3/*4,*4/*4, *5/*5, *5/*6</td><td>Significantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may increase the occurrence of treatment-emergent side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers.</td><td>Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is &lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.<sup>e,f</sup> If unacceptable side effects are present at any time, consider a reduction in dose.</td><td>Moderate</td></tr>
</tbody>
</table>
<p><sup>a</sup> See the CYP2D6 Frequency Table for race-specific allele and phenotype frequencies <a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 tables</a>.<br />
<sup>b</sup> Assignment of allele function and citations for allele function can be found in the CYP2D6 Allele Definition Table and CYP2D6 Allele Functionality Table. For a complete list of CYP2D6 diplotypes and resulting phenotypes, see the CYP2D6 Genotype to Phenotype Table <a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 tables</a>. Note that genotypes with an activity score of 1 are classified as NMs in the online CYP2D6 genotype to phenotype table.<br />
<sup>c</sup> Rating scheme described in Supplement.<br />
<sup>d</sup> Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.<br />
<sup>e</sup> Therapeutic range of 200 to 1000 ng/ml has been proposed [Article:<a href=""/pmid/29493375"">29493375</a>].<br />
<sup>f</sup> Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response.  Available information suggests that clinical response is greater in PMs compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose.  Furthermore, modest improvement in response, defined as reduction in ADHD-RS, is observed at peak concentrations greater than 400 ng/ml.<br />
<sup>g</sup> Doses above 120 mg/day have not been evaluated.<br />
<sup>h</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories. A group of CYP2D6 experts are currently working to standardize the CYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly.<br />
<sup>i</sup> CPIC has general classified patients with activity score of 1 as “normal metabolizer.” However, in the case of atomoxetine, prescribing recommendations for those with an AS of 1.0 are allele-dependent, based on the presence of the CYP2D6*10 allele.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166181885"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166181885"",""name"":""Annotation of CPIC Guideline for atomoxetine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":""b_FiVlMIWpE"",""guidelineGenes"":[{""id"":1.45036936E9,""alleles"":[{""id"":1.450369385E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.450369386E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.450369387E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.450369388E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.450369389E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.45036939E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.450369391E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.450369392E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.450369393E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.450369394E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.450369395E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.450369396E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.450369397E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.450369398E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.450369399E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.4503694E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.450369401E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}},{""id"":1.450369402E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.450369403E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.450369404E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.450369405E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.450369406E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.450369407E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.450369408E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.450369409E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.45036941E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.450369411E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.450369412E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.450369413E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.450369414E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.450369415E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.450369416E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.450369417E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.450369418E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.450369419E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.45036942E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.450369421E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.450369422E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.450369423E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.450369424E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.450369425E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.450369426E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.450369427E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.450369428E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.450369429E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.45036943E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.450369431E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.450369432E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.450369433E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.450369434E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.450369435E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.450369436E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.450369437E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.450369438E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.450369439E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.45036944E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.450369441E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.450369442E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.450369443E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.450369444E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.450369445E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.450369446E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.450369447E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.450369448E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.450369449E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.45036945E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.450369451E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.450369452E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.450369453E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.450369454E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.450369455E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.450369456E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.450369457E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.450369458E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.450369459E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.45036946E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.450369461E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.450369462E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.450369463E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.450369464E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.450369465E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.450369466E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.450369467E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.450369468E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.450369469E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.45036947E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.450369471E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.450369472E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.450369473E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.450369474E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.450369475E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.450369476E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.450369477E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.450369478E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.450369479E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.45036948E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.450369481E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.450369482E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.450369483E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.450369484E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.450369485E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.450369486E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.450369487E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.450369488E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.450369489E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.45036949E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.450369491E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.450369492E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.450369493E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.450369494E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.450369495E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.450369496E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.450369497E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.450369498E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.450369499E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.4503695E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.450369501E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.450369502E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450369503E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.450369524E9,""date"":""2019-02-25T00:00:00-08:00"",""type"":""Update"",""version"":0.0},{""id"":1.45080646E9,""date"":""2019-07-17T13:19:07.508-07:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":0.0},{""id"":1.450824541E9,""date"":""2019-10-24T19:54:01.124-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15101783"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5101783E7,""resourceId"":""30801677"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/30801677"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/30801677"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450369624E9,""resource"":""PubMed"",""resourceId"":""30801677"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/30801677""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1409"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450369625E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1409"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1409""}]},{""@id"":""https://pharmgkb.org/literature/15102221"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102221E7,""resourceId"":""https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"",""title"":""CPIC® Guideline for Atomoxetine based on CYP2D6 genotype – CPIC"",""_sameAs"":""https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450370711E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"",""_url"":""https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA134688071"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA134688071"",""name"":""atomoxetine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.450369184E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for atomoxetine provides therapeutic recommendations for CYP2D6 ultrarapid, normal, intermediate, and poor metabolizer, which includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure, if no clinical response and in the absence of adverse events after 2 weeks of therapy.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.450369185E9,""html"":""\u003cp\u003eThis annotation is based on the CPIC\u0026reg; guideline for \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/\"" target\u003d\""_blank\""\u003eatomoxetine and CYP2D6\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table, Atomoxetine pre- and post-test alerts and flow chart (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eActivity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The current guideline has a specific recommendation for AS of 1 (no CYP2D6*10 allele present); thus, the current published recommendations for normal and intermediate metabolizer will remain unchanged.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The recommendations for ultrarapid and normal metabolizers are the same so this change does not impact the recommended prescribing recommendations. The recommendations for the activity score of 1 (with a CYP2D6*10 allele present) and 0.5 are the same so the current published recommendations for this diplotype will remain unchanged.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""february-2018\""\u003eFebruary 2018\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication February 2019\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe CPIC guidelines regarding the use of pharmacogenomic tests in dosing of atomoxetine have been published in \u003cem\u003eClinical Pharmacology and Therapeutics\u003c/em\u003e by the Clinical Pharmacogenetics Implementation Consortium (CPIC).\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2019 dosing guideline:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;CYP2D6 genetic variation has a profound effect on atomoxetine pharmacokinetics. .... Atomoxetine exposure (AUC) is, on average, 10-fold higher in CYP2D6 PMs compared to non-PMs. .... Individuals with two CYP2D6*10 alleles had higher atomoxetine exposure (5-fold higher peak concentration) when compared to individuals with at least one normal function allele.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;The most well studied pharmacokinetic parameter for atomoxetine relates plasma drug concentrations that approximate the Cmax of the parent compound to reduction of ADHD symptoms. Given this evidence, the therapeutic recommendation for each CYP2D6 phenotype class also includes guidance for plasma drug concentration testing, as a means to estimate atomoxetine exposure (i.e. exposure check). These target reference values are from the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology [Article:\u003ca href\u003d\""/pmid/29493375\""\u003e29493375\u003c/a\u003e], and are meant to guide the clinician in the event that patient response to atomoxetine is inadequate.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Data from both in vitro and in vivo studies (supplemental table 1), as well as consensus recommendations were used in formulating the guidance.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/atomoxetine/2019/30801677.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Atomoxetine Therapy\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/atomoxetine/2019/30801677-supplement.pdf\"" target\u003d\""_blank\""\u003e2019 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eGene-specific Information Tables for CYP2D6\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/atomoxetine/Atomoxetine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eAtomoxetine drug resource mapping\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/atomoxetine/atomoxetine_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eAtomoxetine pre- and post-test alerts and flow chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-atomoxetine-by-cyp2d6-genotype-phenotype-for-children\""\u003eTable 1: Recommended dosing of atomoxetine by CYP2D6 genotype/phenotype for children.\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2019 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eActivity Score\u003c/th\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eExamples of genotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Ultrarapid Metabolizer\u003c/td\u003e\u003ctd\u003e\u0026gt;2\u003c/td\u003e\u003ctd\u003eAn individual carrying duplications of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN, *2/*2xN\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eBased on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If \u0026lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Normal metabolizer\u003c/td\u003e\u003ctd\u003e1.5 and 2\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or one normal function and one decreased function allele\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *1/*9, *1/*41, *2/*2\u003c/td\u003e\u003ctd\u003eNormal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days.   If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If \u0026lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Normal metabolizer or Intermediate metabolizer (controversy remains)\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1 (no *10 allele present)\u003csup\u003eh\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased atomoxetine metabolism compared to those with an AS of 1.5 or 2.\u003c/td\u003e\u003ctd\u003e*1/*4, *1/*5, *41/*41\u003c/td\u003e\u003ctd\u003ePossibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Normal metabolizers may be at an increased risk of increased discontinuation as compared to poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If \u0026lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Normal metabolizer or Intermediate metabolizer (controversy remains)\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1 (*10 allele present)\u003csup\u003eh\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased atomoxetine metabolism compared to those with an AS of 1.5 or 2.\u003c/td\u003e\u003ctd\u003e*10/*10, *10/*41\u003c/td\u003e\u003ctd\u003eDecreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of increased discontinuation as compared to poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing.  If response is inadequate and concentration is \u0026lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e If unacceptable side effects are present at any time, consider a reduction in dose.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Intermediate metabolizer\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased function and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*10,*4/*41, *5/*9\u003c/td\u003e\u003ctd\u003eDecreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2-4 h after dosing.  If response is inadequate and concentration is \u0026lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e If unacceptable side effects are present at any time, consider a reduction in dose.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Poor metabolizer\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no functional alleles\u003c/td\u003e\u003ctd\u003e*3/*4,*4/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eSignificantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may increase the occurrence of treatment-emergent side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 h after dosing.  If response is inadequate and concentration is \u0026lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e If unacceptable side effects are present at any time, consider a reduction in dose.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e See the CYP2D6 Frequency Table for race-specific allele and phenotype frequencies \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 tables\u003c/a\u003e.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e Assignment of allele function and citations for allele function can be found in the CYP2D6 Allele Definition Table and CYP2D6 Allele Functionality Table. For a complete list of CYP2D6 diplotypes and resulting phenotypes, see the CYP2D6 Genotype to Phenotype Table \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 tables\u003c/a\u003e. Note that genotypes with an activity score of 1 are classified as NMs in the online CYP2D6 genotype to phenotype table.\u003cbr /\u003e\n\u003csup\u003ec\u003c/sup\u003e Rating scheme described in Supplement.\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003e Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.\u003cbr /\u003e\n\u003csup\u003ee\u003c/sup\u003e Therapeutic range of 200 to 1000 ng/ml has been proposed [Article:\u003ca href\u003d\""/pmid/29493375\""\u003e29493375\u003c/a\u003e].\u003cbr /\u003e\n\u003csup\u003ef\u003c/sup\u003e Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response.  Available information suggests that clinical response is greater in PMs compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose.  Furthermore, modest improvement in response, defined as reduction in ADHD-RS, is observed at peak concentrations greater than 400 ng/ml.\u003cbr /\u003e\n\u003csup\u003eg\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories. A group of CYP2D6 experts are currently working to standardize the CYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly.\u003cbr /\u003e\n\u003csup\u003eh\u003c/sup\u003e CPIC has general classified patients with activity score of 1 as “normal metabolizer.” However, in the case of atomoxetine, prescribing recommendations for those with an AS of 1.0 are allele-dependent, based on the presence of the CYP2D6*10 allele.\u003c/p\u003e\n\u003ch3 id\u003d\""table-2-recommended-dosing-of-atomoxetine-by-cyp2d6-genotype-phenotype-for-adults\""\u003eTable 2: Recommended dosing of atomoxetine by CYP2D6 genotype/phenotype for adults.\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3 of the 2019 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eActivity Score\u003c/th\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eExamples of genotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Ultrarapid Metabolizer\u003c/td\u003e\u003ctd\u003e\u0026gt;2\u003c/td\u003e\u003ctd\u003eAn individual carrying duplications of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN, *2/*2xN\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eBased on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If \u0026lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e Dosages greater than 100 mg/day may be needed to achieve target concentrations.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Normal metabolizer\u003c/td\u003e\u003ctd\u003e1.5 and 2\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or one normal function and one decreased function allele\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *1/*9, *1/*41, *2/*2\u003c/td\u003e\u003ctd\u003eNormal metabolizers of atomoxetine have a lower likelihood of response as compared to poor metabolizers. This is associated with increased discontinuation due to lack of efficacy as compared to poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If \u0026lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e Dosages greater than 100 mg/day may be needed to achieve target concentrations.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Normal metabolizer or Intermediate metabolizer (controversy remains)\u003csup\u003eh\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1 (no *10 allele present)\u003csup\u003ei\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased atomoxetine metabolism compared to those with an AS of 1.5 or 2.\u003c/td\u003e\u003ctd\u003e*1/*4, *1/*5, *41/*41\u003c/td\u003e\u003ctd\u003ePossibly higher atomoxetine concentrations as compared to normal metabolizers but questionable clinical significance. Normal metabolizers may be at an increased risk of increased discontinuation as compared to poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If \u0026lt;200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e Dosages greater than 100 mg/day may be needed to achieve target concentrations.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Normal metabolizer or Intermediate metabolizer (controversy remains)\u003csup\u003eh\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1 (*10 allele present)\u003csup\u003ei\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased atomoxetine metabolism compared to those with an AS of 1.5 or 2.\u003c/td\u003e\u003ctd\u003e*10/*10, *10/*41\u003c/td\u003e\u003ctd\u003eDecreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Individuals with activity score of 1.0 with CYP2D6*10 may be at an increased risk of increased discontinuation as compared to poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is \u0026lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e If unacceptable side effects are present at any time, consider a reduction in dose.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Intermediate metabolizer\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased function and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*10,*4/*41, *5/*9\u003c/td\u003e\u003ctd\u003eDecreased metabolism of atomoxetine and higher atomoxetine concentrations as compared to normal metabolizers. Intermediate metabolizers may be at an increased risk of discontinuation as compared to poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is \u0026lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e If unacceptable side effects are present at any time, consider a reduction in dose.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Poor metabolizer\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no functional alleles\u003c/td\u003e\u003ctd\u003e*3/*4,*4/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eSignificantly decreased metabolism of atomoxetine may result in higher concentrations as compared to non-poor metabolizers. This may increase the occurrence of treatment-emergent side effects, but also a greater improvement of ADHD symptoms as compared to non-poor metabolizers in those who tolerate treatment. Poor metabolizer status is associated with lower final dose requirements as compared to non-poor metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is \u0026lt;200 ng/ml, consider a proportional dose increase to achieve a concentration to approach 400 ng/ml.\u003csup\u003ee,f\u003c/sup\u003e If unacceptable side effects are present at any time, consider a reduction in dose.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e See the CYP2D6 Frequency Table for race-specific allele and phenotype frequencies \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 tables\u003c/a\u003e.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e Assignment of allele function and citations for allele function can be found in the CYP2D6 Allele Definition Table and CYP2D6 Allele Functionality Table. For a complete list of CYP2D6 diplotypes and resulting phenotypes, see the CYP2D6 Genotype to Phenotype Table \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 tables\u003c/a\u003e. Note that genotypes with an activity score of 1 are classified as NMs in the online CYP2D6 genotype to phenotype table.\u003cbr /\u003e\n\u003csup\u003ec\u003c/sup\u003e Rating scheme described in Supplement.\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003e Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.\u003cbr /\u003e\n\u003csup\u003ee\u003c/sup\u003e Therapeutic range of 200 to 1000 ng/ml has been proposed [Article:\u003ca href\u003d\""/pmid/29493375\""\u003e29493375\u003c/a\u003e].\u003cbr /\u003e\n\u003csup\u003ef\u003c/sup\u003e Limited data are available regarding the relationship between atomoxetine plasma concentrations and clinical response.  Available information suggests that clinical response is greater in PMs compared to non-PMs and may be related to the higher plasma concentrations 1 to 1.5 hours after dosing in PMs compared to non-PMs administered a similar dose.  Furthermore, modest improvement in response, defined as reduction in ADHD-RS, is observed at peak concentrations greater than 400 ng/ml.\u003cbr /\u003e\n\u003csup\u003eg\u003c/sup\u003e Doses above 120 mg/day have not been evaluated.\u003cbr /\u003e\n\u003csup\u003eh\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories. A group of CYP2D6 experts are currently working to standardize the CYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly.\u003cbr /\u003e\n\u003csup\u003ei\u003c/sup\u003e CPIC has general classified patients with activity score of 1 as “normal metabolizer.” However, in the case of atomoxetine, prescribing recommendations for those with an AS of 1.0 are allele-dependent, based on the presence of the CYP2D6*10 allele.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450370711E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"",""_url"":""https://cpicpgx.org/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/""}]},""status"":""success""}"
PA166104989,Guideline Annotation,Annotation of DPWG Guideline for atomoxetine and CYP2D6,t,PA134688071,Dutch Pharmacogenetics Working Group,"<p>The Dutch Pharmacogenetics Working Group Guideline for atomoxetine states for CYP2D6 ultrarapid metabolizers, to be alert to reduced efficacy of atomoxetine or select an alternative drug as a precaution.  Be alert to ADEs in CYP2D6 poor metabolizers.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atomoxetine based on CYP2D6 genotype.</p>
<p><em>Wording in table taken from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>atomoxetine</td><td>The genetic variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As the plasma concentration of the active ingredients decreases as a result, this gene variation can result in reduced efficacy.</td><td>1. Be extra alert to reduced efficacy of the treatment.<br/>2. Advise the patient to contact their doctor in the event of inadequate effect.<br/>3. An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.</td></tr>
<tr><td>CYP2D6 IM</td><td>atomoxetine</td><td>The genetic variation increases the plasma concentration of atomoxetine and can thereby reduce the dose requirement.</td><td>1. In the event of side effects occurring and/or a response later than 9weeks: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 2-3 times higher for IM than for EM at the same dose.</td></tr>
<tr><td>CYP2D6 PM</td><td>atomoxetine</td><td>The genetic variation increases the plasma concentration of atomoxetine and thereby the risk of side effects.</td><td>1. Start with the normal initial dose, bearing in mind that an increase in this dose probably will not be required.<br/>2. Advise the patient to seek contact if side effects occur (such as decreased appetite, vomiting, abdominal pain, constipation, insomnia, early waking, drowsiness, irritability, pupil dilation and itching).<br/>3. If the medicine is effective, but side effects occur: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 8-11 times higher for PM than for EM at the same dose.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001598.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atomoxetine based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Standard dose. Dose increase probably not necessary; be alert to ADEs.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>No recommendations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5; Kinetic effect (S).</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Insufficient data to allow calculation of dose adjustment. Be alert to reduced efficacy or select alternative drug (e.g., methylphenidate, clonidine).</td><td>--</td><td>--</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/atomoxetine_CYP2D6_271111.pdf"">Atomoxetine CYP2D6 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104989"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104989"",""name"":""Annotation of DPWG Guideline for atomoxetine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704445E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415084E9,""date"":""2019-05-23T18:13:59.398-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820769E9,""date"":""2019-10-06T21:32:37.139-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956263E9,""date"":""2020-01-31T13:18:06.104-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450962601E9,""date"":""2020-02-10T09:44:37.440-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA134688071"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA134688071"",""name"":""atomoxetine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982E9,""html"":""\u003cp\u003eThe Dutch Pharmacogenetics Working Group Guideline for atomoxetine states for CYP2D6 ultrarapid metabolizers, to be alert to reduced efficacy of atomoxetine or select an alternative drug as a precaution.  Be alert to ADEs in CYP2D6 poor metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981999E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atomoxetine based on CYP2D6 genotype.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eatomoxetine\u003c/td\u003e\u003ctd\u003eThe genetic variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As the plasma concentration of the active ingredients decreases as a result, this gene variation can result in reduced efficacy.\u003c/td\u003e\u003ctd\u003e1. Be extra alert to reduced efficacy of the treatment.\u003cbr/\u003e2. Advise the patient to contact their doctor in the event of inadequate effect.\u003cbr/\u003e3. An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eatomoxetine\u003c/td\u003e\u003ctd\u003eThe genetic variation increases the plasma concentration of atomoxetine and can thereby reduce the dose requirement.\u003c/td\u003e\u003ctd\u003e1. In the event of side effects occurring and/or a response later than 9weeks: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 2-3 times higher for IM than for EM at the same dose.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eatomoxetine\u003c/td\u003e\u003ctd\u003eThe genetic variation increases the plasma concentration of atomoxetine and thereby the risk of side effects.\u003c/td\u003e\u003ctd\u003e1. Start with the normal initial dose, bearing in mind that an increase in this dose probably will not be required.\u003cbr/\u003e2. Advise the patient to seek contact if side effects occur (such as decreased appetite, vomiting, abdominal pain, constipation, insomnia, early waking, drowsiness, irritability, pupil dilation and itching).\u003cbr/\u003e3. If the medicine is effective, but side effects occur: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 8-11 times higher for PM than for EM at the same dose.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001598.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atomoxetine based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eStandard dose. Dose increase probably not necessary; be alert to ADEs.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026gt; 3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia  \u0026gt; 75x10\u003csup\u003e9\u003c/sup\u003e/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eNo recommendations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5; Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Be alert to reduced efficacy or select alternative drug (e.g., methylphenidate, clonidine).\u003c/td\u003e\u003ctd\u003e--\u003c/td\u003e\u003ctd\u003e--\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/atomoxetine_CYP2D6_271111.pdf\""\u003eAtomoxetine CYP2D6 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182843,Guideline Annotation,Annotation of DPWG Guideline for atorvastatin and SLCO1B1,t,PA448500,Dutch Pharmacogenetics Working Group,"<p>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atorvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, they advise contacting their doctor in the event of muscle symptoms.</p>
<p><em>Wording in table taken from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>512 CC</td><td>atorvastatin</td><td>The genetic polymorphism may lead to reduced atorvastatin transport to the liver. This may increase atorvastatin plasma concentrations and therefore the risk of myopathy.</td><td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td></tr>
<tr><td>512 TC</td><td>atorvastatin</td><td>The genetic polymorphism may lead to reduced atorvastatin transport to the liver. This may increase atorvastatin plasma concentrations and therefore the risk of myopathy.</td><td>- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:<br/>1. Choose an alternative. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.<br/>2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.<br/>- Patient has NO additional significant risk factors for statin-induced myopathy:<br/>1. Advise the patient to contact their doctor in the event of muscle symptoms.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0004058.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182843"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182843"",""name"":""Annotation of DPWG Guideline for atorvastatin and SLCO1B1"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415243E9,""date"":""2019-05-27T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.45082077E9,""date"":""2019-10-06T21:39:33.327-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45096262E9,""date"":""2020-02-10T09:46:49.659-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/variant/PA166154579"",""@context"":""https://api.pharmgkb.org/jsonld/variant.jsonld"",""objCls"":""Variant"",""id"":""PA166154579"",""symbol"":""rs4149056"",""name"":""rs4149056""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448500"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448500"",""name"":""atorvastatin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134865839"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134865839"",""symbol"":""SLCO1B1"",""name"":""solute carrier organic anion transporter family member 1B1""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415241E9,""html"":""\u003cp\u003eChoose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415242E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for atorvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, they advise contacting their doctor in the event of muscle symptoms.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e512 CC\u003c/td\u003e\u003ctd\u003eatorvastatin\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism may lead to reduced atorvastatin transport to the liver. This may increase atorvastatin plasma concentrations and therefore the risk of myopathy.\u003c/td\u003e\u003ctd\u003e- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:\u003cbr/\u003e1. Choose an alternative. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.\u003cbr/\u003e2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.\u003cbr/\u003e- Patient has NO additional significant risk factors for statin-induced myopathy:\u003cbr/\u003e1. Advise the patient to contact their doctor in the event of muscle symptoms.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e512 TC\u003c/td\u003e\u003ctd\u003eatorvastatin\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism may lead to reduced atorvastatin transport to the liver. This may increase atorvastatin plasma concentrations and therefore the risk of myopathy.\u003c/td\u003e\u003ctd\u003e- Patient has ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy:\u003cbr/\u003e1. Choose an alternative. Rosuvastatin and pravastatin are influenced to a similar extent by SLCO1B1 polymorphisms but are not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.\u003cbr/\u003e2. If an alternative is not an option: advise the patient to contact their doctor in the event of muscle symptoms.\u003cbr/\u003e- Patient has NO additional significant risk factors for statin-induced myopathy:\u003cbr/\u003e1. Advise the patient to contact their doctor in the event of muscle symptoms.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0004058.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104933,Guideline Annotation,"Annotation of CPIC Guideline for azathioprine and NUDT15,TPMT",t,PA448515,Clinical Pharmacogenetics Implementation Consortium,"<p>Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"" target=""_blank"">CPIC&reg; guideline for thiopurines and TPMT and NUDT15</a>.</p>
<h3 id=""october-2018-update"">October 2018 Update</h3>
<p><em>Advance online publication November 2018.</em></p>
<ul>
<li>The <a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1304?af=R"" target=""_blank"">2018 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine</a>, have been published in Clinical Pharmacology and Therapeutics.  Literature published between October 2012 to June 2017 was reviewed, recommendations and supplemental information was updated.</li>
<li>These guidelines are applicable to:
<ul>
<li>pediatric patients</li>
<li>adult patients</li>
</ul>
</li>
<li>Excerpt from the 2018 thiopurine dosing guideline update:
<ul>
<li>&quot;TPMT activity exhibits a monogenic co-dominant inheritance and catabolizes
thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines.&quot;</li>
<li>&quot;Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduces the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Submitted.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on <em>TPMT</em> and <em>NUDT15</em> genotypes: 2018 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Supplemental_Material.pdf"" target=""_blank"">2018 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/tpmtRefMaterials"">TPMT Gene-Specific Information Tables</a></li>
<li><a href=""https://www.pharmgkb.org/page/nudt15RefMaterials"">NUDT15 Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/Azathioprine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Azathioprine Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/Thiopurines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Thiopurines Pre and Post Test Alerts and Flow Chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-azathioprine-by-tpmt-phenotype"">Table 1: Recommended dosing of azathioprine by TPMT phenotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2018 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>TPMT phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations</th></tr>
</thead>
<tbody>
<tr><td>Normal Metabolizer</td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Lower concentrations of TGN metabolites, higher meTIMP, this is the &quot;normal&quot; pattern.  Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with normal starting dose<sup>a</sup> (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Intermediate Metabolizer</td><td>An individual carrying one normal function allele and one no function allele</td><td>*1/*2, *1/*3A, *1/*3B, *1/*3C, *1/*4</td><td>Moderate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Possible Intermediate Metabolizer</td><td>An individual carrying one uncertain/unknown function allele and one no function allele</td><td>*2/*8, *3A/*7</td><td>Moderate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Poor Metabolizer</td><td>An individual carrying two no function alleles</td><td>*3A/*3A, *2/*3A, *3A/*3C, *3C/*4, *2/*3C, *3A/*4</td><td>Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no meTIMP metabolites</td><td>For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.  For malignancy, start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines  Allow 4-6 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Indeterminate</td><td>An individual carrying two uncertain/unknown function alleles OR one normal function allele and one uncertain/unknown function allele</td><td>*6/*8, *1/*8</td><td>None</td><td>None</td><td>None</td></tr>
</tbody>
</table>
<p><sup>a</sup>Normal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</p>
<h3 id=""table-2-recommended-dosing-of-azathioprine-by-nudt15-phenotype"">Table 2: Recommended dosing of azathioprine by NUDT15 phenotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2018 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>NUDT15 phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations</th></tr>
</thead>
<tbody>
<tr><td>Normal Metabolizer</td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression</td><td>Start with normal starting dose<sup>a</sup> (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Intermediate Metabolizer</td><td>An individual carrying one normal function allele and one no function allele</td><td>*1/*2, *1/*3</td><td>Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Possible Intermediate Metabolizer</td><td>An individual carrying one uncertain function allele and one no function allele</td><td>*2/*5, *3/*6</td><td>Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Poor Metabolizer</td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression</td><td>For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses<sup>a</sup> (reduce dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Indeterminate</td><td>An individual carrying two uncertain function alleles OR one normal function allele and one uncertain function allele</td><td>*1/*4, *1/*5, *4/*5, *5/*6</td><td>None</td><td>None</td><td>None</td></tr>
</tbody>
</table>
<p><sup>a</sup>Normal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</p>
<h3 id=""table-3-recommended-dosing-of-azathioprine-by-tpmt-and-nudt15-phenotypes"">Table 3: Recommended dosing of azathioprine by TPMT and NUDT15 phenotypes</h3>
<p><em>Adapted from Figure 2 and Table 2 of the 2018 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype</th><th>TPMT Normal Metabolizer</th><th>TPMT Intermediate Metabolizer</th><th>TPMT Possible Intermediate Metabolizer</th><th>TPMT Poor Metabolizer</th><th>Indeterminate</th></tr>
</thead>
<tbody>
<tr><td>NUDT 15 Normal Metabolizer</td><td>Use standard dose</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.</td><td>See TPMT Intermediate Metabolizer.</td><td>For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.  For malignancy, start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines  Allow 4-6 weeks to reach steady-state after each dose adjustment.</td><td>None</td></tr>
<tr><td>NUDT15 Intermediate Metabolizer</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.</td><td>See TPMT Intermediate Metabolizer.</td><td>For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.  For malignancy, start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines  Allow 4-6 weeks to reach steady-state after each dose adjustment.</td><td>None</td></tr>
<tr><td>NUDT15 Possible Intermediate Metabolizer</td><td>See NUDT15 Intermediate Metabolizer.</td><td>See NUDT15 Intermediate Metabolizer.</td><td>See TPMT Intermediate Metabolizer/NUDT15 Intermediate Metabolizer.</td><td>See NUDT15 Intermediate Metabolizer.</td><td>None</td></tr>
<tr><td>NUDT15 Poor  Metabolizer</td><td>For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses<sup>a</sup> (reduce dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.</td><td>For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses<sup>a</sup> (reduce dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.</td><td>See TPMT Intermediate Metabolizer.</td><td>For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.  For malignancy, start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines  Allow 4-6 weeks to reach steady-state after each dose adjustment.</td><td>None</td></tr>
<tr><td>NUDT15 Indeterminate</td><td>None</td><td>None</td><td>None</td><td>None</td><td>None</td></tr>
</tbody>
</table>
<p><sup>a</sup>Normal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</p>
<h3 id=""may-2016-update-on-pharmgkb"">May 2016 Update on PharmGKB</h3>
<p>Several studies have reported that individuals who carry low-function alleles for NUDT15 are unable to tolerate usual doses of thiopurines. [Articles:<a href=""/pmid/25108385"">25108385</a>, <a href=""/pmid/25624441"">25624441</a>, <a href=""/pmid/26033531"">26033531</a>, <a href=""/pmid/26076924"">26076924</a>, <a href=""/pmid/26405151"">26405151</a>, <a href=""/pmid/26503813"">26503813</a>, <a href=""/pmid/26590936"">26590936</a>, <a href=""/pmid/26735160"">26735160</a>, <a href=""/pmid/26878724"">26878724</a>] These alleles are more common among those of Asian ancestry and Hispanic ethnicity than others. [Articles:<a href=""/pmid/25624441"">25624441</a>, <a href=""/pmid/26878724"">26878724</a>] The dose tolerated by those with two low-function alleles is only ~ 10% that tolerated by those with no low-function NUDT15 or TPMT alleles. [Articles:<a href=""/pmid/25624441"">25624441</a>, <a href=""/pmid/26878724"">26878724</a>] CPIC is planning a guideline to address NUDT15 variants and possible dosing recommendations for thiopurines.</p>
<h3 id=""april-2013-update"">April 2013 Update</h3>
<p><em>Advance online publication January 2013.</em></p>
<ul>
<li>The <a rel=""noopener noreferrer"" href=""http://www.nature.com/clpt/journal/vaop/naam/index.html#17012013"" target=""_blank"">2013 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine</a>, have been published in Clinical Pharmacology and Therapeutics.  Literature published between June 2010-November 2012 was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current.</strong></li>
<li>These guidelines are applicable to:
<ul>
<li>pediatric patients</li>
<li>adult patients</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2013/23422873.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2013/23422873-supplement.pdf"" target=""_blank"">2013 supplement</a></li>
</ul>
</li>
</ul>
<h3 id=""march-2011"">March 2011</h3>
<p><em>Advance online publication January 2011.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for azathioprine, thioguanine and mercaptopurine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpt from the 2011 thiopurine dosing guidelines:
<ul>
<li>&quot;Thiopurines are most commonly used to treat nonmalignant conditions but are also critical anticancer agents. The approach to dosing adjustments based on TPMT status may differ depending on the clinical indication and the propensity to initiate therapy at higher vs. lower starting doses. We and others advocate testing for TPMT status prior to initiating thiopurine therapy, so that starting dosages can be adjusted accordingly.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2011/21270794.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2011/21270794-supplement.pdf"" target=""_blank"">2011 supplement</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104933"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104933"",""name"":""Annotation of CPIC Guideline for azathioprine and NUDT15,TPMT"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.183699765E9,""date"":""2011-01-26T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.183699766E9,""date"":""2013-01-17T00:00:00-08:00"",""type"":""Update"",""version"":0.0},{""id"":1.447986815E9,""date"":""2016-05-10T21:43:52.524-07:00"",""description"":""Update guideline with information regarding the NUDT15 gene."",""type"":""Update"",""version"":0.0},{""id"":1.449717122E9,""date"":""2018-08-23T17:58:20.515-07:00"",""description"":""Updated video link"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15101542"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5101542E7,""resourceId"":""30447069"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/30447069"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/30447069"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450043138E9,""resource"":""PubMed"",""resourceId"":""30447069"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/30447069""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1304"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450043139E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1304"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1304""}]},{""@id"":""https://pharmgkb.org/literature/15051187"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051187E7,""resourceId"":""23422873"",""title"":""Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604643"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3604643"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275272E9,""resource"":""PubMed Central"",""resourceId"":""PMC3604643"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604643""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23422873"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275271E9,""resource"":""PubMed"",""resourceId"":""23422873"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23422873""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.4"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275273E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.4"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.4""}]},{""@id"":""https://pharmgkb.org/literature/6690400"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":6690400.0,""resourceId"":""21270794"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3098761"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449245874E9,""resource"":""PubMed Central"",""resourceId"":""PMC3098761"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/21270794"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69164748E8,""resource"":""PubMed"",""resourceId"":""21270794"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21270794""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2010.320"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449245875E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2010.320"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2010.320""}]},{""@id"":""https://pharmgkb.org/literature/15100906"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100906E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""title"":""CPIC® Guideline for Thiopurines and TPMT – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983453E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448515"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448515"",""name"":""azathioprine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134963132"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134963132"",""symbol"":""NUDT15"",""name"":""nudix hydrolase 15""},{""@id"":""https://pharmgkb.org/gene/PA356"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA356"",""symbol"":""TPMT"",""name"":""thiopurine S-methyltransferase""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.449753103E9,""html"":""\u003cp\u003eConsider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.450044397E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for thiopurines and TPMT and NUDT15\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2018-update\""\u003eOctober 2018 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication November 2018.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1304?af\u003dR\"" target\u003d\""_blank\""\u003e2018 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine\u003c/a\u003e, have been published in Clinical Pharmacology and Therapeutics.  Literature published between October 2012 to June 2017 was reviewed, recommendations and supplemental information was updated.\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2018 thiopurine dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;TPMT activity exhibits a monogenic co-dominant inheritance and catabolizes\nthiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduces the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Submitted.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on \u003cem\u003eTPMT\u003c/em\u003e and \u003cem\u003eNUDT15\u003c/em\u003e genotypes: 2018 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Supplemental_Material.pdf\"" target\u003d\""_blank\""\u003e2018 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/tpmtRefMaterials\""\u003eTPMT Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/nudt15RefMaterials\""\u003eNUDT15 Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/Azathioprine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eAzathioprine Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/Thiopurines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eThiopurines Pre and Post Test Alerts and Flow Chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-azathioprine-by-tpmt-phenotype\""\u003eTable 1: Recommended dosing of azathioprine by TPMT phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2018 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eTPMT phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNormal Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eLower concentrations of TGN metabolites, higher meTIMP, this is the \u0026quot;normal\u0026quot; pattern.  Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with normal starting dose\u003csup\u003ea\u003c/sup\u003e (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3A, *1/*3B, *1/*3C, *1/*4\u003c/td\u003e\u003ctd\u003eModerate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePossible Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one uncertain/unknown function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*2/*8, *3A/*7\u003c/td\u003e\u003ctd\u003eModerate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*3A/*3A, *2/*3A, *3A/*3C, *3C/*4, *2/*3C, *3A/*4\u003c/td\u003e\u003ctd\u003eExtremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no meTIMP metabolites\u003c/td\u003e\u003ctd\u003eFor non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.  For malignancy, start with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines  Allow 4-6 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003eAn individual carrying two uncertain/unknown function alleles OR one normal function allele and one uncertain/unknown function allele\u003c/td\u003e\u003ctd\u003e*6/*8, *1/*8\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eNormal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""table-2-recommended-dosing-of-azathioprine-by-nudt15-phenotype\""\u003eTable 2: Recommended dosing of azathioprine by NUDT15 phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2018 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eNUDT15 phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNormal Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal risk of thiopurine-related leukopenia, neutropenia, myelosuppression\u003c/td\u003e\u003ctd\u003eStart with normal starting dose\u003csup\u003ea\u003c/sup\u003e (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3\u003c/td\u003e\u003ctd\u003eIncreased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePossible Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one uncertain function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*2/*5, *3/*6\u003c/td\u003e\u003ctd\u003eIncreased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression\u003c/td\u003e\u003ctd\u003eFor non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses\u003csup\u003ea\u003c/sup\u003e (reduce dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003eAn individual carrying two uncertain function alleles OR one normal function allele and one uncertain function allele\u003c/td\u003e\u003ctd\u003e*1/*4, *1/*5, *4/*5, *5/*6\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eNormal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""table-3-recommended-dosing-of-azathioprine-by-tpmt-and-nudt15-phenotypes\""\u003eTable 3: Recommended dosing of azathioprine by TPMT and NUDT15 phenotypes\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Figure 2 and Table 2 of the 2018 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003c/th\u003e\u003cth\u003eTPMT Normal Metabolizer\u003c/th\u003e\u003cth\u003eTPMT Intermediate Metabolizer\u003c/th\u003e\u003cth\u003eTPMT Possible Intermediate Metabolizer\u003c/th\u003e\u003cth\u003eTPMT Poor Metabolizer\u003c/th\u003e\u003cth\u003eIndeterminate\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT 15 Normal Metabolizer\u003c/td\u003e\u003ctd\u003eUse standard dose\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eFor non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.  For malignancy, start with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines  Allow 4-6 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is 2-3 mg/kg/day, (e.g. 0.6-2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eFor non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.  For malignancy, start with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines  Allow 4-6 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Possible Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eSee NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eSee NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer/NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eSee NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Poor  Metabolizer\u003c/td\u003e\u003ctd\u003eFor non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses\u003csup\u003ea\u003c/sup\u003e (reduce dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eFor non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses\u003csup\u003ea\u003c/sup\u003e (reduce dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eFor non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.  For malignancy, start with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines  Allow 4-6 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Indeterminate\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eNormal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2016-update-on-pharmgkb\""\u003eMay 2016 Update on PharmGKB\u003c/h3\u003e\n\u003cp\u003eSeveral studies have reported that individuals who carry low-function alleles for NUDT15 are unable to tolerate usual doses of thiopurines. [Articles:\u003ca href\u003d\""/pmid/25108385\""\u003e25108385\u003c/a\u003e, \u003ca href\u003d\""/pmid/25624441\""\u003e25624441\u003c/a\u003e, \u003ca href\u003d\""/pmid/26033531\""\u003e26033531\u003c/a\u003e, \u003ca href\u003d\""/pmid/26076924\""\u003e26076924\u003c/a\u003e, \u003ca href\u003d\""/pmid/26405151\""\u003e26405151\u003c/a\u003e, \u003ca href\u003d\""/pmid/26503813\""\u003e26503813\u003c/a\u003e, \u003ca href\u003d\""/pmid/26590936\""\u003e26590936\u003c/a\u003e, \u003ca href\u003d\""/pmid/26735160\""\u003e26735160\u003c/a\u003e, \u003ca href\u003d\""/pmid/26878724\""\u003e26878724\u003c/a\u003e] These alleles are more common among those of Asian ancestry and Hispanic ethnicity than others. [Articles:\u003ca href\u003d\""/pmid/25624441\""\u003e25624441\u003c/a\u003e, \u003ca href\u003d\""/pmid/26878724\""\u003e26878724\u003c/a\u003e] The dose tolerated by those with two low-function alleles is only ~ 10% that tolerated by those with no low-function NUDT15 or TPMT alleles. [Articles:\u003ca href\u003d\""/pmid/25624441\""\u003e25624441\u003c/a\u003e, \u003ca href\u003d\""/pmid/26878724\""\u003e26878724\u003c/a\u003e] CPIC is planning a guideline to address NUDT15 variants and possible dosing recommendations for thiopurines.\u003c/p\u003e\n\u003ch3 id\u003d\""april-2013-update\""\u003eApril 2013 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication January 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.nature.com/clpt/journal/vaop/naam/index.html#17012013\"" target\u003d\""_blank\""\u003e2013 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine\u003c/a\u003e, have been published in Clinical Pharmacology and Therapeutics.  Literature published between June 2010-November 2012 was reviewed and there is \u003cstrong\u003eno new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current.\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2013/23422873.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2013/23422873-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""march-2011\""\u003eMarch 2011\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication January 2011.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for azathioprine, thioguanine and mercaptopurine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2011 thiopurine dosing guidelines:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Thiopurines are most commonly used to treat nonmalignant conditions but are also critical anticancer agents. The approach to dosing adjustments based on TPMT status may differ depending on the clinical indication and the propensity to initiate therapy at higher vs. lower starting doses. We and others advocate testing for TPMT status prior to initiating thiopurine therapy, so that starting dosages can be adjusted accordingly.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2011/21270794.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2011/21270794-supplement.pdf\"" target\u003d\""_blank\""\u003e2011 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983453E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/""}]},""status"":""success""}"
PA166104934,Guideline Annotation,Annotation of DPWG Guideline for azathioprine and TPMT,t,PA448515,Dutch Pharmacogenetics Working Group,"<p>Select an alternative drug or reduce the initial dose of azathioprine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.</p>
","<h3 id=""august-2019-update"">August 2019 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for azathioprine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>TPMT IM</td><td>azathioprine</td><td>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.</td><td>-IMMUNOSUPPRESSION<br/>Start with 50% of the standard dose<br/>Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.<br/>The frequency of monitoring should be increased.<br/>Dose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.<br/>-LEUKAEMIA:<br/>start with 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction<br/>It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. The initial dose should be adjusted based on toxicity (monitoring of the blood counts) and efficacy.<br/>Monitoring should be performed at an increased frequency.<br/>Note: more stringent dose reductions are necessary if the patient is also NUDT15 IM.</td></tr>
<tr><td>TPMT PM</td><td>azathioprine</td><td>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.</td><td>1. Choose an alternative or start with 10% of the standard dose.<br/>Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased.<br/>2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001905.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for azathioprine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>TPMT IM</td><td>azathioprine</td><td>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.</td><td>Start with 50% of the standard dose. Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased. Dose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.</td></tr>
<tr><td>TPMT PM</td><td>azathioprine</td><td>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.</td><td>1. Choose an alternative or start with 10% of the standard dose.Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased. 2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001906.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for azathioprine based on TPMT genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend selecting an alternative drug or reducing the initial dose for patients carrying inactive alleles.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>IM (one inactive allele: *2, *3, *4-*18)</td><td>Select alternative drug or reduce dose by 50%. Increase dose in response of hematologic monitoring and efficacy.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x10<sup>9</sup>/l; leucopenia &lt; 1.0x10<sup>9</sup>/l; thrombocytopenia &lt; 25x10<sup>9</sup>/l; life-threatening complications from diarrhea.</td></tr>
<tr><td>PM (two inactive alleles: *2, *3, *4-*18)</td><td>Select alternative drug or reduce dose by 90%. Increase dose in response of hematologic monitoring and efficacy.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104934"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104934"",""name"":""Annotation of DPWG Guideline for azathioprine and TPMT"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704447E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414858E9,""date"":""2019-05-22T10:52:57.667-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820691E9,""date"":""2019-10-03T21:26:59.435-07:00"",""description"":""Changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450956223E9,""date"":""2020-01-31T13:18:57.518-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096268E9,""date"":""2020-02-10T10:04:01.972-08:00"",""description"":""Fixed links to 2019 guideline pdfs. 2018 link already went to attachment."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448515"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448515"",""name"":""azathioprine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA356"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA356"",""symbol"":""TPMT"",""name"":""thiopurine S-methyltransferase""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.44798185E9,""html"":""\u003cp\u003eSelect an alternative drug or reduce the initial dose of azathioprine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981849E9,""html"":""\u003ch3 id\u003d\""august-2019-update\""\u003eAugust 2019 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for azathioprine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT IM\u003c/td\u003e\u003ctd\u003eazathioprine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003e-IMMUNOSUPPRESSION\u003cbr/\u003eStart with 50% of the standard dose\u003cbr/\u003eAdjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.\u003cbr/\u003eThe frequency of monitoring should be increased.\u003cbr/\u003eDose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.\u003cbr/\u003e-LEUKAEMIA:\u003cbr/\u003estart with 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction\u003cbr/\u003eIt is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. The initial dose should be adjusted based on toxicity (monitoring of the blood counts) and efficacy.\u003cbr/\u003eMonitoring should be performed at an increased frequency.\u003cbr/\u003eNote: more stringent dose reductions are necessary if the patient is also NUDT15 IM.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT PM\u003c/td\u003e\u003ctd\u003eazathioprine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative or start with 10% of the standard dose.\u003cbr/\u003eAny adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased.\u003cbr/\u003e2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001905.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for azathioprine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT IM\u003c/td\u003e\u003ctd\u003eazathioprine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with 50% of the standard dose. Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased. Dose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT PM\u003c/td\u003e\u003ctd\u003eazathioprine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative or start with 10% of the standard dose.Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased. 2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001906.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for azathioprine based on TPMT genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend selecting an alternative drug or reducing the initial dose for patients carrying inactive alleles.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eIM (one inactive allele: *2, *3, *4-*18)\u003c/td\u003e\u003ctd\u003eSelect alternative drug or reduce dose by 50%. Increase dose in response of hematologic monitoring and efficacy.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia \u0026lt; 0.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026lt; 1.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia \u0026lt; 25x10\u003csup\u003e9\u003c/sup\u003e/l; life-threatening complications from diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive alleles: *2, *3, *4-*18)\u003c/td\u003e\u003ctd\u003eSelect alternative drug or reduce dose by 90%. Increase dose in response of hematologic monitoring and efficacy.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166184614,Guideline Annotation,Annotation of DPWG Guideline for azathioprine and NUDT15,t,PA448515,Dutch Pharmacogenetics Working Group,"<p>Select an alternative drug or reduce the initial dose of azathioprine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.</p>
","<h3 id=""august-2019-guideline"">August 2019 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on NUDT15 genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers. They updated the wording for the intermediate metabolizer recommendation, reflected in the table below.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>NUDT15 IM</td><td>azathioprine</td><td>Grade = 2 leukopaenia occurs in 42% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.</td><td>- IMMUNOSUPPRESSION:start with 50% of the standard dose. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>Note: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of &lt; 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.<br/>Note: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.<br/>- LEUKAEMIA: start at 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction. It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>Note: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of &lt; 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.<br/>Note: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.<br/>Note: more stringent dose reductions are necessary if the patient is also TPMT IM.</td></tr>
<tr><td>NUDT15 PM</td><td>azathioprine</td><td>Grade = 2 leukopaenia occurs in 96% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.</td><td>- avoid azathioprine and mercaptopurine.  If it is not possible to avoid azathioprine and mercaptopurine: use 10% of the standard dose and advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur. Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>Note: The percentage of 10% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of &lt; 20% was calculated for NUDT15 PM, but there were insufficient data available to calculate the exact percentage.<br/>Note: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0007035.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166184614"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166184614"",""name"":""Annotation of DPWG Guideline for azathioprine and NUDT15"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450821378E9,""date"":""2019-10-08T22:28:24.883-07:00"",""description"":""August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45096264E9,""date"":""2020-02-10T09:49:57.197-08:00"",""description"":""Fixed links to 2019 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448515"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448515"",""name"":""azathioprine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134963132"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134963132"",""symbol"":""NUDT15"",""name"":""nudix hydrolase 15""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450821375E9,""html"":""\u003cp\u003eSelect an alternative drug or reduce the initial dose of azathioprine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450821376E9,""html"":""\u003ch3 id\u003d\""august-2019-guideline\""\u003eAugust 2019 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on NUDT15 genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers. They updated the wording for the intermediate metabolizer recommendation, reflected in the table below.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 IM\u003c/td\u003e\u003ctd\u003eazathioprine\u003c/td\u003e\u003ctd\u003eGrade \u003d 2 leukopaenia occurs in 42% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.\u003c/td\u003e\u003ctd\u003e- IMMUNOSUPPRESSION:start with 50% of the standard dose. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNote: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of \u0026lt; 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.\u003cbr/\u003eNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\u003cbr/\u003e- LEUKAEMIA: start at 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction. It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNote: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of \u0026lt; 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.\u003cbr/\u003eNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\u003cbr/\u003eNote: more stringent dose reductions are necessary if the patient is also TPMT IM.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 PM\u003c/td\u003e\u003ctd\u003eazathioprine\u003c/td\u003e\u003ctd\u003eGrade \u003d 2 leukopaenia occurs in 96% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.\u003c/td\u003e\u003ctd\u003e- avoid azathioprine and mercaptopurine.  If it is not possible to avoid azathioprine and mercaptopurine: use 10% of the standard dose and advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur. Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNote: The percentage of 10% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of \u0026lt; 20% was calculated for NUDT15 PM, but there were insufficient data available to calculate the exact percentage.\u003cbr/\u003eNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0007035.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104952,Guideline Annotation,Annotation of DPWG Guideline for mercaptopurine and TPMT,t,PA450379,Dutch Pharmacogenetics Working Group,"<p>Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.</p>
","<h3 id=""august-2019-update"">August 2019 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for azathioprine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>TPMT IM</td><td>mercaptopurine</td><td>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.</td><td>-IMMUNOSUPPRESSION<br/>Start with 50% of the standard dose<br/>Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.<br/>The frequency of monitoring should be increased.<br/>Dose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.<br/>-LEUKAEMIA:<br/>start with 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction<br/>It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. The initial dose should be adjusted based on toxicity (monitoring of the blood counts) and efficacy.<br/>Monitoring should be performed at an increased frequency.<br/>Note: more stringent dose reductions are necessary if the patient is also NUDT15 IM.</td></tr>
<tr><td>TPMT PM</td><td>mercaptopurine</td><td>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.</td><td>1. Choose an alternative or start with 10% of the standard dose.<br/>Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased.<br/>2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001905.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mercaptopurine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>TPMT IM</td><td>mercaptopurine</td><td>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.</td><td>Start with 50% of the standard dose. Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased. Dose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.</td></tr>
<tr><td>TPMT PM</td><td>mercaptopurine</td><td>The genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.</td><td>1. Choose an alternative or start with 10% of the standard dose.Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased. 2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001906.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mercaptopurine based on TPMT genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend selecting an alternative drug or reducing the initial dose for patients carrying inactive alleles.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>IM (one inactive allele: *2, *3, *4-*18)</td><td>Select alternative drug or reduce dose by 50%. Increase dose in response of hematologic monitoring and efficacy.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x10<sup>9</sup>/l; leucopenia &lt; 1.0x10<sup>9</sup>/l; thrombocytopenia &lt; 25x10<sup>9</sup>/l; life-threatening complications from diarrhea.</td></tr>
<tr><td>PM (two inactive alleles: *2, *3, *4-*18)</td><td>Select alternative drug or reduce dose by 90%. Increase dose in response of hematologic monitoring and efficacy.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104952"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104952"",""name"":""Annotation of DPWG Guideline for mercaptopurine and TPMT"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704495E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414872E9,""date"":""2019-05-22T16:30:48.610-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820693E9,""date"":""2019-10-03T21:35:54.664-07:00"",""description"":""Changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45095637E9,""date"":""2020-01-31T13:37:54.039-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963586E9,""date"":""2020-02-11T06:34:23.010-08:00"",""description"":""Fixed links to 2019 guideline pdfs. Corrected drug in table to mercaptopurine"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450379"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450379"",""name"":""mercaptopurine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA356"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA356"",""symbol"":""TPMT"",""name"":""thiopurine S-methyltransferase""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981856E9,""html"":""\u003cp\u003eSelect an alternative drug or reduce the initial dose of mercaptopurine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981855E9,""html"":""\u003ch3 id\u003d\""august-2019-update\""\u003eAugust 2019 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for azathioprine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT IM\u003c/td\u003e\u003ctd\u003emercaptopurine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003e-IMMUNOSUPPRESSION\u003cbr/\u003eStart with 50% of the standard dose\u003cbr/\u003eAdjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness.\u003cbr/\u003eThe frequency of monitoring should be increased.\u003cbr/\u003eDose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.\u003cbr/\u003e-LEUKAEMIA:\u003cbr/\u003estart with 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction\u003cbr/\u003eIt is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. The initial dose should be adjusted based on toxicity (monitoring of the blood counts) and efficacy.\u003cbr/\u003eMonitoring should be performed at an increased frequency.\u003cbr/\u003eNote: more stringent dose reductions are necessary if the patient is also NUDT15 IM.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT PM\u003c/td\u003e\u003ctd\u003emercaptopurine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative or start with 10% of the standard dose.\u003cbr/\u003eAny adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased.\u003cbr/\u003e2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001905.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mercaptopurine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT IM\u003c/td\u003e\u003ctd\u003emercaptopurine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with 50% of the standard dose. Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased. Dose adjustment is not required for doses lower than 1.5 mg/kg per day for azathioprine or 0.75 mg/kg per day for mercaptopurine.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT PM\u003c/td\u003e\u003ctd\u003emercaptopurine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of azathioprine and mercaptopurine to mainly inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative or start with 10% of the standard dose.Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased. 2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001906.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mercaptopurine based on TPMT genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend selecting an alternative drug or reducing the initial dose for patients carrying inactive alleles.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eIM (one inactive allele: *2, *3, *4-*18)\u003c/td\u003e\u003ctd\u003eSelect alternative drug or reduce dose by 50%. Increase dose in response of hematologic monitoring and efficacy.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia \u0026lt; 0.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026lt; 1.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia \u0026lt; 25x10\u003csup\u003e9\u003c/sup\u003e/l; life-threatening complications from diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive alleles: *2, *3, *4-*18)\u003c/td\u003e\u003ctd\u003eSelect alternative drug or reduce dose by 90%. Increase dose in response of hematologic monitoring and efficacy.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182816,Guideline Annotation,Annotation of DPWG Guideline for bisoprolol and CYP2D6,f,PA448641,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for bisoprolol based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for bisoprolol based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002457.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182816"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182816"",""name"":""Annotation of DPWG Guideline for bisoprolol and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414999E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.450820771E9,""date"":""2019-10-06T21:43:29.419-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.4509627E9,""date"":""2020-02-10T10:06:56.016-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448641"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448641"",""name"":""bisoprolol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414997E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for bisoprolol based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414998E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for bisoprolol based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002457.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166184527,Guideline Annotation,Annotation of DPWG Guideline for brexpiprazole and CYP2D6,t,PA166160053,Dutch Pharmacogenetics Working Group,"<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the standard dose of brexpiprazole for patients carrying poor metabolizer alleles of CYP2D6.</p>
","<h3 id=""august-2019-guideline"">August 2019 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for brexpiprazole based on CYP2D6 genotype. They recommend to use half of the standard dose of brexpiprazole for CYP2D6 poor metabolizer (PM).</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>brexpiprazole</td><td>-</td><td>NO action is required for this gene-drug interaction. The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy.</td></tr>
<tr><td>CYP2D6 IM</td><td>brexpiprazole</td><td>-</td><td>NO action is required for this gene-drug interaction. There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation.</td></tr>
<tr><td>CYP2D6 PM</td><td>brexpiprazole</td><td>The risk of side effects is theoretically increased, because the gene variation reduces the metabolism of brexpiprazole.</td><td>Use half of the standard dose.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0007047.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166184527"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166184527"",""name"":""Annotation of DPWG Guideline for brexpiprazole and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450820775E9,""date"":""2019-10-06T21:57:30.452-07:00"",""description"":""august 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45096272E9,""date"":""2020-02-10T10:10:07.760-08:00"",""description"":""Fixed links to 2019 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA166160053"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA166160053"",""name"":""brexpiprazole""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450820772E9,""html"":""\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to use half of the standard dose of brexpiprazole for patients carrying poor metabolizer alleles of CYP2D6.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450820773E9,""html"":""\u003ch3 id\u003d\""august-2019-guideline\""\u003eAugust 2019 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for brexpiprazole based on CYP2D6 genotype. They recommend to use half of the standard dose of brexpiprazole for CYP2D6 poor metabolizer (PM).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003ebrexpiprazole\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction. The gene variation results in a reduction of the exposure to brexpiprazole, but there are no indications supporting a decrease in efficacy.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003ebrexpiprazole\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction. There are indications supporting an increase in the exposure to brexpiprazole, but no indications supporting an increase in side effects in patients with this gene variation.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003ebrexpiprazole\u003c/td\u003e\u003ctd\u003eThe risk of side effects is theoretically increased, because the gene variation reduces the metabolism of brexpiprazole.\u003c/td\u003e\u003ctd\u003eUse half of the standard dose.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0007047.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166109594,Guideline Annotation,Annotation of CPIC Guideline for capecitabine and DPYD,t,PA448771,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A&gt;T];[2846A&gt;T] genotype may require a &gt;50% dose reduction.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"" target=""_blank"">CPIC&reg; guideline for fluoropyrimidines and DPYD</a>.</p>
<h3 id=""november-2018-update-on-pharmgkb"">November 2018 Update on PharmGKB</h3>
<ul>
<li>The DPYD guideline published in November 2017 recommended to reduce the dose of fluoropyrimidines by 25-50% (from the full standard dose) in DPYD Intermediate Metabolizers with an activity score of 1.5. At the time of the guideline publication, this dose range was recommended due to limited evidence for genotype-guided dosing of decreased function alleles/variants. However, a recent prospective study [Article:<a href=""/pmid/30348537"">30348537</a>] provides evidence to support a recommendation for a 50% dose reduction in heterozygous carriers of the decreased function variants c.2846A&gt;T (<a href=""https://www.pharmgkb.org/variant/PA166153895"">rs67376798</a>) or c.1129–5923C&gt;G (<a href=""https://www.pharmgkb.org/variant/PA166153906"">rs75017182</a>); HapB3 or its tagging SNP c.1236G&gt;A; <a href=""https://www.pharmgkb.org/variant/PA166153889"">rs56038477</a>). These data suggest that all Intermediate Metabolizers with an activity score of 1.5 should receive a 50% dose reduction. <strong>Therefore CPIC revised its recommendation such that all DPYD Intermediate Metabolizers should receive a 50% dose reduction from the full standard starting dose, whether the activity score is 1 or 1.5 followed by dose titration, based on clinical judgement and ideally therapeutic drug monitoring.</strong></li>
<li>In addition, recent case reports from patients who are homozygous for c.2846A&gt;T (activity score of 1) indicate that a dose reduction of more than 50% may be required in some carriers of this genotype. <strong>Therefore, in patients with an activity score of 1 due to a homozygous c.[2846A&gt;T];[2846A&gt;T] genotype, clinicians should be aware that a &gt;50% reduction in starting dose might be warranted.</strong></li>
</ul>
<h3 id=""november-2017-update"">November 2017 Update</h3>
<p><em>Advance online publication November 2017</em></p>
<ul>
<li>The 2017 update of CPIC guidelines regarding 5-fluorouracil and capecitabine has been accepted for publication in Clinical Pharmacology and Therapeutics.  Literature up to March 2017 was reviewed, and recommendations and supplemental information were updated. In particular, the dosing recommendations were modified to only apply to 5-fluorouracil and capecitabine; they no longer apply to tegafur. Additionally, dosing recommendations are now given in the context of <a rel=""noopener noreferrer"" href=""https://www.ncbi.nlm.nih.gov/pubmed/26265346"" target=""_blank"">DPYD activity score</a>.</li>
<li>Excerpts from the 2017 dosing guideline update:
<ul>
<li>&quot;The strength of the prescribing recommendations is based on the known impact of some variants (c.1905+1G&gt;A, c.1679T&gt;G, c.2846A&gt;T, c.1129– 5923C&gt;G) on DPD activity, the demonstrated relationship between DPD activity and 5-fluorouracil clearance, and between 5-fluorouracil exposure and its toxic effects.&quot;</li>
<li>&quot;At the time of this writing, data on the possible role of DPYD genetic variation in 5-fluorouracil toxicity in pediatric patient populations is extremely scarce; however, there is no evidence to suggest that 5-fluorouracil pharmacokinetics differ from adult patients, and thus no evidence that DPYD variants would affect 5-fluorouracil metabolism differently in children.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729-supplement.pdf"" target=""_blank"">2017 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/dpydRefMaterials"">Gene-specific Information Tables for DPYD</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Capecitabine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Capecitabine drug resource mapping</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Fluoropyrimidines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Fluoropyrimidines pre- and post-test alerts and flow chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-fluoropyrimidines-by-genotype-phenotype"">Table 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.</h3>
<p><em>Adapted from Tables 1 and 2 of the 2017 guideline manuscript (November 2018 Update on PharmGKB).</em></p>
<table class=""table"">
<thead>
<tr><th>Likely Phenotype</th><th>Activity Score<sup>a</sup></th><th>Genotypes<sup>b</sup></th><th>Examples of genotypes<sup>c</sup></th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations<sup>d</sup></th></tr>
</thead>
<tbody>
<tr><td><em>DPYD</em> Normal Metabolizer</td><td>2</td><td>An individual carrying two normal alleles</td><td>c.[=];[=], c.[85T&gt;C<sup>e</sup>];[=], c.[1627A&gt;G<sup>f</sup>];[=]</td><td>Normal DPD activity and “normal” risk for fluoropyrimidine toxicity</td><td>Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration</td><td>Strong</td></tr>
<tr><td><em>DPYD</em> Intermediate Metabolizer</td><td>1 or 1.5</td><td>An individual carrying one normal function allele plus one no function allele or one decreased function allele, or an individual carrying two decreased function alleles</td><td>c.[1905+1G&gt;A<sup>g</sup>];[=], c.[1679T&gt;G<sup>h</sup>];[=], c.[2846A&gt;T<sup>i</sup>];[=]; c.[1129–5923C&gt;G<sup>j</sup>];[=]; c.[1129–5923C&gt;G];[1129–5923C&gt;G]; c.[2846A&gt;T];[2846A&gt;T]</td><td>Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).<br/>Patients with the c.[2846A&gt;T];[2846A&gt;T] genotype may require &gt;50% reduction in starting dose.</td><td>Activity score 1: Strong<br/>Activity score 1.5: Moderate</td></tr>
<tr><td><em>DPYD</em> Poor Metabolizer</td><td>0 or 0.5</td><td>An individual carrying two no function alleles or an individual carrying one no function plus one decreased function allele</td><td>c.[1905+1G&gt;A];[1905+1G&gt;A], c.[1679T&gt;G];[1679T&gt;G], c.[1905+1G&gt;A];[2846A&gt;T] c.[1905+1G&gt;A];[1129-5923C&gt;G]</td><td>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Activity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose<sup>k</sup> with early therapeutic drug monitoring.<sup>l</sup><br/>Activity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> Calculated as the sum of the two lowest individual variant activity scores. See main guideline for further information.<br />
<sup>b</sup> Allele definitions, assignment of allele function and references can be found using the <a href=""https://www.pharmgkb.org/page/dpydRefMaterials"">DPYD Allele Functionality Table</a>.<br />
<sup>c</sup> HGVS nomenclature using the reference sequence NM_000110.3.<br />
<sup>d</sup> Rating scheme described in the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf"" target=""_blank"">Supplement</a>.<br />
<sup>e</sup> Also known as <a href=""/variant/PA166153648"">rs1801265</a> or DPYD*9A<br />
<sup>f</sup> Also known as <a href=""/variant/PA166153646"">rs1801159</a> or DPYD*5<br />
<sup>g</sup> Also known as <a href=""/variant/PA166153760"">rs3918290</a> or DPYD*2A<br />
<sup>h</sup> Also known as <a href=""/variant/PA166153888"">rs55886062</a> or DPYD*13<br />
<sup>i</sup> Also known as <a href=""/variant/PA166153895"">rs67376798</a><br />
<sup>j</sup> Also known as <a href=""/variant/PA166153906"">rs75017182</a>. Likely HapB3 causal variant. See <a href=""https://www.pharmgkb.org/page/dpydRefMaterials"">DPYD Allele Functionality Table</a> for other HapB3 proxy SNPs.<br />
<sup>k</sup> If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of &lt;25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance.<br />
<sup>l</sup> Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue the infusion if the drug level is too high.</p>
<h3 id=""may-2014-update-on-pharmgkb"">May 2014 Update on PharmGKB</h3>
<ul>
<li>The CPIC authors recommend that the <em>DPYD*4</em>, <em>*5</em>, <em>*6</em> and <em>*9A</em> alleles be categorized as &quot;normal&quot; activity, in part based upon the recent publication <a rel=""noopener noreferrer"" href=""http://www.ncbi.nlm.nih.gov/pubmed/?term=24648345"" target=""_blank"">Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity</a>.</li>
</ul>
<h3 id=""december-2013-publication"">December 2013 Publication</h3>
<p><em>Advance online publication October 2013.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in <em>Clinical Pharmacology and Therapeutics</em> by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf"" target=""_blank"">2013 supplement</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166109594"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166109594"",""name"":""Annotation of CPIC Guideline for capecitabine and DPYD"",""cancerGenome"":false,""descriptiveVideoId"":""2wB2l4W9x8s"",""guidelineGenes"":[{""id"":1.449560819E9,""alleles"":[{""id"":1.44956082E9,""_label"":""c.1905+1G\u003eA (*2A)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171117"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171117"",""symbol"":""DPYDc.1905+1G\u003eA (*2A)"",""name"":""c.1905+1G\u003eA (*2A)""}},{""id"":1.449560821E9,""_label"":""c.1679T\u003eG (*13)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171118"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171118"",""symbol"":""DPYDc.1679T\u003eG (*13)"",""name"":""c.1679T\u003eG (*13)""}},{""id"":1.449560822E9,""_label"":""c.2846A\u003eT"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171119"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171119"",""symbol"":""DPYDc.2846A\u003eT"",""name"":""c.2846A\u003eT""}},{""id"":1.449560823E9,""_label"":""c.1129-5923C\u003eG, c.1236G\u003eA (HapB3)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171120"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171120"",""symbol"":""DPYDc.1129-5923C\u003eG, c.1236G\u003eA (HapB3)"",""name"":""c.1129-5923C\u003eG, c.1236G\u003eA (HapB3)""}},{""id"":1.449560824E9,""_label"":""c.1898delC (*3)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171121"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171121"",""symbol"":""DPYDc.1898delC (*3)"",""name"":""c.1898delC (*3)""}},{""id"":1.449560825E9,""_label"":""c.295_298delTCAT (*7)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171122"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171122"",""symbol"":""DPYDc.295_298delTCAT (*7)"",""name"":""c.295_298delTCAT (*7)""}},{""id"":1.449560826E9,""_label"":""c.703C\u003eT (*8)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171123"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171123"",""symbol"":""DPYDc.703C\u003eT (*8)"",""name"":""c.703C\u003eT (*8)""}},{""id"":1.449560827E9,""_label"":""c.2983G\u003eT (*10)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171124"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171124"",""symbol"":""DPYDc.2983G\u003eT (*10)"",""name"":""c.2983G\u003eT (*10)""}},{""id"":1.449560828E9,""_label"":""c.1156G\u003eT (*12)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171125"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171125"",""symbol"":""DPYDc.1156G\u003eT (*12)"",""name"":""c.1156G\u003eT (*12)""}},{""id"":1.449560829E9,""_label"":""c.557A\u003eG"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171126"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171126"",""symbol"":""DPYDc.557A\u003eG"",""name"":""c.557A\u003eG""}},{""id"":1.451060341E9,""_label"":""Any normal function variant or no variant detected"",""allele"":""Any normal function variant or no variant detected"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA145"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA145"",""symbol"":""DPYD"",""name"":""dihydropyrimidine dehydrogenase""}}],""history"":[{""id"":1.183699767E9,""date"":""2013-08-29T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.184511811E9,""date"":""2014-07-30T00:00:00-07:00"",""description"":""created individual pages for tegafur and fluorouracil and took those drugs off of this guideline"",""type"":""Update"",""version"":1.0},{""id"":1.184511804E9,""date"":""2014-07-30T00:00:00-07:00"",""type"":""Update"",""version"":0.0},{""id"":1.184513259E9,""date"":""2014-08-06T00:00:00-07:00"",""description"":""updated extended dosing guidelines to include *4, *5, *6, *9A"",""type"":""Update"",""version"":1.0},{""id"":1.448604657E9,""date"":""2017-03-15T16:18:19.550-07:00"",""description"":""Updated extended dosing guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.449140388E9,""date"":""2017-11-13T10:52:33.972-08:00"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15099812"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5099812E7,""resourceId"":""29152729"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760397"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5760397"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285368E9,""resource"":""PubMed Central"",""resourceId"":""PMC5760397"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760397""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/29152729"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285367E9,""resource"":""PubMed"",""resourceId"":""29152729"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/29152729""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.911"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285369E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.911"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.911""}]},{""@id"":""https://pharmgkb.org/literature/15062135"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5062135E7,""resourceId"":""23988873"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831181"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3831181"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449277398E9,""resource"":""PubMed Central"",""resourceId"":""PMC3831181"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831181""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23988873"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449277397E9,""resource"":""PubMed"",""resourceId"":""23988873"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23988873""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.172"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449277399E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.172"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.172""}]},{""@id"":""https://pharmgkb.org/literature/15100909"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100909E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""title"":""CPIC® Guideline for Fluoropyrimidines and DPYD – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983463E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448771"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448771"",""name"":""capecitabine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA145"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA145"",""symbol"":""DPYD"",""name"":""dihydropyrimidine dehydrogenase""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.450180199E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A\u0026gt;T];[2846A\u0026gt;T] genotype may require a \u0026gt;50% dose reduction.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.4501802E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for fluoropyrimidines and DPYD\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update-on-pharmgkb\""\u003eNovember 2018 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe DPYD guideline published in November 2017 recommended to reduce the dose of fluoropyrimidines by 25-50% (from the full standard dose) in DPYD Intermediate Metabolizers with an activity score of 1.5. At the time of the guideline publication, this dose range was recommended due to limited evidence for genotype-guided dosing of decreased function alleles/variants. However, a recent prospective study [Article:\u003ca href\u003d\""/pmid/30348537\""\u003e30348537\u003c/a\u003e] provides evidence to support a recommendation for a 50% dose reduction in heterozygous carriers of the decreased function variants c.2846A\u0026gt;T (\u003ca href\u003d\""https://www.pharmgkb.org/variant/PA166153895\""\u003ers67376798\u003c/a\u003e) or c.1129–5923C\u0026gt;G (\u003ca href\u003d\""https://www.pharmgkb.org/variant/PA166153906\""\u003ers75017182\u003c/a\u003e); HapB3 or its tagging SNP c.1236G\u0026gt;A; \u003ca href\u003d\""https://www.pharmgkb.org/variant/PA166153889\""\u003ers56038477\u003c/a\u003e). These data suggest that all Intermediate Metabolizers with an activity score of 1.5 should receive a 50% dose reduction. \u003cstrong\u003eTherefore CPIC revised its recommendation such that all DPYD Intermediate Metabolizers should receive a 50% dose reduction from the full standard starting dose, whether the activity score is 1 or 1.5 followed by dose titration, based on clinical judgement and ideally therapeutic drug monitoring.\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eIn addition, recent case reports from patients who are homozygous for c.2846A\u0026gt;T (activity score of 1) indicate that a dose reduction of more than 50% may be required in some carriers of this genotype. \u003cstrong\u003eTherefore, in patients with an activity score of 1 due to a homozygous c.[2846A\u0026gt;T];[2846A\u0026gt;T] genotype, clinicians should be aware that a \u0026gt;50% reduction in starting dose might be warranted.\u003c/strong\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""november-2017-update\""\u003eNovember 2017 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication November 2017\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2017 update of CPIC guidelines regarding 5-fluorouracil and capecitabine has been accepted for publication in Clinical Pharmacology and Therapeutics.  Literature up to March 2017 was reviewed, and recommendations and supplemental information were updated. In particular, the dosing recommendations were modified to only apply to 5-fluorouracil and capecitabine; they no longer apply to tegafur. Additionally, dosing recommendations are now given in the context of \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.ncbi.nlm.nih.gov/pubmed/26265346\"" target\u003d\""_blank\""\u003eDPYD activity score\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2017 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;The strength of the prescribing recommendations is based on the known impact of some variants (c.1905+1G\u0026gt;A, c.1679T\u0026gt;G, c.2846A\u0026gt;T, c.1129– 5923C\u0026gt;G) on DPD activity, the demonstrated relationship between DPD activity and 5-fluorouracil clearance, and between 5-fluorouracil exposure and its toxic effects.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;At the time of this writing, data on the possible role of DPYD genetic variation in 5-fluorouracil toxicity in pediatric patient populations is extremely scarce; however, there is no evidence to suggest that 5-fluorouracil pharmacokinetics differ from adult patients, and thus no evidence that DPYD variants would affect 5-fluorouracil metabolism differently in children.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729-supplement.pdf\"" target\u003d\""_blank\""\u003e2017 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/dpydRefMaterials\""\u003eGene-specific Information Tables for DPYD\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Capecitabine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eCapecitabine drug resource mapping\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Fluoropyrimidines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eFluoropyrimidines pre- and post-test alerts and flow chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-fluoropyrimidines-by-genotype-phenotype\""\u003eTable 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2017 guideline manuscript (November 2018 Update on PharmGKB).\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely Phenotype\u003c/th\u003e\u003cth\u003eActivity Score\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eGenotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eExamples of genotypes\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003csup\u003ed\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eDPYD\u003c/em\u003e Normal Metabolizer\u003c/td\u003e\u003ctd\u003e2\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal alleles\u003c/td\u003e\u003ctd\u003ec.[\u003d];[\u003d], c.[85T\u0026gt;C\u003csup\u003ee\u003c/sup\u003e];[\u003d], c.[1627A\u0026gt;G\u003csup\u003ef\u003c/sup\u003e];[\u003d]\u003c/td\u003e\u003ctd\u003eNormal DPD activity and “normal” risk for fluoropyrimidine toxicity\u003c/td\u003e\u003ctd\u003eBased on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eDPYD\u003c/em\u003e Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003e1 or 1.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele plus one no function allele or one decreased function allele, or an individual carrying two decreased function alleles\u003c/td\u003e\u003ctd\u003ec.[1905+1G\u0026gt;A\u003csup\u003eg\u003c/sup\u003e];[\u003d], c.[1679T\u0026gt;G\u003csup\u003eh\u003c/sup\u003e];[\u003d], c.[2846A\u0026gt;T\u003csup\u003ei\u003c/sup\u003e];[\u003d]; c.[1129–5923C\u0026gt;G\u003csup\u003ej\u003c/sup\u003e];[\u003d]; c.[1129–5923C\u0026gt;G];[1129–5923C\u0026gt;G]; c.[2846A\u0026gt;T];[2846A\u0026gt;T]\u003c/td\u003e\u003ctd\u003eDecreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs\u003c/td\u003e\u003ctd\u003eReduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\u003cbr/\u003ePatients with the c.[2846A\u0026gt;T];[2846A\u0026gt;T] genotype may require \u0026gt;50% reduction in starting dose.\u003c/td\u003e\u003ctd\u003eActivity score 1: Strong\u003cbr/\u003eActivity score 1.5: Moderate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eDPYD\u003c/em\u003e Poor Metabolizer\u003c/td\u003e\u003ctd\u003e0 or 0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles or an individual carrying one no function plus one decreased function allele\u003c/td\u003e\u003ctd\u003ec.[1905+1G\u0026gt;A];[1905+1G\u0026gt;A], c.[1679T\u0026gt;G];[1679T\u0026gt;G], c.[1905+1G\u0026gt;A];[2846A\u0026gt;T] c.[1905+1G\u0026gt;A];[1129-5923C\u0026gt;G]\u003c/td\u003e\u003ctd\u003eComplete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs\u003c/td\u003e\u003ctd\u003eActivity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose\u003csup\u003ek\u003c/sup\u003e with early therapeutic drug monitoring.\u003csup\u003el\u003c/sup\u003e\u003cbr/\u003eActivity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Calculated as the sum of the two lowest individual variant activity scores. See main guideline for further information.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e Allele definitions, assignment of allele function and references can be found using the \u003ca href\u003d\""https://www.pharmgkb.org/page/dpydRefMaterials\""\u003eDPYD Allele Functionality Table\u003c/a\u003e.\u003cbr /\u003e\n\u003csup\u003ec\u003c/sup\u003e HGVS nomenclature using the reference sequence NM_000110.3.\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003e Rating scheme described in the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf\"" target\u003d\""_blank\""\u003eSupplement\u003c/a\u003e.\u003cbr /\u003e\n\u003csup\u003ee\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153648\""\u003ers1801265\u003c/a\u003e or DPYD*9A\u003cbr /\u003e\n\u003csup\u003ef\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153646\""\u003ers1801159\u003c/a\u003e or DPYD*5\u003cbr /\u003e\n\u003csup\u003eg\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153760\""\u003ers3918290\u003c/a\u003e or DPYD*2A\u003cbr /\u003e\n\u003csup\u003eh\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153888\""\u003ers55886062\u003c/a\u003e or DPYD*13\u003cbr /\u003e\n\u003csup\u003ei\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153895\""\u003ers67376798\u003c/a\u003e\u003cbr /\u003e\n\u003csup\u003ej\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153906\""\u003ers75017182\u003c/a\u003e. Likely HapB3 causal variant. See \u003ca href\u003d\""https://www.pharmgkb.org/page/dpydRefMaterials\""\u003eDPYD Allele Functionality Table\u003c/a\u003e for other HapB3 proxy SNPs.\u003cbr /\u003e\n\u003csup\u003ek\u003c/sup\u003e If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of \u0026lt;25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance.\u003cbr /\u003e\n\u003csup\u003el\u003c/sup\u003e Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue the infusion if the drug level is too high.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2014-update-on-pharmgkb\""\u003eMay 2014 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe CPIC authors recommend that the \u003cem\u003eDPYD*4\u003c/em\u003e, \u003cem\u003e*5\u003c/em\u003e, \u003cem\u003e*6\u003c/em\u003e and \u003cem\u003e*9A\u003c/em\u003e alleles be categorized as \u0026quot;normal\u0026quot; activity, in part based upon the recent publication \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.ncbi.nlm.nih.gov/pubmed/?term\u003d24648345\"" target\u003d\""_blank\""\u003eComparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity\u003c/a\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2013-publication\""\u003eDecember 2013 Publication\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication October 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in \u003cem\u003eClinical Pharmacology and Therapeutics\u003c/em\u003e by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983463E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/""}]},""status"":""success""}"
PA166104963,Guideline Annotation,Annotation of DPWG Guideline for capecitabine and DPYD,t,PA448771,Dutch Pharmacogenetics Working Group,"<p>An alternative drug to capecitabine is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for capecitabine, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as &quot;essential&quot; and recommend DPYD testing prior to initiating fluoropyrimidines.</p>
","<h3 id=""dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-of-dpyd-and-fluoropyrimidines-european-journal-of-human-genetics-2019"">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <em>European journal of human genetics (2019)</em></h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines as per the August 2019 update including more details and scoring the clinical implementation <a href=""/literature/15104402"">PMID: 31745289</a>.</p>
<h3 id=""august-2019-update"">August 2019 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil and capecitabine based on DPYD genotype. An alternative drug or reduction in dose is recommended for patients with DPYD activity scores of 0, 1 and 1.5. Patients with genotypes defined by the FENO group should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative, as it is also metabolized by DPD.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>Activity Score 0</td><td>fluorouracil/capecitabine, systemic</td><td>The gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the standard dose is a more than 100-fold overdose.</td><td>1. Avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolised by DPD.<br/>2. If if is not possible to avoid fluorouracil and capecitabine: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped).</td></tr>
<tr><td>Activity Score 1</td><td>fluorouracil/capecitabine</td><td>The gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 50% of the standard dose or avoid fluorouracil and capecitabine. Adjustment of the subsequent dose should be guided by toxicity and effectiveness. However, in one study involving 17 patients with gene activity 1, the average dose after titration was 57% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD.</td></tr>
<tr><td>Activity Score 1.5</td><td>fluorouracil/capecitabine</td><td>The gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 50% of the standard dose or avoid fluorouracil and capecitabine. After starting treatment, the dose should be adjusted based on toxicity and effectiveness. In a study involving 17 patients with genotype <em>1/2846T</em>, the average dose after titration was 64% of the standard dose. For 51 patients with genotype <em>1/1236A</em>, the average dose after titration was 74% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD.</td></tr>
<tr><td>FENO</td><td>fluorouracil/capecitabine</td><td>The gene variation increases the risk of severe, potentially fatal, toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>It is not possible to recommend a dose adjustment for this patient based on the genotype only.<br/>Determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose based on phenotype and genotype, or avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolized by DPD.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0006192.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil and capecitabine based on DPYD genotype. An alternative drug or reduction in dose is recommended for patients with DPYD activity scores of 0, 0.5, 1 and 1.5. Tegafur is not an alternative, as it is also metabolized by DPD.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>Activity Score 0</td><td>fluorouracil/capecitabine, systemic</td><td>Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the standard dose is a more than 100-fold overdose.</td><td>1. Choose an alternative. Tegafur is not an alternative, as this is also metabolised by DPD.<br/>2. If an alternative is not possible: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped). The average Caucasian DPD activity is 9.9 nmol/hour per mg protein. Or, adjust the initial dose based on toxicity and efficacy.<br/><em>NOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and *13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 0.5</td><td>fluorouracil/capecitabine</td><td>Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 25% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.<br/><em>NOTE: This recommendation only applies if the two genetic variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 1</td><td>fluorouracil/capecitabine</td><td>Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 50% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.<br/><em>NB1: The dose reduction described here is well substantiated for *1/*2A and 1236A/1236A. The dose reduction for patients with 2846T (2846T/2846T or 1236A/2846T) is based on, among other factors, the dose reductions identified for *1/2846T.</em><br/><em>NB2: If a patient has two different genetic variations that result in a partially functional DPD enzyme (e.g. 2846T and 1236A), this recommendation applies if the variations are on a different allele. If both variations are on the same allele, the gene activity score is between 1 and 1.5, depending on whether and how the two gene variations influence each other and on other factors that influence the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two different genetic variations can only be determined by measuring the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 1.5</td><td>fluorouracil/capecitabine</td><td>Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 75% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002551.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for capecitabine (a fluorouracil prodrug) based on DPYD genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend that an alternate drug be used for poor metabolizer patients, and a reduced dose or alternate drug for intermediate metabolizer patients.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles, 2 decreased activity alleles, or one inactive and one decreased activity alleles)</td><td>Select alterantive drug.  Tegafur is not a suitable alternative because this drug is also metabolized by DPD.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
<tr><td>IM (1 active allele and 1 inactive or decreased activity allele)</td><td>Reduce dose by 50% or select alternative drug.  Tegafur is not a suitable alternative because this drug is also a substrate for DPD.  Increase dose in response to toxicity and efficacy.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *4, *5, *6, *9A</td></tr>
<tr><td>decreased activity</td><td>*9B, *10</td></tr>
<tr><td>inactive</td><td>*2A, *3, *7, *8, *11, *12, *13, 496A&gt;G, IVS10-15T&gt;C, 1156G&gt;T, 1845G&gt;T</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104963"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104963"",""name"":""Annotation of DPWG Guideline for capecitabine and DPYD"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704449E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415714E9,""date"":""2019-06-03T11:15:05.391-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820718E9,""date"":""2019-10-04T09:19:43.669-07:00"",""description"":""Changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.45095628E9,""date"":""2020-01-31T13:20:21.635-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450962721E9,""date"":""2020-02-10T10:23:14.123-08:00"",""description"":""Fixed links to 2019 guideline pdfs. 2018 link already went to attachment."",""type"":""Update"",""version"":0.0},{""id"":1.45096584E9,""date"":""2020-02-13T09:57:03.871-08:00"",""description"":""Added text and links to DPYD guideline individual paper PMID: 31745289"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15104402"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5104402E7,""resourceId"":""31745289"",""title"":""Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/31745289"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/31745289"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.45096468E9,""resource"":""PubMed"",""resourceId"":""31745289"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/31745289""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/s41431-019-0540-0"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450964681E9,""resource"":""DOI"",""resourceId"":""10.1038/s41431-019-0540-0"",""_url"":""http://dx.doi.org/10.1038%2Fs41431-019-0540-0""}]},{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448771"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448771"",""name"":""capecitabine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA145"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA145"",""symbol"":""DPYD"",""name"":""dihydropyrimidine dehydrogenase""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981934E9,""html"":""\u003cp\u003eAn alternative drug to capecitabine is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for capecitabine, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as \u0026quot;essential\u0026quot; and recommend DPYD testing prior to initiating fluoropyrimidines.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981933E9,""html"":""\u003ch3 id\u003d\""dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-of-dpyd-and-fluoropyrimidines-european-journal-of-human-genetics-2019\""\u003eDutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. \u003cem\u003eEuropean journal of human genetics (2019)\u003c/em\u003e\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines as per the August 2019 update including more details and scoring the clinical implementation \u003ca href\u003d\""/literature/15104402\""\u003ePMID: 31745289\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""august-2019-update\""\u003eAugust 2019 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil and capecitabine based on DPYD genotype. An alternative drug or reduction in dose is recommended for patients with DPYD activity scores of 0, 1 and 1.5. Patients with genotypes defined by the FENO group should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative, as it is also metabolized by DPD.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine, systemic\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the standard dose is a more than 100-fold overdose.\u003c/td\u003e\u003ctd\u003e1. Avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolised by DPD.\u003cbr/\u003e2. If if is not possible to avoid fluorouracil and capecitabine: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 50% of the standard dose or avoid fluorouracil and capecitabine. Adjustment of the subsequent dose should be guided by toxicity and effectiveness. However, in one study involving 17 patients with gene activity 1, the average dose after titration was 57% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1.5\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 50% of the standard dose or avoid fluorouracil and capecitabine. After starting treatment, the dose should be adjusted based on toxicity and effectiveness. In a study involving 17 patients with genotype \u003cem\u003e1/2846T\u003c/em\u003e, the average dose after titration was 64% of the standard dose. For 51 patients with genotype \u003cem\u003e1/1236A\u003c/em\u003e, the average dose after titration was 74% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eFENO\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, potentially fatal, toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eIt is not possible to recommend a dose adjustment for this patient based on the genotype only.\u003cbr/\u003eDetermine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose based on phenotype and genotype, or avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolized by DPD.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0006192.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil and capecitabine based on DPYD genotype. An alternative drug or reduction in dose is recommended for patients with DPYD activity scores of 0, 0.5, 1 and 1.5. Tegafur is not an alternative, as it is also metabolized by DPD.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine, systemic\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the standard dose is a more than 100-fold overdose.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative. Tegafur is not an alternative, as this is also metabolised by DPD.\u003cbr/\u003e2. If an alternative is not possible: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped). The average Caucasian DPD activity is 9.9 nmol/hour per mg protein. Or, adjust the initial dose based on toxicity and efficacy.\u003cbr/\u003e\u003cem\u003eNOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and *13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0.5\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 25% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.\u003cbr/\u003e\u003cem\u003eNOTE: This recommendation only applies if the two genetic variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 50% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.\u003cbr/\u003e\u003cem\u003eNB1: The dose reduction described here is well substantiated for *1/*2A and 1236A/1236A. The dose reduction for patients with 2846T (2846T/2846T or 1236A/2846T) is based on, among other factors, the dose reductions identified for *1/2846T.\u003c/em\u003e\u003cbr/\u003e\u003cem\u003eNB2: If a patient has two different genetic variations that result in a partially functional DPD enzyme (e.g. 2846T and 1236A), this recommendation applies if the variations are on a different allele. If both variations are on the same allele, the gene activity score is between 1 and 1.5, depending on whether and how the two gene variations influence each other and on other factors that influence the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two different genetic variations can only be determined by measuring the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1.5\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 75% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002551.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for capecitabine (a fluorouracil prodrug) based on DPYD genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend that an alternate drug be used for poor metabolizer patients, and a reduced dose or alternate drug for intermediate metabolizer patients.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles, 2 decreased activity alleles, or one inactive and one decreased activity alleles)\u003c/td\u003e\u003ctd\u003eSelect alterantive drug.  Tegafur is not a suitable alternative because this drug is also metabolized by DPD.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (1 active allele and 1 inactive or decreased activity allele)\u003c/td\u003e\u003ctd\u003eReduce dose by 50% or select alternative drug.  Tegafur is not a suitable alternative because this drug is also a substrate for DPD.  Increase dose in response to toxicity and efficacy.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *4, *5, *6, *9A\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9B, *10\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*2A, *3, *7, *8, *11, *12, *13, 496A\u0026gt;G, IVS10-15T\u0026gt;C, 1156G\u0026gt;T, 1845G\u0026gt;T\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166105008,Guideline Annotation,"Annotation of CPIC Guideline for carbamazepine and HLA-A,HLA-B",t,PA448785,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either <em>HLA-B*15:02</em> or <em>HLA-A*31:01</em> due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, <em>HLA-A*31:01</em> is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"" target=""_blank"">CPIC&reg; guideline for carbamazepine, <em>HLA-B</em> and <em>HLA-A</em></a>.</p>
<h3 id=""december-2017"">December 2017</h3>
<p><em>Accepted article preview online January 2018; Advance online publication February 2018.</em></p>
<ul>
<li>The 2017 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of carbamazepine have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Literature up to June 2016 was reviewed, recommendations and supplemental information were updated.</li>
<li>Excerpt from the 2017 dosing guideline update:
<ul>
<li>&quot;There is evidence linking <em>HLA-B*15:02</em> genotype with the risk of carbamazepine- and oxcarbazepine-induced SJS/TEN and linking <em>HLA-A*31:01</em> genotype with the risk of carbamazepine-induced SJS/TEN, DRESS and MPE.&quot;</li>
<li>&quot;Data describing the relationship between <em>HLA-B*15:02</em> and <em>HLA-A*31:01</em> genotype and carbamazepine- or oxcarbazepine-induced cutaneous adverse reactions in pediatric patients are scarce. In the absence of data suggesting a different relationship between these <em>HLA</em> alleles and drug-induced hypersensitivity in pediatric patients, the recommendations may be used to guide use of carbamazepine and oxcarbazepine in both adult and pediatric patients.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <em>HLA</em> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC_Supplemental_Material.pdf"" target=""_blank"">2017 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/hlabRefMaterials"">HLA Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/Carbamazepine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Carbamazepine Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/CBZ_OXC_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Carbamazepine and Oxcarbazepine Pre and Post Tests Alerts and Flow Chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-carbamazepine-therapy-recommendations-based-on-hla-b-and-hla-a-genotype"">Table 1: Carbamazepine therapy recommendations based on <em>HLA-B</em> and <em>HLA-A</em> genotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2017 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of Diplotypes</th><th>Phenotypic Implications</th><th>Therapeutic Recommendations</th><th>Classification of Recommendation <sup>a</sup></th><th>Considerations for other aromatic anticonvulsants</th></tr>
</thead>
<tbody>
<tr><td>Homozygous for alleles other than <em>HLA-B*15:02</em> and <em>HLA-A*31:01</em></td><td>Non-carrier of <em>HLA-B*15:02</em> or <em>HLA-A*31:01</em>.  No <em>HLA-B*15:02</em> or <em>HLA-A*31:01</em> alleles reported, often reported as &quot;negative&quot; on genotyping tests.</td><td>*X/*X <sup>b</sup><br/>*Y/*Y <sup>c</sup></td><td>Normal or reduced risk of carbamazepine-induced SJS/TEN, DRESS and MPE.</td><td>Use carbamazepine per standard dosing guidelines. <sup>d</sup></td><td>Strong</td><td></td></tr>
<tr><td>Heterozygote or homozygous for <em>HLA-A*31:01</em> and homozygous for <em>HLA-B</em> alleles other than <em>*15:02</em></td><td>Carrier of <em>HLA-A*31:01</em>.  One or two <em>*31:01</em> alleles, often reported as &quot;positive&quot; on a genotyping test.<br/>Non-carrier of <em>HLA-B*15:02</em>.  No <em>HLA-B*15:02</em> alleles reported, often reported as &quot;negative&quot; on genotyping tests.</td><td>*X/*X <sup>b</sup><br/><em>*31:01</em>/*Y <sup>c</sup><br/><em>*31:01/*31:01</em></td><td>Increased risk of carbamazepine-induced SJS/TEN, DRESS and MPE</td><td>A. If patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine.<br/>B. If patient is carbamazepine-naive and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.<br/>C. The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within 3 months of regular dosing. Therefore, if patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.</td><td>A. Strong<br/>B. Optional<br/>C. Optional</td><td>A. Other aromatic anticonvulsants (e.g. eslicarbazepine, lamotrigine, phenytoin, fosphenytoin and phenoarbital) have very limited evidence, if any, linking SJS/TEN, DRESS and/or MPE with the _HLA-A*31:01 allele, and thus no recommendation can be made with respect to choosing another aromatic anticonvulsant as an alternative agent.<br/>C. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.</td></tr>
<tr><td>Heterozygote or homozygous for <em>HLA-B*15:02</em> and any <em>HLA-A*31:01</em> genotype (or <em>HLA-A*31:01</em> genotype unknown)</td><td>Carrier of <em>HLA-B*15:02</em>.  One or two <em>*15:02</em> alleles, often reported as &quot;positive&quot; on a genotyping test.</td><td><em>*15:02</em>/*X <sup>b</sup><br/><em>*15:02</em>/<em>*15:02</em></td><td>Increased risk of carbamazepine-induced SJS/TEN</td><td>A. If patient is carbamazepine-naive, do not use carbamazepine.<br/>B. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherance to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.</td><td>A. Strong<br/>B. Optional</td><td>A. Other aromatic anticonvulsants (e.g. eslicarbazepine, lamotrigine, phenytoin, fosphenytoin and phenoarbital) have weaker evidence linking SJS/TEN with the <em>HLA-B*15:02</em> allele; however, caution should still be used in choosing an alternative agent.<br/>B. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.</td></tr>
</tbody>
</table>
<p><sup>a</sup> Rating scheme described in the 2017 update supplement (see above)</p>
<p><sup>b</sup> *X = any <em>HLA-B</em> genotype other than <em>*15:02</em></p>
<p><sup>c</sup> *Y = any <em>HLA-A</em> genotype other than <em>*31:01</em></p>
<p><em>HLA-B</em> = human leukocyte antigen B</p>
<p><em>HLA-A</em> = human leukocyte antigen A</p>
<p><sup>d</sup> <em>HLA-B*15:02</em> has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of <em>HLA-B*15:02</em> for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative <em>HLA-B*15:02</em> test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN.</p>
<h3 id=""september-2013"">September 2013</h3>
<p><em>Accepted article preview online May 2013; Advance online publication June 2013.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for carbamazepine have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpt from the 2013 carbamazepine dosing guidelines:</li>
</ul>
<blockquote class=""blockquote"">
<p>Human leukocyte antigen B (<em>HLA-B</em>) is a gene that encodes a cell surface protein involved in presenting antigens to the immune system.  The variant allele <em>HLA-B*15:02</em> is associated with an increased risk of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) in response to carbamazepine treatment.   We summarize evidence from the published literature supporting this association and provide recommendations for the use of carbamazepine based on <em>HLA-B</em> genotype.</p>
</blockquote>
<ul>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/2013/23695185.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Carbamazepine Dosing</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/2013/23695185-supplement.pdf"" target=""_blank"">2013 supplement</a>.</li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166105008"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166105008"",""name"":""Annotation of CPIC Guideline for carbamazepine and HLA-A,HLA-B"",""cancerGenome"":false,""descriptiveVideoId"":""AFD2W7ugz2I"",""guidelineGenes"":[{""id"":1.449561429E9,""alleles"":[{""id"":1.44956143E9,""_label"":""Other"",""allele"":""Other"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558334"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558334E9,""resource"":""Allele Function"",""term"":""Absence"",""termId"":""haplotypeTags:1445558334""}},{""id"":1.449561431E9,""_label"":""*31:01:02"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165954030"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165954030"",""symbol"":""HLA-A*31:01:02"",""name"":""*31:01:02""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA35055"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35055"",""symbol"":""HLA-A"",""name"":""major histocompatibility complex, class I, A""}},{""id"":1.449561432E9,""alleles"":[{""id"":1.449561433E9,""_label"":""Other"",""allele"":""Other"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558334"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558334E9,""resource"":""Allele Function"",""term"":""Absence"",""termId"":""haplotypeTags:1445558334""}},{""id"":1.449561434E9,""_label"":""*15:02:01"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165954769"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165954769"",""symbol"":""HLA-B*15:02:01"",""name"":""*15:02:01""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}}],""history"":[{""id"":1.183699768E9,""date"":""2013-05-21T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.4491676E9,""date"":""2018-02-07T22:42:48.154-08:00"",""description"":""guideline update"",""type"":""Update"",""version"":0.0},{""id"":1.450372859E9,""date"":""2019-03-20T14:12:46.696-07:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15100356"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100356E7,""resourceId"":""29392710"",""title"":""Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847474"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5847474"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449292006E9,""resource"":""PubMed Central"",""resourceId"":""PMC5847474"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847474""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/29392710"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449292005E9,""resource"":""PubMed"",""resourceId"":""29392710"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/29392710""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1004"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449292007E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1004"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1004""}]},{""@id"":""https://pharmgkb.org/literature/15058356"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5058356E7,""resourceId"":""23695185"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748365"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3748365"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449276532E9,""resource"":""PubMed Central"",""resourceId"":""PMC3748365"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748365""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23695185"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449276531E9,""resource"":""PubMed"",""resourceId"":""23695185"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23695185""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.103"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449276533E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.103"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.103""}]},{""@id"":""https://pharmgkb.org/literature/15100921"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100921E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""title"":""CPIC® Guideline for HLA genotype and Use of Carbamazepine and Oxcarbazepine – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983473E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448785"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448785"",""name"":""carbamazepine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35055"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35055"",""symbol"":""HLA-A"",""name"":""major histocompatibility complex, class I, A""},{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.44798198E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline update for carbamazepine recommends an alternative drug for carbamazepine-naive patients carrying at least one copy of either \u003cem\u003eHLA-B*15:02\u003c/em\u003e or \u003cem\u003eHLA-A*31:01\u003c/em\u003e due to the association of those alleles with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In addition, \u003cem\u003eHLA-A*31:01\u003c/em\u003e is associated with an increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) and maculopapular exanthema (MPE).\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981979E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for carbamazepine, \u003cem\u003eHLA-B\u003c/em\u003e and \u003cem\u003eHLA-A\u003c/em\u003e\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""december-2017\""\u003eDecember 2017\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online January 2018; Advance online publication February 2018.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2017 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of carbamazepine have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Literature up to June 2016 was reviewed, recommendations and supplemental information were updated.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2017 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;There is evidence linking \u003cem\u003eHLA-B*15:02\u003c/em\u003e genotype with the risk of carbamazepine- and oxcarbazepine-induced SJS/TEN and linking \u003cem\u003eHLA-A*31:01\u003c/em\u003e genotype with the risk of carbamazepine-induced SJS/TEN, DRESS and MPE.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Data describing the relationship between \u003cem\u003eHLA-B*15:02\u003c/em\u003e and \u003cem\u003eHLA-A*31:01\u003c/em\u003e genotype and carbamazepine- or oxcarbazepine-induced cutaneous adverse reactions in pediatric patients are scarce. In the absence of data suggesting a different relationship between these \u003cem\u003eHLA\u003c/em\u003e alleles and drug-induced hypersensitivity in pediatric patients, the recommendations may be used to guide use of carbamazepine and oxcarbazepine in both adult and pediatric patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for \u003cem\u003eHLA\u003c/em\u003e Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC_Supplemental_Material.pdf\"" target\u003d\""_blank\""\u003e2017 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/hlabRefMaterials\""\u003eHLA Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/Carbamazepine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eCarbamazepine Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/CBZ_OXC_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eCarbamazepine and Oxcarbazepine Pre and Post Tests Alerts and Flow Chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-carbamazepine-therapy-recommendations-based-on-hla-b-and-hla-a-genotype\""\u003eTable 1: Carbamazepine therapy recommendations based on \u003cem\u003eHLA-B\u003c/em\u003e and \u003cem\u003eHLA-A\u003c/em\u003e genotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2017 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of Diplotypes\u003c/th\u003e\u003cth\u003ePhenotypic Implications\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003c/th\u003e\u003cth\u003eClassification of Recommendation \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eConsiderations for other aromatic anticonvulsants\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eHomozygous for alleles other than \u003cem\u003eHLA-B*15:02\u003c/em\u003e and \u003cem\u003eHLA-A*31:01\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eNon-carrier of \u003cem\u003eHLA-B*15:02\u003c/em\u003e or \u003cem\u003eHLA-A*31:01\u003c/em\u003e.  No \u003cem\u003eHLA-B*15:02\u003c/em\u003e or \u003cem\u003eHLA-A*31:01\u003c/em\u003e alleles reported, often reported as \u0026quot;negative\u0026quot; on genotyping tests.\u003c/td\u003e\u003ctd\u003e*X/*X \u003csup\u003eb\u003c/sup\u003e\u003cbr/\u003e*Y/*Y \u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eNormal or reduced risk of carbamazepine-induced SJS/TEN, DRESS and MPE.\u003c/td\u003e\u003ctd\u003eUse carbamazepine per standard dosing guidelines. \u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eHeterozygote or homozygous for \u003cem\u003eHLA-A*31:01\u003c/em\u003e and homozygous for \u003cem\u003eHLA-B\u003c/em\u003e alleles other than \u003cem\u003e*15:02\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eCarrier of \u003cem\u003eHLA-A*31:01\u003c/em\u003e.  One or two \u003cem\u003e*31:01\u003c/em\u003e alleles, often reported as \u0026quot;positive\u0026quot; on a genotyping test.\u003cbr/\u003eNon-carrier of \u003cem\u003eHLA-B*15:02\u003c/em\u003e.  No \u003cem\u003eHLA-B*15:02\u003c/em\u003e alleles reported, often reported as \u0026quot;negative\u0026quot; on genotyping tests.\u003c/td\u003e\u003ctd\u003e*X/*X \u003csup\u003eb\u003c/sup\u003e\u003cbr/\u003e\u003cem\u003e*31:01\u003c/em\u003e/*Y \u003csup\u003ec\u003c/sup\u003e\u003cbr/\u003e\u003cem\u003e*31:01/*31:01\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eIncreased risk of carbamazepine-induced SJS/TEN, DRESS and MPE\u003c/td\u003e\u003ctd\u003eA. If patient is carbamazepine-naive and alternative agents are available, do not use carbamazepine.\u003cbr/\u003eB. If patient is carbamazepine-naive and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.\u003cbr/\u003eC. The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within 3 months of regular dosing. Therefore, if patient has previously used carbamazepine for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.\u003c/td\u003e\u003ctd\u003eA. Strong\u003cbr/\u003eB. Optional\u003cbr/\u003eC. Optional\u003c/td\u003e\u003ctd\u003eA. Other aromatic anticonvulsants (e.g. eslicarbazepine, lamotrigine, phenytoin, fosphenytoin and phenoarbital) have very limited evidence, if any, linking SJS/TEN, DRESS and/or MPE with the _HLA-A*31:01 allele, and thus no recommendation can be made with respect to choosing another aromatic anticonvulsant as an alternative agent.\u003cbr/\u003eC. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eHeterozygote or homozygous for \u003cem\u003eHLA-B*15:02\u003c/em\u003e and any \u003cem\u003eHLA-A*31:01\u003c/em\u003e genotype (or \u003cem\u003eHLA-A*31:01\u003c/em\u003e genotype unknown)\u003c/td\u003e\u003ctd\u003eCarrier of \u003cem\u003eHLA-B*15:02\u003c/em\u003e.  One or two \u003cem\u003e*15:02\u003c/em\u003e alleles, often reported as \u0026quot;positive\u0026quot; on a genotyping test.\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*15:02\u003c/em\u003e/*X \u003csup\u003eb\u003c/sup\u003e\u003cbr/\u003e\u003cem\u003e*15:02\u003c/em\u003e/\u003cem\u003e*15:02\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eIncreased risk of carbamazepine-induced SJS/TEN\u003c/td\u003e\u003ctd\u003eA. If patient is carbamazepine-naive, do not use carbamazepine.\u003cbr/\u003eB. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherance to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.\u003c/td\u003e\u003ctd\u003eA. Strong\u003cbr/\u003eB. Optional\u003c/td\u003e\u003ctd\u003eA. Other aromatic anticonvulsants (e.g. eslicarbazepine, lamotrigine, phenytoin, fosphenytoin and phenoarbital) have weaker evidence linking SJS/TEN with the \u003cem\u003eHLA-B*15:02\u003c/em\u003e allele; however, caution should still be used in choosing an alternative agent.\u003cbr/\u003eB. Previous tolerance of carbamazepine is not indicative of tolerance to other aromatic anticonvulsants.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Rating scheme described in the 2017 update supplement (see above)\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e *X \u003d any \u003cem\u003eHLA-B\u003c/em\u003e genotype other than \u003cem\u003e*15:02\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e *Y \u003d any \u003cem\u003eHLA-A\u003c/em\u003e genotype other than \u003cem\u003e*31:01\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eHLA-B\u003c/em\u003e \u003d human leukocyte antigen B\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eHLA-A\u003c/em\u003e \u003d human leukocyte antigen A\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e \u003cem\u003eHLA-B*15:02\u003c/em\u003e has a 100% negative predictive value for carbamazepine-induced SJS/TEN, and its use is currently recommended to guide use of carbamazepine and oxcarbazepine only. Because there is a much weaker association and less than 100% negative predictive value of \u003cem\u003eHLA-B*15:02\u003c/em\u003e for SJS/TEN associated with other aromatic anticonvulsants, using these drugs instead of carbamazepine or oxcarbazepine in the setting of a negative \u003cem\u003eHLA-B*15:02\u003c/em\u003e test in Southeast Asians will not result in prevention of anticonvulsant-associated SJS/TEN.\u003c/p\u003e\n\u003ch3 id\u003d\""september-2013\""\u003eSeptember 2013\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online May 2013; Advance online publication June 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for carbamazepine have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2013 carbamazepine dosing guidelines:\u003c/li\u003e\n\u003c/ul\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003eHuman leukocyte antigen B (\u003cem\u003eHLA-B\u003c/em\u003e) is a gene that encodes a cell surface protein involved in presenting antigens to the immune system.  The variant allele \u003cem\u003eHLA-B*15:02\u003c/em\u003e is associated with an increased risk of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) in response to carbamazepine treatment.   We summarize evidence from the published literature supporting this association and provide recommendations for the use of carbamazepine based on \u003cem\u003eHLA-B\u003c/em\u003e genotype.\u003c/p\u003e\n\u003c/blockquote\u003e\n\u003cul\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/2013/23695185.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for \u003cem\u003eHLA-B\u003c/em\u003e Genotype and Carbamazepine Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/2013/23695185-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983473E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/""}]},""status"":""success""}"
PA166117280,Guideline Annotation,Annotation of CPNDS Guideline for carbamazepine and HLA-B,t,PA448785,Canadian Pharmacogenomics Network for Drug Safety,"<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-B*15:02 genotype when prescribing carbamazepine (CBZ).  They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-B*15:02 allele.</p>
","<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published HLA-B based drug dosing guidelines for carbamazepine in <em>Epilepsia</em>.  Excerpts from &quot;Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions&quot; [Article:<a href=""/pmid/24597466"">24597466</a>] follow:</p>
<blockquote class=""blockquote"">
<p>Genetic testing for HLA-B*15:02 is recommended for all CBZ-naive patients before initiation of CBZ therapy...In patients who have previously taken CBZ for &gt; 3 months without any adverse effects, and in whom reinitiation of CBZ is considered, genetic testing is NOT recommended (B). In patients who have previously taken CBZ for a shorter period, genetic testing should be considered (B)...In patients who are positive for HLA-B*15:02 or HLA-A*31:01, alternative medications should be used as first-line therapy (A). Consideration in the choice of alternative medications should be given to the possibility of cross-reactivity with structurally simiar AEDs (oxcarbazepine, lamotrigine, phenytoin, phe- nobarbital, primidone).</p>
</blockquote>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166117280"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166117280"",""name"":""Annotation of CPNDS Guideline for carbamazepine and HLA-B"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.183944054E9,""date"":""2014-03-11T00:00:00-07:00"",""type"":""Create"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15071835"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5071835E7,""resourceId"":""24597466"",""title"":""Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/24597466"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/24597466"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279963E9,""resource"":""PubMed"",""resourceId"":""24597466"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/24597466""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1111/epi.12564"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279964E9,""resource"":""DOI"",""resourceId"":""10.1111/epi.12564"",""_url"":""http://dx.doi.org/10.1111%2Fepi.12564""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448785"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448785"",""name"":""carbamazepine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Canadian Pharmacogenomics Network for Drug Safety"",""summaryMarkdown"":{""id"":1.447982069E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-B*15:02 genotype when prescribing carbamazepine (CBZ).  They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-B*15:02 allele.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982068E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published HLA-B based drug dosing guidelines for carbamazepine in \u003cem\u003eEpilepsia\u003c/em\u003e.  Excerpts from \u0026quot;Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions\u0026quot; [Article:\u003ca href\u003d\""/pmid/24597466\""\u003e24597466\u003c/a\u003e] follow:\u003c/p\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003eGenetic testing for HLA-B*15:02 is recommended for all CBZ-naive patients before initiation of CBZ therapy...In patients who have previously taken CBZ for \u0026gt; 3 months without any adverse effects, and in whom reinitiation of CBZ is considered, genetic testing is NOT recommended (B). In patients who have previously taken CBZ for a shorter period, genetic testing should be considered (B)...In patients who are positive for HLA-B*15:02 or HLA-A*31:01, alternative medications should be used as first-line therapy (A). Consideration in the choice of alternative medications should be given to the possibility of cross-reactivity with structurally simiar AEDs (oxcarbazepine, lamotrigine, phenytoin, phe- nobarbital, primidone).\u003c/p\u003e\n\u003c/blockquote\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104956,Guideline Annotation,Annotation of DPWG Guideline for clopidogrel and CYP2C19,t,PA449053,Dutch Pharmacogenetics Working Group,"<p>Avoid clopidogrel use in patients who are CYP2C19 poor metabolizers and are undergoing percutaneous coronary intervention, stroke or TIA. For CYP2C19 intermediate metabolizers who are undergoing percutaneous coronary intervention, stroke, or TIA, choose an alternative drug or double the dose to 150 mg/day (600 mg loading dose). No action is required for patients who are CYP2C19 ultra-rapid metabolizers.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clopidogrel based on CYP2C19 genotype. In patients who are undergoing percutaneous coronary intervention, stroke, or TIA, they recommend avoiding clopidogrel use in CYP2C19 poor metabolizers, and choosing an alternative drug or doubling the dose to 150 mg/day (600 mg loading dose) in CYP2C19 intermediate metabolizers. No action is required for CYP2C19 ultrarapid metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 PM</td><td>clopidogrel</td><td>The risk of serious cardiovascular and cerebrovascular events is increased in patients undergoing balloon angioplasty or stent placement (percutaneous coronary intervention) and in patients with a stroke or TIA, because the genetic variation reduces the activation of clopidogrel. No negative clinical consequences have been proved in other patients.</td><td><strong>PERCUTANEOUS CORONARY INTERVENTION, STROKE or TIA:</strong> avoid clopidogrel. Prasugrel, ticagrelor and acetylsalicylic acid/dipyridamole are not metabolised by CYP2C19 (or to a lesser extent).<br/><strong>OTHER INDICATIONS:</strong> determine the level of inhibition of platelet aggregation by clopidogrel. Consider an alternative in poor responders. Prasugrel and ticagrelor are not metabolised by CYP2C19 (or to a lesser extent).</td></tr>
<tr><td>CYP2C19 IM</td><td>clopidogrel</td><td>The risk of serious cardiovascular and cerebrovascular events is increased in patients undergoing balloon angioplasty or stent placement (percutaneous coronary intervention) and in patients with a stroke or TIA, as the genetic variation reduces the activation of clopidogrel. No negative clinical consequences have been observed in other patients.</td><td><strong>PERCUTANEOUS CORONARY INTERVENTION, STROKE or TIA</strong>: choose an alternative or double the dose to 150 mg/day (600 mg loading dose). Prasugrel, ticagrelor and acetylsalicylic acid/dipyridamole are not metabolised by CYP2C19 (or to a lesser extent).<br/><strong>OTHER INDICATIONS:</strong> no action required</td></tr>
<tr><td>CYP2C19 UM</td><td>clopidogrel</td><td>NO action is required for this gene-drug interaction</td><td>The genetic variation results in increased conversion of clopidogrel to the active metabolite. However, this can result in both positive effects (reduction in the risk of serious cardiovascular and cerebrovascular events) and negative effects (increase in the risk of bleeding).</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002549.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clopidogrel based on the <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  For the  <em>CYP2C19</em> PM and IM phenotype they conclude an increased risk for reduced response to clopidogrel and recommend to consider an alternative drug. Prasugrel is not or to a much smaller extent metabolized by CYP2C19 but is associated with an increased bleeding risk compared to clopidogrel.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>Increased risk for reduced response to clopidogrel. Consider alternative drug. Prasugrel is not or to a much smaller extent metabolized by CYP2C19 but is associated with an increased bleeding risk compared to clopidogrel</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Clinical effect (statistically significant difference): death; arrhythmia; unanticipated myelosuppression</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>Increased risk for reduced response to clopidogrel. Consider alternative drug. Prasugrel is not or to a much smaller extent metabolized by CYP2C19 but is associated with an increased bleeding risk compared to clopidogrel</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Clinical effect (statistically significant difference): death; arrhythmia; unanticipated myelosuppression</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>None</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 Kinetic effect (statistically significant difference)</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>#wherever one or more of the &quot;good quality&quot; criteria was missing, the quality of the study was considered to be &quot;moderate&quot;</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104956"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104956"",""name"":""Annotation of DPWG Guideline for clopidogrel and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704457E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414943E9,""date"":""2019-05-23T10:03:00.679-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820785E9,""date"":""2019-10-06T22:56:09.726-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45095632E9,""date"":""2020-01-31T13:22:59.462-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.4509628E9,""date"":""2020-02-10T10:53:26.394-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449053"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449053"",""name"":""clopidogrel""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.4479819E9,""html"":""\u003cp\u003eAvoid clopidogrel use in patients who are CYP2C19 poor metabolizers and are undergoing percutaneous coronary intervention, stroke or TIA. For CYP2C19 intermediate metabolizers who are undergoing percutaneous coronary intervention, stroke, or TIA, choose an alternative drug or double the dose to 150 mg/day (600 mg loading dose). No action is required for patients who are CYP2C19 ultra-rapid metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981899E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clopidogrel based on CYP2C19 genotype. In patients who are undergoing percutaneous coronary intervention, stroke, or TIA, they recommend avoiding clopidogrel use in CYP2C19 poor metabolizers, and choosing an alternative drug or doubling the dose to 150 mg/day (600 mg loading dose) in CYP2C19 intermediate metabolizers. No action is required for CYP2C19 ultrarapid metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 PM\u003c/td\u003e\u003ctd\u003eclopidogrel\u003c/td\u003e\u003ctd\u003eThe risk of serious cardiovascular and cerebrovascular events is increased in patients undergoing balloon angioplasty or stent placement (percutaneous coronary intervention) and in patients with a stroke or TIA, because the genetic variation reduces the activation of clopidogrel. No negative clinical consequences have been proved in other patients.\u003c/td\u003e\u003ctd\u003e\u003cstrong\u003ePERCUTANEOUS CORONARY INTERVENTION, STROKE or TIA:\u003c/strong\u003e avoid clopidogrel. Prasugrel, ticagrelor and acetylsalicylic acid/dipyridamole are not metabolised by CYP2C19 (or to a lesser extent).\u003cbr/\u003e\u003cstrong\u003eOTHER INDICATIONS:\u003c/strong\u003e determine the level of inhibition of platelet aggregation by clopidogrel. Consider an alternative in poor responders. Prasugrel and ticagrelor are not metabolised by CYP2C19 (or to a lesser extent).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 IM\u003c/td\u003e\u003ctd\u003eclopidogrel\u003c/td\u003e\u003ctd\u003eThe risk of serious cardiovascular and cerebrovascular events is increased in patients undergoing balloon angioplasty or stent placement (percutaneous coronary intervention) and in patients with a stroke or TIA, as the genetic variation reduces the activation of clopidogrel. No negative clinical consequences have been observed in other patients.\u003c/td\u003e\u003ctd\u003e\u003cstrong\u003ePERCUTANEOUS CORONARY INTERVENTION, STROKE or TIA\u003c/strong\u003e: choose an alternative or double the dose to 150 mg/day (600 mg loading dose). Prasugrel, ticagrelor and acetylsalicylic acid/dipyridamole are not metabolised by CYP2C19 (or to a lesser extent).\u003cbr/\u003e\u003cstrong\u003eOTHER INDICATIONS:\u003c/strong\u003e no action required\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 UM\u003c/td\u003e\u003ctd\u003eclopidogrel\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction\u003c/td\u003e\u003ctd\u003eThe genetic variation results in increased conversion of clopidogrel to the active metabolite. However, this can result in both positive effects (reduction in the risk of serious cardiovascular and cerebrovascular events) and negative effects (increase in the risk of bleeding).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002549.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clopidogrel based on the \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For the  \u003cem\u003eCYP2C19\u003c/em\u003e PM and IM phenotype they conclude an increased risk for reduced response to clopidogrel and recommend to consider an alternative drug. Prasugrel is not or to a much smaller extent metabolized by CYP2C19 but is associated with an increased bleeding risk compared to clopidogrel.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eIncreased risk for reduced response to clopidogrel. Consider alternative drug. Prasugrel is not or to a much smaller extent metabolized by CYP2C19 but is associated with an increased bleeding risk compared to clopidogrel\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eClinical effect (statistically significant difference): death; arrhythmia; unanticipated myelosuppression\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eIncreased risk for reduced response to clopidogrel. Consider alternative drug. Prasugrel is not or to a much smaller extent metabolized by CYP2C19 but is associated with an increased bleeding risk compared to clopidogrel\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eClinical effect (statistically significant difference): death; arrhythmia; unanticipated myelosuppression\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio increase \u0026lt; 4.5 Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003e#wherever one or more of the \u0026quot;good quality\u0026quot; criteria was missing, the quality of the study was considered to be \u0026quot;moderate\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166184613,Guideline Annotation,Annotation of DPWG Guideline for mercaptopurine and NUDT15,t,PA450379,Dutch Pharmacogenetics Working Group,"<p>Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.</p>
","<h3 id=""august-2019-guideline"">August 2019 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mercaptopurine based on NUDT15 genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers. They updated the wording for the intermediate metabolizer recommendation, reflected in the table below.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>NUDT15 IM</td><td>mercaptopurine</td><td>Grade = 2 leukopaenia occurs in 42% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.</td><td>- IMMUNOSUPPRESSION:start with 50% of the standard dose. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>Note: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of &lt; 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.<br/>Note: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.<br/>- LEUKAEMIA: start at 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction. It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>Note: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of &lt; 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.<br/>Note: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.<br/>Note: more stringent dose reductions are necessary if the patient is also TPMT IM.</td></tr>
<tr><td>NUDT15 PM</td><td>mercaptopurine</td><td>Grade = 2 leukopaenia occurs in 96% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.</td><td>- avoid azathioprine and mercaptopurine.  If it is not possible to avoid azathioprine and mercaptopurine: use 10% of the standard dose and advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur. Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>Note: The percentage of 10% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of &lt; 20% was calculated for NUDT15 PM, but there were insufficient data available to calculate the exact percentage.<br/>Note: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0007035.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166184613"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166184613"",""name"":""Annotation of DPWG Guideline for mercaptopurine and NUDT15"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450821374E9,""date"":""2019-10-08T22:26:21.616-07:00"",""description"":""August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450963584E9,""date"":""2020-02-11T06:25:58.977-08:00"",""description"":""Fixed links to 2019 guideline pdfs."",""type"":""Update"",""version"":0.0},{""id"":1.450963585E9,""date"":""2020-02-11T06:28:06.750-08:00"",""description"":""Changed drug name in table to mercaptopurine from thioguanine"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450379"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450379"",""name"":""mercaptopurine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134963132"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134963132"",""symbol"":""NUDT15"",""name"":""nudix hydrolase 15""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450821371E9,""html"":""\u003cp\u003eSelect an alternative drug or reduce the initial dose of mercaptopurine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450821372E9,""html"":""\u003ch3 id\u003d\""august-2019-guideline\""\u003eAugust 2019 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mercaptopurine based on NUDT15 genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers. They updated the wording for the intermediate metabolizer recommendation, reflected in the table below.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 IM\u003c/td\u003e\u003ctd\u003emercaptopurine\u003c/td\u003e\u003ctd\u003eGrade \u003d 2 leukopaenia occurs in 42% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.\u003c/td\u003e\u003ctd\u003e- IMMUNOSUPPRESSION:start with 50% of the standard dose. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNote: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of \u0026lt; 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.\u003cbr/\u003eNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\u003cbr/\u003e- LEUKAEMIA: start at 50% of the standard mercaptopurine dose, or start with the standard dose and reduce to 50% if side effects necessitate a dose reduction. It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNote: The percentage of 50% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of \u0026lt; 70% was calculated for NUDT15, but there were insufficient data available to calculate the exact percentage.\u003cbr/\u003eNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\u003cbr/\u003eNote: more stringent dose reductions are necessary if the patient is also TPMT IM.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 PM\u003c/td\u003e\u003ctd\u003emercaptopurine\u003c/td\u003e\u003ctd\u003eGrade \u003d 2 leukopaenia occurs in 96% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of azathioprine and mercaptopurine.\u003c/td\u003e\u003ctd\u003e- avoid azathioprine and mercaptopurine.  If it is not possible to avoid azathioprine and mercaptopurine: use 10% of the standard dose and advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur. Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNote: The percentage of 10% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. A percentage of \u0026lt; 20% was calculated for NUDT15 PM, but there were insufficient data available to calculate the exact percentage.\u003cbr/\u003eNote: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0007035.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166117281,Guideline Annotation,Annotation of CPNDS Guideline for carbamazepine and HLA-A,t,PA448785,Canadian Pharmacogenomics Network for Drug Safety,"<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-A*31:01 genotype when prescribing carbamazepine (CBZ). They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-A*31:01 allele.</p>
","<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published HLA-A based drug dosing guidelines for carbamazepine in <em>Epilepsia</em>.  Excerpts from &quot;Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions&quot; [Article:<a href=""/pmid/24597466"">24597466</a>] follow:</p>
<blockquote class=""blockquote"">
<p>Genetic testing for HLA-A*31:01 is recommended for all CBZ-naive patients before initiation of CBZ therapy...In patients who have previously taken CBZ for &gt; 3 months without any adverse effects, and in whom reinitiation of CBZ is considered, genetic testing is NOT recommended (B). In patients who have previously taken CBZ for a shorter period, genetic testing should be considered (B)...In patients who are positive for HLA-B*15:02 or HLA-A*31:01, alternative medications should be used as first-line therapy (A). Consideration in the choice of alternative medications should be given to the possibility of cross-reactivity with structurally simiar AEDs (oxcarbazepine, lamotrigine, phenytoin, phe- nobarbital, primidone).</p>
</blockquote>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166117281"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166117281"",""name"":""Annotation of CPNDS Guideline for carbamazepine and HLA-A"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.183944055E9,""date"":""2014-03-11T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.18451645E9,""date"":""2014-08-19T00:00:00-07:00"",""description"":""corrected a typo for the variant in the summary statement"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15071835"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5071835E7,""resourceId"":""24597466"",""title"":""Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/24597466"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/24597466"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279963E9,""resource"":""PubMed"",""resourceId"":""24597466"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/24597466""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1111/epi.12564"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279964E9,""resource"":""DOI"",""resourceId"":""10.1111/epi.12564"",""_url"":""http://dx.doi.org/10.1111%2Fepi.12564""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448785"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448785"",""name"":""carbamazepine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35055"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35055"",""symbol"":""HLA-A"",""name"":""major histocompatibility complex, class I, A""}],""source"":""Canadian Pharmacogenomics Network for Drug Safety"",""summaryMarkdown"":{""id"":1.447982139E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-A*31:01 genotype when prescribing carbamazepine (CBZ). They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-A*31:01 allele.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982138E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published HLA-A based drug dosing guidelines for carbamazepine in \u003cem\u003eEpilepsia\u003c/em\u003e.  Excerpts from \u0026quot;Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions\u0026quot; [Article:\u003ca href\u003d\""/pmid/24597466\""\u003e24597466\u003c/a\u003e] follow:\u003c/p\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003eGenetic testing for HLA-A*31:01 is recommended for all CBZ-naive patients before initiation of CBZ therapy...In patients who have previously taken CBZ for \u0026gt; 3 months without any adverse effects, and in whom reinitiation of CBZ is considered, genetic testing is NOT recommended (B). In patients who have previously taken CBZ for a shorter period, genetic testing should be considered (B)...In patients who are positive for HLA-B*15:02 or HLA-A*31:01, alternative medications should be used as first-line therapy (A). Consideration in the choice of alternative medications should be given to the possibility of cross-reactivity with structurally simiar AEDs (oxcarbazepine, lamotrigine, phenytoin, phe- nobarbital, primidone).\u003c/p\u003e\n\u003c/blockquote\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104974,Guideline Annotation,Annotation of DPWG Guideline for carvedilol and CYP2D6,f,PA448817,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for carvedilol based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for carvedilol based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction. The difference in plasma concentrations for varying CYP2D6 metabolizers has not been shown to demonstrate differences in efficacy or side effects (see <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002345.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for carvedilol based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  They conclude that there are no recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>No recommendations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x109/l; leucopenia &gt; 3.0x109/l; thrombocytopenia  &gt; 75x109/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>No recommendations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5; Kinetic effect (S).</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>No recommendations.</td><td>--</td><td>--</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods</a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104974"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104974"",""name"":""Annotation of DPWG Guideline for carvedilol and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704451E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415002E9,""date"":""2019-05-23T13:45:45.942-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820776E9,""date"":""2019-10-06T22:04:57.986-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956271E9,""date"":""2020-01-31T13:20:47.942-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096274E9,""date"":""2020-02-10T10:26:51.848-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448817"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448817"",""name"":""carvedilol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982016E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for carvedilol based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982015E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for carvedilol based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction. The difference in plasma concentrations for varying CYP2D6 metabolizers has not been shown to demonstrate differences in efficacy or side effects (see \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002345.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for carvedilol based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They conclude that there are no recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eNo recommendations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x109/l; leucopenia \u0026gt; 3.0x109/l; thrombocytopenia  \u0026gt; 75x109/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eNo recommendations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5; Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eNo recommendations.\u003c/td\u003e\u003ctd\u003e--\u003c/td\u003e\u003ctd\u003e--\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods\u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166191841,Guideline Annotation,"Annotation of CPIC Guideline for celecoxib,flurbiprofen,ibuprofen,lornoxicam and CYP2C9",t,PA448871,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of
the lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"" target=""_blank"">CPIC&reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9</a>.</p>
<h3 id=""march-2020"">March 2020</h3>
<p><em>Advance online publication March 2020.</em></p>
<ul>
<li>
<p>The <a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830"" target=""_blank"">CPIC guideline regarding for <em>CYP2C9</em> and Nonsteroidal Anti-inflammatory Drugs</a> is published in Clinical Pharmacology and Therapeutics.</p>
</li>
<li>
<p>These guidelines are applicable to:</p>
<ul>
<li>
<p>pediatric patients</p>
</li>
<li>
<p>adult patients</p>
</li>
</ul>
</li>
<li>
<p>Excerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:</p>
<ul>
<li>
<p>&quot;Substantial evidence links CYP2C9 genotypes with phenotypic variability in CYP2C9 metabolism and plasma NSAID concentrations, with the majority of studies conducted in healthy volunteers.&quot;</p>
</li>
<li>
<p>&quot;Although clinical evidence linking genetic variation in CYP2C9 to an increased rate of adverse events with NSAIDs use is scarce, several studies have established an association between CYP2C9 decreased function and no function alleles and elevated NSAID exposure (Figure 1 and Figure S2). Because most NSAID adverse events are dose-dependent, on-target adverse events involving COX inhibition (19-23) it is reasonable to assume that elevated exposure increases the risk of adverse events.&quot;</p>
</li>
<li>
<p>&quot;CYP2C9 IM and PM phenotypes affect systemic plasma concentrations of NSAIDs by decreasing metabolic clearance and consequently prolonging plasma elimination half-life. Therefore, therapeutic recommendations are broadly organized according to the NSAID plasma elimination half-life in NMs. Where more than two studies reported plasma concentration areaunder-the-curve (AUC), a meta-analysis was conducted to estimate the average impact of CYP2C9 genotype on drug exposure (Figure 1 and Figures S2 to S4).&quot;</p>
</li>
<li>
<p>&quot;<em><strong>Celecoxib, flurbiprofen, ibuprofen, lornoxicam</strong></em>: Based on current evidence, NMs and IMs with an AS of 1.5 are recommended to initiate therapy with the approved starting dose. Despitehaving mildly reduced metabolism, IMs with an AS of 1.5 do not exhibit significant increases in drug exposure relative to NMs... CYP2C9 IMs with an AS of 1 have reduced metabolism and are expected to exhibit a prolonged drug half-life and higher plasma concentrations compared to NMs, which may increase probability of toxicities.For IMs with an AS of 1, it is recommended to initiate NSAID therapy with the lowest recommended starting dose and titrate to clinical effect with close monitoring for adverse events such as elevated blood pressure and kidney dysfunction during course of therapy. Regarding ibuprofen use, it should be taken into consideration that while the CYP2C9*2 allele alone might not cause a clinically relevant reduction in clearance, its strong linkage with the
decreased function CYP2C8*3 allele may result in impaired R (-) ibuprofen hydroxylation and increased exposure to the parent drug...Individuals with a CYP2C9 PM phenotype (AS of 0) are expected to have markedly reduced metabolism and are expected to exhibit a pronounced prolongation of drug half-life and increase in plasma concentrations, which may increase the probability and/or severity of toxicities...It is recommended to initiate therapy with 25-50% of the lowest recommended starting dose (i.e. 50-75% dose reduction), and careful dose titration to clinical effect. Because drug half-life is significantly prolonged in these patients, upward dose titration should not occur until after steady-state is reached, taking into consideration the PM half-life for each drug; of course, dosing may be stopped or decreased due to toxicity at any time. Treatment with an alternative therapy could also be considered. This could include NSAIDs not primarily metabolized by CYP2C9 (such as aspirin, ketorolac (approved for short term use only), metamizole, naproxen, sulindac, etoricoxib, parecoxib, or valdecoxib), or with pharmacokinetic parameters apparently not impacted by CYP2C9 genetic variants in vivo despite CYP2C9 metabolism in vitro&quot;.</p>
</li>
<li>
<p>&quot; <em><strong>Meloxicam</strong></em>. Meloxicam has a longer half-life (15-20 hours, Table S12) than celecoxib and ibuprofen; thus, impaired meloxicam metabolism is expected to cause sustained elevations in drug exposure. Recommendations for CYP2C9 NMs and IMs with an AS of 1.5 are similar to the short half-life NSAIDs and include initiation of therapy with the standard dose while using the lowest effective dosage for shortest duration capable to achieve treatment goals. For IMs with an AS of 1, reduced metabolism and increased plasma concentrations are expected that may increase probability of toxicities...The recommendations are to either initiate therapy with 50% of the lowest recommended starting dose or choose an alternative therapy, consistent with the recommendations in PMs for short half-life NSAIDs (Table 2). Upward dose titration should not occur until after steady-state is reached (at least seven days), and careful monitoring is recommended. CYP2C9 PMs should be prescribed an alternative therapy because markedly prolonged half-life is expected (i.e., &gt;100 hours)&quot;.</p>
</li>
<li>
<p>&quot; <em><strong>Piroxicam and tenoxicam</strong></em>. These drugs have extremely long half-lives (30-86 and 60 hours, respectively), thus
amplifying the potential risks in individuals with reduced CYP2C9 metabolism and hampering dose titration strategies due to lack of data. Accordingly, rather than use of a lower starting dose, IMs with an AS of 1 and PMs are recommended to receive an alternative therapy. This includes drugs that are not metabolized by CYP2C9 or significantly affected by CYP2C9 genetic variants in vivo. Selection of a NSAID with a short half-life (Table 2) could also be considered.&quot;</p>
</li>
<li>
<p>&quot; <em><strong>Aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen</strong></em>. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C&quot;.</p>
</li>
<li>
<p>&quot;<em><strong>Pediatrics</strong></em>: Because CYP2C9 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring. Ultimately, additional research
and clinical trials in pediatric patients investigating the association between CYP2C9 genotype and NSAID systemic exposure and treatment outcomes are needed.&quot;</p>
</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2C9</em> and NSAIDs Therapy</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT_supplement.pdf"" target=""_blank"">2020 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Celecoxib_Drug_Resource_Mappings.xlsx"" target=""_blank"">Celecoxib Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Celecoxib_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Celecoxib Pre and Post Test Alerts</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Flurbiprofen_Drug_Resource_Mappings.xlsx"" target=""_blank"">Flurbiprofen Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Flurbiprofen_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Flurbiprofen Pre and Post Test Alerts</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Ibuprofen_Drug_Resource_Mappings.xlsx"" target=""_blank"">Ibuprofen Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Ibuprofen_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Ibuprofen Pre and Post Test Alerts</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Lornoxicam_Drug_Resource_Mappings.xlsx"" target=""_blank"">Lornoxicam Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Lornoxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Lornoxicam Pre and Post Test Alerts</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-celecoxib-flurbiprofen-ibuprofen-lornoxicam-by-cyp2c9-phenotype"">Table 1: Recommended dosing of <em><strong>celecoxib, flurbiprofen, ibuprofen, lornoxicam</strong></em> by CYP2C9 phenotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2020 guideline.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype<sup>a</sup></th><th>Activity Score</th><th>Genotype</th><th>Examples of genotypes<sup>b</sup></th><th>Implications</th><th>Therapeutic recommendations<sup>c</sup></th><th>Classification of recommendations<sup>d</sup></th><th>Other considerations</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C9</em> Normal metabolizer</td><td>2<sup>c</sup></td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td><td>Strong</td><td></td></tr>
<tr><td><em>CYP2C9</em> Intermediate metabolizer<sup>f</sup></td><td>1.5<sup>c</sup></td><td>An individual carrying one normal function and one decreased function allele.</td><td>*1/*2</td><td>Mildly reduced metabolism</td><td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td><td>Moderate</td><td>IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.</td></tr>
<tr><td><em>CYP2C9</em> Intermediate metabolizer<sup>f</sup></td><td>1<sup>c</sup></td><td>An individual carrying one normal function allele plus one no function allele OR two decreased function alleles.</td><td>*1/*3, *2/*2</td><td>Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities</td><td>Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.</td><td>Moderate</td><td>IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage</td></tr>
<tr><td><em>CYP2C9</em> Poor metabolizer</td><td>0 or 0.5<sup>c</sup></td><td>An individual carrying one no function allele plus one decreased function allele; OR two no function alleles</td><td>*2/*3, *3/*3</td><td>Significantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities</td><td>Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib and 5 days for ibuprofen, flurbiprofen and lornoxicam after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.</td><td>Moderate</td><td>Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</td></tr>
<tr><td>Indeterminate</td><td>n/a<sup>c</sup></td><td>An individual carrying allele combinations with uncertain and/or unknown function alleles</td><td>*1/*7, *1/*10, *7/*10, *1/*57</td><td>n/a</td><td>No recommendation.</td><td>n/a</td><td></td></tr>
</tbody>
</table>
<p><sup>a</sup> See the <a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 frequency table</a> for race-specific allele and phenotype frequencies.<br />
<sup>b</sup> For a complete list of CYP2C9 diplotypes and resulting phenotypes, see the <a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 genotype to phenotype table</a>.</p>
<p><sup>c</sup> CPIC assigned each allele functional status an activity value ranging from 0 to 1 (e.g., 0 for no function, 0.5 for decreased, and 1.0 for normal function), which are summed to calculate the activity score (AS) for each diplotype. The CYP2C9 AS has been translated into the phenotype classification system as follows: individuals with an AS of 0 or 0.5 are poor
metabolizers (PMs), those with a score of 1 or 1.5 are intermediate metabolizers (IMs), and those with a score of 2 are normal metabolizers (NMs).<br />
<sup>d</sup> Rating scheme described in Supplement.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166191841"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166191841"",""name"":""Annotation of CPIC Guideline for celecoxib,flurbiprofen,ibuprofen,lornoxicam and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[{""id"":1.45098358E9,""alleles"":[{""id"":1.45098454E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816542"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816542"",""symbol"":""CYP2C9*1"",""name"":""*1""}},{""id"":1.450984541E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816543"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816543"",""symbol"":""CYP2C9*2"",""name"":""*2""}},{""id"":1.450984542E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816544"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816544"",""symbol"":""CYP2C9*3"",""name"":""*3""}},{""id"":1.450984543E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816545"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816545"",""symbol"":""CYP2C9*4"",""name"":""*4""}},{""id"":1.450984544E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816546"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816546"",""symbol"":""CYP2C9*5"",""name"":""*5""}},{""id"":1.450984545E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816547"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816547"",""symbol"":""CYP2C9*6"",""name"":""*6""}},{""id"":1.450984546E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816548"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816548"",""symbol"":""CYP2C9*7"",""name"":""*7""}},{""id"":1.450984547E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816549"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816549"",""symbol"":""CYP2C9*8"",""name"":""*8""}},{""id"":1.450984548E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816550"",""symbol"":""CYP2C9*9"",""name"":""*9""}},{""id"":1.450984549E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816551"",""symbol"":""CYP2C9*10"",""name"":""*10""}},{""id"":1.45098455E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816552"",""symbol"":""CYP2C9*11"",""name"":""*11""}},{""id"":1.450984551E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816553"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816553"",""symbol"":""CYP2C9*12"",""name"":""*12""}},{""id"":1.450984552E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816554"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816554"",""symbol"":""CYP2C9*13"",""name"":""*13""}},{""id"":1.450984553E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816555"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816555"",""symbol"":""CYP2C9*14"",""name"":""*14""}},{""id"":1.450984554E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816556"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816556"",""symbol"":""CYP2C9*15"",""name"":""*15""}},{""id"":1.450984555E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816557"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816557"",""symbol"":""CYP2C9*16"",""name"":""*16""}},{""id"":1.450984556E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816563"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816563"",""symbol"":""CYP2C9*17"",""name"":""*17""}},{""id"":1.450984557E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816558"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816558"",""symbol"":""CYP2C9*18"",""name"":""*18""}},{""id"":1.450984558E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816564"",""symbol"":""CYP2C9*19"",""name"":""*19""}},{""id"":1.450984559E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816565"",""symbol"":""CYP2C9*20"",""name"":""*20""}},{""id"":1.45098456E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816566"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816566"",""symbol"":""CYP2C9*21"",""name"":""*21""}},{""id"":1.450984561E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816567"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816567"",""symbol"":""CYP2C9*22"",""name"":""*22""}},{""id"":1.450984562E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816568"",""symbol"":""CYP2C9*23"",""name"":""*23""}},{""id"":1.450984563E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816569"",""symbol"":""CYP2C9*24"",""name"":""*24""}},{""id"":1.450984564E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816559"",""symbol"":""CYP2C9*25"",""name"":""*25""}},{""id"":1.450984565E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816570"",""symbol"":""CYP2C9*26"",""name"":""*26""}},{""id"":1.450984566E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816571"",""symbol"":""CYP2C9*27"",""name"":""*27""}},{""id"":1.450984567E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816572"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816572"",""symbol"":""CYP2C9*28"",""name"":""*28""}},{""id"":1.450984568E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816573"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816573"",""symbol"":""CYP2C9*29"",""name"":""*29""}},{""id"":1.450984569E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816574"",""symbol"":""CYP2C9*30"",""name"":""*30""}},{""id"":1.45098457E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816560"",""symbol"":""CYP2C9*31"",""name"":""*31""}},{""id"":1.450984571E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816575"",""symbol"":""CYP2C9*32"",""name"":""*32""}},{""id"":1.450984572E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816561"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816561"",""symbol"":""CYP2C9*33"",""name"":""*33""}},{""id"":1.450984573E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816562"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816562"",""symbol"":""CYP2C9*34"",""name"":""*34""}},{""id"":1.450984574E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048681"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048681"",""symbol"":""CYP2C9*35"",""name"":""*35""}},{""id"":1.450984575E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048682"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048682"",""symbol"":""CYP2C9*36"",""name"":""*36""}},{""id"":1.450984576E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048683"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048683"",""symbol"":""CYP2C9*37"",""name"":""*37""}},{""id"":1.450984577E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048684"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048684"",""symbol"":""CYP2C9*38"",""name"":""*38""}},{""id"":1.450984578E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048685"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048685"",""symbol"":""CYP2C9*39"",""name"":""*39""}},{""id"":1.450984579E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048686"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048686"",""symbol"":""CYP2C9*40"",""name"":""*40""}},{""id"":1.45098458E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048687"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048687"",""symbol"":""CYP2C9*41"",""name"":""*41""}},{""id"":1.450984581E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048688"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048688"",""symbol"":""CYP2C9*42"",""name"":""*42""}},{""id"":1.450984582E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048689"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048689"",""symbol"":""CYP2C9*43"",""name"":""*43""}},{""id"":1.450984583E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048690"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048690"",""symbol"":""CYP2C9*44"",""name"":""*44""}},{""id"":1.450984584E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048691"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048691"",""symbol"":""CYP2C9*45"",""name"":""*45""}},{""id"":1.450984585E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048692"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048692"",""symbol"":""CYP2C9*46"",""name"":""*46""}},{""id"":1.450984586E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048693"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048693"",""symbol"":""CYP2C9*47"",""name"":""*47""}},{""id"":1.450984587E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048694"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048694"",""symbol"":""CYP2C9*48"",""name"":""*48""}},{""id"":1.450984588E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048695"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048695"",""symbol"":""CYP2C9*49"",""name"":""*49""}},{""id"":1.450984589E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048696"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048696"",""symbol"":""CYP2C9*50"",""name"":""*50""}},{""id"":1.45098459E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048697"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048697"",""symbol"":""CYP2C9*51"",""name"":""*51""}},{""id"":1.450984591E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048698"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048698"",""symbol"":""CYP2C9*52"",""name"":""*52""}},{""id"":1.450984592E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048699"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048699"",""symbol"":""CYP2C9*53"",""name"":""*53""}},{""id"":1.450984593E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048700"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048700"",""symbol"":""CYP2C9*54"",""name"":""*54""}},{""id"":1.450984594E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048701"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048701"",""symbol"":""CYP2C9*55"",""name"":""*55""}},{""id"":1.450984595E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048702"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048702"",""symbol"":""CYP2C9*56"",""name"":""*56""}},{""id"":1.450984596E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048703"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048703"",""symbol"":""CYP2C9*57"",""name"":""*57""}},{""id"":1.450984597E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166122566"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166122566"",""symbol"":""CYP2C9*58"",""name"":""*58""}},{""id"":1.450984598E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128210"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128210"",""symbol"":""CYP2C9*59"",""name"":""*59""}},{""id"":1.450984599E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128211"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128211"",""symbol"":""CYP2C9*60"",""name"":""*60""}},{""id"":1.4509846E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166183345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166183345"",""symbol"":""CYP2C9*61"",""name"":""*61""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}}],""history"":[{""id"":1.45109512E9,""date"":""2020-03-19T00:00:00-07:00"",""description"":""Guideline published"",""type"":""Note"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15105062"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5105062E7,""resourceId"":""32189324"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/32189324"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/32189324"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.451090662E9,""resource"":""PubMed"",""resourceId"":""32189324"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/32189324""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1830"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.451090663E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1830"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1830""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA448871"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA448871"",""name"":""celecoxib""},{""@id"":""https://pharmgkb.org/chemical/PA449683"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449683"",""name"":""flurbiprofen""},{""@id"":""https://pharmgkb.org/chemical/PA449957"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449957"",""name"":""ibuprofen""},{""@id"":""https://pharmgkb.org/chemical/PA165958395"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA165958395"",""name"":""lornoxicam""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.45098346E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% of\nthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.45098338E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""march-2020\""\u003eMarch 2020\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication March 2020.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830\"" target\u003d\""_blank\""\u003eCPIC guideline regarding for \u003cem\u003eCYP2C9\u003c/em\u003e and Nonsteroidal Anti-inflammatory Drugs\u003c/a\u003e is published in Clinical Pharmacology and Therapeutics.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThese guidelines are applicable to:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003epediatric patients\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eadult patients\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExcerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Substantial evidence links CYP2C9 genotypes with phenotypic variability in CYP2C9 metabolism and plasma NSAID concentrations, with the majority of studies conducted in healthy volunteers.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Although clinical evidence linking genetic variation in CYP2C9 to an increased rate of adverse events with NSAIDs use is scarce, several studies have established an association between CYP2C9 decreased function and no function alleles and elevated NSAID exposure (Figure 1 and Figure S2). Because most NSAID adverse events are dose-dependent, on-target adverse events involving COX inhibition (19-23) it is reasonable to assume that elevated exposure increases the risk of adverse events.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;CYP2C9 IM and PM phenotypes affect systemic plasma concentrations of NSAIDs by decreasing metabolic clearance and consequently prolonging plasma elimination half-life. Therefore, therapeutic recommendations are broadly organized according to the NSAID plasma elimination half-life in NMs. Where more than two studies reported plasma concentration areaunder-the-curve (AUC), a meta-analysis was conducted to estimate the average impact of CYP2C9 genotype on drug exposure (Figure 1 and Figures S2 to S4).\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cem\u003e\u003cstrong\u003eCelecoxib, flurbiprofen, ibuprofen, lornoxicam\u003c/strong\u003e\u003c/em\u003e: Based on current evidence, NMs and IMs with an AS of 1.5 are recommended to initiate therapy with the approved starting dose. Despitehaving mildly reduced metabolism, IMs with an AS of 1.5 do not exhibit significant increases in drug exposure relative to NMs... CYP2C9 IMs with an AS of 1 have reduced metabolism and are expected to exhibit a prolonged drug half-life and higher plasma concentrations compared to NMs, which may increase probability of toxicities.For IMs with an AS of 1, it is recommended to initiate NSAID therapy with the lowest recommended starting dose and titrate to clinical effect with close monitoring for adverse events such as elevated blood pressure and kidney dysfunction during course of therapy. Regarding ibuprofen use, it should be taken into consideration that while the CYP2C9*2 allele alone might not cause a clinically relevant reduction in clearance, its strong linkage with the\ndecreased function CYP2C8*3 allele may result in impaired R (-) ibuprofen hydroxylation and increased exposure to the parent drug...Individuals with a CYP2C9 PM phenotype (AS of 0) are expected to have markedly reduced metabolism and are expected to exhibit a pronounced prolongation of drug half-life and increase in plasma concentrations, which may increase the probability and/or severity of toxicities...It is recommended to initiate therapy with 25-50% of the lowest recommended starting dose (i.e. 50-75% dose reduction), and careful dose titration to clinical effect. Because drug half-life is significantly prolonged in these patients, upward dose titration should not occur until after steady-state is reached, taking into consideration the PM half-life for each drug; of course, dosing may be stopped or decreased due to toxicity at any time. Treatment with an alternative therapy could also be considered. This could include NSAIDs not primarily metabolized by CYP2C9 (such as aspirin, ketorolac (approved for short term use only), metamizole, naproxen, sulindac, etoricoxib, parecoxib, or valdecoxib), or with pharmacokinetic parameters apparently not impacted by CYP2C9 genetic variants in vivo despite CYP2C9 metabolism in vitro\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003eMeloxicam\u003c/strong\u003e\u003c/em\u003e. Meloxicam has a longer half-life (15-20 hours, Table S12) than celecoxib and ibuprofen; thus, impaired meloxicam metabolism is expected to cause sustained elevations in drug exposure. Recommendations for CYP2C9 NMs and IMs with an AS of 1.5 are similar to the short half-life NSAIDs and include initiation of therapy with the standard dose while using the lowest effective dosage for shortest duration capable to achieve treatment goals. For IMs with an AS of 1, reduced metabolism and increased plasma concentrations are expected that may increase probability of toxicities...The recommendations are to either initiate therapy with 50% of the lowest recommended starting dose or choose an alternative therapy, consistent with the recommendations in PMs for short half-life NSAIDs (Table 2). Upward dose titration should not occur until after steady-state is reached (at least seven days), and careful monitoring is recommended. CYP2C9 PMs should be prescribed an alternative therapy because markedly prolonged half-life is expected (i.e., \u0026gt;100 hours)\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003ePiroxicam and tenoxicam\u003c/strong\u003e\u003c/em\u003e. These drugs have extremely long half-lives (30-86 and 60 hours, respectively), thus\namplifying the potential risks in individuals with reduced CYP2C9 metabolism and hampering dose titration strategies due to lack of data. Accordingly, rather than use of a lower starting dose, IMs with an AS of 1 and PMs are recommended to receive an alternative therapy. This includes drugs that are not metabolized by CYP2C9 or significantly affected by CYP2C9 genetic variants in vivo. Selection of a NSAID with a short half-life (Table 2) could also be considered.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003eAceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen\u003c/strong\u003e\u003c/em\u003e. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cem\u003e\u003cstrong\u003ePediatrics\u003c/strong\u003e\u003c/em\u003e: Because CYP2C9 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring. Ultimately, additional research\nand clinical trials in pediatric patients investigating the association between CYP2C9 genotype and NSAID systemic exposure and treatment outcomes are needed.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for \u003cem\u003eCYP2C9\u003c/em\u003e and NSAIDs Therapy\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT_supplement.pdf\"" target\u003d\""_blank\""\u003e2020 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Celecoxib_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eCelecoxib Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Celecoxib_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eCelecoxib Pre and Post Test Alerts\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Flurbiprofen_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eFlurbiprofen Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Flurbiprofen_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eFlurbiprofen Pre and Post Test Alerts\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Ibuprofen_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eIbuprofen Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Ibuprofen_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eIbuprofen Pre and Post Test Alerts\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Lornoxicam_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eLornoxicam Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Lornoxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eLornoxicam Pre and Post Test Alerts\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-celecoxib-flurbiprofen-ibuprofen-lornoxicam-by-cyp2c9-phenotype\""\u003eTable 1: Recommended dosing of \u003cem\u003e\u003cstrong\u003ecelecoxib, flurbiprofen, ibuprofen, lornoxicam\u003c/strong\u003e\u003c/em\u003e by CYP2C9 phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2020 guideline.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eActivity Score\u003c/th\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eExamples of genotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003csup\u003ed\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eOther considerations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Normal metabolizer\u003c/td\u003e\u003ctd\u003e2\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Intermediate metabolizer\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.5\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function and one decreased function allele.\u003c/td\u003e\u003ctd\u003e*1/*2\u003c/td\u003e\u003ctd\u003eMildly reduced metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eIMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage disequilibrium with CYP2C8*3 and ibuprofen is also metabolized by CYP2C8.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Intermediate metabolizer\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele plus one no function allele OR two decreased function alleles.\u003c/td\u003e\u003ctd\u003e*1/*3, *2/*2\u003c/td\u003e\u003ctd\u003eModerately reduced metabolism; higher plasma concentrations may increase probability of toxicities\u003c/td\u003e\u003ctd\u003eInitiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eIMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Further caution should be taken with ibuprofen use in individuals carrying the CYP2C9*2 allele as it is in linkage\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Poor metabolizer\u003c/td\u003e\u003ctd\u003e0 or 0.5\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one no function allele plus one decreased function allele; OR two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eSignificantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities\u003c/td\u003e\u003ctd\u003eInitiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib and 5 days for ibuprofen, flurbiprofen and lornoxicam after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003en/a\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying allele combinations with uncertain and/or unknown function alleles\u003c/td\u003e\u003ctd\u003e*1/*7, *1/*10, *7/*10, *1/*57\u003c/td\u003e\u003ctd\u003en/a\u003c/td\u003e\u003ctd\u003eNo recommendation.\u003c/td\u003e\u003ctd\u003en/a\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e See the \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 frequency table\u003c/a\u003e for race-specific allele and phenotype frequencies.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e For a complete list of CYP2C9 diplotypes and resulting phenotypes, see the \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 genotype to phenotype table\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e CPIC assigned each allele functional status an activity value ranging from 0 to 1 (e.g., 0 for no function, 0.5 for decreased, and 1.0 for normal function), which are summed to calculate the activity score (AS) for each diplotype. The CYP2C9 AS has been translated into the phenotype classification system as follows: individuals with an AS of 0 or 0.5 are poor\nmetabolizers (PMs), those with a score of 1 or 1.5 are intermediate metabolizers (IMs), and those with a score of 2 are normal metabolizers (NMs).\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003e Rating scheme described in Supplement.\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166170751,Guideline Annotation,Annotation of CPNDS Guideline for cisplatin and TPMT,t,PA449014,Canadian Pharmacogenomics Network for Drug Safety,"<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for <em>TPMT</em> gene variants when prescribing cisplatin in pediatric cancer patients. They recommend testing for the <em>TPMT</em> alleles *2, *3A, *3B or *3C in all pediatric cancer patients due to the association of these alleles with an increased risk of cisplatin-induced ototoxicity.</p>
","<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines in the journal <em>Therapeutic Drug Monitoring</em>. Excerpts from “Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers” [Article:<a href=""/pmid/26960170"">26960170</a>] follow:</p>
<blockquote class=""blockquote"">
<ul>
<li>
<p>We recommend pharmacogenetic testing for the associated functional TPMT variants (*3A, *3B, *3C) and the known, relatively common, and functionally inactive TPMT *2 variant in pediatric patients to receive cisplatin <strong><em>(level A – strong recommendation)</em></strong></p>
</li>
<li>
<p>All of these variants demonstrate reduced <em>in vitro</em> enzyme activity. Around 10% of the population carry one of these TPMT risk variants, which account for approximately 25% of patients with ototoxicity. Thus, the TPMT risk variants do not account for all cases of cisplatin ototoxicity. However, the high positive predictive value (92%) of the TPMT variants indicates that a vast majority of patients who carry these variants develop hearing loss.</p>
</li>
<li>
<p>Currently, the impact of the genetic variants recommended for testing in children is unknown in adult patients. At this point, genetic testing to identify patients at risk for cisplatin-induced hearing loss is NOT recommended in adult patients <strong><em>(level C – optional recommendation)</em></strong></p>
</li>
<li>
<p>Testing for variants in COMT, ABCC3, CTR1, GSTs, LRP2, DNA repair genes and genes associated with deafness is currently not recommended for clinical use <strong><em>(level C – optional recommendation)</em></strong></p>
</li>
</ul>
<p><strong>Management options for patients carrying nonfunctional TPMT variants</strong></p>
<ul>
<li>
<p>Physicians are encouraged to consider the use of otoprotectants (i.e. amifostine, sodium thiosulfate) if the patient’s tumour type is one for which otoprotectants may be effective to prevent cisplatin-induced ototoxicity without adversely affecting antitumour activity <strong><em>(level C - optional recommendation)</em></strong></p>
</li>
<li>
<p>Alternative treatments may be prescribed when they have demonstrated equal efficacy, manageable and acceptable toxicity, less ototoxicity, and are considered options within the current standards of care <strong><em>(level C - optional recommendation)</em></strong></p>
</li>
<li>
<p>Where appropriate, physicians are encouraged to increase monitoring in high-risk patients <strong><em>(level C - optional recommendation)</em></strong></p>
</li>
<li>
<p>High risk patients should be encouraged to receive more frequent follow-up audiometric hearing tests after treatment has ended <strong><em>(level C – optional recommendation)</em></strong></p>
</li>
</ul>
</blockquote>
<p>See full guideline [Article:<a href=""/pmid/26960170"">26960170</a>] for further details and grading scheme.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166170751"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166170751"",""name"":""Annotation of CPNDS Guideline for cisplatin and TPMT"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.449003693E9,""date"":""2017-10-31T00:00:00-07:00"",""description"":""initial save"",""type"":""Create"",""version"":1.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15099517"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5099517E7,""resourceId"":""26960170"",""title"":""Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/26960170"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/26960170"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449284747E9,""resource"":""PubMed"",""resourceId"":""26960170"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/26960170""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1097/FTD.0000000000000298"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449284748E9,""resource"":""DOI"",""resourceId"":""10.1097/FTD.0000000000000298"",""_url"":""http://dx.doi.org/10.1097%2FFTD.0000000000000298""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449014"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449014"",""name"":""cisplatin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA356"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA356"",""symbol"":""TPMT"",""name"":""thiopurine S-methyltransferase""}],""source"":""Canadian Pharmacogenomics Network for Drug Safety"",""summaryMarkdown"":{""id"":1.449003692E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for \u003cem\u003eTPMT\u003c/em\u003e gene variants when prescribing cisplatin in pediatric cancer patients. They recommend testing for the \u003cem\u003eTPMT\u003c/em\u003e alleles *2, *3A, *3B or *3C in all pediatric cancer patients due to the association of these alleles with an increased risk of cisplatin-induced ototoxicity.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.449003691E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines in the journal \u003cem\u003eTherapeutic Drug Monitoring\u003c/em\u003e. Excerpts from “Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers” [Article:\u003ca href\u003d\""/pmid/26960170\""\u003e26960170\u003c/a\u003e] follow:\u003c/p\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eWe recommend pharmacogenetic testing for the associated functional TPMT variants (*3A, *3B, *3C) and the known, relatively common, and functionally inactive TPMT *2 variant in pediatric patients to receive cisplatin \u003cstrong\u003e\u003cem\u003e(level A – strong recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAll of these variants demonstrate reduced \u003cem\u003ein vitro\u003c/em\u003e enzyme activity. Around 10% of the population carry one of these TPMT risk variants, which account for approximately 25% of patients with ototoxicity. Thus, the TPMT risk variants do not account for all cases of cisplatin ototoxicity. However, the high positive predictive value (92%) of the TPMT variants indicates that a vast majority of patients who carry these variants develop hearing loss.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCurrently, the impact of the genetic variants recommended for testing in children is unknown in adult patients. At this point, genetic testing to identify patients at risk for cisplatin-induced hearing loss is NOT recommended in adult patients \u003cstrong\u003e\u003cem\u003e(level C – optional recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eTesting for variants in COMT, ABCC3, CTR1, GSTs, LRP2, DNA repair genes and genes associated with deafness is currently not recommended for clinical use \u003cstrong\u003e\u003cem\u003e(level C – optional recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eManagement options for patients carrying nonfunctional TPMT variants\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003ePhysicians are encouraged to consider the use of otoprotectants (i.e. amifostine, sodium thiosulfate) if the patient’s tumour type is one for which otoprotectants may be effective to prevent cisplatin-induced ototoxicity without adversely affecting antitumour activity \u003cstrong\u003e\u003cem\u003e(level C - optional recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAlternative treatments may be prescribed when they have demonstrated equal efficacy, manageable and acceptable toxicity, less ototoxicity, and are considered options within the current standards of care \u003cstrong\u003e\u003cem\u003e(level C - optional recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eWhere appropriate, physicians are encouraged to increase monitoring in high-risk patients \u003cstrong\u003e\u003cem\u003e(level C - optional recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eHigh risk patients should be encouraged to receive more frequent follow-up audiometric hearing tests after treatment has ended \u003cstrong\u003e\u003cem\u003e(level C – optional recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/blockquote\u003e\n\u003cp\u003eSee full guideline [Article:\u003ca href\u003d\""/pmid/26960170\""\u003e26960170\u003c/a\u003e] for further details and grading scheme.\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166127638,Guideline Annotation,"Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19",t,PA449015,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""august-2015"">August 2015</h3>
<p><em>Advanced online publication May 2015</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing of selective serotonin reuptake inhibitors have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpts from the 2015 selective serotonin reuptake inhibitors dosing guidelines (for citalopram/escitalopram and CYP2C19):
<ul>
<li>&quot;CYP2C19 ultrarapid metabolizers have significantly lower exposure to these drugs when compared to extensive metabolizers, and therefore may have an increased probability of failing therapy. Because there are insufficient data to calculate an initial citalopram or escitalopram dose for CYP2C19 ultrarapid metabolizers, an alternative SSRI not extensively metabolized by CYP2C19 may be an option if deemed appropriate given other medications and clinical considerations.&quot;</li>
<li>&quot;Elevated concentrations of these drugs have been observed in poor metabolizers, which may increase the risk of adverse drug reactions. To potentially prevent an adverse effect, an alternative SSRI not extensively metabolized by CYP2C19 should be considered. If citalopram or escitalopram is warranted an initial dosage decrease of 50% should be considered. For citalopram, the FDA recommends a 50% dose reduction (or a maximum dose of 20 mg/day in adults) for CYP2C19 poor metabolizers due to risk of QT prolongation (the FDA recommendation does not apply to escitalopram).&quot;</li>
<li>&quot;The recommendations in the guideline and below apply primarily to actions based on genetic tests only; drug interactions and other clinical factors can have a major influence for prescribing decisions for SSRIs and should be taken into consideration before initiating drug therapy.&quot;</li>
<li>&quot;Data describing the relationship between CYP2D6 or CYP2C19 genotype and SSRI systemic exposure or steady state plasma concentrations in pediatric patients are scarce...CYP2C19 activity may be increased in children relative to adults; therefore, these recommendations should be used with caution in children and accompanied by close monitoring.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703-supplement.pdf"" target=""_blank"">2015 Supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_2015%20CYP2C19%20SSRI%20translation%20table.xlsx"" target=""_blank"">2015 CYP2C19 SSRI translation table</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2C19%20frequency%20table%20legend.pdf"" target=""_blank"">CYP2C19 frequency table legend</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2C19%20frequency%20table.xlsx"" target=""_blank"">CYP2C19 frequency table</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-citalopram-and-escitalopram-based-on-cyp2c19-phenotype"">Table 1: Dosing recommendations for citalopram and escitalopram based on CYP2C19 phenotype:</h3>
<p><em>Adapted from Tables 1 and 3a of the 2015 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of CYP2C19 diplotypes</th><th>Implications for citalopram/escitalopram metabolism</th><th>Therapeutic Recommendations</th><th>Classification of recommendations <sup>a</sup></th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer (~5-30% of patients) <sup>b</sup></td><td>An individual carrying two increased function alleles or one normal function allele and one increased function allele</td><td>*17/*17, *1/*17</td><td>Increased metabolism when compared to extensive metabolizers.  Lower plasma concentrations will increase probability of pharmacotherapy failure.</td><td>Consider an alternative drug not predominantly metabolized by CYP2C19.<sup>c</sup></td><td>Moderate</td></tr>
<tr><td>Extensive metabolizer (~35-50% of patients)</td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose.</td><td>Strong</td></tr>
<tr><td>Intermediate metabolizer (~18-45% of patients)</td><td>An individual carrying one normal function allele or one increased function allele and one no function allele</td><td>*1/*2, *1/*3, *2/*17 <sup>d</sup></td><td>Reduced metabolism when compared to extensive metabolizers.</td><td>Initiate therapy with recommended starting dose.</td><td>Strong</td></tr>
<tr><td>Poor metabolizer (~2-15% of patients)</td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.</td><td>Consider a 50% reduction <sup>e,f</sup> of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.<sup>c</sup></td><td>Moderate</td></tr>
</tbody>
</table>
<p><sup>a</sup> Rating scheme described in Supplement.</p>
<p><sup>b</sup> CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequency.</p>
<p><sup>c</sup> Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>
<p><sup>d</sup> The predicted metabolizer phenotype for the*2/*17 genotypes is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the no function CYP2C19*2. See Supplemental Materials for a more comprehensive list of predicted metabolizer phenotypes.</p>
<p><sup>e</sup> Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age.</p>
<p><sup>f</sup> Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. [Article:<a href=""/pmid/22565785"">22565785</a>].</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166127638"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166127638"",""name"":""Annotation of CPIC Guideline for citalopram,escitalopram and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":""AkZd9tivN8s"",""guidelineGenes"":[{""id"":1.449561673E9,""alleles"":[{""id"":1.449561674E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980634"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980634"",""symbol"":""CYP2C19*1"",""name"":""*1""}},{""id"":1.449561675E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980635"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980635"",""symbol"":""CYP2C19*2"",""name"":""*2""}},{""id"":1.449561676E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980636"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980636"",""symbol"":""CYP2C19*3"",""name"":""*3""}},{""id"":1.449561679E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980638"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980638"",""symbol"":""CYP2C19*5"",""name"":""*5""}},{""id"":1.44956168E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816522"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816522"",""symbol"":""CYP2C19*6"",""name"":""*6""}},{""id"":1.449561681E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816523"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816523"",""symbol"":""CYP2C19*7"",""name"":""*7""}},{""id"":1.449561682E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816524"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816524"",""symbol"":""CYP2C19*8"",""name"":""*8""}},{""id"":1.449561683E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816525"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816525"",""symbol"":""CYP2C19*9"",""name"":""*9""}},{""id"":1.449561684E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816526"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816526"",""symbol"":""CYP2C19*10"",""name"":""*10""}},{""id"":1.449561685E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816527"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816527"",""symbol"":""CYP2C19*11"",""name"":""*11""}},{""id"":1.449561686E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816528"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816528"",""symbol"":""CYP2C19*12"",""name"":""*12""}},{""id"":1.449561687E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816529"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816529"",""symbol"":""CYP2C19*13"",""name"":""*13""}},{""id"":1.449561688E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816530"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816530"",""symbol"":""CYP2C19*14"",""name"":""*14""}},{""id"":1.449561689E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816531"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816531"",""symbol"":""CYP2C19*15"",""name"":""*15""}},{""id"":1.44956169E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816532"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816532"",""symbol"":""CYP2C19*16"",""name"":""*16""}},{""id"":1.449561691E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816533"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816533"",""symbol"":""CYP2C19*17"",""name"":""*17""}},{""id"":1.449561692E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816534"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816534"",""symbol"":""CYP2C19*18"",""name"":""*18""}},{""id"":1.449561693E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816535"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816535"",""symbol"":""CYP2C19*19"",""name"":""*19""}},{""id"":1.449561694E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816536"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816536"",""symbol"":""CYP2C19*22"",""name"":""*22""}},{""id"":1.449561695E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816537"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816537"",""symbol"":""CYP2C19*23"",""name"":""*23""}},{""id"":1.449561696E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816538"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816538"",""symbol"":""CYP2C19*24"",""name"":""*24""}},{""id"":1.449561697E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816539"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816539"",""symbol"":""CYP2C19*25"",""name"":""*25""}},{""id"":1.449561698E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816540"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816540"",""symbol"":""CYP2C19*26"",""name"":""*26""}},{""id"":1.4495617E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115675"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115675"",""symbol"":""CYP2C19*28"",""name"":""*28""}},{""id"":1.449561701E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123292"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123292"",""symbol"":""CYP2C19*29"",""name"":""*29""}},{""id"":1.449561702E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123293"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123293"",""symbol"":""CYP2C19*30"",""name"":""*30""}},{""id"":1.449561703E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123294"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123294"",""symbol"":""CYP2C19*31"",""name"":""*31""}},{""id"":1.449561704E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123295"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123295"",""symbol"":""CYP2C19*32"",""name"":""*32""}},{""id"":1.449561705E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123296"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123296"",""symbol"":""CYP2C19*33"",""name"":""*33""}},{""id"":1.449561706E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115676"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115676"",""symbol"":""CYP2C19*34"",""name"":""*34""}},{""id"":1.449561707E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128094"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128094"",""symbol"":""CYP2C19*35"",""name"":""*35""}},{""id"":1.450805216E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980637"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980637"",""symbol"":""CYP2C19*4"",""name"":""*4""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}}],""history"":[{""id"":1.444708445E9,""date"":""2015-05-11T14:59:15.789-07:00"",""type"":""Update"",""version"":1.0},{""id"":1.450043136E9,""date"":""2018-11-26T10:13:45.031-08:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15089021"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5089021E7,""resourceId"":""25974703"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4512908"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285932E9,""resource"":""PubMed Central"",""resourceId"":""PMC4512908"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/25974703"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285931E9,""resource"":""PubMed"",""resourceId"":""25974703"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/25974703""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.147"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285933E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.147"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.147""}]},{""@id"":""https://pharmgkb.org/literature/15100911"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100911E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Selective Serotonin Reuptake Inhibitors and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983477E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449015"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449015"",""name"":""citalopram""},{""@id"":""https://pharmgkb.org/chemical/PA10074"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10074"",""name"":""escitalopram""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982401E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.4479824E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""august-2015\""\u003eAugust 2015\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvanced online publication May 2015\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing of selective serotonin reuptake inhibitors have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2015 selective serotonin reuptake inhibitors dosing guidelines (for citalopram/escitalopram and CYP2C19):\n\u003cul\u003e\n\u003cli\u003e\u0026quot;CYP2C19 ultrarapid metabolizers have significantly lower exposure to these drugs when compared to extensive metabolizers, and therefore may have an increased probability of failing therapy. Because there are insufficient data to calculate an initial citalopram or escitalopram dose for CYP2C19 ultrarapid metabolizers, an alternative SSRI not extensively metabolized by CYP2C19 may be an option if deemed appropriate given other medications and clinical considerations.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Elevated concentrations of these drugs have been observed in poor metabolizers, which may increase the risk of adverse drug reactions. To potentially prevent an adverse effect, an alternative SSRI not extensively metabolized by CYP2C19 should be considered. If citalopram or escitalopram is warranted an initial dosage decrease of 50% should be considered. For citalopram, the FDA recommends a 50% dose reduction (or a maximum dose of 20 mg/day in adults) for CYP2C19 poor metabolizers due to risk of QT prolongation (the FDA recommendation does not apply to escitalopram).\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;The recommendations in the guideline and below apply primarily to actions based on genetic tests only; drug interactions and other clinical factors can have a major influence for prescribing decisions for SSRIs and should be taken into consideration before initiating drug therapy.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Data describing the relationship between CYP2D6 or CYP2C19 genotype and SSRI systemic exposure or steady state plasma concentrations in pediatric patients are scarce...CYP2C19 activity may be increased in children relative to adults; therefore, these recommendations should be used with caution in children and accompanied by close monitoring.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703-supplement.pdf\"" target\u003d\""_blank\""\u003e2015 Supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_2015%20CYP2C19%20SSRI%20translation%20table.xlsx\"" target\u003d\""_blank\""\u003e2015 CYP2C19 SSRI translation table\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2C19%20frequency%20table%20legend.pdf\"" target\u003d\""_blank\""\u003eCYP2C19 frequency table legend\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2C19%20frequency%20table.xlsx\"" target\u003d\""_blank\""\u003eCYP2C19 frequency table\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-citalopram-and-escitalopram-based-on-cyp2c19-phenotype\""\u003eTable 1: Dosing recommendations for citalopram and escitalopram based on CYP2C19 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3a of the 2015 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of CYP2C19 diplotypes\u003c/th\u003e\u003cth\u003eImplications for citalopram/escitalopram metabolism\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer (~5-30% of patients) \u003csup\u003eb\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles or one normal function allele and one increased function allele\u003c/td\u003e\u003ctd\u003e*17/*17, *1/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism when compared to extensive metabolizers.  Lower plasma concentrations will increase probability of pharmacotherapy failure.\u003c/td\u003e\u003ctd\u003eConsider an alternative drug not predominantly metabolized by CYP2C19.\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eExtensive metabolizer (~35-50% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer (~18-45% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele or one increased function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3, *2/*17 \u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eReduced metabolism when compared to extensive metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizer (~2-15% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider a 50% reduction \u003csup\u003ee,f\u003c/sup\u003e of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Rating scheme described in Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequency.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e The predicted metabolizer phenotype for the*2/*17 genotypes is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the no function CYP2C19*2. See Supplemental Materials for a more comprehensive list of predicted metabolizer phenotypes.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Per the FDA warning, citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation. FDA product labeling additionally cautions that citalopram dose should be limited to 20 mg/day in patients with hepatic impairment, those taking a CYP2C19 inhibitor, and patients greater than 60 years of age.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. [Article:\u003ca href\u003d\""/pmid/22565785\""\u003e22565785\u003c/a\u003e].\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983477E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166104977,Guideline Annotation,Annotation of DPWG Guideline for citalopram and CYP2C19,t,PA449015,Dutch Pharmacogenetics Working Group,"<p>The Dutch Pharmacogenetics Working Group Guideline for citalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified daily doses.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for citalopram based on CYP2C19 genotype. They recommend to not exceed the below mentioned daily doses for intermediate metabolizer and poor metabolizer (for PM = 50% of the standard maximum dose).</p>
<p><em>Wording in table taken from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 UM</td><td>citalopram</td><td>-</td><td>NO action is needed for this gene-drug interaction. The gene variation increases conversion of citalopram to a weakly active metabolite. However, there is no significant effect on the plasma concentration of citalopram, the tolerance or the response.</td></tr>
<tr><td>CYP2C19 IM</td><td>citalopram</td><td>The risk of QT prolongation and torsades de pointes is theoretically increased because the gene variation leads to an increased citalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration and the theoretically increased risk of QT prolongation will be offset.</td><td>Do not exceed the following daily doses:<br/>1. Adults up to 65 years: 30mg as tablets or 22mg as drops,<br/>2. Adults 65 years or older: 15mg as tablets or 10mg as drops</td></tr>
<tr><td>CYP2C19 PM</td><td>citalopram</td><td>The risk of QT prolongation and therefore also the theoretical risk of torsades de pointes is increased as the gene variation leads to an increased citalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration and the increased risk of QT prolongation will be offset.</td><td>Do not exceed the following daily doses (50% of the standard maximum dose):<br/>1. adults up to 65 years: 20mg as tablets or 16mg as drops,<br/>2. Adults 65 years or older: 10mg as tablets or 8mg as drops</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0004195.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for citalopram based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They conclude to monitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine) for the <em>CYP2C19</em> UM phenotype.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio (INR) increase &lt; 4.5. Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5. Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>Monitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine)</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5. Kinetic effect (statistically significant difference)</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/es_citalopram_CYP2C19_271111.pdf"">Citalopram CYP2C19 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104977"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104977"",""name"":""Annotation of DPWG Guideline for citalopram and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704453E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415087E9,""date"":""2019-05-23T18:39:36.219-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820777E9,""date"":""2019-10-06T22:09:59.875-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956281E9,""date"":""2020-01-31T13:21:20.097-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450962741E9,""date"":""2020-02-10T10:37:53.032-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449015"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449015"",""name"":""citalopram""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982039E9,""html"":""\u003cp\u003eThe Dutch Pharmacogenetics Working Group Guideline for citalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified daily doses.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982038E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for citalopram based on CYP2C19 genotype. They recommend to not exceed the below mentioned daily doses for intermediate metabolizer and poor metabolizer (for PM \u003d 50% of the standard maximum dose).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 UM\u003c/td\u003e\u003ctd\u003ecitalopram\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction. The gene variation increases conversion of citalopram to a weakly active metabolite. However, there is no significant effect on the plasma concentration of citalopram, the tolerance or the response.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 IM\u003c/td\u003e\u003ctd\u003ecitalopram\u003c/td\u003e\u003ctd\u003eThe risk of QT prolongation and torsades de pointes is theoretically increased because the gene variation leads to an increased citalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration and the theoretically increased risk of QT prolongation will be offset.\u003c/td\u003e\u003ctd\u003eDo not exceed the following daily doses:\u003cbr/\u003e1. Adults up to 65 years: 30mg as tablets or 22mg as drops,\u003cbr/\u003e2. Adults 65 years or older: 15mg as tablets or 10mg as drops\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 PM\u003c/td\u003e\u003ctd\u003ecitalopram\u003c/td\u003e\u003ctd\u003eThe risk of QT prolongation and therefore also the theoretical risk of torsades de pointes is increased as the gene variation leads to an increased citalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration and the increased risk of QT prolongation will be offset.\u003c/td\u003e\u003ctd\u003eDo not exceed the following daily doses (50% of the standard maximum dose):\u003cbr/\u003e1. adults up to 65 years: 20mg as tablets or 16mg as drops,\u003cbr/\u003e2. Adults 65 years or older: 10mg as tablets or 8mg as drops\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0004195.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for citalopram based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They conclude to monitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine) for the \u003cem\u003eCYP2C19\u003c/em\u003e UM phenotype.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio (INR) increase \u0026lt; 4.5. Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5. Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eMonitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5. Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/es_citalopram_CYP2C19_271111.pdf\""\u003eCitalopram CYP2C19 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182817,Guideline Annotation,"Annotation of DPWG Guideline for citalopram,escitalopram and CYP2D6",f,PA449015,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for citalopram/escitalopram based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for citalopram/escitalopram based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001999.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182817"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182817"",""name"":""Annotation of DPWG Guideline for citalopram,escitalopram and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415006E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.450820626E9,""date"":""2019-10-03T09:48:37.731-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.45096278E9,""date"":""2020-02-10T10:35:53.685-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449015"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449015"",""name"":""citalopram""},{""@id"":""https://pharmgkb.org/chemical/PA10074"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10074"",""name"":""escitalopram""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415004E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for citalopram/escitalopram based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415005E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for citalopram/escitalopram based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001999.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166105007,Guideline Annotation,"Annotation of CPIC Guideline for clomipramine and CYP2C19,CYP2D6",t,PA449048,Clinical Pharmacogenetics Implementation Consortium,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""http://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.</li>
</ul>
</li>
</ul>
<h3 id=""december-2016-update"">December 2016 Update</h3>
<p><em>Advance online publication December 2016.</em></p>
<ul>
<li>The 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.</li>
<li>Excerpt from the 2016 dosing guideline update:
<ul>
<li>&quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.&quot;</li>
<li>&quot;There is substantial evidence linking <em>CYP2D6</em> and <em>CYP2C19</em> genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have <em>CYP2D6</em> or <em>CYP2C19</em> genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.&quot;</li>
<li>&quot; There are scarce studies focusing solely on <em>CYP2D6</em> or <em>CYP2C19</em> genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.&quot;</li>
</ul>
</li>
<li>The guideline includes dosing recommendation for TCAs based on:
<ul>
<li>CYP2D6 phenotype (<a href=""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1 below</a>)</li>
<li>CYP2C19 phenotype (<a href=""#table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype"">Table 2 below</a>)</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf"" target=""_blank"">2016 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 Gene-specific Information Tables</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c19RefMaterials"">CYP2C19 Gene-specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/Clomipramine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Clomipramine Drug Resource Mappings</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Activity score</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic Recommendations<sup>a, b</sup></th><th>Classification of recommendation for other TCAs <sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 Ultrarapid metabolizer (~1-20% of patients)<sup>d</sup></td><td>&gt;2.0</td><td>An individual carrying more than two copies of functional alleles</td><td>*1/*1xN, *1/*2xN</td><td>Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.</td><td>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Normal metabolizer (~72-88% of patients)<sup>d</sup></td><td>1.0-2.0<sup>f</sup></td><td>An individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0</td><td>*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5</td><td>Normal metabolism of TCAs.</td><td>Initiate therapy with recommended starting dose.<sup>g</sup></td><td>Strong</td></tr>
<tr><td>CYP2D6 Intermediate metabolizer (~1-13% of patients)<sup>d</sup></td><td>0.5</td><td>An individual carrying one decreased and one no function allele</td><td>*4/*41, *5/*9, *4/*10</td><td>Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Consider 25% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Poor metabolizer (~1-10% of patients)<sup>d</sup></td><td>0</td><td>An individual carrying only no function alleles</td><td>*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6</td><td>Greatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider 50% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
<p><sup>g</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<h3 id=""table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype"">Table 2: Dosing recommendations for TCAs based on CYP2C19 phenotype:</h3>
<p><em>Adapted from Tables 1 and 3 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic recommendations<sup>a,b</sup></th><th>Classification of recommendations for amitriptyline<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 Ultrarapid metabolizer (~2-5% of patients)<sup>d</sup></td><td>An individual carrying two increased function alleles</td><td>*17/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Rapid metabolizer (~2-30% of patients)<sup>d</sup></td><td>An individual carrying one normal and one increased function allele</td><td>*1/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Normal metabolizer (~35-50% of patients)<sup>d</sup></td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism of tertiary amines.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Strong</td></tr>
<tr><td>CYP2C19 Intermediate metabolizer (~18-45% of patients)<sup>d</sup></td><td>An individual carrying one normal and one no function allele or one no and one increased function allele</td><td>*1/*2, *1/*3, *2/*17<sup>g</sup></td><td>Reduced metabolism of tertiary amines compared to normal metabolizers.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Poor metabolizer (~2-15% of patients)<sup>d</sup></td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>For tertiary amines, consider a 50% reduction of the recommended starting dose.<sup>f</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2C19 including clomipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<p><sup>g</sup> The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.</p>
<h3 id=""may-2013"">May 2013</h3>
<p>Guidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</p>
<p><strong>Download:</strong> <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a> and <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">supplement</a></p>
<h5 id=""excerpt-from-the-dosing-guidelines"">Excerpt from the dosing guidelines:</h5>
<p><a href=""http://www.pharmgkb.org/drug/PA448385"">Amitriptyline</a> and nortriptyline are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">guideline</a> to other tricyclics including clomipramine (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">Supplementary Table S14</a>), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.</p>
<p>See <a href=""http://www.pharmgkb.org/drug/PA448385"">amitriptyline</a> for excerpts and tables that summarize <em>CYP2D6</em>-based and <em>CYP2C19</em>-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a>).</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166105007"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166105007"",""name"":""Annotation of CPIC Guideline for clomipramine and CYP2C19,CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[{""id"":1.449560831E9,""alleles"":[{""id"":1.449560832E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.449560833E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980634"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980634"",""symbol"":""CYP2C19*1"",""name"":""*1""}},{""id"":1.449560834E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980635"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980635"",""symbol"":""CYP2C19*2"",""name"":""*2""}},{""id"":1.449560835E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980636"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980636"",""symbol"":""CYP2C19*3"",""name"":""*3""}},{""id"":1.449560838E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980638"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980638"",""symbol"":""CYP2C19*5"",""name"":""*5""}},{""id"":1.449560839E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816522"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816522"",""symbol"":""CYP2C19*6"",""name"":""*6""}},{""id"":1.44956084E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816523"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816523"",""symbol"":""CYP2C19*7"",""name"":""*7""}},{""id"":1.449560841E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816524"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816524"",""symbol"":""CYP2C19*8"",""name"":""*8""}},{""id"":1.449560842E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816525"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816525"",""symbol"":""CYP2C19*9"",""name"":""*9""}},{""id"":1.449560843E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816526"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816526"",""symbol"":""CYP2C19*10"",""name"":""*10""}},{""id"":1.449560844E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816527"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816527"",""symbol"":""CYP2C19*11"",""name"":""*11""}},{""id"":1.449560845E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816528"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816528"",""symbol"":""CYP2C19*12"",""name"":""*12""}},{""id"":1.449560846E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816529"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816529"",""symbol"":""CYP2C19*13"",""name"":""*13""}},{""id"":1.449560847E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816530"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816530"",""symbol"":""CYP2C19*14"",""name"":""*14""}},{""id"":1.449560848E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816531"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816531"",""symbol"":""CYP2C19*15"",""name"":""*15""}},{""id"":1.449560849E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816532"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816532"",""symbol"":""CYP2C19*16"",""name"":""*16""}},{""id"":1.44956085E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816533"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816533"",""symbol"":""CYP2C19*17"",""name"":""*17""}},{""id"":1.449560851E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816534"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816534"",""symbol"":""CYP2C19*18"",""name"":""*18""}},{""id"":1.449560852E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816535"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816535"",""symbol"":""CYP2C19*19"",""name"":""*19""}},{""id"":1.449560853E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816536"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816536"",""symbol"":""CYP2C19*22"",""name"":""*22""}},{""id"":1.449560854E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816537"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816537"",""symbol"":""CYP2C19*23"",""name"":""*23""}},{""id"":1.449560855E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816538"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816538"",""symbol"":""CYP2C19*24"",""name"":""*24""}},{""id"":1.449560856E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816539"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816539"",""symbol"":""CYP2C19*25"",""name"":""*25""}},{""id"":1.449560857E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816540"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816540"",""symbol"":""CYP2C19*26"",""name"":""*26""}},{""id"":1.449560859E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115675"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115675"",""symbol"":""CYP2C19*28"",""name"":""*28""}},{""id"":1.44956086E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123292"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123292"",""symbol"":""CYP2C19*29"",""name"":""*29""}},{""id"":1.449560861E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123293"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123293"",""symbol"":""CYP2C19*30"",""name"":""*30""}},{""id"":1.449560862E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123294"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123294"",""symbol"":""CYP2C19*31"",""name"":""*31""}},{""id"":1.449560863E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123295"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123295"",""symbol"":""CYP2C19*32"",""name"":""*32""}},{""id"":1.449560864E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123296"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123296"",""symbol"":""CYP2C19*33"",""name"":""*33""}},{""id"":1.449560865E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115676"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115676"",""symbol"":""CYP2C19*34"",""name"":""*34""}},{""id"":1.449560866E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128094"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128094"",""symbol"":""CYP2C19*35"",""name"":""*35""}},{""id"":1.450805221E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980637"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980637"",""symbol"":""CYP2C19*4"",""name"":""*4""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}},{""id"":1.449560867E9,""alleles"":[{""id"":1.449560868E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.449560869E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.44956087E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449560871E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449560872E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449560873E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449560874E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449560875E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449560876E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449560877E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449560878E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449560879E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.44956088E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449560881E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449560882E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449560883E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449560884E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.449560885E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449560886E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449560887E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.44956089E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449560891E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449560892E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449560893E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449560894E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449560895E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449560896E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449560897E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449560898E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449560899E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.4495609E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449560901E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449560902E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449560903E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449560904E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449560905E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449560906E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449560907E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449560908E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449560909E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.44956091E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449560911E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449560912E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449560913E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449560914E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449560915E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449560916E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449560917E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449560918E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449560919E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.44956092E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449560921E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449560922E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449560923E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449560924E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449560925E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449560926E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449560927E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449560928E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449560929E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.44956093E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449560931E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449560932E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449560933E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449560934E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449560935E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449560936E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449560937E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449560938E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449560939E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.44956094E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.449560941E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449560942E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449560943E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449560944E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449560945E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449560946E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449560947E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449560948E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449560949E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.44956095E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449560951E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449560952E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449560953E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449560954E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449560955E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449560956E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449560957E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449560958E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449560959E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.44956096E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449560961E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449560962E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449560963E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449560964E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449560965E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449560966E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449560967E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449560968E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449560969E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.44956097E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449560971E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449560972E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449560973E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449560974E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449560975E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449560976E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449560977E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449560978E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449560979E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.44956098E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449560981E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449560982E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449560983E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449560984E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449560985E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449560986E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.45004279E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042791E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824681E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.183699769E9,""date"":""2013-01-16T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.448526139E9,""date"":""2016-12-14T14:14:00.655-08:00"",""description"":""2016 TCA CPIC guideline update"",""type"":""Update"",""version"":0.0},{""id"":1.450042792E9,""date"":""2018-11-15T20:25:08.249-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824537E9,""date"":""2019-10-24T18:35:42.838-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098242"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098242E7,""resourceId"":""27997040"",""title"":""Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5478479"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293321E9,""resource"":""PubMed Central"",""resourceId"":""PMC5478479"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/27997040"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44929332E9,""resource"":""PubMed"",""resourceId"":""27997040"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/27997040""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.597"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293322E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.597"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.597""}]},{""@id"":""https://pharmgkb.org/literature/15051926"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051926E7,""resourceId"":""23486447"",""title"":""Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3689226"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275357E9,""resource"":""PubMed Central"",""resourceId"":""PMC3689226"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23486447"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275356E9,""resource"":""PubMed"",""resourceId"":""23486447"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23486447""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.2"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275358E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.2"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.2""}]},{""@id"":""https://pharmgkb.org/literature/15100907"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100907E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449048"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449048"",""name"":""clomipramine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""},{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447981968E9,""html"":""\u003cp\u003eTricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981967E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2016-update\""\u003eDecember 2016 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication December 2016.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2016 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;There is substantial evidence linking \u003cem\u003eCYP2D6\u003c/em\u003e and \u003cem\u003eCYP2C19\u003c/em\u003e genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot; There are scarce studies focusing solely on \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eThe guideline includes dosing recommendation for TCAs based on:\n\u003cul\u003e\n\u003cli\u003eCYP2D6 phenotype (\u003ca href\u003d\""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1 below\u003c/a\u003e)\u003c/li\u003e\n\u003cli\u003eCYP2C19 phenotype (\u003ca href\u003d\""#table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype\""\u003eTable 2 below\u003c/a\u003e)\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf\"" target\u003d\""_blank\""\u003e2016 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c19RefMaterials\""\u003eCYP2C19 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/Clomipramine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eClomipramine Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003csup\u003ea, b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendation for other TCAs \u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Ultrarapid metabolizer (~1-20% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying more than two copies of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN\u003c/td\u003e\u003ctd\u003eIncreased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Normal metabolizer (~72-88% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.0-2.0\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5\u003c/td\u003e\u003ctd\u003eNormal metabolism of TCAs.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Intermediate metabolizer (~1-13% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*41, *5/*9, *4/*10\u003c/td\u003e\u003ctd\u003eReduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Poor metabolizer (~1-10% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no function alleles\u003c/td\u003e\u003ctd\u003e*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider 50% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003ch3 id\u003d\""table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype\""\u003eTable 2: Dosing recommendations for TCAs based on CYP2C19 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ea,b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations for amitriptyline\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Ultrarapid metabolizer (~2-5% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles\u003c/td\u003e\u003ctd\u003e*17/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Rapid metabolizer (~2-30% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Normal metabolizer (~35-50% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism of tertiary amines.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Intermediate metabolizer (~18-45% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one no function allele or one no and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3, *2/*17\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eReduced metabolism of tertiary amines compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Poor metabolizer (~2-15% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eFor tertiary amines, consider a 50% reduction of the recommended starting dose.\u003csup\u003ef\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2C19 including clomipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2013\""\u003eMay 2013\u003c/h3\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDownload:\u003c/strong\u003e \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e and \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003esupplement\u003c/a\u003e\u003c/p\u003e\n\u003ch5 id\u003d\""excerpt-from-the-dosing-guidelines\""\u003eExcerpt from the dosing guidelines:\u003c/h5\u003e\n\u003cp\u003e\u003ca href\u003d\""http://www.pharmgkb.org/drug/PA448385\""\u003eAmitriptyline\u003c/a\u003e and nortriptyline are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003eguideline\u003c/a\u003e to other tricyclics including clomipramine (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003eSupplementary Table S14\u003c/a\u003e), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.\u003c/p\u003e\n\u003cp\u003eSee \u003ca href\u003d\""http://www.pharmgkb.org/drug/PA448385\""\u003eamitriptyline\u003c/a\u003e for excerpts and tables that summarize \u003cem\u003eCYP2D6\u003c/em\u003e-based and \u003cem\u003eCYP2C19\u003c/em\u003e-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e).\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166104964,Guideline Annotation,Annotation of DPWG Guideline for clomipramine and CYP2D6,t,PA449048,Dutch Pharmacogenetics Working Group,"<p>The Dutch Pharmacogenetics Working Group Guideline for clomipramine recommends dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), and intermediate (IM) metabolizer or to avoid clomipramine in PM and ultrarapid (UM) metabolizer.</p>
","<h3 id=""august-2019-update"">August 2019 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clomipramine based on CYP2D6 genotype. They recommend dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), and intermediate (IM) metabolizer or to avoid clomipramine in PM and ultrarapid (UM) metabolizer.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>clomipramine</td><td>The gene variation increases the risk of ineffectiveness for obsessive compulsive disorder and anxiety disorders by reducing the plasma concentration of clomipramine. The gene variation has little to no effect on the plasma concentration of clomipramine+desmethylclomipramine, which determines the efficacy for depression and side effects.</td><td>Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS: avoid clomipramine. Antidepressants that are not metabolised by CYP2C19 - or to a lesser extent - include, for example, fluoxetine, fluvoxamine and paroxetine. If it is not possible to avoid clomipramine: monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is greater than 200 ng/mL in combination with a plasma concentration of desmethylclomipramine that is as low as possible. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. A sum of the plasma concentrations of clomipramine and desmethylclomipramine exceeding 600 ng/mL is considered toxic. Add a low dose of fluvoxamine if necessary, to inhibit CYP2C19 and CYP1A2 and thereby inhibit the conversion of clomipramine to desmethylclomipramine. Indication DEPRESSION: no action required.</td></tr>
<tr><td>CYP2D6 IM</td><td>clomipramine</td><td>The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of clomipramine and the active metabolite desmethylclomipramine.</td><td>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For depression, the therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mLFor obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic.</td></tr>
<tr><td>CYP2D6 PM</td><td>clomipramine</td><td>The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of clomipramine and the active metabolite desmethylclomipramine.</td><td>Indication DEPRESSION: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. The therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. Values higher than 600 ng/mL are considered toxic. Indication ANXIETY DISORDERS or OBSESSIVE COMPULSIVE DISORDER: if side effects occur: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear while the effectiveness is retained. Clomipramine and desmethylclomipramine both contribute to the side effects. Only clomipramine contributes to the effectiveness. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic, whilst the therapeutic upper limit for depression is 400 ng/mL. If dose reduction does not have the desired effect: avoid clomipramine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001480.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clomipramine based on CYP2D6 genotype. They recommend dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid clomipramine in PM and UM.</p>
<p><em>Wording in table taken from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>clomipramine</td><td>The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of clomipramine and the active metabolite desmethylclomipramine and to increased concentrations of the potentially cardiotoxic hydroxy metabolites.</td><td>Use 1.5 times the standard dose and monitor the effect and side effects of the plasma concentrations of clomipramine and desmethylclomipramine to set the maintenance dose. For depression, the therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. If a dose increase is not wanted due to potential cardiotoxic hydroxy metabolites: avoid clomipramine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</td></tr>
<tr><td>CYP2D6 IM</td><td>clomipramine</td><td>The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of clomipramine and the active metabolite desmethylclomipramine.</td><td>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For depression, the therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic.</td></tr>
<tr><td>CYP2D6 PM</td><td>clomipramine</td><td>The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of clomipramine and the active metabolite desmethylclomipramine.</td><td>Indication DEPRESSION: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. The therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. Values higher than 600 ng/mL are considered toxic. Indication ANXIETY DISORDERS or OBSESSIVE COMPULSIVE DISORDER: if side effects occur: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear while the effectiveness is retained. Clomipramine and desmethylclomipramine both contribute to the side effects. Only clomipramine contributes to the effectiveness. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic, whilst the therapeutic upper limit for depression is 400 ng/mL. If dose reduction does not have the desired effect: avoid clomipramine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001482.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clomipramine based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend lower dose for patients carrying the poor metabolizer (PM) alleles and alternative drug for patients carrying the ultrarapid metabolizer (UM) allleles.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Reduce dose by 50% and monitor (desmethyl) clomipramine plasma concentration.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Insufficient data to allow calculation of dose adjustment. Monitor (desmethyl)clomipramine plasma concentration</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Select alternative drug (e.g., citalopram, sertralin) or monitor (desmethyl)clomipramine plasma concentration.</td><td>Published case reports, well documented, and having relevant pharmacokinetic or clinical endpoints. Well documented case series.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/clomipramine_CYP2D6_271111.pdf"">Clomipramine CYP2D6</a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104964"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104964"",""name"":""Annotation of DPWG Guideline for clomipramine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704455E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415092E9,""date"":""2019-05-23T20:29:59.032-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820778E9,""date"":""2019-10-06T22:31:16.519-07:00"",""description"":""August 2019 Guideline update"",""type"":""Update"",""version"":0.0},{""id"":1.4509563E9,""date"":""2020-01-31T13:22:12.315-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450962742E9,""date"":""2020-02-10T10:49:01.846-08:00"",""description"":""Fixed links to 2019 guideline pdfs. 2018 link already went to attachment."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449048"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449048"",""name"":""clomipramine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981906E9,""html"":""\u003cp\u003eThe Dutch Pharmacogenetics Working Group Guideline for clomipramine recommends dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), and intermediate (IM) metabolizer or to avoid clomipramine in PM and ultrarapid (UM) metabolizer.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981905E9,""html"":""\u003ch3 id\u003d\""august-2019-update\""\u003eAugust 2019 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clomipramine based on CYP2D6 genotype. They recommend dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), and intermediate (IM) metabolizer or to avoid clomipramine in PM and ultrarapid (UM) metabolizer.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eclomipramine\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of ineffectiveness for obsessive compulsive disorder and anxiety disorders by reducing the plasma concentration of clomipramine. The gene variation has little to no effect on the plasma concentration of clomipramine+desmethylclomipramine, which determines the efficacy for depression and side effects.\u003c/td\u003e\u003ctd\u003eIndication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS: avoid clomipramine. Antidepressants that are not metabolised by CYP2C19 - or to a lesser extent - include, for example, fluoxetine, fluvoxamine and paroxetine. If it is not possible to avoid clomipramine: monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is greater than 200 ng/mL in combination with a plasma concentration of desmethylclomipramine that is as low as possible. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. A sum of the plasma concentrations of clomipramine and desmethylclomipramine exceeding 600 ng/mL is considered toxic. Add a low dose of fluvoxamine if necessary, to inhibit CYP2C19 and CYP1A2 and thereby inhibit the conversion of clomipramine to desmethylclomipramine. Indication DEPRESSION: no action required.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eclomipramine\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of clomipramine and the active metabolite desmethylclomipramine.\u003c/td\u003e\u003ctd\u003eUse 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For depression, the therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mLFor obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eclomipramine\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of clomipramine and the active metabolite desmethylclomipramine.\u003c/td\u003e\u003ctd\u003eIndication DEPRESSION: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. The therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. Values higher than 600 ng/mL are considered toxic. Indication ANXIETY DISORDERS or OBSESSIVE COMPULSIVE DISORDER: if side effects occur: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear while the effectiveness is retained. Clomipramine and desmethylclomipramine both contribute to the side effects. Only clomipramine contributes to the effectiveness. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic, whilst the therapeutic upper limit for depression is 400 ng/mL. If dose reduction does not have the desired effect: avoid clomipramine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001480.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clomipramine based on CYP2D6 genotype. They recommend dose changes and to monitor the effect and side effects and the plasma concentrations to set the maintenance dose for CYP2D6 poor (PM), intermediate (IM), and ultrarapid (UM) metabolizer or to avoid clomipramine in PM and UM.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eclomipramine\u003c/td\u003e\u003ctd\u003eThe risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of clomipramine and the active metabolite desmethylclomipramine and to increased concentrations of the potentially cardiotoxic hydroxy metabolites.\u003c/td\u003e\u003ctd\u003eUse 1.5 times the standard dose and monitor the effect and side effects of the plasma concentrations of clomipramine and desmethylclomipramine to set the maintenance dose. For depression, the therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. If a dose increase is not wanted due to potential cardiotoxic hydroxy metabolites: avoid clomipramine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eclomipramine\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of clomipramine and the active metabolite desmethylclomipramine.\u003c/td\u003e\u003ctd\u003eUse 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For depression, the therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eclomipramine\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of clomipramine and the active metabolite desmethylclomipramine.\u003c/td\u003e\u003ctd\u003eIndication DEPRESSION: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. The therapeutic range is 200-400 ng/mL for the sum of the plasma concentrations of clomipramine and desmethylclomipramine. Values higher than 600 ng/mL are considered toxic. Indication ANXIETY DISORDERS or OBSESSIVE COMPULSIVE DISORDER: if side effects occur: use 50% of the standard dose and monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine in order to set the maintenance dose. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear while the effectiveness is retained. Clomipramine and desmethylclomipramine both contribute to the side effects. Only clomipramine contributes to the effectiveness. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL, in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is higher than 200 ng/mL, in combination with a plasma concentration of desmethylclomipramine that is as low as possible. A sum of the plasma concentrations of clomipramine and desmethylclomipramine higher than 600 ng/mL is considered toxic, whilst the therapeutic upper limit for depression is 400 ng/mL. If dose reduction does not have the desired effect: avoid clomipramine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include citalopram and sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001482.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clomipramine based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend lower dose for patients carrying the poor metabolizer (PM) alleles and alternative drug for patients carrying the ultrarapid metabolizer (UM) allleles.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eReduce dose by 50% and monitor (desmethyl) clomipramine plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Monitor (desmethyl)clomipramine plasma concentration\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eSelect alternative drug (e.g., citalopram, sertralin) or monitor (desmethyl)clomipramine plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished case reports, well documented, and having relevant pharmacokinetic or clinical endpoints. Well documented case series.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/clomipramine_CYP2D6_271111.pdf\""\u003eClomipramine CYP2D6\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166184528,Guideline Annotation,Annotation of DPWG Guideline for clomipramine and CYP2C19,t,PA449048,Dutch Pharmacogenetics Working Group,"<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2D6 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.</p>
","<h3 id=""august-2019-guideline"">August 2019 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clomipramine based on CYP2C19 genotype. They recommend to avoid clomipramine for CYP2D6 ultrarapid metabolizer (UM) with regards to Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>clomipramine</td><td>The gene variation increases the risk of ineffectiveness for obsessive compulsive disorder and anxiety disorders by reducing the plasma concentration of clomipramine. The gene variation has little to no effect on the plasma concentration of clomipramine+desmethylclomipramine, which determines the efficacy for depression and side effects.</td><td>Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS: avoid clomipramine. Antidepressants that are not metabolised by CYP2C19 - or to a lesser extent - include, for example, fluoxetine, fluvoxamine and paroxetine. If it is not possible to avoid clomipramine: monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is greater than 200 ng/mL in combination with a plasma concentration of desmethylclomipramine that is as low as possible. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. A sum of the plasma concentrations of clomipramine and desmethylclomipramine exceeding 600 ng/mL is considered toxic. Add a low dose of fluvoxamine if necessary, to inhibit CYP2C19 and CYP1A2 and thereby inhibit the conversion of clomipramine to desmethylclomipramine. Indication DEPRESSION: no action required</td></tr>
<tr><td>CYP2D6 IM</td><td>clomipramine</td><td>-</td><td>NO action is required for this gene-drug interaction. The gene variation does increase clomipramine plasma concentrations, but not clomipramine+desmethylclomipramine plasma concentrations, which determines side effects and efficacy in depression. The increase in the plasma concentration of clomipramine is favourable for the efficacy in anxiety and obsessive compulsive disorder.</td></tr>
<tr><td>CYP2D6 PM</td><td>clomipramine</td><td>-</td><td>NO action is required for this gene-drug interaction. The gene variation increases the plasma concentration of clomipramine. However, there is insufficient evidence to substantiate an increase of the plasma concentration of clomipramine+desmethylclomipramine to such an extent that it increases the risk of side effects. The increase in the plasma concentration of clomipramine is favourable for the efficacy in anxiety and obsessive compulsive disorder.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0007028.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166184528"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166184528"",""name"":""Annotation of DPWG Guideline for clomipramine and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450820783E9,""date"":""2019-10-06T22:47:26.963-07:00"",""description"":""August 2019 Guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450962783E9,""date"":""2020-02-10T10:46:35.951-08:00"",""description"":""Fixed links to 2019 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449048"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449048"",""name"":""clomipramine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.45082078E9,""html"":""\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2D6 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450820781E9,""html"":""\u003ch3 id\u003d\""august-2019-guideline\""\u003eAugust 2019 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clomipramine based on CYP2C19 genotype. They recommend to avoid clomipramine for CYP2D6 ultrarapid metabolizer (UM) with regards to Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eclomipramine\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of ineffectiveness for obsessive compulsive disorder and anxiety disorders by reducing the plasma concentration of clomipramine. The gene variation has little to no effect on the plasma concentration of clomipramine+desmethylclomipramine, which determines the efficacy for depression and side effects.\u003c/td\u003e\u003ctd\u003eIndication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS: avoid clomipramine. Antidepressants that are not metabolised by CYP2C19 - or to a lesser extent - include, for example, fluoxetine, fluvoxamine and paroxetine. If it is not possible to avoid clomipramine: monitor the effect and side effects or the plasma concentrations of clomipramine and desmethylclomipramine. For obsessive compulsive disorder, the therapeutic plasma concentration of clomipramine is greater than 200 ng/mL in combination with a plasma concentration of desmethylclomipramine that is as low as possible. For anxiety disorders, the therapeutic plasma concentration of clomipramine is approximately 100 ng/mL in combination with a plasma concentration of desmethylclomipramine lower than 200 ng/mL. A sum of the plasma concentrations of clomipramine and desmethylclomipramine exceeding 600 ng/mL is considered toxic. Add a low dose of fluvoxamine if necessary, to inhibit CYP2C19 and CYP1A2 and thereby inhibit the conversion of clomipramine to desmethylclomipramine. Indication DEPRESSION: no action required\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eclomipramine\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction. The gene variation does increase clomipramine plasma concentrations, but not clomipramine+desmethylclomipramine plasma concentrations, which determines side effects and efficacy in depression. The increase in the plasma concentration of clomipramine is favourable for the efficacy in anxiety and obsessive compulsive disorder.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eclomipramine\u003c/td\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction. The gene variation increases the plasma concentration of clomipramine. However, there is insufficient evidence to substantiate an increase of the plasma concentration of clomipramine+desmethylclomipramine to such an extent that it increases the risk of side effects. The increase in the plasma concentration of clomipramine is favourable for the efficacy in anxiety and obsessive compulsive disorder.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0007028.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182818,Guideline Annotation,Annotation of DPWG Guideline for clonidine and CYP2D6,f,PA449051,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for clonidine based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clonidine based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002531.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182818"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182818"",""name"":""Annotation of DPWG Guideline for clonidine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.45041501E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.450820784E9,""date"":""2019-10-06T22:50:22.989-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450962743E9,""date"":""2020-02-10T10:51:09.935-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449051"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449051"",""name"":""clonidine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415008E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for clonidine based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415009E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clonidine based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002531.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104935,Guideline Annotation,Annotation of DPWG Guideline for clozapine and CYP2D6,f,PA449061,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for clozapine based on CYP2D6 genotypes.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clozapine based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001530.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clozapine based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  They conclude that there are no recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>No recommendations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (not statistically significant difference).</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>No recommendations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (not statistically significant difference).</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>No recommendations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (not statistically significant difference).</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/clozapine_CYP2D6_271111.pdf"">Clozapine CYP2D6 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104935"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104935"",""name"":""Annotation of DPWG Guideline for clozapine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704459E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415016E9,""date"":""2019-05-23T14:10:57.333-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820787E9,""date"":""2019-10-06T22:58:39.539-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45095634E9,""date"":""2020-01-31T13:23:30.342-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096282E9,""date"":""2020-02-10T11:05:37.269-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449061"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449061"",""name"":""clozapine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981852E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for clozapine based on CYP2D6 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981851E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clozapine based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001530.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for clozapine based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They conclude that there are no recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eNo recommendations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (not statistically significant difference).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eNo recommendations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (not statistically significant difference).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eNo recommendations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (not statistically significant difference).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/clozapine_CYP2D6_271111.pdf\""\u003eClozapine CYP2D6 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104996,Guideline Annotation,Annotation of CPIC Guideline for codeine and CYP2D6,t,PA449088,Clinical Pharmacogenetics Implementation Consortium,"<p>Alternate analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific codeine dose is warranted for CYP2D6 extensive and intermediate metabolizers.</p>
","<p><em><strong>Note that the FDA released a <a rel=""noopener noreferrer"" href=""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery"" target=""_blank"">safety announcement</a> on 4/20/2017 stating that codeine and tramadol should not be used in children under 12 years.</strong></em></p>
<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"" target=""_blank"">CPIC&reg; guideline for codeine and CYP2D6</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.</li>
</ul>
</li>
</ul>
<h3 id=""august-2015-update-on-pharmgkb"">August 2015 Update on PharmGKB</h3>
<ul>
<li>Supplemental table S3 (Association between allelic variants and CYP2D6 enzyme activity) was updated with Supplemental table S2 from the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors (2015 Supplement) PMID: 25974703. The table is an updated version including additions to functional status and additional alleles.</li>
</ul>
<h3 id=""april-2014-update"">April 2014 Update</h3>
<p><em>Advance online publication January 2014.</em></p>
<ul>
<li>The 2014 update of CPIC guidelines regarding CYP2D6 and codeine have been published in Clinical Pharmacology and Therapeutics. Literature up to August 2013 was reviewed. <strong>The update addresses the FDA warning regarding codeine use in children following tonsillectomy with or without adenoidectomy, pediatric considerations, and additional considerations for use of alternative opioids metabolized by CYP2D6</strong>. In addition, supplemental information was updated.</li>
<li>Excerpts from the 2014 guideline update:
<ul>
<li>&quot;<em>CYP2D6</em> genotype is expected to be equally reliable for inferring phenotype from genotype in children as in adults. Codeine is not recommended in children less than 2 years of age but presumably would carry additional dangers in neonates and young children who are ultrarapid metabolizers.&quot;</li>
<li>&quot;Caution should be used when prescribing codeine to a breastfeeding woman with an ultrarapid metabolizer status.&quot;</li>
<li>&quot;In February 2013, the FDA announced its strongest and new black box warning against codeine use to manage postoperative pain in children following tonsillectomy with or without adenoidectomy. This warning was in response to further FDA review of the codeine-related deaths and serious adverse drug reactions. The FDA warning is applicable to all children undergoing tonsillectomy with or without adenoidectomy irrespective of their obstructive sleep apnea status or CYP2D6 genotype/phenotype.&quot;</li>
</ul>
</li>
<li>These guidelines are applicable to:
<ul>
<li>pediatric patients</li>
<li>adult patients</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/codeine/2014/24458010.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update </a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/codeine/2014/24458010-supplement.pdf"" target=""_blank"">2014 supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/codeine/2014/24458010-CYP2D6%20allele%20table%20and%20legend%20(R2).pdf"" target=""_blank"">CYP2D6 frequency table legend (R2)</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/codeine/2014/24458010-CYP2D6%20allele%20frequency%20table%20(R2).xlsx"" target=""_blank"">CYP2D6 frequency table (R2)</a></li>
</ul>
</li>
</ul>
<h4 id=""table-1-recommended-dosing-of-codeine-by-cyp2d6-phenotype"">Table 1: Recommended dosing of codeine by CYP2D6 Phenotype</h4>
<p><em>Adapted from Tables 1 and 2 of the 2014 guideline update manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype.<sup>a</sup></th><th>Activity score</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for codeine metabolism</th><th>Recommendations for codeine therapy.<sup>b</sup></th><th>Classification of recommendation for codeine therapy</th><th>Considerations for alternative opioids</th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer (~1-2% of patients)</td><td>&gt;2.0</td><td>An individual carrying more than two copies of functional alleles</td><td>*1/*1xN, *1/*2xN</td><td>Increased formation of morphine following codeine administration, leading to higher risk of toxicity</td><td>Avoid codeine use due to potential for toxicity.</td><td>Strong</td><td>Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity.<sup>d,e</sup></td></tr>
<tr><td>Extensive metabolizer (~77-92% of patients)</td><td>1.0-2.0.<sup>c</sup></td><td>An individual carrying two alleles encoding full or reduced function or one full function allele together with either one nonfunctional or one reduced-function allele</td><td>*1/*1, *1/*2, *2/*2, *1/*41, *1/*4, *2/*5, *10/*10</td><td>Normal morphine formation</td><td>Use label recommended age- or weight-specific dosing.</td><td>Strong</td><td></td></tr>
<tr><td>Intermediate metabolizer (~2-11% of patients)</td><td>0.5.<sup>c</sup></td><td>An individual carrying one reduced and one nonfunctional allele</td><td>*4/*10, *5/*41</td><td>Reduced morphine formation</td><td>Use label recommended age- or weight-specific dosing. If no response, consider alternative analgesics such as morphine or a non-opioid.</td><td>Moderate</td><td>Monitor tramadol use for response.</td></tr>
<tr><td>Poor metabolizer (~5-10% of patients)</td><td>0</td><td>An individual carrying no functional alleles</td><td>*4/*4, *4/*5, *5/*5, *4/*6</td><td>Greatly reduced morphine formation following codeine administration, leading to insufficient pain relief</td><td>Avoid codeine use due to lack of efficacy.</td><td>Strong</td><td>Alternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity; these agents should be avoided.<sup>d,e</sup></td></tr>
</tbody>
</table>
<p><sup>a</sup> Frequency estimates are based on data from Caucasians and may differ substantially for other ethnicities. See 2014 supplement above for estimates of phenotype frequencies among different ethnic/geographic groups.</p>
<p><sup>b</sup> Rating scheme is described in supplemental material - see 2014 update above.</p>
<p><sup>c</sup> Note that some investigators define patients with an activity score of 0.5 and 1.0 as intermediate metabolizers and define patients with an activity score of 1.5 and 2.0 as extensive metabolizers.  Classifying patients with an activity score of 1.0 as extensive metabolizers in this guideline is based on data specific for formation of morphine from codeine in these patients [Article:<a href=""/pmid/19395173"">19395173</a>].</p>
<p><sup>d</sup> There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery.  Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable (see 2014 update above).</p>
<p><sup>e</sup> Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers.</p>
<h3 id=""february-2012"">February 2012</h3>
<p><em>Advance online publication Dec 2011.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for codeine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>These guidelines are applicable to:
<ul>
<li>pediatric patients</li>
<li>adult patients</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/codeine/2012/22205192.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/codeine/2012/22205192-supplement.pdf"" target=""_blank"">2012 supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/codeine/2012/22205192-CYP2D6%20allele%20table%20and%20legend.pdf"" target=""_blank"">CYP2D6 frequency table legend (R2)</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/codeine/2012/22205192-CYP2D6%20allele%20frequency%20table.xlsx"" target=""_blank"">CYP2D6 frequency table</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104996"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104996"",""name"":""Annotation of CPIC Guideline for codeine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":""Rv0Rb7w1u2A"",""guidelineGenes"":[{""id"":1.449562107E9,""alleles"":[{""id"":1.449562223E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449562224E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449562166E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449562167E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449562168E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449562169E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.44956217E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449562171E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449562172E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449562173E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449562174E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449562175E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449562176E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449562177E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449562178E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449562179E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.44956218E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449562181E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449562182E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.449562185E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449562186E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449562187E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449562188E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449562189E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.44956219E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449562191E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449562192E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449562193E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449562194E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449562195E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449562196E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449562197E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449562198E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449562199E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.4495622E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449562201E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449562202E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449562203E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449562204E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449562205E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449562206E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449562207E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449562209E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449562208E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.44956221E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449562211E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449562212E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449562213E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449562214E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449562215E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449562216E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449562217E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449562218E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449562219E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.44956222E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449562221E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449562222E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449562225E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449562108E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449562109E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.44956211E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449562111E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449562112E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449562113E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449562114E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449562115E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449562116E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449562117E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449562118E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449562119E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.44956212E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449562121E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449562122E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449562123E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449562124E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449562125E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449562126E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449562127E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449562128E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449562129E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.44956213E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449562131E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449562132E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449562133E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449562134E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449562135E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449562136E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449562137E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449562138E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449562139E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.44956214E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449562141E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449562142E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449562143E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449562144E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449562145E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449562146E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449562147E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449562148E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449562149E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.44956215E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449562151E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449562152E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449562153E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449562154E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449562155E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449562156E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449562157E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449562158E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449562159E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.44956216E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449562161E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449562162E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449562163E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449562164E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449562165E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.450042763E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042764E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824303E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.183699759E9,""date"":""2011-12-28T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.183703037E9,""date"":""2014-01-24T00:00:00-08:00"",""type"":""Update"",""version"":0.0},{""id"":1.447983994E9,""date"":""2016-05-05T12:28:51.930-07:00"",""description"":""corrected error in guideline link"",""type"":""Update"",""version"":0.0},{""id"":1.448616255E9,""date"":""2017-05-02T11:09:05.935-07:00"",""description"":""added note about FDA safety announcment"",""type"":""Update"",""version"":0.0},{""id"":1.449715166E9,""date"":""2018-08-10T17:04:07.839-07:00"",""description"":""Updated link to new guideline video"",""type"":""Update"",""version"":0.0},{""id"":1.449717118E9,""date"":""2018-08-23T16:37:53.481-07:00"",""description"":""Updated video link"",""type"":""Update"",""version"":0.0},{""id"":1.450042765E9,""date"":""2018-11-15T19:02:16.487-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824543E9,""date"":""2019-10-24T20:01:25.514-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15069654"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5069654E7,""resourceId"":""24458010"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975212"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3975212"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279351E9,""resource"":""PubMed Central"",""resourceId"":""PMC3975212"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975212""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/24458010"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44927935E9,""resource"":""PubMed"",""resourceId"":""24458010"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/24458010""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.254"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279352E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.254"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.254""}]},{""@id"":""https://pharmgkb.org/literature/14821790"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.482179E7,""resourceId"":""22205192"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289963"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3289963"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449266728E9,""resource"":""PubMed Central"",""resourceId"":""PMC3289963"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289963""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/22205192"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":8.27815491E8,""resource"":""PubMed"",""resourceId"":""22205192"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/22205192""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.287"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449266729E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.287"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.287""}]},{""@id"":""https://pharmgkb.org/literature/15100918"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100918E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"",""title"":""CPIC® Guideline for Codeine and CYP2D6 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983494E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449088"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449088"",""name"":""codeine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982022E9,""html"":""\u003cp\u003eAlternate analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. A label recommended age- or weight-specific codeine dose is warranted for CYP2D6 extensive and intermediate metabolizers.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982021E9,""html"":""\u003cp\u003e\u003cem\u003e\u003cstrong\u003eNote that the FDA released a \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source\u003dgovdelivery\u0026amp;utm_medium\u003demail\u0026amp;utm_source\u003dgovdelivery\"" target\u003d\""_blank\""\u003esafety announcement\u003c/a\u003e on 4/20/2017 stating that codeine and tramadol should not be used in children under 12 years.\u003c/strong\u003e\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for codeine and CYP2D6\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""august-2015-update-on-pharmgkb\""\u003eAugust 2015 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eSupplemental table S3 (Association between allelic variants and CYP2D6 enzyme activity) was updated with Supplemental table S2 from the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors (2015 Supplement) PMID: 25974703. The table is an updated version including additions to functional status and additional alleles.\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""april-2014-update\""\u003eApril 2014 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication January 2014.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2014 update of CPIC guidelines regarding CYP2D6 and codeine have been published in Clinical Pharmacology and Therapeutics. Literature up to August 2013 was reviewed. \u003cstrong\u003eThe update addresses the FDA warning regarding codeine use in children following tonsillectomy with or without adenoidectomy, pediatric considerations, and additional considerations for use of alternative opioids metabolized by CYP2D6\u003c/strong\u003e. In addition, supplemental information was updated.\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2014 guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;\u003cem\u003eCYP2D6\u003c/em\u003e genotype is expected to be equally reliable for inferring phenotype from genotype in children as in adults. Codeine is not recommended in children less than 2 years of age but presumably would carry additional dangers in neonates and young children who are ultrarapid metabolizers.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Caution should be used when prescribing codeine to a breastfeeding woman with an ultrarapid metabolizer status.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;In February 2013, the FDA announced its strongest and new black box warning against codeine use to manage postoperative pain in children following tonsillectomy with or without adenoidectomy. This warning was in response to further FDA review of the codeine-related deaths and serious adverse drug reactions. The FDA warning is applicable to all children undergoing tonsillectomy with or without adenoidectomy irrespective of their obstructive sleep apnea status or CYP2D6 genotype/phenotype.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/codeine/2014/24458010.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update \u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/codeine/2014/24458010-supplement.pdf\"" target\u003d\""_blank\""\u003e2014 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/codeine/2014/24458010-CYP2D6%20allele%20table%20and%20legend%20(R2).pdf\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table legend (R2)\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/codeine/2014/24458010-CYP2D6%20allele%20frequency%20table%20(R2).xlsx\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table (R2)\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch4 id\u003d\""table-1-recommended-dosing-of-codeine-by-cyp2d6-phenotype\""\u003eTable 1: Recommended dosing of codeine by CYP2D6 Phenotype\u003c/h4\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2014 guideline update manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype.\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications for codeine metabolism\u003c/th\u003e\u003cth\u003eRecommendations for codeine therapy.\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendation for codeine therapy\u003c/th\u003e\u003cth\u003eConsiderations for alternative opioids\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer (~1-2% of patients)\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying more than two copies of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN\u003c/td\u003e\u003ctd\u003eIncreased formation of morphine following codeine administration, leading to higher risk of toxicity\u003c/td\u003e\u003ctd\u003eAvoid codeine use due to potential for toxicity.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003eAlternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity.\u003csup\u003ed,e\u003c/sup\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eExtensive metabolizer (~77-92% of patients)\u003c/td\u003e\u003ctd\u003e1.0-2.0.\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two alleles encoding full or reduced function or one full function allele together with either one nonfunctional or one reduced-function allele\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *2/*2, *1/*41, *1/*4, *2/*5, *10/*10\u003c/td\u003e\u003ctd\u003eNormal morphine formation\u003c/td\u003e\u003ctd\u003eUse label recommended age- or weight-specific dosing.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer (~2-11% of patients)\u003c/td\u003e\u003ctd\u003e0.5.\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one reduced and one nonfunctional allele\u003c/td\u003e\u003ctd\u003e*4/*10, *5/*41\u003c/td\u003e\u003ctd\u003eReduced morphine formation\u003c/td\u003e\u003ctd\u003eUse label recommended age- or weight-specific dosing. If no response, consider alternative analgesics such as morphine or a non-opioid.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eMonitor tramadol use for response.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizer (~5-10% of patients)\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying no functional alleles\u003c/td\u003e\u003ctd\u003e*4/*4, *4/*5, *5/*5, *4/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced morphine formation following codeine administration, leading to insufficient pain relief\u003c/td\u003e\u003ctd\u003eAvoid codeine use due to lack of efficacy.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003eAlternatives that are not affected by this CYP2D6 phenotype include morphine and non-opioid analgesics. Tramadol, and to a lesser extent hydrocodone and oxycodone, are not good alternatives because their metabolism is affected by CYP2D6 activity; these agents should be avoided.\u003csup\u003ed,e\u003c/sup\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Frequency estimates are based on data from Caucasians and may differ substantially for other ethnicities. See 2014 supplement above for estimates of phenotype frequencies among different ethnic/geographic groups.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Rating scheme is described in supplemental material - see 2014 update above.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Note that some investigators define patients with an activity score of 0.5 and 1.0 as intermediate metabolizers and define patients with an activity score of 1.5 and 2.0 as extensive metabolizers.  Classifying patients with an activity score of 1.0 as extensive metabolizers in this guideline is based on data specific for formation of morphine from codeine in these patients [Article:\u003ca href\u003d\""/pmid/19395173\""\u003e19395173\u003c/a\u003e].\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e There is substantial evidence for decreased efficacy of tramadol in poor metabolizers and a single case report of toxicity in an ultrarapid metabolizer with renal impairment following tramadol post-surgery.  Use of other analgesics in CYP2D6 poor and ultrarapid metabolizers may therefore be preferable (see 2014 update above).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Some other opioid analgesics are metabolized by CYP2D6, such as hydrocodone and oxycodone. To avoid treatment complications, opioids that are not metabolized by CYP2D6, including morphine, oxymorphone, buprenorphine, fentanyl, methadone and hydromorphone, along with non-opioid analgesics, may be considered as alternatives for use in CYP2D6 poor and ultrarapid metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""february-2012\""\u003eFebruary 2012\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication Dec 2011.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for codeine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/codeine/2012/22205192.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/codeine/2012/22205192-supplement.pdf\"" target\u003d\""_blank\""\u003e2012 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/codeine/2012/22205192-CYP2D6%20allele%20table%20and%20legend.pdf\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table legend (R2)\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/codeine/2012/22205192-CYP2D6%20allele%20frequency%20table.xlsx\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983494E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/""}]},""status"":""success""}"
PA166122666,Guideline Annotation,Annotation of CPNDS Guideline for codeine and CYP2D6,t,PA449088,Canadian Pharmacogenomics Network for Drug Safety,"<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of <em>CYP2D6</em> genotype when prescribing codeine. They recommend that poor metabolizers of CYP2D6 should not receive codeine for pain relief, and ultrametabolizers of CYP2D6 should avoid codeine for pain relief.</p>
","<p><strong><em>Note that the FDA released a <a rel=""noopener noreferrer"" href=""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery"" target=""_blank"">safety announcement</a> on 4/20/2017 stating that codeine and tramadol should not be used in children under 12 years.</em></strong></p>
<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published CYP2D6 genotype-based drug dosing guidelines for codeine in the <em>Journal of Population Therapeutics and Clinical Pharmacology</em>. Excerpts from &quot;Clinical Practice Guideline: <em>CYP2D6</em> genotyping for safe and efficacious codeine therapy&quot; [Article:<a href=""/pmid/24214521"">24214521</a>] follow:</p>
<blockquote class=""blockquote"">
<ul>
<li>
<p>Poor metabolizers of CYP2D6 should not receive codeine for pain relief (Grade A - strong recommendation).</p>
</li>
<li>
<p>Ultrarapid metabolizers of CYP2D6 should avoid codeine for pain relief and receive alternative analgesics that do not have potent CYP2D6 metabolites (Grade B - moderate recommendation).</p>
</li>
<li>
<p>Certain populations, especially opioid naïve breastfed neonates of mothers with functional CYP2D6 gene duplications taking codeine and young children may be particularly susceptible to codeine-induced central nervous system depression. Breastfeeding mothers and young children who are ultrarapid metabolizers of CYP2D6 should avoid codeine (Grade A - strong recommendation).</p>
</li>
<li>
<p>In individuals with IM (intermediate metabolizer) or EM (extensive metabolizer) CYP2D6 genotypes, codeine can be used as per standard of care. Existing evidence suggests that caution is still warranted in CYP2D6 EMs receiving codeine if they are receiving maximal therapeutic doses of codeine and have additional risk factors for toxicity.</p>
</li>
</ul>
</blockquote>
<p>See full guideline ([Article:<a href=""/pmid/24214521"">24214521</a>]) for further details and grading scheme.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166122666"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166122666"",""name"":""Annotation of CPNDS Guideline for codeine and CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.184511456E9,""date"":""2014-07-28T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.448616257E9,""date"":""2017-05-02T11:11:47.674-07:00"",""description"":""added note about FDA safety announcment"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15079576"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5079576E7,""resourceId"":""24214521"",""title"":""Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/24214521"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/24214521"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449281975E9,""resource"":""PubMed"",""resourceId"":""24214521"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/24214521""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449088"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449088"",""name"":""codeine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Canadian Pharmacogenomics Network for Drug Safety"",""summaryMarkdown"":{""id"":1.447982053E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of \u003cem\u003eCYP2D6\u003c/em\u003e genotype when prescribing codeine. They recommend that poor metabolizers of CYP2D6 should not receive codeine for pain relief, and ultrametabolizers of CYP2D6 should avoid codeine for pain relief.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982052E9,""html"":""\u003cp\u003e\u003cstrong\u003e\u003cem\u003eNote that the FDA released a \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source\u003dgovdelivery\u0026amp;utm_medium\u003demail\u0026amp;utm_source\u003dgovdelivery\"" target\u003d\""_blank\""\u003esafety announcement\u003c/a\u003e on 4/20/2017 stating that codeine and tramadol should not be used in children under 12 years.\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published CYP2D6 genotype-based drug dosing guidelines for codeine in the \u003cem\u003eJournal of Population Therapeutics and Clinical Pharmacology\u003c/em\u003e. Excerpts from \u0026quot;Clinical Practice Guideline: \u003cem\u003eCYP2D6\u003c/em\u003e genotyping for safe and efficacious codeine therapy\u0026quot; [Article:\u003ca href\u003d\""/pmid/24214521\""\u003e24214521\u003c/a\u003e] follow:\u003c/p\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003ePoor metabolizers of CYP2D6 should not receive codeine for pain relief (Grade A - strong recommendation).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eUltrarapid metabolizers of CYP2D6 should avoid codeine for pain relief and receive alternative analgesics that do not have potent CYP2D6 metabolites (Grade B - moderate recommendation).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCertain populations, especially opioid naïve breastfed neonates of mothers with functional CYP2D6 gene duplications taking codeine and young children may be particularly susceptible to codeine-induced central nervous system depression. Breastfeeding mothers and young children who are ultrarapid metabolizers of CYP2D6 should avoid codeine (Grade A - strong recommendation).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eIn individuals with IM (intermediate metabolizer) or EM (extensive metabolizer) CYP2D6 genotypes, codeine can be used as per standard of care. Existing evidence suggests that caution is still warranted in CYP2D6 EMs receiving codeine if they are receiving maximal therapeutic doses of codeine and have additional risk factors for toxicity.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/blockquote\u003e\n\u003cp\u003eSee full guideline ([Article:\u003ca href\u003d\""/pmid/24214521\""\u003e24214521\u003c/a\u003e]) for further details and grading scheme.\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104970,Guideline Annotation,Annotation of DPWG Guideline for codeine and CYP2D6,t,PA449088,Dutch Pharmacogenetics Working Group,"<p>The Pharmacogenetics Working Group Guideline for codeine includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer, higher or lower doses and additional risk factors are taken into consideration.</p>
","<p><em><strong>Note that the FDA released a <a rel=""noopener noreferrer"" href=""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery"" target=""_blank"">safety announcement</a> on 4/20/2017 stating that codeine and tramadol should not be used in children under 12 years.</strong></em></p>
<h3 id=""november-2018-update"">November 2018 update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for codeine based on CYP2D6 genotype. The guideline includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer the recommendations consider higher or lower doses and additional risk factors.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>codeine</td><td>The genetic variation increases the conversion of codeine to morphine. This can result in an increase in side effects. Death has occurred in children who received analgesic doses. One adult with reduced kidney function and co-medication with two CYP3A4 inhibitors became comatose after use of codeine for a cough.</td><td>DOSES HIGHER THAN 20 mg every 6 hours for adults and 10 mg every 6 hours for children aged 12 years or older AND/OR ADDITIONAL RISK FACTORS, such as co-medication with CYP3A4 inhibitors and/or reduced kidney function:<br/>Codeine is contra-indicated.<br/>if possible, select an alternative<br/>- For PAIN: do not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.<br/>- For COUGH: noscapine is not metabolised by CYP2D6.<br/>&nbsp;<br/>DOSES LOWER THAN OR EQUAL TO 20 mg every 6 hours for adults and 10 mg every 6 hours for children aged 12 years or older AND NO ADDITIONAL RISK FACTORS, such as co-medication with CYP3A4 inhibitors and/or reduced kidney function:<br/>No action required.</td></tr>
<tr><td>CYP2D6 IM</td><td>codeine</td><td>The genetic variation reduces the conversion of codeine to morphine. This can result in reduced analgesia.</td><td>For COUGH:<br/>1. No action required.<br/>&nbsp;<br/>For PAIN:<br/>It is not possible to offer adequately substantiated advice for dose adjustment based on the limited available literature for this phenotype.<br/>1. Be alert to a reduced effectiveness.<br/>2. In the case of inadequate effectiveness: 1. Try a dose increase., 2. If this does not work: choose an alternative.<br/>Do not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.<br/>3. If no alternative is selected: advise the patient to report inadequate analgesia.</td></tr>
<tr><td>CYP2D6 PM</td><td>codeine</td><td>The genetic variation reduces the conversion of codeine to morphine. This can result in reduced analgesia.</td><td>For COUGH:<br/>1. No action required.<br/>&nbsp;<br/>For PAIN:<br/>It is not possible to offer adequately substantiated advice for dose adjustment based on the limited available literature for this phenotype.<br/>1. Choose an alternative.<br/>Do not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.<br/>2. If an alternative is not an option: advise the patient to report inadequate analgesia.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001583.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for codeine based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend alternative analgesics for patients carrying the poor metabolizer (PM) alleles, intermediate metabolizer (IM) alleles or ultrarapid metabolizer (UM) allleles.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Analgesia: select alternative drug (e.g., acetaminophen, NSAID, morphine-not tramadol or oxycodone) or be alert to symptoms of insufficient pain relief. Cough: no.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Analgesia: select alternative drug (e.g., acetaminophen, NSAID, morphine-not tramadol or oxycodone) or be alert to symptoms of insufficient pain relief. Cough: no</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5; Kinetic effect (S).</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Analgesia: select alternative drug (e.g., acetaminophen, NSAID, morphine-not tramadol or oxycodone) or be alert to ADE. Cough: be extra alert to ADEs due to increased morphine plasma concentration.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/codeine_CYP2D6_271111.pdf"">Codeine CYP2D6</a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104970"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104970"",""name"":""Annotation of DPWG Guideline for codeine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704461E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.448616256E9,""date"":""2017-05-02T11:11:02.063-07:00"",""description"":""added note about FDA safety announcement"",""type"":""Update"",""version"":0.0},{""id"":1.450415103E9,""date"":""2019-05-23T22:31:13.255-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820788E9,""date"":""2019-10-06T23:02:33.404-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45095636E9,""date"":""2020-01-31T13:24:33.477-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450962821E9,""date"":""2020-02-10T11:08:09.429-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449088"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449088"",""name"":""codeine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981992E9,""html"":""\u003cp\u003eThe Pharmacogenetics Working Group Guideline for codeine includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer, higher or lower doses and additional risk factors are taken into consideration.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981991E9,""html"":""\u003cp\u003e\u003cem\u003e\u003cstrong\u003eNote that the FDA released a \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source\u003dgovdelivery\u0026amp;utm_medium\u003demail\u0026amp;utm_source\u003dgovdelivery\"" target\u003d\""_blank\""\u003esafety announcement\u003c/a\u003e on 4/20/2017 stating that codeine and tramadol should not be used in children under 12 years.\u003c/strong\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for codeine based on CYP2D6 genotype. The guideline includes individual recommendations for cough or pain for CYP2D6 poor, intermediate, and ultrarapid metabolizer. In addition, for ultrarapid metabolizer the recommendations consider higher or lower doses and additional risk factors.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003ecodeine\u003c/td\u003e\u003ctd\u003eThe genetic variation increases the conversion of codeine to morphine. This can result in an increase in side effects. Death has occurred in children who received analgesic doses. One adult with reduced kidney function and co-medication with two CYP3A4 inhibitors became comatose after use of codeine for a cough.\u003c/td\u003e\u003ctd\u003eDOSES HIGHER THAN 20 mg every 6 hours for adults and 10 mg every 6 hours for children aged 12 years or older AND/OR ADDITIONAL RISK FACTORS, such as co-medication with CYP3A4 inhibitors and/or reduced kidney function:\u003cbr/\u003eCodeine is contra-indicated.\u003cbr/\u003eif possible, select an alternative\u003cbr/\u003e- For PAIN: do not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.\u003cbr/\u003e- For COUGH: noscapine is not metabolised by CYP2D6.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003eDOSES LOWER THAN OR EQUAL TO 20 mg every 6 hours for adults and 10 mg every 6 hours for children aged 12 years or older AND NO ADDITIONAL RISK FACTORS, such as co-medication with CYP3A4 inhibitors and/or reduced kidney function:\u003cbr/\u003eNo action required.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003ecodeine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of codeine to morphine. This can result in reduced analgesia.\u003c/td\u003e\u003ctd\u003eFor COUGH:\u003cbr/\u003e1. No action required.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003eFor PAIN:\u003cbr/\u003eIt is not possible to offer adequately substantiated advice for dose adjustment based on the limited available literature for this phenotype.\u003cbr/\u003e1. Be alert to a reduced effectiveness.\u003cbr/\u003e2. In the case of inadequate effectiveness: 1. Try a dose increase., 2. If this does not work: choose an alternative.\u003cbr/\u003eDo not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.\u003cbr/\u003e3. If no alternative is selected: advise the patient to report inadequate analgesia.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003ecodeine\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of codeine to morphine. This can result in reduced analgesia.\u003c/td\u003e\u003ctd\u003eFor COUGH:\u003cbr/\u003e1. No action required.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003eFor PAIN:\u003cbr/\u003eIt is not possible to offer adequately substantiated advice for dose adjustment based on the limited available literature for this phenotype.\u003cbr/\u003e1. Choose an alternative.\u003cbr/\u003eDo not select tramadol, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.\u003cbr/\u003e2. If an alternative is not an option: advise the patient to report inadequate analgesia.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001583.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for codeine based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend alternative analgesics for patients carrying the poor metabolizer (PM) alleles, intermediate metabolizer (IM) alleles or ultrarapid metabolizer (UM) allleles.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eAnalgesia: select alternative drug (e.g., acetaminophen, NSAID, morphine-not tramadol or oxycodone) or be alert to symptoms of insufficient pain relief. Cough: no.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026gt; 3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia  \u0026gt; 75x10\u003csup\u003e9\u003c/sup\u003e/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eAnalgesia: select alternative drug (e.g., acetaminophen, NSAID, morphine-not tramadol or oxycodone) or be alert to symptoms of insufficient pain relief. Cough: no\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5; Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eAnalgesia: select alternative drug (e.g., acetaminophen, NSAID, morphine-not tramadol or oxycodone) or be alert to ADE. Cough: be extra alert to ADEs due to increased morphine plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/codeine_CYP2D6_271111.pdf\""\u003eCodeine CYP2D6\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166159180,Guideline Annotation,"Annotation of CPNDS Guideline for daunorubicin,doxorubicin and RARG,SLC28A3,UGT1A6",t,PA449212,Canadian Pharmacogenomics Network for Drug Safety,"<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of <em>RARG</em> , <em>SLC28A3</em> , and <em>UGT1A6</em> when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of <em>RARG</em> rs2229774, <em>SLC28A3</em> rs7853758, and <em>UGT1A6 *4</em> (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).</p>
","<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published genotype-based drug dosing guidelines for anthracyclines in the British Journal of Clinical Pharmacology. Excerpts from &quot;Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity.&quot; [Article:<a href=""/pmid/27197003"">27197003</a>] follow:</p>
<blockquote class=""blockquote"">
<ul>
<li>
<p>All other patients should be considered at moderate genetic risk. Pharmacogenomic testing should be performed in all pediatric cancer patients who are treated with doxorubicin or daunorubicin for the following genetic variants <em>RARG</em> rs2229774, <em>SLC28A3</em> rs7853758, <em>UGT1A6*4</em> rs17863783. The rs2229774 A allele and the UGT1A6*4 s17863783 T allele are the high risk variants, whereas the rs7853758 A allele is a low-risk allele. For patients who carry the reduced risk allele without the high-risk alleles, classification into a lower cardiotoxicity risk should be considered ___(Level B - moderate recommendation)___.</p>
</li>
<li>
<p>Genetic testing is not recommended for adults and pediatric patients receiving alternate anthracyclines ___(Level C - optional recommendation)___.</p>
</li>
</ul>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>Management options based on ACT risk</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<ul>
<li>
<p><em>Low risk patients - normal follow up</em> <strong><em>(Level A recommendation)</em></strong></p>
</li>
<li>
<p><em>Moderate risk patients - increase frequency of monitoring</em> <strong><em>(Level A recommendation)</em></strong></p>
</li>
<li>
<p><em>High risk patients - the following management options should be considered</em>:</p>
<ul>
<li>Increase frequency of monitoring with serial yearly echocardiographic monitoring an follow-up as recommended by COG guidelines <strong><em>(Level A recommendation)</em></strong></li>
<li>Aggressive screening and management of cardiovascular risk factors including obesity, diabetes, hypertension, coronary artery idea, lipid disorders and peripheral vascular disease <strong><em>(Level A recommendation)</em></strong></li>
<li>Prescribe dexrazoxane <strong><em>(Level B recommendation)</em></strong></li>
<li>Use liposomal encapsulated anthracycline preparations <strong><em>(Level C recommendation)</em></strong></li>
<li>Use of continuous inclusion or slower inclusion rates <strong><em>(Level C recommendation)</em></strong></li>
<li>Use of less cardiotoxic types of anthracyclines <strong><em>(Level C recommendation)</em></strong></li>
<li>Use of other cardioprotective agents <strong><em>(Level C recommendation)</em></strong></li>
<li>Prescribe alternative chemotherapy regiments for certain tumor types where alternative regiments have been shown to be equally effective <strong><em>(Level C recommendation)</em></strong></li>
</ul>
</li>
</ul>
</blockquote>
<p>See full guideline ([Article:<a href=""/pmid/27197003"">27197003</a>]) for further details and grading scheme.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166159180"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166159180"",""name"":""Annotation of CPNDS Guideline for daunorubicin,doxorubicin and RARG,SLC28A3,UGT1A6"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.448102965E9,""date"":""2016-06-16T00:00:00-07:00"",""type"":""Create"",""version"":1.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15097536"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5097536E7,""resourceId"":""27197003"",""title"":""Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338111"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5338111"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449288594E9,""resource"":""PubMed Central"",""resourceId"":""PMC5338111"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338111""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/27197003"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449288593E9,""resource"":""PubMed"",""resourceId"":""27197003"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/27197003""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1111/bcp.13008"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449288595E9,""resource"":""DOI"",""resourceId"":""10.1111/bcp.13008"",""_url"":""http://dx.doi.org/10.1111%2Fbcp.13008""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449212"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449212"",""name"":""daunorubicin""},{""@id"":""https://pharmgkb.org/chemical/PA449412"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449412"",""name"":""doxorubicin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA34227"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA34227"",""symbol"":""RARG"",""name"":""retinoic acid receptor gamma""},{""@id"":""https://pharmgkb.org/gene/PA426"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA426"",""symbol"":""SLC28A3"",""name"":""solute carrier family 28 member 3""},{""@id"":""https://pharmgkb.org/gene/PA37181"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA37181"",""symbol"":""UGT1A6"",""name"":""UDP glucuronosyltransferase 1 family, polypeptide A6""}],""source"":""Canadian Pharmacogenomics Network for Drug Safety"",""summaryMarkdown"":{""id"":1.448102957E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of \u003cem\u003eRARG\u003c/em\u003e , \u003cem\u003eSLC28A3\u003c/em\u003e , and \u003cem\u003eUGT1A6\u003c/em\u003e when prescribing anthracyclines for pediatric cancer patients. They recommend that pharmacogenomic testing of \u003cem\u003eRARG\u003c/em\u003e rs2229774, \u003cem\u003eSLC28A3\u003c/em\u003e rs7853758, and \u003cem\u003eUGT1A6 *4\u003c/em\u003e (rs17863783) should be performed in all pediatric cancer patients who are treated with daunorubicin or doxorubicin because the association of those genetic variants with anthracycline associated cardiotoxicity (ACT).\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.448102956E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published genotype-based drug dosing guidelines for anthracyclines in the British Journal of Clinical Pharmacology. Excerpts from \u0026quot;Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity.\u0026quot; [Article:\u003ca href\u003d\""/pmid/27197003\""\u003e27197003\u003c/a\u003e] follow:\u003c/p\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAll other patients should be considered at moderate genetic risk. Pharmacogenomic testing should be performed in all pediatric cancer patients who are treated with doxorubicin or daunorubicin for the following genetic variants \u003cem\u003eRARG\u003c/em\u003e rs2229774, \u003cem\u003eSLC28A3\u003c/em\u003e rs7853758, \u003cem\u003eUGT1A6*4\u003c/em\u003e rs17863783. The rs2229774 A allele and the UGT1A6*4 s17863783 T allele are the high risk variants, whereas the rs7853758 A allele is a low-risk allele. For patients who carry the reduced risk allele without the high-risk alleles, classification into a lower cardiotoxicity risk should be considered ___(Level B - moderate recommendation)___.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eGenetic testing is not recommended for adults and pediatric patients receiving alternate anthracyclines ___(Level C - optional recommendation)___.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/blockquote\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003e\u003cstrong\u003eManagement options based on ACT risk\u003c/strong\u003e\u003c/p\u003e\n\u003c/blockquote\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cem\u003eLow risk patients - normal follow up\u003c/em\u003e \u003cstrong\u003e\u003cem\u003e(Level A recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cem\u003eModerate risk patients - increase frequency of monitoring\u003c/em\u003e \u003cstrong\u003e\u003cem\u003e(Level A recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cem\u003eHigh risk patients - the following management options should be considered\u003c/em\u003e:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eIncrease frequency of monitoring with serial yearly echocardiographic monitoring an follow-up as recommended by COG guidelines \u003cstrong\u003e\u003cem\u003e(Level A recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eAggressive screening and management of cardiovascular risk factors including obesity, diabetes, hypertension, coronary artery idea, lipid disorders and peripheral vascular disease \u003cstrong\u003e\u003cem\u003e(Level A recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003ePrescribe dexrazoxane \u003cstrong\u003e\u003cem\u003e(Level B recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eUse liposomal encapsulated anthracycline preparations \u003cstrong\u003e\u003cem\u003e(Level C recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eUse of continuous inclusion or slower inclusion rates \u003cstrong\u003e\u003cem\u003e(Level C recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eUse of less cardiotoxic types of anthracyclines \u003cstrong\u003e\u003cem\u003e(Level C recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eUse of other cardioprotective agents \u003cstrong\u003e\u003cem\u003e(Level C recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003ePrescribe alternative chemotherapy regiments for certain tumor types where alternative regiments have been shown to be equally effective \u003cstrong\u003e\u003cem\u003e(Level C recommendation)\u003c/em\u003e\u003c/strong\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/blockquote\u003e\n\u003cp\u003eSee full guideline ([Article:\u003ca href\u003d\""/pmid/27197003\""\u003e27197003\u003c/a\u003e]) for further details and grading scheme.\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166105002,Guideline Annotation,Annotation of CPIC Guideline for desipramine and CYP2D6,t,PA449233,Clinical Pharmacogenetics Implementation Consortium,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""http://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.</li>
</ul>
</li>
</ul>
<h3 id=""december-2016-update"">December 2016 Update</h3>
<p><em>Advance online publication December 2016.</em></p>
<ul>
<li>The 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.</li>
<li>Excerpt from the 2016 dosing guideline update:
<ul>
<li>&quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.&quot;</li>
<li>&quot;There is substantial evidence linking <em>CYP2D6</em> genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have <em>CYP2D6</em> genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.&quot;</li>
<li>&quot; There are scarce studies focusing solely on <em>CYP2D6</em> genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.&quot;</li>
</ul>
</li>
<li>The guideline includes dosing recommendation for TCAs based on:
<ul>
<li>CYP2D6 phenotype (<a href=""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1 below</a>)</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf"" target=""_blank"">2016 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 Gene-specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/Desipramine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Desipramine Drug Resource Mappings</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Activity score</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic Recommendations<sup>a, b</sup></th><th>Classification of recommendation for other TCAs <sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 Ultrarapid metabolizer (~1-20% of patients)<sup>d</sup></td><td>&gt;2.0</td><td>An individual carrying more than two copies of functional alleles</td><td>*1/*1xN, *1/*2xN</td><td>Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.</td><td>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Normal metabolizer (~72-88% of patients)<sup>d</sup></td><td>1.0-2.0<sup>f</sup></td><td>An individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0</td><td>*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5</td><td>Normal metabolism of TCAs.</td><td>Initiate therapy with recommended starting dose.<sup>g</sup></td><td>Strong</td></tr>
<tr><td>CYP2D6 Intermediate metabolizer (~1-13% of patients)<sup>d</sup></td><td>0.5</td><td>An individual carrying one decreased and one no function allele</td><td>*4/*41, *5/*9, *4/*10</td><td>Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Consider 25% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Poor metabolizer (~1-10% of patients)<sup>d</sup></td><td>0</td><td>An individual carrying only no function alleles</td><td>*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6</td><td>Greatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider 50% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).</p>
<p><sup>d</sup> CYP2D6 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
<p><sup>g</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<h3 id=""may-2013"">May 2013</h3>
<p>Guidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</p>
<p><strong>Download:</strong> <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a> and <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">supplement</a></p>
<h5 id=""excerpt-from-the-dosing-guidelines"">Excerpt from the dosing guidelines:</h5>
<p>Amitriptyline and <a href=""http://www.pharmgkb.org/drug/PA450657"">nortriptyline</a> are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">guideline</a> to other tricyclics including clomipramine (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">Supplementary Table S15</a>), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.</p>
<p>See <a href=""http://www.pharmgkb.org/drug/PA450657"">nortriptyline</a>for excerpts and tables that summarize <em>CYP2D6</em>-based and <em>CYP2C19</em>-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a>).</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166105002"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166105002"",""name"":""Annotation of CPIC Guideline for desipramine and CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[{""id"":1.449560987E9,""alleles"":[{""id"":1.449560988E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449560989E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.44956099E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449560991E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449560992E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449560993E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449560994E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449560995E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449560996E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449560997E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449560998E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449560999E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449561E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449561001E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449561002E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449561003E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.449561004E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449561005E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449561006E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.449561009E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.44956101E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449561011E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449561012E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449561013E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449561014E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449561015E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449561016E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449561017E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449561018E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449561019E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.44956102E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449561021E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449561022E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449561023E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449561024E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449561025E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449561026E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449561027E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449561028E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449561029E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.44956103E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449561031E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449561032E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449561033E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449561034E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449561035E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449561036E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449561037E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449561038E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449561039E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.44956104E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449561041E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449561042E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449561043E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449561044E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449561045E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449561046E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449561047E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449561048E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449561049E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.44956105E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449561051E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449561052E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449561053E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449561054E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449561055E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449561056E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449561057E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449561058E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449561059E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.44956106E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449561061E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449561062E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449561063E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449561064E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449561065E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449561066E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449561067E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449561068E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449561069E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.44956107E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449561071E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449561072E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449561073E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449561074E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449561075E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449561076E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449561077E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449561078E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449561079E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.44956108E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449561081E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449561082E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449561083E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449561084E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449561085E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449561086E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449561087E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449561088E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449561089E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.44956109E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449561091E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449561092E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449561093E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449561094E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449561095E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449561096E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449561097E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449561098E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449561099E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.4495611E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449561101E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449561102E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449561103E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449561104E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.449561105E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.450042772E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042773E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824433E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.183699771E9,""date"":""2013-01-16T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.448526132E9,""date"":""2016-12-14T13:59:58.185-08:00"",""description"":""2016 TCA CPIC guideline update"",""type"":""Update"",""version"":0.0},{""id"":1.450042774E9,""date"":""2018-11-15T19:11:45.722-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824536E9,""date"":""2019-10-24T18:34:48.247-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098242"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098242E7,""resourceId"":""27997040"",""title"":""Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5478479"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293321E9,""resource"":""PubMed Central"",""resourceId"":""PMC5478479"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/27997040"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44929332E9,""resource"":""PubMed"",""resourceId"":""27997040"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/27997040""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.597"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293322E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.597"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.597""}]},{""@id"":""https://pharmgkb.org/literature/15051926"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051926E7,""resourceId"":""23486447"",""title"":""Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3689226"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275357E9,""resource"":""PubMed Central"",""resourceId"":""PMC3689226"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23486447"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275356E9,""resource"":""PubMed"",""resourceId"":""23486447"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23486447""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.2"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275358E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.2"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.2""}]},{""@id"":""https://pharmgkb.org/literature/15100907"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100907E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449233"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449233"",""name"":""desipramine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447981946E9,""html"":""\u003cp\u003eTricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981945E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2016-update\""\u003eDecember 2016 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication December 2016.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2016 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;There is substantial evidence linking \u003cem\u003eCYP2D6\u003c/em\u003e genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have \u003cem\u003eCYP2D6\u003c/em\u003e genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot; There are scarce studies focusing solely on \u003cem\u003eCYP2D6\u003c/em\u003e genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eThe guideline includes dosing recommendation for TCAs based on:\n\u003cul\u003e\n\u003cli\u003eCYP2D6 phenotype (\u003ca href\u003d\""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1 below\u003c/a\u003e)\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf\"" target\u003d\""_blank\""\u003e2016 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/Desipramine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eDesipramine Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003csup\u003ea, b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendation for other TCAs \u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Ultrarapid metabolizer (~1-20% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying more than two copies of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN\u003c/td\u003e\u003ctd\u003eIncreased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Normal metabolizer (~72-88% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.0-2.0\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5\u003c/td\u003e\u003ctd\u003eNormal metabolism of TCAs.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Intermediate metabolizer (~1-13% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*41, *5/*9, *4/*10\u003c/td\u003e\u003ctd\u003eReduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Poor metabolizer (~1-10% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no function alleles\u003c/td\u003e\u003ctd\u003e*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider 50% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2013\""\u003eMay 2013\u003c/h3\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDownload:\u003c/strong\u003e \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e and \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003esupplement\u003c/a\u003e\u003c/p\u003e\n\u003ch5 id\u003d\""excerpt-from-the-dosing-guidelines\""\u003eExcerpt from the dosing guidelines:\u003c/h5\u003e\n\u003cp\u003eAmitriptyline and \u003ca href\u003d\""http://www.pharmgkb.org/drug/PA450657\""\u003enortriptyline\u003c/a\u003e are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003eguideline\u003c/a\u003e to other tricyclics including clomipramine (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003eSupplementary Table S15\u003c/a\u003e), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.\u003c/p\u003e\n\u003cp\u003eSee \u003ca href\u003d\""http://www.pharmgkb.org/drug/PA450657\""\u003enortriptyline\u003c/a\u003efor excerpts and tables that summarize \u003cem\u003eCYP2D6\u003c/em\u003e-based and \u003cem\u003eCYP2C19\u003c/em\u003e-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e).\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166182811,Guideline Annotation,Annotation of DPWG Guideline for disopyramide and CYP2D6,f,PA449373,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for disopyramide based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for disopyramide based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002538.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182811"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182811"",""name"":""Annotation of DPWG Guideline for disopyramide and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.45041495E9,""date"":""2019-05-23T10:09:23.537-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820789E9,""date"":""2019-10-06T23:03:59.912-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450962822E9,""date"":""2020-02-10T11:12:19.180-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449373"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449373"",""name"":""disopyramide""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414946E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for disopyramide based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414947E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for disopyramide based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002538.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166105000,Guideline Annotation,"Annotation of CPIC Guideline for doxepin and CYP2C19,CYP2D6",t,PA449409,Clinical Pharmacogenetics Implementation Consortium,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""http://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.</li>
</ul>
</li>
</ul>
<h3 id=""december-2016-update"">December 2016 Update</h3>
<p><em>Advance online publication December 2016.</em></p>
<ul>
<li>The 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.</li>
<li>Excerpt from the 2016 dosing guideline update:
<ul>
<li>&quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.&quot;</li>
<li>&quot;There is substantial evidence linking <em>CYP2D6</em> and <em>CYP2C19</em> genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have <em>CYP2D6</em> or <em>CYP2C19</em> genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.&quot;</li>
<li>&quot; There are scarce studies focusing solely on <em>CYP2D6</em> or <em>CYP2C19</em> genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.&quot;</li>
</ul>
</li>
<li>The guideline includes dosing recommendation for TCAs based on:
<ul>
<li>CYP2D6 phenotype (<a href=""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1 below</a>)</li>
<li>CYP2C19 phenotype (<a href=""#table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype"">Table 2 below</a>)</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf"" target=""_blank"">2016 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 Gene-specific Information Tables</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c19RefMaterials"">CYP2C19 Gene-specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/Doxepin_Drug_Resource_Mappings.xlsx"" target=""_blank"">Doxepin Drug Resource Mappings</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Activity score</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic Recommendations<sup>a, b</sup></th><th>Classification of recommendation for other TCAs <sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 Ultrarapid metabolizer (~1-20% of patients)<sup>d</sup></td><td>&gt;2.0</td><td>An individual carrying more than two copies of functional alleles</td><td>*1/*1xN, *1/*2xN</td><td>Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.</td><td>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Normal metabolizer (~72-88% of patients)<sup>d</sup></td><td>1.0-2.0<sup>f</sup></td><td>An individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0</td><td>*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5</td><td>Normal metabolism of TCAs.</td><td>Initiate therapy with recommended starting dose.<sup>g</sup></td><td>Strong</td></tr>
<tr><td>CYP2D6 Intermediate metabolizer (~1-13% of patients)<sup>d</sup></td><td>0.5</td><td>An individual carrying one decreased and one no function allele</td><td>*4/*41, *5/*9, *4/*10</td><td>Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Consider 25% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Poor metabolizer (~1-10% of patients)<sup>d</sup></td><td>0</td><td>An individual carrying only no function alleles</td><td>*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6</td><td>Greatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider 50% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
<p><sup>g</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<h3 id=""table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype"">Table 2: Dosing recommendations for TCAs based on CYP2C19 phenotype:</h3>
<p><em>Adapted from Tables 1 and 3 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic recommendations<sup>a,b</sup></th><th>Classification of recommendations for amitriptyline<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 Ultrarapid metabolizer (~2-5% of patients)<sup>d</sup></td><td>An individual carrying two increased function alleles</td><td>*17/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Rapid metabolizer (~2-30% of patients)<sup>d</sup></td><td>An individual carrying one normal and one increased function allele</td><td>*1/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Normal metabolizer (~35-50% of patients)<sup>d</sup></td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism of tertiary amines.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Strong</td></tr>
<tr><td>CYP2C19 Intermediate metabolizer (~18-45% of patients)<sup>d</sup></td><td>An individual carrying one normal and one no function allele or one no and one increased function allele</td><td>*1/*2, *1/*3, *2/*17<sup>g</sup></td><td>Reduced metabolism of tertiary amines compared to normal metabolizers.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Poor metabolizer (~2-15% of patients)<sup>d</sup></td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>For tertiary amines, consider a 50% reduction of the recommended starting dose.<sup>f</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2C19 including clomipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<p><sup>g</sup> The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.</p>
<h3 id=""may-2013"">May 2013</h3>
<p>Guidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</p>
<p><strong>Download:</strong> <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a> and <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">supplement</a></p>
<h5 id=""excerpt-from-the-dosing-guidelines"">Excerpt from the dosing guidelines:</h5>
<p><a href=""http://www.pharmgkb.org/drug/PA448385"">Amitriptyline</a> and nortriptyline are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">guideline</a> to other tricyclics including clomipramine (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">Supplementary Table S16</a>), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.</p>
<p>See <a href=""http://www.pharmgkb.org/drug/PA448385"">amitriptyline</a> for excerpts and tables that summarize <em>CYP2D6</em>-based and <em>CYP2C19</em>-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a>).</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166105000"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166105000"",""name"":""Annotation of CPIC Guideline for doxepin and CYP2C19,CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[{""id"":1.449562712E9,""alleles"":[{""id"":1.449562713E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.449562714E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980634"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980634"",""symbol"":""CYP2C19*1"",""name"":""*1""}},{""id"":1.449562715E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980635"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980635"",""symbol"":""CYP2C19*2"",""name"":""*2""}},{""id"":1.449562716E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980636"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980636"",""symbol"":""CYP2C19*3"",""name"":""*3""}},{""id"":1.449562719E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980638"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980638"",""symbol"":""CYP2C19*5"",""name"":""*5""}},{""id"":1.44956272E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816522"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816522"",""symbol"":""CYP2C19*6"",""name"":""*6""}},{""id"":1.449562721E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816523"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816523"",""symbol"":""CYP2C19*7"",""name"":""*7""}},{""id"":1.449562722E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816524"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816524"",""symbol"":""CYP2C19*8"",""name"":""*8""}},{""id"":1.449562723E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816525"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816525"",""symbol"":""CYP2C19*9"",""name"":""*9""}},{""id"":1.449562724E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816526"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816526"",""symbol"":""CYP2C19*10"",""name"":""*10""}},{""id"":1.449562725E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816527"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816527"",""symbol"":""CYP2C19*11"",""name"":""*11""}},{""id"":1.449562726E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816528"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816528"",""symbol"":""CYP2C19*12"",""name"":""*12""}},{""id"":1.449562727E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816529"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816529"",""symbol"":""CYP2C19*13"",""name"":""*13""}},{""id"":1.449562728E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816530"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816530"",""symbol"":""CYP2C19*14"",""name"":""*14""}},{""id"":1.449562729E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816531"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816531"",""symbol"":""CYP2C19*15"",""name"":""*15""}},{""id"":1.44956273E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816532"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816532"",""symbol"":""CYP2C19*16"",""name"":""*16""}},{""id"":1.449562731E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816533"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816533"",""symbol"":""CYP2C19*17"",""name"":""*17""}},{""id"":1.449562732E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816534"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816534"",""symbol"":""CYP2C19*18"",""name"":""*18""}},{""id"":1.449562733E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816535"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816535"",""symbol"":""CYP2C19*19"",""name"":""*19""}},{""id"":1.449562734E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816536"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816536"",""symbol"":""CYP2C19*22"",""name"":""*22""}},{""id"":1.449562735E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816537"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816537"",""symbol"":""CYP2C19*23"",""name"":""*23""}},{""id"":1.449562736E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816538"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816538"",""symbol"":""CYP2C19*24"",""name"":""*24""}},{""id"":1.449562737E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816539"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816539"",""symbol"":""CYP2C19*25"",""name"":""*25""}},{""id"":1.449562738E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816540"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816540"",""symbol"":""CYP2C19*26"",""name"":""*26""}},{""id"":1.44956274E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115675"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115675"",""symbol"":""CYP2C19*28"",""name"":""*28""}},{""id"":1.449562741E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123292"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123292"",""symbol"":""CYP2C19*29"",""name"":""*29""}},{""id"":1.449562742E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123293"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123293"",""symbol"":""CYP2C19*30"",""name"":""*30""}},{""id"":1.449562743E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123294"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123294"",""symbol"":""CYP2C19*31"",""name"":""*31""}},{""id"":1.449562744E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123295"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123295"",""symbol"":""CYP2C19*32"",""name"":""*32""}},{""id"":1.449562745E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123296"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123296"",""symbol"":""CYP2C19*33"",""name"":""*33""}},{""id"":1.449562746E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115676"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115676"",""symbol"":""CYP2C19*34"",""name"":""*34""}},{""id"":1.449562747E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128094"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128094"",""symbol"":""CYP2C19*35"",""name"":""*35""}},{""id"":1.450805222E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980637"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980637"",""symbol"":""CYP2C19*4"",""name"":""*4""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}},{""id"":1.449562748E9,""alleles"":[{""id"":1.449562749E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.44956275E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449562751E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449562752E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449562753E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449562754E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449562755E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449562756E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449562757E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449562758E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449562759E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.44956276E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449562761E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449562762E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449562763E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449562764E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449562765E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.449562766E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449562767E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449562768E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.449562771E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449562772E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449562773E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449562774E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449562775E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449562776E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449562777E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449562778E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449562779E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.44956278E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449562781E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449562782E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449562783E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449562784E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449562785E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449562786E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449562787E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449562788E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449562789E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.44956279E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449562791E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449562792E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449562793E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449562794E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449562795E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449562796E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449562797E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449562798E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449562799E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.4495628E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449562801E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449562802E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449562803E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449562804E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449562805E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449562806E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449562807E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449562808E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449562809E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.44956281E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449562811E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449562812E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449562813E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449562814E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449562815E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449562816E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449562817E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449562818E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449562819E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.44956282E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449562821E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.449562822E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449562823E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449562824E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449562825E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449562826E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449562827E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449562828E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449562829E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.44956283E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449562831E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449562832E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449562833E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449562834E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449562835E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449562836E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449562837E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449562838E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449562839E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.44956284E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449562841E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449562842E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449562843E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449562844E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449562845E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449562846E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449562847E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449562848E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449562849E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.44956285E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449562851E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449562852E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449562853E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449562854E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449562855E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449562856E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449562857E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449562858E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449562859E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.44956286E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449562861E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449562862E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449562863E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449562864E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449562865E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449562866E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449562867E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.450042777E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042778E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824683E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.183699772E9,""date"":""2013-01-16T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.448526143E9,""date"":""2016-12-14T14:15:53.753-08:00"",""description"":""2016 TCA CPIC guideline update"",""type"":""Update"",""version"":0.0},{""id"":1.450042779E9,""date"":""2018-11-15T20:09:37.338-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824539E9,""date"":""2019-10-24T19:32:05.758-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098242"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098242E7,""resourceId"":""27997040"",""title"":""Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5478479"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293321E9,""resource"":""PubMed Central"",""resourceId"":""PMC5478479"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/27997040"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44929332E9,""resource"":""PubMed"",""resourceId"":""27997040"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/27997040""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.597"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293322E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.597"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.597""}]},{""@id"":""https://pharmgkb.org/literature/15051926"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051926E7,""resourceId"":""23486447"",""title"":""Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3689226"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275357E9,""resource"":""PubMed Central"",""resourceId"":""PMC3689226"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23486447"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275356E9,""resource"":""PubMed"",""resourceId"":""23486447"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23486447""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.2"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275358E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.2"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.2""}]},{""@id"":""https://pharmgkb.org/literature/15100907"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100907E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449409"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449409"",""name"":""doxepin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""},{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447981938E9,""html"":""\u003cp\u003eTricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981937E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2016-update\""\u003eDecember 2016 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication December 2016.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2016 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;There is substantial evidence linking \u003cem\u003eCYP2D6\u003c/em\u003e and \u003cem\u003eCYP2C19\u003c/em\u003e genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot; There are scarce studies focusing solely on \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eThe guideline includes dosing recommendation for TCAs based on:\n\u003cul\u003e\n\u003cli\u003eCYP2D6 phenotype (\u003ca href\u003d\""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1 below\u003c/a\u003e)\u003c/li\u003e\n\u003cli\u003eCYP2C19 phenotype (\u003ca href\u003d\""#table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype\""\u003eTable 2 below\u003c/a\u003e)\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf\"" target\u003d\""_blank\""\u003e2016 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c19RefMaterials\""\u003eCYP2C19 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/Doxepin_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eDoxepin Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003csup\u003ea, b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendation for other TCAs \u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Ultrarapid metabolizer (~1-20% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying more than two copies of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN\u003c/td\u003e\u003ctd\u003eIncreased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Normal metabolizer (~72-88% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.0-2.0\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5\u003c/td\u003e\u003ctd\u003eNormal metabolism of TCAs.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Intermediate metabolizer (~1-13% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*41, *5/*9, *4/*10\u003c/td\u003e\u003ctd\u003eReduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Poor metabolizer (~1-10% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no function alleles\u003c/td\u003e\u003ctd\u003e*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider 50% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003ch3 id\u003d\""table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype\""\u003eTable 2: Dosing recommendations for TCAs based on CYP2C19 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ea,b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations for amitriptyline\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Ultrarapid metabolizer (~2-5% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles\u003c/td\u003e\u003ctd\u003e*17/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Rapid metabolizer (~2-30% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Normal metabolizer (~35-50% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism of tertiary amines.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Intermediate metabolizer (~18-45% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one no function allele or one no and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3, *2/*17\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eReduced metabolism of tertiary amines compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Poor metabolizer (~2-15% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eFor tertiary amines, consider a 50% reduction of the recommended starting dose.\u003csup\u003ef\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2C19 including clomipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2013\""\u003eMay 2013\u003c/h3\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDownload:\u003c/strong\u003e \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e and \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003esupplement\u003c/a\u003e\u003c/p\u003e\n\u003ch5 id\u003d\""excerpt-from-the-dosing-guidelines\""\u003eExcerpt from the dosing guidelines:\u003c/h5\u003e\n\u003cp\u003e\u003ca href\u003d\""http://www.pharmgkb.org/drug/PA448385\""\u003eAmitriptyline\u003c/a\u003e and nortriptyline are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003eguideline\u003c/a\u003e to other tricyclics including clomipramine (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003eSupplementary Table S16\u003c/a\u003e), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.\u003c/p\u003e\n\u003cp\u003eSee \u003ca href\u003d\""http://www.pharmgkb.org/drug/PA448385\""\u003eamitriptyline\u003c/a\u003e for excerpts and tables that summarize \u003cem\u003eCYP2D6\u003c/em\u003e-based and \u003cem\u003eCYP2C19\u003c/em\u003e-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e).\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166184529,Guideline Annotation,Annotation of DPWG Guideline for doxepin and CYP2C19,f,PA449409,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for doxepin based on CYP2C19 genotype.</p>
","<h3 id=""august-2019-guideline"">August 2019 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for doxepin based on CYP2C19 metabolizer (UM, IM, PM). They conclude that NO action is required for this gene-drug interaction, (see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>).</p>
<p>For CYP2C19 UM, IM and PM, the gene variations have an effect on the exposure to doxepin, but not on the exposure to doxepin + the active metabolite nordoxepin, which determines the effect and side effects.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0007023.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166184529"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166184529"",""name"":""Annotation of DPWG Guideline for doxepin and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450820797E9,""date"":""2019-10-06T23:33:44.655-07:00"",""description"":""August 2019 Guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45096284E9,""date"":""2020-02-10T11:21:04.576-08:00"",""description"":""Fixed links to 2019 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449409"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449409"",""name"":""doxepin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450820794E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for doxepin based on CYP2C19 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450820795E9,""html"":""\u003ch3 id\u003d\""august-2019-guideline\""\u003eAugust 2019 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for doxepin based on CYP2C19 metabolizer (UM, IM, PM). They conclude that NO action is required for this gene-drug interaction, (see the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eFor CYP2C19 UM, IM and PM, the gene variations have an effect on the exposure to doxepin, but not on the exposure to doxepin + the active metabolite nordoxepin, which determines the effect and side effects.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0007023.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104942,Guideline Annotation,Annotation of DPWG Guideline for duloxetine and CYP2D6,f,PA10066,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for duloxetine based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for duloxetine based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001675.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for duloxetine based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  They conclude that there are no recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>No recommendation.</td><td>Data on file.</td><td>Clinical effect (not statistically significant difference).</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>No recommendation.</td><td>No evidence.</td><td>--</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>No recommendation.</td><td>No evidence.</td><td>--</td></tr>
</tbody>
</table>
<ul>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/duloxetine_CYP2D6_271111.pdf"">Duloxetine CYP2D6 </a></li>
<li>See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for more background information about the project.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104942"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104942"",""name"":""Annotation of DPWG Guideline for duloxetine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704465E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414967E9,""date"":""2019-05-23T10:45:55.376-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.45082079E9,""date"":""2019-10-06T23:06:16.627-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45095638E9,""date"":""2020-01-31T13:27:55.369-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.4509629E9,""date"":""2020-02-10T11:36:14.709-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10066"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10066"",""name"":""duloxetine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.44798187E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for duloxetine based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981869E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for duloxetine based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction (see \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001675.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for duloxetine based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They conclude that there are no recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eNo recommendation.\u003c/td\u003e\u003ctd\u003eData on file.\u003c/td\u003e\u003ctd\u003eClinical effect (not statistically significant difference).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eNo recommendation.\u003c/td\u003e\u003ctd\u003eNo evidence.\u003c/td\u003e\u003ctd\u003e--\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eNo recommendation.\u003c/td\u003e\u003ctd\u003eNo evidence.\u003c/td\u003e\u003ctd\u003e--\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/duloxetine_CYP2D6_271111.pdf\""\u003eDuloxetine CYP2D6 \u003c/a\u003e\u003c/li\u003e\n\u003cli\u003eSee \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for more background information about the project.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182603,Guideline Annotation,Annotation of CPIC Guideline for efavirenz and CYP2B6,t,PA449441,Clinical Pharmacogenetics Implementation Consortium,"<p>Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/"" target=""_blank"">CPIC&reg; guideline for efavirenz and CYP2B6</a>.</p>
<h3 id=""april-2019"">April 2019</h3>
<p><em>Advance online publication April 2019.</em></p>
<ul>
<li>
<p>The <a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1477"" target=""_blank"">CPIC guideline regarding efavirenz-containing antiretroviral Therapy in the context of <em>CYP2B6</em> genotypes</a> is published in Clinical Pharmacology and Therapeutics.</p>
</li>
<li>
<p>These guidelines are applicable to:</p>
<ul>
<li>
<p>pediatric patients</p>
</li>
<li>
<p>adult patients</p>
</li>
</ul>
</li>
<li>
<p>Excerpts from the 2019 efavirenz dosing guideline:</p>
<ul>
<li>
<p>&quot;Substantial evidence links <em>CYP2B6</em> genotype with variability in plasma efavirenz concentrations and with adverse effects. Most studies have examined the impact of <em>CYP2B6</em> c.516G&gt;T and c.983T&gt;C; therefore, these variants provide the basis for our clinical recommendations.&quot;</p>
</li>
<li>
<p>&quot;Multiple studies have shown that the CYP2B6 poor metabolizer genotype, particularly defined by homozygosity or compound heterozygosity for <em>CYP2B6</em> c.516G&gt;T and/or c.983T&gt;C, is associated with decreased efavirenz clearance and increased risk for efavirenz toxicity (particularly CNS toxicity, hepatic injury, and QTc prolongation) and/or treatment discontinuation, although some studies have not shown such an association.&quot;</p>
</li>
<li>
<p>&quot;Based on current evidence, CYP2B6 normal metabolizers (NMs) are expected to have normal efavirenz metabolism and achieve therapeutic efavirenz concentrations with standard dosing (600 mg/day). CYP2B6 intermediate metabolizers (IMs) may experience higher dose-adjusted trough concentrations compared with NMs, which may put these patients up to a 1.3-fold increased risk of adverse effects. For these patients, there is a “moderate” recommendation to consider initiating efavirenz with a decreased dose of 400 mg/day. CYP2B6 poor metabolizers (PMs) are at greatest risk for higher dose-adjusted trough concentrations compared with NMs and IMs, and greater overall plasma efavirenz exposure, which puts these patients up to a 4.8-fold increased risk for adverse effects and treatment discontinuation. For these patients, there is a “moderate” recommendation to consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day.&quot;</p>
</li>
<li>
<p>&quot;CYP2B6 RMs and UMs may experience slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers, which may be clinically important for efavirenz. However, based on current evidence, the effect of the increased function alleles CYP2B6*4 and *22 appears to be modest. As such, current data are not sufficient to recommend a change from normal prescribing at this time, and patients with the RM or UM phenotype should receive standard efavirenz dosing.&quot;</p>
</li>
<li>
<p>&quot;Pediatrics:
Efavirenz is FDA-approved for use as part of antiretroviral therapy in children = 3 months of age and weighing = 3.5 kg. In the U.S. efavirenz is available as capsules (50 or 200 mg); tablets (600 mg); a fixed dose combination comprised of efavirenz 600 mg, emtricitabine 200 mg and  tenofovir disoproxil fumarate 300 mg; and more recently a fixed dose combination called Symfi Lo® (efavirenz 400 mg,  lamivudine 300 mg, and  tenofovir disoproxil fumarate 300 mg) for children weighing = 35 kg. The U.S. Department of Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection recommends efavirenz in combination with two-nucleoside reverse transcriptase inhibitors (NRTIs) as an alternative non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen for initial treatment of HIV in children aged = 3 years.&quot;</p>
</li>
<li>
<p>&quot;Children age &lt; 3 years. similar to DHHS guidelines, we do not recommend use of efavirenz in infants and children aged 3 months to &lt; 3 years, except under special circumstances such as tuberculosis co-infection. If a clinical situation requires use of efavirenz in this age group, CYP2B6 testing may be informative and dosing could be guided by the current DHHS guidelines, which were  informed by  IMPAACT study P1070 (36). The guidelines recommended an efavirenz dose reduction based on weight groups for CYP2B6 poor (c.516T/T) metabolizers: 5 kg to &lt; 7 kg: 50 mg; 7 kg to &lt; 14 kg: 100 mg; 14 kg to &lt; 17 kg: 150 mg; and = 17 kg: 150 mg.  Dosing for normal (c.516G/G) metabolizers and intermediate (c.516G/T) metabolizers is as follows: 5 kg to &lt; 7 kg: 300 mg; 7 kg to &lt; 14 kg: 400 mg; 14 kg to &lt; 17 kg: 500 mg; and = 17 kg: 600 mg. Although current DHHS guidelines for efavirenz dosing in pediatrics do not consider c.983T&gt;C, we recommend that dosing recommendations for c.516T/T also be applied to c.516T/c.983C and to c.983C/C. We also recommend measuring plasma efavirenz concentrations two weeks after initiation. The mid-dose plasma efavirenz concentration target of 1 to 4 mg/L derived from adult clinical monitoring data is typically also applied to trough concentrations in pediatric patients. &quot;</p>
</li>
<li>
<p>&quot;Children age &gt; 3 years and weighing &lt; 40 kg. While the effect of CYP2B6 genotype on efavirenz exposure has been demonstrated in children older than three years of age who weigh less than 40 kg, specific clinical data supporting CYP2B6 genotype-guided dosing are limited. Thus, although we cannot make a firm recommendation for dose adjustment based on CYP2B6 genotype in this age and weight group, CYP2B6 genotype almost certainly affects efavirenz exposure in these children such that efavirenz dose reduction in CYP2B6 poor metabolizers would also be reasonable. Therapeutic drug monitoring, where available and accessible, could help guide dosing adjustments in this age/weight group, especially in a setting of potential drug-related toxicity, virologic rebound, or lack of response in an adherent patient. For pediatric patients who weigh 40 kg or more, adult dosing applies (see Table 2).&quot;</p>
</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/efavirenz/2019/31006110.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2B6</em> and Efavirenz-containing Antiretroviral Therapy</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/efavirenz/2019/31006110-supplement.pdf"" target=""_blank"">2019 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2b6RefMaterials"">CYP2B6 Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/efavirenz/Efavirenz_Drug_Resource_Mappings.xlsx"" target=""_blank"">Efavirenz Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/efavirenz/Efavirenz_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Efavirenz Pre and Post Test Alerts</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-efavirenz-by-cyp2b6-phenotype"">Table 1: Recommended dosing of Efavirenz by CYP2B6 phenotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2019 guideline.</em></p>
<table class=""table"">
<thead>
<tr><th>CYP2B6 phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations</th></tr>
</thead>
<tbody>
<tr><td>Ultra Rapid Metabolizer</td><td>An individual carrying two increased function alleles</td><td>*4/*4, *22/*22, *4/*22</td><td>Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers</td><td>Initiate efavirenz with standard dosing (600 mg/day)</td><td>Strong</td></tr>
<tr><td>Rapid Metabolizer</td><td>An individual carrying one normal function allele and one increased function allele</td><td>*1/*4, *1/*22</td><td>Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers</td><td>Initiate efavirenz with standard dosing (600 mg/day)</td><td>Strong</td></tr>
<tr><td>Normal Metabolizer</td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal efavirenz metabolism</td><td>Initiate efavirenz with standard dosing (600 mg/day)</td><td>Strong<sup>c</sup></td></tr>
<tr><td>Intermediate Metabolizer</td><td>An individual carrying one normal function allele and one decreased function allele OR one normal function allele and one no function allele OR one increased function allele and one decreased function allele OR one increased function allele and one no function allele</td><td>*1/*6, *1/*18, *4/*6, *4/*18, *6/*22, *18/*22</td><td>Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; increased risk of CNS adverse events.</td><td>Consider initiating efavirenz with decreased dose of 400 mg/day<sup>a,b</sup>.</td><td>Moderate</td></tr>
<tr><td>Poor Metabolizer</td><td>An individual carrying two decreased function alleles OR two no function alleles OR one decreased function allele and one no function allele</td><td>*6/*6, *18/*18, *6/*18</td><td>Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; significantly increased risk of CNS adverse events and treatment discontinuation</td><td>Consider initiating efavirenz with decreased dose of 400 or 200 mg/day<sup>a,b</sup>.</td><td>Moderate</td></tr>
</tbody>
</table>
<p><sup>a</sup>If therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady-state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4 µg/mL).<br />
<sup>b</sup>To prescribe efavirenz at a decreased dose of 400 mg/day or 200 mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.<br />
<sup>c</sup>The ENCORE study showed that in treatment-naïve patients randomized to initiate efavirenz-based regimens (combined with tenofovir and emtricitabine), 400 mg/day was non-inferior to 600 mg/day regardless of CYP2B6 genotype.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182603"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182603"",""name"":""Annotation of CPIC Guideline for efavirenz and CYP2B6"",""cancerGenome"":false,""descriptiveVideoId"":""n0ub1TWSjJ8"",""guidelineGenes"":[{""id"":1.450396143E9,""alleles"":[{""id"":1.450396144E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818750"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818750"",""symbol"":""CYP2B6*1"",""name"":""*1""}},{""id"":1.450396145E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818753"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818753"",""symbol"":""CYP2B6*2"",""name"":""*2""}},{""id"":1.450396146E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818756"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818756"",""symbol"":""CYP2B6*3"",""name"":""*3""}},{""id"":1.450396147E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818757"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818757"",""symbol"":""CYP2B6*4"",""name"":""*4""}},{""id"":1.450396148E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818760"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818760"",""symbol"":""CYP2B6*5"",""name"":""*5""}},{""id"":1.450396149E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818762"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818762"",""symbol"":""CYP2B6*6"",""name"":""*6""}},{""id"":1.45039615E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818765"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818765"",""symbol"":""CYP2B6*7"",""name"":""*7""}},{""id"":1.450396151E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818767"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818767"",""symbol"":""CYP2B6*8"",""name"":""*8""}},{""id"":1.450396152E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818807"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818807"",""symbol"":""CYP2B6*9"",""name"":""*9""}},{""id"":1.450396153E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818768"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818768"",""symbol"":""CYP2B6*10"",""name"":""*10""}},{""id"":1.450396154E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818770"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818770"",""symbol"":""CYP2B6*11"",""name"":""*11""}},{""id"":1.450396155E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818772"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818772"",""symbol"":""CYP2B6*12"",""name"":""*12""}},{""id"":1.450396156E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818773"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818773"",""symbol"":""CYP2B6*13"",""name"":""*13""}},{""id"":1.450396157E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818776"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818776"",""symbol"":""CYP2B6*14"",""name"":""*14""}},{""id"":1.450396158E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818777"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818777"",""symbol"":""CYP2B6*15"",""name"":""*15""}},{""id"":1.450396159E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818780"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818780"",""symbol"":""CYP2B6*16"",""name"":""*16""}},{""id"":1.45039616E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818781"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818781"",""symbol"":""CYP2B6*17"",""name"":""*17""}},{""id"":1.450396161E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818808"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818808"",""symbol"":""CYP2B6*18"",""name"":""*18""}},{""id"":1.450396162E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818784"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818784"",""symbol"":""CYP2B6*19"",""name"":""*19""}},{""id"":1.450396163E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818785"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818785"",""symbol"":""CYP2B6*20"",""name"":""*20""}},{""id"":1.450396164E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818786"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818786"",""symbol"":""CYP2B6*21"",""name"":""*21""}},{""id"":1.450396165E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818809"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818809"",""symbol"":""CYP2B6*22"",""name"":""*22""}},{""id"":1.450396166E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818787"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818787"",""symbol"":""CYP2B6*23"",""name"":""*23""}},{""id"":1.450396167E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818810"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818810"",""symbol"":""CYP2B6*24"",""name"":""*24""}},{""id"":1.450396168E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818811"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818811"",""symbol"":""CYP2B6*25"",""name"":""*25""}},{""id"":1.450396169E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818788"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818788"",""symbol"":""CYP2B6*26"",""name"":""*26""}},{""id"":1.45039617E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818789"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818789"",""symbol"":""CYP2B6*27"",""name"":""*27""}},{""id"":1.450396171E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818812"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818812"",""symbol"":""CYP2B6*28"",""name"":""*28""}},{""id"":1.450396172E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165818813"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818813"",""symbol"":""CYP2B6*29"",""name"":""*29""}},{""id"":1.450396173E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117272"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117272"",""symbol"":""CYP2B6*30"",""name"":""*30""}},{""id"":1.450396174E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166182657"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166182657"",""symbol"":""CYP2B6*31"",""name"":""*31""}},{""id"":1.450396175E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166182658"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166182658"",""symbol"":""CYP2B6*32"",""name"":""*32""}},{""id"":1.450396176E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117273"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117273"",""symbol"":""CYP2B6*33"",""name"":""*33""}},{""id"":1.450396177E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117274"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117274"",""symbol"":""CYP2B6*34"",""name"":""*34""}},{""id"":1.450396178E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117275"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117275"",""symbol"":""CYP2B6*35"",""name"":""*35""}},{""id"":1.450396179E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117276"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117276"",""symbol"":""CYP2B6*36"",""name"":""*36""}},{""id"":1.45039618E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117277"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117277"",""symbol"":""CYP2B6*37"",""name"":""*37""}},{""id"":1.450396181E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117278"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117278"",""symbol"":""CYP2B6*38"",""name"":""*38""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA123"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA123"",""symbol"":""CYP2B6"",""name"":""cytochrome P450 family 2 subfamily B member 6""}}],""history"":[{""id"":1.450396369E9,""date"":""2019-05-01T00:00:00-07:00"",""description"":""released"",""type"":""Update"",""version"":1.0},{""id"":1.450806133E9,""date"":""2019-07-15T14:51:15.405-07:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15102282"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102282E7,""resourceId"":""31006110"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/31006110"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/31006110"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450385489E9,""resource"":""PubMed"",""resourceId"":""31006110"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/31006110""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1477"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.45038549E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1477"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1477""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449441"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449441"",""name"":""efavirenz""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA123"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA123"",""symbol"":""CYP2B6"",""name"":""cytochrome P450 family 2 subfamily B member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.450380342E9,""html"":""\u003cp\u003eConsider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.450380343E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for efavirenz and CYP2B6\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""april-2019\""\u003eApril 2019\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication April 2019.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1477\"" target\u003d\""_blank\""\u003eCPIC guideline regarding efavirenz-containing antiretroviral Therapy in the context of \u003cem\u003eCYP2B6\u003c/em\u003e genotypes\u003c/a\u003e is published in Clinical Pharmacology and Therapeutics.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThese guidelines are applicable to:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003epediatric patients\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eadult patients\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExcerpts from the 2019 efavirenz dosing guideline:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Substantial evidence links \u003cem\u003eCYP2B6\u003c/em\u003e genotype with variability in plasma efavirenz concentrations and with adverse effects. Most studies have examined the impact of \u003cem\u003eCYP2B6\u003c/em\u003e c.516G\u0026gt;T and c.983T\u0026gt;C; therefore, these variants provide the basis for our clinical recommendations.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Multiple studies have shown that the CYP2B6 poor metabolizer genotype, particularly defined by homozygosity or compound heterozygosity for \u003cem\u003eCYP2B6\u003c/em\u003e c.516G\u0026gt;T and/or c.983T\u0026gt;C, is associated with decreased efavirenz clearance and increased risk for efavirenz toxicity (particularly CNS toxicity, hepatic injury, and QTc prolongation) and/or treatment discontinuation, although some studies have not shown such an association.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Based on current evidence, CYP2B6 normal metabolizers (NMs) are expected to have normal efavirenz metabolism and achieve therapeutic efavirenz concentrations with standard dosing (600 mg/day). CYP2B6 intermediate metabolizers (IMs) may experience higher dose-adjusted trough concentrations compared with NMs, which may put these patients up to a 1.3-fold increased risk of adverse effects. For these patients, there is a “moderate” recommendation to consider initiating efavirenz with a decreased dose of 400 mg/day. CYP2B6 poor metabolizers (PMs) are at greatest risk for higher dose-adjusted trough concentrations compared with NMs and IMs, and greater overall plasma efavirenz exposure, which puts these patients up to a 4.8-fold increased risk for adverse effects and treatment discontinuation. For these patients, there is a “moderate” recommendation to consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;CYP2B6 RMs and UMs may experience slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers, which may be clinically important for efavirenz. However, based on current evidence, the effect of the increased function alleles CYP2B6*4 and *22 appears to be modest. As such, current data are not sufficient to recommend a change from normal prescribing at this time, and patients with the RM or UM phenotype should receive standard efavirenz dosing.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Pediatrics:\nEfavirenz is FDA-approved for use as part of antiretroviral therapy in children \u003d 3 months of age and weighing \u003d 3.5 kg. In the U.S. efavirenz is available as capsules (50 or 200 mg); tablets (600 mg); a fixed dose combination comprised of efavirenz 600 mg, emtricitabine 200 mg and  tenofovir disoproxil fumarate 300 mg; and more recently a fixed dose combination called Symfi Lo® (efavirenz 400 mg,  lamivudine 300 mg, and  tenofovir disoproxil fumarate 300 mg) for children weighing \u003d 35 kg. The U.S. Department of Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection recommends efavirenz in combination with two-nucleoside reverse transcriptase inhibitors (NRTIs) as an alternative non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen for initial treatment of HIV in children aged \u003d 3 years.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Children age \u0026lt; 3 years. similar to DHHS guidelines, we do not recommend use of efavirenz in infants and children aged 3 months to \u0026lt; 3 years, except under special circumstances such as tuberculosis co-infection. If a clinical situation requires use of efavirenz in this age group, CYP2B6 testing may be informative and dosing could be guided by the current DHHS guidelines, which were  informed by  IMPAACT study P1070 (36). The guidelines recommended an efavirenz dose reduction based on weight groups for CYP2B6 poor (c.516T/T) metabolizers: 5 kg to \u0026lt; 7 kg: 50 mg; 7 kg to \u0026lt; 14 kg: 100 mg; 14 kg to \u0026lt; 17 kg: 150 mg; and \u003d 17 kg: 150 mg.  Dosing for normal (c.516G/G) metabolizers and intermediate (c.516G/T) metabolizers is as follows: 5 kg to \u0026lt; 7 kg: 300 mg; 7 kg to \u0026lt; 14 kg: 400 mg; 14 kg to \u0026lt; 17 kg: 500 mg; and \u003d 17 kg: 600 mg. Although current DHHS guidelines for efavirenz dosing in pediatrics do not consider c.983T\u0026gt;C, we recommend that dosing recommendations for c.516T/T also be applied to c.516T/c.983C and to c.983C/C. We also recommend measuring plasma efavirenz concentrations two weeks after initiation. The mid-dose plasma efavirenz concentration target of 1 to 4 mg/L derived from adult clinical monitoring data is typically also applied to trough concentrations in pediatric patients. \u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Children age \u0026gt; 3 years and weighing \u0026lt; 40 kg. While the effect of CYP2B6 genotype on efavirenz exposure has been demonstrated in children older than three years of age who weigh less than 40 kg, specific clinical data supporting CYP2B6 genotype-guided dosing are limited. Thus, although we cannot make a firm recommendation for dose adjustment based on CYP2B6 genotype in this age and weight group, CYP2B6 genotype almost certainly affects efavirenz exposure in these children such that efavirenz dose reduction in CYP2B6 poor metabolizers would also be reasonable. Therapeutic drug monitoring, where available and accessible, could help guide dosing adjustments in this age/weight group, especially in a setting of potential drug-related toxicity, virologic rebound, or lack of response in an adherent patient. For pediatric patients who weigh 40 kg or more, adult dosing applies (see Table 2).\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/efavirenz/2019/31006110.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for \u003cem\u003eCYP2B6\u003c/em\u003e and Efavirenz-containing Antiretroviral Therapy\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/efavirenz/2019/31006110-supplement.pdf\"" target\u003d\""_blank\""\u003e2019 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2b6RefMaterials\""\u003eCYP2B6 Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/efavirenz/Efavirenz_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eEfavirenz Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/efavirenz/Efavirenz_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eEfavirenz Pre and Post Test Alerts\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-efavirenz-by-cyp2b6-phenotype\""\u003eTable 1: Recommended dosing of Efavirenz by CYP2B6 phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2019 guideline.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eCYP2B6 phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltra Rapid Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles\u003c/td\u003e\u003ctd\u003e*4/*4, *22/*22, *4/*22\u003c/td\u003e\u003ctd\u003eSlightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers\u003c/td\u003e\u003ctd\u003eInitiate efavirenz with standard dosing (600 mg/day)\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eRapid Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*4, *1/*22\u003c/td\u003e\u003ctd\u003eSlightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers\u003c/td\u003e\u003ctd\u003eInitiate efavirenz with standard dosing (600 mg/day)\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNormal Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal efavirenz metabolism\u003c/td\u003e\u003ctd\u003eInitiate efavirenz with standard dosing (600 mg/day)\u003c/td\u003e\u003ctd\u003eStrong\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one decreased function allele OR one normal function allele and one no function allele OR one increased function allele and one decreased function allele OR one increased function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*1/*6, *1/*18, *4/*6, *4/*18, *6/*22, *18/*22\u003c/td\u003e\u003ctd\u003eHigher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; increased risk of CNS adverse events.\u003c/td\u003e\u003ctd\u003eConsider initiating efavirenz with decreased dose of 400 mg/day\u003csup\u003ea,b\u003c/sup\u003e.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two decreased function alleles OR two no function alleles OR one decreased function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*6/*6, *18/*18, *6/*18\u003c/td\u003e\u003ctd\u003eHigher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; significantly increased risk of CNS adverse events and treatment discontinuation\u003c/td\u003e\u003ctd\u003eConsider initiating efavirenz with decreased dose of 400 or 200 mg/day\u003csup\u003ea,b\u003c/sup\u003e.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eIf therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady-state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4 µg/mL).\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003eTo prescribe efavirenz at a decreased dose of 400 mg/day or 200 mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.\u003cbr /\u003e\n\u003csup\u003ec\u003c/sup\u003eThe ENCORE study showed that in treatment-naïve patients randomized to initiate efavirenz-based regimens (combined with tenofovir and emtricitabine), 400 mg/day was non-inferior to 600 mg/day regardless of CYP2B6 genotype.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450385491E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/"",""_url"":""https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/""}]},""status"":""success""}"
PA166182846,Guideline Annotation,Annotation of DPWG Guideline for efavirenz and CYP2B6,t,PA449441,Dutch Pharmacogenetics Working Group,"<p>Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with CYP2B6 IM phenotype, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for efavirenz based on CYP2B6 genotype.  They recommend adjusting the initial efavirenz dose for patients with the CYP2B6 PM phenotype and titrate the dose to plasma concentration if needed. For patients with CYP2B6 IM phenotype, they recommend determining the efavirenz plasma concentration if side effects occur and reducing the dose if needed.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2B6 IM</td><td>efavirenz</td><td>Genetic variations increase the efavirenz plasma concentration and therefore the risk of side effects. However, the efavirenz plasma concentration remains within the therapeutic range for the majority of patients.</td><td>1. Determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed. In 14 IM adults, a dose reduction to 400 mg/day (2/3rd of the standard dose) was sufficient to achieve therapeutic plasma concentrations and to reduce or resolve side effects. The therapeutic range established for efavirenz is 1000-4000 ng/ml.</td></tr>
<tr><td>CYP2B6 PM</td><td>efavirenz</td><td>Genetic variations increase the risk of side effects. The standard dose leads to an efavirenz concentration in the toxic range in the majority of patients with this genotype.</td><td>* Efavirenz in MONOpreparation, adults and children FROM 40 KG: Body mass index LESS THAN or EQUAL to 25: 1. The recommended initial dose is 400 mg/day and this dose should be titrated to plasma concentration if needed (further reduction to 200 mg/day or in rare cases an increase to 600 mg/day). The therapeutic range established for efavirenz is 1000-4000 ng/ml. Body mass index GREATER than 25: 1. The recommended initial dose is 600 mg/day and this dose should be titrated to plasma concentration if needed (reduction to 400 or 200 mg/day). The therapeutic range established for efavirenz is 1000-4000 ng/ml.<br/>*Efavirenz in MONOpreparation, children LIGHTER THAN 40 KG: 1. Start with the standard dose and titrate this dose to plasma concentration if needed. In adults, therapeutic plasma concentrations were achieved at either 2/3rd of the standard dose (1/3rd of the patients) or 1/3rd of the standard dose (2/3rd of the patients). In children younger than 3 years, therapeutic plasma concentrations were achieved at doses of approximately 10 mg/kg per day (as capsules) (100 mg/day for 7-14 kg and 150 mg/day for 14-17 kg; 50-75% of the standard dose). The therapeutic range established for efavirenz is 1000-4000 ng/ml.<br/>*Efavirenz in COMBINATION preparation: 1. Initiate the combination preparation and titrate the efavirenz dose to plasma concentration if needed (reduction to 400 or 200 mg/day) The therapeutic range established for efavirenz is 1000-4000 ng/ml.</td></tr>
</tbody>
</table>
<p>&quot;Note: the dosing recommendations above are based on PM patients with the *6/*6 genotype. There is evidence that the *18/*18
genotype in PM patients (only present in negroid patients) may require greater dose reductions.
Considerations:
Detailed justification for the recommendation is contained in the risk analysis. The considerations used for adults are also given below. The median or mean plasma concentrations or AUC in PM patients are above the therapeutic range, except in 3 studies with low efavirenz plasma concentrations in EM patients (2 of the 3 studies performed in Africa and 1 study in the United States and Italy). A recent study showed a similar virological response for efavirenz 400 and 600 mg/day in patients not selected on genotype. The risk of underdose is therefore very small if the initial dose is reduced to 400 mg/day. Two small studies showed that dose reductions did not reduce the efficacy (HIV remained undetectable), but side effects did reduce in 24 PM patients. Compliance improves with administration of a combination preparation and the absence of unnecessary side effects due to excessive plasma concentrations.
Consideration to CYP2B6 inducers such as rifampicin is not needed in PM patients. The significantly low or absent metabolic capacity of CYP2B6 makes induction of little to no relevance. Moreover, the effects of enzyme induction by rifampicin and enzyme inhibition by isoniazid on efavirenz plasma concentrations seem to largely cancel each other out, independent of the CYP2B6 phenotype of the patient.&quot;</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0004755.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182846"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182846"",""name"":""Annotation of DPWG Guideline for efavirenz and CYP2B6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415253E9,""date"":""2019-05-27T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.450820791E9,""date"":""2019-10-06T23:09:58.171-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450962901E9,""date"":""2020-02-10T11:38:07.071-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/haplotype/PA165818808"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818808"",""symbol"":""CYP2B6*18"",""name"":""*18""},{""@id"":""https://pharmgkb.org/haplotype/PA165818762"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165818762"",""symbol"":""CYP2B6*6"",""name"":""*6""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449441"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449441"",""name"":""efavirenz""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA123"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA123"",""symbol"":""CYP2B6"",""name"":""cytochrome P450 family 2 subfamily B member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415251E9,""html"":""\u003cp\u003eAdjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with CYP2B6 IM phenotype, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415252E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for efavirenz based on CYP2B6 genotype.  They recommend adjusting the initial efavirenz dose for patients with the CYP2B6 PM phenotype and titrate the dose to plasma concentration if needed. For patients with CYP2B6 IM phenotype, they recommend determining the efavirenz plasma concentration if side effects occur and reducing the dose if needed.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2B6 IM\u003c/td\u003e\u003ctd\u003eefavirenz\u003c/td\u003e\u003ctd\u003eGenetic variations increase the efavirenz plasma concentration and therefore the risk of side effects. However, the efavirenz plasma concentration remains within the therapeutic range for the majority of patients.\u003c/td\u003e\u003ctd\u003e1. Determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed. In 14 IM adults, a dose reduction to 400 mg/day (2/3rd of the standard dose) was sufficient to achieve therapeutic plasma concentrations and to reduce or resolve side effects. The therapeutic range established for efavirenz is 1000-4000 ng/ml.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2B6 PM\u003c/td\u003e\u003ctd\u003eefavirenz\u003c/td\u003e\u003ctd\u003eGenetic variations increase the risk of side effects. The standard dose leads to an efavirenz concentration in the toxic range in the majority of patients with this genotype.\u003c/td\u003e\u003ctd\u003e* Efavirenz in MONOpreparation, adults and children FROM 40 KG: Body mass index LESS THAN or EQUAL to 25: 1. The recommended initial dose is 400 mg/day and this dose should be titrated to plasma concentration if needed (further reduction to 200 mg/day or in rare cases an increase to 600 mg/day). The therapeutic range established for efavirenz is 1000-4000 ng/ml. Body mass index GREATER than 25: 1. The recommended initial dose is 600 mg/day and this dose should be titrated to plasma concentration if needed (reduction to 400 or 200 mg/day). The therapeutic range established for efavirenz is 1000-4000 ng/ml.\u003cbr/\u003e*Efavirenz in MONOpreparation, children LIGHTER THAN 40 KG: 1. Start with the standard dose and titrate this dose to plasma concentration if needed. In adults, therapeutic plasma concentrations were achieved at either 2/3rd of the standard dose (1/3rd of the patients) or 1/3rd of the standard dose (2/3rd of the patients). In children younger than 3 years, therapeutic plasma concentrations were achieved at doses of approximately 10 mg/kg per day (as capsules) (100 mg/day for 7-14 kg and 150 mg/day for 14-17 kg; 50-75% of the standard dose). The therapeutic range established for efavirenz is 1000-4000 ng/ml.\u003cbr/\u003e*Efavirenz in COMBINATION preparation: 1. Initiate the combination preparation and titrate the efavirenz dose to plasma concentration if needed (reduction to 400 or 200 mg/day) The therapeutic range established for efavirenz is 1000-4000 ng/ml.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026quot;Note: the dosing recommendations above are based on PM patients with the *6/*6 genotype. There is evidence that the *18/*18\ngenotype in PM patients (only present in negroid patients) may require greater dose reductions.\nConsiderations:\nDetailed justification for the recommendation is contained in the risk analysis. The considerations used for adults are also given below. The median or mean plasma concentrations or AUC in PM patients are above the therapeutic range, except in 3 studies with low efavirenz plasma concentrations in EM patients (2 of the 3 studies performed in Africa and 1 study in the United States and Italy). A recent study showed a similar virological response for efavirenz 400 and 600 mg/day in patients not selected on genotype. The risk of underdose is therefore very small if the initial dose is reduced to 400 mg/day. Two small studies showed that dose reductions did not reduce the efficacy (HIV remained undetectable), but side effects did reduce in 24 PM patients. Compliance improves with administration of a combination preparation and the absence of unnecessary side effects due to excessive plasma concentrations.\nConsideration to CYP2B6 inducers such as rifampicin is not needed in PM patients. The significantly low or absent metabolic capacity of CYP2B6 makes induction of little to no relevance. Moreover, the effects of enzyme induction by rifampicin and enzyme inhibition by isoniazid on efavirenz plasma concentrations seem to largely cancel each other out, independent of the CYP2B6 phenotype of the patient.\u0026quot;\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0004755.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182823,Guideline Annotation,Annotation of DPWG Guideline for eliglustat and CYP2D6,t,PA166123486,Dutch Pharmacogenetics Working Group,"<p>The Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CYP3A inducers.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for eliglustat based on CYP2D6 genotype. They recommend to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers, recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CPY3A inducers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>eliglustat</td><td>This gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM.</td><td>Eliglustat is contra-indicated. Choose an alternative if possible.</td></tr>
<tr><td>CYP2D6 IM</td><td>eliglustat</td><td>This gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects.</td><td>- Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR: Eliglustat is contra-indicated.<br/>1. Choose an alternative if possible.<br/>Strong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.<br/>&nbsp;<br/>- Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):<br/>1. Use a dose of 84mg eliglustat 1x daily.<br/>&nbsp;<br/>- Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):<br/>1. Consider a dose of 84mg eliglustat 1x daily.<br/>2. Be alert to side effects.<br/>&nbsp;<br/>- Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):<br/>1. Choose an alternative if possible.<br/>2. If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.<br/>&nbsp;<br/>- Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):<br/>1. Choose an alternative.<br/>2. If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.<br/>&nbsp;<br/>- Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.<br/>1. Choose an alternative if possible.<br/>&nbsp;<br/>- NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:<br/>1. Use the standard dose of 84mg 2x daily.</td></tr>
<tr><td>CYP2D6 PM</td><td>eliglustat</td><td>This gene variation reduces the conversion of eliglustat to inactive metabolites. This increases the risk of side effects, such as a (small, dose-dependent) elongation of the QT interval. CYP3A inhibitors increase this risk even further.</td><td>- Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir): Eliglustat is contra-indicated.<br/>1. Choose an alternative if possible.<br/>&nbsp;<br/>- Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine): Eliglustat is not recommended.<br/>1. Choose an alternative if possible.<br/>&nbsp;<br/>- Co-medication with a WEAK CYP3A INHIBITOR (for example amlopidine, cilostazole, fluvoxamine, goldenseal, isoniazide, ranitidine, ranolazine):<br/>1. Choose an alternative for the weak CYP3A inhibitor if possible.<br/>2. If an alternative is not an option: Use a dose of 84mg eliglustat 1x daily and be alert to side effects.<br/>&nbsp;<br/>- Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.<br/>1. Choose an alternative if possible.<br/>&nbsp;<br/>- NO co-medication with a CYP3A inhibitor or strong CYP3A inducer:<br/>1. Use a dose of 84mg 1x daily.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0006137.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182823"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182823"",""name"":""Annotation of DPWG Guideline for eliglustat and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.4504151E9,""date"":""2019-05-23T21:23:23.388-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820792E9,""date"":""2019-10-06T23:12:58.685-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45096292E9,""date"":""2020-02-10T11:39:18.674-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA166123486"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA166123486"",""name"":""eliglustat""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415099E9,""html"":""\u003cp\u003eThe Dutch Pharmacogenetics Working Group Guideline for eliglustat recommends to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CYP3A inducers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415097E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for eliglustat based on CYP2D6 genotype. They recommend to use an alternative in CYP2D6 ultrarapid metabolizer. For CYP2D6 poor metabolizer in combination with CYP3A inhibitors and strong inducers, the guideline recommends to choose an alternative if possible. For intermediate metabolizers, recommendations are provided for co-medication with CYP2D6 and/or CYP3A inhibitors and CPY3A inducers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eeliglustat\u003c/td\u003e\u003ctd\u003eThis gene variation increases the conversion of eliglustat to inactive metabolites. As a result, a normal dose is not effective. There is not enough scientific substantiation to suggest an effective dose for all UM.\u003c/td\u003e\u003ctd\u003eEliglustat is contra-indicated. Choose an alternative if possible.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eeliglustat\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of eliglustat to inactive metabolites. However, in the absence of CYP2D6 and CYP3A inhibitors, this does not result in a clinically significant increased risk of side effects.\u003c/td\u003e\u003ctd\u003e- Co-medication with BOTH a MODERATE to STRONG CYP2D6 INHIBITOR AND a MODERATE to STRONG CYP3A INHIBITOR: Eliglustat is contra-indicated.\u003cbr/\u003e1. Choose an alternative if possible.\u003cbr/\u003eStrong CYP2D6 inhibitor: for example paroxetine, fluoxetine, quinidine, bupropione. Moderate CYP2D6 inhibitor: for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone. Strong CYP3A inhibitor: for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir. Moderate CYP3A inhibitor: for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- Co-medication with a STRONG CYP2D6 INHIBITOR (e.g. paroxetine, fluoxetine, quinidine, bupropione):\u003cbr/\u003e1. Use a dose of 84mg eliglustat 1x daily.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- Co-medication with a MODERATE CYP2D6 INHIBITOR (for example duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone):\u003cbr/\u003e1. Consider a dose of 84mg eliglustat 1x daily.\u003cbr/\u003e2. Be alert to side effects.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir):\u003cbr/\u003e1. Choose an alternative if possible.\u003cbr/\u003e2. If an alternative is not an option: consider a dose of 84 mg eliglustat 1x daily and be alert to side effects.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine):\u003cbr/\u003e1. Choose an alternative.\u003cbr/\u003e2. If an alternative is not an option: consider a dose of 84mg eliglustat 1x daily and be alert to side effects.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.\u003cbr/\u003e1. Choose an alternative if possible.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- NO co-medication with a moderate or strong CYP2D6 or CYP3A inhibitor or strong CYP3A inducer:\u003cbr/\u003e1. Use the standard dose of 84mg 2x daily.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eeliglustat\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of eliglustat to inactive metabolites. This increases the risk of side effects, such as a (small, dose-dependent) elongation of the QT interval. CYP3A inhibitors increase this risk even further.\u003c/td\u003e\u003ctd\u003e- Co-medication with a STRONG CYP3A INHIBITOR (for example ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir): Eliglustat is contra-indicated.\u003cbr/\u003e1. Choose an alternative if possible.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- Co-medication with a MODERATE CYP3A INHIBITOR (for example erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine): Eliglustat is not recommended.\u003cbr/\u003e1. Choose an alternative if possible.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- Co-medication with a WEAK CYP3A INHIBITOR (for example amlopidine, cilostazole, fluvoxamine, goldenseal, isoniazide, ranitidine, ranolazine):\u003cbr/\u003e1. Choose an alternative for the weak CYP3A inhibitor if possible.\u003cbr/\u003e2. If an alternative is not an option: Use a dose of 84mg eliglustat 1x daily and be alert to side effects.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- Co-medication with a STRONG CYP3A INDUCER (for example rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutine, hypericum): Eliglustat is not recommended. The plasma concentration may decrease so sharply that a therapeutic effect cannot be achieved.\u003cbr/\u003e1. Choose an alternative if possible.\u003cbr/\u003e\u0026nbsp;\u003cbr/\u003e- NO co-medication with a CYP3A inhibitor or strong CYP3A inducer:\u003cbr/\u003e1. Use a dose of 84mg 1x daily.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0006137.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104975,Guideline Annotation,Annotation of DPWG Guideline for escitalopram and CYP2C19,t,PA10074,Dutch Pharmacogenetics Working Group,"<p>The Dutch Pharmacogenetics Working Group Guideline for escitalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified doses and for CYP2C19 ultrarapid metabolizer to avoid escitalopram.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for escitalopram based on CYP2C19 genotype. They recommend to not exceed the below mentioned doses for intermediate metabolizer (for IM = 75% of the standard maximum dose) and poor metabolizer (for PM = 50% of the standard maximum dose). For CYP2C19 ultrarapid metabolizer, the recommendation is to avoid escitalopram.</p>
<p><em>Wording in table taken from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">the Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 UM</td><td>escitalopram</td><td>The risk of conversion to another antidepressant is increased as the gene variation leads to a reduction in the escitalopram plasma concentration.</td><td>Avoid escitalopram. Antidepressants that are not metabolised or that are metabolised to a lesser extent by CYP2C19 are, for example, paroxetine or fluvoxamine.</td></tr>
<tr><td>CYP2C19 IM</td><td>escitalopram</td><td>The risk of QT prolongation and torsades de pointes is theoretically increased because the gene variation leads to an increased escitalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration and the theoretically increased risk of QT prolongation will be offset.</td><td>Do not exceed the following doses (75% of the standard maximum dose): adults &lt; 65 years 15 mg/day, =65 years 7.5 mg/day</td></tr>
<tr><td>CYP2C19 PM</td><td>escitalopram</td><td>The risk of conversion to another antidepressant is increased. In addition, the risk of QT prolongation and torsades de pointes is theoretically increased because the gene variation leads to an increased escitalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration, the theoretically increased risk of QT prolongation and the increased risk of conversion to another antidepressant will be offset.</td><td>Do not exceed the following doses (50% of the standard maximum dose): adults &lt; 65 years 10 mg/day, =65 years 5 mg/day</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001821.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for escitalopram based on the <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They conclude to monitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine) for the <em>CYP2C19</em> UM phenotype.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio (INR) increase &lt; 4.5. Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5. Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>Monitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine)</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5. Kinetic effect (statistically significant difference)</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/es_citalopram_CYP2C19_271111.pdf"">Escitalopram CYP2C19</a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104975"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104975"",""name"":""Annotation of DPWG Guideline for escitalopram and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704467E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415089E9,""date"":""2019-05-23T19:29:31.216-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820625E9,""date"":""2019-10-03T09:38:55.481-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.4509564E9,""date"":""2020-01-31T13:28:48.137-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450962902E9,""date"":""2020-02-10T11:41:41.194-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10074"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10074"",""name"":""escitalopram""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982026E9,""html"":""\u003cp\u003eThe Dutch Pharmacogenetics Working Group Guideline for escitalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified doses and for CYP2C19 ultrarapid metabolizer to avoid escitalopram.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982025E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for escitalopram based on CYP2C19 genotype. They recommend to not exceed the below mentioned doses for intermediate metabolizer (for IM \u003d 75% of the standard maximum dose) and poor metabolizer (for PM \u003d 50% of the standard maximum dose). For CYP2C19 ultrarapid metabolizer, the recommendation is to avoid escitalopram.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003ethe Dutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 UM\u003c/td\u003e\u003ctd\u003eescitalopram\u003c/td\u003e\u003ctd\u003eThe risk of conversion to another antidepressant is increased as the gene variation leads to a reduction in the escitalopram plasma concentration.\u003c/td\u003e\u003ctd\u003eAvoid escitalopram. Antidepressants that are not metabolised or that are metabolised to a lesser extent by CYP2C19 are, for example, paroxetine or fluvoxamine.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 IM\u003c/td\u003e\u003ctd\u003eescitalopram\u003c/td\u003e\u003ctd\u003eThe risk of QT prolongation and torsades de pointes is theoretically increased because the gene variation leads to an increased escitalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration and the theoretically increased risk of QT prolongation will be offset.\u003c/td\u003e\u003ctd\u003eDo not exceed the following doses (75% of the standard maximum dose): adults \u0026lt; 65 years 15 mg/day, \u003d65 years 7.5 mg/day\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 PM\u003c/td\u003e\u003ctd\u003eescitalopram\u003c/td\u003e\u003ctd\u003eThe risk of conversion to another antidepressant is increased. In addition, the risk of QT prolongation and torsades de pointes is theoretically increased because the gene variation leads to an increased escitalopram plasma concentration. If you follow the dose recommendation below, the increased plasma concentration, the theoretically increased risk of QT prolongation and the increased risk of conversion to another antidepressant will be offset.\u003c/td\u003e\u003ctd\u003eDo not exceed the following doses (50% of the standard maximum dose): adults \u0026lt; 65 years 10 mg/day, \u003d65 years 5 mg/day\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001821.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for escitalopram based on the \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They conclude to monitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine) for the \u003cem\u003eCYP2C19\u003c/em\u003e UM phenotype.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio (INR) increase \u0026lt; 4.5. Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5. Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eMonitor plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event or select alternative drug (e.g. fluoxetine, paroxetine)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5. Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/es_citalopram_CYP2C19_271111.pdf\""\u003eEscitalopram CYP2C19\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104931,Guideline Annotation,Annotation of DPWG Guideline for esomeprazole and CYP2C19,f,PA10075,Dutch Pharmacogenetics Working Group,"<p>No action is needed for this gene-drug interaction.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for esomeprazole based on CYP2C19 genotype. They conclude that no action is needed for this gene-drug interaction. Although genetic variation leads to higher plasma concentrations or faster inactivation of esomeprazole, there is insufficient evidence to support an effect on the therapeutic effectiveness and side effects (see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2 018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001824.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for esomeprazole based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  For the <em>CYP2C19</em> UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 50-100%.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Positive clinical effects</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Positive clinical effects</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>Helicobacter pylori eradication: increase dose by 50-100%. Be extra alert to insufficient response. Other: be extra alert to insufficient response. Consider dose increase by 50-100%</td><td>no data was retrieved with the literature search</td><td>no data was retrieved with the literature search</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104931"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104931"",""name"":""Annotation of DPWG Guideline for esomeprazole and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704469E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414962E9,""date"":""2019-05-23T10:35:24.687-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820627E9,""date"":""2019-10-03T09:52:08.418-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956346E9,""date"":""2020-01-31T13:29:18.686-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096296E9,""date"":""2020-02-10T11:44:10.253-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10075"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10075"",""name"":""esomeprazole""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981838E9,""html"":""\u003cp\u003eNo action is needed for this gene-drug interaction.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981837E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for esomeprazole based on CYP2C19 genotype. They conclude that no action is needed for this gene-drug interaction. Although genetic variation leads to higher plasma concentrations or faster inactivation of esomeprazole, there is insufficient evidence to support an effect on the therapeutic effectiveness and side effects (see the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2 018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001824.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for esomeprazole based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For the \u003cem\u003eCYP2C19\u003c/em\u003e UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 50-100%.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003ePositive clinical effects\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003ePositive clinical effects\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eHelicobacter pylori eradication: increase dose by 50-100%. Be extra alert to insufficient response. Other: be extra alert to insufficient response. Consider dose increase by 50-100%\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104969,Guideline Annotation,Annotation of DPWG Guideline for flecainide and CYP2D6,t,PA449646,Dutch Pharmacogenetics Working Group,"<p>Reduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flecainide based on CYP2D6 genotype.  They recommend reducing flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and recording an ECG and monitor the plasma concentration. For CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome, they recommend reducing the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.</p>
<p><em>Wording in table taken from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">the Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 IM</td><td>flecainide</td><td>The genetic variation reduces conversion of flecainide to inactive metabolites. This may increase the risk of side effects.</td><td>1. Indications other than diagnosis of Brugada syndrome: reduce the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.2.Provocation test for diagnosis of Brugada syndrome:No action required.At a dose of 2.0 mg/kg body weight to a maximum of 150 mg, the response is better for patients with alleles that result in reduced activity.All 5 patients with these alleles and 20% of the patients with two fully active alleles exhibited a response within 30 minutes.</td></tr>
<tr><td>CYP2D6 PM</td><td>flecanide</td><td>The genetic variation reduces conversion of flecainide to inactive metabolites. This increases the risk of side effects.</td><td>1. reduce the dose to 50% of the standard dose and record an ECG and monitor the plasma concentration.</td></tr>
<tr><td>CYP2D6 UM</td><td>flecanide</td><td>The genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result.</td><td>There are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001594.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flecainide based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend a lower dose for patients carrying the poor metabolizer (PM) alleles and intermediate metabolizer (IM) alleles.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Reduce dose by 50%, record ECG, monitor plasma concentration.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5; Kinetic effect (S)</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Reduce dose by 25%, record ECG, monitor plasma concentration.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5; Kinetic effect (S)</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Record ECG and monitor plasma concentration or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone).</td><td>no evidence.</td><td>--</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104969"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104969"",""name"":""Annotation of DPWG Guideline for flecainide and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704471E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415007E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820628E9,""date"":""2019-10-03T10:16:41.319-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956347E9,""date"":""2020-01-31T13:29:47.086-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450962903E9,""date"":""2020-02-10T11:46:15.826-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449646"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449646"",""name"":""flecainide""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981986E9,""html"":""\u003cp\u003eReduce flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and record an ECG and monitor the plasma concentration. Reduce flecainide dose to 75% of the standard dose for CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome and record an ECG and monitor the plasma concentration.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981985E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flecainide based on CYP2D6 genotype.  They recommend reducing flecainide dose by 50% for CYP2D6 poor metabolizer (PM) and recording an ECG and monitor the plasma concentration. For CYP2D6 intermediate metabolizer (IM) patients with indications other than diagnosis of Brugada syndrome, they recommend reducing the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003ethe Dutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eflecainide\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces conversion of flecainide to inactive metabolites. This may increase the risk of side effects.\u003c/td\u003e\u003ctd\u003e1. Indications other than diagnosis of Brugada syndrome: reduce the dose to 75% of the standard dose and record an ECG and monitor the plasma concentration.2.Provocation test for diagnosis of Brugada syndrome:No action required.At a dose of 2.0 mg/kg body weight to a maximum of 150 mg, the response is better for patients with alleles that result in reduced activity.All 5 patients with these alleles and 20% of the patients with two fully active alleles exhibited a response within 30 minutes.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eflecanide\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces conversion of flecainide to inactive metabolites. This increases the risk of side effects.\u003c/td\u003e\u003ctd\u003e1. reduce the dose to 50% of the standard dose and record an ECG and monitor the plasma concentration.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eflecanide\u003c/td\u003e\u003ctd\u003eThe genetic variation increases conversion of flecainide to inactive metabolites. A higher dose is possibly required as a result.\u003c/td\u003e\u003ctd\u003eThere are no data about the pharmacokinetics and/or the effects of flecainide in UM. Monitor the plasma concentration as a precaution and record an ECG or select an alternative. Examples of anti-arrhythmic drugs that are not metabolized via CYP2D6 (or to a lesser extent) include sotalol, disopyramide, quinidine and amiodarone.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001594.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flecainide based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend a lower dose for patients carrying the poor metabolizer (PM) alleles and intermediate metabolizer (IM) alleles.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eReduce dose by 50%, record ECG, monitor plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5; Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eReduce dose by 25%, record ECG, monitor plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5; Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eRecord ECG and monitor plasma concentration or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone).\u003c/td\u003e\u003ctd\u003eno evidence.\u003c/td\u003e\u003ctd\u003e--\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166192301,Guideline Annotation,Annotation of CPIC Guideline for meloxicam and CYP2C9,t,PA450353,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"" target=""_blank"">CPIC&reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9</a>.</p>
<h3 id=""march-2020"">March 2020</h3>
<p><em>Advance online publication March 2020.</em></p>
<ul>
<li>
<p>The <a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830"" target=""_blank"">CPIC guideline regarding for <em>CYP2C9</em> and Nonsteroidal Anti-inflammatory Drugs</a> is published in Clinical Pharmacology and Therapeutics.</p>
</li>
<li>
<p>These guidelines are applicable to:</p>
<ul>
<li>
<p>pediatric patients</p>
</li>
<li>
<p>adult patients</p>
</li>
</ul>
</li>
<li>
<p>Excerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:</p>
<ul>
<li>
<p>&quot;Substantial evidence links CYP2C9 genotypes with phenotypic variability in CYP2C9 metabolism and plasma NSAID concentrations, with the majority of studies conducted in healthy volunteers.&quot;</p>
</li>
<li>
<p>&quot;Although clinical evidence linking genetic variation in CYP2C9 to an increased rate of adverse events with NSAIDs use is scarce, several studies have established an association between CYP2C9 decreased function and no function alleles and elevated NSAID exposure (Figure 1 and Figure S2). Because most NSAID adverse events are dose-dependent, on-target adverse events involving COX inhibition (19-23) it is reasonable to assume that elevated exposure increases the risk of adverse events.&quot;</p>
</li>
<li>
<p>&quot;CYP2C9 IM and PM phenotypes affect systemic plasma concentrations of NSAIDs by decreasing metabolic clearance and consequently prolonging plasma elimination half-life. Therefore, therapeutic recommendations are broadly organized according to the NSAID plasma elimination half-life in NMs. Where more than two studies reported plasma concentration areaunder-the-curve (AUC), a meta-analysis was conducted to estimate the average impact of CYP2C9 genotype on drug exposure (Figure 1 and Figures S2 to S4).&quot;</p>
</li>
<li>
<p>&quot; <em><strong>Meloxicam</strong></em>. Meloxicam has a longer half-life (15-20 hours, Table S12) than celecoxib and ibuprofen; thus, impaired meloxicam metabolism is expected to cause sustained elevations in drug exposure. Recommendations for CYP2C9 NMs and IMs with an AS of 1.5 are similar to the short half-life NSAIDs and include initiation of therapy with the standard dose while using the lowest effective dosage for shortest duration capable to achieve treatment goals. For IMs with an AS of 1, reduced metabolism and increased plasma concentrations are expected that may increase probability of toxicities...The recommendations are to either initiate therapy with 50% of the lowest recommended starting dose or choose an alternative therapy, consistent with the recommendations in PMs for short half-life NSAIDs (Table 2). Upward dose titration should not occur until after steady-state is reached (at least seven days), and careful monitoring is recommended. CYP2C9 PMs should be prescribed an alternative therapy because markedly prolonged half-life is expected (i.e., &gt;100 hours)&quot;.</p>
</li>
<li>
<p>&quot;<em><strong>Celecoxib, flurbiprofen, ibuprofen, lornoxicam</strong></em>: Based on current evidence, NMs and IMs with an AS of 1.5 are recommended to initiate therapy with the approved starting dose. Despitehaving mildly reduced metabolism, IMs with an AS of 1.5 do not exhibit significant increases in drug exposure relative to NMs... CYP2C9 IMs with an AS of 1 have reduced metabolism and are expected to exhibit a prolonged drug half-life and higher plasma concentrations compared to NMs, which may increase probability of toxicities.For IMs with an AS of 1, it is recommended to initiate NSAID therapy with the lowest recommended starting dose and titrate to clinical effect with close monitoring for adverse events such as elevated blood pressure and kidney dysfunction during course of therapy. Regarding ibuprofen use, it should be taken into consideration that while the CYP2C9*2 allele alone might not cause a clinically relevant reduction in clearance, its strong linkage with the
decreased function CYP2C8*3 allele may result in impaired R (-) ibuprofen hydroxylation and increased exposure to the parent drug...Individuals with a CYP2C9 PM phenotype (AS of 0) are expected to have markedly reduced metabolism and are expected to exhibit a pronounced prolongation of drug half-life and increase in plasma concentrations, which may increase the probability and/or severity of toxicities...It is recommended to initiate therapy with 25-50% of the lowest recommended starting dose (i.e. 50-75% dose reduction), and careful dose titration to clinical effect. Because drug half-life is significantly prolonged in these patients, upward dose titration should not occur until after steady-state is reached, taking into consideration the PM half-life for each drug; of course, dosing may be stopped or decreased due to toxicity at any time. Treatment with an alternative therapy could also be considered. This could include NSAIDs not primarily metabolized by CYP2C9 (such as aspirin, ketorolac (approved for short term use only), metamizole, naproxen, sulindac, etoricoxib, parecoxib, or valdecoxib), or with pharmacokinetic parameters apparently not impacted by CYP2C9 genetic variants in vivo despite CYP2C9 metabolism in vitro&quot;.</p>
</li>
<li>
<p>&quot; <em><strong>Piroxicam and tenoxicam</strong></em>. These drugs have extremely long half-lives (30-86 and 60 hours, respectively), thus
amplifying the potential risks in individuals with reduced CYP2C9 metabolism and hampering dose titration strategies due to lack of data. Accordingly, rather than use of a lower starting dose, IMs with an AS of 1 and PMs are recommended to receive an alternative therapy. This includes drugs that are not metabolized by CYP2C9 or significantly affected by CYP2C9 genetic variants in vivo. Selection of a NSAID with a short half-life (Table 2) could also be considered.&quot;</p>
</li>
<li>
<p>&quot; <em><strong>Aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen</strong></em>. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C&quot;.</p>
</li>
<li>
<p>&quot;<em><strong>Pediatrics</strong></em>: Because CYP2C9 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring. Ultimately, additional research
and clinical trials in pediatric patients investigating the association between CYP2C9 genotype and NSAID systemic exposure and treatment outcomes are needed.&quot;</p>
</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2C9</em> and NSAIDs Therapy</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT_supplement.pdf"" target=""_blank"">2020 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Meloxicam_Drug_Resource_Mappings.xlsx"" target=""_blank"">meloxicam Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Meloxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">meloxicam Pre and Post Test Alerts</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-meloxicam-by-cyp2c9-phenotype"">Table 1: Recommended dosing of <em><strong>meloxicam</strong></em> by CYP2C9 phenotype</h3>
<p><em>Adapted from Tables 1 and 3 of the 2020 guideline.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype<sup>a</sup></th><th>Activity Score</th><th>Genotype</th><th>Examples of genotypes<sup>b</sup></th><th>Implications</th><th>Therapeutic recommendations<sup>c</sup></th><th>Classification of recommendations<sup>d</sup></th><th>Other considerations</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C9</em> Normal metabolizer</td><td>2<sup>c</sup></td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td><td>Strong</td><td></td></tr>
<tr><td><em>CYP2C9</em> Intermediate metabolizer<sup>f</sup></td><td>1.5<sup>c</sup></td><td>An individual carrying one normal function and one decreased function allele.</td><td>*1/*2</td><td>Mildly reduced metabolism</td><td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td><td>Moderate</td><td>IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.</td></tr>
<tr><td><em>CYP2C9</em> Intermediate metabolizer<sup>f</sup></td><td>1<sup>c</sup></td><td>An individual carrying one normal function allele plus one no function allele OR two decreased function alleles.</td><td>*1/*3, *2/*2</td><td>Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities</td><td>Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).</td><td>Moderate</td><td>IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</td></tr>
<tr><td><em>CYP2C9</em> Poor metabolizer</td><td>0 or 0.5<sup>c</sup></td><td>An individual carrying one no function allele plus one decreased function allele; OR two no function alleles</td><td>*2/*3, *3/*3</td><td>Significantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities</td><td>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).</td><td>Moderate</td><td>Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</td></tr>
<tr><td>Indeterminate</td><td>n/a<sup>c</sup></td><td>An individual carrying allele combinations with uncertain and/or unknown function alleles</td><td>*1/*7, *1/*10, *7/*10, *1/*57</td><td>n/a</td><td>No recommendation.</td><td>n/a</td><td></td></tr>
</tbody>
</table>
<p><sup>a</sup> See the <a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 frequency table</a> for race-specific allele and phenotype frequencies.<br />
<sup>b</sup> For a complete list of CYP2C9 diplotypes and resulting phenotypes, see the <a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 genotype to phenotype table</a>.</p>
<p><sup>c</sup> CPIC assigned each allele functional status an activity value ranging from 0 to 1 (e.g., 0 for no function, 0.5 for decreased, and 1.0 for normal function), which are summed to calculate the activity score (AS) for each diplotype. The CYP2C9 AS has been translated into the phenotype classification system as follows: individuals with an AS of 0 or 0.5 are poor
metabolizers (PMs), those with a score of 1 or 1.5 are intermediate metabolizers (IMs), and those with a score of 2 are normal metabolizers (NMs).<br />
<sup>d</sup> Rating scheme described in Supplement.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166192301"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166192301"",""name"":""Annotation of CPIC Guideline for meloxicam and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[{""id"":1.45098678E9,""alleles"":[{""id"":1.450986781E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816542"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816542"",""symbol"":""CYP2C9*1"",""name"":""*1""}},{""id"":1.450986782E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816543"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816543"",""symbol"":""CYP2C9*2"",""name"":""*2""}},{""id"":1.450986783E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816544"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816544"",""symbol"":""CYP2C9*3"",""name"":""*3""}},{""id"":1.450986784E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816545"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816545"",""symbol"":""CYP2C9*4"",""name"":""*4""}},{""id"":1.450986785E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816546"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816546"",""symbol"":""CYP2C9*5"",""name"":""*5""}},{""id"":1.450986786E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816547"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816547"",""symbol"":""CYP2C9*6"",""name"":""*6""}},{""id"":1.450986787E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816548"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816548"",""symbol"":""CYP2C9*7"",""name"":""*7""}},{""id"":1.450986788E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816549"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816549"",""symbol"":""CYP2C9*8"",""name"":""*8""}},{""id"":1.450986789E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816550"",""symbol"":""CYP2C9*9"",""name"":""*9""}},{""id"":1.45098679E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816551"",""symbol"":""CYP2C9*10"",""name"":""*10""}},{""id"":1.450986791E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816552"",""symbol"":""CYP2C9*11"",""name"":""*11""}},{""id"":1.450986792E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816553"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816553"",""symbol"":""CYP2C9*12"",""name"":""*12""}},{""id"":1.450986793E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816554"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816554"",""symbol"":""CYP2C9*13"",""name"":""*13""}},{""id"":1.450986794E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816555"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816555"",""symbol"":""CYP2C9*14"",""name"":""*14""}},{""id"":1.450986795E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816556"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816556"",""symbol"":""CYP2C9*15"",""name"":""*15""}},{""id"":1.450986796E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816557"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816557"",""symbol"":""CYP2C9*16"",""name"":""*16""}},{""id"":1.450986797E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816563"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816563"",""symbol"":""CYP2C9*17"",""name"":""*17""}},{""id"":1.450986798E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816558"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816558"",""symbol"":""CYP2C9*18"",""name"":""*18""}},{""id"":1.450986799E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816564"",""symbol"":""CYP2C9*19"",""name"":""*19""}},{""id"":1.4509868E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816565"",""symbol"":""CYP2C9*20"",""name"":""*20""}},{""id"":1.450986801E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816566"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816566"",""symbol"":""CYP2C9*21"",""name"":""*21""}},{""id"":1.450986802E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816567"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816567"",""symbol"":""CYP2C9*22"",""name"":""*22""}},{""id"":1.450986803E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816568"",""symbol"":""CYP2C9*23"",""name"":""*23""}},{""id"":1.450986804E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816569"",""symbol"":""CYP2C9*24"",""name"":""*24""}},{""id"":1.450986805E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816559"",""symbol"":""CYP2C9*25"",""name"":""*25""}},{""id"":1.450986806E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816570"",""symbol"":""CYP2C9*26"",""name"":""*26""}},{""id"":1.450986807E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816571"",""symbol"":""CYP2C9*27"",""name"":""*27""}},{""id"":1.450986808E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816572"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816572"",""symbol"":""CYP2C9*28"",""name"":""*28""}},{""id"":1.450986809E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816573"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816573"",""symbol"":""CYP2C9*29"",""name"":""*29""}},{""id"":1.45098681E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816574"",""symbol"":""CYP2C9*30"",""name"":""*30""}},{""id"":1.450986811E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816560"",""symbol"":""CYP2C9*31"",""name"":""*31""}},{""id"":1.450986812E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816575"",""symbol"":""CYP2C9*32"",""name"":""*32""}},{""id"":1.450986813E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816561"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816561"",""symbol"":""CYP2C9*33"",""name"":""*33""}},{""id"":1.450986814E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816562"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816562"",""symbol"":""CYP2C9*34"",""name"":""*34""}},{""id"":1.450986815E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048681"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048681"",""symbol"":""CYP2C9*35"",""name"":""*35""}},{""id"":1.450986816E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048682"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048682"",""symbol"":""CYP2C9*36"",""name"":""*36""}},{""id"":1.450986817E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048683"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048683"",""symbol"":""CYP2C9*37"",""name"":""*37""}},{""id"":1.450986818E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048684"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048684"",""symbol"":""CYP2C9*38"",""name"":""*38""}},{""id"":1.450986819E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048685"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048685"",""symbol"":""CYP2C9*39"",""name"":""*39""}},{""id"":1.45098682E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048686"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048686"",""symbol"":""CYP2C9*40"",""name"":""*40""}},{""id"":1.450986821E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048687"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048687"",""symbol"":""CYP2C9*41"",""name"":""*41""}},{""id"":1.450986822E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048688"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048688"",""symbol"":""CYP2C9*42"",""name"":""*42""}},{""id"":1.450986823E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048689"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048689"",""symbol"":""CYP2C9*43"",""name"":""*43""}},{""id"":1.450986824E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048690"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048690"",""symbol"":""CYP2C9*44"",""name"":""*44""}},{""id"":1.450986825E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048691"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048691"",""symbol"":""CYP2C9*45"",""name"":""*45""}},{""id"":1.450986826E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048692"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048692"",""symbol"":""CYP2C9*46"",""name"":""*46""}},{""id"":1.450986827E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048693"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048693"",""symbol"":""CYP2C9*47"",""name"":""*47""}},{""id"":1.450986828E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048694"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048694"",""symbol"":""CYP2C9*48"",""name"":""*48""}},{""id"":1.450986829E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048695"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048695"",""symbol"":""CYP2C9*49"",""name"":""*49""}},{""id"":1.45098683E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048696"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048696"",""symbol"":""CYP2C9*50"",""name"":""*50""}},{""id"":1.450986831E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048697"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048697"",""symbol"":""CYP2C9*51"",""name"":""*51""}},{""id"":1.450986832E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048698"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048698"",""symbol"":""CYP2C9*52"",""name"":""*52""}},{""id"":1.450986833E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048699"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048699"",""symbol"":""CYP2C9*53"",""name"":""*53""}},{""id"":1.450986834E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048700"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048700"",""symbol"":""CYP2C9*54"",""name"":""*54""}},{""id"":1.450986835E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048701"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048701"",""symbol"":""CYP2C9*55"",""name"":""*55""}},{""id"":1.450986836E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048702"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048702"",""symbol"":""CYP2C9*56"",""name"":""*56""}},{""id"":1.450986837E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048703"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048703"",""symbol"":""CYP2C9*57"",""name"":""*57""}},{""id"":1.450986838E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166122566"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166122566"",""symbol"":""CYP2C9*58"",""name"":""*58""}},{""id"":1.450986839E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128210"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128210"",""symbol"":""CYP2C9*59"",""name"":""*59""}},{""id"":1.45098684E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128211"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128211"",""symbol"":""CYP2C9*60"",""name"":""*60""}},{""id"":1.450986841E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166183345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166183345"",""symbol"":""CYP2C9*61"",""name"":""*61""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}}],""history"":[{""id"":1.45109514E9,""date"":""2020-03-19T00:00:00-07:00"",""description"":""Guideline published"",""type"":""Note"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15105062"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5105062E7,""resourceId"":""32189324"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/32189324"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/32189324"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.451090662E9,""resource"":""PubMed"",""resourceId"":""32189324"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/32189324""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1830"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.451090663E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1830"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1830""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450353"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450353"",""name"":""meloxicam""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.45098648E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450986481E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""march-2020\""\u003eMarch 2020\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication March 2020.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830\"" target\u003d\""_blank\""\u003eCPIC guideline regarding for \u003cem\u003eCYP2C9\u003c/em\u003e and Nonsteroidal Anti-inflammatory Drugs\u003c/a\u003e is published in Clinical Pharmacology and Therapeutics.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThese guidelines are applicable to:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003epediatric patients\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eadult patients\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExcerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Substantial evidence links CYP2C9 genotypes with phenotypic variability in CYP2C9 metabolism and plasma NSAID concentrations, with the majority of studies conducted in healthy volunteers.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Although clinical evidence linking genetic variation in CYP2C9 to an increased rate of adverse events with NSAIDs use is scarce, several studies have established an association between CYP2C9 decreased function and no function alleles and elevated NSAID exposure (Figure 1 and Figure S2). Because most NSAID adverse events are dose-dependent, on-target adverse events involving COX inhibition (19-23) it is reasonable to assume that elevated exposure increases the risk of adverse events.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;CYP2C9 IM and PM phenotypes affect systemic plasma concentrations of NSAIDs by decreasing metabolic clearance and consequently prolonging plasma elimination half-life. Therefore, therapeutic recommendations are broadly organized according to the NSAID plasma elimination half-life in NMs. Where more than two studies reported plasma concentration areaunder-the-curve (AUC), a meta-analysis was conducted to estimate the average impact of CYP2C9 genotype on drug exposure (Figure 1 and Figures S2 to S4).\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003eMeloxicam\u003c/strong\u003e\u003c/em\u003e. Meloxicam has a longer half-life (15-20 hours, Table S12) than celecoxib and ibuprofen; thus, impaired meloxicam metabolism is expected to cause sustained elevations in drug exposure. Recommendations for CYP2C9 NMs and IMs with an AS of 1.5 are similar to the short half-life NSAIDs and include initiation of therapy with the standard dose while using the lowest effective dosage for shortest duration capable to achieve treatment goals. For IMs with an AS of 1, reduced metabolism and increased plasma concentrations are expected that may increase probability of toxicities...The recommendations are to either initiate therapy with 50% of the lowest recommended starting dose or choose an alternative therapy, consistent with the recommendations in PMs for short half-life NSAIDs (Table 2). Upward dose titration should not occur until after steady-state is reached (at least seven days), and careful monitoring is recommended. CYP2C9 PMs should be prescribed an alternative therapy because markedly prolonged half-life is expected (i.e., \u0026gt;100 hours)\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cem\u003e\u003cstrong\u003eCelecoxib, flurbiprofen, ibuprofen, lornoxicam\u003c/strong\u003e\u003c/em\u003e: Based on current evidence, NMs and IMs with an AS of 1.5 are recommended to initiate therapy with the approved starting dose. Despitehaving mildly reduced metabolism, IMs with an AS of 1.5 do not exhibit significant increases in drug exposure relative to NMs... CYP2C9 IMs with an AS of 1 have reduced metabolism and are expected to exhibit a prolonged drug half-life and higher plasma concentrations compared to NMs, which may increase probability of toxicities.For IMs with an AS of 1, it is recommended to initiate NSAID therapy with the lowest recommended starting dose and titrate to clinical effect with close monitoring for adverse events such as elevated blood pressure and kidney dysfunction during course of therapy. Regarding ibuprofen use, it should be taken into consideration that while the CYP2C9*2 allele alone might not cause a clinically relevant reduction in clearance, its strong linkage with the\ndecreased function CYP2C8*3 allele may result in impaired R (-) ibuprofen hydroxylation and increased exposure to the parent drug...Individuals with a CYP2C9 PM phenotype (AS of 0) are expected to have markedly reduced metabolism and are expected to exhibit a pronounced prolongation of drug half-life and increase in plasma concentrations, which may increase the probability and/or severity of toxicities...It is recommended to initiate therapy with 25-50% of the lowest recommended starting dose (i.e. 50-75% dose reduction), and careful dose titration to clinical effect. Because drug half-life is significantly prolonged in these patients, upward dose titration should not occur until after steady-state is reached, taking into consideration the PM half-life for each drug; of course, dosing may be stopped or decreased due to toxicity at any time. Treatment with an alternative therapy could also be considered. This could include NSAIDs not primarily metabolized by CYP2C9 (such as aspirin, ketorolac (approved for short term use only), metamizole, naproxen, sulindac, etoricoxib, parecoxib, or valdecoxib), or with pharmacokinetic parameters apparently not impacted by CYP2C9 genetic variants in vivo despite CYP2C9 metabolism in vitro\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003ePiroxicam and tenoxicam\u003c/strong\u003e\u003c/em\u003e. These drugs have extremely long half-lives (30-86 and 60 hours, respectively), thus\namplifying the potential risks in individuals with reduced CYP2C9 metabolism and hampering dose titration strategies due to lack of data. Accordingly, rather than use of a lower starting dose, IMs with an AS of 1 and PMs are recommended to receive an alternative therapy. This includes drugs that are not metabolized by CYP2C9 or significantly affected by CYP2C9 genetic variants in vivo. Selection of a NSAID with a short half-life (Table 2) could also be considered.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003eAceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen\u003c/strong\u003e\u003c/em\u003e. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cem\u003e\u003cstrong\u003ePediatrics\u003c/strong\u003e\u003c/em\u003e: Because CYP2C9 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring. Ultimately, additional research\nand clinical trials in pediatric patients investigating the association between CYP2C9 genotype and NSAID systemic exposure and treatment outcomes are needed.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for \u003cem\u003eCYP2C9\u003c/em\u003e and NSAIDs Therapy\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT_supplement.pdf\"" target\u003d\""_blank\""\u003e2020 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Meloxicam_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003emeloxicam Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Meloxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003emeloxicam Pre and Post Test Alerts\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-meloxicam-by-cyp2c9-phenotype\""\u003eTable 1: Recommended dosing of \u003cem\u003e\u003cstrong\u003emeloxicam\u003c/strong\u003e\u003c/em\u003e by CYP2C9 phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3 of the 2020 guideline.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eActivity Score\u003c/th\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eExamples of genotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003csup\u003ed\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eOther considerations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Normal metabolizer\u003c/td\u003e\u003ctd\u003e2\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Intermediate metabolizer\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.5\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function and one decreased function allele.\u003c/td\u003e\u003ctd\u003e*1/*2\u003c/td\u003e\u003ctd\u003eMildly reduced metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eIMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Intermediate metabolizer\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele plus one no function allele OR two decreased function alleles.\u003c/td\u003e\u003ctd\u003e*1/*3, *2/*2\u003c/td\u003e\u003ctd\u003eModerately reduced metabolism; higher plasma concentrations may increase probability of toxicities\u003c/td\u003e\u003ctd\u003eInitiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eIMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age. Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Poor metabolizer\u003c/td\u003e\u003ctd\u003e0 or 0.5\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one no function allele plus one decreased function allele; OR two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eSignificantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities\u003c/td\u003e\u003ctd\u003eChoose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003en/a\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying allele combinations with uncertain and/or unknown function alleles\u003c/td\u003e\u003ctd\u003e*1/*7, *1/*10, *7/*10, *1/*57\u003c/td\u003e\u003ctd\u003en/a\u003c/td\u003e\u003ctd\u003eNo recommendation.\u003c/td\u003e\u003ctd\u003en/a\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e See the \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 frequency table\u003c/a\u003e for race-specific allele and phenotype frequencies.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e For a complete list of CYP2C9 diplotypes and resulting phenotypes, see the \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 genotype to phenotype table\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e CPIC assigned each allele functional status an activity value ranging from 0 to 1 (e.g., 0 for no function, 0.5 for decreased, and 1.0 for normal function), which are summed to calculate the activity score (AS) for each diplotype. The CYP2C9 AS has been translated into the phenotype classification system as follows: individuals with an AS of 0 or 0.5 are poor\nmetabolizers (PMs), those with a score of 1 or 1.5 are intermediate metabolizers (IMs), and those with a score of 2 are normal metabolizers (NMs).\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003e Rating scheme described in Supplement.\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182810,Guideline Annotation,Annotation of DPWG Guideline for flucloxacillin and HLA-B,t,PA164781042,Dutch Pharmacogenetics Working Group,"<p>Monitor for liver function and select an alternative drug instead of flucloxacillin if liver enzymes or bilirubin is elevated, for patients that are HLA-B*5701.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flucloxacillin and HLA-B*5701.</p>
<p><em>Wording in table taken from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">the Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>ALLELE/GENOTYPE/PHENOTYPE</th><th>DRUG</th><th>DESCRIPTION</th><th>RECOMMENDATION</th></tr>
</thead>
<tbody>
<tr><td>HLA-B*5701</td><td>flucloxacillin</td><td>HLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals).</td><td>1. Regularly monitor the patient’s liver function<br/>2. Choose an alternative if liver enzymes and/or bilirubin levels are elevated</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0004652.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182810"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182810"",""name"":""Annotation of DPWG Guideline for flucloxacillin and HLA-B"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414938E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820629E9,""date"":""2019-10-03T10:21:52.121-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450962961E9,""date"":""2020-02-10T11:49:27.957-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/haplotype/PA165987830"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165987830"",""symbol"":""HLA-B*57:01"",""name"":""*57:01""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA164781042"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA164781042"",""name"":""flucloxacillin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414935E9,""html"":""\u003cp\u003eMonitor for liver function and select an alternative drug instead of flucloxacillin if liver enzymes or bilirubin is elevated, for patients that are HLA-B*5701.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414936E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flucloxacillin and HLA-B*5701.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003ethe Dutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eALLELE/GENOTYPE/PHENOTYPE\u003c/th\u003e\u003cth\u003eDRUG\u003c/th\u003e\u003cth\u003eDESCRIPTION\u003c/th\u003e\u003cth\u003eRECOMMENDATION\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eHLA-B*5701\u003c/td\u003e\u003ctd\u003eflucloxacillin\u003c/td\u003e\u003ctd\u003eHLA-B*5701-positive patients have an 80-fold elevated risk of flucloxacillin-induced liver injury. However, the incidence is low (1-2 per 1000 individuals).\u003c/td\u003e\u003ctd\u003e1. Regularly monitor the patient’s liver function\u003cbr/\u003e2. Choose an alternative if liver enzymes and/or bilirubin levels are elevated\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0004652.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166122686,Guideline Annotation,Annotation of CPIC Guideline for fluorouracil and DPYD,t,PA128406956,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A&gt;T];[2846A&gt;T] genotype may require a &gt;50% dose reduction.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"" target=""_blank"">CPIC&reg; guideline for fluoropyrimidines and DPYD</a>.</p>
<h3 id=""november-2018-update-on-pharmgkb"">November 2018 Update on PharmGKB</h3>
<ul>
<li>The DPYD guideline published in November 2017 recommended to reduce the dose of fluoropyrimidines by 25-50% (from the full standard dose) in DPYD Intermediate Metabolizers with an activity score of 1.5. At the time of the guideline publication, this dose range was recommended due to limited evidence for genotype-guided dosing of decreased function alleles/variants. However, a recent prospective study [Article:<a href=""/pmid/30348537"">30348537</a>] provides evidence to support a recommendation for a 50% dose reduction in heterozygous carriers of the decreased function variants c.2846A&gt;T (<a href=""https://www.pharmgkb.org/variant/PA166153895"">rs67376798</a>) or c.1129–5923C&gt;G (<a href=""https://www.pharmgkb.org/variant/PA166153906"">rs75017182</a>); HapB3 or its tagging SNP c.1236G&gt;A; <a href=""https://www.pharmgkb.org/variant/PA166153889"">rs56038477</a>). These data suggest that all Intermediate Metabolizers with an activity score of 1.5 should receive a 50% dose reduction. <strong>Therefore CPIC revised its recommendation such that all DPYD Intermediate Metabolizers should receive a 50% dose reduction from the full standard starting dose, whether the activity score is 1 or 1.5 followed by dose titration, based on clinical judgement and ideally therapeutic drug monitoring.</strong></li>
<li>In addition, recent case reports from patients who are homozygous for c.2846A&gt;T (activity score of 1) indicate that a dose reduction of more than 50% may be required in some carriers of this genotype. <strong>Therefore, in patients with an activity score of 1 due to a homozygous c.[2846A&gt;T];[2846A&gt;T] genotype, clinicians should be aware that a &gt;50% reduction in starting dose might be warranted.</strong></li>
</ul>
<h3 id=""november-2017-update"">November 2017 Update</h3>
<p><em>Advance online publication November 2017</em></p>
<ul>
<li>The 2017 update of CPIC guidelines regarding 5-fluorouracil and capecitabine has been accepted for publication in Clinical Pharmacology and Therapeutics.  Literature up to March 2017 was reviewed, and recommendations and supplemental information were updated. In particular, the dosing recommendations were modified to only apply to 5-fluorouracil and capecitabine; they no longer apply to tegafur. Additionally, dosing recommendations are now given in the context of <a rel=""noopener noreferrer"" href=""https://www.ncbi.nlm.nih.gov/pubmed/26265346"" target=""_blank"">DPYD activity score</a>.</li>
<li>Excerpts from the 2017 dosing guideline update:
<ul>
<li>&quot;The strength of the prescribing recommendations is based on the known impact of some variants (c.1905+1G&gt;A, c.1679T&gt;G, c.2846A&gt;T, c.1129– 5923C&gt;G) on DPD activity, the demonstrated relationship between DPD activity and 5-fluorouracil clearance, and between 5-fluorouracil exposure and its toxic effects.&quot;</li>
<li>&quot;At the time of this writing, data on the possible role of DPYD genetic variation in 5-fluorouracil toxicity in pediatric patient populations is extremely scarce; however, there is no evidence to suggest that 5-fluorouracil pharmacokinetics differ from adult patients, and thus no evidence that DPYD variants would affect 5-fluorouracil metabolism differently in children.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729-supplement.pdf"" target=""_blank"">2017 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/dpydRefMaterials"">Gene-specific Information Tables for DPYD</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Capecitabine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Capecitabine drug resource mapping</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Fluoropyrimidines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Fluoropyrimidines pre- and post-test alerts and flow chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-fluoropyrimidines-by-genotype-phenotype"">Table 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.</h3>
<p><em>Adapted from Tables 1 and 2 of the 2017 guideline manuscript (November 2018 Update on PharmGKB).</em></p>
<table class=""table"">
<thead>
<tr><th>Likely Phenotype</th><th>Activity Score<sup>a</sup></th><th>Genotypes<sup>b</sup></th><th>Examples of genotypes<sup>c</sup></th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations<sup>d</sup></th></tr>
</thead>
<tbody>
<tr><td><em>DPYD</em> Normal Metabolizer</td><td>2</td><td>An individual carrying two normal alleles</td><td>c.[=];[=], c.[85T&gt;C<sup>e</sup>];[=], c.[1627A&gt;G<sup>f</sup>];[=]</td><td>Normal DPD activity and “normal” risk for fluoropyrimidine toxicity</td><td>Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration</td><td>Strong</td></tr>
<tr><td><em>DPYD</em> Intermediate Metabolizer</td><td>1 or 1.5</td><td>An individual carrying one normal function allele plus one no function allele or one decreased function allele, or an individual carrying two decreased function alleles</td><td>c.[1905+1G&gt;A<sup>g</sup>];[=], c.[1679T&gt;G<sup>h</sup>];[=], c.[2846A&gt;T<sup>i</sup>];[=]; c.[1129–5923C&gt;G<sup>j</sup>];[=]; c.[1129–5923C&gt;G];[1129–5923C&gt;G]; c.[2846A&gt;T];[2846A&gt;T]</td><td>Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).<br/>Patients with the c.[2846A&gt;T];[2846A&gt;T] genotype may require &gt;50% reduction in starting dose.</td><td>Activity score 1: Strong<br/>Activity score 1.5: Moderate</td></tr>
<tr><td><em>DPYD</em> Poor Metabolizer</td><td>0 or 0.5</td><td>An individual carrying two no function alleles or an individual carrying one no function plus one decreased function allele</td><td>c.[1905+1G&gt;A];[1905+1G&gt;A], c.[1679T&gt;G];[1679T&gt;G], c.[1905+1G&gt;A];[2846A&gt;T] c.[1905+1G&gt;A];[1129-5923C&gt;G]</td><td>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Activity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose<sup>k</sup> with early therapeutic drug monitoring.<sup>l</sup><br/>Activity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> Calculated as the sum of the two lowest individual variant activity scores. See main guideline for further information.<br />
<sup>b</sup> Allele definitions, assignment of allele function and references can be found using the <a href=""https://www.pharmgkb.org/page/dpydRefMaterials"">DPYD Allele Functionality Table</a>.<br />
<sup>c</sup> HGVS nomenclature using the reference sequence NM_000110.3.<br />
<sup>d</sup> Rating scheme described in the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf"" target=""_blank"">Supplement</a>.<br />
<sup>e</sup> Also known as <a href=""/variant/PA166153648"">rs1801265</a> or DPYD*9A<br />
<sup>f</sup> Also known as <a href=""/variant/PA166153646"">rs1801159</a> or DPYD*5<br />
<sup>g</sup> Also known as <a href=""/variant/PA166153760"">rs3918290</a> or DPYD*2A<br />
<sup>h</sup> Also known as <a href=""/variant/PA166153888"">rs55886062</a> or DPYD*13<br />
<sup>i</sup> Also known as <a href=""/variant/PA166153895"">rs67376798</a><br />
<sup>j</sup> Also known as <a href=""/variant/PA166153906"">rs75017182</a>. Likely HapB3 causal variant. See <a href=""https://www.pharmgkb.org/page/dpydRefMaterials"">DPYD Allele Functionality Table</a> for other HapB3 proxy SNPs.<br />
<sup>k</sup> If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of &lt;25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance.<br />
<sup>l</sup> Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue the infusion if the drug level is too high.</p>
<h3 id=""may-2014-update-on-pharmgkb"">May 2014 Update on PharmGKB</h3>
<ul>
<li>The CPIC authors recommend that the <em>DPYD*4</em>, <em>*5</em>, <em>*6</em> and <em>*9A</em> alleles be categorized as &quot;normal&quot; activity, in part based upon the recent publication <a rel=""noopener noreferrer"" href=""http://www.ncbi.nlm.nih.gov/pubmed/?term=24648345"" target=""_blank"">Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity</a>.</li>
</ul>
<h3 id=""december-2013-publication"">December 2013 Publication</h3>
<p><em>Advance online publication October 2013.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in <em>Clinical Pharmacology and Therapeutics</em> by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf"" target=""_blank"">2013 supplement</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166122686"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166122686"",""name"":""Annotation of CPIC Guideline for fluorouracil and DPYD"",""cancerGenome"":false,""descriptiveVideoId"":""2wB2l4W9x8s"",""guidelineGenes"":[{""id"":1.449561417E9,""alleles"":[{""id"":1.449561418E9,""_label"":""c.1679T\u003eG (*13)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171118"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171118"",""symbol"":""DPYDc.1679T\u003eG (*13)"",""name"":""c.1679T\u003eG (*13)""}},{""id"":1.449561419E9,""_label"":""c.2846A\u003eT"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171119"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171119"",""symbol"":""DPYDc.2846A\u003eT"",""name"":""c.2846A\u003eT""}},{""id"":1.44956142E9,""_label"":""c.1129-5923C\u003eG, c.1236G\u003eA (HapB3)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171120"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171120"",""symbol"":""DPYDc.1129-5923C\u003eG, c.1236G\u003eA (HapB3)"",""name"":""c.1129-5923C\u003eG, c.1236G\u003eA (HapB3)""}},{""id"":1.449561421E9,""_label"":""c.1898delC (*3)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171121"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171121"",""symbol"":""DPYDc.1898delC (*3)"",""name"":""c.1898delC (*3)""}},{""id"":1.449561422E9,""_label"":""c.295_298delTCAT (*7)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171122"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171122"",""symbol"":""DPYDc.295_298delTCAT (*7)"",""name"":""c.295_298delTCAT (*7)""}},{""id"":1.449561423E9,""_label"":""c.703C\u003eT (*8)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171123"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171123"",""symbol"":""DPYDc.703C\u003eT (*8)"",""name"":""c.703C\u003eT (*8)""}},{""id"":1.449561424E9,""_label"":""c.2983G\u003eT (*10)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171124"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171124"",""symbol"":""DPYDc.2983G\u003eT (*10)"",""name"":""c.2983G\u003eT (*10)""}},{""id"":1.449561425E9,""_label"":""c.1156G\u003eT (*12)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171125"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171125"",""symbol"":""DPYDc.1156G\u003eT (*12)"",""name"":""c.1156G\u003eT (*12)""}},{""id"":1.449561426E9,""_label"":""c.557A\u003eG"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171126"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171126"",""symbol"":""DPYDc.557A\u003eG"",""name"":""c.557A\u003eG""}},{""id"":1.449561428E9,""_label"":""c.1905+1G\u003eA (*2A)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166171117"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166171117"",""symbol"":""DPYDc.1905+1G\u003eA (*2A)"",""name"":""c.1905+1G\u003eA (*2A)""}},{""id"":1.45106036E9,""_label"":""Any normal function variant or no variant detected"",""allele"":""Any normal function variant or no variant detected"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA145"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA145"",""symbol"":""DPYD"",""name"":""dihydropyrimidine dehydrogenase""}}],""history"":[{""id"":1.184511807E9,""date"":""2014-07-30T00:00:00-07:00"",""type"":""Update"",""version"":0.0},{""id"":1.448604804E9,""date"":""2017-03-16T17:47:59.311-07:00"",""description"":""Updated extended dosing guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.449140397E9,""date"":""2017-11-13T10:55:34.511-08:00"",""type"":""Update"",""version"":0.0},{""id"":1.449154751E9,""date"":""2017-11-28T10:14:26.842-08:00"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15099812"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5099812E7,""resourceId"":""29152729"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760397"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5760397"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285368E9,""resource"":""PubMed Central"",""resourceId"":""PMC5760397"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760397""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/29152729"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285367E9,""resource"":""PubMed"",""resourceId"":""29152729"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/29152729""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.911"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285369E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.911"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.911""}]},{""@id"":""https://pharmgkb.org/literature/15062135"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5062135E7,""resourceId"":""23988873"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831181"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3831181"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449277398E9,""resource"":""PubMed Central"",""resourceId"":""PMC3831181"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831181""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23988873"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449277397E9,""resource"":""PubMed"",""resourceId"":""23988873"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23988873""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.172"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449277399E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.172"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.172""}]},{""@id"":""https://pharmgkb.org/literature/15100909"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100909E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""title"":""CPIC® Guideline for Fluoropyrimidines and DPYD – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983463E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA128406956"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA128406956"",""name"":""fluorouracil""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA145"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA145"",""symbol"":""DPYD"",""name"":""dihydropyrimidine dehydrogenase""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.450180196E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A\u0026gt;T];[2846A\u0026gt;T] genotype may require a \u0026gt;50% dose reduction.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.450180197E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for fluoropyrimidines and DPYD\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update-on-pharmgkb\""\u003eNovember 2018 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe DPYD guideline published in November 2017 recommended to reduce the dose of fluoropyrimidines by 25-50% (from the full standard dose) in DPYD Intermediate Metabolizers with an activity score of 1.5. At the time of the guideline publication, this dose range was recommended due to limited evidence for genotype-guided dosing of decreased function alleles/variants. However, a recent prospective study [Article:\u003ca href\u003d\""/pmid/30348537\""\u003e30348537\u003c/a\u003e] provides evidence to support a recommendation for a 50% dose reduction in heterozygous carriers of the decreased function variants c.2846A\u0026gt;T (\u003ca href\u003d\""https://www.pharmgkb.org/variant/PA166153895\""\u003ers67376798\u003c/a\u003e) or c.1129–5923C\u0026gt;G (\u003ca href\u003d\""https://www.pharmgkb.org/variant/PA166153906\""\u003ers75017182\u003c/a\u003e); HapB3 or its tagging SNP c.1236G\u0026gt;A; \u003ca href\u003d\""https://www.pharmgkb.org/variant/PA166153889\""\u003ers56038477\u003c/a\u003e). These data suggest that all Intermediate Metabolizers with an activity score of 1.5 should receive a 50% dose reduction. \u003cstrong\u003eTherefore CPIC revised its recommendation such that all DPYD Intermediate Metabolizers should receive a 50% dose reduction from the full standard starting dose, whether the activity score is 1 or 1.5 followed by dose titration, based on clinical judgement and ideally therapeutic drug monitoring.\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eIn addition, recent case reports from patients who are homozygous for c.2846A\u0026gt;T (activity score of 1) indicate that a dose reduction of more than 50% may be required in some carriers of this genotype. \u003cstrong\u003eTherefore, in patients with an activity score of 1 due to a homozygous c.[2846A\u0026gt;T];[2846A\u0026gt;T] genotype, clinicians should be aware that a \u0026gt;50% reduction in starting dose might be warranted.\u003c/strong\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""november-2017-update\""\u003eNovember 2017 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication November 2017\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2017 update of CPIC guidelines regarding 5-fluorouracil and capecitabine has been accepted for publication in Clinical Pharmacology and Therapeutics.  Literature up to March 2017 was reviewed, and recommendations and supplemental information were updated. In particular, the dosing recommendations were modified to only apply to 5-fluorouracil and capecitabine; they no longer apply to tegafur. Additionally, dosing recommendations are now given in the context of \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.ncbi.nlm.nih.gov/pubmed/26265346\"" target\u003d\""_blank\""\u003eDPYD activity score\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2017 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;The strength of the prescribing recommendations is based on the known impact of some variants (c.1905+1G\u0026gt;A, c.1679T\u0026gt;G, c.2846A\u0026gt;T, c.1129– 5923C\u0026gt;G) on DPD activity, the demonstrated relationship between DPD activity and 5-fluorouracil clearance, and between 5-fluorouracil exposure and its toxic effects.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;At the time of this writing, data on the possible role of DPYD genetic variation in 5-fluorouracil toxicity in pediatric patient populations is extremely scarce; however, there is no evidence to suggest that 5-fluorouracil pharmacokinetics differ from adult patients, and thus no evidence that DPYD variants would affect 5-fluorouracil metabolism differently in children.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729-supplement.pdf\"" target\u003d\""_blank\""\u003e2017 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/dpydRefMaterials\""\u003eGene-specific Information Tables for DPYD\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Capecitabine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eCapecitabine drug resource mapping\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/Fluoropyrimidines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eFluoropyrimidines pre- and post-test alerts and flow chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-fluoropyrimidines-by-genotype-phenotype\""\u003eTable 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2017 guideline manuscript (November 2018 Update on PharmGKB).\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely Phenotype\u003c/th\u003e\u003cth\u003eActivity Score\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eGenotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eExamples of genotypes\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003csup\u003ed\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eDPYD\u003c/em\u003e Normal Metabolizer\u003c/td\u003e\u003ctd\u003e2\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal alleles\u003c/td\u003e\u003ctd\u003ec.[\u003d];[\u003d], c.[85T\u0026gt;C\u003csup\u003ee\u003c/sup\u003e];[\u003d], c.[1627A\u0026gt;G\u003csup\u003ef\u003c/sup\u003e];[\u003d]\u003c/td\u003e\u003ctd\u003eNormal DPD activity and “normal” risk for fluoropyrimidine toxicity\u003c/td\u003e\u003ctd\u003eBased on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eDPYD\u003c/em\u003e Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003e1 or 1.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele plus one no function allele or one decreased function allele, or an individual carrying two decreased function alleles\u003c/td\u003e\u003ctd\u003ec.[1905+1G\u0026gt;A\u003csup\u003eg\u003c/sup\u003e];[\u003d], c.[1679T\u0026gt;G\u003csup\u003eh\u003c/sup\u003e];[\u003d], c.[2846A\u0026gt;T\u003csup\u003ei\u003c/sup\u003e];[\u003d]; c.[1129–5923C\u0026gt;G\u003csup\u003ej\u003c/sup\u003e];[\u003d]; c.[1129–5923C\u0026gt;G];[1129–5923C\u0026gt;G]; c.[2846A\u0026gt;T];[2846A\u0026gt;T]\u003c/td\u003e\u003ctd\u003eDecreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs\u003c/td\u003e\u003ctd\u003eReduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).\u003cbr/\u003ePatients with the c.[2846A\u0026gt;T];[2846A\u0026gt;T] genotype may require \u0026gt;50% reduction in starting dose.\u003c/td\u003e\u003ctd\u003eActivity score 1: Strong\u003cbr/\u003eActivity score 1.5: Moderate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eDPYD\u003c/em\u003e Poor Metabolizer\u003c/td\u003e\u003ctd\u003e0 or 0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles or an individual carrying one no function plus one decreased function allele\u003c/td\u003e\u003ctd\u003ec.[1905+1G\u0026gt;A];[1905+1G\u0026gt;A], c.[1679T\u0026gt;G];[1679T\u0026gt;G], c.[1905+1G\u0026gt;A];[2846A\u0026gt;T] c.[1905+1G\u0026gt;A];[1129-5923C\u0026gt;G]\u003c/td\u003e\u003ctd\u003eComplete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs\u003c/td\u003e\u003ctd\u003eActivity score 0.5: Avoid use of 5- fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose\u003csup\u003ek\u003c/sup\u003e with early therapeutic drug monitoring.\u003csup\u003el\u003c/sup\u003e\u003cbr/\u003eActivity score 0: Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Calculated as the sum of the two lowest individual variant activity scores. See main guideline for further information.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e Allele definitions, assignment of allele function and references can be found using the \u003ca href\u003d\""https://www.pharmgkb.org/page/dpydRefMaterials\""\u003eDPYD Allele Functionality Table\u003c/a\u003e.\u003cbr /\u003e\n\u003csup\u003ec\u003c/sup\u003e HGVS nomenclature using the reference sequence NM_000110.3.\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003e Rating scheme described in the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf\"" target\u003d\""_blank\""\u003eSupplement\u003c/a\u003e.\u003cbr /\u003e\n\u003csup\u003ee\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153648\""\u003ers1801265\u003c/a\u003e or DPYD*9A\u003cbr /\u003e\n\u003csup\u003ef\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153646\""\u003ers1801159\u003c/a\u003e or DPYD*5\u003cbr /\u003e\n\u003csup\u003eg\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153760\""\u003ers3918290\u003c/a\u003e or DPYD*2A\u003cbr /\u003e\n\u003csup\u003eh\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153888\""\u003ers55886062\u003c/a\u003e or DPYD*13\u003cbr /\u003e\n\u003csup\u003ei\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153895\""\u003ers67376798\u003c/a\u003e\u003cbr /\u003e\n\u003csup\u003ej\u003c/sup\u003e Also known as \u003ca href\u003d\""/variant/PA166153906\""\u003ers75017182\u003c/a\u003e. Likely HapB3 causal variant. See \u003ca href\u003d\""https://www.pharmgkb.org/page/dpydRefMaterials\""\u003eDPYD Allele Functionality Table\u003c/a\u003e for other HapB3 proxy SNPs.\u003cbr /\u003e\n\u003csup\u003ek\u003c/sup\u003e If available, a phenotyping test (see main text for further details) should be considered to estimate the starting dose. In absence of phenotyping data, a dose of \u0026lt;25% of the normal starting dose is estimated assuming additive effects of alleles on 5-FU clearance.\u003cbr /\u003e\n\u003csup\u003el\u003c/sup\u003e Therapeutic drug monitoring should be done at the earliest time point possible (e.g., minimum time point in steady state) in order to immediately discontinue the infusion if the drug level is too high.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2014-update-on-pharmgkb\""\u003eMay 2014 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe CPIC authors recommend that the \u003cem\u003eDPYD*4\u003c/em\u003e, \u003cem\u003e*5\u003c/em\u003e, \u003cem\u003e*6\u003c/em\u003e and \u003cem\u003e*9A\u003c/em\u003e alleles be categorized as \u0026quot;normal\u0026quot; activity, in part based upon the recent publication \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.ncbi.nlm.nih.gov/pubmed/?term\u003d24648345\"" target\u003d\""_blank\""\u003eComparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity\u003c/a\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2013-publication\""\u003eDecember 2013 Publication\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication October 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in \u003cem\u003eClinical Pharmacology and Therapeutics\u003c/em\u003e by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983463E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/""}]},""status"":""success""}"
PA166104939,Guideline Annotation,Annotation of DPWG Guideline for fluorouracil and DPYD,t,PA128406956,Dutch Pharmacogenetics Working Group,"<p>An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as &quot;essential&quot; and recommend DPYD testing prior to initiating fluoropyrimidines.</p>
","<h3 id=""dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-of-dpyd-and-fluoropyrimidines-european-journal-of-human-genetics-2019"">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <em>European journal of human genetics (2019)</em></h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines as per the August 2019 update including more details and scoring the clinical implementation <a href=""/literature/15104402"">PMID: 31745289</a>.</p>
<h3 id=""august-2019-update"">August 2019 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil and capecitabine based on DPYD genotype. An alternative drug or reduction in dose is recommended for patients with DPYD activity scores of 0, 1 and 1.5. Patients with genotypes defined by the FENO group should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative, as it is also metabolized by DPD.</p>
<p><em>Wording in table taken from the <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"" target=""_blank"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>Activity Score 0</td><td>fluorouracil, cutaneous</td><td>The gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Avoid fluorouracil.<br/><em>NOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and* 13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient actually has gene activity score 1, for which no increased risk of severe, potentially fatal toxicity has been found with cutaneous use. These two situations can only be distinguished by determining the enzyme activity (phenotyping). This recommendation only applies if the patient has virtually no enzyme activity</em></td></tr>
<tr><td>Activity Score 0</td><td>fluorouracil/capecitabine, systemic</td><td>The gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the standard dose is a more than 100-fold overdose.</td><td>1. Avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolised by DPD.<br/>2. If if is not possible to avoid fluorouracil and capecitabine: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped).</td></tr>
<tr><td>Activity Score 1</td><td>fluorouracil/capecitabine</td><td>The gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 50% of the standard dose or avoid fluorouracil and capecitabine. Adjustment of the subsequent dose should be guided by toxicity and effectiveness. However, in one study involving 17 patients with gene activity 1, the average dose after titration was 57% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD.</td></tr>
<tr><td>Activity Score 1.5</td><td>fluorouracil/capecitabine</td><td>The gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 50% of the standard dose or avoid fluorouracil and capecitabine. After starting treatment, the dose should be adjusted based on toxicity and effectiveness. In a study involving 17 patients with genotype <em>1/2846T</em>, the average dose after titration was 64% of the standard dose. For 51 patients with genotype <em>1/1236A</em>, the average dose after titration was 74% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD.</td></tr>
<tr><td>FENO</td><td>fluorouracil/capecitabine</td><td>The gene variation increases the risk of severe, potentially fatal, toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>It is not possible to recommend a dose adjustment for this patient based on the genotype only.<br/>Determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose based on phenotype and genotype, or avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolized by DPD.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0006192.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil and capecitabine based on DPYD genotype. An alternative drug or reduction in dose is recommended for patients with DPYD activity scores of 0, 0.5, 1 and 1.5. Tegafur is not an alternative, as it is also metabolized by DPD.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>Activity Score 0</td><td>fluorouracil, cutaneous</td><td>Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Choose an alternative.<br/><em>NOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and* 13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1, for which no increased risk of severe, potentially fatal toxicity has been found with cutaneous use. These two situations can only be distinguished by determining the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 0</td><td>fluorouracil/capecitabine, systemic</td><td>Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the standard dose is a more than 100-fold overdose.</td><td>1. Choose an alternative. Tegafur is not an alternative, as this is also metabolised by DPD.<br/>2. If an alternative is not possible: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped). The average Caucasian DPD activity is 9.9 nmol/hour per mg protein. Or, adjust the initial dose based on toxicity and efficacy.<br/><em>NOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and *13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 0.5</td><td>fluorouracil/capecitabine</td><td>Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 25% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.<br/><em>NOTE: This recommendation only applies if the two genetic variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 1</td><td>fluorouracil/capecitabine</td><td>Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 50% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.<br/><em>NB1: The dose reduction described here is well substantiated for *1/*2A and 1236A/1236A. The dose reduction for patients with 2846T (2846T/2846T or 1236A/2846T) is based on, among other factors, the dose reductions identified for *1/2846T.</em><br/><em>NB2: If a patient has two different genetic variations that result in a partially functional DPD enzyme (e.g. 2846T and 1236A), this recommendation applies if the variations are on a different allele. If both variations are on the same allele, the gene activity score is between 1 and 1.5, depending on whether and how the two gene variations influence each other and on other factors that influence the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two different genetic variations can only be determined by measuring the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 1.5</td><td>fluorouracil/capecitabine</td><td>Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.</td><td>Start with 75% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002551.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil based on DPYD genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend that an alternate drug be used for poor metabolizer patients, and a reduced dose or alternate drug for intermediate metabolizer patients.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles, 2 decreased activity alleles, or one inactive and one decreased activity alleles)</td><td>Select alterantive drug.  Tegafur is not a suitable alternative because this drug is also metabolized by DPD.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
<tr><td>IM (1 active allele and 1 inactive or decreased activity allele)</td><td>Reduce dose by 50% or select alternative drug.  Tegafur is not a suitable alternative because this drug is also a substrate for DPD.  Increase dose in response to toxicity and efficacy.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *4, *5, *6, *9A</td></tr>
<tr><td>decreased activity</td><td>*9B, *10</td></tr>
<tr><td>inactive</td><td>*2A, *3, *7, *8, *11, *12, *13, 496A&gt;G, IVS10-15T&gt;C, 1156G&gt;T, 1845G&gt;T</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104939"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104939"",""name"":""Annotation of DPWG Guideline for fluorouracil and DPYD"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704473E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.45041498E9,""date"":""2019-05-23T11:23:35.569-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820645E9,""date"":""2019-10-03T13:13:15.174-07:00"",""description"":""Changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956401E9,""date"":""2020-01-31T13:30:28.156-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450965842E9,""date"":""2020-02-13T09:58:53.342-08:00"",""description"":""Added text and links to DPYD guideline individual paper PMID: 31745289"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15104402"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5104402E7,""resourceId"":""31745289"",""title"":""Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/31745289"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/31745289"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.45096468E9,""resource"":""PubMed"",""resourceId"":""31745289"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/31745289""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/s41431-019-0540-0"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450964681E9,""resource"":""DOI"",""resourceId"":""10.1038/s41431-019-0540-0"",""_url"":""http://dx.doi.org/10.1038%2Fs41431-019-0540-0""}]},{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA128406956"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA128406956"",""name"":""fluorouracil""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA145"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA145"",""symbol"":""DPYD"",""name"":""dihydropyrimidine dehydrogenase""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981858E9,""html"":""\u003cp\u003eAn alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as \u0026quot;essential\u0026quot; and recommend DPYD testing prior to initiating fluoropyrimidines.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981857E9,""html"":""\u003ch3 id\u003d\""dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-of-dpyd-and-fluoropyrimidines-european-journal-of-human-genetics-2019\""\u003eDutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. \u003cem\u003eEuropean journal of human genetics (2019)\u003c/em\u003e\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines as per the August 2019 update including more details and scoring the clinical implementation \u003ca href\u003d\""/literature/15104402\""\u003ePMID: 31745289\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""august-2019-update\""\u003eAugust 2019 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil and capecitabine based on DPYD genotype. An alternative drug or reduction in dose is recommended for patients with DPYD activity scores of 0, 1 and 1.5. Patients with genotypes defined by the FENO group should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative, as it is also metabolized by DPD.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf\"" target\u003d\""_blank\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0\u003c/td\u003e\u003ctd\u003efluorouracil, cutaneous\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eAvoid fluorouracil.\u003cbr/\u003e\u003cem\u003eNOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and* 13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient actually has gene activity score 1, for which no increased risk of severe, potentially fatal toxicity has been found with cutaneous use. These two situations can only be distinguished by determining the enzyme activity (phenotyping). This recommendation only applies if the patient has virtually no enzyme activity\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine, systemic\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the standard dose is a more than 100-fold overdose.\u003c/td\u003e\u003ctd\u003e1. Avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolised by DPD.\u003cbr/\u003e2. If if is not possible to avoid fluorouracil and capecitabine: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 50% of the standard dose or avoid fluorouracil and capecitabine. Adjustment of the subsequent dose should be guided by toxicity and effectiveness. However, in one study involving 17 patients with gene activity 1, the average dose after titration was 57% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1.5\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 50% of the standard dose or avoid fluorouracil and capecitabine. After starting treatment, the dose should be adjusted based on toxicity and effectiveness. In a study involving 17 patients with genotype \u003cem\u003e1/2846T\u003c/em\u003e, the average dose after titration was 64% of the standard dose. For 51 patients with genotype \u003cem\u003e1/1236A\u003c/em\u003e, the average dose after titration was 74% of the standard dose. Tegafur is not an alternative, as this is also metabolised by DPD.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eFENO\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, potentially fatal, toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eIt is not possible to recommend a dose adjustment for this patient based on the genotype only.\u003cbr/\u003eDetermine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose based on phenotype and genotype, or avoid fluorouracil and capecitabine. Tegafur is not an alternative, as this is also metabolized by DPD.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0006192.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil and capecitabine based on DPYD genotype. An alternative drug or reduction in dose is recommended for patients with DPYD activity scores of 0, 0.5, 1 and 1.5. Tegafur is not an alternative, as it is also metabolized by DPD.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0\u003c/td\u003e\u003ctd\u003efluorouracil, cutaneous\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eChoose an alternative.\u003cbr/\u003e\u003cem\u003eNOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and* 13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1, for which no increased risk of severe, potentially fatal toxicity has been found with cutaneous use. These two situations can only be distinguished by determining the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine, systemic\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the standard dose is a more than 100-fold overdose.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative. Tegafur is not an alternative, as this is also metabolised by DPD.\u003cbr/\u003e2. If an alternative is not possible: determine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every third dose skipped). The average Caucasian DPD activity is 9.9 nmol/hour per mg protein. Or, adjust the initial dose based on toxicity and efficacy.\u003cbr/\u003e\u003cem\u003eNOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and *13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0.5\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 25% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.\u003cbr/\u003e\u003cem\u003eNOTE: This recommendation only applies if the two genetic variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 50% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.\u003cbr/\u003e\u003cem\u003eNB1: The dose reduction described here is well substantiated for *1/*2A and 1236A/1236A. The dose reduction for patients with 2846T (2846T/2846T or 1236A/2846T) is based on, among other factors, the dose reductions identified for *1/2846T.\u003c/em\u003e\u003cbr/\u003e\u003cem\u003eNB2: If a patient has two different genetic variations that result in a partially functional DPD enzyme (e.g. 2846T and 1236A), this recommendation applies if the variations are on a different allele. If both variations are on the same allele, the gene activity score is between 1 and 1.5, depending on whether and how the two gene variations influence each other and on other factors that influence the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two different genetic variations can only be determined by measuring the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1.5\u003c/td\u003e\u003ctd\u003efluorouracil/capecitabine\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eStart with 75% of the standard dose or choose an alternative. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not an alternative, as this is also metabolised by DPD.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002551.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluorouracil based on DPYD genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend that an alternate drug be used for poor metabolizer patients, and a reduced dose or alternate drug for intermediate metabolizer patients.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles, 2 decreased activity alleles, or one inactive and one decreased activity alleles)\u003c/td\u003e\u003ctd\u003eSelect alterantive drug.  Tegafur is not a suitable alternative because this drug is also metabolized by DPD.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (1 active allele and 1 inactive or decreased activity allele)\u003c/td\u003e\u003ctd\u003eReduce dose by 50% or select alternative drug.  Tegafur is not a suitable alternative because this drug is also a substrate for DPD.  Increase dose in response to toxicity and efficacy.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *4, *5, *6, *9A\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9B, *10\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*2A, *3, *7, *8, *11, *12, *13, 496A\u0026gt;G, IVS10-15T\u0026gt;C, 1156G\u0026gt;T, 1845G\u0026gt;T\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182852,Guideline Annotation,Annotation of DPWG Guideline for fluoxetine and CYP2D6,f,PA449673,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for fluoxetine based on CYP2D6 genotype.</p>
","<h3 id=""august-2019-guideline"">August 2019 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for fluoxetine based on CYP2D6 genotype. There are currently no dosing recommendations for fluoxetine based on CYP2D6 genotype.
<em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>fluoxetine</td><td>The ratio of fluoxetine/norfluoxetine decreases as a result of the increased activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is no effect on adverse events or response.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
<tr><td>CYP2D6 IM</td><td>fluoxetine</td><td>The ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is no effect on adverse events or response.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
<tr><td>CYP2D6 PM</td><td>fluoxetine</td><td>The ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is insufficient evidence to support an effect on adverse events or response.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0005996.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for fluoxetine based on CYP2D6 genotype. There are currently no dosing recommendations for fluoxetine based on CYP2D6 genotype.
<em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 IM</td><td>fluoxetine</td><td>The ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is no effect on adverse events or response.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
<tr><td>CYP2D6 PM</td><td>fluoxetine</td><td>The ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is insufficient evidence to support an effect on adverse events or response.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0005996.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182852"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182852"",""name"":""Annotation of DPWG Guideline for fluoxetine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415331E9,""date"":""2019-05-28T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.450820648E9,""date"":""2019-10-03T13:58:34.213-07:00"",""description"":""Changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.4509635E9,""date"":""2020-02-11T05:45:35.594-08:00"",""description"":""Fixed links to 2019 guideline pdfs. 2018 link already went to attachment."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449673"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449673"",""name"":""fluoxetine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415329E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for fluoxetine based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.45041533E9,""html"":""\u003ch3 id\u003d\""august-2019-guideline\""\u003eAugust 2019 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for fluoxetine based on CYP2D6 genotype. There are currently no dosing recommendations for fluoxetine based on CYP2D6 genotype.\n\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003efluoxetine\u003c/td\u003e\u003ctd\u003eThe ratio of fluoxetine/norfluoxetine decreases as a result of the increased activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is no effect on adverse events or response.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003efluoxetine\u003c/td\u003e\u003ctd\u003eThe ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is no effect on adverse events or response.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003efluoxetine\u003c/td\u003e\u003ctd\u003eThe ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is insufficient evidence to support an effect on adverse events or response.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0005996.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for fluoxetine based on CYP2D6 genotype. There are currently no dosing recommendations for fluoxetine based on CYP2D6 genotype.\n\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003efluoxetine\u003c/td\u003e\u003ctd\u003eThe ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is no effect on adverse events or response.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003efluoxetine\u003c/td\u003e\u003ctd\u003eThe ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of the plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is insufficient evidence to support an effect on adverse events or response.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0005996.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104981,Guideline Annotation,Annotation of DPWG Guideline for flupenthixol and CYP2D6,f,PA10268,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for flupenthixol based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flupenthixol based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction.</p>
<p>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001532.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flupenthixol based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They did not find evidence for a gene-drug interaction and therefore provide no dosing recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>None.</td><td>None.</td><td>None.</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>None.</td><td>None.</td><td>None.</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>None.</td><td>None.</td><td>None.</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for more background information about the project.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104981"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104981"",""name"":""Annotation of DPWG Guideline for flupenthixol and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704475E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.45041497E9,""date"":""2019-05-23T10:51:36.965-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release\"""",""type"":""Update"",""version"":0.0},{""id"":1.450820649E9,""date"":""2019-10-03T14:00:17.747-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956381E9,""date"":""2020-01-31T13:31:02.905-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963501E9,""date"":""2020-02-11T05:48:56.380-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10268"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10268"",""name"":""flupenthixol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981952E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for flupenthixol based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981951E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flupenthixol based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction.\u003c/p\u003e\n\u003cp\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001532.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for flupenthixol based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They did not find evidence for a gene-drug interaction and therefore provide no dosing recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003eSee \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for more background information about the project.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182812,Guideline Annotation,Annotation of DPWG Guideline for fluphenazine and CYP2D6,f,PA449676,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for fluphenazine based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluphenazine based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction. Despite the fact that the SmPC for fluphenazine lists CYP2D6 as the metabolising enzyme, this cannot be substantiated by the available literature.</p>
<p>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002450.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182812"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182812"",""name"":""Annotation of DPWG Guideline for fluphenazine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414971E9,""date"":""2019-05-23T10:54:51.995-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820631E9,""date"":""2019-10-03T10:24:55.098-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450963502E9,""date"":""2020-02-11T05:50:46.656-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449676"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449676"",""name"":""fluphenazine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414958E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for fluphenazine based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414959E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluphenazine based on CYP2D6 genotypes (UM, IM and PM). They conclude that this is NOT a gene-drug interaction. Despite the fact that the SmPC for fluphenazine lists CYP2D6 as the metabolising enzyme, this cannot be substantiated by the available literature.\u003c/p\u003e\n\u003cp\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002450.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182845,Guideline Annotation,Annotation of DPWG Guideline for fluvastatin and SLCO1B1,f,PA449688,Dutch Pharmacogenetics Working Group,"<p>There are currently no recommendations for fluvastatin dosing based on SLCO1B1 genotypes.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for fluvastatin based on SLCO1B1 genotypes. They conclude that no action is needed for this gene-drug interaction. (See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>)</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0004060.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182845"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182845"",""name"":""Annotation of DPWG Guideline for fluvastatin and SLCO1B1"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.45041525E9,""date"":""2019-05-27T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.45082065E9,""date"":""2019-10-03T14:02:27.606-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450963503E9,""date"":""2020-02-11T05:55:06.690-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/variant/PA166154579"",""@context"":""https://api.pharmgkb.org/jsonld/variant.jsonld"",""objCls"":""Variant"",""id"":""PA166154579"",""symbol"":""rs4149056"",""name"":""rs4149056""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449688"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449688"",""name"":""fluvastatin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134865839"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134865839"",""symbol"":""SLCO1B1"",""name"":""solute carrier organic anion transporter family member 1B1""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415248E9,""html"":""\u003cp\u003eThere are currently no recommendations for fluvastatin dosing based on SLCO1B1 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415249E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for fluvastatin based on SLCO1B1 genotypes. They conclude that no action is needed for this gene-drug interaction. (See the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e)\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0004060.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166127637,Guideline Annotation,Annotation of CPIC Guideline for fluvoxamine and CYP2D6,t,PA449690,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.</li>
</ul>
</li>
</ul>
<h3 id=""august-2015"">August 2015</h3>
<p><em>Advanced online publication May 2015</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing of selective serotonin reuptake inhibitors have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpts from the 2015 selective serotonin reuptake inhibitors dosing guidelines (for fluvoxamine and CYP2D6):
<ul>
<li>&quot;Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided...It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.&quot;</li>
<li>&quot;When administered similar doses, CYP2D6 poor metabolizers have significantly greater drug exposure to fluvoxamine when compared to extensive metabolizers...The US Food and Drug Administration (FDA) states that fluvoxamine should be used cautiously in patients known to have reduced levels of CYP2D6 activity. To potentially prevent an adverse effect, an alternative SSRI not extensively metabolized by CYP2D6 should be considered for poor metabolizers.&quot;</li>
<li>&quot;The recommendations in the guideline and below apply primarily to actions based on genetic tests only; drug interactions and other clinical factors can have a major influence for prescribing decisions for SSRIs and should be taken into consideration before initiating drug therapy.&quot;</li>
<li>&quot; Data describing the relationship between CYP2D6 or CYP2C19 genotype and SSRI systemic exposure or steady state plasma concentrations in pediatric patients are scarce. Because CYP2D6 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703-supplement.pdf"" target=""_blank"">2015 Supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_2015%20CYP2D6%20SSRI%20translation%20table.xlsx"" target=""_blank"">2015 CYP2D6 SSRI translation table</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2D6%20frequency%20table%20legend%20(R3).pdf"" target=""_blank"">CYP2D6 frequency table legend (R3)</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2D6%20frequency%20table%20(R3).xlsx"" target=""_blank"">CYP2D6 frequency table (R3)</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-fluvoxamine-based-on-cyp2d6-phenotype"">Table 1: Dosing recommendations for fluvoxamine based on CYP2D6 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2b of the 2015 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Activity Score</th><th>Genotypes</th><th>Examples of CYP2D6 diplotypes</th><th>Implications for fluvoxamine metabolism</th><th>Therapeutic Recommendations</th><th>Classification of recommendations <sup>a</sup></th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer (~1-2% of patients)<sup>b</sup></td><td>&gt; 2.0</td><td>An individual carrying duplications of functional alleles</td><td>*1/*1xN, *1/*2xN, *2/*2xN <sup>c</sup></td><td>No data available for CYP2D6 Ultrarapid Metabolizers.</td><td>No recommendation due to lack of evidence. <sup>d</sup></td><td>Optional</td></tr>
<tr><td>Extensive metabolizer (~77-92% of patients)</td><td>2.0-1.0 <sup>e</sup></td><td>An individual carrying two normal function alleles or two decreased function alleles or one normal function and one no function allele or one  normal function and one decreased function allele</td><td>*1/*1, *1/*2, *1/*4, *1/*5, *1/*9, *1/*41, *2/*2,*41/*41</td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose.</td><td>Strong</td></tr>
<tr><td>Intermediate metabolizer (~2-11% of patients)</td><td>0.5</td><td>An individual carrying one decreased function and one no function allele</td><td>*4/*10,*4/*41, *5/*9</td><td>Reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.</td><td>Initiate therapy with recommended starting dose.</td><td>Moderate</td></tr>
<tr><td>Poor metabolizers (~5-10% of patients)</td><td>0</td><td>An individual carrying only no functional alleles</td><td>*3/*4,*4/*4, *5/*5, *5/*6</td><td>Greatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.</td><td>Consider a 25-50% reduction <sup>f</sup> of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6. <sup>g</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> Rating scheme described in Supplement.</p>
<p><sup>b</sup> CYP2D6 metabolizer status frequencies are based on data from Caucasians and may differ from other ethnicities. See Supplemental note for information on the chances of observing specific diplotypes in different major race/ethnic groups.</p>
<p><sup>c</sup> Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.</p>
<p><sup>d</sup> Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.</p>
<p><sup>e</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
<p><sup>f</sup> Dose extrapolations based on differences in pharmacokinetic parameters between phenotype groups suggest a 30% dose reduction of fluvoxamine (1). However, a 30% decrease in dose may not be feasible given the dosage forms, therefore, decreasing the starting dose of fluvoxamine by 25-50% should be considered.</p>
<p><sup>g</sup> Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166127637"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166127637"",""name"":""Annotation of CPIC Guideline for fluvoxamine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":""UJAuS7u-NtA"",""guidelineGenes"":[{""id"":1.449560602E9,""alleles"":[{""id"":1.449560603E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449560604E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449560605E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449560606E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449560607E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449560608E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449560609E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.44956061E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449560611E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449560612E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449560613E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449560614E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449560615E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449560616E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449560617E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449560618E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.449560619E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.44956062E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449560621E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.449560624E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449560625E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449560626E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449560627E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449560628E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449560629E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.44956063E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449560631E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449560632E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449560633E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449560634E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449560635E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449560636E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449560637E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449560638E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449560639E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.44956064E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449560641E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449560642E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449560643E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449560644E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449560645E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449560646E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449560647E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449560648E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449560649E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.44956065E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449560651E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449560652E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449560653E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449560654E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449560655E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449560656E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449560657E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449560658E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449560659E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.44956066E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449560661E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449560662E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449560663E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449560664E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449560665E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449560666E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449560667E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449560668E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449560669E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.44956067E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449560671E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449560672E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449560673E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.449560674E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449560675E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449560676E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449560677E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449560678E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449560679E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.44956068E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449560681E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449560682E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449560683E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449560684E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449560685E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449560686E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449560687E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449560688E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449560689E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.44956069E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449560691E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449560692E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449560693E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449560694E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449560695E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449560696E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449560697E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449560698E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449560699E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.4495607E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449560701E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449560702E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449560703E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449560704E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449560705E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449560706E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449560707E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449560708E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449560709E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.44956071E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449560711E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449560712E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449560713E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449560714E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449560715E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449560716E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449560717E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449560718E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449560719E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.44956072E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.450042744E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042745E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824247E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.444708096E9,""date"":""2015-05-08T00:00:00-07:00"",""description"":""initial save"",""type"":""Create"",""version"":1.0},{""id"":1.450042746E9,""date"":""2018-11-15T14:13:43.817-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar update"",""type"":""Update"",""version"":0.0},{""id"":1.450043039E9,""date"":""2018-11-20T00:00:00-08:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":1.0},{""id"":1.450824547E9,""date"":""2019-10-24T20:19:16.966-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15089021"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5089021E7,""resourceId"":""25974703"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4512908"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285932E9,""resource"":""PubMed Central"",""resourceId"":""PMC4512908"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/25974703"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285931E9,""resource"":""PubMed"",""resourceId"":""25974703"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/25974703""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.147"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285933E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.147"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.147""}]},{""@id"":""https://pharmgkb.org/literature/15100911"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100911E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Selective Serotonin Reuptake Inhibitors and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983477E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449690"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449690"",""name"":""fluvoxamine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982315E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for the selective serotonin reuptake inhibitor fluvoxamine recommends to consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6 for CYP2D6 poor metabolizers.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982314E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""august-2015\""\u003eAugust 2015\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvanced online publication May 2015\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing of selective serotonin reuptake inhibitors have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2015 selective serotonin reuptake inhibitors dosing guidelines (for fluvoxamine and CYP2D6):\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided...It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;When administered similar doses, CYP2D6 poor metabolizers have significantly greater drug exposure to fluvoxamine when compared to extensive metabolizers...The US Food and Drug Administration (FDA) states that fluvoxamine should be used cautiously in patients known to have reduced levels of CYP2D6 activity. To potentially prevent an adverse effect, an alternative SSRI not extensively metabolized by CYP2D6 should be considered for poor metabolizers.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;The recommendations in the guideline and below apply primarily to actions based on genetic tests only; drug interactions and other clinical factors can have a major influence for prescribing decisions for SSRIs and should be taken into consideration before initiating drug therapy.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot; Data describing the relationship between CYP2D6 or CYP2C19 genotype and SSRI systemic exposure or steady state plasma concentrations in pediatric patients are scarce. Because CYP2D6 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703-supplement.pdf\"" target\u003d\""_blank\""\u003e2015 Supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_2015%20CYP2D6%20SSRI%20translation%20table.xlsx\"" target\u003d\""_blank\""\u003e2015 CYP2D6 SSRI translation table\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2D6%20frequency%20table%20legend%20(R3).pdf\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table legend (R3)\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2D6%20frequency%20table%20(R3).xlsx\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table (R3)\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-fluvoxamine-based-on-cyp2d6-phenotype\""\u003eTable 1: Dosing recommendations for fluvoxamine based on CYP2D6 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2b of the 2015 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eActivity Score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of CYP2D6 diplotypes\u003c/th\u003e\u003cth\u003eImplications for fluvoxamine metabolism\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer (~1-2% of patients)\u003csup\u003eb\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e\u0026gt; 2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying duplications of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN, *2/*2xN \u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eNo data available for CYP2D6 Ultrarapid Metabolizers.\u003c/td\u003e\u003ctd\u003eNo recommendation due to lack of evidence. \u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eExtensive metabolizer (~77-92% of patients)\u003c/td\u003e\u003ctd\u003e2.0-1.0 \u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or two decreased function alleles or one normal function and one no function allele or one  normal function and one decreased function allele\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *1/*4, *1/*5, *1/*9, *1/*41, *2/*2,*41/*41\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer (~2-11% of patients)\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased function and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*10,*4/*41, *5/*9\u003c/td\u003e\u003ctd\u003eReduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizers (~5-10% of patients)\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no functional alleles\u003c/td\u003e\u003ctd\u003e*3/*4,*4/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider a 25-50% reduction \u003csup\u003ef\u003c/sup\u003e of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6. \u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Rating scheme described in Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e CYP2D6 metabolizer status frequencies are based on data from Caucasians and may differ from other ethnicities. See Supplemental note for information on the chances of observing specific diplotypes in different major race/ethnic groups.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e Data are lacking describing the effect of CYP2D6 ultrarapid metabolism on fluvoxamine therapy; therefore no dosing recommendations are provided for fluvoxamine use for of CYP2D6 ultrarapid metabolizers. It may be reasonable, though, to select an alternative SSRI not extensively metabolized by CYP2D6 due to the lack of data describing how CYP2D6 ultrarapid metabolizer status influences fluvoxamine therapy.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Dose extrapolations based on differences in pharmacokinetic parameters between phenotype groups suggest a 30% dose reduction of fluvoxamine (1). However, a 30% decrease in dose may not be feasible given the dosage forms, therefore, decreasing the starting dose of fluvoxamine by 25-50% should be considered.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983477E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166182813,Guideline Annotation,Annotation of DPWG Guideline for fluvoxamine and CYP2D6,f,PA449690,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for fluvoxamine based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluvoxamine based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction. The difference in plasma concentrations for varying CYP2D6 metabolizers (PM, IM, UM) has not been shown to demonstrate differences in side effects. See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0005994.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182813"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182813"",""name"":""Annotation of DPWG Guideline for fluvoxamine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414977E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820652E9,""date"":""2019-10-03T14:19:39.287-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450963504E9,""date"":""2020-02-11T05:56:51.642-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449690"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449690"",""name"":""fluvoxamine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414974E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for fluvoxamine based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414975E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluvoxamine based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction. The difference in plasma concentrations for varying CYP2D6 metabolizers (PM, IM, UM) has not been shown to demonstrate differences in side effects. See the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0005994.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182814,Guideline Annotation,Annotation of DPWG Guideline for fluvoxamine and CYP2C19,f,PA449690,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for fluvoxamine based on CYP2C19 genotypes.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluvoxamine based on CYP2C19 genotypes. They conclude that there is not a gene-drug interaction (see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0003510.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182814"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182814"",""name"":""Annotation of DPWG Guideline for fluvoxamine and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414989E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.450820662E9,""date"":""2019-10-03T14:31:47.823-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450963505E9,""date"":""2020-02-11T05:59:24.702-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449690"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449690"",""name"":""fluvoxamine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414987E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for fluvoxamine based on CYP2C19 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414988E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for fluvoxamine based on CYP2C19 genotypes. They conclude that there is not a gene-drug interaction (see the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0003510.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182809,Guideline Annotation,Annotation of DPWG Guideline for gefitinib and CYP2D6,f,PA131301952,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for gefitinib based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for gefitinib based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>ALLELE/GENOTYPE/PHENOTYPE</th><th>DRUG</th><th>DESCRIPTION</th><th>RECOMMENDATION</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 PM</td><td>gefitinib</td><td>The gefitinib plasma concentration may increase due to reduced CYP2D6 activity. However, there is no evidence to suggest that side effects increase to an extent that adjustment of therapy is needed.</td><td>NO action is needed</td></tr>
<tr><td>CYP2D6 IM</td><td>gefitinib</td><td>Side effects can occur more frequently, as the gene variation increases the gefitinib plasma concentration. However, the side effects are reversible and manageable, to an extent that adjustment of the therapy in advance is not necessary.</td><td>NO action is needed</td></tr>
<tr><td>CYP2D6 UM</td><td>gefitinib</td><td>The gene variation may lead to a decrease in the gefitinib plasma concentration. In practice, an alternative is only chosen if non-response to gefitinib has been proved. Moreover, dose adjustments guided by the gefitinib plasma concentration are rarely performed in clinical practice as the analytical method is not available in most hospitals.</td><td>NO action is needed</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0004872.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182809"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182809"",""name"":""Annotation of DPWG Guideline for gefitinib and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414931E9,""date"":""2019-05-23T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820663E9,""date"":""2019-10-03T14:33:59.263-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.45096352E9,""date"":""2020-02-11T06:00:27.787-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA131301952"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA131301952"",""name"":""gefitinib""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414927E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for gefitinib based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414928E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for gefitinib based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eALLELE/GENOTYPE/PHENOTYPE\u003c/th\u003e\u003cth\u003eDRUG\u003c/th\u003e\u003cth\u003eDESCRIPTION\u003c/th\u003e\u003cth\u003eRECOMMENDATION\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003egefitinib\u003c/td\u003e\u003ctd\u003eThe gefitinib plasma concentration may increase due to reduced CYP2D6 activity. However, there is no evidence to suggest that side effects increase to an extent that adjustment of therapy is needed.\u003c/td\u003e\u003ctd\u003eNO action is needed\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003egefitinib\u003c/td\u003e\u003ctd\u003eSide effects can occur more frequently, as the gene variation increases the gefitinib plasma concentration. However, the side effects are reversible and manageable, to an extent that adjustment of the therapy in advance is not necessary.\u003c/td\u003e\u003ctd\u003eNO action is needed\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003egefitinib\u003c/td\u003e\u003ctd\u003eThe gene variation may lead to a decrease in the gefitinib plasma concentration. In practice, an alternative is only chosen if non-response to gefitinib has been proved. Moreover, dose adjustments guided by the gefitinib plasma concentration are rarely performed in clinical practice as the analytical method is not available in most hospitals.\u003c/td\u003e\u003ctd\u003eNO action is needed\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0004872.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104953,Guideline Annotation,Annotation of DPWG Guideline for glibenclamide and CYP2C9,f,PA449782,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for glibenclamide based on CYP2C9 genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for glibenclamide based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction (see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001882.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for glibenclamide based on CYP2C9 genotype [Article:<a href=""/pmid/21412232"">21412232</a>]. They conclude that there are no recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>CYP2C9 *1/*2</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *2/*2</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *1/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>CYP2C9 *2/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *3/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt; 4.5 Kinetic effect (S)</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104953"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104953"",""name"":""Annotation of DPWG Guideline for glibenclamide and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704477E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415072E9,""date"":""2019-05-23T16:34:52.537-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820664E9,""date"":""2019-10-03T15:01:11.599-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956367E9,""date"":""2020-01-31T13:33:36.050-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096354E9,""date"":""2020-02-11T06:01:51.641-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449782"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449782"",""name"":""glibenclamide""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981888E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for glibenclamide based on CYP2C9 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981887E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for glibenclamide based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction (see the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001882.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for glibenclamide based on CYP2C9 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e]. They conclude that there are no recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*2\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*2\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026gt; 3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia  \u0026gt; 75x10\u003csup\u003e9\u003c/sup\u003e/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *3/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms females, \u0026lt;470 ms males); INR increase \u0026lt; 4.5 Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104945,Guideline Annotation,"Annotation of CPIC Guideline for mercaptopurine and NUDT15,TPMT",t,PA450379,Clinical Pharmacogenetics Implementation Consortium,"<p>Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"" target=""_blank"">CPIC&reg; guideline for thiopurines and TPMT and NUDT15</a>.</p>
<h3 id=""october-2018-update"">October 2018 Update</h3>
<p><em>Advance online publication November 2018.</em></p>
<ul>
<li>The <a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1304?af=R"" target=""_blank"">2018 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine</a>, have been published in Clinical Pharmacology and Therapeutics.  Literature published between October 2012 to June 2017 was reviewed, recommendations and supplemental information was updated.</li>
<li>These guidelines are applicable to:
<ul>
<li>pediatric patients</li>
<li>adult patients</li>
</ul>
</li>
<li>Excerpt from the 2018 thiopurine dosing guideline update:
<ul>
<li>&quot;TPMT activity exhibits a monogenic co-dominant inheritance and catabolizes
thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines.&quot;</li>
<li>&quot;Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduces the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Submitted.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on <em>TPMT</em> and <em>NUDT15</em> genotypes: 2018 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Supplemental_Material.pdf"" target=""_blank"">2018 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/tpmtRefMaterials"">TPMT Gene-Specific Information Tables</a></li>
<li><a href=""https://www.pharmgkb.org/page/nudt15RefMaterials"">NUDT15 Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/Mercaptopurine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Mercaptopurine Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/Thiopurines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Thiopurines Pre and Post Test Alerts and Flow Chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-mercaptopurine-by-tpmt-phenotype"">Table 1: Recommended dosing of mercaptopurine by TPMT phenotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2018 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>TPMT phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations</th></tr>
</thead>
<tbody>
<tr><td>Normal Metabolizer</td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Lower concentrations of TGN metabolites, higher meTIMP, this is the &quot;normal&quot; pattern.  Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with normal starting dose<sup>a</sup> (e.g., 75 mg/m<sup>2</sup>/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents.  Allow at least 2 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Intermediate Metabolizer</td><td>An individual carrying one normal function allele and one no function allele</td><td>*1/*2, *1/*3A, *1/*3B, *1/*3C, *1/*4</td><td>Moderate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 75 mg/m<sup>2</sup>/day or &gt; or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m<sup>2</sup>/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already &lt; 75 mg/m<sup>2</sup>/day or &lt; 1.5 mg/kg/day, dose reduction may not be recommended.</td><td>Strong</td></tr>
<tr><td>Possible Intermediate Metabolizer</td><td>An individual carrying one uncertain/unknown function allele and one no function allele</td><td>*2/*8, *3A/*7</td><td>Moderate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 75 mg/m<sup>2</sup>/day or &gt; or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m<sup>2</sup>/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already &lt; 75 mg/m<sup>2</sup>/day or &lt; 1.5 mg/kg/day, dose reduction may not be recommended.</td><td>Strong</td></tr>
<tr><td>Poor Metabolizer</td><td>An individual carrying two no function alleles</td><td>*3A/*3A, *2/*3A, *3A/*3C, *3C/*4, *2/*3C, *3A/*4</td><td>Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no meTIMP metabolites</td><td>For malignancy, start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m<sup>2</sup>/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>Strong</td></tr>
<tr><td>Indeterminate</td><td>An individual carrying two uncertain/unknown function alleles OR one normal function allele and one uncertain/unknown function allele</td><td>*6/*8, *1/*8</td><td>None</td><td>None</td><td>None</td></tr>
</tbody>
</table>
<p><sup>a</sup>Normal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</p>
<h3 id=""table-2-recommended-dosing-of-mercaptopurine-by-nudt15-phenotype"">Table 2: Recommended dosing of mercaptopurine by NUDT15 phenotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2018 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>NUDT15 phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations</th></tr>
</thead>
<tbody>
<tr><td>Normal Metabolizer</td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression</td><td>Start with normal starting dose<sup>a</sup> (e.g., 75 mg/m<sup>2</sup>/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents.  Allow at least 2 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Intermediate Metabolizer</td><td>An individual carrying one normal function allele and one no function allele</td><td>*1/*2, *1/*3</td><td>Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 75 mg/m<sup>2</sup>/day or &gt; or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m<sup>2</sup>/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already &lt; 75 mg/m<sup>2</sup>/day or 1.5 mg/kg/day, dose reduction may not be recommended.</td><td>Strong</td></tr>
<tr><td>Possible Intermediate Metabolizer</td><td>An individual carrying one uncertain function allele and one no function allele</td><td>*2/*5, *3/*6</td><td>Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 75 mg/m<sup>2</sup>/day or &gt; or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m<sup>2</sup>/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already &lt; 75 mg/m<sup>2</sup>/day or 1.5 mg/kg/day, dose reduction may not be recommended.</td><td>Strong</td></tr>
<tr><td>Poor Metabolizer</td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression</td><td>For malignancy, initiate dose at 10 mg/m<sup>2</sup>/day and adjust dose based on myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>Strong</td></tr>
<tr><td>Indeterminate</td><td>An individual carrying two uncertain function alleles OR one normal function allele and one uncertain function allele</td><td>*1/*4, *1/*5, *4/*5, *5/*6</td><td>None</td><td>None</td><td>None</td></tr>
</tbody>
</table>
<p><sup>a</sup>Normal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</p>
<h3 id=""table-3-recommended-dosing-of-mercaptopurine-by-tpmt-and-nudt15-phenotypes"">Table 3: Recommended dosing of mercaptopurine by TPMT and NUDT15 phenotypes</h3>
<p><em>Adapted from Figure 2 and Table 2 of the 2018 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype</th><th>TPMT Normal Metabolizer</th><th>TPMT Intermediate Metabolizer</th><th>TPMT Possible Intermediate Metabolizer</th><th>TPMT Poor Metabolizer</th><th>Indeterminate</th></tr>
</thead>
<tbody>
<tr><td>NUDT 15 Normal Metabolizer</td><td>Use standard dose</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 75 mg/m<sup>2</sup>/day or &gt; or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m<sup>2</sup>/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already &lt; 75 mg/m<sup>2</sup>/day or &lt; 1.5 mg/kg/day, dose reduction may not be recommended.</td><td>See TPMT Intermediate Metabolizer.</td><td>For malignancy, start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m<sup>2</sup>/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>None</td></tr>
<tr><td>NUDT15 Intermediate Metabolizer</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 75 mg/m<sup>2</sup>/day or &gt; or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m<sup>2</sup>/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already &lt; 75 mg/m<sup>2</sup>/day or 1.5 mg/kg/day, dose reduction may not be recommended.</td><td>Start with reduced starting doses (30-80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 75 mg/m<sup>2</sup>/day or &gt; or = 1.5 mg/kg/day (e.g. start at 25-60 mg/m<sup>2</sup>/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already &lt; 75 mg/m<sup>2</sup>/day or &lt; 1.5 mg/kg/day, dose reduction may not be recommended.</td><td>See TPMT Intermediate Metabolizer.</td><td>For malignancy, start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m<sup>2</sup>/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>None</td></tr>
<tr><td>NUDT15 Possible Intermediate Metabolizer</td><td>See NUDT15 Intermediate Metabolizer.</td><td>See NUDT15 Intermediate Metabolizer.</td><td>See TPMT Intermediate Metabolizer/NUDT15 Intermediate Metabolizer.</td><td>See NUDT15 Intermediate Metabolizer.</td><td>None</td></tr>
<tr><td>NUDT15 Poor  Metabolizer</td><td>For malignancy, initiate dose at 10 mg/m<sup>2</sup>/day and adjust dose based on myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>For malignancy, initiate dose at 10 mg/m<sup>2</sup>/day and adjust dose based on myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>See TPMT Intermediate Metabolizer.</td><td>For malignancy, start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m<sup>2</sup>/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>None</td></tr>
<tr><td>NUDT15 Indeterminate</td><td>None</td><td>None</td><td>None</td><td>None</td><td>None</td></tr>
</tbody>
</table>
<p><sup>a</sup>Normal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</p>
<h3 id=""may-2016-update-on-pharmgkb"">May 2016 Update on PharmGKB</h3>
<p>Several studies have reported that individuals who carry low-function alleles for NUDT15 are unable to tolerate usual doses of thiopurines. [Articles:<a href=""/pmid/25108385"">25108385</a>, <a href=""/pmid/25624441"">25624441</a>, <a href=""/pmid/26033531"">26033531</a>, <a href=""/pmid/26076924"">26076924</a>, <a href=""/pmid/26405151"">26405151</a>, <a href=""/pmid/26503813"">26503813</a>, <a href=""/pmid/26590936"">26590936</a>, <a href=""/pmid/26735160"">26735160</a>, <a href=""/pmid/26878724"">26878724</a>] These alleles are more common among those of Asian ancestry and Hispanic ethnicity than others. [Articles:<a href=""/pmid/25624441"">25624441</a>, <a href=""/pmid/26878724"">26878724</a>] The dose tolerated by those with two low-function alleles is only ~ 10% that tolerated by those with no low-function NUDT15 or TPMT alleles. [Articles:<a href=""/pmid/25624441"">25624441</a>, <a href=""/pmid/26878724"">26878724</a>] CPIC is planning a guideline to address NUDT15 variants and possible dosing recommendations for thiopurines.</p>
<h3 id=""april-2013-update"">April 2013 Update</h3>
<p><em>Advance online publication January 2013</em></p>
<ul>
<li>The <a rel=""noopener noreferrer"" href=""http://www.nature.com/clpt/journal/vaop/naam/index.html#17012013"" target=""_blank"">2013 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine</a>, have been published in Clinical Pharmacology and Therapeutics.  Literature published between June 2010-November 2012 was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current.</strong></li>
<li>These guidelines are applicable to:
<ul>
<li>pediatric patients</li>
<li>adult patients</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a href=""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_TPMT_update.pdf"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update</a></li>
<li><a href=""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_TPMT_update_supp.pdf"">2013 supplement</a></li>
</ul>
</li>
</ul>
<h3 id=""march-2011"">March 2011</h3>
<p><em>Advance online publication January 2011.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for azathioprine, thioguanine and mercaptopurine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpt from the 2011 thiopurine dosing guidelines:
<ul>
<li>&quot;Thiopurines are most commonly used to treat nonmalignant conditions but are also critical anticancer agents. The approach to dosing adjustments based on TPMT status may differ depending on the clinical indication and the propensity to initiate therapy at higher vs. lower starting doses. We and others advocate testing for TPMT status prior to initiating thiopurine therapy, so that starting dosages can be adjusted accordingly.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a href=""https://api.pharmgkb.org/v1/download/file/attachment/cpic-tpmt-article.pdf"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing</a></li>
<li><a href=""https://api.pharmgkb.org/v1/download/file/attachment/cpic-tpmt-supplement.pdf"">2011 supplement</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104945"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104945"",""name"":""Annotation of CPIC Guideline for mercaptopurine and NUDT15,TPMT"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.183699774E9,""date"":""2011-01-26T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.183699775E9,""date"":""2013-01-17T00:00:00-08:00"",""type"":""Update"",""version"":0.0},{""id"":1.447986819E9,""date"":""2016-05-10T21:44:54.940-07:00"",""description"":""Update guideline with information regarding the NUDT15 gene."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15101542"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5101542E7,""resourceId"":""30447069"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/30447069"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/30447069"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450043138E9,""resource"":""PubMed"",""resourceId"":""30447069"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/30447069""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1304"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450043139E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1304"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1304""}]},{""@id"":""https://pharmgkb.org/literature/15051187"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051187E7,""resourceId"":""23422873"",""title"":""Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604643"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3604643"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275272E9,""resource"":""PubMed Central"",""resourceId"":""PMC3604643"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604643""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23422873"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275271E9,""resource"":""PubMed"",""resourceId"":""23422873"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23422873""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.4"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275273E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.4"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.4""}]},{""@id"":""https://pharmgkb.org/literature/6690400"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":6690400.0,""resourceId"":""21270794"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3098761"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449245874E9,""resource"":""PubMed Central"",""resourceId"":""PMC3098761"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/21270794"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69164748E8,""resource"":""PubMed"",""resourceId"":""21270794"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21270794""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2010.320"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449245875E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2010.320"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2010.320""}]},{""@id"":""https://pharmgkb.org/literature/15100906"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100906E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""title"":""CPIC® Guideline for Thiopurines and TPMT – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983453E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450379"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450379"",""name"":""mercaptopurine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134963132"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134963132"",""symbol"":""NUDT15"",""name"":""nudix hydrolase 15""},{""@id"":""https://pharmgkb.org/gene/PA356"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA356"",""symbol"":""TPMT"",""name"":""thiopurine S-methyltransferase""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.45004416E9,""html"":""\u003cp\u003eConsider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.450044401E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for thiopurines and TPMT and NUDT15\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2018-update\""\u003eOctober 2018 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication November 2018.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1304?af\u003dR\"" target\u003d\""_blank\""\u003e2018 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine\u003c/a\u003e, have been published in Clinical Pharmacology and Therapeutics.  Literature published between October 2012 to June 2017 was reviewed, recommendations and supplemental information was updated.\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2018 thiopurine dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;TPMT activity exhibits a monogenic co-dominant inheritance and catabolizes\nthiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduces the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Submitted.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on \u003cem\u003eTPMT\u003c/em\u003e and \u003cem\u003eNUDT15\u003c/em\u003e genotypes: 2018 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Supplemental_Material.pdf\"" target\u003d\""_blank\""\u003e2018 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/tpmtRefMaterials\""\u003eTPMT Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/nudt15RefMaterials\""\u003eNUDT15 Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/Mercaptopurine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eMercaptopurine Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/Thiopurines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eThiopurines Pre and Post Test Alerts and Flow Chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-mercaptopurine-by-tpmt-phenotype\""\u003eTable 1: Recommended dosing of mercaptopurine by TPMT phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2018 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eTPMT phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNormal Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eLower concentrations of TGN metabolites, higher meTIMP, this is the \u0026quot;normal\u0026quot; pattern.  Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with normal starting dose\u003csup\u003ea\u003c/sup\u003e (e.g., 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents.  Allow at least 2 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3A, *1/*3B, *1/*3C, *1/*4\u003c/td\u003e\u003ctd\u003eModerate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026gt; or \u003d 1.5 mg/kg/day (e.g. start at 25-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already \u0026lt; 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026lt; 1.5 mg/kg/day, dose reduction may not be recommended.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePossible Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one uncertain/unknown function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*2/*8, *3A/*7\u003c/td\u003e\u003ctd\u003eModerate to high concentrations of TGN metabolites; low concentrations of meTIMP. Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026gt; or \u003d 1.5 mg/kg/day (e.g. start at 25-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already \u0026lt; 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026lt; 1.5 mg/kg/day, dose reduction may not be recommended.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*3A/*3A, *2/*3A, *3A/*3C, *3C/*4, *2/*3C, *3A/*4\u003c/td\u003e\u003ctd\u003eExtremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease; no meTIMP metabolites\u003c/td\u003e\u003ctd\u003eFor malignancy, start with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m\u003csup\u003e2\u003c/sup\u003e/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003eAn individual carrying two uncertain/unknown function alleles OR one normal function allele and one uncertain/unknown function allele\u003c/td\u003e\u003ctd\u003e*6/*8, *1/*8\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eNormal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""table-2-recommended-dosing-of-mercaptopurine-by-nudt15-phenotype\""\u003eTable 2: Recommended dosing of mercaptopurine by NUDT15 phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2018 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eNUDT15 phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNormal Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal risk of thiopurine-related leukopenia, neutropenia, myelosuppression\u003c/td\u003e\u003ctd\u003eStart with normal starting dose\u003csup\u003ea\u003c/sup\u003e (e.g., 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents.  Allow at least 2 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3\u003c/td\u003e\u003ctd\u003eIncreased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026gt; or \u003d 1.5 mg/kg/day (e.g. start at 25-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already \u0026lt; 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 1.5 mg/kg/day, dose reduction may not be recommended.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePossible Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one uncertain function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*2/*5, *3/*6\u003c/td\u003e\u003ctd\u003eIncreased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026gt; or \u003d 1.5 mg/kg/day (e.g. start at 25-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already \u0026lt; 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 1.5 mg/kg/day, dose reduction may not be recommended.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression\u003c/td\u003e\u003ctd\u003eFor malignancy, initiate dose at 10 mg/m\u003csup\u003e2\u003c/sup\u003e/day and adjust dose based on myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003eAn individual carrying two uncertain function alleles OR one normal function allele and one uncertain function allele\u003c/td\u003e\u003ctd\u003e*1/*4, *1/*5, *4/*5, *5/*6\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eNormal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""table-3-recommended-dosing-of-mercaptopurine-by-tpmt-and-nudt15-phenotypes\""\u003eTable 3: Recommended dosing of mercaptopurine by TPMT and NUDT15 phenotypes\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Figure 2 and Table 2 of the 2018 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003c/th\u003e\u003cth\u003eTPMT Normal Metabolizer\u003c/th\u003e\u003cth\u003eTPMT Intermediate Metabolizer\u003c/th\u003e\u003cth\u003eTPMT Possible Intermediate Metabolizer\u003c/th\u003e\u003cth\u003eTPMT Poor Metabolizer\u003c/th\u003e\u003cth\u003eIndeterminate\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT 15 Normal Metabolizer\u003c/td\u003e\u003ctd\u003eUse standard dose\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026gt; or \u003d 1.5 mg/kg/day (e.g. start at 25-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already \u0026lt; 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026lt; 1.5 mg/kg/day, dose reduction may not be recommended.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eFor malignancy, start with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m\u003csup\u003e2\u003c/sup\u003e/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026gt; or \u003d 1.5 mg/kg/day (e.g. start at 25-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents. If normal starting dose is already \u0026lt; 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 1.5 mg/kg/day, dose reduction may not be recommended.\u003c/td\u003e\u003ctd\u003eStart with reduced starting doses (30-80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026gt; or \u003d 1.5 mg/kg/day (e.g. start at 25-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents.  If normal starting dose is already \u0026lt; 75 mg/m\u003csup\u003e2\u003c/sup\u003e/day or \u0026lt; 1.5 mg/kg/day, dose reduction may not be recommended.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eFor malignancy, start with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m\u003csup\u003e2\u003c/sup\u003e/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Possible Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eSee NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eSee NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer/NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eSee NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Poor  Metabolizer\u003c/td\u003e\u003ctd\u003eFor malignancy, initiate dose at 10 mg/m\u003csup\u003e2\u003c/sup\u003e/day and adjust dose based on myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eFor malignancy, initiate dose at 10 mg/m\u003csup\u003e2\u003c/sup\u003e/day and adjust dose based on myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eFor malignancy, start with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and reduce frequency to thrice weekly instead of daily, e.g. 10 mg/m\u003csup\u003e2\u003c/sup\u003e/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Indeterminate\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eNormal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2016-update-on-pharmgkb\""\u003eMay 2016 Update on PharmGKB\u003c/h3\u003e\n\u003cp\u003eSeveral studies have reported that individuals who carry low-function alleles for NUDT15 are unable to tolerate usual doses of thiopurines. [Articles:\u003ca href\u003d\""/pmid/25108385\""\u003e25108385\u003c/a\u003e, \u003ca href\u003d\""/pmid/25624441\""\u003e25624441\u003c/a\u003e, \u003ca href\u003d\""/pmid/26033531\""\u003e26033531\u003c/a\u003e, \u003ca href\u003d\""/pmid/26076924\""\u003e26076924\u003c/a\u003e, \u003ca href\u003d\""/pmid/26405151\""\u003e26405151\u003c/a\u003e, \u003ca href\u003d\""/pmid/26503813\""\u003e26503813\u003c/a\u003e, \u003ca href\u003d\""/pmid/26590936\""\u003e26590936\u003c/a\u003e, \u003ca href\u003d\""/pmid/26735160\""\u003e26735160\u003c/a\u003e, \u003ca href\u003d\""/pmid/26878724\""\u003e26878724\u003c/a\u003e] These alleles are more common among those of Asian ancestry and Hispanic ethnicity than others. [Articles:\u003ca href\u003d\""/pmid/25624441\""\u003e25624441\u003c/a\u003e, \u003ca href\u003d\""/pmid/26878724\""\u003e26878724\u003c/a\u003e] The dose tolerated by those with two low-function alleles is only ~ 10% that tolerated by those with no low-function NUDT15 or TPMT alleles. [Articles:\u003ca href\u003d\""/pmid/25624441\""\u003e25624441\u003c/a\u003e, \u003ca href\u003d\""/pmid/26878724\""\u003e26878724\u003c/a\u003e] CPIC is planning a guideline to address NUDT15 variants and possible dosing recommendations for thiopurines.\u003c/p\u003e\n\u003ch3 id\u003d\""april-2013-update\""\u003eApril 2013 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication January 2013\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.nature.com/clpt/journal/vaop/naam/index.html#17012013\"" target\u003d\""_blank\""\u003e2013 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine\u003c/a\u003e, have been published in Clinical Pharmacology and Therapeutics.  Literature published between June 2010-November 2012 was reviewed and there is \u003cstrong\u003eno new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current.\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_TPMT_update.pdf\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_TPMT_update_supp.pdf\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""march-2011\""\u003eMarch 2011\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication January 2011.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for azathioprine, thioguanine and mercaptopurine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2011 thiopurine dosing guidelines:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Thiopurines are most commonly used to treat nonmalignant conditions but are also critical anticancer agents. The approach to dosing adjustments based on TPMT status may differ depending on the clinical indication and the propensity to initiate therapy at higher vs. lower starting doses. We and others advocate testing for TPMT status prior to initiating thiopurine therapy, so that starting dosages can be adjusted accordingly.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/cpic-tpmt-article.pdf\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/cpic-tpmt-supplement.pdf\""\u003e2011 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983453E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/""}]},""status"":""success""}"
PA166104971,Guideline Annotation,Annotation of DPWG Guideline for gliclazide and CYP2C9,f,PA10892,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for gliclazide based on CYP2C9 genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for gliclazide based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction (see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001889.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>CYP2C9 *1/*2</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *2/*2</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *1/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *2/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *3/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
<li>NS: non-significant</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104971"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104971"",""name"":""Annotation of DPWG Guideline for gliclazide and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704479E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415073E9,""date"":""2019-05-23T16:39:32.661-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820665E9,""date"":""2019-10-03T15:08:23.734-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956348E9,""date"":""2020-01-31T13:34:00.035-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963521E9,""date"":""2020-02-11T06:03:20.440-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10892"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10892"",""name"":""gliclazide""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981998E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for gliclazide based on CYP2C9 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981997E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for gliclazide based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction (see the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001889.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*2\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*2\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *3/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003eNS: non-significant\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104978,Guideline Annotation,Annotation of DPWG Guideline for glimepiride and CYP2C9,t,PA449761,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for glimepiride based on CYP2C9 genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for glimepiride based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction (see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001896.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for glimepiride based on CYP2C9 genotype [Article:<a href=""/pmid/21412232"">21412232</a>]. They conclude that there are no recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>CYP2C9 *1/*2</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *2/*2</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *1/*3</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *2/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10<sup>9</sup>/l; leucopenia 1.0-2.0x10<sup>9</sup>/l; thrombocytopenia 25-50x10<sup>9</sup>/l; severe diarrhea</td></tr>
<tr><td>CYP2C9 *3/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10<sup>9</sup>/l; leucopenia 1.0-2.0x10<sup>9</sup>/l; thrombocytopenia 25-50x10<sup>9</sup>/l; severe diarrhea</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104978"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104978"",""name"":""Annotation of DPWG Guideline for glimepiride and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704481E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415076E9,""date"":""2019-05-23T16:42:45.852-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820666E9,""date"":""2019-10-03T15:09:43.544-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956382E9,""date"":""2020-01-31T13:34:30.960-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963522E9,""date"":""2020-02-11T06:04:40.372-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449761"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449761"",""name"":""glimepiride""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981936E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for glimepiride based on CYP2C9 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981935E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for glimepiride based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction (see the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001896.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for glimepiride based on CYP2C9 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e]. They conclude that there are no recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*2\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*2\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10\u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *3/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10\u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104988,Guideline Annotation,Annotation of DPWG Guideline for haloperidol and CYP2D6,t,PA449841,Dutch Pharmacogenetics Working Group,"<p>Reduce haloperidol dose by 50% or select an alternative drug for CYP2D6 poor metabolizer (PM) genotype patients.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for haloperidol based on CYP2D6 genotype.  They recommend reducing haloperidol dose by 50% or select an alternative drug for CYP2D6 poor metabolizer (PM).</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 IM</td><td>haloperidol</td><td></td><td>NO action is required for this gene-drug interaction.</td></tr>
<tr><td>CYP2D6 PM</td><td>haloperidol</td><td>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause increased plasma concentrations of haloperidol and the active metabolite.</td><td>1. Advise the prescriber to: 1. decrease the initial dose to 50% of the standard initial dose and adjust the dose according to the effect, 2. or prescribe an alternative. Anti-psychotics that are not metabolised via CYP2D6 - or to a much lesser extent - include, for example, flupentixol, fluphenazine, quetiapine, olanzapine or clozapine.</td></tr>
<tr><td>CYP2D6 UM</td><td>haloperidol</td><td>The genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause decreased plasma concentrations of haloperidol and the active metabolite reduced haloperidol.</td><td>It is not possible to offer substantiated advice for dose adjustment due to the limited amount of available literature. 1. Advise the prescriber to: 1. be alert to possible reduced plasma concentrations of haloperidol and reduced haloperidol and increase the dose based on results of therapeutic drug monitoring, 2. or prescribe an alternative according to the current guidelines. Anti-psychotics that are not metabolised via CYP2D6 - or to a much lesser extent - include, for example, flupentixol, fluphenazine, quetiapine, olanzapine or clozapine.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001552.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for haloperidol based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend dose reduction for poor metabolizer patients.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>Reduce dose by 50% or select alternative drug (e.g., pimozide, flupenthixol, fluphenazine, quetiapine, olanzapine, clozapine).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>None.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms women, &lt;470 ms men); INR increase &lt; 4.5 Kinetic effect (S).</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>Insufficient data to allow calculation of dose adjustent.  Be alert to decreased haloperidol plasma concentration and adjust maintenance dose in response to haloperidol plasma concentration or select alternative drug (e.g., pimozide, flupenthixol, fluphenazine, quetiapine, olanzapine, clozapine).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104988"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104988"",""name"":""Annotation of DPWG Guideline for haloperidol and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704483E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415226E9,""date"":""2019-05-27T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820667E9,""date"":""2019-10-03T15:12:05.853-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956383E9,""date"":""2020-01-31T13:35:04.866-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963523E9,""date"":""2020-02-11T06:05:48.586-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449841"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449841"",""name"":""haloperidol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981994E9,""html"":""\u003cp\u003eReduce haloperidol dose by 50% or select an alternative drug for CYP2D6 poor metabolizer (PM) genotype patients.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981993E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for haloperidol based on CYP2D6 genotype.  They recommend reducing haloperidol dose by 50% or select an alternative drug for CYP2D6 poor metabolizer (PM).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003ehaloperidol\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003ehaloperidol\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause increased plasma concentrations of haloperidol and the active metabolite.\u003c/td\u003e\u003ctd\u003e1. Advise the prescriber to: 1. decrease the initial dose to 50% of the standard initial dose and adjust the dose according to the effect, 2. or prescribe an alternative. Anti-psychotics that are not metabolised via CYP2D6 - or to a much lesser extent - include, for example, flupentixol, fluphenazine, quetiapine, olanzapine or clozapine.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003ehaloperidol\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause decreased plasma concentrations of haloperidol and the active metabolite reduced haloperidol.\u003c/td\u003e\u003ctd\u003eIt is not possible to offer substantiated advice for dose adjustment due to the limited amount of available literature. 1. Advise the prescriber to: 1. be alert to possible reduced plasma concentrations of haloperidol and reduced haloperidol and increase the dose based on results of therapeutic drug monitoring, 2. or prescribe an alternative according to the current guidelines. Anti-psychotics that are not metabolised via CYP2D6 - or to a much lesser extent - include, for example, flupentixol, fluphenazine, quetiapine, olanzapine or clozapine.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001552.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for haloperidol based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend dose reduction for poor metabolizer patients.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eReduce dose by 50% or select alternative drug (e.g., pimozide, flupenthixol, fluphenazine, quetiapine, olanzapine, clozapine).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms women, \u0026lt;470 ms men); INR increase \u0026lt; 4.5 Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustent.  Be alert to decreased haloperidol plasma concentration and adjust maintenance dose in response to haloperidol plasma concentration or select alternative drug (e.g., pimozide, flupenthixol, fluphenazine, quetiapine, olanzapine, clozapine).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104955,Guideline Annotation,Annotation of DPWG Guideline for hormonal contraceptives for systemic use and F5,t,PA452637,Dutch Pharmacogenetics Working Group,"<p>In individuals who carry the Factor V Leiden allele and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for hormonal contraceptives for systemic use based on Factor V Leiden (FVL, or F5) genotype. They suggest that in individuals who carry the Factor V Leiden allele and have a family history of thrombotic events or a previous thrombosis, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>Factor V Leiden heterozygous</td><td>contraceptive with oestrogens</td><td>The heterozygously present genetic polymorphism “factor V Leiden” causes an increased tendency to coagulation, resulting in an increased risk of venous thromboembolism. Contraceptives containing oestrogens can increase this risk even further.</td><td>- If the patient has a FAMILY HISTORY WITH A LOT OF THROMBOSIS, or has had a PREVIOUS THROMBOSIS:<br/>1. Advise the prescriber to avoid the use of contraceptives that contain oestrogens and prescribe an on-hormone contraceptive-such as a copper IUD - as an alternative. One could also opt for a progestogen-only contraceptive method, such as the depot injection, an IUD with levonorgestrel or an implant with etonogestrel.<br/>- OTHER CASES:<br/>1. Advise the patient to avoid additional risk factors for thrombosis (obesity, smoking, etc.).</td></tr>
<tr><td>Factor V Leiden homozygous</td><td>contraceptive with oestrogens</td><td>The homozygously present genetic polymorphism “factor V Leiden” causes an increased tendency to coagulation, resulting in an increased risk of venous thromboembolism. Contraceptives containing oestrogens can increase this risk even further.</td><td>- If the patient has a FAMILY HISTORY WITH A LOT OF THROMBOSIS, or has had a PREVIOUS THROMBOSIS:<br/>1. Advise the prescriber to avoid the use of contraceptives that contain oestrogens and prescribe a non-hormone contraceptive-such as a copper IUD - as an alternative. One could also opt for a progestogen-only contraceptive method, such as the depot injection, an IUD with levonorgestrel or an implant with etonogestrel.<br/>- OTHER CASES:<br/>1. Advise the patient to avoid additional risk factors for thrombosis (obesity, smoking, etc.).</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001567.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for hormonal contraceptives for systemic use based on Factor V Leiden (FVL, or F5) genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They suggest that in individuals who carry the Factor V Leiden allele and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>F5 homozygous <a href=""/variant/PA166153554"">rs6025</a> TT</td><td>Positive (family) history of thrombotic events: avoid estrogen-containing oral contraceptives and select alternative (e.g., copper intrauterine device, progestin-only contraceptive). Negative (family) history of thrombotic events: avoid additional risk factors (e.g., obesity, smoking).</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10<sup>9</sup>/l; leucopenia 1.0-2.0x10<sup>9</sup>/l; thrombocytopenia 25-50x10<sup>9</sup>/l; severe diarrhea</td></tr>
<tr><td>F5 heterozygous <a href=""/variant/PA166153554"">rs6025</a> CT</td><td>Positive (family) history of thrombotic events: avoid estrogen-containing oral contraceptives and select alternative (e.g., copper intrauterine device, progestin-only contraceptive). Negative (family) history of thrombotic events: avoid additional risk factors (e.g., obesity, smoking).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10<sup>9</sup>/l; leucopenia 1.0-2.0x10<sup>9</sup>/l; thrombocytopenia 25-50x10<sup>9</sup>/l; severe diarrhea</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104955"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104955"",""name"":""Annotation of DPWG Guideline for hormonal contraceptives for systemic use and F5"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704485E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415353E9,""date"":""2019-05-28T10:56:50.705-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820668E9,""date"":""2019-10-03T15:16:11.394-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956349E9,""date"":""2020-01-31T13:35:34.517-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096358E9,""date"":""2020-02-11T06:16:19.942-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA452637"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA452637"",""name"":""hormonal contraceptives for systemic use""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA159"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA159"",""symbol"":""F5"",""name"":""coagulation factor V""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981892E9,""html"":""\u003cp\u003eIn individuals who carry the Factor V Leiden allele and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981891E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for hormonal contraceptives for systemic use based on Factor V Leiden (FVL, or F5) genotype. They suggest that in individuals who carry the Factor V Leiden allele and have a family history of thrombotic events or a previous thrombosis, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eFactor V Leiden heterozygous\u003c/td\u003e\u003ctd\u003econtraceptive with oestrogens\u003c/td\u003e\u003ctd\u003eThe heterozygously present genetic polymorphism “factor V Leiden” causes an increased tendency to coagulation, resulting in an increased risk of venous thromboembolism. Contraceptives containing oestrogens can increase this risk even further.\u003c/td\u003e\u003ctd\u003e- If the patient has a FAMILY HISTORY WITH A LOT OF THROMBOSIS, or has had a PREVIOUS THROMBOSIS:\u003cbr/\u003e1. Advise the prescriber to avoid the use of contraceptives that contain oestrogens and prescribe an on-hormone contraceptive-such as a copper IUD - as an alternative. One could also opt for a progestogen-only contraceptive method, such as the depot injection, an IUD with levonorgestrel or an implant with etonogestrel.\u003cbr/\u003e- OTHER CASES:\u003cbr/\u003e1. Advise the patient to avoid additional risk factors for thrombosis (obesity, smoking, etc.).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eFactor V Leiden homozygous\u003c/td\u003e\u003ctd\u003econtraceptive with oestrogens\u003c/td\u003e\u003ctd\u003eThe homozygously present genetic polymorphism “factor V Leiden” causes an increased tendency to coagulation, resulting in an increased risk of venous thromboembolism. Contraceptives containing oestrogens can increase this risk even further.\u003c/td\u003e\u003ctd\u003e- If the patient has a FAMILY HISTORY WITH A LOT OF THROMBOSIS, or has had a PREVIOUS THROMBOSIS:\u003cbr/\u003e1. Advise the prescriber to avoid the use of contraceptives that contain oestrogens and prescribe a non-hormone contraceptive-such as a copper IUD - as an alternative. One could also opt for a progestogen-only contraceptive method, such as the depot injection, an IUD with levonorgestrel or an implant with etonogestrel.\u003cbr/\u003e- OTHER CASES:\u003cbr/\u003e1. Advise the patient to avoid additional risk factors for thrombosis (obesity, smoking, etc.).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001567.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for hormonal contraceptives for systemic use based on Factor V Leiden (FVL, or F5) genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They suggest that in individuals who carry the Factor V Leiden allele and have a family history of thrombotic events, estrogen-containing oral contraceptives should be avoided and alternative forms of contraception used.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eF5 homozygous \u003ca href\u003d\""/variant/PA166153554\""\u003ers6025\u003c/a\u003e TT\u003c/td\u003e\u003ctd\u003ePositive (family) history of thrombotic events: avoid estrogen-containing oral contraceptives and select alternative (e.g., copper intrauterine device, progestin-only contraceptive). Negative (family) history of thrombotic events: avoid additional risk factors (e.g., obesity, smoking).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10\u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eF5 heterozygous \u003ca href\u003d\""/variant/PA166153554\""\u003ers6025\u003c/a\u003e CT\u003c/td\u003e\u003ctd\u003ePositive (family) history of thrombotic events: avoid estrogen-containing oral contraceptives and select alternative (e.g., copper intrauterine device, progestin-only contraceptive). Negative (family) history of thrombotic events: avoid additional risk factors (e.g., obesity, smoking).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10\u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104999,Guideline Annotation,"Annotation of CPIC Guideline for imipramine and CYP2C19,CYP2D6",t,PA449969,Clinical Pharmacogenetics Implementation Consortium,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.</li>
</ul>
</li>
</ul>
<h3 id=""december-2016-update"">December 2016 Update</h3>
<p><em>Advance online publication December 2016.</em></p>
<ul>
<li>The 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.</li>
<li>Excerpt from the 2016 dosing guideline update:
<ul>
<li>&quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.&quot;</li>
<li>&quot;There is substantial evidence linking <em>CYP2D6</em> and <em>CYP2C19</em> genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have <em>CYP2D6</em> or <em>CYP2C19</em> genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.&quot;</li>
<li>&quot; There are scarce studies focusing solely on <em>CYP2D6</em> or <em>CYP2C19</em> genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.&quot;</li>
</ul>
</li>
<li>The guideline includes dosing recommendation for TCAs based on:
<ul>
<li>CYP2D6 phenotype (<a href=""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1 below</a>)</li>
<li>CYP2C19 phenotype (<a href=""#table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype"">Table 2 below</a>)</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf"" target=""_blank"">2016 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 Gene-specific Information Tables</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c19RefMaterials"">CYP2C19 Gene-specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/Imipramine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Imipramine Drug Resource Mappings</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Activity score</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic Recommendations<sup>a, b</sup></th><th>Classification of recommendation for other TCAs <sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 Ultrarapid metabolizer (~1-20% of patients)<sup>d</sup></td><td>&gt;2.0</td><td>An individual carrying more than two copies of functional alleles</td><td>*1/*1xN, *1/*2xN</td><td>Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.</td><td>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Normal metabolizer (~72-88% of patients)<sup>d</sup></td><td>1.0-2.0<sup>f</sup></td><td>An individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0</td><td>*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5</td><td>Normal metabolism of TCAs.</td><td>Initiate therapy with recommended starting dose.<sup>g</sup></td><td>Strong</td></tr>
<tr><td>CYP2D6 Intermediate metabolizer (~1-13% of patients)<sup>d</sup></td><td>0.5</td><td>An individual carrying one decreased and one no function allele</td><td>*4/*41, *5/*9, *4/*10</td><td>Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Consider 25% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Poor metabolizer (~1-10% of patients)<sup>d</sup></td><td>0</td><td>An individual carrying only no function alleles</td><td>*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6</td><td>Greatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider 50% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
<p><sup>g</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<h3 id=""table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype"">Table 2: Dosing recommendations for TCAs based on CYP2C19 phenotype:</h3>
<p><em>Adapted from Tables 1 and 3 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic recommendations<sup>a,b</sup></th><th>Classification of recommendations for amitriptyline<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 Ultrarapid metabolizer (~2-5% of patients)<sup>d</sup></td><td>An individual carrying two increased function alleles</td><td>*17/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Rapid metabolizer (~2-30% of patients)<sup>d</sup></td><td>An individual carrying one normal and one increased function allele</td><td>*1/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Normal metabolizer (~35-50% of patients)<sup>d</sup></td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism of tertiary amines.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Strong</td></tr>
<tr><td>CYP2C19 Intermediate metabolizer (~18-45% of patients)<sup>d</sup></td><td>An individual carrying one normal and one no function allele or one no and one increased function allele</td><td>*1/*2, *1/*3, *2/*17<sup>g</sup></td><td>Reduced metabolism of tertiary amines compared to normal metabolizers.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Poor metabolizer (~2-15% of patients)<sup>d</sup></td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>For tertiary amines, consider a 50% reduction of the recommended starting dose.<sup>f</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2C19 including clomipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<p><sup>g</sup> The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.</p>
<h3 id=""may-2013"">May 2013</h3>
<p>Guidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</p>
<p><strong>Download:</strong> <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a> and <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">supplement</a></p>
<h5 id=""excerpt-from-the-dosing-guidelines"">Excerpt from the dosing guidelines:</h5>
<p><a href=""http://www.pharmgkb.org/drug/PA448385"">Amitriptyline</a> and nortriptyline are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">guideline</a> to other tricyclics including clomipramine (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">Supplementary Table S17</a>), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.</p>
<p>See <a href=""http://www.pharmgkb.org/drug/PA448385"">amitriptyline</a> for excerpts and tables that summarize <em>CYP2D6</em>-based and <em>CYP2C19</em>-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a>).</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104999"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104999"",""name"":""Annotation of CPIC Guideline for imipramine and CYP2C19,CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[{""id"":1.44956176E9,""alleles"":[{""id"":1.449561761E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.449561762E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980634"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980634"",""symbol"":""CYP2C19*1"",""name"":""*1""}},{""id"":1.449561763E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980635"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980635"",""symbol"":""CYP2C19*2"",""name"":""*2""}},{""id"":1.449561764E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980636"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980636"",""symbol"":""CYP2C19*3"",""name"":""*3""}},{""id"":1.449561767E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980638"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980638"",""symbol"":""CYP2C19*5"",""name"":""*5""}},{""id"":1.449561768E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816522"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816522"",""symbol"":""CYP2C19*6"",""name"":""*6""}},{""id"":1.449561769E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816523"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816523"",""symbol"":""CYP2C19*7"",""name"":""*7""}},{""id"":1.44956177E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816524"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816524"",""symbol"":""CYP2C19*8"",""name"":""*8""}},{""id"":1.449561771E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816525"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816525"",""symbol"":""CYP2C19*9"",""name"":""*9""}},{""id"":1.449561772E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816526"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816526"",""symbol"":""CYP2C19*10"",""name"":""*10""}},{""id"":1.449561773E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816527"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816527"",""symbol"":""CYP2C19*11"",""name"":""*11""}},{""id"":1.449561774E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816528"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816528"",""symbol"":""CYP2C19*12"",""name"":""*12""}},{""id"":1.449561775E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816529"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816529"",""symbol"":""CYP2C19*13"",""name"":""*13""}},{""id"":1.449561776E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816530"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816530"",""symbol"":""CYP2C19*14"",""name"":""*14""}},{""id"":1.449561777E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816531"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816531"",""symbol"":""CYP2C19*15"",""name"":""*15""}},{""id"":1.449561778E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816532"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816532"",""symbol"":""CYP2C19*16"",""name"":""*16""}},{""id"":1.449561779E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816533"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816533"",""symbol"":""CYP2C19*17"",""name"":""*17""}},{""id"":1.44956178E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816534"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816534"",""symbol"":""CYP2C19*18"",""name"":""*18""}},{""id"":1.449561781E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816535"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816535"",""symbol"":""CYP2C19*19"",""name"":""*19""}},{""id"":1.449561782E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816536"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816536"",""symbol"":""CYP2C19*22"",""name"":""*22""}},{""id"":1.449561783E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816537"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816537"",""symbol"":""CYP2C19*23"",""name"":""*23""}},{""id"":1.449561784E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816538"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816538"",""symbol"":""CYP2C19*24"",""name"":""*24""}},{""id"":1.449561785E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816539"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816539"",""symbol"":""CYP2C19*25"",""name"":""*25""}},{""id"":1.449561786E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816540"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816540"",""symbol"":""CYP2C19*26"",""name"":""*26""}},{""id"":1.449561788E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115675"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115675"",""symbol"":""CYP2C19*28"",""name"":""*28""}},{""id"":1.449561789E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123292"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123292"",""symbol"":""CYP2C19*29"",""name"":""*29""}},{""id"":1.44956179E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123293"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123293"",""symbol"":""CYP2C19*30"",""name"":""*30""}},{""id"":1.449561791E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123294"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123294"",""symbol"":""CYP2C19*31"",""name"":""*31""}},{""id"":1.449561792E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123295"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123295"",""symbol"":""CYP2C19*32"",""name"":""*32""}},{""id"":1.449561793E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123296"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123296"",""symbol"":""CYP2C19*33"",""name"":""*33""}},{""id"":1.449561794E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115676"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115676"",""symbol"":""CYP2C19*34"",""name"":""*34""}},{""id"":1.449561795E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128094"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128094"",""symbol"":""CYP2C19*35"",""name"":""*35""}},{""id"":1.450805219E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980637"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980637"",""symbol"":""CYP2C19*4"",""name"":""*4""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}},{""id"":1.449561796E9,""alleles"":[{""id"":1.449561824E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449561825E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449561826E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449561827E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449561828E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449561829E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.44956183E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449561831E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449561832E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449561833E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449561834E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449561835E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449561836E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449561837E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449561838E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449561839E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.45082468E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}},{""id"":1.44956184E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449561841E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449561842E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.450042784E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.449561845E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449561846E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449561847E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449561848E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449561849E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.44956185E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449561851E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449561852E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449561853E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449561854E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449561855E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449561856E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449561857E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449561858E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449561859E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.44956186E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449561861E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449561862E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449561863E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449561864E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449561865E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449561866E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449561867E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449561869E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449561868E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.44956187E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449561871E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449561872E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449561873E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449561874E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449561875E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449561876E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449561877E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449561884E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449561878E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449561879E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.44956188E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449561881E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449561882E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449561883E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449561885E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449561886E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449561887E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449561888E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449561889E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.44956189E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449561891E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449561892E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449561893E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449561894E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449561895E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.449561896E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449561897E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449561898E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449561899E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.4495619E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449561901E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449561902E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449561903E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449561904E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449561905E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449561906E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449561907E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449561908E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449561909E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.44956191E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449561911E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449561912E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449561913E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449561914E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449561915E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449561797E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449561798E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449561799E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.4495618E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449561801E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449561802E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449561803E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449561804E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449561805E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449561806E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449561807E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449561808E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449561809E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.44956181E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449561811E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449561812E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449561813E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449561814E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449561815E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449561816E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449561817E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449561818E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449561819E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.44956182E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449561821E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449561822E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.450042783E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.449561823E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.183699773E9,""date"":""2013-01-16T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.448526131E9,""date"":""2016-12-14T13:59:25.687-08:00"",""description"":""2016 TCA CPIC guideline update"",""type"":""Update"",""version"":0.0},{""id"":1.450042785E9,""date"":""2018-11-15T20:17:44.806-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824535E9,""date"":""2019-10-24T18:33:23.733-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098242"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098242E7,""resourceId"":""27997040"",""title"":""Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5478479"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293321E9,""resource"":""PubMed Central"",""resourceId"":""PMC5478479"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/27997040"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44929332E9,""resource"":""PubMed"",""resourceId"":""27997040"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/27997040""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.597"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293322E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.597"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.597""}]},{""@id"":""https://pharmgkb.org/literature/15051926"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051926E7,""resourceId"":""23486447"",""title"":""Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3689226"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275357E9,""resource"":""PubMed Central"",""resourceId"":""PMC3689226"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23486447"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275356E9,""resource"":""PubMed"",""resourceId"":""23486447"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23486447""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.2"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275358E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.2"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.2""}]},{""@id"":""https://pharmgkb.org/literature/15100907"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100907E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449969"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449969"",""name"":""imipramine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""},{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.44798203E9,""html"":""\u003cp\u003eTricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982029E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2016-update\""\u003eDecember 2016 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication December 2016.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2016 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;There is substantial evidence linking \u003cem\u003eCYP2D6\u003c/em\u003e and \u003cem\u003eCYP2C19\u003c/em\u003e genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot; There are scarce studies focusing solely on \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eThe guideline includes dosing recommendation for TCAs based on:\n\u003cul\u003e\n\u003cli\u003eCYP2D6 phenotype (\u003ca href\u003d\""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1 below\u003c/a\u003e)\u003c/li\u003e\n\u003cli\u003eCYP2C19 phenotype (\u003ca href\u003d\""#table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype\""\u003eTable 2 below\u003c/a\u003e)\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf\"" target\u003d\""_blank\""\u003e2016 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c19RefMaterials\""\u003eCYP2C19 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/Imipramine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eImipramine Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003csup\u003ea, b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendation for other TCAs \u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Ultrarapid metabolizer (~1-20% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying more than two copies of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN\u003c/td\u003e\u003ctd\u003eIncreased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Normal metabolizer (~72-88% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.0-2.0\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5\u003c/td\u003e\u003ctd\u003eNormal metabolism of TCAs.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Intermediate metabolizer (~1-13% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*41, *5/*9, *4/*10\u003c/td\u003e\u003ctd\u003eReduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Poor metabolizer (~1-10% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no function alleles\u003c/td\u003e\u003ctd\u003e*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider 50% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003ch3 id\u003d\""table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype\""\u003eTable 2: Dosing recommendations for TCAs based on CYP2C19 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ea,b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations for amitriptyline\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Ultrarapid metabolizer (~2-5% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles\u003c/td\u003e\u003ctd\u003e*17/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Rapid metabolizer (~2-30% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Normal metabolizer (~35-50% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism of tertiary amines.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Intermediate metabolizer (~18-45% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one no function allele or one no and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3, *2/*17\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eReduced metabolism of tertiary amines compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Poor metabolizer (~2-15% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eFor tertiary amines, consider a 50% reduction of the recommended starting dose.\u003csup\u003ef\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2C19 including clomipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2013\""\u003eMay 2013\u003c/h3\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDownload:\u003c/strong\u003e \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e and \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003esupplement\u003c/a\u003e\u003c/p\u003e\n\u003ch5 id\u003d\""excerpt-from-the-dosing-guidelines\""\u003eExcerpt from the dosing guidelines:\u003c/h5\u003e\n\u003cp\u003e\u003ca href\u003d\""http://www.pharmgkb.org/drug/PA448385\""\u003eAmitriptyline\u003c/a\u003e and nortriptyline are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003eguideline\u003c/a\u003e to other tricyclics including clomipramine (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003eSupplementary Table S17\u003c/a\u003e), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.\u003c/p\u003e\n\u003cp\u003eSee \u003ca href\u003d\""http://www.pharmgkb.org/drug/PA448385\""\u003eamitriptyline\u003c/a\u003e for excerpts and tables that summarize \u003cem\u003eCYP2D6\u003c/em\u003e-based and \u003cem\u003eCYP2C19\u003c/em\u003e-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e).\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166104954,Guideline Annotation,Annotation of DPWG Guideline for imipramine and CYP2C19,t,PA449969,Dutch Pharmacogenetics Working Group,"<p>CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine, or imipramine should be avoided in these patients. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on CYP2C19 genotype. Patients who are CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine or imipramine should be avoided. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. No action is required for CYP2C19 intermediate or ultra-rapid metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 PM</td><td>imipramine</td><td>The risk of side effects is increased. The gene variation results in an increase in the plasma concentration of imipramine+desipramine.</td><td>Use 70% of the standard dose and monitor the effect and side effects or the imipramine and desipramine plasma concentrations to determine the maintenance dose, or, avoid imipramine. Antidepressants that are not or to a lesser extent metabolised by CYP2C19 include, for example, nortriptyline, fluvoxamine and mirtazapine.</td></tr>
<tr><td>CYP2C19 IM</td><td>imipramine</td><td>NO action is required for this gene-drug interaction.</td><td>The genetic variation increases imipramine plasma concentrations, but not imipramine+desipramine plasma concentrations, which govern effectiveness and side effects.</td></tr>
<tr><td>CYP2C19 UM</td><td>imipramine</td><td>NO action is required for this gene-drug interaction</td><td>The genetic variation decreases imipramine plasma concentrations, but not imipramine+desipramine plasma concentrations, which govern effectiveness and side effects.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001913.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>Reduce dose by 30% and monitor plasma concentration of imipramine and desipramine or select alternative drug (e.g. fluvoxamine, mirtazapine)</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>Insufficient data to allow calculation of dose adjustment. Select alternative drug (e.g. fluvoxamine, mirtazapine)</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>None</td><td>no data was retrieved with the literature search</td><td>no data was retrieved with the literature search</td></tr>
</tbody>
</table>
<ul>
<li>#See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/imipramine_CYP2C19_271111.pdf"">Imipramine CYP2C19 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104954"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104954"",""name"":""Annotation of DPWG Guideline for imipramine and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704487E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415025E9,""date"":""2019-05-23T14:23:12.166-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820669E9,""date"":""2019-10-03T15:19:09.246-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956368E9,""date"":""2020-01-31T13:36:05.127-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963581E9,""date"":""2020-02-11T06:17:54.329-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449969"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449969"",""name"":""imipramine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.44798189E9,""html"":""\u003cp\u003eCYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine, or imipramine should be avoided in these patients. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981889E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on CYP2C19 genotype. Patients who are CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine or imipramine should be avoided. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. No action is required for CYP2C19 intermediate or ultra-rapid metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 PM\u003c/td\u003e\u003ctd\u003eimipramine\u003c/td\u003e\u003ctd\u003eThe risk of side effects is increased. The gene variation results in an increase in the plasma concentration of imipramine+desipramine.\u003c/td\u003e\u003ctd\u003eUse 70% of the standard dose and monitor the effect and side effects or the imipramine and desipramine plasma concentrations to determine the maintenance dose, or, avoid imipramine. Antidepressants that are not or to a lesser extent metabolised by CYP2C19 include, for example, nortriptyline, fluvoxamine and mirtazapine.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 IM\u003c/td\u003e\u003ctd\u003eimipramine\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction.\u003c/td\u003e\u003ctd\u003eThe genetic variation increases imipramine plasma concentrations, but not imipramine+desipramine plasma concentrations, which govern effectiveness and side effects.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 UM\u003c/td\u003e\u003ctd\u003eimipramine\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction\u003c/td\u003e\u003ctd\u003eThe genetic variation decreases imipramine plasma concentrations, but not imipramine+desipramine plasma concentrations, which govern effectiveness and side effects.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001913.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eReduce dose by 30% and monitor plasma concentration of imipramine and desipramine or select alternative drug (e.g. fluvoxamine, mirtazapine)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio increase \u0026lt; 4.5 Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Select alternative drug (e.g. fluvoxamine, mirtazapine)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio increase \u0026lt; 4.5 Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e#See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/imipramine_CYP2C19_271111.pdf\""\u003eImipramine CYP2C19 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104972,Guideline Annotation,Annotation of DPWG Guideline for imipramine and CYP2D6,t,PA449969,Dutch Pharmacogenetics Working Group,"<p>CYP2D6 poor metabolizers should receive 30% of the standard dose of imipramine, CYP2D6 intermediate metabolizers should receive 70% of the standard dose, and CYP2D6 ultra-rapid metabolizers should receive 1.7 times the standard dose. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on CYP2D6 genotype. Patients who are CYP2D6 poor, intermediate or ultra-rapid metabolizers should receive an adjusted imipramine dose, and have the effect and side effects or plasma concentrations of imipramine and desipramine monitored in order to set the maintenance dose.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 PM</td><td>imipramine</td><td>The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and the active metabolite desipramine.</td><td>Use 30% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.</td></tr>
<tr><td>CYP2D6 IM</td><td>imipramine</td><td>The risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and desipramine.</td><td>Use 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.</td></tr>
<tr><td>CYP2D6 UM</td><td>imipramine</td><td>The risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites.</td><td>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001544.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend reducing the dose for poor and intermediate metabolizer patients, and selecting an alternative drug for ultra metabolizers.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>Reduce dose by 70% and monitor imipramine and desipramine plasma concentrations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>Reduce dose by 30% and monitor imipramine and desipramine plasma concentrations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S).</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>Select alternative drug (e.g., citalopram, sertraline) or increase dose by 70% and monitor imipramine and desipramine plasma concentrations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S).</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/imipramine_CYP2D6_271111.pdf"">Imipramine CYP2D6</a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104972"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104972"",""name"":""Annotation of DPWG Guideline for imipramine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704489E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415026E9,""date"":""2019-05-23T14:23:14.162-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.45082067E9,""date"":""2019-10-03T15:26:44.683-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956384E9,""date"":""2020-01-31T13:36:30.592-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.4509636E9,""date"":""2020-02-11T06:19:49.625-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA449969"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA449969"",""name"":""imipramine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982002E9,""html"":""\u003cp\u003eCYP2D6 poor metabolizers should receive 30% of the standard dose of imipramine, CYP2D6 intermediate metabolizers should receive 70% of the standard dose, and CYP2D6 ultra-rapid metabolizers should receive 1.7 times the standard dose. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982001E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on CYP2D6 genotype. Patients who are CYP2D6 poor, intermediate or ultra-rapid metabolizers should receive an adjusted imipramine dose, and have the effect and side effects or plasma concentrations of imipramine and desipramine monitored in order to set the maintenance dose.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eimipramine\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and the active metabolite desipramine.\u003c/td\u003e\u003ctd\u003eUse 30% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eimipramine\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to increased plasma concentrations of imipramine and desipramine.\u003c/td\u003e\u003ctd\u003eUse 70% of the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. The therapeutic range is 150-300 ng/mL for the sum of the imipramine and desipramine plasma concentrations. Values exceeding 500 ng/mL are considered toxic.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eimipramine\u003c/td\u003e\u003ctd\u003eThe risk of ineffectiveness and cardiotoxic side effects may be increased. The gene variation leads to reduced plasma concentrations of imipramine and the active metabolite desipramine and to increased plasma concentrations of the potentially cardiotoxic hydroxy metabolites.\u003c/td\u003e\u003ctd\u003eUse 1.7 times the standard dose and monitor the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose. If a dose increase is not wanted due to the potentially cardiotoxic hydroxy metabolites: avoid imipramine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001544.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend reducing the dose for poor and intermediate metabolizer patients, and selecting an alternative drug for ultra metabolizers.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eReduce dose by 70% and monitor imipramine and desipramine plasma concentrations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eReduce dose by 30% and monitor imipramine and desipramine plasma concentrations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms men, \u0026lt;470 ms women); INR increase \u0026lt; 4.5. Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eSelect alternative drug (e.g., citalopram, sertraline) or increase dose by 70% and monitor imipramine and desipramine plasma concentrations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms men, \u0026lt;470 ms women); INR increase \u0026lt; 4.5. Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/imipramine_CYP2D6_271111.pdf\""\u003eImipramine CYP2D6\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104951,Guideline Annotation,Annotation of DPWG Guideline for irinotecan and UGT1A1,t,PA450085,Dutch Pharmacogenetics Working Group,"<p>Dose reductions are recommended for irinotecan for patients who are UGT1A1 *28/*28 or UGT1A1 PM, starting with 70% of starting dose and increasing as tolerated, guided by neutrophil count.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for irinotecan based on UGT1A1 genotype.  They recommend reducing the initial dose for patients who are poor metabolizers or homozygotes for UGT1A1*28.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>UGT1A1 *1/*28</td><td>irinotecan</td><td>This genetic variation (*1/*28) is more common in Western populations than the wild-type (*1/*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is therefore not useful.</td><td>NO action is needed for this gene-drug interaction</td></tr>
<tr><td>UGT1A1 *28/*28</td><td>irinotecan</td><td>Serious, life-threatening adverse events occur more often in patients with this genetic variation. The genetic variation reduces conversion of irinotecan to inactive metabolites.</td><td>Start with 70% of the standard dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count.</td></tr>
<tr><td>UGT1A1 IM</td><td>irinotecan</td><td>This genetic variation (IM) is more common in Western populations than the wild-type (*1/*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is therefore not useful.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
<tr><td>UGT1A1 PM</td><td>irinotecan</td><td>Serious, life-threatening adverse events occur more often in patients with this genetic variation. The genetic variation reduces conversion of irinotecan to inactive metabolites.</td><td>Start with 70% of the standard dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001693.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for irinotecan based on UGT1A1 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend reducing the dose for *28 homozygous patients receiving more than 250 mg/m<sup>2</sup>.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>*1/*28</td><td>None.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints..</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
<tr><td>*28/*28</td><td>Dose &gt;250mg/m<sup>2</sup>: reduce initial dose by 30%. Increase dose in response to neutrophil count.  Dose &lt;=250mg/m<sup>2</sup>: no dose adjustment.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x10<sup>9</sup>/l; leucopenia &lt; 1.0x10<sup>9</sup>/l; thrombocytopenia &lt; 25x10<sup>9</sup>/l; life-threatening complications from diarrhea.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104951"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104951"",""name"":""Annotation of DPWG Guideline for irinotecan and UGT1A1"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704491E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414915E9,""date"":""2019-05-23T06:43:59.845-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820671E9,""date"":""2019-10-03T15:43:15.918-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956385E9,""date"":""2020-01-31T13:36:54.782-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963582E9,""date"":""2020-02-11T06:20:47.778-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450085"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450085"",""name"":""irinotecan""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA420"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA420"",""symbol"":""UGT1A1"",""name"":""UDP glucuronosyltransferase 1 family, polypeptide A1""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981882E9,""html"":""\u003cp\u003eDose reductions are recommended for irinotecan for patients who are UGT1A1 *28/*28 or UGT1A1 PM, starting with 70% of starting dose and increasing as tolerated, guided by neutrophil count.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981881E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for irinotecan based on UGT1A1 genotype.  They recommend reducing the initial dose for patients who are poor metabolizers or homozygotes for UGT1A1*28.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUGT1A1 *1/*28\u003c/td\u003e\u003ctd\u003eirinotecan\u003c/td\u003e\u003ctd\u003eThis genetic variation (*1/*28) is more common in Western populations than the wild-type (*1/*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is therefore not useful.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUGT1A1 *28/*28\u003c/td\u003e\u003ctd\u003eirinotecan\u003c/td\u003e\u003ctd\u003eSerious, life-threatening adverse events occur more often in patients with this genetic variation. The genetic variation reduces conversion of irinotecan to inactive metabolites.\u003c/td\u003e\u003ctd\u003eStart with 70% of the standard dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUGT1A1 IM\u003c/td\u003e\u003ctd\u003eirinotecan\u003c/td\u003e\u003ctd\u003eThis genetic variation (IM) is more common in Western populations than the wild-type (*1/*1). This means that treatment is largely geared to patients with this genetic variation. Adjustment of the treatment is therefore not useful.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUGT1A1 PM\u003c/td\u003e\u003ctd\u003eirinotecan\u003c/td\u003e\u003ctd\u003eSerious, life-threatening adverse events occur more often in patients with this genetic variation. The genetic variation reduces conversion of irinotecan to inactive metabolites.\u003c/td\u003e\u003ctd\u003eStart with 70% of the standard dose If the patient tolerates this initial dose, the dose can be increased, guided by the neutrophil count.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001693.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for irinotecan based on UGT1A1 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend reducing the dose for *28 homozygous patients receiving more than 250 mg/m\u003csup\u003e2\u003c/sup\u003e.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e*1/*28\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints..\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e*28/*28\u003c/td\u003e\u003ctd\u003eDose \u0026gt;250mg/m\u003csup\u003e2\u003c/sup\u003e: reduce initial dose by 30%. Increase dose in response to neutrophil count.  Dose \u0026lt;\u003d250mg/m\u003csup\u003e2\u003c/sup\u003e: no dose adjustment.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia \u0026lt; 0.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026lt; 1.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia \u0026lt; 25x10\u003csup\u003e9\u003c/sup\u003e/l; life-threatening complications from diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166127626,Guideline Annotation,Annotation of PRO Guideline for irinotecan and UGT1A1,t,PA450085,Professional Society,"<p>A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of <em>UGT1A1*28</em> genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the <em>UGT1A1*28/*28</em> genotype, and that high-dose irinotecan (&gt;=240 mg/m2) only be prescribed to patients with the <em>UGT1A1*1/*1</em> genotype.</p>
","<p>The French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published <em>UGT1A1</em>-based drug dosing guidelines for irinotecan in <em>Fundamental &amp; Clinical Pharmacology</em>. Excerpts from &quot;<em>UGT1A1</em> genotype and irinotecan therapy: general review and implementation in routine practice&quot; [Article:<a href=""/pmid/25817555"">25817555</a>] follow:</p>
<blockquote class=""blockquote"">
<p>...we recommend pretreatment UGT1A1 genotyping of the TATA box (*28, *36, *37) for all patients scheduled to receive an irinotecan dose &gt;=180 mg/m2. The rare allele *36 (proficient) can be interpreted as an *1 allele and allele *37 (deficient) as an allele *28.</p>
</blockquote>
<blockquote class=""blockquote"">
<p>For low irinotecan doses (&lt;180 mg/m2/week) UGT1A1 genotyping is not indicated as hematological and gastrointestinal toxicities are quite similar regardless of the genotype.</p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>For initially scheduled doses between 180 and 230 mg/m2 every 2-3 weeks, *28/*28 patients are at increased risk of developing hematological and/or digestive toxicity as compared to other genotypes...a 25-30% dose reduction at the first cycle is recommended, particularly in cases of associated risk factors (performance status &gt;3).</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p><strong>For initially scheduled doses &gt;=240 mg/m2 every 2-3 weeks, *28/*28 patients are at a much higher risk of hematological toxicity (neutropenia) as compared to other genotypes. We thus recommend contraindicating such an intensified dose in *28/*28 patients. The administration of an intensified dose (240 mg/m2) is only possible in *1/*1 patients, as well as in *1/*28 patients, in the absence of additional risk factors and under strict medical surveillance.</strong></p>
</blockquote>
<blockquote class=""blockquote"">
<p>This...analysis is limited by the fact that other UGT1A1 deficient variants are relevant in non-Caucasian populations, particularly the *6 and *27 alleles in Asian populations.</p>
</blockquote>
<p>The joint working group also provided a decision tree to guide irinotecan dosing based on <em>UGT1A1</em> genotype:</p>
<p><img src=""https://s3.pgkb.org/attachment/Decision_tree_for_irinotecan_dosing.png"" alt=""Decision tree for irinotecan dosing"" /></p>
<p><em><sup>Reprinted with permission from Etienne-Grimaldi et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundamental &amp; Clinical Pharmacology (2015)</sup></em></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166127626"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166127626"",""name"":""Annotation of PRO Guideline for irinotecan and UGT1A1"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.444706897E9,""date"":""2015-04-30T00:00:00-07:00"",""description"":""initial save"",""type"":""Create"",""version"":1.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15087357"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5087357E7,""resourceId"":""25817555"",""title"":""UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/25817555"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/25817555"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449295644E9,""resource"":""PubMed"",""resourceId"":""25817555"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/25817555""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1111/fcp.12117"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449295645E9,""resource"":""DOI"",""resourceId"":""10.1111/fcp.12117"",""_url"":""http://dx.doi.org/10.1111%2Ffcp.12117""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450085"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450085"",""name"":""irinotecan""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA420"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA420"",""symbol"":""UGT1A1"",""name"":""UDP glucuronosyltransferase 1 family, polypeptide A1""}],""source"":""Professional Society"",""summaryMarkdown"":{""id"":1.447982399E9,""html"":""\u003cp\u003eA French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of \u003cem\u003eUGT1A1*28\u003c/em\u003e genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the \u003cem\u003eUGT1A1*28/*28\u003c/em\u003e genotype, and that high-dose irinotecan (\u0026gt;\u003d240 mg/m2) only be prescribed to patients with the \u003cem\u003eUGT1A1*1/*1\u003c/em\u003e genotype.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982398E9,""html"":""\u003cp\u003eThe French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published \u003cem\u003eUGT1A1\u003c/em\u003e-based drug dosing guidelines for irinotecan in \u003cem\u003eFundamental \u0026amp; Clinical Pharmacology\u003c/em\u003e. Excerpts from \u0026quot;\u003cem\u003eUGT1A1\u003c/em\u003e genotype and irinotecan therapy: general review and implementation in routine practice\u0026quot; [Article:\u003ca href\u003d\""/pmid/25817555\""\u003e25817555\u003c/a\u003e] follow:\u003c/p\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003e...we recommend pretreatment UGT1A1 genotyping of the TATA box (*28, *36, *37) for all patients scheduled to receive an irinotecan dose \u0026gt;\u003d180 mg/m2. The rare allele *36 (proficient) can be interpreted as an *1 allele and allele *37 (deficient) as an allele *28.\u003c/p\u003e\n\u003c/blockquote\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003eFor low irinotecan doses (\u0026lt;180 mg/m2/week) UGT1A1 genotyping is not indicated as hematological and gastrointestinal toxicities are quite similar regardless of the genotype.\u003c/p\u003e\n\u003c/blockquote\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003e\u003cstrong\u003eFor initially scheduled doses between 180 and 230 mg/m2 every 2-3 weeks, *28/*28 patients are at increased risk of developing hematological and/or digestive toxicity as compared to other genotypes...a 25-30% dose reduction at the first cycle is recommended, particularly in cases of associated risk factors (performance status \u0026gt;3).\u003c/strong\u003e\u003c/p\u003e\n\u003c/blockquote\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003e\u003cstrong\u003eFor initially scheduled doses \u0026gt;\u003d240 mg/m2 every 2-3 weeks, *28/*28 patients are at a much higher risk of hematological toxicity (neutropenia) as compared to other genotypes. We thus recommend contraindicating such an intensified dose in *28/*28 patients. The administration of an intensified dose (240 mg/m2) is only possible in *1/*1 patients, as well as in *1/*28 patients, in the absence of additional risk factors and under strict medical surveillance.\u003c/strong\u003e\u003c/p\u003e\n\u003c/blockquote\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cp\u003eThis...analysis is limited by the fact that other UGT1A1 deficient variants are relevant in non-Caucasian populations, particularly the *6 and *27 alleles in Asian populations.\u003c/p\u003e\n\u003c/blockquote\u003e\n\u003cp\u003eThe joint working group also provided a decision tree to guide irinotecan dosing based on \u003cem\u003eUGT1A1\u003c/em\u003e genotype:\u003c/p\u003e\n\u003cp\u003e\u003cimg src\u003d\""https://s3.pgkb.org/attachment/Decision_tree_for_irinotecan_dosing.png\"" alt\u003d\""Decision tree for irinotecan dosing\"" /\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003e\u003csup\u003eReprinted with permission from Etienne-Grimaldi et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundamental \u0026amp; Clinical Pharmacology (2015)\u003c/sup\u003e\u003c/em\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166114461,Guideline Annotation,Annotation of CPIC Guideline for ivacaftor and CFTR,t,PA165950341,Clinical Pharmacogenetics Implementation Consortium,"<p>Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain <em>CFTR</em> variants.  See full guideline for disclaimers, further details and supporting evidence.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/"" target=""_blank"">CPIC&reg; guideline for ivacaftor and CFTR</a>.</p>
<h3 id=""may-2019-update-on-pharmgkb"">May 2019 Update on PharmGKB</h3>
<ul>
<li>Since the most recent update to the CPIC ivacaftor dosing guideline in April 2014, and the most recent update on PharmGKB in June 2017, the <a href=""/label/PA166104890"">FDA-approved drug label</a> has been updated again to include 5 additional CFTR variants that are approved for KALYDECO use, bringing the total number of indicated variants to 38: 2789+5G-&gt;A (<a href=""/variant/PA166162698"">rs80224560</a>), 3272-26A-&gt;G (<a href=""/variant/PA166184909"">rs76151804</a>), 3849+10kbC-&gt;T (<a href=""/variant/PA166157514"">rs75039782</a>), 711+1G-&gt;T (<a href=""/variant/PA166162707"">rs77188391</a>) and E831X (<a href=""/variant/PA166157519"">rs78655421</a>). Table 1, below, has been updated.</li>
</ul>
<h3 id=""june-2017-update-on-pharmgkb"">June 2017 Update on PharmGKB</h3>
<ul>
<li>Since the most recent update to the CPIC ivacaftor dosing guideline in April 2014, and the most recent update on PharmGKB in May 2016, the <a href=""/label/PA166104890"">FDA-approved drug label</a> has been updated again to include 23 additional CFTR variants that are approved for KALYDECO use, bringing the total number of indicated variants to 33. Please see the <a rel=""noopener noreferrer"" href=""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm559212.htm"" target=""_blank"">FDA News Release</a> from May 17th, 2017 for more information. In light of this change, the CPIC guideline annotation on this PharmGKB webpage has been update to include these additional CFTR variants (see Table 1, below). These variants were not discussed in the 2014 guideline publication. These variants are as follows: E56K (<a href=""/variant/PA166164939"">rs397508256</a>), P67L (<a href=""/variant/PA166164940"">rs368505753</a>), R74W (<a href=""/variant/PA166164941"">rs115545701</a>), D110E (<a href=""/variant/PA166164942"">rs397508537</a>), D110H (<a href=""/variant/PA166164943"">rs113993958</a>), R117C (<a href=""/variant/PA166164944"">rs77834169</a>), E193K (<a href=""/variant/PA166164945"">rs397508759</a>), L206W (<a href=""/variant/PA166164946"">rs121908752</a>), R347H (<a href=""/variant/PA166161186"">rs77932196</a>), R352Q (<a href=""/variant/PA166164947"">rs121908753</a>), A455E (<a href=""/variant/PA166162705"">rs74551128</a>), D579G (<a href=""/variant/PA166164948"">rs397508288</a>), S945L (<a href=""/variant/PA166164949"">rs397508442</a>), S977F (<a href=""/variant/PA166164950"">rs141033578</a>), F1052V (<a href=""/variant/PA166164951"">rs150212784</a>), K1060T (<a href=""/variant/PA166164952"">rs397508513</a>), A1067T (<a href=""/variant/PA166164953"">rs121909020</a>), G1069R (<a href=""/variant/PA166164954"">rs200321110</a>), R1070Q (<a href=""/variant/PA166164955"">rs78769542</a>), R1070W (<a href=""/variant/PA166164956"">rs202179988</a>), F1074L (<a href=""/variant/PA166164957"">rs186045772</a>), D1152H (<a href=""/variant/PA166164958"">rs75541969</a>), D1270N (<a href=""/variant/PA166164959"">rs11971167</a>).</li>
</ul>
<h3 id=""may-2016-update-on-pharmgkb"">May 2016 Update on PharmGKB</h3>
<ul>
<li>Since the most recent update to the CPIC ivacaftor dosing guideline in April 2014, the <a href=""/label/PA166104890"">FDA-approved drug label</a> has been updated again to include the variant R117H (<a href=""/variant/PA166157519"">rs78655421</a>). In light of this change, the CPIC guideline annotation on this PharmGKB webpage has been updated to include this additional <em>CFTR</em> variant (see Table 1 and Figure 1, below). This variant is not discussed in the 2014 guideline publication. Additionally, the updated drug label indicates ivacaftor use for patients 2 years and older; previously it was indicated only for patients 6 years and older.</li>
</ul>
<h3 id=""april-2014-update-on-pharmgkb"">April 2014 Update on PharmGKB</h3>
<ul>
<li>After the submission and review of the CPIC guideline manuscript, the <a href=""/label/PA166104890"">FDA-approved drug label</a> for ivacaftor was updated to include additional variants. In light of these changes, the CPIC guideline annotation on this PharmGKB webpage has been updated to include additional <em>CFTR</em> variants, specifically G1244E (<a href=""/variant/PA166157537"">rs267606723</a>), G1349D (<a href=""/variant/PA166157534"">rs193922525</a>), G178R (<a href=""/variant/PA166157521"">rs80282562</a>), G551S (<a href=""/variant/PA166157532"">rs121909013</a>), S1251N (<a href=""/variant/PA166157511"">rs74503330</a>), S1255P (<a href=""/variant/PA166157533"">rs121909041</a>), S549N (<a href=""/variant/PA166157529"">rs121908755</a>) and S549R (<a href=""/variant/PA166157530"">rs121908757</a> and <a href=""/variant/PA166157531"">rs121909005</a>) (see Table 1 and Figure 1, below).  These variants are not discussed in the 2014 guideline publication.</li>
</ul>
<h3 id=""march-2014"">March 2014</h3>
<p><em>Accepted article preview online March 2014; Advance online publication March 2014.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in determining whether ivacaftor treatment should be undertaken have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>These guidelines are applicable to
<ul>
<li>cystic fibrosis patients</li>
<li>pediatrics, 6 years and older</li>
<li>adults</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/ivacaftor/2014/24598717.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/ivacaftor/2014/24598717-supplement.pdf"" target=""_blank"">2014 supplement</a> (2019 update)</li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-therapeutic-use-of-ivacaftor-based-on-cftr-genotype"">Table 1: Recommended therapeutic use of ivacaftor based on <em>CFTR</em> genotype</h3>
<p><em>Adapted from Table 2 of the 2014 guideline manuscript (June 2017 Update on PharmGKB).  Variants have been added to the table below that are not in the published 2014 guideline or supplement; specifically, variants other than G551D and F508del.</em></p>
<table class=""table"">
<thead>
<tr><th>CFTR Genotype</th><th>Examples of diplotypes</th><th>Implications for ivacaftor effects</th><th>Recommendations for ivacaftor therapy</th><th>Classification of recommendation for ivacaftor therapy<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>Homozygous or Heterozygous G551D-CFTR, <a href=""/variant/PA166157516"">rs75527207</a> genotype AA or AG</td><td>G551D/ F508del, G551D/ G551D</td><td>Significant improvement in lung function, weight, risk of pulmonary exacerbation, patient reported outcomes, and reduction in sweat chloride concentrations through enhanced CFTR channel activity (increase probability of open channel).</td><td>Use ivacaftor according to the product label</td><td>Strong</td></tr>
<tr><td>Homozygous for F508del-CFTR, <a href=""/variant/PA166157525"">rs113993960</a> or <a href=""/variant/PA166157536"">rs199826652</a> genotype del/del</td><td>F508del/F508del</td><td>No significant reduction in sweat chloride concentrations; no changes in other clinical measurements including spirometric measurements, pulmonary exacerbations, or body weight<sup>b</sup>. Unlikely to respond to treatment.</td><td>Ivacaftor is not recommended<sup>a</sup></td><td>Moderate<sup>b</sup></td></tr>
<tr><td>Homozygous or heterozygous for one of the following CFTR variants: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S997F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, G1349D, 2789+5G-&gt;A, 3272-26A-&gt;G, 3849+10kbC-&gt;T, 711+1G-&gt;T and E831X<sup>d</sup></td><td>F508del/S549N</td><td>Significantly enhanced channel open probability <em>in vitro</em> [Article:<a href=""/pmid/22293084"">22293084</a>]. <em>In vitro</em> assays with CFBEo- cells expressing S549N-CFTR showed ivacaftor potentiated chloride channel function [Article:<a href=""/pmid/23027855"">23027855</a>], and a case study showed improved lung function after ivacaftor treatment in a 12-year-old girl with CF with a copy of the S549N variant [Article:<a href=""/pmid/24081349"">24081349</a>]. Improvement in sweat chloride and CFQ-R respiratory domain scores in patients with the R117H variant [Article:<a href=""/pmid/26070913"">26070913</a>]. Or, variant was listed in the <a href=""https://www.pharmgkb.org/label/PA166104890"">FDA-approved drug label</a> as being responsive to ivacaftor.</td><td>Use ivacaftor according to the product label</td><td>Moderate</td></tr>
</tbody>
</table>
<p><sup>a</sup> These recommendations are based on treatment of CF patients with ivacaftor alone and current evidence. Clinical trials are currently underway to investigate ivacaftor alone or in combination with other drugs to treat CF patients with CFTR variants other than G551D, therefore there is potential that ivacaftor may be effective in these patients. See the 2014 guidelines for further details.</p>
<p><sup>b</sup> The recommendation for patients with the F508del/F508del genotype is based on ivacaftor mechanism of action and clinical observational data. The clinical study however was a safety study and was not powered to detect a difference in efficacy [Article:<a href=""/pmid/22383668"">22383668</a>].</p>
<p><sup>c</sup> Rating scheme described in the 2014 supplement.</p>
<p><sup>d</sup> Variants listed in this table include those added to the updated <a href=""/label/PA166104890"">drug label for ivacaftor</a>. The modifications to this table were made after the acceptance of publication of the 2014 CPIC Ivacaftor-CFTR guideline [Article:<a href=""/pmid/24598717"">24598717</a>] and are not reflected in the PDFs of the CPIC guideline main manuscript or supplement.</p>
<h3 id=""figure-1-treatment-algorithm-for-clinical-use-of-ivacaftor-for-cystic-fibrosis-patients-based-on-cftr-genotype"">Figure 1: Treatment algorithm for clinical use of Ivacaftor for cystic fibrosis patients based on <em>CFTR</em> genotype.</h3>
<p><em>Adapted from Figure 1 of the 2014 guideline manuscript (June 2017 Update on PharmGKB).  Variants have been added to this figure that are not in the published 2014 guideline or supplement; specifically, variants other than G551D and F508del. Additionally, the age has been updated to 2 years old or older from 6 years and older, due to an update in the FDA-approved drug label for ivacaftor.</em></p>
<p><img src=""https://s3.pgkb.org/attachment/Ivacaftor_Figure_1_Update_June_2017.png"" alt=""Adapted diagram from Figure 1"" /></p>
<p><sup>e</sup> Ivacaftor is not recommended for CF patients with other CFTR variants or in patients homozygous for the F508del variant (see 2014 guideline for further details, supporting evidence and disclaimers). Future clinical trials for other CFTR variants are ongoing.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166114461"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166114461"",""name"":""Annotation of CPIC Guideline for ivacaftor and CFTR"",""cancerGenome"":false,""descriptiveVideoId"":""Ru50LgwdTPw"",""guidelineGenes"":[{""id"":1.449561722E9,""alleles"":[{""id"":1.449561723E9,""_label"":""F508del(CTT)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117963"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117963"",""symbol"":""CFTRF508del(CTT)"",""name"":""F508del(CTT)""}},{""id"":1.449561724E9,""_label"":""Other"",""allele"":""Other"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.449561725E9,""_label"":""F508del(TCT)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117964"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117964"",""symbol"":""CFTRF508del(TCT)"",""name"":""F508del(TCT)""}},{""id"":1.449561726E9,""_label"":""G551D"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558330"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44555833E9,""resource"":""Allele Function"",""term"":""Loss of function"",""termId"":""haplotypeTags:1445558330""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117965"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117965"",""symbol"":""CFTRG551D"",""name"":""G551D""}},{""id"":1.449561727E9,""_label"":""G1244E"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117966"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117966"",""symbol"":""CFTRG1244E"",""name"":""G1244E""}},{""id"":1.449561728E9,""_label"":""G1349D"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117967"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117967"",""symbol"":""CFTRG1349D"",""name"":""G1349D""}},{""id"":1.449561729E9,""_label"":""G178R"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117968"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117968"",""symbol"":""CFTRG178R"",""name"":""G178R""}},{""id"":1.44956173E9,""_label"":""G551S"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117969"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117969"",""symbol"":""CFTRG551S"",""name"":""G551S""}},{""id"":1.449561731E9,""_label"":""S1251N"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117970"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117970"",""symbol"":""CFTRS1251N"",""name"":""S1251N""}},{""id"":1.449561732E9,""_label"":""S1255P"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117971"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117971"",""symbol"":""CFTRS1255P"",""name"":""S1255P""}},{""id"":1.449561733E9,""_label"":""S549N"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117972"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117972"",""symbol"":""CFTRS549N"",""name"":""S549N""}},{""id"":1.449561734E9,""_label"":""S549R(A\u003eC)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117973"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117973"",""symbol"":""CFTRS549R(A\u003eC)"",""name"":""S549R(A\u003eC)""}},{""id"":1.449561735E9,""_label"":""S549R(T\u003eG)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166117974"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166117974"",""symbol"":""CFTRS549R(T\u003eG)"",""name"":""S549R(T\u003eG)""}},{""id"":1.449561736E9,""_label"":""R117H"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765952"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765952E9,""resource"":""Allele Function"",""term"":""Class IV"",""termId"":""haplotypeTags:1446765952""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166153136"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166153136"",""symbol"":""CFTRR117H"",""name"":""R117H""}},{""id"":1.449561737E9,""_label"":""R347H"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164960"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164960"",""symbol"":""CFTRR347H"",""name"":""R347H""}},{""id"":1.449561738E9,""_label"":""A455E"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166162727"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166162727"",""symbol"":""CFTRA455E"",""name"":""A455E""}},{""id"":1.449561739E9,""_label"":""E56K"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164961"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164961"",""symbol"":""CFTRE56K"",""name"":""E56K""}},{""id"":1.44956174E9,""_label"":""P67L"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164962"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164962"",""symbol"":""CFTRP67L"",""name"":""P67L""}},{""id"":1.449561741E9,""_label"":""R74W"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164963"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164963"",""symbol"":""CFTRR74W"",""name"":""R74W""}},{""id"":1.449561742E9,""_label"":""D110E"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164964"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164964"",""symbol"":""CFTRD110E"",""name"":""D110E""}},{""id"":1.449561743E9,""_label"":""D110H"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164965"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164965"",""symbol"":""CFTRD110H"",""name"":""D110H""}},{""id"":1.449561744E9,""_label"":""R117C"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164966"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164966"",""symbol"":""CFTRR117C"",""name"":""R117C""}},{""id"":1.449561745E9,""_label"":""E193K"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164967"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164967"",""symbol"":""CFTRE193K"",""name"":""E193K""}},{""id"":1.449561746E9,""_label"":""L206W"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164968"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164968"",""symbol"":""CFTRL206W"",""name"":""L206W""}},{""id"":1.449561747E9,""_label"":""R352Q"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164969"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164969"",""symbol"":""CFTRR352Q"",""name"":""R352Q""}},{""id"":1.449561748E9,""_label"":""D579G"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164970"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164970"",""symbol"":""CFTRD579G"",""name"":""D579G""}},{""id"":1.449561749E9,""_label"":""S945L"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164971"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164971"",""symbol"":""CFTRS945L"",""name"":""S945L""}},{""id"":1.44956175E9,""_label"":""S977F"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164972"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164972"",""symbol"":""CFTRS977F"",""name"":""S977F""}},{""id"":1.449561751E9,""_label"":""F1052V"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164973"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164973"",""symbol"":""CFTRF1052V"",""name"":""F1052V""}},{""id"":1.449561752E9,""_label"":""K1060T"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164974"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164974"",""symbol"":""CFTRK1060T"",""name"":""K1060T""}},{""id"":1.449561753E9,""_label"":""A1067T"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164975"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164975"",""symbol"":""CFTRA1067T"",""name"":""A1067T""}},{""id"":1.449561754E9,""_label"":""G1069R"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164976"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164976"",""symbol"":""CFTRG1069R"",""name"":""G1069R""}},{""id"":1.449561755E9,""_label"":""R1070Q"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164977"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164977"",""symbol"":""CFTRR1070Q"",""name"":""R1070Q""}},{""id"":1.449561756E9,""_label"":""R1070W"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164978"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164978"",""symbol"":""CFTRR1070W"",""name"":""R1070W""}},{""id"":1.449561757E9,""_label"":""F1074L"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164979"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164979"",""symbol"":""CFTRF1074L"",""name"":""F1074L""}},{""id"":1.449561758E9,""_label"":""D1152H"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164980"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164980"",""symbol"":""CFTRD1152H"",""name"":""D1152H""}},{""id"":1.449561759E9,""_label"":""D1270N"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166164981"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166164981"",""symbol"":""CFTRD1270N"",""name"":""D1270N""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA109"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA109"",""symbol"":""CFTR"",""name"":""cystic fibrosis transmembrane conductance regulator""}}],""history"":[{""id"":1.183848388E9,""date"":""2014-03-05T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.18396013E9,""date"":""2014-03-17T00:00:00-07:00"",""description"":""Addition of other variants."",""type"":""Update"",""version"":1.0},{""id"":1.184214951E9,""date"":""2014-05-06T00:00:00-07:00"",""description"":""Formatting and content changes"",""type"":""Update"",""version"":0.0},{""id"":1.447986336E9,""date"":""2016-05-10T14:57:16.865-07:00"",""description"":""Guideline on PharmGKB updated due to changes to the FDA-approved label for ivacaftor"",""type"":""Update"",""version"":0.0},{""id"":1.448624943E9,""date"":""2017-06-02T11:19:44.411-07:00"",""description"":""FDA expanded approved use of ivacaftor to treat an additional 23 CFTR mutations."",""type"":""Update"",""version"":0.0},{""id"":1.44956455E9,""date"":""2018-06-14T00:00:00-07:00"",""description"":""Added guideline video."",""type"":""Update"",""version"":0.0},{""id"":1.449717117E9,""date"":""2018-08-23T16:13:37.866-07:00"",""description"":""Updated video link"",""type"":""Update"",""version"":0.0},{""id"":1.450824213E9,""date"":""2019-10-21T10:33:27.258-07:00"",""description"":""Added new variants based on ivacaftor drug label and approved by CPIC authors in May 2019"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15071319"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5071319E7,""resourceId"":""24598717"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026598"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4026598"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279797E9,""resource"":""PubMed Central"",""resourceId"":""PMC4026598"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026598""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/24598717"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279796E9,""resource"":""PubMed"",""resourceId"":""24598717"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/24598717""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2014.54"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449279798E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2014.54"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2014.54""}]},{""@id"":""https://pharmgkb.org/literature/15100910"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.510091E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/"",""title"":""CPIC® Guideline for Ivacaftor and CFTR – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983498E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA165950341"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA165950341"",""name"":""ivacaftor""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA109"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA109"",""symbol"":""CFTR"",""name"":""cystic fibrosis transmembrane conductance regulator""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447981606E9,""html"":""\u003cp\u003eIvacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain \u003cem\u003eCFTR\u003c/em\u003e variants.  See full guideline for disclaimers, further details and supporting evidence.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981605E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for ivacaftor and CFTR\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2019-update-on-pharmgkb\""\u003eMay 2019 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eSince the most recent update to the CPIC ivacaftor dosing guideline in April 2014, and the most recent update on PharmGKB in June 2017, the \u003ca href\u003d\""/label/PA166104890\""\u003eFDA-approved drug label\u003c/a\u003e has been updated again to include 5 additional CFTR variants that are approved for KALYDECO use, bringing the total number of indicated variants to 38: 2789+5G-\u0026gt;A (\u003ca href\u003d\""/variant/PA166162698\""\u003ers80224560\u003c/a\u003e), 3272-26A-\u0026gt;G (\u003ca href\u003d\""/variant/PA166184909\""\u003ers76151804\u003c/a\u003e), 3849+10kbC-\u0026gt;T (\u003ca href\u003d\""/variant/PA166157514\""\u003ers75039782\u003c/a\u003e), 711+1G-\u0026gt;T (\u003ca href\u003d\""/variant/PA166162707\""\u003ers77188391\u003c/a\u003e) and E831X (\u003ca href\u003d\""/variant/PA166157519\""\u003ers78655421\u003c/a\u003e). Table 1, below, has been updated.\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""june-2017-update-on-pharmgkb\""\u003eJune 2017 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eSince the most recent update to the CPIC ivacaftor dosing guideline in April 2014, and the most recent update on PharmGKB in May 2016, the \u003ca href\u003d\""/label/PA166104890\""\u003eFDA-approved drug label\u003c/a\u003e has been updated again to include 23 additional CFTR variants that are approved for KALYDECO use, bringing the total number of indicated variants to 33. Please see the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm559212.htm\"" target\u003d\""_blank\""\u003eFDA News Release\u003c/a\u003e from May 17th, 2017 for more information. In light of this change, the CPIC guideline annotation on this PharmGKB webpage has been update to include these additional CFTR variants (see Table 1, below). These variants were not discussed in the 2014 guideline publication. These variants are as follows: E56K (\u003ca href\u003d\""/variant/PA166164939\""\u003ers397508256\u003c/a\u003e), P67L (\u003ca href\u003d\""/variant/PA166164940\""\u003ers368505753\u003c/a\u003e), R74W (\u003ca href\u003d\""/variant/PA166164941\""\u003ers115545701\u003c/a\u003e), D110E (\u003ca href\u003d\""/variant/PA166164942\""\u003ers397508537\u003c/a\u003e), D110H (\u003ca href\u003d\""/variant/PA166164943\""\u003ers113993958\u003c/a\u003e), R117C (\u003ca href\u003d\""/variant/PA166164944\""\u003ers77834169\u003c/a\u003e), E193K (\u003ca href\u003d\""/variant/PA166164945\""\u003ers397508759\u003c/a\u003e), L206W (\u003ca href\u003d\""/variant/PA166164946\""\u003ers121908752\u003c/a\u003e), R347H (\u003ca href\u003d\""/variant/PA166161186\""\u003ers77932196\u003c/a\u003e), R352Q (\u003ca href\u003d\""/variant/PA166164947\""\u003ers121908753\u003c/a\u003e), A455E (\u003ca href\u003d\""/variant/PA166162705\""\u003ers74551128\u003c/a\u003e), D579G (\u003ca href\u003d\""/variant/PA166164948\""\u003ers397508288\u003c/a\u003e), S945L (\u003ca href\u003d\""/variant/PA166164949\""\u003ers397508442\u003c/a\u003e), S977F (\u003ca href\u003d\""/variant/PA166164950\""\u003ers141033578\u003c/a\u003e), F1052V (\u003ca href\u003d\""/variant/PA166164951\""\u003ers150212784\u003c/a\u003e), K1060T (\u003ca href\u003d\""/variant/PA166164952\""\u003ers397508513\u003c/a\u003e), A1067T (\u003ca href\u003d\""/variant/PA166164953\""\u003ers121909020\u003c/a\u003e), G1069R (\u003ca href\u003d\""/variant/PA166164954\""\u003ers200321110\u003c/a\u003e), R1070Q (\u003ca href\u003d\""/variant/PA166164955\""\u003ers78769542\u003c/a\u003e), R1070W (\u003ca href\u003d\""/variant/PA166164956\""\u003ers202179988\u003c/a\u003e), F1074L (\u003ca href\u003d\""/variant/PA166164957\""\u003ers186045772\u003c/a\u003e), D1152H (\u003ca href\u003d\""/variant/PA166164958\""\u003ers75541969\u003c/a\u003e), D1270N (\u003ca href\u003d\""/variant/PA166164959\""\u003ers11971167\u003c/a\u003e).\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""may-2016-update-on-pharmgkb\""\u003eMay 2016 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eSince the most recent update to the CPIC ivacaftor dosing guideline in April 2014, the \u003ca href\u003d\""/label/PA166104890\""\u003eFDA-approved drug label\u003c/a\u003e has been updated again to include the variant R117H (\u003ca href\u003d\""/variant/PA166157519\""\u003ers78655421\u003c/a\u003e). In light of this change, the CPIC guideline annotation on this PharmGKB webpage has been updated to include this additional \u003cem\u003eCFTR\u003c/em\u003e variant (see Table 1 and Figure 1, below). This variant is not discussed in the 2014 guideline publication. Additionally, the updated drug label indicates ivacaftor use for patients 2 years and older; previously it was indicated only for patients 6 years and older.\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""april-2014-update-on-pharmgkb\""\u003eApril 2014 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eAfter the submission and review of the CPIC guideline manuscript, the \u003ca href\u003d\""/label/PA166104890\""\u003eFDA-approved drug label\u003c/a\u003e for ivacaftor was updated to include additional variants. In light of these changes, the CPIC guideline annotation on this PharmGKB webpage has been updated to include additional \u003cem\u003eCFTR\u003c/em\u003e variants, specifically G1244E (\u003ca href\u003d\""/variant/PA166157537\""\u003ers267606723\u003c/a\u003e), G1349D (\u003ca href\u003d\""/variant/PA166157534\""\u003ers193922525\u003c/a\u003e), G178R (\u003ca href\u003d\""/variant/PA166157521\""\u003ers80282562\u003c/a\u003e), G551S (\u003ca href\u003d\""/variant/PA166157532\""\u003ers121909013\u003c/a\u003e), S1251N (\u003ca href\u003d\""/variant/PA166157511\""\u003ers74503330\u003c/a\u003e), S1255P (\u003ca href\u003d\""/variant/PA166157533\""\u003ers121909041\u003c/a\u003e), S549N (\u003ca href\u003d\""/variant/PA166157529\""\u003ers121908755\u003c/a\u003e) and S549R (\u003ca href\u003d\""/variant/PA166157530\""\u003ers121908757\u003c/a\u003e and \u003ca href\u003d\""/variant/PA166157531\""\u003ers121909005\u003c/a\u003e) (see Table 1 and Figure 1, below).  These variants are not discussed in the 2014 guideline publication.\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""march-2014\""\u003eMarch 2014\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online March 2014; Advance online publication March 2014.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in determining whether ivacaftor treatment should be undertaken have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to\n\u003cul\u003e\n\u003cli\u003ecystic fibrosis patients\u003c/li\u003e\n\u003cli\u003epediatrics, 6 years and older\u003c/li\u003e\n\u003cli\u003eadults\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/ivacaftor/2014/24598717.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/ivacaftor/2014/24598717-supplement.pdf\"" target\u003d\""_blank\""\u003e2014 supplement\u003c/a\u003e (2019 update)\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-therapeutic-use-of-ivacaftor-based-on-cftr-genotype\""\u003eTable 1: Recommended therapeutic use of ivacaftor based on \u003cem\u003eCFTR\u003c/em\u003e genotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Table 2 of the 2014 guideline manuscript (June 2017 Update on PharmGKB).  Variants have been added to the table below that are not in the published 2014 guideline or supplement; specifically, variants other than G551D and F508del.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eCFTR Genotype\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications for ivacaftor effects\u003c/th\u003e\u003cth\u003eRecommendations for ivacaftor therapy\u003c/th\u003e\u003cth\u003eClassification of recommendation for ivacaftor therapy\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eHomozygous or Heterozygous G551D-CFTR, \u003ca href\u003d\""/variant/PA166157516\""\u003ers75527207\u003c/a\u003e genotype AA or AG\u003c/td\u003e\u003ctd\u003eG551D/ F508del, G551D/ G551D\u003c/td\u003e\u003ctd\u003eSignificant improvement in lung function, weight, risk of pulmonary exacerbation, patient reported outcomes, and reduction in sweat chloride concentrations through enhanced CFTR channel activity (increase probability of open channel).\u003c/td\u003e\u003ctd\u003eUse ivacaftor according to the product label\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eHomozygous for F508del-CFTR, \u003ca href\u003d\""/variant/PA166157525\""\u003ers113993960\u003c/a\u003e or \u003ca href\u003d\""/variant/PA166157536\""\u003ers199826652\u003c/a\u003e genotype del/del\u003c/td\u003e\u003ctd\u003eF508del/F508del\u003c/td\u003e\u003ctd\u003eNo significant reduction in sweat chloride concentrations; no changes in other clinical measurements including spirometric measurements, pulmonary exacerbations, or body weight\u003csup\u003eb\u003c/sup\u003e. Unlikely to respond to treatment.\u003c/td\u003e\u003ctd\u003eIvacaftor is not recommended\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003csup\u003eb\u003c/sup\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eHomozygous or heterozygous for one of the following CFTR variants: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S997F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, G1349D, 2789+5G-\u0026gt;A, 3272-26A-\u0026gt;G, 3849+10kbC-\u0026gt;T, 711+1G-\u0026gt;T and E831X\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eF508del/S549N\u003c/td\u003e\u003ctd\u003eSignificantly enhanced channel open probability \u003cem\u003ein vitro\u003c/em\u003e [Article:\u003ca href\u003d\""/pmid/22293084\""\u003e22293084\u003c/a\u003e]. \u003cem\u003eIn vitro\u003c/em\u003e assays with CFBEo- cells expressing S549N-CFTR showed ivacaftor potentiated chloride channel function [Article:\u003ca href\u003d\""/pmid/23027855\""\u003e23027855\u003c/a\u003e], and a case study showed improved lung function after ivacaftor treatment in a 12-year-old girl with CF with a copy of the S549N variant [Article:\u003ca href\u003d\""/pmid/24081349\""\u003e24081349\u003c/a\u003e]. Improvement in sweat chloride and CFQ-R respiratory domain scores in patients with the R117H variant [Article:\u003ca href\u003d\""/pmid/26070913\""\u003e26070913\u003c/a\u003e]. Or, variant was listed in the \u003ca href\u003d\""https://www.pharmgkb.org/label/PA166104890\""\u003eFDA-approved drug label\u003c/a\u003e as being responsive to ivacaftor.\u003c/td\u003e\u003ctd\u003eUse ivacaftor according to the product label\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e These recommendations are based on treatment of CF patients with ivacaftor alone and current evidence. Clinical trials are currently underway to investigate ivacaftor alone or in combination with other drugs to treat CF patients with CFTR variants other than G551D, therefore there is potential that ivacaftor may be effective in these patients. See the 2014 guidelines for further details.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e The recommendation for patients with the F508del/F508del genotype is based on ivacaftor mechanism of action and clinical observational data. The clinical study however was a safety study and was not powered to detect a difference in efficacy [Article:\u003ca href\u003d\""/pmid/22383668\""\u003e22383668\u003c/a\u003e].\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Rating scheme described in the 2014 supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e Variants listed in this table include those added to the updated \u003ca href\u003d\""/label/PA166104890\""\u003edrug label for ivacaftor\u003c/a\u003e. The modifications to this table were made after the acceptance of publication of the 2014 CPIC Ivacaftor-CFTR guideline [Article:\u003ca href\u003d\""/pmid/24598717\""\u003e24598717\u003c/a\u003e] and are not reflected in the PDFs of the CPIC guideline main manuscript or supplement.\u003c/p\u003e\n\u003ch3 id\u003d\""figure-1-treatment-algorithm-for-clinical-use-of-ivacaftor-for-cystic-fibrosis-patients-based-on-cftr-genotype\""\u003eFigure 1: Treatment algorithm for clinical use of Ivacaftor for cystic fibrosis patients based on \u003cem\u003eCFTR\u003c/em\u003e genotype.\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Figure 1 of the 2014 guideline manuscript (June 2017 Update on PharmGKB).  Variants have been added to this figure that are not in the published 2014 guideline or supplement; specifically, variants other than G551D and F508del. Additionally, the age has been updated to 2 years old or older from 6 years and older, due to an update in the FDA-approved drug label for ivacaftor.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cimg src\u003d\""https://s3.pgkb.org/attachment/Ivacaftor_Figure_1_Update_June_2017.png\"" alt\u003d\""Adapted diagram from Figure 1\"" /\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Ivacaftor is not recommended for CF patients with other CFTR variants or in patients homozygous for the F508del variant (see 2014 guideline for further details, supporting evidence and disclaimers). Future clinical trials for other CFTR variants are ongoing.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983498E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/""}]},""status"":""success""}"
PA166104987,Guideline Annotation,Annotation of DPWG Guideline for lansoprazole and CYP2C19,t,PA450180,Dutch Pharmacogenetics Working Group,"<p>For CYP2C19 ultrarapid metabolizers who are undergoing <em>H. pylori</em> eradication therapy, use a 4-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 4-fold higher dose.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for lansoprazole based on CYP2C19 genotype. Patients who are CYP2C19 ultrarapid metabolizers who are undergoing <em>H. pylori</em> eradication therapy should receive a 4-fold higher dose. In CYP2C19 ultrarapid metabolizer patients with other indications, be alert to reduced effectiveness, and, if necessary, use a 4-fold higher dose. Patients should be advised to report persisting symptoms of dyspepsia.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 PM</td><td>lansoprazole</td><td>NO action is needed for this gene-drug interaction.</td><td>The higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects.</td></tr>
<tr><td>CYP2C19 IM</td><td>lansoprazole</td><td>NO action is needed for this gene-drug interaction.</td><td>The higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects.</td></tr>
<tr><td>CYP2C19 UM</td><td>lansoprazole</td><td>The genetic variation may reduce lansoprazole plasma concentrations and therefore lansoprazole effectiveness.</td><td><strong>For Helicobacter pylori ERADICATION THERAPY:</strong> 1. Use a 4-fold higher dose. 2. Advise the patient to contact their doctor if symptoms of dyspepsia persist.<br/><strong>OTHER INDICATIONS:</strong> 1. Be alert to reduced effectiveness. 2. If necessary, use a 4-fold higher dose. 3. Advise the patient to report persisting symptoms of dyspepsia.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001833.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for lansoprazole based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  For the <em>CYP2C19</em> UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 200%.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Positive clinical effects</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Positive clinical effects</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>Helicobacter pylori eradication: increase dose by 200%. Be extra alert to insufficient response<br/>Other: be extra alert to insufficient response. Consider dose increase by 200%</td><td>no data was retrieved with the literature search</td><td>no data was retrieved with the literature search</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104987"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104987"",""name"":""Annotation of DPWG Guideline for lansoprazole and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704493E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415033E9,""date"":""2019-05-23T14:39:33.456-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820672E9,""date"":""2019-10-03T16:02:22.199-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.450956369E9,""date"":""2020-01-31T13:37:33.415-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963583E9,""date"":""2020-02-11T06:23:40.109-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450180"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450180"",""name"":""lansoprazole""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981988E9,""html"":""\u003cp\u003eFor CYP2C19 ultrarapid metabolizers who are undergoing \u003cem\u003eH. pylori\u003c/em\u003e eradication therapy, use a 4-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 4-fold higher dose.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981987E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for lansoprazole based on CYP2C19 genotype. Patients who are CYP2C19 ultrarapid metabolizers who are undergoing \u003cem\u003eH. pylori\u003c/em\u003e eradication therapy should receive a 4-fold higher dose. In CYP2C19 ultrarapid metabolizer patients with other indications, be alert to reduced effectiveness, and, if necessary, use a 4-fold higher dose. Patients should be advised to report persisting symptoms of dyspepsia.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 PM\u003c/td\u003e\u003ctd\u003elansoprazole\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003ctd\u003eThe higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 IM\u003c/td\u003e\u003ctd\u003elansoprazole\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003ctd\u003eThe higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 UM\u003c/td\u003e\u003ctd\u003elansoprazole\u003c/td\u003e\u003ctd\u003eThe genetic variation may reduce lansoprazole plasma concentrations and therefore lansoprazole effectiveness.\u003c/td\u003e\u003ctd\u003e\u003cstrong\u003eFor Helicobacter pylori ERADICATION THERAPY:\u003c/strong\u003e 1. Use a 4-fold higher dose. 2. Advise the patient to contact their doctor if symptoms of dyspepsia persist.\u003cbr/\u003e\u003cstrong\u003eOTHER INDICATIONS:\u003c/strong\u003e 1. Be alert to reduced effectiveness. 2. If necessary, use a 4-fold higher dose. 3. Advise the patient to report persisting symptoms of dyspepsia.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001833.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for lansoprazole based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For the \u003cem\u003eCYP2C19\u003c/em\u003e UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 200%.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003ePositive clinical effects\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003ePositive clinical effects\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eHelicobacter pylori eradication: increase dose by 200%. Be extra alert to insufficient response\u003cbr/\u003eOther: be extra alert to insufficient response. Consider dose increase by 200%\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182808,Guideline Annotation,Annotation of DPWG Guideline for methylphenidate and CYP2D6,f,PA450464,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for methylphenidate based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for methylphenidate based on CYP2D6 genotypes. They conclude that there is not a gene-drug interaction. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em>.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002528.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182808"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182808"",""name"":""Annotation of DPWG Guideline for methylphenidate and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414901E9,""date"":""2019-05-22T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820956E9,""date"":""2019-10-07T14:12:34.331-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45096364E9,""date"":""2020-02-11T06:37:16.484-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450464"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450464"",""name"":""methylphenidate""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414898E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for methylphenidate based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414899E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for methylphenidate based on CYP2D6 genotypes. They conclude that there is not a gene-drug interaction. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002528.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104995,Guideline Annotation,Annotation of DPWG Guideline for metoprolol and CYP2D6,t,PA450480,Dutch Pharmacogenetics Working Group,"<p>For CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, increase the dose in smaller steps and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for metoprolol based on CYP2D6 genotype.  For CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, increase the dose in smaller steps and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 IM</td><td>metoprolol</td><td>The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia.</td><td>If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA: 1. increase the dose in smaller steps and/or prescribe no more than 50% of the standard dose. OTHER CASES: 1. no action required</td></tr>
<tr><td>CYP2D6 PM</td><td>metoprolol</td><td>The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia.</td><td>If a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA: 1. increase the dose in smaller steps and/or prescribe no more than 25% of the standard dose. OTHER CASES: 1. no action required</td></tr>
<tr><td>CYP2D6 UM</td><td>metoprolol</td><td>The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate.</td><td>1. use the maximum dose for the relevant indication as a target dose. 2. if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative. Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001556.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for metoprolol based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend either selecting another drug or dose reduction for poor and intermediate metabolizer patients, with dose titration for ultra metabolizers.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>Heart failure: select alternative drug (e.g., bisoprolol, carvedilol) or reduce dose by 75%.  Other indications: be alert to ADEs (e.g., bradycardia, cold extremities) or select alternative drug (e.g., atenolol, bisoprolol).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>Heart failure: select alternative drug (e.g., bisoprolol, carvedilol) or reduce dose by 50%.  Other indications: be alert to ADEs (e.g., bradycardia, cold extremities) or select alternative drug (e.g., atenolol, bisoprolol).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>Heart failure: select alternative drug (e.g., bisoprolol, carvedilol) or titrate dose to a maximum of 250% of the normal dose in response to efficacy and ADE.  Other indications: select alternative drug (e.g., atenolol, bisoprolol) or titrate dose to a maximum of 250% of the normal dose in response to efficacy and ADE.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10<sup>9</sup>/l; leucopenia 1.0-2.0x10<sup>9</sup>/l; thrombocytopenia 25-50x10<sup>9</sup>/l; severe diarrhea.</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104995"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104995"",""name"":""Annotation of DPWG Guideline for metoprolol and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704497E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415228E9,""date"":""2019-05-27T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820225E9,""date"":""2019-09-30T11:52:04.350-07:00"",""description"":""update the text for November 2018 Update"",""type"":""Update"",""version"":0.0},{""id"":1.450820959E9,""date"":""2019-10-07T14:20:31.092-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45095635E9,""date"":""2020-01-31T13:38:27.507-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096366E9,""date"":""2020-02-11T06:39:11.616-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450480"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450480"",""name"":""metoprolol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982028E9,""html"":""\u003cp\u003eFor CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, increase the dose in smaller steps and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982027E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for metoprolol based on CYP2D6 genotype.  For CYP2D6 poor and intermediate metabolizer patients, if a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA, increase the dose in smaller steps and/or prescribe no more than 25% or 50% of the standard dose, respectively. For CYP2D6 ultra metabolizers, use the maximum dose for the relevant indication as a target dose, and if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative drug.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003emetoprolol\u003c/td\u003e\u003ctd\u003eThe gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia.\u003c/td\u003e\u003ctd\u003eIf a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA: 1. increase the dose in smaller steps and/or prescribe no more than 50% of the standard dose. OTHER CASES: 1. no action required\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003emetoprolol\u003c/td\u003e\u003ctd\u003eThe gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia.\u003c/td\u003e\u003ctd\u003eIf a GRADUAL REDUCTION in HEART RATE is desired, or in the event of SYMPTOMATIC BRADYCARDIA: 1. increase the dose in smaller steps and/or prescribe no more than 25% of the standard dose. OTHER CASES: 1. no action required\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003emetoprolol\u003c/td\u003e\u003ctd\u003eThe gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate.\u003c/td\u003e\u003ctd\u003e1. use the maximum dose for the relevant indication as a target dose. 2. if the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative. Possible alternatives include: HEART FAILURE: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6. OTHER INDICATIONS: atenolol or bisoprolol. Neither is metabolised by CYP2D6.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001556.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for metoprolol based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend either selecting another drug or dose reduction for poor and intermediate metabolizer patients, with dose titration for ultra metabolizers.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eHeart failure: select alternative drug (e.g., bisoprolol, carvedilol) or reduce dose by 75%.  Other indications: be alert to ADEs (e.g., bradycardia, cold extremities) or select alternative drug (e.g., atenolol, bisoprolol).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eHeart failure: select alternative drug (e.g., bisoprolol, carvedilol) or reduce dose by 50%.  Other indications: be alert to ADEs (e.g., bradycardia, cold extremities) or select alternative drug (e.g., atenolol, bisoprolol).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026gt; 3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia  \u0026gt; 75x10\u003csup\u003e9\u003c/sup\u003e/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eHeart failure: select alternative drug (e.g., bisoprolol, carvedilol) or titrate dose to a maximum of 250% of the normal dose in response to efficacy and ADE.  Other indications: select alternative drug (e.g., atenolol, bisoprolol) or titrate dose to a maximum of 250% of the normal dose in response to efficacy and ADE.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10\u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104967,Guideline Annotation,Annotation of DPWG Guideline for mirtazapine and CYP2D6,f,PA450522,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for mirtazapine based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mirtazapine based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction. The difference in plasma concentrations for varying CYP2D6 metabolizers has not been shown to demonstrate differences in efficacy or side effects. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002002.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mirtazapine based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They do not provide dosing recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>None.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>None.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S).</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>None.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S).</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104967"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104967"",""name"":""Annotation of DPWG Guideline for mirtazapine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704499E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414886E9,""date"":""2019-05-22T17:22:09.389-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820961E9,""date"":""2019-10-07T14:26:11.769-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956386E9,""date"":""2020-01-31T13:38:54.007-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.4509637E9,""date"":""2020-02-11T06:42:54.889-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450522"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450522"",""name"":""mirtazapine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981926E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for mirtazapine based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981925E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mirtazapine based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction. The difference in plasma concentrations for varying CYP2D6 metabolizers has not been shown to demonstrate differences in efficacy or side effects. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002002.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mirtazapine based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They do not provide dosing recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026gt; 3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia  \u0026gt; 75x10\u003csup\u003e9\u003c/sup\u003e/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms men, \u0026lt;470 ms women); INR increase \u0026lt; 4.5. Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms men, \u0026lt;470 ms women); INR increase \u0026lt; 4.5. Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182805,Guideline Annotation,Annotation of DPWG Guideline for mirtazapine and CYP2C19,f,PA450522,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for mirtazapine based on CYP2C19 genotypes.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mirtazapine based on CYP2C19 genotypes. They conclude that there is not a gene-drug interaction. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0003507.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182805"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182805"",""name"":""Annotation of DPWG Guideline for mirtazapine and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.45041488E9,""date"":""2019-05-22T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.45082096E9,""date"":""2019-10-07T14:23:23.100-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45096368E9,""date"":""2020-02-11T06:41:14.996-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450522"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450522"",""name"":""mirtazapine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414877E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for mirtazapine based on CYP2C19 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414878E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for mirtazapine based on CYP2C19 genotypes. They conclude that there is not a gene-drug interaction. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0003507.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104941,Guideline Annotation,Annotation of DPWG Guideline for moclobemide and CYP2C19,f,PA452615,Dutch Pharmacogenetics Working Group,"<p>No action is needed for this gene-drug interaction.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for moclobemide based on CYP2C19 genotype. They conclude that no action is needed for this gene-drug interaction. Although moclobemide plasma concentration may increase or decrease as a result of decreased or increased CYP2C19 metabolic capacity, this does not lead to an increased incidence of side effects, or increased effectiveness, in as far as is known. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001991.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for moclobemide based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They concluded that there are no recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>None</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5. Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>None</td><td>no data was retrieved with the literature search</td><td>no data was retrieved with the literature search</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>None</td><td>no data was retrieved with the literature search</td><td>no data was retrieved with the literature search</td></tr>
</tbody>
</table>
<ul>
<li>#See <a href=""http://www.pharmgkb.org/home/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104941"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104941"",""name"":""Annotation of DPWG Guideline for moclobemide and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704501E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415038E9,""date"":""2019-05-23T14:49:05.327-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820962E9,""date"":""2019-10-07T14:30:07.428-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956387E9,""date"":""2020-01-31T13:39:28.530-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963701E9,""date"":""2020-02-11T06:44:41.034-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA452615"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA452615"",""name"":""moclobemide""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981862E9,""html"":""\u003cp\u003eNo action is needed for this gene-drug interaction.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981861E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for moclobemide based on CYP2C19 genotype. They conclude that no action is needed for this gene-drug interaction. Although moclobemide plasma concentration may increase or decrease as a result of decreased or increased CYP2C19 metabolic capacity, this does not lead to an increased incidence of side effects, or increased effectiveness, in as far as is known. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001991.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for moclobemide based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They concluded that there are no recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio increase \u0026lt; 4.5. Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e#See \u003ca href\u003d\""http://www.pharmgkb.org/home/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104998,Guideline Annotation,Annotation of CPIC Guideline for nortriptyline and CYP2D6,t,PA450657,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.</li>
</ul>
</li>
</ul>
<h3 id=""december-2016-update"">December 2016 Update</h3>
<p><em>Advance online publication December 2016.</em></p>
<ul>
<li>The 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.</li>
<li>Excerpt from the 2016 dosing guideline update:
<ul>
<li>&quot;There is substantial evidence linking <em>CYP2D6</em> genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have <em>CYP2D6</em> genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.&quot;</li>
<li>&quot; There are scarce studies focusing solely on <em>CYP2D6</em> genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf"" target=""_blank"">2016 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 Gene-specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/Nortriptyline_Drug_Resource_Mappings.xlsx"" target=""_blank"">Nortriptyline Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/Nortriptyline_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Nortriptyline Pre and Post Test Alerts and Flow Chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-nortriptyline-based-on-cyp2d6-phenotype"">Table 1: Dosing recommendations for nortriptyline based on CYP2D6 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Activity score</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic Recommendations<sup>b</sup></th><th>Classification of recommendation for amitriptyline and nortriptyline<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 Ultrarapid metabolizer (~1-20% of patients)<sup>d</sup></td><td>&gt;2.0</td><td>An individual carrying more than two copies of functional alleles</td><td>*1/*1xN, *1/*2xN</td><td>Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.</td><td>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Strong</td></tr>
<tr><td>CYP2D6 Normal metabolizer (~72-88% of patients)<sup>d</sup></td><td>1.0-2.0<sup>f</sup></td><td>An individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0</td><td>*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5</td><td>Normal metabolism of TCAs.</td><td>Initiate therapy with recommended starting dose.<sup>g</sup></td><td>Strong</td></tr>
<tr><td>CYP2D6 Intermediate metabolizer (~1-13% of patients)<sup>d</sup></td><td>0.5</td><td>An individual carrying one decreased and one no function allele</td><td>*4/*41, *5/*9, *4/*10</td><td>Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Consider 25% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Moderate</td></tr>
<tr><td>CYP2D6 Poor metabolizer (~1-10% of patients)<sup>d</sup></td><td>0</td><td>An individual carrying only no function alleles</td><td>*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6</td><td>Greatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider 50% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement.</p>
<p><sup>d</sup> CYP2D6 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
<p><sup>g</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<h3 id=""may-2013"">May 2013</h3>
<p><em>Advance online publication January 2013.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing of amitriptyline and nortriptyline have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">2013 supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-CYP2D6%20frequency%20table%20legend%20(R2).pdf"" target=""_blank"">CYP2D6 frequency table legend (R2)</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-CYP2D6%20frequency%20table%20(R2).xlsx"" target=""_blank"">CYP2D6 frequency table (R2)</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104998"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104998"",""name"":""Annotation of CPIC Guideline for nortriptyline and CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[{""id"":1.449561263E9,""alleles"":[{""id"":1.449561355E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449561356E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449561357E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449561358E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449561359E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.44956136E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449561361E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449561362E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449561363E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449561364E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449561365E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449561366E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449561367E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449561368E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449561369E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.44956137E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.450824407E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}},{""id"":1.449561371E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449561372E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449561373E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.45004277E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.449561376E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449561377E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449561378E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449561379E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.44956138E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449561381E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449561264E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449561265E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449561266E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449561267E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449561268E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449561269E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.44956127E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449561271E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449561272E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449561273E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449561274E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449561275E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449561276E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449561277E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449561278E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449561279E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.44956128E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449561282E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449561281E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449561283E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449561284E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449561285E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449561286E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449561287E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449561288E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449561289E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.44956129E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449561291E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449561292E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449561293E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449561294E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449561295E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449561296E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449561297E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449561298E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449561299E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.4495613E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449561301E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449561302E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449561303E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449561304E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449561305E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449561306E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449561307E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449561308E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.449561309E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.44956131E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449561311E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449561312E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449561313E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449561314E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449561315E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449561316E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449561317E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449561318E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449561319E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.44956132E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449561322E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449561323E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449561324E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449561321E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449561325E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449561326E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449561327E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449561328E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449561329E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.44956133E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449561331E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449561332E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449561333E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449561334E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449561335E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449561336E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449561354E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449561337E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449561338E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449561339E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.44956134E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449561341E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449561342E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449561343E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449561344E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449561345E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449561346E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449561347E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449561348E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449561349E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.44956135E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449561351E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449561352E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449561353E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.450042769E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.183699776E9,""date"":""2013-01-16T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.448526127E9,""date"":""2016-12-14T13:55:21.811-08:00"",""description"":""2016 TCA CPIC guideline update"",""type"":""Update"",""version"":0.0},{""id"":1.450042771E9,""date"":""2018-11-15T19:09:00.873-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824534E9,""date"":""2019-10-24T18:32:29.535-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098242"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098242E7,""resourceId"":""27997040"",""title"":""Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5478479"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293321E9,""resource"":""PubMed Central"",""resourceId"":""PMC5478479"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/27997040"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44929332E9,""resource"":""PubMed"",""resourceId"":""27997040"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/27997040""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.597"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293322E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.597"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.597""}]},{""@id"":""https://pharmgkb.org/literature/15051926"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051926E7,""resourceId"":""23486447"",""title"":""Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3689226"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275357E9,""resource"":""PubMed Central"",""resourceId"":""PMC3689226"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23486447"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275356E9,""resource"":""PubMed"",""resourceId"":""23486447"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23486447""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.2"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275358E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.2"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.2""}]},{""@id"":""https://pharmgkb.org/literature/15100907"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100907E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450657"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450657"",""name"":""nortriptyline""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982024E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline update for nortriptyline recommends a 25% dose reduction for CYP2D6 intermediate metabolizers. For CYP2D6 ultrarapid or poor metabolizers, an alternative drug should be considered. If nortriptyline is warranted, consider a 50% dose reduction in CYP2D6 poor metabolizers.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982023E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2016-update\""\u003eDecember 2016 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication December 2016.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2016 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;There is substantial evidence linking \u003cem\u003eCYP2D6\u003c/em\u003e genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have \u003cem\u003eCYP2D6\u003c/em\u003e genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot; There are scarce studies focusing solely on \u003cem\u003eCYP2D6\u003c/em\u003e genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf\"" target\u003d\""_blank\""\u003e2016 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/Nortriptyline_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eNortriptyline Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/Nortriptyline_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eNortriptyline Pre and Post Test Alerts and Flow Chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-nortriptyline-based-on-cyp2d6-phenotype\""\u003eTable 1: Dosing recommendations for nortriptyline based on CYP2D6 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendation for amitriptyline and nortriptyline\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Ultrarapid metabolizer (~1-20% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying more than two copies of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN\u003c/td\u003e\u003ctd\u003eIncreased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Normal metabolizer (~72-88% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.0-2.0\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5\u003c/td\u003e\u003ctd\u003eNormal metabolism of TCAs.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Intermediate metabolizer (~1-13% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*41, *5/*9, *4/*10\u003c/td\u003e\u003ctd\u003eReduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Poor metabolizer (~1-10% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no function alleles\u003c/td\u003e\u003ctd\u003e*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider 50% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2013\""\u003eMay 2013\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication January 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing of amitriptyline and nortriptyline have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-CYP2D6%20frequency%20table%20legend%20(R2).pdf\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table legend (R2)\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-CYP2D6%20frequency%20table%20(R2).xlsx\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table (R2)\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166104961,Guideline Annotation,Annotation of DPWG Guideline for nortriptyline and CYP2D6,t,PA450657,Dutch Pharmacogenetics Working Group,"<p>The Dutch Pharmacogenetics Working Group Guideline for nortriptyline recommends a dose reduction for CYP2D6 poor or intermediate metabolizer patients. For CYP2D6 ultrarapid metabolizers, select an alternative drug or use 1.7 times the standard dose. Monitoring of nortriptyline and 10-hydroxynortriptyline plasma concentrations is recommended.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for nortriptyline based on CYP2D6 genotype. They recommend a dose increase or use of an alternative antidepressant in CYP2D6 ultrarapid metabolizers (UMs) and a dose reduction in CYP2D6 poor metabolizers (PMs). Monitoring of nortriptyline and Z-10-hydroxynortriptyline plasma concentrations is also recommended.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>nortriptyline</td><td>The risk of ineffectiveness and cardiotoxic effects may be increased. The gene variation leads to a decrease in the plasma concentration of nortriptyline and an increase in the plasma concentration of the cardiotoxic metabolite Z-10-hydroxynortriptyline.</td><td>Use 1.7 times the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline and be alert to an increase in the plasma concentration of the cardiotoxic metabolite Z-10-hydroxynortriptyline. Plasma concentrations of Z-hydroxynortriptyline exceeding 40 ng/mL are considered toxic.<br/>If a dose increase is not wanted due to the cardiotoxic hydroxy metabolite: avoid nortriptyline. Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</td></tr>
<tr><td>CYP2D6 IM</td><td>nortriptyline</td><td>The risk of side effects may be increased, because the gene variation leads to an increased plasma concentration of nortriptyline.</td><td>Use 60% of the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline in order to set the maintenance dose.<br/>The therapeutic range of nortriptyline is 50-150 ng/mL. Values exceeding 250 ng/mL are considered toxic.</td></tr>
<tr><td>CYP2D6 PM</td><td>nortriptyline</td><td>The risk of side effects may be increased, because the gene variation leads to an increased plasma concentration of nortriptyline.</td><td>Use 40% of the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline in order to set the maintenance dose.<br/>The therapeutic range of nortriptyline is 50-150 ng/mL. Values exceeding 250 ng/mL are considered toxic.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001557.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for nortriptyline based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend reducing the dose for poor and intermediate metabolizer patients and selecting an alternative drug or increasing the dose for ultra metabolizers.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>Reduce dose by 60% and monitor nortriptyline + 10-hydroxynortriptyline plasma concentrations.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>Reduce dose by 40% and monitor nortriptyline + 10-hydroxynortriptyline plasma concentrations.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>Select alternative drug (e.g., citalopram, sertraline) or increase dose by 60% and monitor nortriptyline + 10-hydroxynortriptyline plasma concentrations.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/nortiptyline_CYP2D6_271111.pdf"">Nortriptyline CYP2D6 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104961"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104961"",""name"":""Annotation of DPWG Guideline for nortriptyline and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704503E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414979E9,""date"":""2019-05-23T11:22:02.683-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820969E9,""date"":""2019-10-07T14:32:21.470-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956388E9,""date"":""2020-01-31T13:39:56.178-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096372E9,""date"":""2020-02-11T06:47:31.383-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450657"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450657"",""name"":""nortriptyline""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.44798193E9,""html"":""\u003cp\u003eThe Dutch Pharmacogenetics Working Group Guideline for nortriptyline recommends a dose reduction for CYP2D6 poor or intermediate metabolizer patients. For CYP2D6 ultrarapid metabolizers, select an alternative drug or use 1.7 times the standard dose. Monitoring of nortriptyline and 10-hydroxynortriptyline plasma concentrations is recommended.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981929E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for nortriptyline based on CYP2D6 genotype. They recommend a dose increase or use of an alternative antidepressant in CYP2D6 ultrarapid metabolizers (UMs) and a dose reduction in CYP2D6 poor metabolizers (PMs). Monitoring of nortriptyline and Z-10-hydroxynortriptyline plasma concentrations is also recommended.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003enortriptyline\u003c/td\u003e\u003ctd\u003eThe risk of ineffectiveness and cardiotoxic effects may be increased. The gene variation leads to a decrease in the plasma concentration of nortriptyline and an increase in the plasma concentration of the cardiotoxic metabolite Z-10-hydroxynortriptyline.\u003c/td\u003e\u003ctd\u003eUse 1.7 times the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline and be alert to an increase in the plasma concentration of the cardiotoxic metabolite Z-10-hydroxynortriptyline. Plasma concentrations of Z-hydroxynortriptyline exceeding 40 ng/mL are considered toxic.\u003cbr/\u003eIf a dose increase is not wanted due to the cardiotoxic hydroxy metabolite: avoid nortriptyline. Antidepressants that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003enortriptyline\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to an increased plasma concentration of nortriptyline.\u003c/td\u003e\u003ctd\u003eUse 60% of the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline in order to set the maintenance dose.\u003cbr/\u003eThe therapeutic range of nortriptyline is 50-150 ng/mL. Values exceeding 250 ng/mL are considered toxic.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003enortriptyline\u003c/td\u003e\u003ctd\u003eThe risk of side effects may be increased, because the gene variation leads to an increased plasma concentration of nortriptyline.\u003c/td\u003e\u003ctd\u003eUse 40% of the standard dose and monitor the effect and side effects or the plasma concentration of nortriptyline in order to set the maintenance dose.\u003cbr/\u003eThe therapeutic range of nortriptyline is 50-150 ng/mL. Values exceeding 250 ng/mL are considered toxic.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001557.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for nortriptyline based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend reducing the dose for poor and intermediate metabolizer patients and selecting an alternative drug or increasing the dose for ultra metabolizers.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eReduce dose by 60% and monitor nortriptyline + 10-hydroxynortriptyline plasma concentrations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eReduce dose by 40% and monitor nortriptyline + 10-hydroxynortriptyline plasma concentrations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eSelect alternative drug (e.g., citalopram, sertraline) or increase dose by 60% and monitor nortriptyline + 10-hydroxynortriptyline plasma concentrations.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/nortiptyline_CYP2D6_271111.pdf\""\u003eNortriptyline CYP2D6 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104946,Guideline Annotation,Annotation of DPWG Guideline for olanzapine and CYP2D6,f,PA450688,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for olanzapine based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for olanzapine based on CYP2D6 genotypes. They conclude that there is not a gene-drug interaction. &quot;Studies with PM and IM found no significant association between the genotype and clinical effects (clinical improvements, non-response and extrapyramidal side effects and changes in insulin levels). No studies have been published in which the pharmacokinetics and effects of the use of olanzapine on UM phenotype were studied.&quot; <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001562.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for olanzapine based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They do not provide dosing recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>None.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS). Kinetic effect (NS).</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>None.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS). Kinetic effect (NS).</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>None.</td><td>None.</td><td>None.</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>* See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods</a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>NS: not statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104946"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104946"",""name"":""Annotation of DPWG Guideline for olanzapine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704505E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414896E9,""date"":""2019-05-22T17:49:10.048-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.45082097E9,""date"":""2019-10-07T14:35:09.976-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956389E9,""date"":""2020-01-31T13:42:42.307-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963681E9,""date"":""2020-02-11T06:49:16.627-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450688"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450688"",""name"":""olanzapine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981878E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for olanzapine based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981877E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for olanzapine based on CYP2D6 genotypes. They conclude that there is not a gene-drug interaction. \u0026quot;Studies with PM and IM found no significant association between the genotype and clinical effects (clinical improvements, non-response and extrapyramidal side effects and changes in insulin levels). No studies have been published in which the pharmacokinetics and effects of the use of olanzapine on UM phenotype were studied.\u0026quot; \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001562.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for olanzapine based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They do not provide dosing recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS). Kinetic effect (NS).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS). Kinetic effect (NS).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e* See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods\u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eNS: not statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104957,Guideline Annotation,Annotation of DPWG Guideline for omeprazole and CYP2C19,t,PA450704,Dutch Pharmacogenetics Working Group,"<p>For CYP2C19 ultrarapid metabolizers who are undergoing <em>H. pylori</em> eradication therapy, use a 3-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 3-fold higher dose.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for omeprazole based on CYP2C19 genotype. Patients who are CYP2C19 ultrarapid metabolizers who are undergoing <em>H. pylori</em> eradication therapy should receive a 3-fold higher dose. In CYP2C19 ultrarapid metabolizer patients with other indications, be alert to reduced effectiveness, and, if necessary, use a 3-fold higher dose. Patients should be advised to report persisting symptoms of dyspepsia.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 PM</td><td>omeprazole</td><td>NO action is required for this gene-drug interaction.</td><td>The higher plasma concentration of omeprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects.</td></tr>
<tr><td>CYP2C19 IM</td><td>omeprazole</td><td>NO action is required for this gene-drug interaction.</td><td>The higher plasma concentration of omeprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects.</td></tr>
<tr><td>CYP2C19 UM</td><td>omeprazole</td><td>The genetic variation may lead to a reduced omeprazole plasma concentration and therefore reduced effectiveness.</td><td><strong>For Helicobacter pylori ERADICATION THERAPY:</strong> 1. use a 3-fold higher dose. 2. advise the patient to contact their doctor if symptoms of dyspepsia persist.<br/><strong>OTHER INDICATIONS:</strong> 1. be alert to reduced effectiveness. 2. if necessary, use a 3-fold higher dose. 3. advise the patient to report persisting symptoms of dyspepsia.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001841.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for omeprazole based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  For the <em>CYP2C19</em> UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 100-200%.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Positive clinical effects</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Positive clinical effects</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>Helicobacter pylori eradication: increase dose by 100-200%. Be extra alert to insufficient response. Other: be extra alert to insufficient response. Consider dose increase by 100-200%</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 Kinetic effect (statistically significant difference)</td></tr>
</tbody>
</table>
<ul>
<li>* and # See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/omeprazole_CYP2C19_271111.pdf"">Omeprazole CYP2C19 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104957"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104957"",""name"":""Annotation of DPWG Guideline for omeprazole and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704507E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.45041504E9,""date"":""2019-05-23T15:01:55.626-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820977E9,""date"":""2019-10-07T14:37:18.101-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45095639E9,""date"":""2020-01-31T13:43:11.730-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963682E9,""date"":""2020-02-11T07:03:22.643-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450704"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450704"",""name"":""omeprazole""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981902E9,""html"":""\u003cp\u003eFor CYP2C19 ultrarapid metabolizers who are undergoing \u003cem\u003eH. pylori\u003c/em\u003e eradication therapy, use a 3-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 3-fold higher dose.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981901E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for omeprazole based on CYP2C19 genotype. Patients who are CYP2C19 ultrarapid metabolizers who are undergoing \u003cem\u003eH. pylori\u003c/em\u003e eradication therapy should receive a 3-fold higher dose. In CYP2C19 ultrarapid metabolizer patients with other indications, be alert to reduced effectiveness, and, if necessary, use a 3-fold higher dose. Patients should be advised to report persisting symptoms of dyspepsia.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 PM\u003c/td\u003e\u003ctd\u003eomeprazole\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction.\u003c/td\u003e\u003ctd\u003eThe higher plasma concentration of omeprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 IM\u003c/td\u003e\u003ctd\u003eomeprazole\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction.\u003c/td\u003e\u003ctd\u003eThe higher plasma concentration of omeprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 UM\u003c/td\u003e\u003ctd\u003eomeprazole\u003c/td\u003e\u003ctd\u003eThe genetic variation may lead to a reduced omeprazole plasma concentration and therefore reduced effectiveness.\u003c/td\u003e\u003ctd\u003e\u003cstrong\u003eFor Helicobacter pylori ERADICATION THERAPY:\u003c/strong\u003e 1. use a 3-fold higher dose. 2. advise the patient to contact their doctor if symptoms of dyspepsia persist.\u003cbr/\u003e\u003cstrong\u003eOTHER INDICATIONS:\u003c/strong\u003e 1. be alert to reduced effectiveness. 2. if necessary, use a 3-fold higher dose. 3. advise the patient to report persisting symptoms of dyspepsia.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001841.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for omeprazole based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For the \u003cem\u003eCYP2C19\u003c/em\u003e UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 100-200%.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003ePositive clinical effects\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003ePositive clinical effects\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eHelicobacter pylori eradication: increase dose by 100-200%. Be extra alert to insufficient response. Other: be extra alert to insufficient response. Consider dose increase by 100-200%\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio increase \u0026lt; 4.5 Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e* and # See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/omeprazole_CYP2C19_271111.pdf\""\u003eOmeprazole CYP2C19 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166161954,Guideline Annotation,Annotation of CPIC Guideline for ondansetron and CYP2D6,t,PA450705,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"" target=""_blank"">CPIC&reg; guideline for ondansetron and tropisetron and CYP2D6</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.</li>
</ul>
</li>
</ul>
<h3 id=""december-2016"">December 2016</h3>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for ondansetron were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpt from the 2016 ondansetron dosing guidelines:
<ul>
<li>&quot;Gene duplication has been shown to be associated with higher metabolism and clearance of ondansetron resulting in lower area under the plasma concentration-time curve. This translates clinically into a decreased response to ondansetron and tropisetron, specifically increased risk of vomiting in CYP2D6 ultrarapid metabolizers. If CYP2D6 genotype is known, alternative 5-HT3 receptor antagonist antiemetics not metabolized by CYP2D6 (e.g., granisetron) should be considered in CYP2D6 ultrarapid metabolizers. &quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/ondansetron/2016/28002639.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/ondansetron/2016/28002639-supplement.pdf"" target=""_blank"">2016 supplement</a></li>
<li><a href=""/page/cyp2d6RefMaterials"">Gene-specific Information Tables for CYP2D6</a></li>
<li><a rel=""noopener noreferrer"" href=""https://raw.githubusercontent.com/PharmGKB/cpic-guidelines/master/ondansetron/2016/Ondansetron_Drug_Resource_Mappings.xlsx"" target=""_blank"">Ondansetron Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://raw.githubusercontent.com/PharmGKB/cpic-guidelines/master/ondansetron/2016/Ondansetron_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Ondansetron Pre- and Post-Test Alerts and Flow Chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-ondansetron-based-on-cyp2d6-phenotype-genotype"">Table 1: Dosing recommendations for ondansetron based on CYP2D6 phenotype/genotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>CYP2D6 Phenotype</th><th>Activity score</th><th>CYP2D6 Genotypes<sup>a</sup></th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic recommendations</th><th>Classification of Recommendations<sup>b</sup></th><th>Consideration for alternative 5-HT<sub>3</sub> receptor antagonists antiemetics<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer</td><td>&gt;2.0</td><td>An individual carrying duplications of function alleles</td><td><em>*1/*1xN, *1/*2xN, *2/*2xN</em><sup>d</sup></td><td>Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).</td><td>Select and alternative drug not predominantly metabolized by CYP2D6 (i.e. granisetron).<sup>e</sup></td><td>Moderate</td><td>Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6.  Limited evidence is available regarding the utilization of <em>CYP2D6</em> genetic variation to guide use of these drugs.</td></tr>
<tr><td>Normal metabolizer</td><td>2.0-1.0<sup>f</sup></td><td>An individual carrying two normal function alleles, or two decreased function alleles, or one normal function and one no function allele, or one normal function and one decreased function allele, or combinations of duplicated alleles that result in an activity score of 1.0-2.0</td><td><em>*1/*1, *1/*2, *1/*4, *1/*5, *1/*9, *1/*41, *2/*2,*41/*41</em></td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose.</td><td>Strong</td><td></td></tr>
<tr><td>Intermediate metabolizer</td><td>0.5</td><td>An individual carrying one decreased function and one no function allele</td><td><em>*4/*10,*4/*41, *5/*9</em></td><td>Very limited data available for CYP2D6 intermediate metabolizers</td><td>Insufficient evidence demonstrating clinical impact based on <em>CYP2D6</em> genotype.  Initiate therapy with recommended starting dose.</td><td>No recommendation</td><td></td></tr>
<tr><td>Poor metabolizer</td><td>0</td><td>An individual carrying no functional alleles</td><td><em>*3/*4,*4/*4, *5/*5, *5/*6</em></td><td>Very limited data available for CYP2D6 poor metabolizers</td><td>Insufficient evidence demonstrating clinical impact based on <em>CYP2D6</em> genotype.  Initiate therapy with recommended starting dose.</td><td>No recommendation</td><td></td></tr>
</tbody>
</table>
<p><sup>a</sup> Assignment of allele function and citations for allele function can be found on PharmGKB: <a href=""/page/cyp2d6RefMaterials"">CYP2D6 Allele Definition Table and CYP2D6 Allele Functionality Table</a>.</p>
<p><sup>b</sup> Rating scheme is described in the 2016 Supplement</p>
<p><sup>c</sup> CPIC strength of recommendation: No Recommendation. See rating scheme described in the Supplement.</p>
<p><sup>d</sup> Where <em>xN</em> represents the number of <em>CYP2D6</em> gene copies.  For individuals with <em>CYP2D6</em> duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.</p>
<p><sup>e</sup> Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>
<p><sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166161954"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166161954"",""name"":""Annotation of CPIC Guideline for ondansetron and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":""OHD9LFRlJ4g"",""guidelineGenes"":[{""id"":1.449561554E9,""alleles"":[{""id"":1.449561555E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449561556E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449561557E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449561558E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449561559E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.44956156E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449561561E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449561562E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449561563E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449561564E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449561565E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449561566E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449561567E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449561568E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449561569E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.44956157E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.449561571E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449561572E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449561573E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.449561576E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449561577E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449561578E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449561579E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.44956158E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449561581E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449561582E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449561583E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449561584E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449561585E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449561586E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449561587E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449561588E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449561589E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.44956159E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449561591E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449561592E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449561593E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449561594E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449561595E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449561596E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449561597E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449561598E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449561599E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.4495616E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449561601E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449561602E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449561603E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449561604E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449561605E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449561606E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449561607E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449561608E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449561609E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.44956161E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449561611E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449561612E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449561613E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449561614E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449561615E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449561616E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449561617E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449561618E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449561619E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.44956162E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449561621E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449561622E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449561623E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449561624E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449561625E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449561626E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.449561627E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449561628E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449561629E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.44956163E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449561631E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449561632E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449561633E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449561634E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449561635E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449561636E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449561637E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449561638E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449561639E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.44956164E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449561641E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449561642E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449561643E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449561644E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449561645E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449561646E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449561647E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449561648E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449561649E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.44956165E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449561651E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449561652E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449561653E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449561654E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449561655E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449561656E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449561657E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449561658E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449561659E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.44956166E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449561661E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449561662E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449561663E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449561664E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449561665E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449561666E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449561667E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449561668E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449561669E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.44956167E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449561671E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449561672E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.450042757E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042758E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824312E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.448526496E9,""date"":""2016-12-23T16:12:51.760-08:00"",""type"":""Update"",""version"":0.0},{""id"":1.449717054E9,""date"":""2018-08-23T09:21:51.656-07:00"",""description"":""Added link to YouTube video for this guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450042759E9,""date"":""2018-11-15T18:55:13.118-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824544E9,""date"":""2019-10-24T20:12:43.110-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098241"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098241E7,""resourceId"":""28002639"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479760"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5479760"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293318E9,""resource"":""PubMed Central"",""resourceId"":""PMC5479760"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479760""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/28002639"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293317E9,""resource"":""PubMed"",""resourceId"":""28002639"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/28002639""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.598"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293319E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.598"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.598""}]},{""@id"":""https://pharmgkb.org/literature/15100912"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100912E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""title"":""CPIC® Guideline for Ondansetron and Tropisetron based on CYP2D6 genotype – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.448526498E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450705"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450705"",""name"":""ondansetron""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.448526106E9,""html"":""\u003cp\u003eThe CPIC dosing guideline for ondansetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.448526123E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for ondansetron and tropisetron and CYP2D6\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2016\""\u003eDecember 2016\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for ondansetron were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2016 ondansetron dosing guidelines:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Gene duplication has been shown to be associated with higher metabolism and clearance of ondansetron resulting in lower area under the plasma concentration-time curve. This translates clinically into a decreased response to ondansetron and tropisetron, specifically increased risk of vomiting in CYP2D6 ultrarapid metabolizers. If CYP2D6 genotype is known, alternative 5-HT3 receptor antagonist antiemetics not metabolized by CYP2D6 (e.g., granisetron) should be considered in CYP2D6 ultrarapid metabolizers. \u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/ondansetron/2016/28002639.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/ondansetron/2016/28002639-supplement.pdf\"" target\u003d\""_blank\""\u003e2016 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""/page/cyp2d6RefMaterials\""\u003eGene-specific Information Tables for CYP2D6\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://raw.githubusercontent.com/PharmGKB/cpic-guidelines/master/ondansetron/2016/Ondansetron_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eOndansetron Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://raw.githubusercontent.com/PharmGKB/cpic-guidelines/master/ondansetron/2016/Ondansetron_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eOndansetron Pre- and Post-Test Alerts and Flow Chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-ondansetron-based-on-cyp2d6-phenotype-genotype\""\u003eTable 1: Dosing recommendations for ondansetron based on CYP2D6 phenotype/genotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eCYP2D6 Phenotype\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eCYP2D6 Genotypes\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003c/th\u003e\u003cth\u003eClassification of Recommendations\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eConsideration for alternative 5-HT\u003csub\u003e3\u003c/sub\u003e receptor antagonists antiemetics\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying duplications of function alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*1xN, *1/*2xN, *2/*2xN\u003c/em\u003e\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eIncreased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).\u003c/td\u003e\u003ctd\u003eSelect and alternative drug not predominantly metabolized by CYP2D6 (i.e. granisetron).\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eDolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6.  Limited evidence is available regarding the utilization of \u003cem\u003eCYP2D6\u003c/em\u003e genetic variation to guide use of these drugs.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNormal metabolizer\u003c/td\u003e\u003ctd\u003e2.0-1.0\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles, or two decreased function alleles, or one normal function and one no function allele, or one normal function and one decreased function allele, or combinations of duplicated alleles that result in an activity score of 1.0-2.0\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*1, *1/*2, *1/*4, *1/*5, *1/*9, *1/*41, *2/*2,*41/*41\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased function and one no function allele\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*4/*10,*4/*41, *5/*9\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eVery limited data available for CYP2D6 intermediate metabolizers\u003c/td\u003e\u003ctd\u003eInsufficient evidence demonstrating clinical impact based on \u003cem\u003eCYP2D6\u003c/em\u003e genotype.  Initiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eNo recommendation\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizer\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying no functional alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*3/*4,*4/*4, *5/*5, *5/*6\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eVery limited data available for CYP2D6 poor metabolizers\u003c/td\u003e\u003ctd\u003eInsufficient evidence demonstrating clinical impact based on \u003cem\u003eCYP2D6\u003c/em\u003e genotype.  Initiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eNo recommendation\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Assignment of allele function and citations for allele function can be found on PharmGKB: \u003ca href\u003d\""/page/cyp2d6RefMaterials\""\u003eCYP2D6 Allele Definition Table and CYP2D6 Allele Functionality Table\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Rating scheme is described in the 2016 Supplement\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e CPIC strength of recommendation: No Recommendation. See rating scheme described in the Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e Where \u003cem\u003exN\u003c/em\u003e represents the number of \u003cem\u003eCYP2D6\u003c/em\u003e gene copies.  For individuals with \u003cem\u003eCYP2D6\u003c/em\u003e duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.448526498E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/""}]},""status"":""success""}"
PA166176623,Guideline Annotation,Annotation of CPIC Guideline for oxcarbazepine and HLA-B,t,PA450732,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for oxcarbazepine recommends an alternative drug for oxcarbazepine-naive patients carrying at least one copy of <em>HLA-B*15:02</em> due to the association of this allele with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"" target=""_blank"">CPIC&reg; guideline for oxcarbazepine and <em>HLA-B</em></a>.</p>
<h3 id=""december-2017"">December 2017</h3>
<p><em>Accepted article preview online January 2018; Advance online publication February 2018.</em></p>
<ul>
<li>The 2017 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of carbamazepine expanded to include information on pharmacogenomic tests in dosing of oxcarbazepine. The updated guidelines were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Literature up to June 2016 was reviewed, recommendations and supplemental information were updated.</li>
<li>Excerpts from the 2017 dosing guideline update:
<ul>
<li>&quot;There is evidence linking <em>HLA-B*15:02</em> genotype with the risk of carbamazepine- and oxcarbazepine-induced SJS/TEN.&quot;</li>
<li>&quot;Data describing the relationship between <em>HLA-B*15:02</em> and <em>HLA-A*31:01</em> genotype and carbamazepine- or oxcarbazepine-induced cutaneous adverse reactions in pediatric patients are scarce. In the absence of data suggesting a different relationship between these <em>HLA</em> alleles and drug-induced hypersensitivity in pediatric patients, the recommendations may be used to guide use of carbamazepine and oxcarbazepine in both adult and pediatric patients.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <em>HLA</em> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC_Supplemental_Material.pdf"" target=""_blank"">2017 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/hlabRefMaterials"">HLA Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/Oxcarbazepine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Oxcarbazepine Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/carbamazepine/CBZ_OXC_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Carbamazepine and Oxcarbazepine Pre and Post Tests Alerts and Flow Chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-oxcarbazepine-therapy-recommendations-based-on-hla-b-genotype"">Table 1: Oxcarbazepine therapy recommendations based on <em>HLA-B</em> genotype</h3>
<p><em>Adapted from Tables 1 and 3 of the 2017 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of Diplotypes</th><th>Phenotypic Implications</th><th>Therapeutic Recommendations</th><th>Classification of Recommendation <sup>a</sup></th><th>Considerations for other aromatic anticonvulsants</th></tr>
</thead>
<tbody>
<tr><td>Homozygous for alleles other than <em>HLA-B*15:02</em></td><td>Non-carrier of <em>HLA-B*15:02</em>.  No <em>HLA-B*15:02</em> alleles reported, often reported as &quot;negative&quot; on genotyping tests.</td><td>*X/*X <sup>b</sup></td><td>Normal or reduced risk of oxcarbazepine-induced SJS/TEN.</td><td>Use oxcarbazepine per standard dosing guidelines.</td><td>Strong</td><td></td></tr>
<tr><td>Heterozygote or homozygous for <em>HLA-B*15:02</em></td><td>Carrier of <em>HLA-B*15:02</em>.  One or two <em>*15:02</em> alleles, often reported as &quot;positive&quot; on a genotyping test.</td><td><em>*15:02</em>/*X <sup>b</sup><br/><em>*15:02</em>/<em>*15:02</em></td><td>Increased risk of oxcarbazepine-induced SJS/TEN</td><td>A. If patient is oxcarbazepine-naive, do not use oxcarbazepine.<br/>B. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherance to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.</td><td>A. Strong<br/>B. Optional</td><td>A. Other aromatic anticonvulsants (e.g. eslicarbazepine, lamotrigine, phenytoin, fosphenytoin and phenoarbital) have weaker evidence linking SJS/TEN with the <em>HLA-B*15:02</em> allele; however, caution should still be used in choosing an alternative agent.<br/>B. Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants.</td></tr>
</tbody>
</table>
<p><sup>a</sup> Rating scheme described in the 2017 update supplement (see above)</p>
<p><sup>b</sup> *X = any <em>HLA-B</em> genotype other than <em>*15:02</em></p>
<p><em>HLA-B</em> = human leukocyte antigen B</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166176623"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166176623"",""name"":""Annotation of CPIC Guideline for oxcarbazepine and HLA-B"",""cancerGenome"":false,""descriptiveVideoId"":""AFD2W7ugz2I"",""guidelineGenes"":[{""id"":1.449560816E9,""alleles"":[{""id"":1.449560817E9,""_label"":""Other"",""allele"":""Other"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558334"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558334E9,""resource"":""Allele Function"",""term"":""Absence"",""termId"":""haplotypeTags:1445558334""}},{""id"":1.449560818E9,""_label"":""*15:02:01"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558333"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558333E9,""resource"":""Allele Function"",""term"":""Presence"",""termId"":""haplotypeTags:1445558333""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165954769"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165954769"",""symbol"":""HLA-B*15:02:01"",""name"":""*15:02:01""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}}],""history"":[{""id"":1.449167601E9,""date"":""2018-02-07T22:43:45.748-08:00"",""description"":""guideline added"",""type"":""Update"",""version"":0.0},{""id"":1.450372858E9,""date"":""2019-03-20T14:12:21.385-07:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15100356"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100356E7,""resourceId"":""29392710"",""title"":""Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847474"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5847474"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449292006E9,""resource"":""PubMed Central"",""resourceId"":""PMC5847474"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847474""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/29392710"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449292005E9,""resource"":""PubMed"",""resourceId"":""29392710"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/29392710""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1004"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449292007E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1004"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1004""}]},{""@id"":""https://pharmgkb.org/literature/15100921"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100921E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""title"":""CPIC® Guideline for HLA genotype and Use of Carbamazepine and Oxcarbazepine – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983473E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450732"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450732"",""name"":""oxcarbazepine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.44916368E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for oxcarbazepine recommends an alternative drug for oxcarbazepine-naive patients carrying at least one copy of \u003cem\u003eHLA-B*15:02\u003c/em\u003e due to the association of this allele with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.44916394E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for oxcarbazepine and \u003cem\u003eHLA-B\u003c/em\u003e\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""december-2017\""\u003eDecember 2017\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online January 2018; Advance online publication February 2018.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2017 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of carbamazepine expanded to include information on pharmacogenomic tests in dosing of oxcarbazepine. The updated guidelines were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Literature up to June 2016 was reviewed, recommendations and supplemental information were updated.\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2017 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;There is evidence linking \u003cem\u003eHLA-B*15:02\u003c/em\u003e genotype with the risk of carbamazepine- and oxcarbazepine-induced SJS/TEN.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Data describing the relationship between \u003cem\u003eHLA-B*15:02\u003c/em\u003e and \u003cem\u003eHLA-A*31:01\u003c/em\u003e genotype and carbamazepine- or oxcarbazepine-induced cutaneous adverse reactions in pediatric patients are scarce. In the absence of data suggesting a different relationship between these \u003cem\u003eHLA\u003c/em\u003e alleles and drug-induced hypersensitivity in pediatric patients, the recommendations may be used to guide use of carbamazepine and oxcarbazepine in both adult and pediatric patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for \u003cem\u003eHLA\u003c/em\u003e Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/2017/CPIC_HLA_CBZ_OXC_Supplemental_Material.pdf\"" target\u003d\""_blank\""\u003e2017 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/hlabRefMaterials\""\u003eHLA Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/Oxcarbazepine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eOxcarbazepine Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/carbamazepine/CBZ_OXC_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eCarbamazepine and Oxcarbazepine Pre and Post Tests Alerts and Flow Chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-oxcarbazepine-therapy-recommendations-based-on-hla-b-genotype\""\u003eTable 1: Oxcarbazepine therapy recommendations based on \u003cem\u003eHLA-B\u003c/em\u003e genotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3 of the 2017 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of Diplotypes\u003c/th\u003e\u003cth\u003ePhenotypic Implications\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003c/th\u003e\u003cth\u003eClassification of Recommendation \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eConsiderations for other aromatic anticonvulsants\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eHomozygous for alleles other than \u003cem\u003eHLA-B*15:02\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eNon-carrier of \u003cem\u003eHLA-B*15:02\u003c/em\u003e.  No \u003cem\u003eHLA-B*15:02\u003c/em\u003e alleles reported, often reported as \u0026quot;negative\u0026quot; on genotyping tests.\u003c/td\u003e\u003ctd\u003e*X/*X \u003csup\u003eb\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eNormal or reduced risk of oxcarbazepine-induced SJS/TEN.\u003c/td\u003e\u003ctd\u003eUse oxcarbazepine per standard dosing guidelines.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eHeterozygote or homozygous for \u003cem\u003eHLA-B*15:02\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eCarrier of \u003cem\u003eHLA-B*15:02\u003c/em\u003e.  One or two \u003cem\u003e*15:02\u003c/em\u003e alleles, often reported as \u0026quot;positive\u0026quot; on a genotyping test.\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*15:02\u003c/em\u003e/*X \u003csup\u003eb\u003c/sup\u003e\u003cbr/\u003e\u003cem\u003e*15:02\u003c/em\u003e/\u003cem\u003e*15:02\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eIncreased risk of oxcarbazepine-induced SJS/TEN\u003c/td\u003e\u003ctd\u003eA. If patient is oxcarbazepine-naive, do not use oxcarbazepine.\u003cbr/\u003eB. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherance to therapy (~4-28 days), and cases usually occur within 3 months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than 3 months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.\u003c/td\u003e\u003ctd\u003eA. Strong\u003cbr/\u003eB. Optional\u003c/td\u003e\u003ctd\u003eA. Other aromatic anticonvulsants (e.g. eslicarbazepine, lamotrigine, phenytoin, fosphenytoin and phenoarbital) have weaker evidence linking SJS/TEN with the \u003cem\u003eHLA-B*15:02\u003c/em\u003e allele; however, caution should still be used in choosing an alternative agent.\u003cbr/\u003eB. Previous tolerance of oxcarbazepine is not indicative of tolerance to other aromatic anticonvulsants.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Rating scheme described in the 2017 update supplement (see above)\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e *X \u003d any \u003cem\u003eHLA-B\u003c/em\u003e genotype other than \u003cem\u003e*15:02\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eHLA-B\u003c/em\u003e \u003d human leukocyte antigen B\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983473E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/""}]},""status"":""success""}"
PA166104973,Guideline Annotation,Annotation of DPWG Guideline for oxycodone and CYP2D6,f,PA450741,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for oxycodone based on CYP2D6 genotypes.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for oxycodone based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction. The reduced conversion of oxycodone to the more active metabolite oxymorphone does not result in reduced analgesia in patients and the increased conversion of oxycodone to the more active metabolite oxymorphone does not result in an increase in side effects in patients. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001588.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for oxycodone based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend using an alternate drug for poor, intermediate and ultra metabolizer patients.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>Insufficient data to allow calculation of dose adjustment.  Select alternate drug - not tramadol or codeine - or be alert to symptoms of insufficient pain relief.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9/l; leucopenia &gt; 3.0x10</sup>9/l; thrombocytopenia  &gt; 75x10^9/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>Insufficient data to allow calculation of dose adjustment.  Select alternate drug - not tramadol or codeine - or be alert to symptoms of insufficient pain relief.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS). Kinetic effect (NS).</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>Insufficient data to allow calculation of dose adjustment.  Select alternate drug (NOT tramadol or codeine) or be alert to ADEs (e.g., nausea, vomiting, constipation, respiratory depression, confusion, urinary retention).</td><td>Published incomplete case reports. Product information.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S).</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods</a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
<li>NS: not statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104973"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104973"",""name"":""Annotation of DPWG Guideline for oxycodone and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704509E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414888E9,""date"":""2019-05-22T17:29:12.184-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820987E9,""date"":""2019-10-07T14:43:22.263-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956391E9,""date"":""2020-01-31T13:43:35.628-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963721E9,""date"":""2020-02-11T07:04:34.504-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450741"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450741"",""name"":""oxycodone""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982012E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for oxycodone based on CYP2D6 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982011E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for oxycodone based on CYP2D6 genotypes. They conclude that NO action is required for this gene-drug interaction. The reduced conversion of oxycodone to the more active metabolite oxymorphone does not result in reduced analgesia in patients and the increased conversion of oxycodone to the more active metabolite oxymorphone does not result in an increase in side effects in patients. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001588.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for oxycodone based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend using an alternate drug for poor, intermediate and ultra metabolizer patients.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment.  Select alternate drug - not tramadol or codeine - or be alert to symptoms of insufficient pain relief.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x10\u003csup\u003e9/l; leucopenia \u0026gt; 3.0x10\u003c/sup\u003e9/l; thrombocytopenia  \u0026gt; 75x10^9/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment.  Select alternate drug - not tramadol or codeine - or be alert to symptoms of insufficient pain relief.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS). Kinetic effect (NS).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment.  Select alternate drug (NOT tramadol or codeine) or be alert to ADEs (e.g., nausea, vomiting, constipation, respiratory depression, confusion, urinary retention).\u003c/td\u003e\u003ctd\u003ePublished incomplete case reports. Product information.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms men, \u0026lt;470 ms women); INR increase \u0026lt; 4.5. Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods\u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003eNS: not statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104958,Guideline Annotation,Annotation of DPWG Guideline for pantoprazole and CYP2C19,t,PA450774,Dutch Pharmacogenetics Working Group,"<p>For CYP2C19 ultrarapid metabolizers who are undergoing <em>H. pylori</em> eradication therapy, use a 5-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 5-fold higher dose.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for pantoprazole based on CYP2C19 genotype. Patients who are CYP2C19 ultrarapid metabolizers who are undergoing <em>H. pylori</em> eradication therapy should receive a 5-fold higher dose. In CYP2C19 ultrarapid metabolizer patients with other indications, be alert to reduced effectiveness, and, if necessary, use a 5-fold higher dose. Patients should be advised to report persisting symptoms of dyspepsia.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 PM</td><td>pantoprazole</td><td>NO action is required for this gene-drug interaction.</td><td>The higher plasma concentration of pantoprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects.</td></tr>
<tr><td>CYP2C19 IM</td><td>pantoprazole</td><td>NO action is required for this gene-drug interaction.</td><td>The higher plasma concentration of pantoprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects.</td></tr>
<tr><td>CYP2C19 UM</td><td>pantoprazole</td><td>The genetic variation may lead to a reduced pantoprazole plasma concentration and therefore reduced pantoprazole effectiveness.</td><td><strong>For Helicobacter pylori ERADICATION THERAPY:</strong> 1. use a 5-fold higher dose. 2. advise the patient to contact their doctor if symptoms of dyspepsia persist.<br/><strong>OTHER INDICATIONS:</strong> 1. be alert to reduced effectiveness. 2. if necessary, use a 5-fold higher dose. 3. advise the patient to report persisting symptoms of dyspepsia.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001849.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for pantoprazole based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  For the <em>CYP2C19</em> UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 400%.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>None</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Positive clinical effects</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>None</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Positive clinical effects</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>Helicobacter pylori eradication: increase dose by 400%. Be extra alert to insufficient response. Other: be extra alert to insufficient response. Consider dose increase by 400%</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Clinical effect (not statistically significant difference); Kinetic effect (not statistically significant difference)</td></tr>
</tbody>
</table>
<ul>
<li>#See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104958"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104958"",""name"":""Annotation of DPWG Guideline for pantoprazole and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704511E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415041E9,""date"":""2019-05-23T15:05:19.630-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.45082102E9,""date"":""2019-10-07T18:02:32.357-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956351E9,""date"":""2020-01-31T13:44:00.384-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963722E9,""date"":""2020-02-11T07:06:07.421-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450774"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450774"",""name"":""pantoprazole""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981904E9,""html"":""\u003cp\u003eFor CYP2C19 ultrarapid metabolizers who are undergoing \u003cem\u003eH. pylori\u003c/em\u003e eradication therapy, use a 5-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 5-fold higher dose.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981903E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for pantoprazole based on CYP2C19 genotype. Patients who are CYP2C19 ultrarapid metabolizers who are undergoing \u003cem\u003eH. pylori\u003c/em\u003e eradication therapy should receive a 5-fold higher dose. In CYP2C19 ultrarapid metabolizer patients with other indications, be alert to reduced effectiveness, and, if necessary, use a 5-fold higher dose. Patients should be advised to report persisting symptoms of dyspepsia.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 PM\u003c/td\u003e\u003ctd\u003epantoprazole\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction.\u003c/td\u003e\u003ctd\u003eThe higher plasma concentration of pantoprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 IM\u003c/td\u003e\u003ctd\u003epantoprazole\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction.\u003c/td\u003e\u003ctd\u003eThe higher plasma concentration of pantoprazole results in an increase in the therapeutic effectiveness, without an increase in the side effects.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 UM\u003c/td\u003e\u003ctd\u003epantoprazole\u003c/td\u003e\u003ctd\u003eThe genetic variation may lead to a reduced pantoprazole plasma concentration and therefore reduced pantoprazole effectiveness.\u003c/td\u003e\u003ctd\u003e\u003cstrong\u003eFor Helicobacter pylori ERADICATION THERAPY:\u003c/strong\u003e 1. use a 5-fold higher dose. 2. advise the patient to contact their doctor if symptoms of dyspepsia persist.\u003cbr/\u003e\u003cstrong\u003eOTHER INDICATIONS:\u003c/strong\u003e 1. be alert to reduced effectiveness. 2. if necessary, use a 5-fold higher dose. 3. advise the patient to report persisting symptoms of dyspepsia.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001849.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for pantoprazole based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For the \u003cem\u003eCYP2C19\u003c/em\u003e UM phenotype, they conclude to be extra alert to insufficient response and recommend to consider dose increase by 400%.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003ePositive clinical effects\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003ePositive clinical effects\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eHelicobacter pylori eradication: increase dose by 400%. Be extra alert to insufficient response. Other: be extra alert to insufficient response. Consider dose increase by 400%\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eClinical effect (not statistically significant difference); Kinetic effect (not statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e#See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166127636,Guideline Annotation,Annotation of CPIC Guideline for paroxetine and CYP2D6,t,PA450801,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers and for CYP2D6 poor metabolizers. For CYP2D6 poor metabolizers, if paroxetine use is warranted, consider a 50% reduction of recommended starting dose and titrate to response.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.</li>
</ul>
</li>
</ul>
<h3 id=""august-2015"">August 2015</h3>
<p><em>Advanced online publication May 2015</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing of selective serotonin reuptake inhibitors have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpts from the 2015 selective serotonin reuptake inhibitors dosing guidelines (for paroxetine and CYP2D6):
<ul>
<li>&quot;Multiple studies have demonstrated that CYP2D6 ultrarapid metabolizers have low or undetectable paroxetine plasma concentrations...Because of the risk for therapy failure due to lower drug exposure, an alternative SSRI not extensively metabolized by CYP2D6 should be considered for CYP2D6.&quot;</li>
<li>&quot;When administered similar doses, CYP2D6 poor metabolizers have significantly greater drug exposure to paroxetine when compared to extensive metabolizers...To potentially prevent an adverse effect, an alternative SSRI not extensively metabolized by CYP2D6 should be considered for poor metabolizers.&quot;</li>
<li>&quot;The recommendations in the guideline and below apply primarily to actions based on genetic tests only; drug interactions and other clinical factors can have a major influence for prescribing decisions for SSRIs and should be taken into consideration before initiating drug therapy.&quot;</li>
<li>&quot; Data describing the relationship between CYP2D6 or CYP2C19 genotype and SSRI systemic exposure or steady state plasma concentrations in pediatric patients are scarce. Because CYP2D6 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703-supplement.pdf"" target=""_blank"">2015 Supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_2015%20CYP2D6%20SSRI%20translation%20table.xlsx"" target=""_blank"">2015 CYP2D6 SSRI translation table</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2D6%20frequency%20table%20legend%20(R3).pdf"" target=""_blank"">CYP2D6 frequency table legend (R3)</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2D6%20frequency%20table%20(R3).xlsx"" target=""_blank"">CYP2D6 frequency table (R3)</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-paroxetine-based-on-cyp2d6-phenotype"">Table 1: Dosing recommendations for paroxetine based on CYP2D6 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2a of the 2015 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Activity Score</th><th>Genotypes</th><th>Examples of CYP2D6 diplotypes</th><th>Implications for paroxetine metabolism</th><th>Therapeutic Recommendations</th><th>Classification of recommendations <sup>a</sup></th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer (~1-2% of patients)<sup>b</sup></td><td>&gt; 2.0</td><td>An individual carrying duplications of functional alleles</td><td>*1/*1xN, *1/*2xN, *2/*2xN <sup>c</sup></td><td>Increased metabolism to less active compounds when compared to extensive metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure.</td><td>Select alternative drug not predominantly metabolized by CYP2D6.<sup>d</sup></td><td>Strong</td></tr>
<tr><td>Extensive metabolizer (~77-92% of patients)</td><td>2.0-1.0 <sup>e</sup></td><td>An individual carrying two normal function alleles or two decreased function alleles or one normal function and one no function allele or one  normal function and one decreased function allele</td><td>*1/*1, *1/*2, *1/*4, *1/*5, *1/*9, *1/*41, *2/*2,*41/*41</td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose.</td><td>Strong</td></tr>
<tr><td>Intermediate metabolizer (~2-11% of patients)</td><td>0.5</td><td>An individual carrying one decreased function and one no function allele</td><td>*4/*10,*4/*41, *5/*9</td><td>Reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.</td><td>Initiate therapy with recommended starting dose.</td><td>Moderate</td></tr>
<tr><td>Poor metabolizers (~5-10% of patients)</td><td>0</td><td>An individual carrying only no functional alleles</td><td>*3/*4,*4/*4, *5/*5, *5/*6</td><td>Greatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.</td><td>Select alternative drug not predominantly metabolized by CYP2D6 <sup>d</sup> or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response.</td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> Rating scheme described in Supplement.</p>
<p><sup>b</sup> CYP2D6 metabolizer status frequencies are based on data from Caucasians and may differ from other ethnicities. See Supplemental note for information on the chances of observing specific diplotypes in different major race/ethnic groups.</p>
<p><sup>c</sup> Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.</p>
<p><sup>d</sup> Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>
<p><sup>e</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166127636"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166127636"",""name"":""Annotation of CPIC Guideline for paroxetine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":""dUTJVrkmwpc"",""guidelineGenes"":[{""id"":1.449561106E9,""alleles"":[{""id"":1.449561107E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449561108E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449561109E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.44956111E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449561111E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449561112E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449561113E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449561114E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449561115E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449561116E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449561117E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449561118E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449561119E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.44956112E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449561121E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449561122E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.450824234E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}},{""id"":1.449561123E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449561124E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449561125E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.450042733E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.449561199E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449561128E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449561129E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.44956113E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449561131E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449561132E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449561133E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449561134E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449561135E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449561136E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449561137E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449561138E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449561139E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.44956114E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449561141E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449561142E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449561143E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449561144E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449561145E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449561146E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449561147E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449561148E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449561149E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449561151E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.44956115E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449561152E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449561153E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449561154E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449561155E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449561156E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449561157E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449561158E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449561159E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.44956116E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449561161E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449561162E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449561163E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449561164E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449561165E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449561166E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449561167E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449561168E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449561169E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.44956117E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449561171E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449561172E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449561173E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449561174E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449561175E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449561176E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449561177E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.449561178E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449561179E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.44956118E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449561181E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449561182E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449561183E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449561184E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449561185E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449561186E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449561187E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449561188E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449561189E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.44956119E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449561191E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449561192E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449561193E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449561194E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449561195E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449561196E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449561197E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449561198E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449561224E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.4495612E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449561201E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449561202E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449561203E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449561204E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449561205E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449561206E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449561207E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449561208E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449561209E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.44956121E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449561211E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449561212E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449561213E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449561214E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449561215E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449561216E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449561217E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449561218E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449561219E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.44956122E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449561221E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449561222E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449561223E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.450042732E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.444708092E9,""date"":""2015-05-08T00:00:00-07:00"",""description"":""initial save"",""type"":""Create"",""version"":1.0},{""id"":1.450042747E9,""date"":""2018-11-15T14:33:04.863-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450043042E9,""date"":""2018-11-20T17:45:17.764-08:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":0.0},{""id"":1.450824546E9,""date"":""2019-10-24T20:18:25.780-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15089021"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5089021E7,""resourceId"":""25974703"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4512908"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285932E9,""resource"":""PubMed Central"",""resourceId"":""PMC4512908"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/25974703"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285931E9,""resource"":""PubMed"",""resourceId"":""25974703"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/25974703""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.147"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285933E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.147"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.147""}]},{""@id"":""https://pharmgkb.org/literature/15100911"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100911E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Selective Serotonin Reuptake Inhibitors and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983477E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450801"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450801"",""name"":""paroxetine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982281E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for the selective serotonin reuptake inhibitor paroxetine recommends an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers and for CYP2D6 poor metabolizers. For CYP2D6 poor metabolizers, if paroxetine use is warranted, consider a 50% reduction of recommended starting dose and titrate to response.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.44798228E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""august-2015\""\u003eAugust 2015\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvanced online publication May 2015\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing of selective serotonin reuptake inhibitors have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2015 selective serotonin reuptake inhibitors dosing guidelines (for paroxetine and CYP2D6):\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Multiple studies have demonstrated that CYP2D6 ultrarapid metabolizers have low or undetectable paroxetine plasma concentrations...Because of the risk for therapy failure due to lower drug exposure, an alternative SSRI not extensively metabolized by CYP2D6 should be considered for CYP2D6.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;When administered similar doses, CYP2D6 poor metabolizers have significantly greater drug exposure to paroxetine when compared to extensive metabolizers...To potentially prevent an adverse effect, an alternative SSRI not extensively metabolized by CYP2D6 should be considered for poor metabolizers.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;The recommendations in the guideline and below apply primarily to actions based on genetic tests only; drug interactions and other clinical factors can have a major influence for prescribing decisions for SSRIs and should be taken into consideration before initiating drug therapy.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot; Data describing the relationship between CYP2D6 or CYP2C19 genotype and SSRI systemic exposure or steady state plasma concentrations in pediatric patients are scarce. Because CYP2D6 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703-supplement.pdf\"" target\u003d\""_blank\""\u003e2015 Supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_2015%20CYP2D6%20SSRI%20translation%20table.xlsx\"" target\u003d\""_blank\""\u003e2015 CYP2D6 SSRI translation table\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2D6%20frequency%20table%20legend%20(R3).pdf\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table legend (R3)\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2D6%20frequency%20table%20(R3).xlsx\"" target\u003d\""_blank\""\u003eCYP2D6 frequency table (R3)\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-paroxetine-based-on-cyp2d6-phenotype\""\u003eTable 1: Dosing recommendations for paroxetine based on CYP2D6 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2a of the 2015 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eActivity Score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of CYP2D6 diplotypes\u003c/th\u003e\u003cth\u003eImplications for paroxetine metabolism\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer (~1-2% of patients)\u003csup\u003eb\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e\u0026gt; 2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying duplications of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN, *2/*2xN \u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eIncreased metabolism to less active compounds when compared to extensive metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure.\u003c/td\u003e\u003ctd\u003eSelect alternative drug not predominantly metabolized by CYP2D6.\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eExtensive metabolizer (~77-92% of patients)\u003c/td\u003e\u003ctd\u003e2.0-1.0 \u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or two decreased function alleles or one normal function and one no function allele or one  normal function and one decreased function allele\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *1/*4, *1/*5, *1/*9, *1/*41, *2/*2,*41/*41\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer (~2-11% of patients)\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased function and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*10,*4/*41, *5/*9\u003c/td\u003e\u003ctd\u003eReduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizers (~5-10% of patients)\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no functional alleles\u003c/td\u003e\u003ctd\u003e*3/*4,*4/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eSelect alternative drug not predominantly metabolized by CYP2D6 \u003csup\u003ed\u003c/sup\u003e or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response.\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Rating scheme described in Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e CYP2D6 metabolizer status frequencies are based on data from Caucasians and may differ from other ethnicities. See Supplemental note for information on the chances of observing specific diplotypes in different major race/ethnic groups.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983477E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166104976,Guideline Annotation,Annotation of DPWG Guideline for paroxetine and CYP2D6,t,PA450801,Dutch Pharmacogenetics Working Group,"<p>Select an alternative drug rather than paroxetine for CYP2D6 ultrarapid metabolizer patients.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for paroxetine based on CYP2D6 genotype. They recommend paroxetine be avoided in patients who are CYP2D6 ultrarapid metabolizers (UMs). There are no recommendations for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs).</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>paroxetine</td><td>Efficacy will probably be lacking. The genetic variation increases the conversion of paroxetine.</td><td>It is not possible to offer substantiated advice for dose adjustment based on the literature. Avoid paroxetine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include for example citalopram or sertraline.</td></tr>
<tr><td>CYP2D6 IM</td><td>paroxetine</td><td>The plasma concentration of paroxetine can increase as a result of the reduced activity of CYP2D6. However, studies did not find any clinical effects.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
<tr><td>CYP2D6 PM</td><td>paroxetine</td><td>The plasma concentration of paroxetine can increase as a result of the reduced activity of CYP2D6. However, studies did not find any clinical effects.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001563.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for paroxetine based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They suggest using an alternative drug for ultra metabolizers.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>None.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S).</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>None.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S).</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>Insufficient data to allow calculation of dose adjustment.  Select alternative drug (e.g., citalopram, sertraline).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104976"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104976"",""name"":""Annotation of DPWG Guideline for paroxetine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704513E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415003E9,""date"":""2019-05-23T13:52:15.463-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821021E9,""date"":""2019-10-07T18:04:31.410-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956392E9,""date"":""2020-01-31T13:44:22.058-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096374E9,""date"":""2020-02-11T07:09:26.873-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450801"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450801"",""name"":""paroxetine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982034E9,""html"":""\u003cp\u003eSelect an alternative drug rather than paroxetine for CYP2D6 ultrarapid metabolizer patients.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982033E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for paroxetine based on CYP2D6 genotype. They recommend paroxetine be avoided in patients who are CYP2D6 ultrarapid metabolizers (UMs). There are no recommendations for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003eparoxetine\u003c/td\u003e\u003ctd\u003eEfficacy will probably be lacking. The genetic variation increases the conversion of paroxetine.\u003c/td\u003e\u003ctd\u003eIt is not possible to offer substantiated advice for dose adjustment based on the literature. Avoid paroxetine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include for example citalopram or sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003eparoxetine\u003c/td\u003e\u003ctd\u003eThe plasma concentration of paroxetine can increase as a result of the reduced activity of CYP2D6. However, studies did not find any clinical effects.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003eparoxetine\u003c/td\u003e\u003ctd\u003eThe plasma concentration of paroxetine can increase as a result of the reduced activity of CYP2D6. However, studies did not find any clinical effects.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001563.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for paroxetine based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They suggest using an alternative drug for ultra metabolizers.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms men, \u0026lt;470 ms women); INR increase \u0026lt; 4.5. Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms men, \u0026lt;470 ms women); INR increase \u0026lt; 4.5. Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment.  Select alternative drug (e.g., citalopram, sertraline).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166110235,Guideline Annotation,"Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3",t,PA164749390,Clinical Pharmacogenetics Implementation Consortium,"<p>IFNL3 (IL28B) variation (<a href=""/variant/PA166155468"">rs12979860</a>) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (<a href=""/variant/PA166155468"">rs12979860</a> CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (<a href=""/variant/PA166155468"">rs12979860</a> CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/"" target=""_blank"">CPIC&reg; guideline for PEG interferon-alpha-based regimens and IFNL3</a>.</p>
<h3 id=""february-2014"">February 2014</h3>
<p><em>Accepted article preview online October 2013; Advance online publication November 2013.</em></p>
<ul>
<li>
<p>Guidelines regarding the use of pharmacogenomic tests in PEG-interferon-alpha (PEG-IFN alpha) and ribavirin (RBV) therapy have been published in Clinical Pharmacology and Therapeutics by the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</p>
</li>
<li>
<p>These guidelines are applicable to</p>
<ul>
<li>adults</li>
</ul>
</li>
<li>
<p>Excerpt from the 2013 PEG-interferon-alpha therapy dosing guidelines:</p>
<ul>
<li>&quot;The role of IFNL3 genotyping depends on treatment selection. IFNL3 genotype is only one factor that could influence response rates to PEG-IFN alpha and RBV therapy in HCV genotype 1 infection and should be interpreted in the context of other clinical and genetic factors. &quot;</li>
<li>&quot;For patients treated with PEG-IFN alpha and RBV alone, IFNL3 genotype is the strongest pretreatment predictor of HCV treatment response. In the intention to treat analysis of the original discovery cohort with <a href=""/variant/PA166155468"">rs12979860</a>, Caucasian CC genotype patients were more likely than CT or TT patients to be undetectable by week 4 (28% versus 5% and 5%, P&lt;0.0001) and to achieve SVR (69% versus 33% and 27%, P&lt;0.0001). Similar patterns were observed in Hispanic and African American patients in this cohort. HCV treatment is associated with significant side effects, and the likelihood of response treatment influences shared decision making between clinicians and patients about initiating treatment.&quot;</li>
<li>&quot;For treatment naïve patients with genotype 1 infection who are treated with protease inhibitor combinations, all IFNL3 genotypes have improved response rates compared to PEG-IFN alpha and RBV only. However, patients with the favorable IFNL3 genotype still have higher response rates with the protease inhibitor combination in treatment naïve patients, and these response rates may guide patients and clinicians in their treatment decisions. In the boceprevir phase 3 naïve study of combination with PEG-IFN alpha and RBV, SVR rates for <a href=""/variant/PA166155468"">rs12979860</a> CC patients receiving boceprevir ranged from 80-82% compared to 65-71% for CT patients and 59-65% for TT patients. Moreover, multivariate regression analysis revealed that <a href=""/variant/PA166155468"">rs12979860</a> CC was a predictor of SVR compared to CT (odds ratio (OR) 2.6, 95% CI 1.3-5.1) and TT genotypes (OR 2.1, 95% CI 1.2-3.7).&quot;</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/pegintron/2013/24096968.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/pegintron/2013/24096968-supplement.pdf"" target=""_blank"">2013 supplement</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-therapeutic-use-of-peg-interferon-alpha-containing-regimens-based-on-ifnl3-genotype"">Table 1: Recommended therapeutic use of  PEG-interferon-alpha containing regimens based on <em>IFNL3</em> genotype</h3>
<p><em>Adapted from Table 1 and 2 of the 2013 guideline manuscript</em></p>
<table class=""table"">
<thead>
<tr><th>Genotype at <a href=""/variant/PA166155468"">rs12979860</a></th><th>Phenotype</th><th>Implications for PEG-IFN alpha and RBV <sup>a</sup></th><th>Implications for protease inhibitor combinations with PEG-IFN alpha and RBV therapy</th><th>Classification of recommendations <sup>b</sup></th></tr>
</thead>
<tbody>
<tr><td>CC</td><td>Favorable response genotype</td><td>Approximately 70% chance for SVR <sup>c</sup> after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.</td><td>Approximately 90% chance for SVR after 24-48 weeks of treatment. Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks)<sup>d</sup>. Weighs in favor of using PEG-IFN alpha and RBV containing regimens.</td><td>Strong</td></tr>
<tr><td>CT or TT</td><td>Unfavorable response genotype</td><td>Approximately 30% chance for SVR <sup>c</sup> after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.</td><td>Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks)<sup>d</sup>. Consider implications before initiating PEG-IFN and RBV containing regimens.</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> In cases where a protease inhibitor is not available.</p>
<p><sup>b</sup> Rating scheme described in Supplement.</p>
<p><sup>c</sup> SVR; sustained virologic response (defined by undetectable serum viral RNA 12-24 weeks after the end of treatment).</p>
<p><sup>d</sup> Patients receiving boceprevir are eligible for 24-28 weeks instead of the standard 48 weeks if HCV RNA is undetectable by week eight. Patients receiving telaprevir are eligible for 24 weeks of therapy instead of the standard 48 weeks if HCV RNA is undetectable by week four.</p>
<p>PEG-IFN alpha: pegylated-interferon alpha 2a or 2b; RBV: ribavirin</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166110235"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166110235"",""name"":""Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3"",""cancerGenome"":false,""descriptiveVideoId"":""MY5f_qlLH30"",""guidelineGenes"":[{""id"":1.449560775E9,""alleles"":[{""id"":1.449560776E9,""_label"":""rs12979860C"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446767120"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676712E9,""resource"":""Allele Function"",""term"":""Favorable response allele"",""termId"":""haplotypeTags:1446767120""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129427"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129427"",""symbol"":""IFNL3 rs12979860C"",""name"":""rs12979860C""}},{""id"":1.449560777E9,""_label"":""rs12979860T"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446767121"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446767121E9,""resource"":""Allele Function"",""term"":""Unfavorable response allele"",""termId"":""haplotypeTags:1446767121""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129428"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129428"",""symbol"":""IFNL3 rs12979860T"",""name"":""rs12979860T""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA134952671"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134952671"",""symbol"":""IFNL3"",""name"":""interferon lambda 3""}}],""history"":[{""id"":1.183631742E9,""date"":""2013-10-05T00:00:00-07:00"",""type"":""Create"",""version"":2.0},{""id"":1.184469994E9,""date"":""2014-06-19T00:00:00-07:00"",""type"":""Update"",""version"":0.0},{""id"":1.447946687E9,""date"":""2016-02-25T09:39:25.272-08:00"",""description"":""Boceprevir and telaprevir are removed as the guideline focuses on peg interferon alpha-based regimens"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15064565"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5064565E7,""resourceId"":""24096968"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904555"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3904555"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449278051E9,""resource"":""PubMed Central"",""resourceId"":""PMC3904555"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904555""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/24096968"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44927805E9,""resource"":""PubMed"",""resourceId"":""24096968"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/24096968""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.203"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449278052E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.203"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.203""}]},{""@id"":""https://pharmgkb.org/literature/15100919"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100919E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/"",""title"":""CPIC® Guideline for PEG Interferon-Alpha-Based Regimens and IFNL3 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983502E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA164749390"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA164749390"",""name"":""peginterferon alfa-2a""},{""@id"":""https://pharmgkb.org/chemical/PA164784024"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA164784024"",""name"":""peginterferon alfa-2b""},{""@id"":""https://pharmgkb.org/chemical/PA451241"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451241"",""name"":""ribavirin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134952671"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134952671"",""symbol"":""IFNL3"",""name"":""interferon lambda 3""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447981876E9,""html"":""\u003cp\u003eIFNL3 (IL28B) variation (\u003ca href\u003d\""/variant/PA166155468\""\u003ers12979860\u003c/a\u003e) is the strongest baseline predictor of response to PEG-interferon-alpha-containing regimens in HCV genotype 1 patients.  Patients with the favorable response genotype (\u003ca href\u003d\""/variant/PA166155468\""\u003ers12979860\u003c/a\u003e CC) have increased likelihood of response (higher SVR rate) to PEG-interferon-alpha-containing regimens as compared to patients with unfavorable response genotype (\u003ca href\u003d\""/variant/PA166155468\""\u003ers12979860\u003c/a\u003e CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981875E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for PEG interferon-alpha-based regimens and IFNL3\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""february-2014\""\u003eFebruary 2014\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online October 2013; Advance online publication November 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in PEG-interferon-alpha (PEG-IFN alpha) and ribavirin (RBV) therapy have been published in Clinical Pharmacology and Therapeutics by the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThese guidelines are applicable to\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eadults\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExcerpt from the 2013 PEG-interferon-alpha therapy dosing guidelines:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026quot;The role of IFNL3 genotyping depends on treatment selection. IFNL3 genotype is only one factor that could influence response rates to PEG-IFN alpha\u0001 and RBV therapy in HCV genotype 1 infection and should be interpreted in the context of other clinical and genetic factors. \u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;For patients treated with PEG-IFN alpha\u0001 and RBV alone, IFNL3 genotype is the strongest pretreatment predictor of HCV treatment response. In the intention to treat analysis of the original discovery cohort with \u003ca href\u003d\""/variant/PA166155468\""\u003ers12979860\u003c/a\u003e, Caucasian CC genotype patients were more likely than CT or TT patients to be undetectable by week 4 (28% versus 5% and 5%, P\u0026lt;0.0001) and to achieve SVR (69% versus 33% and 27%, P\u0026lt;0.0001). Similar patterns were observed in Hispanic and African American patients in this cohort. HCV treatment is associated with significant side effects, and the likelihood of response treatment influences shared decision making between clinicians and patients about initiating treatment.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;For treatment naïve patients with genotype 1 infection who are treated with protease inhibitor combinations, all IFNL3 genotypes have improved response rates compared to PEG-IFN alpha\u0001 and RBV only. However, patients with the favorable IFNL3 genotype still have higher response rates with the protease inhibitor combination in treatment naïve patients, and these response rates may guide patients and clinicians in their treatment decisions. In the boceprevir phase 3 naïve study of combination with PEG-IFN alpha\u0001 and RBV, SVR rates for \u003ca href\u003d\""/variant/PA166155468\""\u003ers12979860\u003c/a\u003e CC patients receiving boceprevir ranged from 80-82% compared to 65-71% for CT patients and 59-65% for TT patients. Moreover, multivariate regression analysis revealed that \u003ca href\u003d\""/variant/PA166155468\""\u003ers12979860\u003c/a\u003e CC was a predictor of SVR compared to CT (odds ratio (OR) 2.6, 95% CI 1.3-5.1) and TT genotypes (OR 2.1, 95% CI 1.2-3.7).\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/pegintron/2013/24096968.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-alpha-based regimens\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/pegintron/2013/24096968-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-therapeutic-use-of-peg-interferon-alpha-containing-regimens-based-on-ifnl3-genotype\""\u003eTable 1: Recommended therapeutic use of  PEG-interferon-alpha containing regimens based on \u003cem\u003eIFNL3\u003c/em\u003e genotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Table 1 and 2 of the 2013 guideline manuscript\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype at \u003ca href\u003d\""/variant/PA166155468\""\u003ers12979860\u003c/a\u003e\u003c/th\u003e\u003cth\u003ePhenotype\u003c/th\u003e\u003cth\u003eImplications for PEG-IFN alpha\u0001 and RBV \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications for protease inhibitor combinations with PEG-IFN alpha\u0001 and RBV therapy\u003c/th\u003e\u003cth\u003eClassification of recommendations \u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCC\u003c/td\u003e\u003ctd\u003eFavorable response genotype\u003c/td\u003e\u003ctd\u003eApproximately 70% chance for SVR \u003csup\u003ec\u003c/sup\u003e after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\u003c/td\u003e\u003ctd\u003eApproximately 90% chance for SVR after 24-48 weeks of treatment. Approximately 80-90% of patients are eligible for shortened therapy (24-28 weeks vs. 48 weeks)\u003csup\u003ed\u003c/sup\u003e. Weighs in favor of using PEG-IFN\u0001 alpha and RBV containing regimens.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCT or TT\u003c/td\u003e\u003ctd\u003eUnfavorable response genotype\u003c/td\u003e\u003ctd\u003eApproximately 30% chance for SVR \u003csup\u003ec\u003c/sup\u003e after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.\u003c/td\u003e\u003ctd\u003eApproximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks)\u003csup\u003ed\u003c/sup\u003e. Consider implications before initiating PEG-IFN\u0001 and RBV containing regimens.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e In cases where a protease inhibitor is not available.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Rating scheme described in Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e SVR; sustained virologic response (defined by undetectable serum viral RNA 12-24 weeks after the end of treatment).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e Patients receiving boceprevir are eligible for 24-28 weeks instead of the standard 48 weeks if HCV RNA is undetectable by week eight. Patients receiving telaprevir are eligible for 24 weeks of therapy instead of the standard 48 weeks if HCV RNA is undetectable by week four.\u003c/p\u003e\n\u003cp\u003ePEG-IFN alpha\u0001: pegylated-interferon alpha 2a or 2b; RBV: ribavirin\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983502E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-peg-interferon-alpha-based-regimens-and-ifnl3/""}]},""status"":""success""}"
PA166104940,Guideline Annotation,Annotation of DPWG Guideline for phenprocoumon and VKORC1,t,PA450921,Dutch Pharmacogenetics Working Group,"<p>Patients with the VKORC1 -1639 (rs9923231) AA genotype is recommended to be given 50% of the standard initial dose of phenprocoumon and more frequent monitoring of INR. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There is no recommendation for patients with the VKORC1 -1639 AG genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for phenprocoumon based on VKORC1 genotype. They recommend that patients with the VKORC1 -1639 (<a href=""/variant/PA166155091"">rs9923231</a>) AA genotype receive 50% of the standard initial dose and more frequent monitoring of INR. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There is no recommendation for patients with the VKORC1 -1639 AG genotype.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>VKORC1 -1639 AA</td><td>phenprocoumon</td><td>An INR = 6, resulting in an increased risk of bleeding, occurs in 17% of these patients with standard regulation by the Anticoagulation Clinic. The genetic variation increases the sensitivity to phenprocoumon.</td><td>1. Monitoring by a ANTICOAGULATION CLINIC: recommend to use 50% of the standard initial dose.<br/>2.NO monitoring by a anticoagulation clinic: recommend to use 50% of the standard initial dose, recommend more frequent monitoring of the INR.<br/>For patients younger than 75 years, the initial dose and the maintenance dose can be calculated using an algorithm as found in EUPACT: see <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a> for a calculation tool in the form of an Excel file. However, for patients aged 75 years and older, this algorithm increases the risk of an INR above the therapeutic range compared to an algorithm without gene variations. Therefore, use of this algorithm is not recommended for these patients.</td></tr>
<tr><td>VKORC1 -1639 AG</td><td>phenprocoumon</td><td>The gene variation leads to a lower dose requirement, but regular monitoring of patients ensures that this does not lead to a distinct increase in the risk of bleeding.</td><td>NO action is needed for this gene-drug interaction</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001912.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline:</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenprocoumon based on VKORC1 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They found that VKORC1 <a href=""/variant/PA166155096"">rs9934438</a> genotype contributes to dose variability.  However, they make no dosing recommendations at this time &quot;because of strict international normalized ratio monitoring by the Dutch Thrombosis Service.&quot;</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>VKORC1 <a href=""/variant/PA166155096"">rs9934438</a> AG</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms); INR increase &lt; 4.5 Kinetic effect (S).</td></tr>
<tr><td>VKORC1 <a href=""/variant/PA166155096"">rs9934438</a> AA</td><td>Check INR more frequently.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms); INR increase &lt; 4.5 Kinetic effect (S).</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104940"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104940"",""name"":""Annotation of DPWG Guideline for phenprocoumon and VKORC1"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704517E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415348E9,""date"":""2019-05-28T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821023E9,""date"":""2019-10-07T18:14:28.619-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956393E9,""date"":""2020-01-31T13:44:49.466-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096402E9,""date"":""2020-02-11T00:00:00-08:00"",""description"":""Fixed link to algorithms."",""type"":""Update"",""version"":0.0},{""id"":1.45096376E9,""date"":""2020-02-11T07:11:39.065-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450921"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450921"",""name"":""phenprocoumon""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA133787052"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA133787052"",""symbol"":""VKORC1"",""name"":""vitamin K epoxide reductase complex subunit 1""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.44798186E9,""html"":""\u003cp\u003ePatients with the VKORC1 -1639 (rs9923231) AA genotype is recommended to be given 50% of the standard initial dose of phenprocoumon and more frequent monitoring of INR. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There is no recommendation for patients with the VKORC1 -1639 AG genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981859E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for phenprocoumon based on VKORC1 genotype. They recommend that patients with the VKORC1 -1639 (\u003ca href\u003d\""/variant/PA166155091\""\u003ers9923231\u003c/a\u003e) AA genotype receive 50% of the standard initial dose and more frequent monitoring of INR. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There is no recommendation for patients with the VKORC1 -1639 AG genotype.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 -1639 AA\u003c/td\u003e\u003ctd\u003ephenprocoumon\u003c/td\u003e\u003ctd\u003eAn INR \u003d 6, resulting in an increased risk of bleeding, occurs in 17% of these patients with standard regulation by the Anticoagulation Clinic. The genetic variation increases the sensitivity to phenprocoumon.\u003c/td\u003e\u003ctd\u003e1. Monitoring by a ANTICOAGULATION CLINIC: recommend to use 50% of the standard initial dose.\u003cbr/\u003e2.NO monitoring by a anticoagulation clinic: recommend to use 50% of the standard initial dose, recommend more frequent monitoring of the INR.\u003cbr/\u003eFor patients younger than 75 years, the initial dose and the maintenance dose can be calculated using an algorithm as found in EUPACT: see \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e for a calculation tool in the form of an Excel file. However, for patients aged 75 years and older, this algorithm increases the risk of an INR above the therapeutic range compared to an algorithm without gene variations. Therefore, use of this algorithm is not recommended for these patients.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 -1639 AG\u003c/td\u003e\u003ctd\u003ephenprocoumon\u003c/td\u003e\u003ctd\u003eThe gene variation leads to a lower dose requirement, but regular monitoring of patients ensures that this does not lead to a distinct increase in the risk of bleeding.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001912.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline:\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenprocoumon based on VKORC1 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They found that VKORC1 \u003ca href\u003d\""/variant/PA166155096\""\u003ers9934438\u003c/a\u003e genotype contributes to dose variability.  However, they make no dosing recommendations at this time \u0026quot;because of strict international normalized ratio monitoring by the Dutch Thrombosis Service.\u0026quot;\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 \u003ca href\u003d\""/variant/PA166155096\""\u003ers9934438\u003c/a\u003e AG\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms , \u0026lt;470 ms); INR increase \u0026lt; 4.5 Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 \u003ca href\u003d\""/variant/PA166155096\""\u003ers9934438\u003c/a\u003e AA\u003c/td\u003e\u003ctd\u003eCheck INR more frequently.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms , \u0026lt;470 ms); INR increase \u0026lt; 4.5 Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166105004,Guideline Annotation,Annotation of DPWG Guideline for phenprocoumon and CYP2C9,f,PA450921,Dutch Pharmacogenetics Working Group,"<p>There are currently no recommendations for phenprocoumon dosing based on CYP2C9 genotypes.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for phenprocoumon based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction. The genetic variation can result in a reduction in the required maintenance dose. However, there is not enough evidence to confirm that this causes problems with normal initiation of the therapy (i.e. frequent INR monitoring). <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p>The annotation of the DPWG guideline for phenprocoumon and VKORC1 can be found <a href=""https://www.pharmgkb.org/guidelineAnnotation/PA166104940"">here</a>.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001875.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenprocoumon based on CYP2C9 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>]. They recommend checking INR more frequently in individuals with CYP2C9 2*/2*, 2*/3*, or 3*/3* genotype.</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>CYP2C9 *1/*2</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression</td></tr>
<tr><td>CYP2C9 *2/*2</td><td>Check INR more frequently</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression</td></tr>
<tr><td>CYP2C9 *1/*3</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression</td></tr>
<tr><td>CYP2C9 *2/*3</td><td>Check INR more frequently</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression</td></tr>
<tr><td>CYP2C9 *3/*3</td><td>Check INR more frequently</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10{<sup>}9</sup>/l; leucopenia 1.0-2.0x10{<sup>}9</sup>/l; thrombocytopenia 25-50x10{<sup>}9</sup>/l; severe diarrhea</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods</a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166105004"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166105004"",""name"":""Annotation of DPWG Guideline for phenprocoumon and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704515E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415071E9,""date"":""2019-05-23T16:20:47.708-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821022E9,""date"":""2019-10-07T18:11:58.639-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956394E9,""date"":""2020-01-31T13:45:10.776-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096378E9,""date"":""2020-02-11T07:13:58.042-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/haplotype/PA165816543"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816543"",""symbol"":""CYP2C9*2"",""name"":""*2""},{""@id"":""https://pharmgkb.org/haplotype/PA165816544"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816544"",""symbol"":""CYP2C9*3"",""name"":""*3""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450921"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450921"",""name"":""phenprocoumon""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981956E9,""html"":""\u003cp\u003eThere are currently no recommendations for phenprocoumon dosing based on CYP2C9 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981955E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for phenprocoumon based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction. The genetic variation can result in a reduction in the required maintenance dose. However, there is not enough evidence to confirm that this causes problems with normal initiation of the therapy (i.e. frequent INR monitoring). \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eThe annotation of the DPWG guideline for phenprocoumon and VKORC1 can be found \u003ca href\u003d\""https://www.pharmgkb.org/guidelineAnnotation/PA166104940\""\u003ehere\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001875.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenprocoumon based on CYP2C9 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e]. They recommend checking INR more frequently in individuals with CYP2C9 2*/2*, 2*/3*, or 3*/3* genotype.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*2\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*2\u003c/td\u003e\u003ctd\u003eCheck INR more frequently\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*3\u003c/td\u003e\u003ctd\u003eCheck INR more frequently\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *3/*3\u003c/td\u003e\u003ctd\u003eCheck INR more frequently\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10{\u003csup\u003e}9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10{\u003csup\u003e}9\u003c/sup\u003e/l; thrombocytopenia 25-50x10{\u003csup\u003e}9\u003c/sup\u003e/l; severe diarrhea\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods\u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166122806,Guideline Annotation,"Annotation of CPIC Guideline for phenytoin and CYP2C9,HLA-B",t,PA450947,Clinical Pharmacogenetics Implementation Consortium,"<p>Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (&quot;HLA-B*15:02-positive&quot;) due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype may require reduced doses of phenytoin.</p>
<p><strong>This guideline is currently being updated by CPIC. We will make the genotype picker tool available again as soon as the updated guideline has been finalized.</strong></p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"" target=""_blank"">CPIC&reg; guideline for phenytoin and CYP2C9 and HLA-B</a>.</p>
<h3 id=""november-2014"">November 2014</h3>
<p><em>Accepted article preview online August 2014; Advance online publication September 2014</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for phenytoin have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpt from the 2014 phenytoin dosing guidelines:
<ul>
<li>&quot;[A]t least a 25% reduction of the recommended starting maintenance dose may be considered for CYP2C9 intermediate metabolizers with subsequent maintenance doses adjusted based on therapeutic drug monitoring and response. For CYP2C9 poor metabolizers, consider at least a 50% reduction of starting maintenance dose with subsequent maintenance doses adjusted based on therapeutic drug monitoring or response.&quot;</li>
<li>&quot;[R]egardless of the CYP2C9 genotype and individual's ancestry or age, if the HLA-B*15:02 test result is positive, the recommendation is to consider using an anticonvulsant other than carbamazepine and phenytoin unless the benefits of treating the underlying disease clearly outweigh the risks... Alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele and thus caution should be used in choosing alternatives to phenytoin.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/phenytoin/2014/25099164.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/phenytoin/2014/25099164-supplement.pdf"" target=""_blank"">2014 supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/phenytoin/2014/25099164-Phenytoin_translation_table_final.xlsx"" target=""_blank"">2014 phenytoin translation table</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-phenytoin-fosphenytoin-therapy-recommendations-based-on-hla-b-and-cyp2c9-phenotype-genotype"">Table 1: Phenytoin/fosphenytoin therapy recommendations based on <em>HLA-B</em> and <em>CYP2C9</em> phenotype/genotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2014 guideline manuscript.</em></p>
<ul>
<li>HLA-B*15:02 &quot;positive&quot;: 1 or 2 *15:02 alleles</li>
<li>HLA-B*15:02 &quot;negative&quot;: No HLA-B*15:02 alleles reported</li>
</ul>
<table class=""table"">
<thead>
<tr><th>CYP2C9 Phenotype</th><th>CYP2C9 genotype</th><th>HLA-B*15:02 &quot;positive&quot; - Implications</th><th>HLA-B*15:02 &quot;positive&quot; - Therapeutic recommendation</th><th>HLA-B*15:02 &quot;positive&quot; - Classification of recommendation</th><th>HLA-B*15:02 &quot;negative&quot;- Implications</th><th>HLA-B*15:02 &quot;negative&quot;-Therapeutic recommendation</th><th>HLA-B*15:02 &quot;negative&quot;-Classification of Recommendation</th></tr>
</thead>
<tbody>
<tr><td><strong>CYP2C9 Extensive Metabolizer</strong></td><td>Normal activity ~91% of patients;  An individual carrying 2 normal activity alleles; Example diplotype:*1/*1</td><td>Increased risk of phenytoin-induced SJS/TEN</td><td>If patient is phenytoin-naive <sup>b</sup>, do not use phenytoin/fosphenytoin.</td><td>STRONG</td><td>Normal phenytoin metabolism</td><td>Initiate therapy with recommended maintenance dose <sup>d</sup>.</td><td>STRONG</td></tr>
<tr><td><strong>CYP2C9 Intermediate Metabolizer</strong></td><td>Heterozygote ~8% of patients; An individual carrying one normal activity allele plus one decreased function allele; Example diplotypes: *1/*3, *1/*2</td><td>Increased risk of phenytoin-induced SJS/TEN</td><td>If patient is phenytoin-naive <sup>b</sup>, do not use phenytoin/fosphenytoin.</td><td>STRONG</td><td>Reduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities.</td><td>Consider 25% reduction of recommended starting maintenance dose <sup>d</sup>.  Subsequent doses should be adjusted according to therapeutic drug monitoring and response.</td><td>MODERATE</td></tr>
<tr><td><strong>CYP2C9 Poor Metabolizer</strong></td><td>Homozygous variant ~1% of patients;  An individual carrying 2 decreased function alleles; Example diplotypes: *2/*2, *3/*3, *2/*3</td><td>Increased risk of phenytoin-induced SJS/TEN.</td><td>If patient is phenytoin-naive <sup>b</sup>, do not use phenytoin/fosphenytoin.</td><td>STRONG</td><td>Reduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities.</td><td>Consider 50% reduction of recommended starting maintenance dose <sup>d</sup>.  Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.</td><td>STRONG</td></tr>
</tbody>
</table>
<p><sup>b</sup> If the patient has previously used phenytoin for longer than 3 months without incidence of cutaneous adverse reactions, reinitiate phenytoin with caution. Adjust dose based on <em>CYP2C9</em> genotype if known.
<sup>d</sup> Recommended maintenance dose based on patient’s clinical characteristics.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166122806"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166122806"",""name"":""Annotation of CPIC Guideline for phenytoin and CYP2C9,HLA-B"",""cancerGenome"":false,""descriptiveVideoId"":""GfDInZklKEw"",""guidelineGenes"":[],""history"":[{""id"":1.184512517E9,""date"":""2014-08-05T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.4509836E9,""date"":""2020-03-09T13:35:29.101-07:00"",""description"":""Temporarily removed genotype picker and added explanatory note in summary section"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15080841"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5080841E7,""resourceId"":""25099164"",""title"":""Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206662"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4206662"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449282294E9,""resource"":""PubMed Central"",""resourceId"":""PMC4206662"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206662""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/25099164"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449282293E9,""resource"":""PubMed"",""resourceId"":""25099164"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/25099164""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2014.159"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449282295E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2014.159"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2014.159""}]},{""@id"":""https://pharmgkb.org/literature/15100913"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100913E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"",""title"":""CPIC® Guideline for Phenytoin and CYP2C9 and HLA-B – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983504E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450947"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450947"",""name"":""phenytoin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""},{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.44798165E9,""html"":""\u003cp\u003ePhenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele (\u0026quot;HLA-B*15:02-positive\u0026quot;) due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype may require reduced doses of phenytoin.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eThis guideline is currently being updated by CPIC. We will make the genotype picker tool available again as soon as the updated guideline has been finalized.\u003c/strong\u003e\u003c/p\u003e\n""},""summaryVideoId"":""F6Ny6kzCzno"",""textMarkdown"":{""id"":1.447981649E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for phenytoin and CYP2C9 and HLA-B\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""november-2014\""\u003eNovember 2014\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online August 2014; Advance online publication September 2014\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for phenytoin have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2014 phenytoin dosing guidelines:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;[A]t least a 25% reduction of the recommended starting maintenance dose may be considered for CYP2C9 intermediate metabolizers with subsequent maintenance doses adjusted based on therapeutic drug monitoring and response. For CYP2C9 poor metabolizers, consider at least a 50% reduction of starting maintenance dose with subsequent maintenance doses adjusted based on therapeutic drug monitoring or response.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;[R]egardless of the CYP2C9 genotype and individual\u0027s ancestry or age, if the HLA-B*15:02 test result is positive, the recommendation is to consider using an anticonvulsant other than carbamazepine and phenytoin unless the benefits of treating the underlying disease clearly outweigh the risks... Alternative medications such as oxcarbazepine, eslicarbazepine acetate, and lamotrigine have some evidence linking SJS/TEN with the HLA-B*15:02 allele and thus caution should be used in choosing alternatives to phenytoin.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/phenytoin/2014/25099164.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/phenytoin/2014/25099164-supplement.pdf\"" target\u003d\""_blank\""\u003e2014 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/phenytoin/2014/25099164-Phenytoin_translation_table_final.xlsx\"" target\u003d\""_blank\""\u003e2014 phenytoin translation table\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-phenytoin-fosphenytoin-therapy-recommendations-based-on-hla-b-and-cyp2c9-phenotype-genotype\""\u003eTable 1: Phenytoin/fosphenytoin therapy recommendations based on \u003cem\u003eHLA-B\u003c/em\u003e and \u003cem\u003eCYP2C9\u003c/em\u003e phenotype/genotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2014 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eHLA-B*15:02 \u0026quot;positive\u0026quot;: 1 or 2 *15:02 alleles\u003c/li\u003e\n\u003cli\u003eHLA-B*15:02 \u0026quot;negative\u0026quot;: No HLA-B*15:02 alleles reported\u003c/li\u003e\n\u003c/ul\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eCYP2C9 Phenotype\u003c/th\u003e\u003cth\u003eCYP2C9 genotype\u003c/th\u003e\u003cth\u003eHLA-B*15:02 \u0026quot;positive\u0026quot; - Implications\u003c/th\u003e\u003cth\u003eHLA-B*15:02 \u0026quot;positive\u0026quot; - Therapeutic recommendation\u003c/th\u003e\u003cth\u003eHLA-B*15:02 \u0026quot;positive\u0026quot; - Classification of recommendation\u003c/th\u003e\u003cth\u003eHLA-B*15:02 \u0026quot;negative\u0026quot;- Implications\u003c/th\u003e\u003cth\u003eHLA-B*15:02 \u0026quot;negative\u0026quot;-Therapeutic recommendation\u003c/th\u003e\u003cth\u003eHLA-B*15:02 \u0026quot;negative\u0026quot;-Classification of Recommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cstrong\u003eCYP2C9 Extensive Metabolizer\u003c/strong\u003e\u003c/td\u003e\u003ctd\u003eNormal activity ~91% of patients;  An individual carrying 2 normal activity alleles; Example diplotype:*1/*1\u003c/td\u003e\u003ctd\u003eIncreased risk of phenytoin-induced SJS/TEN\u003c/td\u003e\u003ctd\u003eIf patient is phenytoin-naive \u003csup\u003eb\u003c/sup\u003e, do not use phenytoin/fosphenytoin.\u003c/td\u003e\u003ctd\u003eSTRONG\u003c/td\u003e\u003ctd\u003eNormal phenytoin metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended maintenance dose \u003csup\u003ed\u003c/sup\u003e.\u003c/td\u003e\u003ctd\u003eSTRONG\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cstrong\u003eCYP2C9 Intermediate Metabolizer\u003c/strong\u003e\u003c/td\u003e\u003ctd\u003eHeterozygote ~8% of patients; An individual carrying one normal activity allele plus one decreased function allele; Example diplotypes: *1/*3, *1/*2\u003c/td\u003e\u003ctd\u003eIncreased risk of phenytoin-induced SJS/TEN\u003c/td\u003e\u003ctd\u003eIf patient is phenytoin-naive \u003csup\u003eb\u003c/sup\u003e, do not use phenytoin/fosphenytoin.\u003c/td\u003e\u003ctd\u003eSTRONG\u003c/td\u003e\u003ctd\u003eReduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities.\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting maintenance dose \u003csup\u003ed\u003c/sup\u003e.  Subsequent doses should be adjusted according to therapeutic drug monitoring and response.\u003c/td\u003e\u003ctd\u003eMODERATE\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cstrong\u003eCYP2C9 Poor Metabolizer\u003c/strong\u003e\u003c/td\u003e\u003ctd\u003eHomozygous variant ~1% of patients;  An individual carrying 2 decreased function alleles; Example diplotypes: *2/*2, *3/*3, *2/*3\u003c/td\u003e\u003ctd\u003eIncreased risk of phenytoin-induced SJS/TEN.\u003c/td\u003e\u003ctd\u003eIf patient is phenytoin-naive \u003csup\u003eb\u003c/sup\u003e, do not use phenytoin/fosphenytoin.\u003c/td\u003e\u003ctd\u003eSTRONG\u003c/td\u003e\u003ctd\u003eReduced phenytoin metabolism, higher plasma concentrations will increase probability of toxicities.\u003c/td\u003e\u003ctd\u003eConsider 50% reduction of recommended starting maintenance dose \u003csup\u003ed\u003c/sup\u003e.  Subsequent maintenance doses should be adjusted according to therapeutic drug monitoring and response.\u003c/td\u003e\u003ctd\u003eSTRONG\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e If the patient has previously used phenytoin for longer than 3 months without incidence of cutaneous adverse reactions, reinitiate phenytoin with caution. Adjust dose based on \u003cem\u003eCYP2C9\u003c/em\u003e genotype if known.\n\u003csup\u003ed\u003c/sup\u003e Recommended maintenance dose based on patient’s clinical characteristics.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983504E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/""}]},""status"":""success""}"
PA166104984,Guideline Annotation,Annotation of DPWG Guideline for phenytoin and CYP2C9,t,PA450947,Dutch Pharmacogenetics Working Group,"<p>Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenytoin based on CYP2C9 genotype. They recommend a reduction in the maintenance dose for patients with the CYP2C9*1/*2, *1/*3, *2/*2, *2/*3, *3/*3 or other CYP2C9 genotypes which lead to an intermediate metabolizer (IM) or poor metabolizer (PM) phenotype. Patient response, serum concentrations and potential ADEs should be monitored.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C9 IM</td><td>phenytoin</td><td>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</td><td>1. The loading dose does not need to be adjusted.<br/>2. For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.<br/>3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</td></tr>
<tr><td>CYP2C9 PM</td><td>phenytoin</td><td>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</td><td>1. The loading dose does not need to be adjusted.<br/>2. For the other doses, use 40-50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.<br/>3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</td></tr>
<tr><td>CYP2C9 *1/*2</td><td>phenytoin</td><td>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</td><td>1. The loading dose does not need to be adjusted.<br/>2. For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.<br/>3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</td></tr>
<tr><td>CYP2C9 *1/*3</td><td>phenytoin</td><td>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects. The life-threatening cutaneous side effects Stevens-Johnson Syndrome and toxic epidermal necrolysis may occur, especially in Asian patients.</td><td>1. The loading dose does not need to be adjusted.<br/>2. For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.<br/>3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur.</td></tr>
<tr><td>CYP2C9 *2/*2</td><td>phenytoin</td><td>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</td><td>1. The loading dose does not need to be adjusted.<br/>2. For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.<br/>3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</td></tr>
<tr><td>CYP2C9 *2/*3</td><td>phenytoin</td><td>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.</td><td>1. The loading dose does not need to be adjusted.<br/>2. For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.<br/>3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.</td></tr>
<tr><td>CYP2C9 *3/*3</td><td>phenytoin</td><td>Genetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects. The life-threatening cutaneous side effects Stevens-Johnson Syndrome and toxic epidermal necrolysis may occur, especially in Asian patients.</td><td>1. The loading dose does not need to be adjusted.<br/>2. For the other doses, use 40% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.<br/>3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001676.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenytoin based on CYP2C9 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>CYP2C9 *1/*2</td><td>Standard loading dose. Reduce maintenance dose by 25%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt; 4.5Kinetic effect (S)</td></tr>
<tr><td>CYP2C9 *2/*2</td><td>Standard loading dose. Reduce maintenance dose by 50%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt; 4.5Kinetic effect (S)</td></tr>
<tr><td>CYP2C9 *1/*3</td><td>Standard loading dose. Reduce maintenance dose by 25%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10<sup>9</sup>/l; leucopenia 1.0-2.0x10<sup>9</sup>/l; thrombocytopenia 25-50x10<sup>9</sup>/l; severe diarrhea</td></tr>
<tr><td>CYP2C9 *2/*3</td><td>Standard loading dose. Reduce maintenance dose by 50%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt; 4.5Kinetic effect (S)</td></tr>
<tr><td>CYP2C9 *3/*3</td><td>Standard loading dose. Reduce maintenance dose by 50%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10<sup>9</sup>/l; leucopenia 1.0-2.0x10<sup>9</sup>/l; thrombocytopenia 25-50x10<sup>9</sup>/l; severe diarrhea</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104984"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104984"",""name"":""Annotation of DPWG Guideline for phenytoin and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704519E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414973E9,""date"":""2019-05-23T10:59:44.720-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821024E9,""date"":""2019-10-07T18:16:57.352-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956371E9,""date"":""2020-01-31T13:45:35.815-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963781E9,""date"":""2020-02-11T07:20:07.518-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450947"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450947"",""name"":""phenytoin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981976E9,""html"":""\u003cp\u003eUse the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981975E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenytoin based on CYP2C9 genotype. They recommend a reduction in the maintenance dose for patients with the CYP2C9*1/*2, *1/*3, *2/*2, *2/*3, *3/*3 or other CYP2C9 genotypes which lead to an intermediate metabolizer (IM) or poor metabolizer (PM) phenotype. Patient response, serum concentrations and potential ADEs should be monitored.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 IM\u003c/td\u003e\u003ctd\u003ephenytoin\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.\u003c/td\u003e\u003ctd\u003e1. The loading dose does not need to be adjusted.\u003cbr/\u003e2. For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\u003cbr/\u003e3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 PM\u003c/td\u003e\u003ctd\u003ephenytoin\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.\u003c/td\u003e\u003ctd\u003e1. The loading dose does not need to be adjusted.\u003cbr/\u003e2. For the other doses, use 40-50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\u003cbr/\u003e3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*2\u003c/td\u003e\u003ctd\u003ephenytoin\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.\u003c/td\u003e\u003ctd\u003e1. The loading dose does not need to be adjusted.\u003cbr/\u003e2. For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\u003cbr/\u003e3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*3\u003c/td\u003e\u003ctd\u003ephenytoin\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects. The life-threatening cutaneous side effects Stevens-Johnson Syndrome and toxic epidermal necrolysis may occur, especially in Asian patients.\u003c/td\u003e\u003ctd\u003e1. The loading dose does not need to be adjusted.\u003cbr/\u003e2. For the other doses, use 75% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\u003cbr/\u003e3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*2\u003c/td\u003e\u003ctd\u003ephenytoin\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.\u003c/td\u003e\u003ctd\u003e1. The loading dose does not need to be adjusted.\u003cbr/\u003e2. For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\u003cbr/\u003e3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*3\u003c/td\u003e\u003ctd\u003ephenytoin\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects.\u003c/td\u003e\u003ctd\u003e1. The loading dose does not need to be adjusted.\u003cbr/\u003e2. For the other doses, use 50% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\u003cbr/\u003e3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or rash) occur.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *3/*3\u003c/td\u003e\u003ctd\u003ephenytoin\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of phenytoin to inactive metabolites. This increases the risk of side effects. The life-threatening cutaneous side effects Stevens-Johnson Syndrome and toxic epidermal necrolysis may occur, especially in Asian patients.\u003c/td\u003e\u003ctd\u003e1. The loading dose does not need to be adjusted.\u003cbr/\u003e2. For the other doses, use 40% of the standard dose and assess the dose based on effect and serum concentration after 7-10 days.\u003cbr/\u003e3. Advise the patient to get in touch if side effects (such as ataxia, nystagmus, slurred speech, sedation or, especially in Asian patients, rash) occur.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001676.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenytoin based on CYP2C9 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*2\u003c/td\u003e\u003ctd\u003eStandard loading dose. Reduce maintenance dose by 25%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms females, \u0026lt;470 ms males); INR increase \u0026lt; 4.5Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*2\u003c/td\u003e\u003ctd\u003eStandard loading dose. Reduce maintenance dose by 50%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms females, \u0026lt;470 ms males); INR increase \u0026lt; 4.5Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*3\u003c/td\u003e\u003ctd\u003eStandard loading dose. Reduce maintenance dose by 25%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10\u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*3\u003c/td\u003e\u003ctd\u003eStandard loading dose. Reduce maintenance dose by 50%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms females, \u0026lt;470 ms males); INR increase \u0026lt; 4.5Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *3/*3\u003c/td\u003e\u003ctd\u003eStandard loading dose. Reduce maintenance dose by 50%. Evaluate response and serum concentration after 7-10 days. Be alert to ADEs (e.g., ataxia, nystagmus, dysarthria, sedation)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10\u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182819,Guideline Annotation,Annotation of DPWG Guideline for pimozide and CYP2D6,t,PA450965,Dutch Pharmacogenetics Working Group,"<p>Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for pimozide based on CYP2D6 genotype. They recommend a dose reduction for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs). There are no recommendations for patients who are CYP2D6 ultrarapid metabolizers (UMs).</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>pimozide</td><td>This gene variation can result in lower pimozide concentrations. However, there is no evidence of reduced effectiveness.</td><td>NO action is required for this gene-drug interaction.</td></tr>
<tr><td>CYP2D6 IM</td><td>pimozide</td><td>The risk of QT-prolongation – and thereby also the risk of torsade de points – is theoretically increased, because the genetic variation results in an increase in the plasma concentration of pimozide. The risk of an excessively high plasma concentration can be negated by following the dose recommendations provided.</td><td>Use no more than the following doses (80% of the standard maximum dose):<br/>adults 16 mg/day<br/>children 0.08 mg/kg per day to a maximum of 3 mg/day</td></tr>
<tr><td>CYP2D6 PM</td><td>pimozide</td><td>The risk of QT-prolongation – and thereby also the risk of torsade de points – is theoretically increased, because the genetic variation results in an increase in the plasma concentration of pimozide. The risk of an excessively high plasma concentration can be negated by following the dose recommendations provided.</td><td>Use no more than the following doses (50% of the standard maximum dose):<br/>adults 10 mg/day<br/>children 0.05 mg/kg per day to a maximum of 2 mg/day</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002448.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182819"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182819"",""name"":""Annotation of DPWG Guideline for pimozide and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415022E9,""date"":""2019-05-23T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450821025E9,""date"":""2019-10-07T18:19:00.092-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450963782E9,""date"":""2020-02-11T07:34:57.514-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450965"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450965"",""name"":""pimozide""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.45041502E9,""html"":""\u003cp\u003ePatients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415021E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for pimozide based on CYP2D6 genotype. They recommend a dose reduction for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs). There are no recommendations for patients who are CYP2D6 ultrarapid metabolizers (UMs).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003epimozide\u003c/td\u003e\u003ctd\u003eThis gene variation can result in lower pimozide concentrations. However, there is no evidence of reduced effectiveness.\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003epimozide\u003c/td\u003e\u003ctd\u003eThe risk of QT-prolongation – and thereby also the risk of torsade de points – is theoretically increased, because the genetic variation results in an increase in the plasma concentration of pimozide. The risk of an excessively high plasma concentration can be negated by following the dose recommendations provided.\u003c/td\u003e\u003ctd\u003eUse no more than the following doses (80% of the standard maximum dose):\u003cbr/\u003eadults 16 mg/day\u003cbr/\u003echildren 0.08 mg/kg per day to a maximum of 3 mg/day\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003epimozide\u003c/td\u003e\u003ctd\u003eThe risk of QT-prolongation – and thereby also the risk of torsade de points – is theoretically increased, because the genetic variation results in an increase in the plasma concentration of pimozide. The risk of an excessively high plasma concentration can be negated by following the dose recommendations provided.\u003c/td\u003e\u003ctd\u003eUse no more than the following doses (50% of the standard maximum dose):\u003cbr/\u003eadults 10 mg/day\u003cbr/\u003echildren 0.05 mg/kg per day to a maximum of 2 mg/day\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002448.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166192321,Guideline Annotation,Annotation of CPIC Guideline for piroxicam and CYP2C9,t,PA450985,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"" target=""_blank"">CPIC&reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9</a>.</p>
<h3 id=""march-2020"">March 2020</h3>
<p><em>Advance online publication March 2020.</em></p>
<ul>
<li>
<p>The <a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830"" target=""_blank"">CPIC guideline regarding for <em>CYP2C9</em> and Nonsteroidal Anti-inflammatory Drugs</a> is published in Clinical Pharmacology and Therapeutics.</p>
</li>
<li>
<p>These guidelines are applicable to:</p>
<ul>
<li>
<p>pediatric patients</p>
</li>
<li>
<p>adult patients</p>
</li>
</ul>
</li>
<li>
<p>Excerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:</p>
<ul>
<li>
<p>&quot;Substantial evidence links CYP2C9 genotypes with phenotypic variability in CYP2C9 metabolism and plasma NSAID concentrations, with the majority of studies conducted in healthy volunteers.&quot;</p>
</li>
<li>
<p>&quot;Although clinical evidence linking genetic variation in CYP2C9 to an increased rate of adverse events with NSAIDs use is scarce, several studies have established an association between CYP2C9 decreased function and no function alleles and elevated NSAID exposure (Figure 1 and Figure S2). Because most NSAID adverse events are dose-dependent, on-target adverse events involving COX inhibition (19-23) it is reasonable to assume that elevated exposure increases the risk of adverse events.&quot;</p>
</li>
<li>
<p>&quot;CYP2C9 IM and PM phenotypes affect systemic plasma concentrations of NSAIDs by decreasing metabolic clearance and consequently prolonging plasma elimination half-life. Therefore, therapeutic recommendations are broadly organized according to the NSAID plasma elimination half-life in NMs. Where more than two studies reported plasma concentration areaunder-the-curve (AUC), a meta-analysis was conducted to estimate the average impact of CYP2C9 genotype on drug exposure (Figure 1 and Figures S2 to S4).&quot;</p>
</li>
<li>
<p>&quot; <em><strong>Piroxicam and tenoxicam</strong></em>. These drugs have extremely long half-lives (30-86 and 60 hours, respectively), thus
amplifying the potential risks in individuals with reduced CYP2C9 metabolism and hampering dose titration strategies due to lack of data. Accordingly, rather than use of a lower starting dose, IMs with an AS of 1 and PMs are recommended to receive an alternative therapy. This includes drugs that are not metabolized by CYP2C9 or significantly affected by CYP2C9 genetic variants in vivo. Selection of a NSAID with a short half-life (Table 2) could also be considered.&quot;</p>
</li>
<li>
<p>&quot; <em><strong>Meloxicam</strong></em>. Meloxicam has a longer half-life (15-20 hours, Table S12) than celecoxib and ibuprofen; thus, impaired meloxicam metabolism is expected to cause sustained elevations in drug exposure. Recommendations for CYP2C9 NMs and IMs with an AS of 1.5 are similar to the short half-life NSAIDs and include initiation of therapy with the standard dose while using the lowest effective dosage for shortest duration capable to achieve treatment goals. For IMs with an AS of 1, reduced metabolism and increased plasma concentrations are expected that may increase probability of toxicities...The recommendations are to either initiate therapy with 50% of the lowest recommended starting dose or choose an alternative therapy, consistent with the recommendations in PMs for short half-life NSAIDs (Table 2). Upward dose titration should not occur until after steady-state is reached (at least seven days), and careful monitoring is recommended. CYP2C9 PMs should be prescribed an alternative therapy because markedly prolonged half-life is expected (i.e., &gt;100 hours)&quot;.</p>
</li>
<li>
<p>&quot;<em><strong>Celecoxib, flurbiprofen, ibuprofen, lornoxicam</strong></em>: Based on current evidence, NMs and IMs with an AS of 1.5 are recommended to initiate therapy with the approved starting dose. Despitehaving mildly reduced metabolism, IMs with an AS of 1.5 do not exhibit significant increases in drug exposure relative to NMs... CYP2C9 IMs with an AS of 1 have reduced metabolism and are expected to exhibit a prolonged drug half-life and higher plasma concentrations compared to NMs, which may increase probability of toxicities.For IMs with an AS of 1, it is recommended to initiate NSAID therapy with the lowest recommended starting dose and titrate to clinical effect with close monitoring for adverse events such as elevated blood pressure and kidney dysfunction during course of therapy. Regarding ibuprofen use, it should be taken into consideration that while the CYP2C9*2 allele alone might not cause a clinically relevant reduction in clearance, its strong linkage with the
decreased function CYP2C8*3 allele may result in impaired R (-) ibuprofen hydroxylation and increased exposure to the parent drug...Individuals with a CYP2C9 PM phenotype (AS of 0) are expected to have markedly reduced metabolism and are expected to exhibit a pronounced prolongation of drug half-life and increase in plasma concentrations, which may increase the probability and/or severity of toxicities...It is recommended to initiate therapy with 25-50% of the lowest recommended starting dose (i.e. 50-75% dose reduction), and careful dose titration to clinical effect. Because drug half-life is significantly prolonged in these patients, upward dose titration should not occur until after steady-state is reached, taking into consideration the PM half-life for each drug; of course, dosing may be stopped or decreased due to toxicity at any time. Treatment with an alternative therapy could also be considered. This could include NSAIDs not primarily metabolized by CYP2C9 (such as aspirin, ketorolac (approved for short term use only), metamizole, naproxen, sulindac, etoricoxib, parecoxib, or valdecoxib), or with pharmacokinetic parameters apparently not impacted by CYP2C9 genetic variants in vivo despite CYP2C9 metabolism in vitro&quot;.</p>
</li>
<li>
<p>&quot; <em><strong>Aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen</strong></em>. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C&quot;.</p>
</li>
<li>
<p>&quot;<em><strong>Pediatrics</strong></em>: Because CYP2C9 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring. Ultimately, additional research
and clinical trials in pediatric patients investigating the association between CYP2C9 genotype and NSAID systemic exposure and treatment outcomes are needed.&quot;</p>
</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2C9</em> and NSAIDs Therapy</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT_supplement.pdf"" target=""_blank"">2020 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Piroxicam_Drug_Resource_Mappings.xlsx"" target=""_blank"">piroxicam Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Piroxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">piroxicam Pre and Post Test Alerts</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-piroxicam-by-cyp2c9-phenotype"">Table 1: Recommended dosing of <em><strong>piroxicam</strong></em> by CYP2C9 phenotype</h3>
<p><em>Adapted from Tables 1 and 4 of the 2020 guideline.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype<sup>a</sup></th><th>Activity Score</th><th>Genotype</th><th>Examples of genotypes<sup>b</sup></th><th>Implications</th><th>Therapeutic recommendations<sup>c</sup></th><th>Classification of recommendations<sup>d</sup></th><th>Other considerations</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C9</em> Normal metabolizer</td><td>2<sup>c</sup></td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td><td>Strong</td><td></td></tr>
<tr><td><em>CYP2C9</em> Intermediate metabolizer<sup>f</sup></td><td>1.5<sup>c</sup></td><td>An individual carrying one normal function and one decreased function allele.</td><td>*1/*2</td><td>Mildly reduced metabolism</td><td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td><td>Moderate</td><td>IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.</td></tr>
<tr><td><em>CYP2C9</em> Intermediate metabolizer<sup>f</sup></td><td>1<sup>c</sup></td><td>An individual carrying one normal function allele plus one no function allele OR two decreased function alleles.</td><td>*1/*3, *2/*2</td><td>Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities</td><td>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).</td><td>Moderate</td><td>Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</td></tr>
<tr><td><em>CYP2C9</em> Poor metabolizer</td><td>0 or 0.5<sup>c</sup></td><td>An individual carrying one no function allele plus one decreased function allele; OR two no function alleles</td><td>*2/*3, *3/*3</td><td>Significantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities</td><td>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).</td><td>Moderate</td><td>Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</td></tr>
<tr><td>Indeterminate</td><td>n/a<sup>c</sup></td><td>An individual carrying allele combinations with uncertain and/or unknown function alleles</td><td>*1/*7, *1/*10, *7/*10, *1/*57</td><td>n/a</td><td>No recommendation.</td><td>n/a</td><td></td></tr>
</tbody>
</table>
<p><sup>a</sup> See the <a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 frequency table</a> for race-specific allele and phenotype frequencies.<br />
<sup>b</sup> For a complete list of CYP2C9 diplotypes and resulting phenotypes, see the <a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 genotype to phenotype table</a>.</p>
<p><sup>c</sup> CPIC assigned each allele functional status an activity value ranging from 0 to 1 (e.g., 0 for no function, 0.5 for decreased, and 1.0 for normal function), which are summed to calculate the activity score (AS) for each diplotype. The CYP2C9 AS has been translated into the phenotype classification system as follows: individuals with an AS of 0 or 0.5 are poor
metabolizers (PMs), those with a score of 1 or 1.5 are intermediate metabolizers (IMs), and those with a score of 2 are normal metabolizers (NMs).<br />
<sup>d</sup> Rating scheme described in Supplement.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166192321"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166192321"",""name"":""Annotation of CPIC Guideline for piroxicam and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[{""id"":1.4509866E9,""alleles"":[{""id"":1.450986601E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816542"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816542"",""symbol"":""CYP2C9*1"",""name"":""*1""}},{""id"":1.450986602E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816543"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816543"",""symbol"":""CYP2C9*2"",""name"":""*2""}},{""id"":1.450986603E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816544"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816544"",""symbol"":""CYP2C9*3"",""name"":""*3""}},{""id"":1.450986604E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816545"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816545"",""symbol"":""CYP2C9*4"",""name"":""*4""}},{""id"":1.450986605E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816546"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816546"",""symbol"":""CYP2C9*5"",""name"":""*5""}},{""id"":1.450986606E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816547"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816547"",""symbol"":""CYP2C9*6"",""name"":""*6""}},{""id"":1.450986607E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816548"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816548"",""symbol"":""CYP2C9*7"",""name"":""*7""}},{""id"":1.450986608E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816549"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816549"",""symbol"":""CYP2C9*8"",""name"":""*8""}},{""id"":1.450986609E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816550"",""symbol"":""CYP2C9*9"",""name"":""*9""}},{""id"":1.45098661E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816551"",""symbol"":""CYP2C9*10"",""name"":""*10""}},{""id"":1.450986611E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816552"",""symbol"":""CYP2C9*11"",""name"":""*11""}},{""id"":1.450986612E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816553"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816553"",""symbol"":""CYP2C9*12"",""name"":""*12""}},{""id"":1.450986613E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816554"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816554"",""symbol"":""CYP2C9*13"",""name"":""*13""}},{""id"":1.450986614E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816555"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816555"",""symbol"":""CYP2C9*14"",""name"":""*14""}},{""id"":1.450986615E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816556"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816556"",""symbol"":""CYP2C9*15"",""name"":""*15""}},{""id"":1.450986616E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816557"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816557"",""symbol"":""CYP2C9*16"",""name"":""*16""}},{""id"":1.450986617E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816563"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816563"",""symbol"":""CYP2C9*17"",""name"":""*17""}},{""id"":1.450986618E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816558"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816558"",""symbol"":""CYP2C9*18"",""name"":""*18""}},{""id"":1.450986619E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816564"",""symbol"":""CYP2C9*19"",""name"":""*19""}},{""id"":1.45098662E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816565"",""symbol"":""CYP2C9*20"",""name"":""*20""}},{""id"":1.450986621E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816566"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816566"",""symbol"":""CYP2C9*21"",""name"":""*21""}},{""id"":1.450986622E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816567"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816567"",""symbol"":""CYP2C9*22"",""name"":""*22""}},{""id"":1.450986623E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816568"",""symbol"":""CYP2C9*23"",""name"":""*23""}},{""id"":1.450986624E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816569"",""symbol"":""CYP2C9*24"",""name"":""*24""}},{""id"":1.450986625E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816559"",""symbol"":""CYP2C9*25"",""name"":""*25""}},{""id"":1.450986626E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816570"",""symbol"":""CYP2C9*26"",""name"":""*26""}},{""id"":1.450986627E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816571"",""symbol"":""CYP2C9*27"",""name"":""*27""}},{""id"":1.450986628E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816572"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816572"",""symbol"":""CYP2C9*28"",""name"":""*28""}},{""id"":1.450986629E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816573"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816573"",""symbol"":""CYP2C9*29"",""name"":""*29""}},{""id"":1.45098663E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816574"",""symbol"":""CYP2C9*30"",""name"":""*30""}},{""id"":1.450986631E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816560"",""symbol"":""CYP2C9*31"",""name"":""*31""}},{""id"":1.450986632E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816575"",""symbol"":""CYP2C9*32"",""name"":""*32""}},{""id"":1.450986633E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816561"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816561"",""symbol"":""CYP2C9*33"",""name"":""*33""}},{""id"":1.450986634E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816562"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816562"",""symbol"":""CYP2C9*34"",""name"":""*34""}},{""id"":1.450986635E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048681"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048681"",""symbol"":""CYP2C9*35"",""name"":""*35""}},{""id"":1.450986636E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048682"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048682"",""symbol"":""CYP2C9*36"",""name"":""*36""}},{""id"":1.450986637E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048683"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048683"",""symbol"":""CYP2C9*37"",""name"":""*37""}},{""id"":1.450986638E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048684"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048684"",""symbol"":""CYP2C9*38"",""name"":""*38""}},{""id"":1.450986639E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048685"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048685"",""symbol"":""CYP2C9*39"",""name"":""*39""}},{""id"":1.45098664E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048686"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048686"",""symbol"":""CYP2C9*40"",""name"":""*40""}},{""id"":1.450986641E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048687"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048687"",""symbol"":""CYP2C9*41"",""name"":""*41""}},{""id"":1.450986642E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048688"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048688"",""symbol"":""CYP2C9*42"",""name"":""*42""}},{""id"":1.450986643E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048689"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048689"",""symbol"":""CYP2C9*43"",""name"":""*43""}},{""id"":1.450986644E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048690"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048690"",""symbol"":""CYP2C9*44"",""name"":""*44""}},{""id"":1.450986645E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048691"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048691"",""symbol"":""CYP2C9*45"",""name"":""*45""}},{""id"":1.450986646E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048692"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048692"",""symbol"":""CYP2C9*46"",""name"":""*46""}},{""id"":1.450986647E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048693"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048693"",""symbol"":""CYP2C9*47"",""name"":""*47""}},{""id"":1.450986648E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048694"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048694"",""symbol"":""CYP2C9*48"",""name"":""*48""}},{""id"":1.450986649E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048695"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048695"",""symbol"":""CYP2C9*49"",""name"":""*49""}},{""id"":1.45098665E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048696"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048696"",""symbol"":""CYP2C9*50"",""name"":""*50""}},{""id"":1.450986651E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048697"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048697"",""symbol"":""CYP2C9*51"",""name"":""*51""}},{""id"":1.450986652E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048698"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048698"",""symbol"":""CYP2C9*52"",""name"":""*52""}},{""id"":1.450986653E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048699"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048699"",""symbol"":""CYP2C9*53"",""name"":""*53""}},{""id"":1.450986654E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048700"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048700"",""symbol"":""CYP2C9*54"",""name"":""*54""}},{""id"":1.450986655E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048701"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048701"",""symbol"":""CYP2C9*55"",""name"":""*55""}},{""id"":1.450986656E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048702"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048702"",""symbol"":""CYP2C9*56"",""name"":""*56""}},{""id"":1.450986657E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048703"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048703"",""symbol"":""CYP2C9*57"",""name"":""*57""}},{""id"":1.450986658E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166122566"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166122566"",""symbol"":""CYP2C9*58"",""name"":""*58""}},{""id"":1.450986659E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128210"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128210"",""symbol"":""CYP2C9*59"",""name"":""*59""}},{""id"":1.45098666E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128211"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128211"",""symbol"":""CYP2C9*60"",""name"":""*60""}},{""id"":1.450986661E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166183345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166183345"",""symbol"":""CYP2C9*61"",""name"":""*61""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}}],""history"":[{""id"":1.45109516E9,""date"":""2020-03-19T00:00:00-07:00"",""description"":""Guideline published"",""type"":""Note"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15105062"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5105062E7,""resourceId"":""32189324"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/32189324"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/32189324"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.451090662E9,""resource"":""PubMed"",""resourceId"":""32189324"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/32189324""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1830"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.451090663E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1830"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1830""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA450985"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA450985"",""name"":""piroxicam""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.450986503E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450986504E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""march-2020\""\u003eMarch 2020\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication March 2020.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830\"" target\u003d\""_blank\""\u003eCPIC guideline regarding for \u003cem\u003eCYP2C9\u003c/em\u003e and Nonsteroidal Anti-inflammatory Drugs\u003c/a\u003e is published in Clinical Pharmacology and Therapeutics.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThese guidelines are applicable to:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003epediatric patients\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eadult patients\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExcerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Substantial evidence links CYP2C9 genotypes with phenotypic variability in CYP2C9 metabolism and plasma NSAID concentrations, with the majority of studies conducted in healthy volunteers.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Although clinical evidence linking genetic variation in CYP2C9 to an increased rate of adverse events with NSAIDs use is scarce, several studies have established an association between CYP2C9 decreased function and no function alleles and elevated NSAID exposure (Figure 1 and Figure S2). Because most NSAID adverse events are dose-dependent, on-target adverse events involving COX inhibition (19-23) it is reasonable to assume that elevated exposure increases the risk of adverse events.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;CYP2C9 IM and PM phenotypes affect systemic plasma concentrations of NSAIDs by decreasing metabolic clearance and consequently prolonging plasma elimination half-life. Therefore, therapeutic recommendations are broadly organized according to the NSAID plasma elimination half-life in NMs. Where more than two studies reported plasma concentration areaunder-the-curve (AUC), a meta-analysis was conducted to estimate the average impact of CYP2C9 genotype on drug exposure (Figure 1 and Figures S2 to S4).\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003ePiroxicam and tenoxicam\u003c/strong\u003e\u003c/em\u003e. These drugs have extremely long half-lives (30-86 and 60 hours, respectively), thus\namplifying the potential risks in individuals with reduced CYP2C9 metabolism and hampering dose titration strategies due to lack of data. Accordingly, rather than use of a lower starting dose, IMs with an AS of 1 and PMs are recommended to receive an alternative therapy. This includes drugs that are not metabolized by CYP2C9 or significantly affected by CYP2C9 genetic variants in vivo. Selection of a NSAID with a short half-life (Table 2) could also be considered.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003eMeloxicam\u003c/strong\u003e\u003c/em\u003e. Meloxicam has a longer half-life (15-20 hours, Table S12) than celecoxib and ibuprofen; thus, impaired meloxicam metabolism is expected to cause sustained elevations in drug exposure. Recommendations for CYP2C9 NMs and IMs with an AS of 1.5 are similar to the short half-life NSAIDs and include initiation of therapy with the standard dose while using the lowest effective dosage for shortest duration capable to achieve treatment goals. For IMs with an AS of 1, reduced metabolism and increased plasma concentrations are expected that may increase probability of toxicities...The recommendations are to either initiate therapy with 50% of the lowest recommended starting dose or choose an alternative therapy, consistent with the recommendations in PMs for short half-life NSAIDs (Table 2). Upward dose titration should not occur until after steady-state is reached (at least seven days), and careful monitoring is recommended. CYP2C9 PMs should be prescribed an alternative therapy because markedly prolonged half-life is expected (i.e., \u0026gt;100 hours)\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cem\u003e\u003cstrong\u003eCelecoxib, flurbiprofen, ibuprofen, lornoxicam\u003c/strong\u003e\u003c/em\u003e: Based on current evidence, NMs and IMs with an AS of 1.5 are recommended to initiate therapy with the approved starting dose. Despitehaving mildly reduced metabolism, IMs with an AS of 1.5 do not exhibit significant increases in drug exposure relative to NMs... CYP2C9 IMs with an AS of 1 have reduced metabolism and are expected to exhibit a prolonged drug half-life and higher plasma concentrations compared to NMs, which may increase probability of toxicities.For IMs with an AS of 1, it is recommended to initiate NSAID therapy with the lowest recommended starting dose and titrate to clinical effect with close monitoring for adverse events such as elevated blood pressure and kidney dysfunction during course of therapy. Regarding ibuprofen use, it should be taken into consideration that while the CYP2C9*2 allele alone might not cause a clinically relevant reduction in clearance, its strong linkage with the\ndecreased function CYP2C8*3 allele may result in impaired R (-) ibuprofen hydroxylation and increased exposure to the parent drug...Individuals with a CYP2C9 PM phenotype (AS of 0) are expected to have markedly reduced metabolism and are expected to exhibit a pronounced prolongation of drug half-life and increase in plasma concentrations, which may increase the probability and/or severity of toxicities...It is recommended to initiate therapy with 25-50% of the lowest recommended starting dose (i.e. 50-75% dose reduction), and careful dose titration to clinical effect. Because drug half-life is significantly prolonged in these patients, upward dose titration should not occur until after steady-state is reached, taking into consideration the PM half-life for each drug; of course, dosing may be stopped or decreased due to toxicity at any time. Treatment with an alternative therapy could also be considered. This could include NSAIDs not primarily metabolized by CYP2C9 (such as aspirin, ketorolac (approved for short term use only), metamizole, naproxen, sulindac, etoricoxib, parecoxib, or valdecoxib), or with pharmacokinetic parameters apparently not impacted by CYP2C9 genetic variants in vivo despite CYP2C9 metabolism in vitro\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003eAceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen\u003c/strong\u003e\u003c/em\u003e. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cem\u003e\u003cstrong\u003ePediatrics\u003c/strong\u003e\u003c/em\u003e: Because CYP2C9 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring. Ultimately, additional research\nand clinical trials in pediatric patients investigating the association between CYP2C9 genotype and NSAID systemic exposure and treatment outcomes are needed.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for \u003cem\u003eCYP2C9\u003c/em\u003e and NSAIDs Therapy\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT_supplement.pdf\"" target\u003d\""_blank\""\u003e2020 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Piroxicam_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003epiroxicam Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Piroxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003epiroxicam Pre and Post Test Alerts\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-piroxicam-by-cyp2c9-phenotype\""\u003eTable 1: Recommended dosing of \u003cem\u003e\u003cstrong\u003epiroxicam\u003c/strong\u003e\u003c/em\u003e by CYP2C9 phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 4 of the 2020 guideline.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eActivity Score\u003c/th\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eExamples of genotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003csup\u003ed\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eOther considerations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Normal metabolizer\u003c/td\u003e\u003ctd\u003e2\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Intermediate metabolizer\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.5\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function and one decreased function allele.\u003c/td\u003e\u003ctd\u003e*1/*2\u003c/td\u003e\u003ctd\u003eMildly reduced metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eIMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Intermediate metabolizer\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele plus one no function allele OR two decreased function alleles.\u003c/td\u003e\u003ctd\u003e*1/*3, *2/*2\u003c/td\u003e\u003ctd\u003eModerately reduced metabolism; higher plasma concentrations may increase probability of toxicities\u003c/td\u003e\u003ctd\u003eChoose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Poor metabolizer\u003c/td\u003e\u003ctd\u003e0 or 0.5\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one no function allele plus one decreased function allele; OR two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eSignificantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities\u003c/td\u003e\u003ctd\u003eChoose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003en/a\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying allele combinations with uncertain and/or unknown function alleles\u003c/td\u003e\u003ctd\u003e*1/*7, *1/*10, *7/*10, *1/*57\u003c/td\u003e\u003ctd\u003en/a\u003c/td\u003e\u003ctd\u003eNo recommendation.\u003c/td\u003e\u003ctd\u003en/a\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e See the \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 frequency table\u003c/a\u003e for race-specific allele and phenotype frequencies.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e For a complete list of CYP2C9 diplotypes and resulting phenotypes, see the \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 genotype to phenotype table\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e CPIC assigned each allele functional status an activity value ranging from 0 to 1 (e.g., 0 for no function, 0.5 for decreased, and 1.0 for normal function), which are summed to calculate the activity score (AS) for each diplotype. The CYP2C9 AS has been translated into the phenotype classification system as follows: individuals with an AS of 0 or 0.5 are poor\nmetabolizers (PMs), those with a score of 1 or 1.5 are intermediate metabolizers (IMs), and those with a score of 2 are normal metabolizers (NMs).\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003e Rating scheme described in Supplement.\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182820,Guideline Annotation,Annotation of DPWG Guideline for prasugrel and CYP2C19,f,PA154410481,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for prasugrel based on CYP2C19 genotypes.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for prasugrel based on CYP2C19 genotypes. They conclude that there is not a gene-drug interaction. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002546.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182820"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182820"",""name"":""Annotation of DPWG Guideline for prasugrel and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415045E9,""date"":""2019-05-23T15:07:53.320-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821026E9,""date"":""2019-10-07T18:20:13.348-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45096382E9,""date"":""2020-02-11T07:36:09.709-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA154410481"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA154410481"",""name"":""prasugrel""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415042E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for prasugrel based on CYP2C19 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415043E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for prasugrel based on CYP2C19 genotypes. They conclude that there is not a gene-drug interaction. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002546.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104962,Guideline Annotation,Annotation of DPWG Guideline for propafenone and CYP2D6,t,PA451131,Dutch Pharmacogenetics Working Group,"<p>Reduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor pimozide plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for propafenone based on CYP2D6 genotype. They recommend monitoring plasma concentrations and performing an ECG or selecting an alternative antiarrhythmic drug for CYP2D6 ultrarapid metabolizers (UMs) and intermeidate metabolizers (IMs). They also recommend that patients who are CYP2D6 poor metabolizers (PMs) receive 30% of a standard dose of propafenone.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>propafenone</td><td>Genetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy</td><td>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.<br/>1. Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.<br/>2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</td></tr>
<tr><td>CYP2D6 IM</td><td>propafenone</td><td>Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects.</td><td>It is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.<br/>1. Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects<br/>2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.</td></tr>
<tr><td>CYP2D6 PM</td><td>propafenone</td><td>Genetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of side effects.</td><td>Reduce the dose to 30% of the standard dose, perform an ECG and monitor plasma concentrations.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001596.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for propafenone based on CYP2D6 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They suggest a reduced dose for poor metabolizers, and adjusting dose according to plasma concentrations or using an alternative drug for intermediate and ultrarapid metabolizers.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles)</td><td>Reduce dose by 70%, record ECG, monitor plasma concentration</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10 <sup>9</sup>/l; leucopenia 2.0-3.0x10 <sup>9</sup>/l; thrombocytopenia 50-75x10 <sup>9</sup>/l</td></tr>
<tr><td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td><td>Insufficient data to allow calculation of dose adjustment. Adjust dose in response to plasma concentration and record ECG or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone)</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms male, &lt;470 ms female); INR increase &lt; 4.5, Kinetic effect (S)</td></tr>
<tr><td>UM (gene duplication in absence of inactive or decreased activity alleles)</td><td>Insufficient data to allow calculation of dose adjustment. Adjust dose in response to plasma concentration and record ECG or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone)</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10 <sup>9</sup>/l; leucopenia 1.0-2.0x10 <sup>9</sup>/l; thrombocytopenia 25-50x10 <sup>9</sup>/l; severe diarrhea</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *2, *33, *35</td></tr>
<tr><td>decreased activity</td><td>*9, *10, *17, *29, *36, *41</td></tr>
<tr><td>inactive</td><td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104962"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104962"",""name"":""Annotation of DPWG Guideline for propafenone and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704521E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.45041503E9,""date"":""2019-05-23T14:33:30.713-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821027E9,""date"":""2019-10-07T18:21:56.510-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956352E9,""date"":""2020-01-31T13:46:20.579-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096384E9,""date"":""2020-02-11T07:37:30.144-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451131"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451131"",""name"":""propafenone""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981932E9,""html"":""\u003cp\u003eReduce the dose of propafenone by 70% for CYP2D6 poor metabolizers, and monitor pimozide plasma concentrations or use an alternative drug for CYP2D6 intermediate and ultrarapid metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981931E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for propafenone based on CYP2D6 genotype. They recommend monitoring plasma concentrations and performing an ECG or selecting an alternative antiarrhythmic drug for CYP2D6 ultrarapid metabolizers (UMs) and intermeidate metabolizers (IMs). They also recommend that patients who are CYP2D6 poor metabolizers (PMs) receive 30% of a standard dose of propafenone.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003epropafenone\u003c/td\u003e\u003ctd\u003eGenetic variation decreases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of reduced or no efficacy\u003c/td\u003e\u003ctd\u003eIt is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.\u003cbr/\u003e1. Either monitor plasma concentrations, perform an ECG and be alert to reduced efficacy of the therapy.\u003cbr/\u003e2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003epropafenone\u003c/td\u003e\u003ctd\u003eGenetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This may increase the risk of side effects.\u003c/td\u003e\u003ctd\u003eIt is not possible to offer adequately substantiated recommendations for dose adjustment based on the literature.\u003cbr/\u003e1. Either guide the dose by therapeutic drug monitoring, perform an ECG and be alert to side effects\u003cbr/\u003e2. Or choose an alternative. Antiarrhythmic drugs that are hardly if at all metabolised by CYP2D6 include, for example, sotalol, disopyramide, quinidine and amiodarone.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003epropafenone\u003c/td\u003e\u003ctd\u003eGenetic variation increases the sum of the plasma concentrations of propafenone and the active metabolite 5-hydroxypropafenone. This increases the risk of side effects.\u003c/td\u003e\u003ctd\u003eReduce the dose to 30% of the standard dose, perform an ECG and monitor plasma concentrations.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001596.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for propafenone based on CYP2D6 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They suggest a reduced dose for poor metabolizers, and adjusting dose according to plasma concentrations or using an alternative drug for intermediate and ultrarapid metabolizers.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles)\u003c/td\u003e\u003ctd\u003eReduce dose by 70%, record ECG, monitor plasma concentration\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10 \u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10 \u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10 \u003csup\u003e9\u003c/sup\u003e/l\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Adjust dose in response to plasma concentration and record ECG or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms male, \u0026lt;470 ms female); INR increase \u0026lt; 4.5, Kinetic effect (S)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (gene duplication in absence of inactive or decreased activity alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Adjust dose in response to plasma concentration and record ECG or select alternative drug (e.g., sotalol, disopyramide, quinidine, amiodarone)\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10 \u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10 \u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10 \u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *2, *33, *35\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9, *10, *17, *29, *36, *41\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*3-*8, *11-*16, *19-*21, *38, *40, *42\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182854,Guideline Annotation,Annotation of DPWG Guideline for quetiapine and CYP2D6,f,PA451201,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for quetiapine based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for quetiapine based on CYP2D6 genotypes. They conclude that this is not a gene-drug interaction. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002394.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182854"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182854"",""name"":""Annotation of DPWG Guideline for quetiapine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.45041534E9,""date"":""2019-05-28T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821028E9,""date"":""2019-10-07T18:23:24.671-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.45096386E9,""date"":""2020-02-11T07:38:51.936-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451201"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451201"",""name"":""quetiapine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415337E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for quetiapine based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415338E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for quetiapine based on CYP2D6 genotypes. They conclude that this is not a gene-drug interaction. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002394.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182803,Guideline Annotation,Annotation of DPWG Guideline for quinidine and CYP2D6,f,PA451209,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for quinidine based on CYP2D6 genotypes.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for quinidine based on CYP2D6 genotypes. They conclude that there is not a gene-drug interaction (see the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>).</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002534.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182803"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182803"",""name"":""Annotation of DPWG Guideline for quinidine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414855E9,""date"":""2019-05-22T10:40:54.451-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820673E9,""date"":""2019-10-03T16:04:43.903-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Note"",""version"":0.0},{""id"":1.45096388E9,""date"":""2020-02-11T07:41:01.746-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451209"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451209"",""name"":""quinidine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450414852E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for quinidine based on CYP2D6 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414853E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for quinidine based on CYP2D6 genotypes. They conclude that there is not a gene-drug interaction (see the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002534.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104985,Guideline Annotation,Annotation of DPWG Guideline for rabeprazole and CYP2C19,f,PA451216,Dutch Pharmacogenetics Working Group,"<p>No action is needed for this gene-drug interaction.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for rabeprazole based on CYP2C19 genotype. They conclude that no action is needed for this gene-drug interaction, since higher plasma concentrations of rabeprazole do not result in an increase in side effects, and there is currently insufficient information about CYP2C19 ultrarapid metabolizers and rabeprazole to recommend any action. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001857.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for rabeprazole based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They conclude that there are no recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Positive clinical effects</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Clinical effect (not statistically significant difference); Kinetic effect (not statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>None</td><td>no data was retrieved with the literature search</td><td>no data was retrieved with the literature search</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104985"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104985"",""name"":""Annotation of DPWG Guideline for rabeprazole and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704523E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.45041505E9,""date"":""2019-05-23T15:11:11.531-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821029E9,""date"":""2019-10-07T18:24:44.653-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956395E9,""date"":""2020-01-31T13:47:00.516-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963881E9,""date"":""2020-02-11T07:42:13.740-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451216"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451216"",""name"":""rabeprazole""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981978E9,""html"":""\u003cp\u003eNo action is needed for this gene-drug interaction.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981977E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for rabeprazole based on CYP2C19 genotype. They conclude that no action is needed for this gene-drug interaction, since higher plasma concentrations of rabeprazole do not result in an increase in side effects, and there is currently insufficient information about CYP2C19 ultrarapid metabolizers and rabeprazole to recommend any action. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001857.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for rabeprazole based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They conclude that there are no recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003ePositive clinical effects\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eClinical effect (not statistically significant difference); Kinetic effect (not statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166119846,Guideline Annotation,Annotation of CPIC Guideline for rasburicase and G6PD,t,PA10176,Clinical Pharmacogenetics Implementation Consortium,"<p>Rasburicase is contraindicated in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a negative or inconclusive genetic test result an enzyme activity test is recommended prior to rasburicase treatment to determine whether a patient is G6PD deficient. The <em>G6PD</em> gene is X-linked and therefore males only have one copy, whereas females have two copies. See full guideline for disclaimers, further details and supporting evidence.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"" target=""_blank"">CPIC&reg; guideline for rasburicase and G6PD</a>.</p>
<h3 id=""september-2018-update"">September 2018 Update</h3>
<p>The CPIC authors recommend that the <em>G6PD A</em> variant be categorized as IV/normal function (previously II-IV/Deficient-Normal function) based on new evidence supporting function [Article:<a href=""/pmid/27040960"">27040960</a>] and [Article:<a href=""/pmid/30206300"">30206300</a>]. This change has been incorporated into the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/G6PD_allele_definition_table.xlsx"">G6PD allele definition table</a>.</p>
<h3 id=""august-2014"">August 2014</h3>
<p><em>Accepted article preview online May 2014, advance online publication 11 June 2014</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in determining whether rasburicase treatment should be undertaken have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpt from the 2014 rasburicase guideline:
<ul>
<li>&quot;As stated above, rasburicase is contraindicated by the FDA, the EMA, and PMDA in those with G6PD deficiency (32-34) (see Table 2). If, on the basis of genotyping, a deficient status can be unambiguously assigned to a patient, that would be a sufficient contraindication to the use of rasburicase. However, due to the limitations of genetic testing (discussed above), in most cases it is necessary to perform G6PD enzyme testing to assign G6PD status.&quot;</li>
</ul>
</li>
<li>These guidelines are applicable to
<ul>
<li>neonates</li>
<li>pediatrics</li>
<li>adults</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/rasburicase/2014/24787449.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the context of G6PD Deficiency Genotype.</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/rasburicase/2014/24787449-supplement.pdf"" target=""_blank"">2014 supplement</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-rasburicase-by-g6pd-phenotype"">Table 1: Recommended dosing of rasburicase by G6PD phenotype</h3>
<p><em>Adapted from Table 1 and Table 2 of the 2014 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype) <sup>a</sup></th><th>Examples of diplotypes <sup>b</sup></th><th>Implications for phenotypic measures</th><th>Dosing recommendations for rasburicase</th><th>Classification of recommendations <sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>Normal <sup>d</sup>. A male carrying a non-deficient (class IV) allele or a female carrying two non-deficient (class IV) alleles.</td><td>Male: B, Sao Boria. Female: B/B, B/ Sao Boria.</td><td>Low or reduced risk of hemolytic anemia.</td><td>No reason to withhold rasburicase based on G6PD status <sup>d</sup>.</td><td>Strong</td></tr>
<tr><td>Deficient or Deficient with CNSHA. A male carrying a class I, II or III allele, a female carrying two deficient class I-III alleles.</td><td>Male: A-, Orissa, Kalyan-Kerala, Mediterranean, Canton, Chatham, Bangkok, Villeurbanne. Female: A-/A-, A-/ Orissa, Orissa/ Kalyan-Kerala, Mediterranean/ Mediterranean, Chatham/Mediterranean, Canton/ Viangchan, Bangkok/ Bangkok, Bangkok/ Villeurbanne.</td><td>At risk of acute hemolytic anemia.</td><td>Rasburicase is contraindicated; alternatives include allopurinol <sup>e</sup>.</td><td>Strong</td></tr>
<tr><td>Variable <sup>d,f</sup>. A female carrying one non-deficient (class IV) and one deficient (class I-III variants) allele.</td><td>B/A-, B/Mediterranean, B/Bangkok.</td><td>Unknown risk of hemolytic anemia.</td><td>To ascertain that G6PD status is normal, enzyme activity must be measured; alternatives include allopurinol <sup>e</sup>.</td><td>Moderate</td></tr>
</tbody>
</table>
<p><sup>a</sup> &quot;Class&quot; refers to the WHO classifications from [Article:<a href=""/pmid/22293322"">22293322</a>], other details from [Article:<a href=""/pmid/4963040"">4963040</a>]. Class I variants are extremely rare; the distinction between class II and III variants is not clear; and the &quot;class V&quot; very high activity variant has only been reported in a single case [Article:<a href=""/pmid/4963040"">4963040</a>]. Therefore, almost all patients will carry class II, III, or IV alleles. It should be noted that the class of a variant may have been assigned only by the clinical manifestations of a patient in which the variant was subsequently identified.</p>
<p>(*) Luzzatto, L. &amp; Poggi, V. Glucose-6-Phosphate Dehydrogenase Deficiency In: Nathan and Oski's Hematology of Infancy and Childhood, 7th Edition  (ed. Meloni, D., Anderson, A. Authors of the book: Orkin, S.H., Fisher, D.E., Look, A.T., Lux IV, S.E., Ginsburg, D., Nathan, D.G. ) (Saunders, Elsevier., 2009).</p>
<p><sup>b</sup> Due to the large number of G6PD variants, many other diplotypes may be possible besides those given as examples here; see Supplemental Table S1 for a more comprehensive list of variant alleles with their assigned WHO class.</p>
<p><sup>c</sup> Rating scheme described in Supplement (See Strength of Recommendations material).</p>
<p><sup>d</sup> A negative or inconclusive genetic test cannot be assumed to indicate normal G6PD phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.</p>
<p><sup>e</sup> Allopurinol is associated with severe cutaneous reactions in the rare carriers of the HLA-B*58:01 allele [Article:<a href=""/pmid/23232549"">23232549</a>].</p>
<p><sup>f</sup> Due to X-linked mosaicism, females heterozygous for one non-deficient (class IV) and one deficient (class I-III variants) allele may display a normal or a deficient phenotype. It is therefore difficult to predict the phenotype of these individuals (Supplement, G6PD heterozygotes).</p>
<h3 id=""figure-1-workflow-for-interpreting-g6pd-genotype-and-for-assessing-need-for-an-enzyme-activity-test"">Figure 1: Workflow for interpreting G6PD genotype and for assessing need for an enzyme activity test.</h3>
<p><em>Figure 1 from the guideline manuscript.</em></p>
<p><img src=""https://s3.pgkb.org/attachment/CPIC_G6PD_rasburicase_guideline_Figure_1.png"" alt=""CPIC G6PD rasburicase guideline"" /></p>
<p>*It should be noted that the class of a variant may have been assigned only by the clinical manifestations of a patient in which the variant was subsequently identified [Article:<a href=""/pmid/22293322"">22293322</a>].</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166119846"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166119846"",""name"":""Annotation of CPIC Guideline for rasburicase and G6PD"",""cancerGenome"":false,""descriptiveVideoId"":""sM3d4OL2inI"",""guidelineGenes"":[{""id"":1.449562345E9,""alleles"":[{""id"":1.449562346E9,""_label"":""Mexico City"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121099"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121099"",""symbol"":""G6PD Mexico City"",""name"":""Mexico City""}},{""id"":1.449562347E9,""_label"":""Miaoli"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121126"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121126"",""symbol"":""G6PD Miaoli"",""name"":""Miaoli""}},{""id"":1.449562348E9,""_label"":""Minnesota, Marion, Gastonia, LeJeune"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121218"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121218"",""symbol"":""G6PD Minnesota, Marion, Gastonia, LeJeune"",""name"":""Minnesota, Marion, Gastonia, LeJeune""}},{""id"":1.449562349E9,""_label"":""Mira d\u0027Aire"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765952"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765952E9,""resource"":""Allele Function"",""term"":""Class IV"",""termId"":""haplotypeTags:1446765952""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121070"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121070"",""symbol"":""G6PD Mira d\u0027Aire"",""name"":""Mira d\u0027Aire""}},{""id"":1.44956235E9,""_label"":""Mizushima"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121134"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121134"",""symbol"":""G6PD Mizushima"",""name"":""Mizushima""}},{""id"":1.449562351E9,""_label"":""Montalbano"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121103"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121103"",""symbol"":""G6PD Montalbano"",""name"":""Montalbano""}},{""id"":1.449562352E9,""_label"":""Montpellier"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121165"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121165"",""symbol"":""G6PD Montpellier"",""name"":""Montpellier""}},{""id"":1.449562353E9,""_label"":""Mt Sinai"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121210"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121210"",""symbol"":""G6PD Mt Sinai"",""name"":""Mt Sinai""}},{""id"":1.449562354E9,""_label"":""Munich"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121190"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121190"",""symbol"":""G6PD Munich"",""name"":""Munich""}},{""id"":1.449562355E9,""_label"":""Murcia Oristano"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121086"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121086"",""symbol"":""G6PD Murcia Oristano"",""name"":""Murcia Oristano""}},{""id"":1.449562356E9,""_label"":""Musashino"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121084"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121084"",""symbol"":""G6PD Musashino"",""name"":""Musashino""}},{""id"":1.449562357E9,""_label"":""Namouru"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121111"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121111"",""symbol"":""G6PD Namouru"",""name"":""Namouru""}},{""id"":1.449562358E9,""_label"":""Nankang"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121125"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121125"",""symbol"":""G6PD Nankang"",""name"":""Nankang""}},{""id"":1.449562359E9,""_label"":""Nanning"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121100"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121100"",""symbol"":""G6PD Nanning"",""name"":""Nanning""}},{""id"":1.44956236E9,""_label"":""Naone"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121124"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121124"",""symbol"":""G6PD Naone"",""name"":""Naone""}},{""id"":1.449562361E9,""_label"":""Nara"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121236"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121236"",""symbol"":""G6PD Nara"",""name"":""Nara""}},{""id"":1.449562362E9,""_label"":""Nashville, Anaheim, Portici"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121179"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121179"",""symbol"":""G6PD Nashville, Anaheim, Portici"",""name"":""Nashville, Anaheim, Portici""}},{""id"":1.449562363E9,""_label"":""Neapolis"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121078"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121078"",""symbol"":""G6PD Neapolis"",""name"":""Neapolis""}},{""id"":1.449562364E9,""_label"":""Nilgiri"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121129"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121129"",""symbol"":""G6PD Nilgiri"",""name"":""Nilgiri""}},{""id"":1.449562365E9,""_label"":""North Dallas"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121221"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121221"",""symbol"":""G6PD North Dallas"",""name"":""North Dallas""}},{""id"":1.449562366E9,""_label"":""Olomouc"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121168"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121168"",""symbol"":""G6PD Olomouc"",""name"":""Olomouc""}},{""id"":1.449562367E9,""_label"":""Omiya"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121235"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121235"",""symbol"":""G6PD Omiya"",""name"":""Omiya""}},{""id"":1.449562368E9,""_label"":""Orissa"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121075"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121075"",""symbol"":""G6PD Orissa"",""name"":""Orissa""}},{""id"":1.449562369E9,""_label"":""Osaka"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121135"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121135"",""symbol"":""G6PD Osaka"",""name"":""Osaka""}},{""id"":1.44956237E9,""_label"":""Palestrina"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121082"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121082"",""symbol"":""G6PD Palestrina"",""name"":""Palestrina""}},{""id"":1.449562371E9,""_label"":""Partenope"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121141"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121141"",""symbol"":""G6PD Partenope"",""name"":""Partenope""}},{""id"":1.449562372E9,""_label"":""Pawnee"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121146"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121146"",""symbol"":""G6PD Pawnee"",""name"":""Pawnee""}},{""id"":1.449562373E9,""_label"":""Pedoplis-Ckaro"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121216"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121216"",""symbol"":""G6PD Pedoplis-Ckaro"",""name"":""Pedoplis-Ckaro""}},{""id"":1.449562374E9,""_label"":""Piotrkow"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121233"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121233"",""symbol"":""G6PD Piotrkow"",""name"":""Piotrkow""}},{""id"":1.449562375E9,""_label"":""Plymouth"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121211"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121211"",""symbol"":""G6PD Plymouth"",""name"":""Plymouth""}},{""id"":1.449562376E9,""_label"":""Praha"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121176"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121176"",""symbol"":""G6PD Praha"",""name"":""Praha""}},{""id"":1.449562377E9,""_label"":""Puerto Limon"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121182"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121182"",""symbol"":""G6PD Puerto Limon"",""name"":""Puerto Limon""}},{""id"":1.449562378E9,""_label"":""Quing Yan"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121093"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121093"",""symbol"":""G6PD Quing Yan"",""name"":""Quing Yan""}},{""id"":1.449562379E9,""_label"":""Radlowo"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121130"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121130"",""symbol"":""G6PD Radlowo"",""name"":""Radlowo""}},{""id"":1.44956238E9,""_label"":""Rehevot"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121238"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121238"",""symbol"":""G6PD Rehevot"",""name"":""Rehevot""}},{""id"":1.449562381E9,""_label"":""Rignano"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121074"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121074"",""symbol"":""G6PD Rignano"",""name"":""Rignano""}},{""id"":1.449562382E9,""_label"":""Riley"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121167"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121167"",""symbol"":""G6PD Riley"",""name"":""Riley""}},{""id"":1.449562383E9,""_label"":""Riverside"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121187"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121187"",""symbol"":""G6PD Riverside"",""name"":""Riverside""}},{""id"":1.449562384E9,""_label"":""Roubaix"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121131"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121131"",""symbol"":""G6PD Roubaix"",""name"":""Roubaix""}},{""id"":1.449562385E9,""_label"":""S. Antioco"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121147"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121147"",""symbol"":""G6PD S. Antioco"",""name"":""S. Antioco""}},{""id"":1.449562386E9,""_label"":""Salerno Pyrgos"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121092"",""symbol"":""G6PD Salerno Pyrgos"",""name"":""Salerno Pyrgos""}},{""id"":1.449562387E9,""_label"":""Santa Maria"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121115"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121115"",""symbol"":""G6PD Santa Maria"",""name"":""Santa Maria""}},{""id"":1.449562388E9,""_label"":""Santiago"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121217"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121217"",""symbol"":""G6PD Santiago"",""name"":""Santiago""}},{""id"":1.449562389E9,""_label"":""Santiago de Cuba, Morioka"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121194"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121194"",""symbol"":""G6PD Santiago de Cuba, Morioka"",""name"":""Santiago de Cuba, Morioka""}},{""id"":1.44956239E9,""_label"":""Sao Borja"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765952"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765952E9,""resource"":""Allele Function"",""term"":""Class IV"",""termId"":""haplotypeTags:1446765952""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121071"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121071"",""symbol"":""G6PD Sao Borja"",""name"":""Sao Borja""}},{""id"":1.449562391E9,""_label"":""Seattle, Lodi, Modena, Ferrara II, Athens-like"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121101"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121101"",""symbol"":""G6PD Seattle, Lodi, Modena, Ferrara II, Athens-like"",""name"":""Seattle, Lodi, Modena, Ferrara II, Athens-like""}},{""id"":1.449562392E9,""_label"":""Seoul"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121137"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121137"",""symbol"":""G6PD Seoul"",""name"":""Seoul""}},{""id"":1.449562393E9,""_label"":""Serres"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121160"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121160"",""symbol"":""G6PD Serres"",""name"":""Serres""}},{""id"":1.449562394E9,""_label"":""Shenzen"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121121"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121121"",""symbol"":""G6PD Shenzen"",""name"":""Shenzen""}},{""id"":1.449562395E9,""_label"":""Shinshu"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121213"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121213"",""symbol"":""G6PD Shinshu"",""name"":""Shinshu""}},{""id"":1.449562396E9,""_label"":""Sibari"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121098"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121098"",""symbol"":""G6PD Sibari"",""name"":""Sibari""}},{""id"":1.449562397E9,""_label"":""Sinnai"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121091"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121091"",""symbol"":""G6PD Sinnai"",""name"":""Sinnai""}},{""id"":1.449562398E9,""_label"":""Songklanagarind"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121109"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121109"",""symbol"":""G6PD Songklanagarind"",""name"":""Songklanagarind""}},{""id"":1.449562399E9,""_label"":""Split"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121080"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121080"",""symbol"":""G6PD Split"",""name"":""Split""}},{""id"":1.4495624E9,""_label"":""Stonybrook"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121224"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121224"",""symbol"":""G6PD Stonybrook"",""name"":""Stonybrook""}},{""id"":1.449562401E9,""_label"":""Sugao"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121230"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121230"",""symbol"":""G6PD Sugao"",""name"":""Sugao""}},{""id"":1.449562402E9,""_label"":""Sumare"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121192"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121192"",""symbol"":""G6PD Sumare"",""name"":""Sumare""}},{""id"":1.449562403E9,""_label"":""Sunderland"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121158"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121158"",""symbol"":""G6PD Sunderland"",""name"":""Sunderland""}},{""id"":1.449562404E9,""_label"":""Surabaya"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121145"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121145"",""symbol"":""G6PD Surabaya"",""name"":""Surabaya""}},{""id"":1.449562405E9,""_label"":""Suwalki"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121186"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121186"",""symbol"":""G6PD Suwalki"",""name"":""Suwalki""}},{""id"":1.449562406E9,""_label"":""Swansea"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121207"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121207"",""symbol"":""G6PD Swansea"",""name"":""Swansea""}},{""id"":1.449562407E9,""_label"":""Taipei\u0027 Chinese-3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121122"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121122"",""symbol"":""G6PD Taipei\u0027 Chinese-3"",""name"":""Taipei\u0027 Chinese-3""}},{""id"":1.449562408E9,""_label"":""Telti/Kobe"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121193"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121193"",""symbol"":""G6PD Telti/Kobe"",""name"":""Telti/Kobe""}},{""id"":1.449562409E9,""_label"":""Tenri"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121164"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121164"",""symbol"":""G6PD Tenri"",""name"":""Tenri""}},{""id"":1.44956241E9,""_label"":""Toledo"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121123"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121123"",""symbol"":""G6PD Toledo"",""name"":""Toledo""}},{""id"":1.449562411E9,""_label"":""Tomah"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121169"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121169"",""symbol"":""G6PD Tomah"",""name"":""Tomah""}},{""id"":1.449562412E9,""_label"":""Tondela"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121161"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121161"",""symbol"":""G6PD Tondela"",""name"":""Tondela""}},{""id"":1.449562413E9,""_label"":""Torun"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121157"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121157"",""symbol"":""G6PD Torun"",""name"":""Torun""}},{""id"":1.449562414E9,""_label"":""Tsukui"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121215"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121215"",""symbol"":""G6PD Tsukui"",""name"":""Tsukui""}},{""id"":1.449562415E9,""_label"":""Ube Konan"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121087"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121087"",""symbol"":""G6PD Ube Konan"",""name"":""Ube Konan""}},{""id"":1.449562416E9,""_label"":""Union,Maewo, Chinese-2, Kalo"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121150"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121150"",""symbol"":""G6PD Union,Maewo, Chinese-2, Kalo"",""name"":""Union,Maewo, Chinese-2, Kalo""}},{""id"":1.449562417E9,""_label"":""Urayasu"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121208"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121208"",""symbol"":""G6PD Urayasu"",""name"":""Urayasu""}},{""id"":1.449562418E9,""_label"":""Utrecht"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121185"",""symbol"":""G6PD Utrecht"",""name"":""Utrecht""}},{""id"":1.449562419E9,""_label"":""Valladolid"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121118"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121118"",""symbol"":""G6PD Valladolid"",""name"":""Valladolid""}},{""id"":1.44956242E9,""_label"":""Vancouver"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121209"",""symbol"":""G6PD Vancouver"",""name"":""Vancouver""}},{""id"":1.449562421E9,""_label"":""Vanua Lava"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121117"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121117"",""symbol"":""G6PD Vanua Lava"",""name"":""Vanua Lava""}},{""id"":1.449562422E9,""_label"":""Viangchan, Jammu"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121136"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121136"",""symbol"":""G6PD Viangchan, Jammu"",""name"":""Viangchan, Jammu""}},{""id"":1.449562423E9,""_label"":""Villeurbanne"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121156"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121156"",""symbol"":""G6PD Villeurbanne"",""name"":""Villeurbanne""}},{""id"":1.449562424E9,""_label"":""Volendam"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121212"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121212"",""symbol"":""G6PD Volendam"",""name"":""Volendam""}},{""id"":1.449562425E9,""_label"":""Wayne"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121225"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121225"",""symbol"":""G6PD Wayne"",""name"":""Wayne""}},{""id"":1.449562426E9,""_label"":""West Virginia"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121234"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121234"",""symbol"":""G6PD West Virginia"",""name"":""West Virginia""}},{""id"":1.449562427E9,""_label"":""Wexham"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121232"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121232"",""symbol"":""G6PD Wexham"",""name"":""Wexham""}},{""id"":1.449562428E9,""_label"":""Wisconsin"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121178"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121178"",""symbol"":""G6PD Wisconsin"",""name"":""Wisconsin""}},{""id"":1.449562429E9,""_label"":""Coimbra Shunde"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121128"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121128"",""symbol"":""G6PD Coimbra Shunde"",""name"":""Coimbra Shunde""}},{""id"":1.44956243E9,""_label"":""Cosenza"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121152"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121152"",""symbol"":""G6PD Cosenza"",""name"":""Cosenza""}},{""id"":1.449562431E9,""_label"":""Costanzo"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121107"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121107"",""symbol"":""G6PD Costanzo"",""name"":""Costanzo""}},{""id"":1.449562432E9,""_label"":""Covao do Lobo"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121183"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121183"",""symbol"":""G6PD Covao do Lobo"",""name"":""Covao do Lobo""}},{""id"":1.449562433E9,""_label"":""Crispim"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121113"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121113"",""symbol"":""G6PD Crispim"",""name"":""Crispim""}},{""id"":1.449562434E9,""_label"":""Durham"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121223"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121223"",""symbol"":""G6PD Durham"",""name"":""Durham""}},{""id"":1.449562435E9,""_label"":""Figuera da Foz"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121196"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121196"",""symbol"":""G6PD Figuera da Foz"",""name"":""Figuera da Foz""}},{""id"":1.449562436E9,""_label"":""Flores"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121154"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121154"",""symbol"":""G6PD Flores"",""name"":""Flores""}},{""id"":1.449562437E9,""_label"":""Fukaya"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121199"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121199"",""symbol"":""G6PD Fukaya"",""name"":""Fukaya""}},{""id"":1.449562438E9,""_label"":""Fushan"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121140"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121140"",""symbol"":""G6PD Fushan"",""name"":""Fushan""}},{""id"":1.449562439E9,""_label"":""A- 680T_376G"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947828"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947828"",""symbol"":""G6PD A- 680T_376G"",""name"":""A- 680T_376G""}},{""id"":1.44956244E9,""_label"":""A- 968C_376G"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947829"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947829"",""symbol"":""G6PD A- 968C_376G"",""name"":""A- 968C_376G""}},{""id"":1.449562441E9,""_label"":""Nice"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121076"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121076"",""symbol"":""G6PD Nice"",""name"":""Nice""}},{""id"":1.449562442E9,""_label"":""Gaohe"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121105"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121105"",""symbol"":""G6PD Gaohe"",""name"":""Gaohe""}},{""id"":1.449562443E9,""_label"":""Georgia"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121191"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121191"",""symbol"":""G6PD Georgia"",""name"":""Georgia""}},{""id"":1.449562444E9,""_label"":""Absent"",""allele"":""Absent"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558334"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558334E9,""resource"":""Allele Function"",""term"":""Absence"",""termId"":""haplotypeTags:1445558334""}},{""id"":1.449562445E9,""_label"":""202G\u003eA_376A\u003eG_1264C\u003eG"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121206"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121206"",""symbol"":""G6PD 202G\u003eA_376A\u003eG_1264C\u003eG"",""name"":""202G\u003eA_376A\u003eG_1264C\u003eG""}},{""id"":1.449562446E9,""_label"":""A- 202A_376G"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947827"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947827"",""symbol"":""G6PD A- 202A_376G"",""name"":""A- 202A_376G""}},{""id"":1.449562447E9,""_label"":""Aachen"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121163"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121163"",""symbol"":""G6PD Aachen"",""name"":""Aachen""}},{""id"":1.449562448E9,""_label"":""Abeno"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121144"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121144"",""symbol"":""G6PD Abeno"",""name"":""Abeno""}},{""id"":1.449562449E9,""_label"":""Acrokorinthos"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121114"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121114"",""symbol"":""G6PD Acrokorinthos"",""name"":""Acrokorinthos""}},{""id"":1.44956245E9,""_label"":""Alhambra"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121180"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121180"",""symbol"":""G6PD Alhambra"",""name"":""Alhambra""}},{""id"":1.449562451E9,""_label"":""Amazonia"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121108"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121108"",""symbol"":""G6PD Amazonia"",""name"":""Amazonia""}},{""id"":1.449562452E9,""_label"":""Amiens"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121197"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121197"",""symbol"":""G6PD Amiens"",""name"":""Amiens""}},{""id"":1.449562453E9,""_label"":""Amsterdam"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121205"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121205"",""symbol"":""G6PD Amsterdam"",""name"":""Amsterdam""}},{""id"":1.449562454E9,""_label"":""Anadia"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121143"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121143"",""symbol"":""G6PD Anadia"",""name"":""Anadia""}},{""id"":1.449562455E9,""_label"":""Ananindeua"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121116"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121116"",""symbol"":""G6PD Ananindeua"",""name"":""Ananindeua""}},{""id"":1.449562456E9,""_label"":""Andalus"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121151"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121151"",""symbol"":""G6PD Andalus"",""name"":""Andalus""}},{""id"":1.449562457E9,""_label"":""Arakawa"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121202"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121202"",""symbol"":""G6PD Arakawa"",""name"":""Arakawa""}},{""id"":1.449562458E9,""_label"":""Asahi"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121085"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121085"",""symbol"":""G6PD Asahi"",""name"":""Asahi""}},{""id"":1.449562459E9,""_label"":""Asahikawa"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121222"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121222"",""symbol"":""G6PD Asahikawa"",""name"":""Asahikawa""}},{""id"":1.44956246E9,""_label"":""Aures"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121079"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121079"",""symbol"":""G6PD Aures"",""name"":""Aures""}},{""id"":1.449562461E9,""_label"":""Aveiro"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121226"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121226"",""symbol"":""G6PD Aveiro"",""name"":""Aveiro""}},{""id"":1.449562462E9,""_label"":""B (wildtype)"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765952"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765952E9,""resource"":""Allele Function"",""term"":""Class IV"",""termId"":""haplotypeTags:1446765952""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947826"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947826"",""symbol"":""G6PD B (wildtype)"",""name"":""B (wildtype)""}},{""id"":1.449562463E9,""_label"":""Bajo Maumere"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121102"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121102"",""symbol"":""G6PD Bajo Maumere"",""name"":""Bajo Maumere""}},{""id"":1.449562464E9,""_label"":""Bangkok"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121229"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121229"",""symbol"":""G6PD Bangkok"",""name"":""Bangkok""}},{""id"":1.449562465E9,""_label"":""Bangkok Noi"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121198"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121198"",""symbol"":""G6PD Bangkok Noi"",""name"":""Bangkok Noi""}},{""id"":1.449562466E9,""_label"":""Bao Loc"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121112"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121112"",""symbol"":""G6PD Bao Loc"",""name"":""Bao Loc""}},{""id"":1.449562467E9,""_label"":""Bari"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121181"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121181"",""symbol"":""G6PD Bari"",""name"":""Bari""}},{""id"":1.449562468E9,""_label"":""Belem"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121119"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121119"",""symbol"":""G6PD Belem"",""name"":""Belem""}},{""id"":1.449562469E9,""_label"":""Beverly Hills, Genova, Iwate, Niigata, Yamaguchi"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121174"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121174"",""symbol"":""G6PD Beverly Hills, Genova, Iwate, Niigata, Yamaguchi"",""name"":""Beverly Hills, Genova, Iwate, Niigata, Yamaguchi""}},{""id"":1.44956247E9,""_label"":""Brighton"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121203"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121203"",""symbol"":""G6PD Brighton"",""name"":""Brighton""}},{""id"":1.449562471E9,""_label"":""Buenos Aires"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121201"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121201"",""symbol"":""G6PD Buenos Aires"",""name"":""Buenos Aires""}},{""id"":1.449562472E9,""_label"":""Calvo Mackenna"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121166"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121166"",""symbol"":""G6PD Calvo Mackenna"",""name"":""Calvo Mackenna""}},{""id"":1.449562473E9,""_label"":""Campinas"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121200"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121200"",""symbol"":""G6PD Campinas"",""name"":""Campinas""}},{""id"":1.449562474E9,""_label"":""Canton, Taiwan-Hakka, Gifu-like, Agrigento-like"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121153"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121153"",""symbol"":""G6PD Canton, Taiwan-Hakka, Gifu-like, Agrigento-like"",""name"":""Canton, Taiwan-Hakka, Gifu-like, Agrigento-like""}},{""id"":1.449562475E9,""_label"":""Cassano"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121148"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121148"",""symbol"":""G6PD Cassano"",""name"":""Cassano""}},{""id"":1.449562476E9,""_label"":""Chatham"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121139"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121139"",""symbol"":""G6PD Chatham"",""name"":""Chatham""}},{""id"":1.449562477E9,""_label"":""Chikugo"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121214"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121214"",""symbol"":""G6PD Chikugo"",""name"":""Chikugo""}},{""id"":1.449562478E9,""_label"":""Chinese-1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121133"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121133"",""symbol"":""G6PD Chinese-1"",""name"":""Chinese-1""}},{""id"":1.449562479E9,""_label"":""Chinese-5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121073"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121073"",""symbol"":""G6PD Chinese-5"",""name"":""Chinese-5""}},{""id"":1.44956248E9,""_label"":""Cincinnati"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121219"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121219"",""symbol"":""G6PD Cincinnati"",""name"":""Cincinnati""}},{""id"":1.449562481E9,""_label"":""Cleveland Corum"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121227"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121227"",""symbol"":""G6PD Cleveland Corum"",""name"":""Cleveland Corum""}},{""id"":1.449562482E9,""_label"":""Clinic"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121184"",""symbol"":""G6PD Clinic"",""name"":""Clinic""}},{""id"":1.449562483E9,""_label"":""Guadalajara"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121173"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121173"",""symbol"":""G6PD Guadalajara"",""name"":""Guadalajara""}},{""id"":1.449562484E9,""_label"":""Guangzhou"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121089"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121089"",""symbol"":""G6PD Guangzhou"",""name"":""Guangzhou""}},{""id"":1.449562485E9,""_label"":""Haikou"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121132"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121132"",""symbol"":""G6PD Haikou"",""name"":""Haikou""}},{""id"":1.449562486E9,""_label"":""Hammersmith"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121090"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121090"",""symbol"":""G6PD Hammersmith"",""name"":""Hammersmith""}},{""id"":1.449562487E9,""_label"":""Harilaou"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121220"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121220"",""symbol"":""G6PD Harilaou"",""name"":""Harilaou""}},{""id"":1.449562488E9,""_label"":""Harima"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121195"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121195"",""symbol"":""G6PD Harima"",""name"":""Harima""}},{""id"":1.449562489E9,""_label"":""Hartford"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121175"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121175"",""symbol"":""G6PD Hartford"",""name"":""Hartford""}},{""id"":1.44956249E9,""_label"":""Hechi"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121110"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121110"",""symbol"":""G6PD Hechi"",""name"":""Hechi""}},{""id"":1.449562491E9,""_label"":""Hermoupolis"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121149"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121149"",""symbol"":""G6PD Hermoupolis"",""name"":""Hermoupolis""}},{""id"":1.449562492E9,""_label"":""Honiara"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121239"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121239"",""symbol"":""G6PD Honiara"",""name"":""Honiara""}},{""id"":1.449562493E9,""_label"":""Ierapetra"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121142"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121142"",""symbol"":""G6PD Ierapetra"",""name"":""Ierapetra""}},{""id"":1.449562494E9,""_label"":""Ilesha"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121095"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121095"",""symbol"":""G6PD Ilesha"",""name"":""Ilesha""}},{""id"":1.449562495E9,""_label"":""Insuli"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765952"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765952E9,""resource"":""Allele Function"",""term"":""Class IV"",""termId"":""haplotypeTags:1446765952""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121072"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121072"",""symbol"":""G6PD Insuli"",""name"":""Insuli""}},{""id"":1.449562496E9,""_label"":""Iowa, Walter Reed, Springfield"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121172"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121172"",""symbol"":""G6PD Iowa, Walter Reed, Springfield"",""name"":""Iowa, Walter Reed, Springfield""}},{""id"":1.449562497E9,""_label"":""Iwatsuki"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121159"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121159"",""symbol"":""G6PD Iwatsuki"",""name"":""Iwatsuki""}},{""id"":1.449562498E9,""_label"":""Japan, Shinagawa"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121188"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121188"",""symbol"":""G6PD Japan, Shinagawa"",""name"":""Japan, Shinagawa""}},{""id"":1.449562499E9,""_label"":""Kaiping, Anant, Dhon, Sapporo-like, Wosera"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121155"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121155"",""symbol"":""G6PD Kaiping, Anant, Dhon, Sapporo-like, Wosera"",""name"":""Kaiping, Anant, Dhon, Sapporo-like, Wosera""}},{""id"":1.4495625E9,""_label"":""Kalyan-Kerala, Jamnaga, Rohini"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121104"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121104"",""symbol"":""G6PD Kalyan-Kerala, Jamnaga, Rohini"",""name"":""Kalyan-Kerala, Jamnaga, Rohini""}},{""id"":1.449562501E9,""_label"":""Kambos"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121081"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121081"",""symbol"":""G6PD Kambos"",""name"":""Kambos""}},{""id"":1.449562502E9,""_label"":""Kamiube, Keelung"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121077"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121077"",""symbol"":""G6PD Kamiube, Keelung"",""name"":""Kamiube, Keelung""}},{""id"":1.449562503E9,""_label"":""Kamogawa"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121106"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121106"",""symbol"":""G6PD Kamogawa"",""name"":""Kamogawa""}},{""id"":1.449562504E9,""_label"":""Kawasaki"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121189"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121189"",""symbol"":""G6PD Kawasaki"",""name"":""Kawasaki""}},{""id"":1.449562505E9,""_label"":""Kozukata"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121204"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121204"",""symbol"":""G6PD Kozukata"",""name"":""Kozukata""}},{""id"":1.449562506E9,""_label"":""Krakow"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121177"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121177"",""symbol"":""G6PD Krakow"",""name"":""Krakow""}},{""id"":1.449562507E9,""_label"":""La Jolla"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121231"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121231"",""symbol"":""G6PD La Jolla"",""name"":""La Jolla""}},{""id"":1.449562508E9,""_label"":""Lages"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121094"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121094"",""symbol"":""G6PD Lages"",""name"":""Lages""}},{""id"":1.449562509E9,""_label"":""Lagosanto"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121088"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121088"",""symbol"":""G6PD Lagosanto"",""name"":""Lagosanto""}},{""id"":1.44956251E9,""_label"":""Lille"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121228"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121228"",""symbol"":""G6PD Lille"",""name"":""Lille""}},{""id"":1.449562511E9,""_label"":""Liuzhou"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121120"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121120"",""symbol"":""G6PD Liuzhou"",""name"":""Liuzhou""}},{""id"":1.449562512E9,""_label"":""Loma Linda"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121162"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121162"",""symbol"":""G6PD Loma Linda"",""name"":""Loma Linda""}},{""id"":1.449562513E9,""_label"":""Ludhiana"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121138"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121138"",""symbol"":""G6PD Ludhiana"",""name"":""Ludhiana""}},{""id"":1.449562514E9,""_label"":""Lynwood"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121170"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121170"",""symbol"":""G6PD Lynwood"",""name"":""Lynwood""}},{""id"":1.449562515E9,""_label"":""Madrid"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121171"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121171"",""symbol"":""G6PD Madrid"",""name"":""Madrid""}},{""id"":1.449562516E9,""_label"":""Mahidol"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121096"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121096"",""symbol"":""G6PD Mahidol"",""name"":""Mahidol""}},{""id"":1.449562517E9,""_label"":""Malaga"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121097"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121097"",""symbol"":""G6PD Malaga"",""name"":""Malaga""}},{""id"":1.449562518E9,""_label"":""Manhattan"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765949"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765949E9,""resource"":""Allele Function"",""term"":""Class I"",""termId"":""haplotypeTags:1446765949""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121237"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121237"",""symbol"":""G6PD Manhattan"",""name"":""Manhattan""}},{""id"":1.449562519E9,""_label"":""Mediterranean, Dallas, Panama\u0027 Sassari, Cagliari, Birmingham"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765950"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.44676595E9,""resource"":""Allele Function"",""term"":""Class II"",""termId"":""haplotypeTags:1446765950""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121127"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121127"",""symbol"":""G6PD Mediterranean, Dallas, Panama\u0027 Sassari, Cagliari, Birmingham"",""name"":""Mediterranean, Dallas, Panama\u0027 Sassari, Cagliari, Birmingham""}},{""id"":1.44956252E9,""_label"":""Metaponto"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765951"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765951E9,""resource"":""Allele Function"",""term"":""Class III"",""termId"":""haplotypeTags:1446765951""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121083"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121083"",""symbol"":""G6PD Metaponto"",""name"":""Metaponto""}},{""id"":1.450042028E9,""_label"":""A"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1446765952"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.446765952E9,""resource"":""Allele Function"",""term"":""Class IV"",""termId"":""haplotypeTags:1446765952""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166121247"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166121247"",""symbol"":""G6PD A"",""name"":""A""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA28469"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA28469"",""symbol"":""G6PD"",""name"":""glucose-6-phosphate dehydrogenase""}}],""history"":[{""id"":1.184175211E9,""date"":""2014-05-04T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.18423383E9,""date"":""2014-05-09T00:00:00-07:00"",""type"":""Update"",""version"":0.0},{""id"":1.450042027E9,""date"":""2018-11-13T15:55:54.755-08:00"",""description"":""Added text regarding September 2018 update to the guideline and added the G6PD A allele to the extended dosing guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450043031E9,""date"":""2018-11-20T09:54:16.026-08:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15074661"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5074661E7,""resourceId"":""24787449"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111801"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4111801"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449280689E9,""resource"":""PubMed Central"",""resourceId"":""PMC4111801"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111801""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/24787449"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449280688E9,""resource"":""PubMed"",""resourceId"":""24787449"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/24787449""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2014.97"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44928069E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2014.97"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2014.97""}]},{""@id"":""https://pharmgkb.org/literature/15100917"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100917E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"",""title"":""CPIC® Guideline for Rasburicase and G6PD – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983506E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10176"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10176"",""name"":""rasburicase""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA28469"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA28469"",""symbol"":""G6PD"",""name"":""glucose-6-phosphate dehydrogenase""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982051E9,""html"":""\u003cp\u003eRasburicase is contraindicated in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a negative or inconclusive genetic test result an enzyme activity test is recommended prior to rasburicase treatment to determine whether a patient is G6PD deficient. The \u003cem\u003eG6PD\u003c/em\u003e gene is X-linked and therefore males only have one copy, whereas females have two copies. See full guideline for disclaimers, further details and supporting evidence.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.450042024E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for rasburicase and G6PD\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""september-2018-update\""\u003eSeptember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe CPIC authors recommend that the \u003cem\u003eG6PD A\u003c/em\u003e variant be categorized as IV/normal function (previously II-IV/Deficient-Normal function) based on new evidence supporting function [Article:\u003ca href\u003d\""/pmid/27040960\""\u003e27040960\u003c/a\u003e] and [Article:\u003ca href\u003d\""/pmid/30206300\""\u003e30206300\u003c/a\u003e]. This change has been incorporated into the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/G6PD_allele_definition_table.xlsx\""\u003eG6PD allele definition table\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""august-2014\""\u003eAugust 2014\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online May 2014, advance online publication 11 June 2014\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in determining whether rasburicase treatment should be undertaken have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2014 rasburicase guideline:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;As stated above, rasburicase is contraindicated by the FDA, the EMA, and PMDA in those with G6PD deficiency (32-34) (see Table 2). If, on the basis of genotyping, a deficient status can be unambiguously assigned to a patient, that would be a sufficient contraindication to the use of rasburicase. However, due to the limitations of genetic testing (discussed above), in most cases it is necessary to perform G6PD enzyme testing to assign G6PD status.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to\n\u003cul\u003e\n\u003cli\u003eneonates\u003c/li\u003e\n\u003cli\u003epediatrics\u003c/li\u003e\n\u003cli\u003eadults\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/rasburicase/2014/24787449.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the context of G6PD Deficiency Genotype.\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/rasburicase/2014/24787449-supplement.pdf\"" target\u003d\""_blank\""\u003e2014 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-rasburicase-by-g6pd-phenotype\""\u003eTable 1: Recommended dosing of rasburicase by G6PD phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Table 1 and Table 2 of the 2014 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype) \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eExamples of diplotypes \u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications for phenotypic measures\u003c/th\u003e\u003cth\u003eDosing recommendations for rasburicase\u003c/th\u003e\u003cth\u003eClassification of recommendations \u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNormal \u003csup\u003ed\u003c/sup\u003e. A male carrying a non-deficient (class IV) allele or a female carrying two non-deficient (class IV) alleles.\u003c/td\u003e\u003ctd\u003eMale: B, Sao Boria. Female: B/B, B/ Sao Boria.\u003c/td\u003e\u003ctd\u003eLow or reduced risk of hemolytic anemia.\u003c/td\u003e\u003ctd\u003eNo reason to withhold rasburicase based on G6PD status \u003csup\u003ed\u003c/sup\u003e.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eDeficient or Deficient with CNSHA. A male carrying a class I, II or III allele, a female carrying two deficient class I-III alleles.\u003c/td\u003e\u003ctd\u003eMale: A-, Orissa, Kalyan-Kerala, Mediterranean, Canton, Chatham, Bangkok, Villeurbanne. Female: A-/A-, A-/ Orissa, Orissa/ Kalyan-Kerala, Mediterranean/ Mediterranean, Chatham/Mediterranean, Canton/ Viangchan, Bangkok/ Bangkok, Bangkok/ Villeurbanne.\u003c/td\u003e\u003ctd\u003eAt risk of acute hemolytic anemia.\u003c/td\u003e\u003ctd\u003eRasburicase is contraindicated; alternatives include allopurinol \u003csup\u003ee\u003c/sup\u003e.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eVariable \u003csup\u003ed,f\u003c/sup\u003e. A female carrying one non-deficient (class IV) and one deficient (class I-III variants) allele.\u003c/td\u003e\u003ctd\u003eB/A-, B/Mediterranean, B/Bangkok.\u003c/td\u003e\u003ctd\u003eUnknown risk of hemolytic anemia.\u003c/td\u003e\u003ctd\u003eTo ascertain that G6PD status is normal, enzyme activity must be measured; alternatives include allopurinol \u003csup\u003ee\u003c/sup\u003e.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e \u0026quot;Class\u0026quot; refers to the WHO classifications from [Article:\u003ca href\u003d\""/pmid/22293322\""\u003e22293322\u003c/a\u003e], other details from [Article:\u003ca href\u003d\""/pmid/4963040\""\u003e4963040\u003c/a\u003e]. Class I variants are extremely rare; the distinction between class II and III variants is not clear; and the \u0026quot;class V\u0026quot; very high activity variant has only been reported in a single case [Article:\u003ca href\u003d\""/pmid/4963040\""\u003e4963040\u003c/a\u003e]. Therefore, almost all patients will carry class II, III, or IV alleles. It should be noted that the class of a variant may have been assigned only by the clinical manifestations of a patient in which the variant was subsequently identified.\u003c/p\u003e\n\u003cp\u003e(*) Luzzatto, L. \u0026amp; Poggi, V. Glucose-6-Phosphate Dehydrogenase Deficiency In: Nathan and Oski\u0027s Hematology of Infancy and Childhood, 7th Edition  (ed. Meloni, D., Anderson, A. Authors of the book: Orkin, S.H., Fisher, D.E., Look, A.T., Lux IV, S.E., Ginsburg, D., Nathan, D.G. ) (Saunders, Elsevier., 2009).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Due to the large number of G6PD variants, many other diplotypes may be possible besides those given as examples here; see Supplemental Table S1 for a more comprehensive list of variant alleles with their assigned WHO class.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Rating scheme described in Supplement (See Strength of Recommendations material).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e A negative or inconclusive genetic test cannot be assumed to indicate normal G6PD phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Allopurinol is associated with severe cutaneous reactions in the rare carriers of the HLA-B*58:01 allele [Article:\u003ca href\u003d\""/pmid/23232549\""\u003e23232549\u003c/a\u003e].\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Due to X-linked mosaicism, females heterozygous for one non-deficient (class IV) and one deficient (class I-III variants) allele may display a normal or a deficient phenotype. It is therefore difficult to predict the phenotype of these individuals (Supplement, G6PD heterozygotes).\u003c/p\u003e\n\u003ch3 id\u003d\""figure-1-workflow-for-interpreting-g6pd-genotype-and-for-assessing-need-for-an-enzyme-activity-test\""\u003eFigure 1: Workflow for interpreting G6PD genotype and for assessing need for an enzyme activity test.\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eFigure 1 from the guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cimg src\u003d\""https://s3.pgkb.org/attachment/CPIC_G6PD_rasburicase_guideline_Figure_1.png\"" alt\u003d\""CPIC G6PD rasburicase guideline\"" /\u003e\u003c/p\u003e\n\u003cp\u003e*It should be noted that the class of a variant may have been assigned only by the clinical manifestations of a patient in which the variant was subsequently identified [Article:\u003ca href\u003d\""/pmid/22293322\""\u003e22293322\u003c/a\u003e].\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983506E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/""}]},""status"":""success""}"
PA166124619,Guideline Annotation,Annotation of CPIC Guideline for tacrolimus and CYP3A5,t,PA451578,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"" target=""_blank"">CPIC&reg; guideline for tacrolimus and CYP3A5</a>.</p>
<h3 id=""july-2015"">July 2015</h3>
<p><em>Advanced online publication March 2015</em></p>
<ul>
<li>
<p>Guidelines regarding the use of pharmacogenomic tests in dosing of tacrolimus have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">(CPIC)</a>.</p>
</li>
<li>
<p>These guidelines are applicable to:</p>
<ul>
<li>Patients undergoing kidney, heart, lung, or hematopoietic stem cell transplant.</li>
<li>Patients undergoing liver transplant where the donor and recipient <em>CYP3A5</em> genotypes are identical.</li>
</ul>
</li>
<li>
<p>Excerpts from the 2015 tacrolimus dosing guidelines:</p>
<ul>
<li>&quot;Blood concentrations of tacrolimus are strongly influenced by <em>CYP3A5</em> genotype, with substantial evidence linking <em>CYP3A5</em> genotype with phenotypic variability...In kidney, heart and lung transplant patients, over 50 studies have found that individuals with the <em>CYP3A5*1/*1</em> or <em>CYP3A5*1/*3</em> genotype have significantly lower dose-adjusted trough concentrations of tacrolimus as compared to those with the <em>CYP3A5*3/*3</em> genotype...&quot;</li>
<li>&quot;Those recipients with an extensive or intermediate metabolizer phenotype will generally require an increased dose of tacrolimus to achieve therapeutic drug concentrations. We recommend a dose 1.5 - 2 times higher than standard dosing, but not to exceed 0.3 mg/kg/day, followed by [therapeutic drug monitoring] given the risk of arterial vasoconstriction, hypertension and nephrotoxicity that can occur with supratherapeutic tacrolimus concentrations.&quot;</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for <em>CYP3A5</em> genotypes and Tacrolimus Dosing</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146-supplement.pdf"" target=""_blank"">2015 Supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146-CYP3A5%20translation%20table.xlsx"" target=""_blank"">2015 Tacrolimus translation table</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146-CYP3A5%20allele%20frequency%20table.xlsx"" target=""_blank"">CYP3A5 allele frequency table</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-tacrolimus-based-on-cyp3a5-phenotype"">Table 1: Dosing recommendations for tacrolimus based on CYP3A5 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2 of the 2015 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype <sup>a</sup></th><th>Genotypes</th><th>Examples of diplotypes <sup>b</sup></th><th>Implications for tacrolimus pharmacologic measures</th><th>Therapeutic Recommendations <sup>c</sup></th><th>Classification of recommendations <sup>e</sup></th></tr>
</thead>
<tbody>
<tr><td>Extensive metabolizer (CYP3A5 expresser)</td><td>An individual carrying two functional alleles</td><td>*1/*1</td><td>Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations</td><td>Increase starting dose 1.5 to 2 times recommended starting dose <sup>d</sup>. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments</td><td>Strong</td></tr>
<tr><td>Intermediate metabolizer (CYP3A5 expresser)</td><td>An individual carrying one functional allele and one non-functional allele</td><td>*1/*3, *1/*6, *1/*7</td><td>Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations</td><td>Increase starting dose 1.5 to 2 times recommended starting dose <sup>d</sup>. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments</td><td>Strong</td></tr>
<tr><td>Poor metabolizer (CYP3A5 non-expresser)</td><td>An individual carrying two non-functional alleles</td><td>*3/*3, *6/*6, *7/*7, *3/*6, *3/*7, *6/*7</td><td>Higher (“normal”) dose-adjusted trough concentrations of tacrolimus and increased chance of achieving target tacrolimus concentrations</td><td>Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> Typically with other CYP enzymes, an extensive metabolizer would be classified as a “normal” metabolizer, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e. CYP3A5 extensive metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e. poor metabolizer) would require the standard recommended starting dose.</p>
<p><sup>b</sup> Additional rare variants such as <em>CYP3A5*2, *8</em>, and <em>*9</em> may be found which are of unknown functional significance. However, if a copy of <em>*1</em> is present, expected phenotype would be intermediate metabolizer.</p>
<p><sup>c</sup> This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical.</p>
<p><sup>d</sup> Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function)</p>
<p><sup>e</sup> Rating scheme is described in 2015 Supplement.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166124619"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166124619"",""name"":""Annotation of CPIC Guideline for tacrolimus and CYP3A5"",""cancerGenome"":false,""descriptiveVideoId"":""OGP4_sQsnBE"",""guidelineGenes"":[{""id"":1.449560765E9,""alleles"":[{""id"":1.449560766E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558337"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558337E9,""resource"":""Allele Function"",""term"":""Extensive Metabolizer"",""termId"":""haplotypeTags:1445558337""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128213"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128213"",""symbol"":""CYP3A5*1"",""name"":""*1""}},{""id"":1.449560767E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128218"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128218"",""symbol"":""CYP3A5*2"",""name"":""*2""}},{""id"":1.449560768E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558339"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558339E9,""resource"":""Allele Function"",""term"":""Poor Metabolizer"",""termId"":""haplotypeTags:1445558339""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128219"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128219"",""symbol"":""CYP3A5*3"",""name"":""*3""}},{""id"":1.449560769E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128231"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128231"",""symbol"":""CYP3A5*4"",""name"":""*4""}},{""id"":1.44956077E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128232"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128232"",""symbol"":""CYP3A5*5"",""name"":""*5""}},{""id"":1.449560771E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558339"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558339E9,""resource"":""Allele Function"",""term"":""Poor Metabolizer"",""termId"":""haplotypeTags:1445558339""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128233"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128233"",""symbol"":""CYP3A5*6"",""name"":""*6""}},{""id"":1.449560772E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558339"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558339E9,""resource"":""Allele Function"",""term"":""Poor Metabolizer"",""termId"":""haplotypeTags:1445558339""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128234"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128234"",""symbol"":""CYP3A5*7"",""name"":""*7""}},{""id"":1.449560773E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128235"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128235"",""symbol"":""CYP3A5*8"",""name"":""*8""}},{""id"":1.449560774E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128236"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128236"",""symbol"":""CYP3A5*9"",""name"":""*9""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA131"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA131"",""symbol"":""CYP3A5"",""name"":""cytochrome P450 family 3 subfamily A member 5""}}],""history"":[{""id"":1.445556716E9,""date"":""2015-08-11T00:00:00-07:00"",""type"":""Approve"",""version"":1.0},{""id"":1.450043032E9,""date"":""2018-11-20T09:59:29.307-08:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15087045"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5087045E7,""resourceId"":""25801146"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481158"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4481158"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449295555E9,""resource"":""PubMed Central"",""resourceId"":""PMC4481158"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481158""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/25801146"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449295554E9,""resource"":""PubMed"",""resourceId"":""25801146"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/25801146""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.113"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449295556E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.113"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.113""}]},{""@id"":""https://pharmgkb.org/literature/15100924"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100924E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"",""title"":""CPIC® Guideline for Tacrolimus and CYP3A5 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983514E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451578"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451578"",""name"":""tacrolimus""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA131"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA131"",""symbol"":""CYP3A5"",""name"":""cytochrome P450 family 3 subfamily A member 5""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982329E9,""html"":""\u003cp\u003eThe CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982328E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for tacrolimus and CYP3A5\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""july-2015\""\u003eJuly 2015\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvanced online publication March 2015\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in dosing of tacrolimus have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThese guidelines are applicable to:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003ePatients undergoing kidney, heart, lung, or hematopoietic stem cell transplant.\u003c/li\u003e\n\u003cli\u003ePatients undergoing liver transplant where the donor and recipient \u003cem\u003eCYP3A5\u003c/em\u003e genotypes are identical.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExcerpts from the 2015 tacrolimus dosing guidelines:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Blood concentrations of tacrolimus are strongly influenced by \u003cem\u003eCYP3A5\u003c/em\u003e genotype, with substantial evidence linking \u003cem\u003eCYP3A5\u003c/em\u003e genotype with phenotypic variability...In kidney, heart and lung transplant patients, over 50 studies have found that individuals with the \u003cem\u003eCYP3A5*1/*1\u003c/em\u003e or \u003cem\u003eCYP3A5*1/*3\u003c/em\u003e genotype have significantly lower dose-adjusted trough concentrations of tacrolimus as compared to those with the \u003cem\u003eCYP3A5*3/*3\u003c/em\u003e genotype...\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Those recipients with an extensive or intermediate metabolizer phenotype will generally require an increased dose of tacrolimus to achieve therapeutic drug concentrations. We recommend a dose 1.5 - 2 times higher than standard dosing, but not to exceed 0.3 mg/kg/day, followed by [therapeutic drug monitoring] given the risk of arterial vasoconstriction, hypertension and nephrotoxicity that can occur with supratherapeutic tacrolimus concentrations.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for \u003cem\u003eCYP3A5\u003c/em\u003e genotypes and Tacrolimus Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146-supplement.pdf\"" target\u003d\""_blank\""\u003e2015 Supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146-CYP3A5%20translation%20table.xlsx\"" target\u003d\""_blank\""\u003e2015 Tacrolimus translation table\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/tacrolimus/2015/25801146-CYP3A5%20allele%20frequency%20table.xlsx\"" target\u003d\""_blank\""\u003eCYP3A5 allele frequency table\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-tacrolimus-based-on-cyp3a5-phenotype\""\u003eTable 1: Dosing recommendations for tacrolimus based on CYP3A5 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2015 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes \u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications for tacrolimus pharmacologic measures\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations \u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations \u003csup\u003ee\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eExtensive metabolizer (CYP3A5 expresser)\u003c/td\u003e\u003ctd\u003eAn individual carrying two functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eLower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations\u003c/td\u003e\u003ctd\u003eIncrease starting dose 1.5 to 2 times recommended starting dose \u003csup\u003ed\u003c/sup\u003e. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer (CYP3A5 expresser)\u003c/td\u003e\u003ctd\u003eAn individual carrying one functional allele and one non-functional allele\u003c/td\u003e\u003ctd\u003e*1/*3, *1/*6, *1/*7\u003c/td\u003e\u003ctd\u003eLower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations\u003c/td\u003e\u003ctd\u003eIncrease starting dose 1.5 to 2 times recommended starting dose \u003csup\u003ed\u003c/sup\u003e. Total starting dose should not exceed 0.3mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizer (CYP3A5 non-expresser)\u003c/td\u003e\u003ctd\u003eAn individual carrying two non-functional alleles\u003c/td\u003e\u003ctd\u003e*3/*3, *6/*6, *7/*7, *3/*6, *3/*7, *6/*7\u003c/td\u003e\u003ctd\u003eHigher (“normal”) dose-adjusted trough concentrations of tacrolimus and increased chance of achieving target tacrolimus concentrations\u003c/td\u003e\u003ctd\u003eInitiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Typically with other CYP enzymes, an extensive metabolizer would be classified as a “normal” metabolizer, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e. CYP3A5 extensive metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e. poor metabolizer) would require the standard recommended starting dose.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Additional rare variants such as \u003cem\u003eCYP3A5*2, *8\u003c/em\u003e, and \u003cem\u003e*9\u003c/em\u003e may be found which are of unknown functional significance. However, if a copy of \u003cem\u003e*1\u003c/em\u003e is present, expected phenotype would be intermediate metabolizer.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function)\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Rating scheme is described in 2015 Supplement.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983514E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/""}]},""status"":""success""}"
PA166104983,Guideline Annotation,Annotation of DPWG Guideline for tacrolimus and CYP3A5,t,PA451578,Dutch Pharmacogenetics Working Group,"<p>Increased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor. Where heterozygous CYP3A5 expressor is most commonly CYP3A5*1/*3, and homozygous CYP3A5 expressor most commonly CYP3A5*1/*1.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tacrolimus based on CYP3A5 status and includes recommendations for liver transplantations and other transplantations. Genetic variation results in an increased conversion of tacrolimus to inactive metabolites and as a result a higher dose is required. Adjustment of the initial dose results in an increased chance of reaching a tacrolimus concentration within the target range before the start of therapeutic drug monitoring on day three. However, there is no direct evidence that this results in improved clinical results.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Recommendation Indications OTHER than liver transplantation</th><th>Recommendation LIVER transplantation</th></tr>
</thead>
<tbody>
<tr><td>CYP3A5 heterozygote expressor</td><td>tacrolimus</td><td>Start with 1.75 times of the standard initial dose that would yield the desired result in non-expressors. Adjustment of the dose should then be based on therapeutic drug monitoring.</td><td>In addition to the patient’s genotype, the metabolism of tacrolimus is also determined by the genotype of the transplanted liver.<br/>LIVER is also of the genotype HETEROZYGOUS EXPRESSOR: Start with 1.75 times the standard initial dose Adjustment of the dose should then be based on therapeutic drug monitoring.<br/>If LIVER has a DIFFERENT genotype: There is insufficient evidence in the literature to support a dose recommendation.</td></tr>
<tr><td>CYP3A5 homozygous expressor</td><td>tacrolimus</td><td>Start with 2.5 times the standard initial dose that would yield the desired result in non-expressors Adjustment of the dose should then be based on therapeutic drug monitoring.</td><td>In addition to the patient’s genotype, the metabolism of tacrolimus is also determined by the genotype of the transplanted liver.<br/>LIVER is also of the genotype HOMOZYGOUS EXPRESSOR: Start with 2.5 times the standard initial dose Adjustment of the dose should then be based on therapeutic drug monitoring.<br/>LIVER has a DIFFERENT genotype: There is insufficient evidence in the literature to support a dose recommendation.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002357.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tacrolimus based on CYP3A5 genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They found evidence to support an interaction between tacrolimus and CYP3A5.  However, they make no dosing recommendations at this time, due to fact that &quot;in Dutch transplantation hospitals the tacrolimus dose is titrated in response to therapeutic drug monitoring.&quot;</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>CYP3A5 *1/*1</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x109/l; leucopenia &gt; 3.0x109/l; thrombocytopenia  &gt; 75x109/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>CYP3A5 *1/*3</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x109/l; leucopenia 1.0-2.0x109/l; thrombocytopenia 25-50x109/l; severe diarrhea.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104983"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104983"",""name"":""Annotation of DPWG Guideline for tacrolimus and CYP3A5"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704531E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414922E9,""date"":""2019-05-23T08:19:51.154-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820682E9,""date"":""2019-10-03T16:38:07.181-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45095642E9,""date"":""2020-01-31T14:18:56.499-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963904E9,""date"":""2020-02-11T07:58:37.393-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451578"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451578"",""name"":""tacrolimus""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA131"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA131"",""symbol"":""CYP3A5"",""name"":""cytochrome P450 family 3 subfamily A member 5""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981954E9,""html"":""\u003cp\u003eIncreased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor. Where heterozygous CYP3A5 expressor is most commonly CYP3A5*1/*3, and homozygous CYP3A5 expressor most commonly CYP3A5*1/*1.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981953E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tacrolimus based on CYP3A5 status and includes recommendations for liver transplantations and other transplantations. Genetic variation results in an increased conversion of tacrolimus to inactive metabolites and as a result a higher dose is required. Adjustment of the initial dose results in an increased chance of reaching a tacrolimus concentration within the target range before the start of therapeutic drug monitoring on day three. However, there is no direct evidence that this results in improved clinical results.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eRecommendation Indications OTHER than liver transplantation\u003c/th\u003e\u003cth\u003eRecommendation LIVER transplantation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP3A5 heterozygote expressor\u003c/td\u003e\u003ctd\u003etacrolimus\u003c/td\u003e\u003ctd\u003eStart with 1.75 times of the standard initial dose that would yield the desired result in non-expressors. Adjustment of the dose should then be based on therapeutic drug monitoring.\u003c/td\u003e\u003ctd\u003eIn addition to the patient’s genotype, the metabolism of tacrolimus is also determined by the genotype of the transplanted liver.\u003cbr/\u003eLIVER is also of the genotype HETEROZYGOUS EXPRESSOR: Start with 1.75 times the standard initial dose Adjustment of the dose should then be based on therapeutic drug monitoring.\u003cbr/\u003eIf LIVER has a DIFFERENT genotype: There is insufficient evidence in the literature to support a dose recommendation.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP3A5 homozygous expressor\u003c/td\u003e\u003ctd\u003etacrolimus\u003c/td\u003e\u003ctd\u003eStart with 2.5 times the standard initial dose that would yield the desired result in non-expressors Adjustment of the dose should then be based on therapeutic drug monitoring.\u003c/td\u003e\u003ctd\u003eIn addition to the patient’s genotype, the metabolism of tacrolimus is also determined by the genotype of the transplanted liver.\u003cbr/\u003eLIVER is also of the genotype HOMOZYGOUS EXPRESSOR: Start with 2.5 times the standard initial dose Adjustment of the dose should then be based on therapeutic drug monitoring.\u003cbr/\u003eLIVER has a DIFFERENT genotype: There is insufficient evidence in the literature to support a dose recommendation.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002357.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tacrolimus based on CYP3A5 genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They found evidence to support an interaction between tacrolimus and CYP3A5.  However, they make no dosing recommendations at this time, due to fact that \u0026quot;in Dutch transplantation hospitals the tacrolimus dose is titrated in response to therapeutic drug monitoring.\u0026quot;\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP3A5 *1/*1\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x109/l; leucopenia \u0026gt; 3.0x109/l; thrombocytopenia  \u0026gt; 75x109/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP3A5 *1/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x109/l; leucopenia 1.0-2.0x109/l; thrombocytopenia 25-50x109/l; severe diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104947,Guideline Annotation,Annotation of DPWG Guideline for ribavirin and HLA-B,f,PA451241,Dutch Pharmacogenetics Working Group,"<p>Although there is some evidence for lower treatment response in HLA-B*44 negative patients,  there are no dosing recommendations for ribavirin at this time.</p>
","<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for ribavirin based on HLA-B*44 [Article:<a href=""/pmid/21412232"">21412232</a>].  They found some evidence for lower treatment response in HLA-B*44 negative patients.  However, they conclude that there are no dosing recommendations at this time, &quot;given that ~90% of the population is HLA-B*44-negative and that no alternative treatment is available.&quot;</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>HLA-B*44</td><td>None</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104947"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104947"",""name"":""Annotation of DPWG Guideline for ribavirin and HLA-B"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704525E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450956396E9,""date"":""2020-01-31T13:47:20.029-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45097054E9,""date"":""2020-02-20T14:25:04.370-08:00"",""description"":""changed tag to say \""no recommendation\"""",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451241"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451241"",""name"":""ribavirin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA35056"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA35056"",""symbol"":""HLA-B"",""name"":""major histocompatibility complex, class I, B""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.44798188E9,""html"":""\u003cp\u003eAlthough there is some evidence for lower treatment response in HLA-B*44 negative patients,  there are no dosing recommendations for ribavirin at this time.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981879E9,""html"":""\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for ribavirin based on HLA-B*44 [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They found some evidence for lower treatment response in HLA-B*44 negative patients.  However, they conclude that there are no dosing recommendations at this time, \u0026quot;given that ~90% of the population is HLA-B*44-negative and that no alternative treatment is available.\u0026quot;\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eHLA-B*44\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104943,Guideline Annotation,Annotation of DPWG Guideline for risperidone and CYP2D6,f,PA451257,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for risperidone based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for risperidone based on CYP2D6 genotype. They recommend NO action is needed for this gene-drug interaction.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 IM</td><td>risperidone</td><td>There is little evidence to support an increase in side effects caused by the genetic variation. The genetic variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
<tr><td>CYP2D6 PM</td><td>risperidone</td><td>The genetic variation can result in both an increase in side effects and a stronger decrease in schizophrenia symptoms. In addition to this, the genetic variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
<tr><td>CYP2D6 UM</td><td>risperidone</td><td>Genetic variation may lead to an increase in the required maintenance dose. However, as the effect is smaller than that of the normal biological variation, action is not useful.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001536.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for risperidone based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  For patients who are CYP2D6 poor metabolizers, intermediate metabolizers, or ultrarapid metabolizers, they recommend selecting an alternative drug or being extra alert to Adverse Drug Events and adjusting dose to clinical response.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Insufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., quetiapine,olanzapine, clozapine) or be extra alert to ADEs and adjust dose to clinical response.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10<sup>9</sup>/l; leucopenia 1.0-2.0x10<sup>9</sup>/l; thrombocytopenia 25-50x10<sup>9</sup>/l; severe diarrhea.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Insufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., quetiapine, olanzapine, clozapine) or be extra alert to ADEs and adjust dose to clinical response.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Insufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., quetiapine, olanzapine, clozapine) or be extra alert to ADEs and adjust dose to clinical response.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104943"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104943"",""name"":""Annotation of DPWG Guideline for risperidone and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704527E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415341E9,""date"":""2019-05-28T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.45082103E9,""date"":""2019-10-07T18:28:51.136-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450824023E9,""date"":""2019-10-18T14:05:28.837-07:00"",""description"":""Added reference to August 2019 update"",""type"":""Update"",""version"":0.0},{""id"":1.450956353E9,""date"":""2020-01-31T13:47:41.450-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963882E9,""date"":""2020-02-11T07:46:13.228-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451257"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451257"",""name"":""risperidone""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981874E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for risperidone based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981873E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for risperidone based on CYP2D6 genotype. They recommend NO action is needed for this gene-drug interaction.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003erisperidone\u003c/td\u003e\u003ctd\u003eThere is little evidence to support an increase in side effects caused by the genetic variation. The genetic variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003erisperidone\u003c/td\u003e\u003ctd\u003eThe genetic variation can result in both an increase in side effects and a stronger decrease in schizophrenia symptoms. In addition to this, the genetic variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003erisperidone\u003c/td\u003e\u003ctd\u003eGenetic variation may lead to an increase in the required maintenance dose. However, as the effect is smaller than that of the normal biological variation, action is not useful.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001536.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for risperidone based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For patients who are CYP2D6 poor metabolizers, intermediate metabolizers, or ultrarapid metabolizers, they recommend selecting an alternative drug or being extra alert to Adverse Drug Events and adjusting dose to clinical response.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., quetiapine,olanzapine, clozapine) or be extra alert to ADEs and adjust dose to clinical response.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10\u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., quetiapine, olanzapine, clozapine) or be extra alert to ADEs and adjust dose to clinical response.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Select alternative drug (e.g., quetiapine, olanzapine, clozapine) or be extra alert to ADEs and adjust dose to clinical response.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166127639,Guideline Annotation,Annotation of CPIC Guideline for sertraline and CYP2C19,t,PA451333,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""august-2015"">August 2015</h3>
<p><em>Advanced online publication May 2015</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing of selective serotonin reuptake inhibitors have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpts from the 2015 selective serotonin reuptake inhibitors dosing guidelines (for sertraline and CYP2C19):
<ul>
<li>&quot;No dose adjustment is recommended for CYP2C19 ultrarapid metabolizers; however, if a patient is not responding to adequate maintenance doses of sertraline, consider an alternative SSRI not predominantly metabolized by CYP2C19.&quot;</li>
<li>&quot;Pharmacokinetic data show reduced oral clearance of sertraline in CYP2C19 poor metabolizers...Side effects in CYP2C19 poor metabolizers have also been reported to be more frequent than in normal metabolizers. Therefore, in CYP2C19 poor metabolizers a dose reduction of 50% is recommended or an alternative SSRI not extensively metabolized by CYP2C19 should be considered.&quot;</li>
<li>&quot;The recommendations in the guideline and below apply primarily to actions based on genetic tests only; drug interactions and other clinical factors can have a major influence for prescribing decisions for SSRIs and should be taken into consideration before initiating drug therapy.&quot;</li>
<li>&quot;Data describing the relationship between CYP2D6 or CYP2C19 genotype and SSRI systemic exposure or steady state plasma concentrations in pediatric patients are scarce...CYP2C19 activity may be increased in children relative to adults; therefore, these recommendations should be used with caution in children and accompanied by close monitoring.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703-supplement.pdf"" target=""_blank"">2015 Supplement</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_2015%20CYP2C19%20SSRI%20translation%20table.xlsx"" target=""_blank"">2015 CYP2C19 SSRI translation table</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2C19%20frequency%20table%20legend.pdf"" target=""_blank"">CYP2C19 frequency table legend</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2C19%20frequency%20table.xlsx"" target=""_blank"">CYP2C19 frequency table</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-sertraline-based-on-cyp2c19-phenotype"">Table 1: Dosing recommendations for sertraline based on CYP2C19 phenotype:</h3>
<p><em>Adapted from Tables 1 and 3b of the 2015 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of CYP2C19 diplotypes</th><th>Implications for sertraline metabolism</th><th>Therapeutic Recommendations</th><th>Classification of recommendations <sup>a</sup></th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer (~5-30% of patients) <sup>b</sup></td><td>An individual carrying two increased function alleles or one normal function allele and one increased function allele</td><td>*17/*17, *1/*17</td><td>Increased metabolism when compared to extensive metabolizers.</td><td>Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19.<sup>c</sup></td><td>Optional</td></tr>
<tr><td>Extensive metabolizer (~35-50% of patients)</td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose.</td><td>Strong</td></tr>
<tr><td>Intermediate metabolizer (~18-45% of patients)</td><td>An individual carrying one normal function allele or one increased function allele and one no function allele</td><td>*1/*2, *1/*3, *2/*17 <sup>d</sup></td><td>Reduced metabolism when compared to extensive metabolizers.</td><td>Initiate therapy with recommended starting dose.</td><td>Strong</td></tr>
<tr><td>Poor metabolizer (~2-15% of patients)</td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.</td><td>Consider a 50% reduction <sup>e</sup> of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.<sup>c</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> Rating scheme described in Supplement.</p>
<p><sup>b</sup> CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequency.</p>
<p><sup>c</sup> Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.</p>
<p><sup>d</sup> The predicted metabolizer phenotype for the*2/*17 genotypes is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the no function CYP2C19*2. See Supplemental Materials for a more comprehensive list of predicted metabolizer phenotypes.</p>
<p><sup>e</sup> Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. [Article:<a href=""/pmid/22565785"">22565785</a>].</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166127639"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166127639"",""name"":""Annotation of CPIC Guideline for sertraline and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":""iAbdY1rv-rg"",""guidelineGenes"":[{""id"":1.449561382E9,""alleles"":[{""id"":1.449561383E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980634"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980634"",""symbol"":""CYP2C19*1"",""name"":""*1""}},{""id"":1.449561384E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980635"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980635"",""symbol"":""CYP2C19*2"",""name"":""*2""}},{""id"":1.449561385E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980636"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980636"",""symbol"":""CYP2C19*3"",""name"":""*3""}},{""id"":1.449561388E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980638"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980638"",""symbol"":""CYP2C19*5"",""name"":""*5""}},{""id"":1.449561389E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816522"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816522"",""symbol"":""CYP2C19*6"",""name"":""*6""}},{""id"":1.44956139E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816537"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816537"",""symbol"":""CYP2C19*23"",""name"":""*23""}},{""id"":1.449561391E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816523"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816523"",""symbol"":""CYP2C19*7"",""name"":""*7""}},{""id"":1.449561392E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816524"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816524"",""symbol"":""CYP2C19*8"",""name"":""*8""}},{""id"":1.449561393E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816525"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816525"",""symbol"":""CYP2C19*9"",""name"":""*9""}},{""id"":1.449561394E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816526"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816526"",""symbol"":""CYP2C19*10"",""name"":""*10""}},{""id"":1.449561395E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816527"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816527"",""symbol"":""CYP2C19*11"",""name"":""*11""}},{""id"":1.449561396E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816528"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816528"",""symbol"":""CYP2C19*12"",""name"":""*12""}},{""id"":1.449561397E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816529"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816529"",""symbol"":""CYP2C19*13"",""name"":""*13""}},{""id"":1.449561398E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816530"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816530"",""symbol"":""CYP2C19*14"",""name"":""*14""}},{""id"":1.449561399E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816531"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816531"",""symbol"":""CYP2C19*15"",""name"":""*15""}},{""id"":1.4495614E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816532"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816532"",""symbol"":""CYP2C19*16"",""name"":""*16""}},{""id"":1.449561401E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816533"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816533"",""symbol"":""CYP2C19*17"",""name"":""*17""}},{""id"":1.449561402E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816534"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816534"",""symbol"":""CYP2C19*18"",""name"":""*18""}},{""id"":1.449561403E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816535"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816535"",""symbol"":""CYP2C19*19"",""name"":""*19""}},{""id"":1.449561404E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816536"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816536"",""symbol"":""CYP2C19*22"",""name"":""*22""}},{""id"":1.449561405E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816538"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816538"",""symbol"":""CYP2C19*24"",""name"":""*24""}},{""id"":1.449561406E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816539"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816539"",""symbol"":""CYP2C19*25"",""name"":""*25""}},{""id"":1.449561407E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816540"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816540"",""symbol"":""CYP2C19*26"",""name"":""*26""}},{""id"":1.449561409E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115675"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115675"",""symbol"":""CYP2C19*28"",""name"":""*28""}},{""id"":1.44956141E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123292"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123292"",""symbol"":""CYP2C19*29"",""name"":""*29""}},{""id"":1.449561411E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123293"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123293"",""symbol"":""CYP2C19*30"",""name"":""*30""}},{""id"":1.449561412E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123294"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123294"",""symbol"":""CYP2C19*31"",""name"":""*31""}},{""id"":1.449561413E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123295"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123295"",""symbol"":""CYP2C19*32"",""name"":""*32""}},{""id"":1.449561414E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123296"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123296"",""symbol"":""CYP2C19*33"",""name"":""*33""}},{""id"":1.449561415E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115676"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115676"",""symbol"":""CYP2C19*34"",""name"":""*34""}},{""id"":1.449561416E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128094"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128094"",""symbol"":""CYP2C19*35"",""name"":""*35""}},{""id"":1.450805214E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980637"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980637"",""symbol"":""CYP2C19*4"",""name"":""*4""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}}],""history"":[{""id"":1.4447081E9,""date"":""2015-05-08T00:00:00-07:00"",""description"":""initial save"",""type"":""Create"",""version"":1.0},{""id"":1.450043036E9,""date"":""2018-11-20T12:15:20.656-08:00"",""description"":""Added link to guideline video"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15089021"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5089021E7,""resourceId"":""25974703"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4512908"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285932E9,""resource"":""PubMed Central"",""resourceId"":""PMC4512908"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/25974703"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285931E9,""resource"":""PubMed"",""resourceId"":""25974703"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/25974703""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.147"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449285933E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.147"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.147""}]},{""@id"":""https://pharmgkb.org/literature/15100911"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100911E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Selective Serotonin Reuptake Inhibitors and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983477E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451333"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451333"",""name"":""sertraline""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982317E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982316E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""august-2015\""\u003eAugust 2015\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvanced online publication May 2015\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing of selective serotonin reuptake inhibitors have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2015 selective serotonin reuptake inhibitors dosing guidelines (for sertraline and CYP2C19):\n\u003cul\u003e\n\u003cli\u003e\u0026quot;No dose adjustment is recommended for CYP2C19 ultrarapid metabolizers; however, if a patient is not responding to adequate maintenance doses of sertraline, consider an alternative SSRI not predominantly metabolized by CYP2C19.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Pharmacokinetic data show reduced oral clearance of sertraline in CYP2C19 poor metabolizers...Side effects in CYP2C19 poor metabolizers have also been reported to be more frequent than in normal metabolizers. Therefore, in CYP2C19 poor metabolizers a dose reduction of 50% is recommended or an alternative SSRI not extensively metabolized by CYP2C19 should be considered.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;The recommendations in the guideline and below apply primarily to actions based on genetic tests only; drug interactions and other clinical factors can have a major influence for prescribing decisions for SSRIs and should be taken into consideration before initiating drug therapy.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Data describing the relationship between CYP2D6 or CYP2C19 genotype and SSRI systemic exposure or steady state plasma concentrations in pediatric patients are scarce...CYP2C19 activity may be increased in children relative to adults; therefore, these recommendations should be used with caution in children and accompanied by close monitoring.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703-supplement.pdf\"" target\u003d\""_blank\""\u003e2015 Supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_2015%20CYP2C19%20SSRI%20translation%20table.xlsx\"" target\u003d\""_blank\""\u003e2015 CYP2C19 SSRI translation table\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2C19%20frequency%20table%20legend.pdf\"" target\u003d\""_blank\""\u003eCYP2C19 frequency table legend\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/SSRI/2015/25974703_CYP2C19%20frequency%20table.xlsx\"" target\u003d\""_blank\""\u003eCYP2C19 frequency table\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-sertraline-based-on-cyp2c19-phenotype\""\u003eTable 1: Dosing recommendations for sertraline based on CYP2C19 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3b of the 2015 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of CYP2C19 diplotypes\u003c/th\u003e\u003cth\u003eImplications for sertraline metabolism\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer (~5-30% of patients) \u003csup\u003eb\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles or one normal function allele and one increased function allele\u003c/td\u003e\u003ctd\u003e*17/*17, *1/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism when compared to extensive metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19.\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eExtensive metabolizer (~35-50% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer (~18-45% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele or one increased function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3, *2/*17 \u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eReduced metabolism when compared to extensive metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizer (~2-15% of patients)\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism when compared to extensive metabolizers. Higher plasma concentrations may increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider a 50% reduction \u003csup\u003ee\u003c/sup\u003e of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Rating scheme described in Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequency.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e The predicted metabolizer phenotype for the*2/*17 genotypes is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the no function CYP2C19*2. See Supplemental Materials for a more comprehensive list of predicted metabolizer phenotypes.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Percent dose adjustments corresponding to percent difference in oral clearances have been calculated/estimated by Stingl et al. [Article:\u003ca href\u003d\""/pmid/22565785\""\u003e22565785\u003c/a\u003e].\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983477E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166104980,Guideline Annotation,Annotation of DPWG Guideline for sertraline and CYP2C19,t,PA451333,Dutch Pharmacogenetics Working Group,"<p>Do not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for sertraline based on CYP2C19 genotype. Patients with CYP2C19 poor metabolizer genotypes should not receive doses exceeding 75 mg/day, and dose should be guided by response and side effects and/or sertraline plasma concentration. No action is recommended for CYP2C19 intermediate or ultrarapid metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 PM</td><td>sertraline</td><td>The risk of side effects is increased. The gene variation leads to increased plasma concentrations of sertraline.</td><td>Do not give doses exceeding 75 mg/day. Guide the dose by response and side effects and/or sertraline plasma concentration.</td></tr>
<tr><td>CYP2C19 IM</td><td>sertraline</td><td>NO action is needed for this gene-drug interaction.</td><td>The gene variation has a minor effect on the sertraline plasma concentration. No effect on side effects was found.</td></tr>
<tr><td>CYP2C19 UM</td><td>sertraline</td><td>NO action is needed for this gene-drug interaction.</td><td>The gene variation has a negligible effect on the plasma concentration of sertraline. Moreover, no significant effect on response and side effects has been found.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002008.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for sertraline based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>Reduce dose by 50%.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Clinical effect (statistically significant difference): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; adverse drug events resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); international normalized ratio 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>Insufficient data to allow calculation of dose adjustment. Be extra alert to adverse drug events (e.g., nausea, vomiting, diarrhea).</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5; Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>None</td><td>no data was retrieved with the literature search</td><td>no data was retrieved with the literature search</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/sertraline_CYP2C19_271111.pdf"">Sertraline CYP2C19 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104980"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104980"",""name"":""Annotation of DPWG Guideline for sertraline and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704529E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415055E9,""date"":""2019-05-23T15:21:18.200-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821032E9,""date"":""2019-10-07T18:31:05.298-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450956354E9,""date"":""2020-01-31T13:48:08.133-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963901E9,""date"":""2020-02-11T07:51:58.173-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451333"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451333"",""name"":""sertraline""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981948E9,""html"":""\u003cp\u003eDo not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981947E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for sertraline based on CYP2C19 genotype. Patients with CYP2C19 poor metabolizer genotypes should not receive doses exceeding 75 mg/day, and dose should be guided by response and side effects and/or sertraline plasma concentration. No action is recommended for CYP2C19 intermediate or ultrarapid metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 PM\u003c/td\u003e\u003ctd\u003esertraline\u003c/td\u003e\u003ctd\u003eThe risk of side effects is increased. The gene variation leads to increased plasma concentrations of sertraline.\u003c/td\u003e\u003ctd\u003eDo not give doses exceeding 75 mg/day. Guide the dose by response and side effects and/or sertraline plasma concentration.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 IM\u003c/td\u003e\u003ctd\u003esertraline\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003ctd\u003eThe gene variation has a minor effect on the sertraline plasma concentration. No effect on side effects was found.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 UM\u003c/td\u003e\u003ctd\u003esertraline\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003ctd\u003eThe gene variation has a negligible effect on the plasma concentration of sertraline. Moreover, no significant effect on response and side effects has been found.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002008.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for sertraline based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eReduce dose by 50%.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eClinical effect (statistically significant difference): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; adverse drug events resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); international normalized ratio 4.5-6.0; neutropenia 1.0-1.5x109/l; leucopenia 2.0-3.0x109/l; thrombocytopenia 50-75x109/l\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Be extra alert to adverse drug events (e.g., nausea, vomiting, diarrhea).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio increase \u0026lt; 4.5; Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003ctd\u003eno data was retrieved with the literature search\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/sertraline_CYP2C19_271111.pdf\""\u003eSertraline CYP2C19 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182821,Guideline Annotation,Annotation of DPWG Guideline for sertraline and CYP2D6,f,PA451333,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for sertraline based on CYP2D6 genotypes.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for sertraline based on CYP2D6 genotypes. They conclude that this is not a gene-drug interaction. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0003513.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182821"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182821"",""name"":""Annotation of DPWG Guideline for sertraline and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.45041506E9,""date"":""2019-05-23T15:24:50.090-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821033E9,""date"":""2019-10-07T18:32:08.869-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.4509639E9,""date"":""2020-02-11T07:48:46.397-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451333"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451333"",""name"":""sertraline""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415056E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for sertraline based on CYP2D6 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415057E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for sertraline based on CYP2D6 genotypes. They conclude that this is not a gene-drug interaction. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0003513.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166105005,Guideline Annotation,Annotation of CPIC Guideline for simvastatin and SLCO1B1,t,PA451363,Clinical Pharmacogenetics Implementation Consortium,"<p>The FDA recommends against 80mg daily simvastatin dosage. In patients with the C allele at SLCO1B1 <a href=""/variant/PA166154579"">rs4149056</a>, there are modest increases in myopathy risk even at lower simvastatin doses (40mg daily); if optimal efficacy is not achieved with a lower dose, alternate agents should be considered.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"" target=""_blank"">CPIC&reg; guideline for simvastatin and SLCO1B1</a>.</p>
<h3 id=""october-2014-update"">October 2014 Update</h3>
<p><em>Advance online publication 9 July 2014.</em></p>
<ul>
<li>
<p>The <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/simvastatin/2014/24918167.pdf"" target=""_blank"">2014 update of CPIC guideline regarding SLCO1B1 and simvastatin-induced myopathy</a>, has been published in Clinical Pharmacology and Therapeutics.  CPIC extensively reviewed the literature from February 2011 to December 2013 and concluded the dosing recommendations provided in the 2012 CPIC guideline for SLCO1B1 and simvastatin-induced myopathy have not changed. However, this updated guideline also provides a brief review regarding SLCO1B1 genotype and risk of myopathy for other statins.  Furthermore, comprehensive translation tables mapping SLCO1B1 genotypes to coded genotype/phenotype summaries, EHR priority result notation and interpretation (consultation) text were created to facilitate incorporation of SLCO1B1 pharmacogenetics into an electronic health record with clinical decision support.</p>
</li>
<li>
<p>This guideline is applicable to:</p>
<ul>
<li>adult patients</li>
<li>pediatric patients</li>
</ul>
</li>
<li>
<p>Excerpt from the 2014 simvastatin dosing guideline:</p>
<ul>
<li>&quot;For simvastatin, the evidence linking myopathy to <a href=""/variant/PA166154579"">rs4149056</a> in SLCO1B1 is of high quality, and this association has been reproduced in randomized trials and clinical practice-based cohorts. Conversely, the association of <a href=""/variant/PA166154579"">rs4149056</a> with myopathy has been less compelling for other statins. We therefore focus this guideline on simvastatin.&quot;</li>
</ul>
</li>
</ul>
<p>&quot;In 2011 and updated in 2013, the FDA added warnings to the simvastatin product label to direct providers away from initiating at the 80 mg simvastatin dose. &quot;</p>
<p>&quot;At lower simvastatin doses (e.g., 40 mg daily), it is our position that SLCO1B1 genotype (if available) could be used to warn providers about modest increases in myopathy risk for patients with a C allele at <a href=""/variant/PA166154579"">rs4149056</a>. In these circumstances, we recommend a lower dose of simvastatin or use an alternative statin (e.g. pravastatin or rosuvastatin) and we also highlight the potential utility of routine CK surveillance (Table 2). If patients with a C allele at <a href=""/variant/PA166154579"">rs4149056</a> do not achieve optimal LDL cholesterol-lowering efficacy with a lower dose (e.g. 20 mg) of simvastatin, we recommend the prescribing physician consider an alternate statin based on (i) potency differences (i.e., use a lower dose of a higher potency statin such as atorvastatin, rosuvastatin, or pitavastatin), (ii) drug-drug interactions (e.g., boceprevir, clarithromycin, cyclosporine, strong CYP3A4 inhibitors, etc.), and (iii) relevant co-morbidities (e.g., trauma, significant renal impairment, post-solid organ transplant, thyroid disease etc.).&quot;</p>
<p>&quot;At the time of this writing, there are no data available regarding SLCO1B1 genotype effects on simvastatin response or myopathy in pediatric patient populations, although there is no reason to suspect that the polymorphisms in SLCO1B1 will affect simvastatin's metabolism differently in children compared to adults.&quot;</p>
<ul>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/simvastatin/2014/24918167.pdf"" target=""_blank"">The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/simvastatin/2014/24918167-supplement.pdf"" target=""_blank"">2014 supplement</a></li>
<li><a href=""/page/slco1b1RefMaterials"">Gene-specific Information Tables for SLCO1B1</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-simvastatin-based-on-slco1b1-phenotype"">Table 1: Recommended dosing of simvastatin based on SLCO1B1 phenotype</h3>
<p><em>Adapted from Table 1 and 2 of the 2014 guideline update manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype</th><th>Examples of diplotypes <sup>a</sup></th><th>Genotype at <a href=""/variant/PA166154579"">rs4149056</a></th><th>Implications for simvastatin</th><th>Dosing recommendations for simvastatin <sup>b,c</sup></th><th>Classification of recommendations <sup>d</sup></th></tr>
</thead>
<tbody>
<tr><td>Normal function, Homozygous wild-type (two normal function alleles)</td><td>*1a/*1a, *1a/*1b, *1b/*1b</td><td>TT</td><td>Normal myopathy risk</td><td>Prescribe desired starting dose and adjust doses of simvastatin based on disease-specific guidelines.</td><td>Strong</td></tr>
<tr><td>Intermediate function, Heterozygous (one normal function allele plus one decreased function allele)</td><td>*1a/*5, *1a/*15, *1a/*17, *1b/*5, *1b/*15, *1b/*17</td><td>TC</td><td>Intermediate myopathy risk</td><td>Prescribe a lower dose or consider an alternative statin (e.g. pravastatin or rosuvastatin); consider routine CK surveillance.</td><td>Strong</td></tr>
<tr><td>Low function, Homozygous variant or mutant (two decreased function alleles)</td><td>*5/*5, *5/*15, *5/*17, *15/*15, *15/*17, *17/*17</td><td>CC</td><td>High myopathy risk</td><td>Prescribe a lower dose or consider an alternative statin (e.g. pravastatin or rosuvastatin); consider routine CK surveillance.</td><td>Strong</td></tr>
</tbody>
</table>
<p>CK, creatine kinase.</p>
<p><sup>a</sup> SLCO1B1 alleles are often named using <a href=""http://www.pharmgkb.org/gene/PA134865839#tabview=tab4&amp;subtab=33"">star allele nomenclature, representing various SNPs alone or in combination</a> (2014 Update Supplemental Table S1) that are associated with low SLCO1B1 protein expression or function (2014 Update Supplemental Table S2). The minor C allele at <a href=""/variant/PA166154579"">rs4149056</a> is contained within SLCO1B1*5 (<a href=""/variant/PA166154579"">rs4149056</a> alone) as well as the *15 and *17 haplotypes and is associated with lower plasma clearance of simvastatin. The magnitude of this effect is similar for *5, *15, and *17 haplotypes.</p>
<p><sup>b</sup> In all cases, the potential for drug-drug interaction should be evaluated prior to initiating a prescription.</p>
<p><sup>c</sup> FDA recommends against 80mg (unless already tolerated 12 months).</p>
<p><sup>d</sup> See Supplementary Materials (text section entitled &quot;Levels of Evidence&quot;) online for additional details regarding the three-tiered system used to grade the quality of evidence.</p>
<h3 id=""july-2012"">July 2012</h3>
<p><em>Advance online publication May 2012.</em></p>
<ul>
<li>Guideline regarding the use of pharmacogenomic tests in dosing for simvastatin was published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">(CPIC)</a>.</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/simvastatin/2012/22617227.pdf"" target=""_blank"">The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/simvastatin/2012/22617227-supplement.pdf"" target=""_blank"">2012 supplement</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166105005"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166105005"",""name"":""Annotation of CPIC Guideline for simvastatin and SLCO1B1"",""cancerGenome"":false,""descriptiveVideoId"":""VHIRIeQ2b08"",""guidelineGenes"":[{""id"":1.449561225E9,""alleles"":[{""id"":1.449561226E9,""_label"":""*1A"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819250"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819250"",""symbol"":""SLCO1B1*1A"",""name"":""*1A""}},{""id"":1.449561227E9,""_label"":""*1B"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819251"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819251"",""symbol"":""SLCO1B1*1B"",""name"":""*1B""}},{""id"":1.449561228E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445918941"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445918941E9,""resource"":""Allele Function"",""term"":""Possible Decreased function"",""termId"":""haplotypeTags:1445918941""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819252"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819252"",""symbol"":""SLCO1B1*2"",""name"":""*2""}},{""id"":1.449561229E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445918941"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445918941E9,""resource"":""Allele Function"",""term"":""Possible Decreased function"",""termId"":""haplotypeTags:1445918941""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819253"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819253"",""symbol"":""SLCO1B1*3"",""name"":""*3""}},{""id"":1.44956123E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819254"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819254"",""symbol"":""SLCO1B1*4"",""name"":""*4""}},{""id"":1.449561231E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819255"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819255"",""symbol"":""SLCO1B1*5"",""name"":""*5""}},{""id"":1.449561232E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445918941"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445918941E9,""resource"":""Allele Function"",""term"":""Possible Decreased function"",""termId"":""haplotypeTags:1445918941""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819256"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819256"",""symbol"":""SLCO1B1*6"",""name"":""*6""}},{""id"":1.449561233E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819257"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819257"",""symbol"":""SLCO1B1*7"",""name"":""*7""}},{""id"":1.449561234E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819258"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819258"",""symbol"":""SLCO1B1*8"",""name"":""*8""}},{""id"":1.449561235E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445918941"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445918941E9,""resource"":""Allele Function"",""term"":""Possible Decreased function"",""termId"":""haplotypeTags:1445918941""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819259"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819259"",""symbol"":""SLCO1B1*9"",""name"":""*9""}},{""id"":1.449561236E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445918941"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445918941E9,""resource"":""Allele Function"",""term"":""Possible Decreased function"",""termId"":""haplotypeTags:1445918941""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819260"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819260"",""symbol"":""SLCO1B1*10"",""name"":""*10""}},{""id"":1.449561237E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819261"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819261"",""symbol"":""SLCO1B1*11"",""name"":""*11""}},{""id"":1.449561238E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819262"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819262"",""symbol"":""SLCO1B1*12"",""name"":""*12""}},{""id"":1.449561239E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819263"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819263"",""symbol"":""SLCO1B1*13"",""name"":""*13""}},{""id"":1.44956124E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445918882"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445918882E9,""resource"":""Allele Function"",""term"":""Possible Increased function"",""termId"":""haplotypeTags:1445918882""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819264"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819264"",""symbol"":""SLCO1B1*14"",""name"":""*14""}},{""id"":1.449561241E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819265"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819265"",""symbol"":""SLCO1B1*15"",""name"":""*15""}},{""id"":1.449561242E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165949164"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165949164"",""symbol"":""SLCO1B1*16"",""name"":""*16""}},{""id"":1.449561243E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165819266"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165819266"",""symbol"":""SLCO1B1*17"",""name"":""*17""}},{""id"":1.449561244E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988674"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988674"",""symbol"":""SLCO1B1*18"",""name"":""*18""}},{""id"":1.449561245E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988675"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988675"",""symbol"":""SLCO1B1*19"",""name"":""*19""}},{""id"":1.449561246E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988676"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988676"",""symbol"":""SLCO1B1*20"",""name"":""*20""}},{""id"":1.449561247E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988677"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988677"",""symbol"":""SLCO1B1*21"",""name"":""*21""}},{""id"":1.449561248E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947863"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947863"",""symbol"":""SLCO1B1*22"",""name"":""*22""}},{""id"":1.449561249E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445918941"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445918941E9,""resource"":""Allele Function"",""term"":""Possible Decreased function"",""termId"":""haplotypeTags:1445918941""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947864"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947864"",""symbol"":""SLCO1B1*23"",""name"":""*23""}},{""id"":1.44956125E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947865"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947865"",""symbol"":""SLCO1B1*24"",""name"":""*24""}},{""id"":1.449561251E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947866"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947866"",""symbol"":""SLCO1B1*25"",""name"":""*25""}},{""id"":1.449561252E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947867"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947867"",""symbol"":""SLCO1B1*26"",""name"":""*26""}},{""id"":1.449561253E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947868"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947868"",""symbol"":""SLCO1B1*27"",""name"":""*27""}},{""id"":1.449561254E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947869"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947869"",""symbol"":""SLCO1B1*28"",""name"":""*28""}},{""id"":1.449561255E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947870"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947870"",""symbol"":""SLCO1B1*29"",""name"":""*29""}},{""id"":1.449561256E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947871"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947871"",""symbol"":""SLCO1B1*30"",""name"":""*30""}},{""id"":1.449561257E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445918941"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445918941E9,""resource"":""Allele Function"",""term"":""Possible Decreased function"",""termId"":""haplotypeTags:1445918941""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947872"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947872"",""symbol"":""SLCO1B1*31"",""name"":""*31""}},{""id"":1.449561258E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947873"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947873"",""symbol"":""SLCO1B1*32"",""name"":""*32""}},{""id"":1.449561259E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947874"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947874"",""symbol"":""SLCO1B1*33"",""name"":""*33""}},{""id"":1.44956126E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947875"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947875"",""symbol"":""SLCO1B1*34"",""name"":""*34""}},{""id"":1.449561261E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445918882"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445918882E9,""resource"":""Allele Function"",""term"":""Possible Increased function"",""termId"":""haplotypeTags:1445918882""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947876"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947876"",""symbol"":""SLCO1B1*35"",""name"":""*35""}},{""id"":1.449561262E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448569185"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448569185E9,""resource"":""Allele Function"",""term"":""Unknown or Uncertain function"",""termId"":""haplotypeTags:1448569185""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165947877"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165947877"",""symbol"":""SLCO1B1*36"",""name"":""*36""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA134865839"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134865839"",""symbol"":""SLCO1B1"",""name"":""solute carrier organic anion transporter family member 1B1""}}],""history"":[{""id"":1.183699778E9,""date"":""2012-05-23T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.184348497E9,""date"":""2014-05-12T00:00:00-07:00"",""description"":""added SLCO1B1 translation table"",""type"":""Update"",""version"":0.0},{""id"":1.184469595E9,""date"":""2014-06-17T00:00:00-07:00"",""type"":""Update"",""version"":0.0},{""id"":1.184472225E9,""date"":""2014-06-30T00:00:00-07:00"",""description"":""Updated translation table to version from 27 June 2014"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15077441"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5077441E7,""resourceId"":""24918167"",""title"":""The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169720"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC4169720"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449281448E9,""resource"":""PubMed Central"",""resourceId"":""PMC4169720"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169720""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/24918167"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449281447E9,""resource"":""PubMed"",""resourceId"":""24918167"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/24918167""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2014.125"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449281449E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2014.125"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2014.125""}]},{""@id"":""https://pharmgkb.org/literature/15013653"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5013653E7,""resourceId"":""22617227"",""title"":""The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384438"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3384438"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449267851E9,""resource"":""PubMed Central"",""resourceId"":""PMC3384438"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384438""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/22617227"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":9.78636635E8,""resource"":""PubMed"",""resourceId"":""22617227"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/22617227""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2012.57"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449267852E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2012.57"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2012.57""}]},{""@id"":""https://pharmgkb.org/literature/15100916"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100916E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"",""title"":""CPIC® Guideline for Simvastatin and SLCO1B1 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44798351E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451363"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451363"",""name"":""simvastatin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134865839"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134865839"",""symbol"":""SLCO1B1"",""name"":""solute carrier organic anion transporter family member 1B1""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447981966E9,""html"":""\u003cp\u003eThe FDA recommends against 80mg daily simvastatin dosage. In patients with the C allele at SLCO1B1 \u003ca href\u003d\""/variant/PA166154579\""\u003ers4149056\u003c/a\u003e, there are modest increases in myopathy risk even at lower simvastatin doses (40mg daily); if optimal efficacy is not achieved with a lower dose, alternate agents should be considered.\u003c/p\u003e\n""},""summaryVideoId"":""V4iRKeTOxjc"",""textMarkdown"":{""id"":1.447981965E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for simvastatin and SLCO1B1\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2014-update\""\u003eOctober 2014 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication 9 July 2014.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/simvastatin/2014/24918167.pdf\"" target\u003d\""_blank\""\u003e2014 update of CPIC guideline regarding SLCO1B1 and simvastatin-induced myopathy\u003c/a\u003e, has been published in Clinical Pharmacology and Therapeutics.  CPIC extensively reviewed the literature from February 2011 to December 2013 and concluded the dosing recommendations provided in the 2012 CPIC guideline for SLCO1B1 and simvastatin-induced myopathy have not changed. However, this updated guideline also provides a brief review regarding SLCO1B1 genotype and risk of myopathy for other statins.  Furthermore, comprehensive translation tables mapping SLCO1B1 genotypes to coded genotype/phenotype summaries, EHR priority result notation and interpretation (consultation) text were created to facilitate incorporation of SLCO1B1 pharmacogenetics into an electronic health record with clinical decision support.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThis guideline is applicable to:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExcerpt from the 2014 simvastatin dosing guideline:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026quot;For simvastatin, the evidence linking myopathy to \u003ca href\u003d\""/variant/PA166154579\""\u003ers4149056\u003c/a\u003e in SLCO1B1 is of high quality, and this association has been reproduced in randomized trials and clinical practice-based cohorts. Conversely, the association of \u003ca href\u003d\""/variant/PA166154579\""\u003ers4149056\u003c/a\u003e with myopathy has been less compelling for other statins. We therefore focus this guideline on simvastatin.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u0026quot;In 2011 and updated in 2013, the FDA added warnings to the simvastatin product label to direct providers away from initiating at the 80 mg simvastatin dose. \u0026quot;\u003c/p\u003e\n\u003cp\u003e\u0026quot;At lower simvastatin doses (e.g., 40 mg daily), it is our position that SLCO1B1 genotype (if available) could be used to warn providers about modest increases in myopathy risk for patients with a C allele at \u003ca href\u003d\""/variant/PA166154579\""\u003ers4149056\u003c/a\u003e. In these circumstances, we recommend a lower dose of simvastatin or use an alternative statin (e.g. pravastatin or rosuvastatin) and we also highlight the potential utility of routine CK surveillance (Table 2). If patients with a C allele at \u003ca href\u003d\""/variant/PA166154579\""\u003ers4149056\u003c/a\u003e do not achieve optimal LDL cholesterol-lowering efficacy with a lower dose (e.g. 20 mg) of simvastatin, we recommend the prescribing physician consider an alternate statin based on (i) potency differences (i.e., use a lower dose of a higher potency statin such as atorvastatin, rosuvastatin, or pitavastatin), (ii) drug-drug interactions (e.g., boceprevir, clarithromycin, cyclosporine, strong CYP3A4 inhibitors, etc.), and (iii) relevant co-morbidities (e.g., trauma, significant renal impairment, post-solid organ transplant, thyroid disease etc.).\u0026quot;\u003c/p\u003e\n\u003cp\u003e\u0026quot;At the time of this writing, there are no data available regarding SLCO1B1 genotype effects on simvastatin response or myopathy in pediatric patient populations, although there is no reason to suspect that the polymorphisms in SLCO1B1 will affect simvastatin\u0027s metabolism differently in children compared to adults.\u0026quot;\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/simvastatin/2014/24918167.pdf\"" target\u003d\""_blank\""\u003eThe Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/simvastatin/2014/24918167-supplement.pdf\"" target\u003d\""_blank\""\u003e2014 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""/page/slco1b1RefMaterials\""\u003eGene-specific Information Tables for SLCO1B1\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-simvastatin-based-on-slco1b1-phenotype\""\u003eTable 1: Recommended dosing of simvastatin based on SLCO1B1 phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Table 1 and 2 of the 2014 guideline update manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003c/th\u003e\u003cth\u003eExamples of diplotypes \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eGenotype at \u003ca href\u003d\""/variant/PA166154579\""\u003ers4149056\u003c/a\u003e\u003c/th\u003e\u003cth\u003eImplications for simvastatin\u003c/th\u003e\u003cth\u003eDosing recommendations for simvastatin \u003csup\u003eb,c\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations \u003csup\u003ed\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNormal function, Homozygous wild-type (two normal function alleles)\u003c/td\u003e\u003ctd\u003e*1a/*1a, *1a/*1b, *1b/*1b\u003c/td\u003e\u003ctd\u003eTT\u003c/td\u003e\u003ctd\u003eNormal myopathy risk\u003c/td\u003e\u003ctd\u003ePrescribe desired starting dose and adjust doses of simvastatin based on disease-specific guidelines.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate function, Heterozygous (one normal function allele plus one decreased function allele)\u003c/td\u003e\u003ctd\u003e*1a/*5, *1a/*15, *1a/*17, *1b/*5, *1b/*15, *1b/*17\u003c/td\u003e\u003ctd\u003eTC\u003c/td\u003e\u003ctd\u003eIntermediate myopathy risk\u003c/td\u003e\u003ctd\u003ePrescribe a lower dose or consider an alternative statin (e.g. pravastatin or rosuvastatin); consider routine CK surveillance.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eLow function, Homozygous variant or mutant (two decreased function alleles)\u003c/td\u003e\u003ctd\u003e*5/*5, *5/*15, *5/*17, *15/*15, *15/*17, *17/*17\u003c/td\u003e\u003ctd\u003eCC\u003c/td\u003e\u003ctd\u003eHigh myopathy risk\u003c/td\u003e\u003ctd\u003ePrescribe a lower dose or consider an alternative statin (e.g. pravastatin or rosuvastatin); consider routine CK surveillance.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eCK, creatine kinase.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e SLCO1B1 alleles are often named using \u003ca href\u003d\""http://www.pharmgkb.org/gene/PA134865839#tabview\u003dtab4\u0026amp;subtab\u003d33\""\u003estar allele nomenclature, representing various SNPs alone or in combination\u003c/a\u003e (2014 Update Supplemental Table S1) that are associated with low SLCO1B1 protein expression or function (2014 Update Supplemental Table S2). The minor C allele at \u003ca href\u003d\""/variant/PA166154579\""\u003ers4149056\u003c/a\u003e is contained within SLCO1B1*5 (\u003ca href\u003d\""/variant/PA166154579\""\u003ers4149056\u003c/a\u003e alone) as well as the *15 and *17 haplotypes and is associated with lower plasma clearance of simvastatin. The magnitude of this effect is similar for *5, *15, and *17 haplotypes.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e In all cases, the potential for drug-drug interaction should be evaluated prior to initiating a prescription.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e FDA recommends against 80mg (unless already tolerated 12 months).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e See Supplementary Materials (text section entitled \u0026quot;Levels of Evidence\u0026quot;) online for additional details regarding the three-tiered system used to grade the quality of evidence.\u003c/p\u003e\n\u003ch3 id\u003d\""july-2012\""\u003eJuly 2012\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication May 2012.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuideline regarding the use of pharmacogenomic tests in dosing for simvastatin was published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/simvastatin/2012/22617227.pdf\"" target\u003d\""_blank\""\u003eThe clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/simvastatin/2012/22617227-supplement.pdf\"" target\u003d\""_blank\""\u003e2012 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44798351E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/""}]},""status"":""success""}"
PA166182844,Guideline Annotation,Annotation of DPWG Guideline for simvastatin and SLCO1B1,t,PA451363,Dutch Pharmacogenetics Working Group,"<p>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for simvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>512 CC</td><td>simvastatin</td><td>The genetic polymorphism leads to reduced simvastatin transport to the liver. This increases simvastatin plasma concentrations and therefore the risk of myopathy.</td><td>1. Choose an alternative. Consider any additional risk factors for statin-induced myopathy. Rosuvastatin and pravastatin are influenced to a lesser extent by SLCO1B1 polymorphisms. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.</td></tr>
<tr><td>512 TC</td><td>simvastatin</td><td>The genetic polymorphism may lead to reduced simvastatin transport to the liver. This may increase simvastatin plasma concentrations and therefore the risk of myopathy.</td><td>1. Choose an alternative. Consider any additional risk factors for statin-induced myopathy. Rosuvastatin and pravastatin are influenced to a lesser extent by SLCO1B1 polymorphisms. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.<br/>2. If an alternative is not an option:<br/>1. Avoid simvastatin doses exceeding 40 mg/day<br/>2. Advise the patient to contact their doctor in the event of muscle symptoms.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0004056.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182844"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182844"",""name"":""Annotation of DPWG Guideline for simvastatin and SLCO1B1"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415247E9,""date"":""2019-05-27T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821034E9,""date"":""2019-10-07T18:33:59.696-07:00"",""description"":""No changes based on August 2019 guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450963902E9,""date"":""2020-02-11T07:53:52.150-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0},{""id"":1.450963883E9,""date"":""2020-02-11T07:54:48.614-08:00"",""description"":""Fixed table where said atorvastatin instead of simvastatin"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/variant/PA166154579"",""@context"":""https://api.pharmgkb.org/jsonld/variant.jsonld"",""objCls"":""Variant"",""id"":""PA166154579"",""symbol"":""rs4149056"",""name"":""rs4149056""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451363"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451363"",""name"":""simvastatin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134865839"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134865839"",""symbol"":""SLCO1B1"",""name"":""solute carrier organic anion transporter family member 1B1""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415244E9,""html"":""\u003cp\u003eChoose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415245E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for simvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e512 CC\u003c/td\u003e\u003ctd\u003esimvastatin\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to reduced simvastatin transport to the liver. This increases simvastatin plasma concentrations and therefore the risk of myopathy.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative. Consider any additional risk factors for statin-induced myopathy. Rosuvastatin and pravastatin are influenced to a lesser extent by SLCO1B1 polymorphisms. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e512 TC\u003c/td\u003e\u003ctd\u003esimvastatin\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism may lead to reduced simvastatin transport to the liver. This may increase simvastatin plasma concentrations and therefore the risk of myopathy.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative. Consider any additional risk factors for statin-induced myopathy. Rosuvastatin and pravastatin are influenced to a lesser extent by SLCO1B1 polymorphisms. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.\u003cbr/\u003e2. If an alternative is not an option:\u003cbr/\u003e1. Avoid simvastatin doses exceeding 40 mg/day\u003cbr/\u003e2. Advise the patient to contact their doctor in the event of muscle symptoms.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0004056.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182855,Guideline Annotation,Annotation of DPWG Guideline for sotalol and CYP2D6,f,PA451457,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for sotalol based on CYP2D6 genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for sotalol based on CYP2D6 genotype. They conclude that this is NOT a gene-drug interaction. <em>See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002540.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182855"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182855"",""name"":""Annotation of DPWG Guideline for sotalol and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415347E9,""date"":""2019-05-28T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820683E9,""date"":""2019-10-03T16:41:01.416-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450963903E9,""date"":""2020-02-11T07:56:44.541-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451457"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451457"",""name"":""sotalol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415342E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for sotalol based on CYP2D6 genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415343E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for sotalol based on CYP2D6 genotype. They conclude that this is NOT a gene-drug interaction. \u003cem\u003eSee the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002540.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166176068,Guideline Annotation,Annotation of CPIC Guideline for tamoxifen and CYP2D6,t,PA451581,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy.</p>
","<p>This annotation is based on the CPIC&reg; guideline for <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"" target=""_blank"">tamoxifen and CYP2D6</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table, Tamoxifen pre- and post-test alerts and flow chart (access tables below):</p>
<ul>
<li>Activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The current guideline has a specific recommendation for AS of 1 (no CYP2D6*10 allele present); thus, the current published recommendations for normal and intermediate metabolizer will remain unchanged.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The recommendations for ultrarapid and normal metabolizers are the same so this change does not impact the recommended prescribing recommendations. The recommendations for the activity score of 1 (with a CYP2D6*10 allele present) and 0.5 are the same so the current published recommendations for this diplotype will remain unchanged.</li>
</ul>
</li>
</ul>
<h3 id=""may-2018"">May 2018</h3>
<p><em>Accepted article preview online January 2018; Advance online publication January 2018</em></p>
<ul>
<li>The CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tamoxifen is accepted by <em>Clinical Pharmacology and Therapeutics</em>.</li>
<li>Excerpts from the 2018 dosing guideline:
<ul>
<li>&quot;There is substantial evidence linking CYP2D6 genotype with phenotypic variability in endoxifen concentrations. The evidence was considered uniformly strong that CYP2D6 PMs (AS=0) have lower plasma endoxifen concentrations among patients taking adjuvant tamoxifen compared to CYP2D6 NMs, and that reduced CYP2D6 activity (AS=0 to 1) is associated with lower plasma endoxifen concentrations among patients taking adjuvant tamoxifen compared to normal CYP2D6 activity.&quot;</li>
<li>&quot;Because of the extensive biological variability across the various clinical settings where tamoxifen is administered  (prevention, ductal carcinoma in situ, premenopausal and postmenopausal adjuvant setting, and metastatic), the current CPIC guidelines focuses only on the role of CYP2D6 genotype in the adjuvant treatment of ER+  breast cancer, using the endpoints of recurrence, recurrence-free survival, disease-free survival, distant relapse-free survival, breast cancer specific survival, and overall survival.&quot;</li>
<li>&quot;CYP2D6 UMs and NMs are expected to achieve therapeutic endoxifen concentrations after administration of tamoxifen and should receive the recommended standard of care doses of tamoxifen. CYP2D6 PMs and IMs (including patients with an activity score of 1.0, see below) are expected to have lower endoxifen concentrations compared to NMs and have a higher risk of breast cancer recurrence, and worse event-free survival compared to NMs.&quot;</li>
<li>&quot;For CYP2D6 PMs, a “strong” therapeutic recommendation was provided to recommend alternative hormonal therapy such as an aromatase inhibitor (AI) for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:<a href=""/pmid/26211827"">26211827</a>, <a href=""/pmid/24881463"">24881463</a>] and based on knowledge that CYP2D6 PMs patients who switch from tamoxifen to anastrozole do not exhibit an increased risk of recurrence [Article:<a href=""/pmid/23213055"">23213055</a>]. Given that escalation of tamoxifen dose from 20-40 mg/day in CYP2D6 PM significantly increases endoxifen concentrations (but not to concentrations achieved in CYP2D6 NMs [Article:<a href=""/pmid/27226358"">27226358</a>]), the use of an aromatase inhibitor (+/- ovarian function suppression) is recommended in this setting. Tamoxifen 40 mg/day can be considered for CYP2D6 PM if there are contraindications to AI use.</li>
<li>&quot;For CYP2D6 IMs and CYP2D6*10/*10 or CYP2D6*10/decreased function allele, a “moderate” recommendation was made to consider use of an alternative hormonal therapy (i.e. aromatase inhibitor) for postmenopausal women or aromatase inhibitor plus ovarian function suppression in premenopausal women is recommended. In CYP2D6 IMs, if aromatase inhibitors are contraindicated, consideration can be given for the use of a higher FDA-approved dose of tamoxifen (40 mg/day), which is known to result in significantly higher endoxifen concentrations without an increase in toxicity [Article:<a href=""/pmid/27226358"">27226358</a>]. Based on extrapolation from evidence in *10 individuals, a similar recommendation applies to individuals who carry other decreased function alleles resulting in an activity score of 1.0 but with an “optional” recommendation, given the paucity of data for this group.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/tamoxifen/2017/tamoxifen_reprint.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/tamoxifen/2017/tamoxifen_reprint_supplement.pdf"" target=""_blank"">2018 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">Gene-specific Information Tables for CYP2D6</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/tamoxifen/Tamoxifen_Drug_Resource_Mappings.xlsx"" target=""_blank"">Tamoxifen drug resource mapping</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/tamoxifen/Tamoxifen_Pre_and_Post_Test_Alerts_and_Flow.xlsx"" target=""_blank"">Tamoxifen pre- and post-test alerts and flow chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-tamoxifen-by-cyp2d6-genotype-phenotype"">Table 1: Recommended dosing of tamoxifen by CYP2D6 genotype/phenotype.</h3>
<p><em>Adapted from Tables 1 and 2 of the 2017 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype<sup>a</sup></th><th>Activity Score</th><th>Genotype</th><th>Examples of genotypes<sup>b</sup></th><th>Implications</th><th>Therapeutic recommendations<sup>c</sup></th><th>Classification of recommendations<sup>d</sup></th></tr>
</thead>
<tbody>
<tr><td><em>CYP2D6</em> Ultrarapid Metabolizer</td><td>&gt;2</td><td>An individual carrying duplications of functional alleles</td><td>*1/*1xN, *1/*2xN, *2/*2xN<sup>e</sup></td><td>Therapeutic endoxifen concentrations</td><td>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</td><td>Strong</td></tr>
<tr><td><em>CYP2D6</em> Normal metabolizer</td><td>1.5 and 2</td><td>An individual carrying two normal function alleles or one  normal function and one decreased function allele</td><td>*1/*1, *1/*2, *1/*9, *1/*41, *2/*2</td><td>Therapeutic endoxifen concentrations</td><td>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</td><td>Strong</td></tr>
<tr><td><em>CYP2D6</em> Normal metabolizer or Intermediate metabolizer (controversy remains)<sup>f</sup></td><td>1 (no *10 allele present)<sup>c</sup></td><td>An individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased tamoxifen metabolism to endoxifen compared to those with an AS of 1.5 or 2.</td><td>*1/*4, *1/*5, *41/*41</td><td>Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.</td><td>Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:<a href=""/pmid/26211827"">26211827</a>, <a href=""/pmid/24881463"">24881463</a>]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:<a href=""/pmid/27226358"">27226358</a>]. Avoid CYP2D6 strong to weak inhibitors.</td><td>Optional<sup>c</sup></td></tr>
<tr><td><em>CYP2D6</em> Normal metabolizer or Intermediate metabolizer (controversy remains)<sup>f</sup></td><td>1 (*10 allele present)<sup>c</sup></td><td>An individual carrying two decreased function alleles with the *10 allele present. An activity score (AS) of 1.0 is associated with decreased tamoxifen metabolism to endoxifen compared to those with an AS of 1.5 or 2.</td><td>*10/*10, *10/*41</td><td>Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.</td><td>Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:<a href=""/pmid/26211827"">26211827</a>, <a href=""/pmid/24881463"">24881463</a>]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:<a href=""/pmid/27226358"">27226358</a>]. Avoid CYP2D6 strong to weak inhibitors.</td><td>Moderate<sup>c</sup></td></tr>
<tr><td><em>CYP2D6</em> Intermediate metabolizer</td><td>0.5</td><td>An individual carrying one decreased function and one no function allele</td><td>*4/*10,*4/*41, *5/*9</td><td>Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.</td><td>Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:<a href=""/pmid/26211827"">26211827</a>, <a href=""/pmid/24881463"">24881463</a>]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:<a href=""/pmid/27226358"">27226358</a>]. Avoid CYP2D6 strong to weak inhibitors.</td><td>Moderate</td></tr>
<tr><td><em>CYP2D6</em> Poor metabolizer</td><td>0</td><td>An individual carrying only no functional alleles</td><td>*3/*4,*4/*4, *5/*5, *5/*6</td><td>Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.</td><td>Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:<a href=""/pmid/26211827"">26211827</a>, <a href=""/pmid/24881463"">24881463</a>] and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence [Article:<a href=""/pmid/23213055"">23213055</a>]. Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy [Articles:<a href=""/pmid/27226358"">27226358</a>, <a href=""/pmid/21768473"">21768473</a>].</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> See the <a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 frequency table</a> for race-specific allele and phenotype frequencies.<br />
<sup>b</sup> For a complete list of CYP2D6 diplotypes and resulting phenotypes, see the CYP2D6 genotype to phenotype table . Note that genotypes with an activity score of 1 are classified as NMs in the online CYP2D6 genotype to phenotype table.<br />
<sup>c</sup> CPIC has generally classified patients with an activity score of 1 as a “normal metabolizer”.  However, in the case of tamoxifen, prescribing recommendations for those with an AS of 1.0 are allele dependent, based on the presence of the *10 allele.  Those patients with an AS of 1.0 on the basis a *10 allele are provided a “moderate,” recommendation.  In contrast, prescribing recommendations for those with an activity score of 1 based on the presence of CYP2D6 alleles other than *10 are graded as “optional” because the recommendations are primarily extrapolated from evidence generated from *10 individuals (i.e. limited data for clinical outcomes and pharmacokinetics for this group).<br />
<sup>d</sup> Rating scheme described in Supplement.<br />
<sup>e</sup> Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.<br />
<sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.  A group of CYP2D6 experts are currently working to standardize the CYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly <a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 genotype to phenotype table</a>.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166176068"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166176068"",""name"":""Annotation of CPIC Guideline for tamoxifen and CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[{""id"":1.449561435E9,""alleles"":[{""id"":1.449561436E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449561437E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449561438E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449561439E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.44956144E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449561441E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449561442E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449561443E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449561444E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449561445E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449561446E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449561447E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449561448E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449561449E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.44956145E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449561451E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.449561452E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449561453E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449561454E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.449561457E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449561458E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449561459E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.44956146E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449561461E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449561462E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449561463E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449561464E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449561465E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449561466E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449561467E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449561468E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449561469E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.44956147E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449561471E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449561472E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449561473E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449561474E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449561475E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449561476E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449561477E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449561478E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449561479E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.44956148E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449561481E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449561482E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449561483E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449561484E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449561485E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449561486E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449561487E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449561488E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449561489E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.44956149E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449561491E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449561492E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449561493E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449561494E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449561495E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449561496E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449561497E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449561498E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449561499E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.4495615E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449561501E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449561502E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449561503E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449561504E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449561505E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449561506E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449561507E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.449561508E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449561509E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.44956151E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449561511E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449561512E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449561513E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449561514E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449561515E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449561516E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449561517E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449561518E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449561519E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.44956152E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449561521E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449561522E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449561523E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449561524E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449561525E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449561526E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449561527E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449561528E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449561529E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.44956153E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449561531E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449561532E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449561533E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449561534E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449561535E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449561536E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449561537E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449561538E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449561539E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.44956154E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449561541E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449561542E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449561543E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449561544E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449561545E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449561546E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449561547E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449561548E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449561549E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.44956155E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449561551E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449561552E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449561553E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.450042766E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042767E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824356E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.449161729E9,""date"":""2018-01-11T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.450042768E9,""date"":""2018-11-15T19:05:53.046-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.45082454E9,""date"":""2019-10-24T19:41:04.335-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15100237"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100237E7,""resourceId"":""29385237"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/29385237"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/29385237"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449291806E9,""resource"":""PubMed"",""resourceId"":""29385237"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/29385237""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1007"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449291807E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1007"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1007""}]},{""@id"":""https://pharmgkb.org/literature/15100920"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.510092E7,""resourceId"":""https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"",""title"":""CPIC® Guideline for Tamoxifen based on CYP2D6 genotype – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449161093E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"",""_url"":""https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451581"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451581"",""name"":""tamoxifen""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.44915762E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for tamoxifen recommends the use of alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women for CYP2D6 poor metabolizer, if aromatase inhibitor use is not contraindicated. For CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an activity score (AS) of 1 the recommendation is to consider the recommendations stated for the CYP2D6 poor metabolizer. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose for CYP2D6 intermediate metabolizers and CYP2D6 allele combinations resulting in an AS of 1. For poor metabolizer, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.449157623E9,""html"":""\u003cp\u003eThis annotation is based on the CPIC\u0026reg; guideline for \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/\"" target\u003d\""_blank\""\u003etamoxifen and CYP2D6\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table, Tamoxifen pre- and post-test alerts and flow chart (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eActivity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The current guideline has a specific recommendation for AS of 1 (no CYP2D6*10 allele present); thus, the current published recommendations for normal and intermediate metabolizer will remain unchanged.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The recommendations for ultrarapid and normal metabolizers are the same so this change does not impact the recommended prescribing recommendations. The recommendations for the activity score of 1 (with a CYP2D6*10 allele present) and 0.5 are the same so the current published recommendations for this diplotype will remain unchanged.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""may-2018\""\u003eMay 2018\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online January 2018; Advance online publication January 2018\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tamoxifen is accepted by \u003cem\u003eClinical Pharmacology and Therapeutics\u003c/em\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpts from the 2018 dosing guideline:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;There is substantial evidence linking CYP2D6 genotype with phenotypic variability in endoxifen concentrations. The evidence was considered uniformly strong that CYP2D6 PMs (AS\u003d0) have lower plasma endoxifen concentrations among patients taking adjuvant tamoxifen compared to CYP2D6 NMs, and that reduced CYP2D6 activity (AS\u003d0 to 1) is associated with lower plasma endoxifen concentrations among patients taking adjuvant tamoxifen compared to normal CYP2D6 activity.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Because of the extensive biological variability across the various clinical settings where tamoxifen is administered  (prevention, ductal carcinoma in situ, premenopausal and postmenopausal adjuvant setting, and metastatic), the current CPIC guidelines focuses only on the role of CYP2D6 genotype in the adjuvant treatment of ER+  breast cancer, using the endpoints of recurrence, recurrence-free survival, disease-free survival, distant relapse-free survival, breast cancer specific survival, and overall survival.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;CYP2D6 UMs and NMs are expected to achieve therapeutic endoxifen concentrations after administration of tamoxifen and should receive the recommended standard of care doses of tamoxifen. CYP2D6 PMs and IMs (including patients with an activity score of 1.0, see below) are expected to have lower endoxifen concentrations compared to NMs and have a higher risk of breast cancer recurrence, and worse event-free survival compared to NMs.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;For CYP2D6 PMs, a “strong” therapeutic recommendation was provided to recommend alternative hormonal therapy such as an aromatase inhibitor (AI) for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:\u003ca href\u003d\""/pmid/26211827\""\u003e26211827\u003c/a\u003e, \u003ca href\u003d\""/pmid/24881463\""\u003e24881463\u003c/a\u003e] and based on knowledge that CYP2D6 PMs patients who switch from tamoxifen to anastrozole do not exhibit an increased risk of recurrence [Article:\u003ca href\u003d\""/pmid/23213055\""\u003e23213055\u003c/a\u003e]. Given that escalation of tamoxifen dose from 20-40 mg/day in CYP2D6 PM significantly increases endoxifen concentrations (but not to concentrations achieved in CYP2D6 NMs [Article:\u003ca href\u003d\""/pmid/27226358\""\u003e27226358\u003c/a\u003e]), the use of an aromatase inhibitor (+/- ovarian function suppression) is recommended in this setting. Tamoxifen 40 mg/day can be considered for CYP2D6 PM if there are contraindications to AI use.\u003c/li\u003e\n\u003cli\u003e\u0026quot;For CYP2D6 IMs and CYP2D6*10/*10 or CYP2D6*10/decreased function allele, a “moderate” recommendation was made to consider use of an alternative hormonal therapy (i.e. aromatase inhibitor) for postmenopausal women or aromatase inhibitor plus ovarian function suppression in premenopausal women is recommended. In CYP2D6 IMs, if aromatase inhibitors are contraindicated, consideration can be given for the use of a higher FDA-approved dose of tamoxifen (40 mg/day), which is known to result in significantly higher endoxifen concentrations without an increase in toxicity [Article:\u003ca href\u003d\""/pmid/27226358\""\u003e27226358\u003c/a\u003e]. Based on extrapolation from evidence in *10 individuals, a similar recommendation applies to individuals who carry other decreased function alleles resulting in an activity score of 1.0 but with an “optional” recommendation, given the paucity of data for this group.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/tamoxifen/2017/tamoxifen_reprint.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/tamoxifen/2017/tamoxifen_reprint_supplement.pdf\"" target\u003d\""_blank\""\u003e2018 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eGene-specific Information Tables for CYP2D6\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/tamoxifen/Tamoxifen_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eTamoxifen drug resource mapping\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/tamoxifen/Tamoxifen_Pre_and_Post_Test_Alerts_and_Flow.xlsx\"" target\u003d\""_blank\""\u003eTamoxifen pre- and post-test alerts and flow chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-tamoxifen-by-cyp2d6-genotype-phenotype\""\u003eTable 1: Recommended dosing of tamoxifen by CYP2D6 genotype/phenotype.\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2017 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eActivity Score\u003c/th\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eExamples of genotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003csup\u003ed\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Ultrarapid Metabolizer\u003c/td\u003e\u003ctd\u003e\u0026gt;2\u003c/td\u003e\u003ctd\u003eAn individual carrying duplications of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN, *2/*2xN\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eTherapeutic endoxifen concentrations\u003c/td\u003e\u003ctd\u003eAvoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Normal metabolizer\u003c/td\u003e\u003ctd\u003e1.5 and 2\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or one  normal function and one decreased function allele\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *1/*9, *1/*41, *2/*2\u003c/td\u003e\u003ctd\u003eTherapeutic endoxifen concentrations\u003c/td\u003e\u003ctd\u003eAvoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Normal metabolizer or Intermediate metabolizer (controversy remains)\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1 (no *10 allele present)\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two decreased function alleles or one normal function and one no function allele. An activity score (AS) of 1.0 is associated with decreased tamoxifen metabolism to endoxifen compared to those with an AS of 1.5 or 2.\u003c/td\u003e\u003ctd\u003e*1/*4, *1/*5, *41/*41\u003c/td\u003e\u003ctd\u003eLower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eConsider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:\u003ca href\u003d\""/pmid/26211827\""\u003e26211827\u003c/a\u003e, \u003ca href\u003d\""/pmid/24881463\""\u003e24881463\u003c/a\u003e]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:\u003ca href\u003d\""/pmid/27226358\""\u003e27226358\u003c/a\u003e]. Avoid CYP2D6 strong to weak inhibitors.\u003c/td\u003e\u003ctd\u003eOptional\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Normal metabolizer or Intermediate metabolizer (controversy remains)\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1 (*10 allele present)\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two decreased function alleles with the *10 allele present. An activity score (AS) of 1.0 is associated with decreased tamoxifen metabolism to endoxifen compared to those with an AS of 1.5 or 2.\u003c/td\u003e\u003ctd\u003e*10/*10, *10/*41\u003c/td\u003e\u003ctd\u003eLower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eConsider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:\u003ca href\u003d\""/pmid/26211827\""\u003e26211827\u003c/a\u003e, \u003ca href\u003d\""/pmid/24881463\""\u003e24881463\u003c/a\u003e]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:\u003ca href\u003d\""/pmid/27226358\""\u003e27226358\u003c/a\u003e]. Avoid CYP2D6 strong to weak inhibitors.\u003c/td\u003e\u003ctd\u003eModerate\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Intermediate metabolizer\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased function and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*10,*4/*41, *5/*9\u003c/td\u003e\u003ctd\u003eLower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eConsider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:\u003ca href\u003d\""/pmid/26211827\""\u003e26211827\u003c/a\u003e, \u003ca href\u003d\""/pmid/24881463\""\u003e24881463\u003c/a\u003e]. If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day) [Article:\u003ca href\u003d\""/pmid/27226358\""\u003e27226358\u003c/a\u003e]. Avoid CYP2D6 strong to weak inhibitors.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2D6\u003c/em\u003e Poor metabolizer\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no functional alleles\u003c/td\u003e\u003ctd\u003e*3/*4,*4/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eLower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eRecommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype [Articles:\u003ca href\u003d\""/pmid/26211827\""\u003e26211827\u003c/a\u003e, \u003ca href\u003d\""/pmid/24881463\""\u003e24881463\u003c/a\u003e] and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence [Article:\u003ca href\u003d\""/pmid/23213055\""\u003e23213055\u003c/a\u003e]. Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy [Articles:\u003ca href\u003d\""/pmid/27226358\""\u003e27226358\u003c/a\u003e, \u003ca href\u003d\""/pmid/21768473\""\u003e21768473\u003c/a\u003e].\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e See the \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 frequency table\u003c/a\u003e for race-specific allele and phenotype frequencies.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e For a complete list of CYP2D6 diplotypes and resulting phenotypes, see the CYP2D6 genotype to phenotype table . Note that genotypes with an activity score of 1 are classified as NMs in the online CYP2D6 genotype to phenotype table.\u003cbr /\u003e\n\u003csup\u003ec\u003c/sup\u003e CPIC has generally classified patients with an activity score of 1 as a “normal metabolizer”.  However, in the case of tamoxifen, prescribing recommendations for those with an AS of 1.0 are allele dependent, based on the presence of the *10 allele.  Those patients with an AS of 1.0 on the basis a *10 allele are provided a “moderate,” recommendation.  In contrast, prescribing recommendations for those with an activity score of 1 based on the presence of CYP2D6 alleles other than *10 are graded as “optional” because the recommendations are primarily extrapolated from evidence generated from *10 individuals (i.e. limited data for clinical outcomes and pharmacokinetics for this group).\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003e Rating scheme described in Supplement.\u003cbr /\u003e\n\u003csup\u003ee\u003c/sup\u003e Where xN represents the number of CYP2D6 gene copies. For individuals with CYP2D6 duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.\u003cbr /\u003e\n\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.  A group of CYP2D6 experts are currently working to standardize the CYP2D6 genotype to phenotype translation system. CPIC will update the CPIC website accordingly \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 genotype to phenotype table\u003c/a\u003e.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449161093E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"",""_url"":""https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/""}]},""status"":""success""}"
PA166181721,Guideline Annotation,Annotation of CPNDS Guideline for tamoxifen and CYP2D6,t,PA451581,Canadian Pharmacogenomics Network for Drug Safety,"<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for <em>CYP2D6</em> as a treatment decision aid for ER-positive non-metastatic breast cancer patients. The guidelines recommend that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers with an emphasis on the use of comprehensive CYP2D6 genotyping panels in guiding treatment decisions.</p>
","<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for <em>CYP2D6</em> as a treatment decision aid for ER-positive non-metastatic breast cancer patients in the journal <em>Breast Cancer Research and Treatment</em>.
Excerpts from &quot;<em>CYP2D6</em> as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines&quot; [Article:<a href=""/pmid/30411242"">30411242</a>] follow:</p>
<p>Literature review</p>
<ul>
<li>Evidence was only evaluated regarding the treatment of ER-positive breast cancer with tamoxifen, the recommendations do not apply to ER-negative or triple-negative breast cancer.</li>
<li>48 articles were identified for inclusion and systematically evaluated.</li>
<li>Examination of confounding factors based on 38 studies showed that comprehensive genotyping panels being more likely to report a significant association with CYP2D6-survival outcome (P = 0.006).</li>
<li>Majority of evidence points toward the influence that <em>CYP2D6</em> genetic variation exerts on survival outcomes after treatment with tamoxifen.</li>
</ul>
<p>Guidance</p>
<p><strong>Which patients should be tested for <em>CYP2D6</em>?</strong></p>
<ul>
<li>Genetic testing for <em>CYP2D6</em> is RECOMMENDED prior to initiation of adjuvant tamoxifen treatment (Grade B— Moderate) for postmenopausal women with non-metastatic ER-positive breast cancer in whom tamoxifen is being considered as a therapeutic alternative to aromatase inhibitors (AIs).
<ul>
<li>In cases where initial tamoxifen treatment is being considered, <em>CYP2D6</em> genotyping should be performed and individuals who are CYP2D6 poor/intermediate metabolizers should opt for 5 years of AI treatment.</li>
</ul>
</li>
<li>Genetic testing for <em>CYP2D6</em> is RECOMMENDED prior to initiation of adjuvant treatment in higher-risk breast cancer patients (Grade B—moderate) for premenopausal women with non-metastatic ER-positive breast cancer.
<ul>
<li>Without ovarian suppression, aromatase inhibitors (AIs) are not a viable therapeutic alternative in premenopausal women. In such patients, if tamoxifen is the only therapeutic option, <em>CYP2D6</em> genotyping prior to initiation of treatment may inform dosing decisions.</li>
</ul>
</li>
</ul>
<p>Table 1 - Treatment guidelines for non-metastatic ER-positive breast cancer patients based on CYP2D6 activity scores from the publication “<em>CYP2D6</em> as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines&quot; [Article:<a href=""/pmid/30411242"">30411242</a>]</p>
<table class=""table"">
<thead>
<tr><th>CYP2D6 metabolizer status</th><th>Therapeutic recommendation - AIs are viable treatment option</th><th>Therapeutic recommendation - AIs are contraindicated</th><th>Strength of recommendation</th></tr>
</thead>
<tbody>
<tr><td>Poor Metabolizer (AS = 0.0)</td><td>AI (with ovarian suppressor in premenopausal women)</td><td>Tamoxifen (40 mg/day) <sup>a,b</sup></td><td>Grade B—moderate</td></tr>
<tr><td>Intermediate Metabolizer (AS = 0.5–1.0)</td><td>AI (with ovarian suppressor in premenopausal women)</td><td>Tamoxifen (40 mg/day) <sup>b</sup></td><td>Grade B—moderate</td></tr>
<tr><td>Normal/Ultrarapid Metabolizer (AS = 1.5) <sup>c</sup></td><td>AI (with ovarian suppressor in premenopausal women) or tamoxifen (20 mg/day) <sup>b</sup></td><td>Tamoxifen (20 mg/day) <sup>b</sup></td><td>Grade B—moderate</td></tr>
</tbody>
</table>
<p>AI- aromatase inhibitor, AS activity score</p>
<p><sup>a</sup> Studies have shown that in individuals with AS=0.0, although a dosage change increases endoxifen levels, these levels do not completely normalize. Therefore, AIs may be a preferred treatment in these individuals<br />
<sup>b</sup> In individuals receiving tamoxifen, moderate or strong CYP2D6 inhibitors (refer to the Flockhart P450 Drug Interaction Table for classification of CYP2D6 inhibitors) should be avoided<br />
<sup>c</sup> Evidence is currently limited regarding whether individuals with an AS=1.0 should be considered intermediate metabolizers. Therefore, dosing decisions for these individuals may be made in accordance with NM/IM dosing guidelines</p>
<p><strong>Which genetic variants should be tested for <em>CYP2D6</em>?</strong></p>
<ul>
<li>Testing of all common genetic variants is RECOMMENDED (Grade A—strong)
<ul>
<li>Due to the large number of genetic variants observed in <em>CYP2D6</em>, exhaustive genotyping panels including both common and rare variants are preferred. However, where this is not feasible, patients should preferably be genotyped for variants affecting the function of CYP2D6 occurring at a frequency of &gt; 1% in major ethnic groups. See supplemental material for variants.</li>
</ul>
</li>
</ul>
<p><strong>Which biological samples are recommended for genotyping?</strong></p>
<ul>
<li>The use of DNA that is derived from a source other than tumor or FFPE samples is RECOMMENDED (Grade A— strong)</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166181721"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166181721"",""name"":""Annotation of CPNDS Guideline for tamoxifen and CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.450361953E9,""date"":""2019-01-28T14:27:26.413-08:00"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15101667"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5101667E7,""resourceId"":""30411242"",""title"":""CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/30411242"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/30411242"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450361941E9,""resource"":""PubMed"",""resourceId"":""30411242"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/30411242""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1007/s10549-018-5027-0"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450361942E9,""resource"":""DOI"",""resourceId"":""10.1007/s10549-018-5027-0"",""_url"":""http://dx.doi.org/10.1007%2Fs10549-018-5027-0""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451581"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451581"",""name"":""tamoxifen""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Canadian Pharmacogenomics Network for Drug Safety"",""summaryMarkdown"":{""id"":1.450361939E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for \u003cem\u003eCYP2D6\u003c/em\u003e as a treatment decision aid for ER-positive non-metastatic breast cancer patients. The guidelines recommend that alternatives to standard tamoxifen treatments may be considered in CYP2D6 poor or intermediate metabolizers with an emphasis on the use of comprehensive CYP2D6 genotyping panels in guiding treatment decisions.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.45036194E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published clinical practice guidelines for \u003cem\u003eCYP2D6\u003c/em\u003e as a treatment decision aid for ER-positive non-metastatic breast cancer patients in the journal \u003cem\u003eBreast Cancer Research and Treatment\u003c/em\u003e.\nExcerpts from \u0026quot;\u003cem\u003eCYP2D6\u003c/em\u003e as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines\u0026quot; [Article:\u003ca href\u003d\""/pmid/30411242\""\u003e30411242\u003c/a\u003e] follow:\u003c/p\u003e\n\u003cp\u003eLiterature review\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eEvidence was only evaluated regarding the treatment of ER-positive breast cancer with tamoxifen, the recommendations do not apply to ER-negative or triple-negative breast cancer.\u003c/li\u003e\n\u003cli\u003e48 articles were identified for inclusion and systematically evaluated.\u003c/li\u003e\n\u003cli\u003eExamination of confounding factors based on 38 studies showed that comprehensive genotyping panels being more likely to report a significant association with CYP2D6-survival outcome (P \u003d 0.006).\u003c/li\u003e\n\u003cli\u003eMajority of evidence points toward the influence that \u003cem\u003eCYP2D6\u003c/em\u003e genetic variation exerts on survival outcomes after treatment with tamoxifen.\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eGuidance\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhich patients should be tested for \u003cem\u003eCYP2D6\u003c/em\u003e?\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGenetic testing for \u003cem\u003eCYP2D6\u003c/em\u003e is RECOMMENDED prior to initiation of adjuvant tamoxifen treatment (Grade B— Moderate) for postmenopausal women with non-metastatic ER-positive breast cancer in whom tamoxifen is being considered as a therapeutic alternative to aromatase inhibitors (AIs).\n\u003cul\u003e\n\u003cli\u003eIn cases where initial tamoxifen treatment is being considered, \u003cem\u003eCYP2D6\u003c/em\u003e genotyping should be performed and individuals who are CYP2D6 poor/intermediate metabolizers should opt for 5 years of AI treatment.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eGenetic testing for \u003cem\u003eCYP2D6\u003c/em\u003e is RECOMMENDED prior to initiation of adjuvant treatment in higher-risk breast cancer patients (Grade B—moderate) for premenopausal women with non-metastatic ER-positive breast cancer.\n\u003cul\u003e\n\u003cli\u003eWithout ovarian suppression, aromatase inhibitors (AIs) are not a viable therapeutic alternative in premenopausal women. In such patients, if tamoxifen is the only therapeutic option, \u003cem\u003eCYP2D6\u003c/em\u003e genotyping prior to initiation of treatment may inform dosing decisions.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eTable 1 - Treatment guidelines for non-metastatic ER-positive breast cancer patients based on CYP2D6 activity scores from the publication “\u003cem\u003eCYP2D6\u003c/em\u003e as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines\u0026quot; [Article:\u003ca href\u003d\""/pmid/30411242\""\u003e30411242\u003c/a\u003e]\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eCYP2D6 metabolizer status\u003c/th\u003e\u003cth\u003eTherapeutic recommendation - AIs are viable treatment option\u003c/th\u003e\u003cth\u003eTherapeutic recommendation - AIs are contraindicated\u003c/th\u003e\u003cth\u003eStrength of recommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePoor Metabolizer (AS \u003d 0.0)\u003c/td\u003e\u003ctd\u003eAI (with ovarian suppressor in premenopausal women)\u003c/td\u003e\u003ctd\u003eTamoxifen (40 mg/day) \u003csup\u003ea,b\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eGrade B—moderate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate Metabolizer (AS \u003d 0.5–1.0)\u003c/td\u003e\u003ctd\u003eAI (with ovarian suppressor in premenopausal women)\u003c/td\u003e\u003ctd\u003eTamoxifen (40 mg/day) \u003csup\u003eb\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eGrade B—moderate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNormal/Ultrarapid Metabolizer (AS \u003d 1.5) \u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAI (with ovarian suppressor in premenopausal women) or tamoxifen (20 mg/day) \u003csup\u003eb\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eTamoxifen (20 mg/day) \u003csup\u003eb\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eGrade B—moderate\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAI- aromatase inhibitor, AS activity score\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Studies have shown that in individuals with AS\u003d0.0, although a dosage change increases endoxifen levels, these levels do not completely normalize. Therefore, AIs may be a preferred treatment in these individuals\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e In individuals receiving tamoxifen, moderate or strong CYP2D6 inhibitors (refer to the Flockhart P450 Drug Interaction Table for classification of CYP2D6 inhibitors) should be avoided\u003cbr /\u003e\n\u003csup\u003ec\u003c/sup\u003e Evidence is currently limited regarding whether individuals with an AS\u003d1.0 should be considered intermediate metabolizers. Therefore, dosing decisions for these individuals may be made in accordance with NM/IM dosing guidelines\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhich genetic variants should be tested for \u003cem\u003eCYP2D6\u003c/em\u003e?\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eTesting of all common genetic variants is RECOMMENDED (Grade A—strong)\n\u003cul\u003e\n\u003cli\u003eDue to the large number of genetic variants observed in \u003cem\u003eCYP2D6\u003c/em\u003e, exhaustive genotyping panels including both common and rare variants are preferred. However, where this is not feasible, patients should preferably be genotyped for variants affecting the function of CYP2D6 occurring at a frequency of \u0026gt; 1% in major ethnic groups. See supplemental material for variants.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eWhich biological samples are recommended for genotyping?\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe use of DNA that is derived from a source other than tumor or FFPE samples is RECOMMENDED (Grade A— strong)\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104966,Guideline Annotation,Annotation of DPWG Guideline for tamoxifen and CYP2D6,t,PA451581,Dutch Pharmacogenetics Working Group,"<p>For CYP2D6 poor and intermediate metabolizers, consider an alternative medication or a dose increase. For intermediate metabolizers, avoid concomitant CYP2D6 inhibitor use.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tamoxifen based on CYP2D6 genotype. They recommend that alternative medication be considered for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs). Alternatively, a dose increase can be consider for these patients. Concomitant use of CYP2D6 inhibitors should be avoided in CYP2D6 IMs.</p>
<p>There are no recommendations for CYP2D6 ultrarapid metabolizers (UMs).</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>tamoxifen</td><td>As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects.</td><td>NO action is needed for this gene-drug interaction.</td></tr>
<tr><td>CYP2D6 IM</td><td>tamoxifen</td><td>This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness.</td><td>1. Select an alternative or measure the endoxifen concentration and increase the dose if necessary by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.<br/>2. If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine</td></tr>
<tr><td>CYP2D6 PM</td><td>tamoxifen</td><td>This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness.</td><td>Select an alternative or increase the dose to 40 mg/day and monitor the endoxifen concentration. Studies have demonstrated that PM can achieve an adequate endoxifen concentration when the dose is increased to 40-60 mg/day. Aromatase inhibitors are a possible alternative for post-menopausal women.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001602.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tamoxifen based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  For PM and IM genotypes, they recommend considering using aromatase inhibitors for postmenopausal women due to increased risk for relapse of breast cancer with tamoxifen.  For IM genotypes, they recommend avoiding concomitant CYP2D6 inhibitor use.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Increased risk for relapse of breast cancer. Consider aromatase inhibitor for postmenopausal women.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x10<sup>9</sup>/l; leucopenia &lt; 1.0x10<sup>9</sup>/l; thrombocytopenia &lt; 25x10<sup>9</sup>/l; life-threatening complications from diarrhea.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Increased risk for relapse of breast cancer. Avoid concomitant use of CYP2D6 inhibitors. Consider aromatase inhibitor for postmenopausal women.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia &lt; 0.5x10<sup>9</sup>/l; leucopenia &lt; 1.0x10<sup>9</sup>/l; thrombocytopenia &lt; 25x10<sup>9</sup>/l; life-threatening complications from diarrhea.</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>No.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5.  Kinetic effect (S).</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104966"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104966"",""name"":""Annotation of DPWG Guideline for tamoxifen and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704533E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.183704535E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415034E9,""date"":""2019-05-23T14:42:13.468-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820681E9,""date"":""2019-10-03T16:35:35.267-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450956421E9,""date"":""2020-01-31T14:19:18.737-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963905E9,""date"":""2020-02-11T08:00:08.753-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451581"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451581"",""name"":""tamoxifen""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.44798192E9,""html"":""\u003cp\u003eFor CYP2D6 poor and intermediate metabolizers, consider an alternative medication or a dose increase. For intermediate metabolizers, avoid concomitant CYP2D6 inhibitor use.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981919E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tamoxifen based on CYP2D6 genotype. They recommend that alternative medication be considered for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs). Alternatively, a dose increase can be consider for these patients. Concomitant use of CYP2D6 inhibitors should be avoided in CYP2D6 IMs.\u003c/p\u003e\n\u003cp\u003eThere are no recommendations for CYP2D6 ultrarapid metabolizers (UMs).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003etamoxifen\u003c/td\u003e\u003ctd\u003eAs a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003etamoxifen\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness.\u003c/td\u003e\u003ctd\u003e1. Select an alternative or measure the endoxifen concentration and increase the dose if necessary by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.\u003cbr/\u003e2. If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003etamoxifen\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness.\u003c/td\u003e\u003ctd\u003eSelect an alternative or increase the dose to 40 mg/day and monitor the endoxifen concentration. Studies have demonstrated that PM can achieve an adequate endoxifen concentration when the dose is increased to 40-60 mg/day. Aromatase inhibitors are a possible alternative for post-menopausal women.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001602.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tamoxifen based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For PM and IM genotypes, they recommend considering using aromatase inhibitors for postmenopausal women due to increased risk for relapse of breast cancer with tamoxifen.  For IM genotypes, they recommend avoiding concomitant CYP2D6 inhibitor use.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eIncreased risk for relapse of breast cancer. Consider aromatase inhibitor for postmenopausal women.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia \u0026lt; 0.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026lt; 1.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia \u0026lt; 25x10\u003csup\u003e9\u003c/sup\u003e/l; life-threatening complications from diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eIncreased risk for relapse of breast cancer. Avoid concomitant use of CYP2D6 inhibitors. Consider aromatase inhibitor for postmenopausal women.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): Failure of lifesaving therapy e.g. anticipated myelosuppression; prevention of breast cancer relapse; arrhythmia; neutropenia \u0026lt; 0.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026lt; 1.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia \u0026lt; 25x10\u003csup\u003e9\u003c/sup\u003e/l; life-threatening complications from diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eNo.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5.  Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166122687,Guideline Annotation,Annotation of CPIC Guideline for tegafur and DPYD,f,PA452620,Clinical Pharmacogenetics Implementation Consortium,"<p><strong>As of the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729.pdf"" target=""_blank"">November 2017 update</a> of CPIC guidelines regarding fluoropyrimidine dosing, there are no longer dosing recommendations for tegafur based on <em>DPYD</em>  genotype. This is due to limited evidence regarding the impact of <em>DPYD</em> variants on tegafur toxicity risk. The guidelines currently only apply to 5-fluorouracil and capecitabine dosing.</strong></p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"" target=""_blank"">CPIC&reg; guideline for fluoropyrimidines and DPYD</a>.</p>
<h3 id=""november-2017-update-on-pharmgkb"">November 2017 Update on PharmGKB</h3>
<p><em>Advance online publication November 2017</em></p>
<ul>
<li>The 2017 update of CPIC guidelines regarding 5-fluorouracil and capecitabine has been accepted for publication in Clinical Pharmacology and Therapeutics.  Literature up to March 2017 was reviewed, and recommendations and supplemental information were updated. <strong>In particular, the dosing recommendations were modified to only apply to 5-fluorouracil and capecitabine; they no longer apply to tegafur. This is due to limited evidence regarding the impact of <em>DPYD</em> variants on tegafur toxicity risk.</strong></li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729-supplement.pdf"" target=""_blank"">2017 supplement</a></li>
</ul>
</li>
</ul>
<h3 id=""may-2014-update-on-pharmgkb"">May 2014 Update on PharmGKB</h3>
<ul>
<li>The CPIC authors recommend that the <em>DPYD*4</em>, <em>*5</em>, <em>*6</em> and <em>*9A</em> alleles be categorized as &quot;normal&quot; activity, in part based upon the recent publication <a rel=""noopener noreferrer"" href=""http://www.ncbi.nlm.nih.gov/pubmed/?term=24648345"" target=""_blank"">Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity</a>.</li>
</ul>
<h3 id=""december-2013-publication"">December 2013 Publication</h3>
<p><em>Accepted article preview online August 2013; Advance online publication October 2013.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in <em>Clinical Pharmacology and Therapeutics</em> by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">(CPIC)</a>.</li>
<li>These guidelines are applicable to:
<ul>
<li>at the time of this writing, there are no data available on the possible role of DPYD*2A, *13, or <a href=""/variant/PA166153895"">rs67376798</a> in 5-fluorouracil toxicities in pediatric patient populations; however, there is no reason to suspect that DPYD variant alleles would affect 5-fluorouracil metabolism differently in children compared to adults.</li>
</ul>
</li>
<li>Excerpt from the fluoropyrimidine dosing guideline based on DPYD genotype:
<ul>
<li>&quot;The strength of the dosing recommendations is based on the fact that some variants (DPYD*2A, *13, and <a href=""/variant/PA166153895"">rs67376798</a>) clearly affect DPD activity, and DPD activity is clearly related to 5-fluorouracil clearance, and 5-fluorouracil exposure is associated with its toxic effects. Therefore, reduction of fluoropyrimidine dosage in patients with these variants may prevent severe and possibly life-threatening toxicities. However, available evidence does not clearly indicate a degree of dose reduction needed to prevent fluoropyrimidine related toxicities...[Based on literature review (see full manuscript),] our recommendation is to start with at least a 50% reduction of the starting dose followed by an increase in dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy, a decrease in dose in patients who do not tolerate the starting dose to minimize toxicities or pharmacokinetic guided dose adjustments (if available). Patients who are homozygous for DPYD*2A, *13, or <a href=""/variant/PA166153895"">rs67376798</a> may demonstrate complete DPD deficiency and the use of 5-fluorouracil or capecitabine is not recommended in these patients.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf"" target=""_blank"">2013 supplement</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-fluoropyrimidines-by-genotype-phenotype"">Table 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.</h3>
<p><em>Adapted from Tables 1 and 2 of the 2013 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype (genotype)</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Dosing recommendations</th><th>Classification of recommendations <sup>a</sup></th></tr>
</thead>
<tbody>
<tr><td>Homozygous wild-type or normal, high DPD activity (two or more functional *1 alleles)</td><td>*1/*1</td><td>Normal DPD activity and &quot;normal&quot; risk for fluoropyrimidine toxicity</td><td>Use label-recommended dosage and administration</td><td>Moderate</td></tr>
<tr><td>Heterozygous or intermediate activity (~3-5% of patients), may have partial DPD deficiency, at risk for toxicity with drug exposure (one functional allele *1, plus one nonfunctional allele - *2A, *13 or rs67376798A <sup>c</sup>)</td><td>*1/*2A; *1/*13; *1/ rs67376798A <sup>c</sup>)</td><td>Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Start with at least a 50% reduction in starting dose followed by titration of dose based on toxicity <sup>b</sup> or pharmacokinetic test (if available)</td><td>Moderate</td></tr>
<tr><td>Homozygous variant, DPD deficiency (~0.2% of patients), at risk for toxicity with drug exposure (2 nonfunctional alleles - *2A, *13 or rs67376798A <sup>c</sup>)</td><td>*2A/*2A; *13/*13; rs67376798A <sup>c</sup> / rs67376798A <sup>c</sup></td><td>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Select alternate drug</td><td>Strong</td></tr>
</tbody>
</table>
<p><sup>a</sup> Rating scheme described in 2013 supplement.</p>
<p><sup>b</sup> Increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.</p>
<p><sup>c</sup> Note that the rs67376798A allele refers to the allele on the positive chromosomal strand.  This is important because DPYD is on the minus chromosomal strand and <a href=""/variant/PA166153895"">rs67376798</a> is a T/A snp.  Therefore, the T allele on the gene confers the deficiency, while the complement on the positive chromosomal strand (A allele) is indicative of deficiency.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166122687"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166122687"",""name"":""Annotation of CPIC Guideline for tegafur and DPYD"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.184511813E9,""date"":""2014-07-30T00:00:00-07:00"",""type"":""Update"",""version"":0.0},{""id"":1.448604798E9,""date"":""2017-03-16T17:31:25.756-07:00"",""description"":""Updated extended dosing guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.449140377E9,""date"":""2017-11-13T00:00:00-08:00"",""description"":""October 2017 guideline update"",""type"":""Update"",""version"":1.0},{""id"":1.449165692E9,""date"":""2018-02-02T12:02:50.660-08:00"",""description"":""Changed CPIC level from A to C due to new guidelines"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15062135"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5062135E7,""resourceId"":""23988873"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831181"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3831181"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449277398E9,""resource"":""PubMed Central"",""resourceId"":""PMC3831181"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831181""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23988873"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449277397E9,""resource"":""PubMed"",""resourceId"":""23988873"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23988873""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.172"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449277399E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.172"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.172""}]},{""@id"":""https://pharmgkb.org/literature/15100909"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100909E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""title"":""CPIC® Guideline for Fluoropyrimidines and DPYD – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983463E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA452620"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA452620"",""name"":""tegafur""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA145"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA145"",""symbol"":""DPYD"",""name"":""dihydropyrimidine dehydrogenase""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447982075E9,""html"":""\u003cp\u003e\u003cstrong\u003eAs of the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729.pdf\"" target\u003d\""_blank\""\u003eNovember 2017 update\u003c/a\u003e of CPIC guidelines regarding fluoropyrimidine dosing, there are no longer dosing recommendations for tegafur based on \u003cem\u003eDPYD\u003c/em\u003e  genotype. This is due to limited evidence regarding the impact of \u003cem\u003eDPYD\u003c/em\u003e variants on tegafur toxicity risk. The guidelines currently only apply to 5-fluorouracil and capecitabine dosing.\u003c/strong\u003e\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447982074E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for fluoropyrimidines and DPYD\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""november-2017-update-on-pharmgkb\""\u003eNovember 2017 Update on PharmGKB\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication November 2017\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2017 update of CPIC guidelines regarding 5-fluorouracil and capecitabine has been accepted for publication in Clinical Pharmacology and Therapeutics.  Literature up to March 2017 was reviewed, and recommendations and supplemental information were updated. \u003cstrong\u003eIn particular, the dosing recommendations were modified to only apply to 5-fluorouracil and capecitabine; they no longer apply to tegafur. This is due to limited evidence regarding the impact of \u003cem\u003eDPYD\u003c/em\u003e variants on tegafur toxicity risk.\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2017/29152729-supplement.pdf\"" target\u003d\""_blank\""\u003e2017 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""may-2014-update-on-pharmgkb\""\u003eMay 2014 Update on PharmGKB\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eThe CPIC authors recommend that the \u003cem\u003eDPYD*4\u003c/em\u003e, \u003cem\u003e*5\u003c/em\u003e, \u003cem\u003e*6\u003c/em\u003e and \u003cem\u003e*9A\u003c/em\u003e alleles be categorized as \u0026quot;normal\u0026quot; activity, in part based upon the recent publication \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.ncbi.nlm.nih.gov/pubmed/?term\u003d24648345\"" target\u003d\""_blank\""\u003eComparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity\u003c/a\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2013-publication\""\u003eDecember 2013 Publication\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAccepted article preview online August 2013; Advance online publication October 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in \u003cem\u003eClinical Pharmacology and Therapeutics\u003c/em\u003e by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003eat the time of this writing, there are no data available on the possible role of DPYD*2A, *13, or \u003ca href\u003d\""/variant/PA166153895\""\u003ers67376798\u003c/a\u003e in 5-fluorouracil toxicities in pediatric patient populations; however, there is no reason to suspect that DPYD variant alleles would affect 5-fluorouracil metabolism differently in children compared to adults.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eExcerpt from the fluoropyrimidine dosing guideline based on DPYD genotype:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;The strength of the dosing recommendations is based on the fact that some variants (DPYD*2A, *13, and \u003ca href\u003d\""/variant/PA166153895\""\u003ers67376798\u003c/a\u003e) clearly affect DPD activity, and DPD activity is clearly related to 5-fluorouracil clearance, and 5-fluorouracil exposure is associated with its toxic effects. Therefore, reduction of fluoropyrimidine dosage in patients with these variants may prevent severe and possibly life-threatening toxicities. However, available evidence does not clearly indicate a degree of dose reduction needed to prevent fluoropyrimidine related toxicities...[Based on literature review (see full manuscript),] our recommendation is to start with at least a 50% reduction of the starting dose followed by an increase in dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy, a decrease in dose in patients who do not tolerate the starting dose to minimize toxicities or pharmacokinetic guided dose adjustments (if available). Patients who are homozygous for DPYD*2A, *13, or \u003ca href\u003d\""/variant/PA166153895\""\u003ers67376798\u003c/a\u003e may demonstrate complete DPD deficiency and the use of 5-fluorouracil or capecitabine is not recommended in these patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf\"" target\u003d\""_blank\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-fluoropyrimidines-by-genotype-phenotype\""\u003eTable 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2013 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (genotype)\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications for phenotypic measures\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations \u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eHomozygous wild-type or normal, high DPD activity (two or more functional *1 alleles)\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal DPD activity and \u0026quot;normal\u0026quot; risk for fluoropyrimidine toxicity\u003c/td\u003e\u003ctd\u003eUse label-recommended dosage and administration\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eHeterozygous or intermediate activity (~3-5% of patients), may have partial DPD deficiency, at risk for toxicity with drug exposure (one functional allele *1, plus one nonfunctional allele - *2A, *13 or rs67376798A \u003csup\u003ec\u003c/sup\u003e)\u003c/td\u003e\u003ctd\u003e*1/*2A; *1/*13; *1/ rs67376798A \u003csup\u003ec\u003c/sup\u003e)\u003c/td\u003e\u003ctd\u003eDecreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs\u003c/td\u003e\u003ctd\u003eStart with at least a 50% reduction in starting dose followed by titration of dose based on toxicity \u003csup\u003eb\u003c/sup\u003e or pharmacokinetic test (if available)\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eHomozygous variant, DPD deficiency (~0.2% of patients), at risk for toxicity with drug exposure (2 nonfunctional alleles - *2A, *13 or rs67376798A \u003csup\u003ec\u003c/sup\u003e)\u003c/td\u003e\u003ctd\u003e*2A/*2A; *13/*13; rs67376798A \u003csup\u003ec\u003c/sup\u003e / rs67376798A \u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eComplete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs\u003c/td\u003e\u003ctd\u003eSelect alternate drug\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Rating scheme described in 2013 supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Note that the rs67376798A allele refers to the allele on the positive chromosomal strand.  This is important because DPYD is on the minus chromosomal strand and \u003ca href\u003d\""/variant/PA166153895\""\u003ers67376798\u003c/a\u003e is a T/A snp.  Therefore, the T allele on the gene confers the deficiency, while the complement on the positive chromosomal strand (A allele) is indicative of deficiency.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983463E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/""}]},""status"":""success""}"
PA166104944,Guideline Annotation,Annotation of DPWG Guideline for tegafur and DPYD,t,PA452620,Dutch Pharmacogenetics Working Group,"<p>Choose an alternative drug to tegafur for patients with DPYD Activity Score of 0. For patients with a DPYD Activity Score of 1 or 1.5, avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives for tegafur, as these are also metabolized by DPD. The DPWG evaluated DPYD genotyping as &quot;essential&quot; and recommend DPYD testing prior to initiating fluoropyrimidines.</p>
","<h3 id=""dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-of-dpyd-and-fluoropyrimidines-european-journal-of-human-genetics-2019"">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. <em>European journal of human genetics</em> (2019)</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines as per the August 2019 update including more details and scoring the clinical implementation <a href=""/literature/15104402"">PMID: 31745289</a>.</p>
<h3 id=""august-2019-guideline"">August 2019 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tegafur based on DPYD genotype. An alternative drug or starting with a lower dose then adjusting the initial dose based on toxicity and efficacy is recommended.  Fluorouracil or capecitabine are not an alternatives, as these are also metabolized by DPD.</p>
<p><em>Wording in table taken from the <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"" target=""_blank"">Dutch guidelines</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>Activity Score 0</td><td>tegafur</td><td>The gene variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that the normal dose is an overdose.</td><td>- avoid tegafur<br/>Fluorouracil and capecitabine are not suitable alternatives, as these are also metabolised by DPD.<br/>- If it is not possible to avoid tegafur: start with a very low dose and adjust the initial dose based on toxicity and efficacy. A substantiated recommendation for dose reduction cannot be made based on the literature.</td></tr>
<tr><td>FENO</td><td>tegafur</td><td>The gene variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that the normal dose is an overdose.</td><td>Avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.</td></tr>
<tr><td>Activity Score 1</td><td>tegafur</td><td>The gene variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive metabolites means that the normal dose is an overdose.</td><td>Avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD.  It is not possible to offer substantiated advice for dose reduction based on the literature.</td></tr>
<tr><td>Activity Score 1.5</td><td>tegafur</td><td>The gene variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive metabolites means that the normal dose is an overdose.</td><td>Avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy.  Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0002553.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tegafur based on DPYD genotype. An alternative drug or starting with a lower dose then adjusting the initial dose based on toxicity and efficacy is recommended for patients with DPYD activity scores of 0, 0.5, 1 and 1.5.  Fluorouracil or capecitabine are not an alternatives, as these are also metabolized by DPD.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>Activity Score 0</td><td>tegafur</td><td>Genetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that the normal dose is an overdose.</td><td>Choose an alternative. Do not choose fluorouracil or capecitabine, as these are also metabolised by DPD. If an alternative is not possible: start with a very low dose and adjust the initial dose based on toxicity and efficacy. A substantiated recommendation for dose reduction cannot be made based on the literature. The recommendation for fluorouracil and capecitabine is to determine the residual DPD activity in mononuclear cells from peripheral blood and to adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard capecitabine dose (150 mg every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard capecitabine dose (150 mg every 5 days with every third dose skipped). The average Caucasian DPD activity is 9.9 nmol/hour per mg protein.<br/><em>NOTE: If a patient has two different gene variations that lead to a non-functional DPD enzyme (e.g. *2A and *13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 0.5</td><td>tegafur</td><td>Genetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that the normal dose is an overdose.</td><td>Choose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.<br/><em>NOTE: This recommendation only applies if the two gene variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 1</td><td>tegafur</td><td>Genetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive metabolites means that the normal dose is an overdose.</td><td>Choose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.<br/><em>NOTE: If a patient has two different gene variations that result in a partially functional DPD enzyme (e.g. 2846T and 1236A), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, the gene activity score is between 1 and 1.5, depending on whether and how the two gene variations influence each other and on other factors that influence the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two different genetic variations can only be determined by measuring the enzyme activity (phenotyping).</em></td></tr>
<tr><td>Activity Score 1.5</td><td>tegafur</td><td>Genetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive metabolites means that the normal dose is an overdose.</td><td>Choose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0004891.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tegafur/uracil combination based on DPYD genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend that an alternate drug be used for poor metabolizer patients, but do not provide a recommendation for intermediate metabolizer patients.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (2 inactive alleles, 2 decreased activity alleles, or one inactive and one decreased activity alleles)</td><td>Select alterantive drug.  Fluorouracil or capecitabine are not suitable alternatives because both are also metabolized by DPD.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS). Kinetic effect (NS).</td></tr>
<tr><td>IM (1 active allele and 1 inactive or decreased activity allele)</td><td>None.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS). Kinetic effect (NS).</td></tr>
</tbody>
</table>
<table class=""table"">
<thead>
<tr><th>Allele Type</th><th>Alleles</th></tr>
</thead>
<tbody>
<tr><td>active</td><td>*1, *4, *5, *6, *9A</td></tr>
<tr><td>decreased activity</td><td>*9B, *10</td></tr>
<tr><td>inactive</td><td>*2A, *3, *7, *8, *11, *12, *13, 496A&gt;G, IVS10-15T&gt;C, 1156G&gt;T, 1845G&gt;T</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>NS: not statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104944"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104944"",""name"":""Annotation of DPWG Guideline for tegafur and DPYD"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704537E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415061E9,""date"":""2019-05-23T15:37:10.335-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.45082069E9,""date"":""2019-10-03T21:03:43.093-07:00"",""description"":""Changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45095646E9,""date"":""2020-01-31T14:19:55.353-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450965841E9,""date"":""2020-02-13T09:58:49.261-08:00"",""description"":""Added text and links to DPYD guideline individual paper PMID: 31745289"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15104402"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5104402E7,""resourceId"":""31745289"",""title"":""Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/31745289"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/31745289"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.45096468E9,""resource"":""PubMed"",""resourceId"":""31745289"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/31745289""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/s41431-019-0540-0"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450964681E9,""resource"":""DOI"",""resourceId"":""10.1038/s41431-019-0540-0"",""_url"":""http://dx.doi.org/10.1038%2Fs41431-019-0540-0""}]},{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA452620"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA452620"",""name"":""tegafur""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA145"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA145"",""symbol"":""DPYD"",""name"":""dihydropyrimidine dehydrogenase""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981872E9,""html"":""\u003cp\u003eChoose an alternative drug to tegafur for patients with DPYD Activity Score of 0. For patients with a DPYD Activity Score of 1 or 1.5, avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives for tegafur, as these are also metabolized by DPD. The DPWG evaluated DPYD genotyping as \u0026quot;essential\u0026quot; and recommend DPYD testing prior to initiating fluoropyrimidines.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981871E9,""html"":""\u003ch3 id\u003d\""dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-of-dpyd-and-fluoropyrimidines-european-journal-of-human-genetics-2019\""\u003eDutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. \u003cem\u003eEuropean journal of human genetics\u003c/em\u003e (2019)\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines as per the August 2019 update including more details and scoring the clinical implementation \u003ca href\u003d\""/literature/15104402\""\u003ePMID: 31745289\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""august-2019-guideline\""\u003eAugust 2019 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tegafur based on DPYD genotype. An alternative drug or starting with a lower dose then adjusting the initial dose based on toxicity and efficacy is recommended.  Fluorouracil or capecitabine are not an alternatives, as these are also metabolized by DPD.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf\"" target\u003d\""_blank\""\u003eDutch guidelines\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0\u003c/td\u003e\u003ctd\u003etegafur\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003e- avoid tegafur\u003cbr/\u003eFluorouracil and capecitabine are not suitable alternatives, as these are also metabolised by DPD.\u003cbr/\u003e- If it is not possible to avoid tegafur: start with a very low dose and adjust the initial dose based on toxicity and efficacy. A substantiated recommendation for dose reduction cannot be made based on the literature.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eFENO\u003c/td\u003e\u003ctd\u003etegafur\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eAvoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1\u003c/td\u003e\u003ctd\u003etegafur\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eAvoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD.  It is not possible to offer substantiated advice for dose reduction based on the literature.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1.5\u003c/td\u003e\u003ctd\u003etegafur\u003c/td\u003e\u003ctd\u003eThe gene variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eAvoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy.  Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0002553.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tegafur based on DPYD genotype. An alternative drug or starting with a lower dose then adjusting the initial dose based on toxicity and efficacy is recommended for patients with DPYD activity scores of 0, 0.5, 1 and 1.5.  Fluorouracil or capecitabine are not an alternatives, as these are also metabolized by DPD.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0\u003c/td\u003e\u003ctd\u003etegafur\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eChoose an alternative. Do not choose fluorouracil or capecitabine, as these are also metabolised by DPD. If an alternative is not possible: start with a very low dose and adjust the initial dose based on toxicity and efficacy. A substantiated recommendation for dose reduction cannot be made based on the literature. The recommendation for fluorouracil and capecitabine is to determine the residual DPD activity in mononuclear cells from peripheral blood and to adjust the initial dose accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard capecitabine dose (150 mg every 5 days). A patient with undetectable DPD activity tolerated 0.43% of the standard capecitabine dose (150 mg every 5 days with every third dose skipped). The average Caucasian DPD activity is 9.9 nmol/hour per mg protein.\u003cbr/\u003e\u003cem\u003eNOTE: If a patient has two different gene variations that lead to a non-functional DPD enzyme (e.g. *2A and *13), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 0.5\u003c/td\u003e\u003ctd\u003etegafur\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eChoose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.\u003cbr/\u003e\u003cem\u003eNOTE: This recommendation only applies if the two gene variations are on a different allele. If both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1\u003c/td\u003e\u003ctd\u003etegafur\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eChoose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.\u003cbr/\u003e\u003cem\u003eNOTE: If a patient has two different gene variations that result in a partially functional DPD enzyme (e.g. 2846T and 1236A), this recommendation only applies if the variations are on a different allele. If both variations are on the same allele, the gene activity score is between 1 and 1.5, depending on whether and how the two gene variations influence each other and on other factors that influence the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two different genetic variations can only be determined by measuring the enzyme activity (phenotyping).\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eActivity Score 1.5\u003c/td\u003e\u003ctd\u003etegafur\u003c/td\u003e\u003ctd\u003eGenetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive metabolites means that the normal dose is an overdose.\u003c/td\u003e\u003ctd\u003eChoose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. It is not possible to offer substantiated advice for dose reduction based on the literature.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0004891.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tegafur/uracil combination based on DPYD genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend that an alternate drug be used for poor metabolizer patients, but do not provide a recommendation for intermediate metabolizer patients.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (2 inactive alleles, 2 decreased activity alleles, or one inactive and one decreased activity alleles)\u003c/td\u003e\u003ctd\u003eSelect alterantive drug.  Fluorouracil or capecitabine are not suitable alternatives because both are also metabolized by DPD.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS). Kinetic effect (NS).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (1 active allele and 1 inactive or decreased activity allele)\u003c/td\u003e\u003ctd\u003eNone.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS). Kinetic effect (NS).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele Type\u003c/th\u003e\u003cth\u003eAlleles\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eactive\u003c/td\u003e\u003ctd\u003e*1, *4, *5, *6, *9A\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003edecreased activity\u003c/td\u003e\u003ctd\u003e*9B, *10\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003einactive\u003c/td\u003e\u003ctd\u003e*2A, *3, *7, *8, *11, *12, *13, 496A\u0026gt;G, IVS10-15T\u0026gt;C, 1156G\u0026gt;T, 1845G\u0026gt;T\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eNS: not statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166192341,Guideline Annotation,Annotation of CPIC Guideline for tenoxicam and CYP2C9,t,PA131890625,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"" target=""_blank"">CPIC&reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9</a>.</p>
<h3 id=""march-2020"">March 2020</h3>
<p><em>Advance online publication March 2020.</em></p>
<ul>
<li>
<p>The <a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830"" target=""_blank"">CPIC guideline regarding for <em>CYP2C9</em> and Nonsteroidal Anti-inflammatory Drugs</a> is published in Clinical Pharmacology and Therapeutics.</p>
</li>
<li>
<p>These guidelines are applicable to:</p>
<ul>
<li>
<p>pediatric patients</p>
</li>
<li>
<p>adult patients</p>
</li>
</ul>
</li>
<li>
<p>Excerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:</p>
<ul>
<li>
<p>&quot;Substantial evidence links CYP2C9 genotypes with phenotypic variability in CYP2C9 metabolism and plasma NSAID concentrations, with the majority of studies conducted in healthy volunteers.&quot;</p>
</li>
<li>
<p>&quot;Although clinical evidence linking genetic variation in CYP2C9 to an increased rate of adverse events with NSAIDs use is scarce, several studies have established an association between CYP2C9 decreased function and no function alleles and elevated NSAID exposure (Figure 1 and Figure S2). Because most NSAID adverse events are dose-dependent, on-target adverse events involving COX inhibition (19-23) it is reasonable to assume that elevated exposure increases the risk of adverse events.&quot;</p>
</li>
<li>
<p>&quot;CYP2C9 IM and PM phenotypes affect systemic plasma concentrations of NSAIDs by decreasing metabolic clearance and consequently prolonging plasma elimination half-life. Therefore, therapeutic recommendations are broadly organized according to the NSAID plasma elimination half-life in NMs. Where more than two studies reported plasma concentration areaunder-the-curve (AUC), a meta-analysis was conducted to estimate the average impact of CYP2C9 genotype on drug exposure (Figure 1 and Figures S2 to S4).&quot;</p>
</li>
<li>
<p>&quot; <em><strong>Piroxicam and tenoxicam</strong></em>. These drugs have extremely long half-lives (30-86 and 60 hours, respectively), thus
amplifying the potential risks in individuals with reduced CYP2C9 metabolism and hampering dose titration strategies due to lack of data. Accordingly, rather than use of a lower starting dose, IMs with an AS of 1 and PMs are recommended to receive an alternative therapy. This includes drugs that are not metabolized by CYP2C9 or significantly affected by CYP2C9 genetic variants in vivo. Selection of a NSAID with a short half-life (Table 2) could also be considered.&quot;</p>
</li>
<li>
<p>&quot; <em><strong>Meloxicam</strong></em>. Meloxicam has a longer half-life (15-20 hours, Table S12) than celecoxib and ibuprofen; thus, impaired meloxicam metabolism is expected to cause sustained elevations in drug exposure. Recommendations for CYP2C9 NMs and IMs with an AS of 1.5 are similar to the short half-life NSAIDs and include initiation of therapy with the standard dose while using the lowest effective dosage for shortest duration capable to achieve treatment goals. For IMs with an AS of 1, reduced metabolism and increased plasma concentrations are expected that may increase probability of toxicities...The recommendations are to either initiate therapy with 50% of the lowest recommended starting dose or choose an alternative therapy, consistent with the recommendations in PMs for short half-life NSAIDs (Table 2). Upward dose titration should not occur until after steady-state is reached (at least seven days), and careful monitoring is recommended. CYP2C9 PMs should be prescribed an alternative therapy because markedly prolonged half-life is expected (i.e., &gt;100 hours)&quot;.</p>
</li>
<li>
<p>&quot;<em><strong>Celecoxib, flurbiprofen, ibuprofen, lornoxicam</strong></em>: Based on current evidence, NMs and IMs with an AS of 1.5 are recommended to initiate therapy with the approved starting dose. Despitehaving mildly reduced metabolism, IMs with an AS of 1.5 do not exhibit significant increases in drug exposure relative to NMs... CYP2C9 IMs with an AS of 1 have reduced metabolism and are expected to exhibit a prolonged drug half-life and higher plasma concentrations compared to NMs, which may increase probability of toxicities.For IMs with an AS of 1, it is recommended to initiate NSAID therapy with the lowest recommended starting dose and titrate to clinical effect with close monitoring for adverse events such as elevated blood pressure and kidney dysfunction during course of therapy. Regarding ibuprofen use, it should be taken into consideration that while the CYP2C9*2 allele alone might not cause a clinically relevant reduction in clearance, its strong linkage with the
decreased function CYP2C8*3 allele may result in impaired R (-) ibuprofen hydroxylation and increased exposure to the parent drug...Individuals with a CYP2C9 PM phenotype (AS of 0) are expected to have markedly reduced metabolism and are expected to exhibit a pronounced prolongation of drug half-life and increase in plasma concentrations, which may increase the probability and/or severity of toxicities...It is recommended to initiate therapy with 25-50% of the lowest recommended starting dose (i.e. 50-75% dose reduction), and careful dose titration to clinical effect. Because drug half-life is significantly prolonged in these patients, upward dose titration should not occur until after steady-state is reached, taking into consideration the PM half-life for each drug; of course, dosing may be stopped or decreased due to toxicity at any time. Treatment with an alternative therapy could also be considered. This could include NSAIDs not primarily metabolized by CYP2C9 (such as aspirin, ketorolac (approved for short term use only), metamizole, naproxen, sulindac, etoricoxib, parecoxib, or valdecoxib), or with pharmacokinetic parameters apparently not impacted by CYP2C9 genetic variants in vivo despite CYP2C9 metabolism in vitro&quot;.</p>
</li>
<li>
<p>&quot; <em><strong>Aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen</strong></em>. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C&quot;.</p>
</li>
<li>
<p>&quot;<em><strong>Pediatrics</strong></em>: Because CYP2C9 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring. Ultimately, additional research
and clinical trials in pediatric patients investigating the association between CYP2C9 genotype and NSAID systemic exposure and treatment outcomes are needed.&quot;</p>
</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for <em>CYP2C9</em> and NSAIDs Therapy</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT_supplement.pdf"" target=""_blank"">2020 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Tenoxicam_Drug_Resource_Mappings.xlsx"" target=""_blank"">tenoxicam Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/NSAID/Tenoxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">tenoxicam Pre and Post Test Alerts</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-tenoxicam-by-cyp2c9-phenotype"">Table 1: Recommended dosing of <em><strong>tenoxicam</strong></em> by CYP2C9 phenotype</h3>
<p><em>Adapted from Tables 1 and 4 of the 2020 guideline.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype<sup>a</sup></th><th>Activity Score</th><th>Genotype</th><th>Examples of genotypes<sup>b</sup></th><th>Implications</th><th>Therapeutic recommendations<sup>c</sup></th><th>Classification of recommendations<sup>d</sup></th><th>Other considerations</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C9</em> Normal metabolizer</td><td>2<sup>c</sup></td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td><td>Strong</td><td></td></tr>
<tr><td><em>CYP2C9</em> Intermediate metabolizer<sup>f</sup></td><td>1.5<sup>c</sup></td><td>An individual carrying one normal function and one decreased function allele.</td><td>*1/*2</td><td>Mildly reduced metabolism</td><td>Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.</td><td>Moderate</td><td>IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.</td></tr>
<tr><td><em>CYP2C9</em> Intermediate metabolizer<sup>f</sup></td><td>1<sup>c</sup></td><td>An individual carrying one normal function allele plus one no function allele OR two decreased function alleles.</td><td>*1/*3, *2/*2</td><td>Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities</td><td>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).</td><td>Optional</td><td>Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</td></tr>
<tr><td><em>CYP2C9</em> Poor metabolizer</td><td>0 or 0.5<sup>c</sup></td><td>An individual carrying one no function allele plus one decreased function allele; OR two no function alleles</td><td>*2/*3, *3/*3</td><td>Significantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities</td><td>Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).</td><td>Optional</td><td>Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.</td></tr>
<tr><td>Indeterminate</td><td>n/a<sup>c</sup></td><td>An individual carrying allele combinations with uncertain and/or unknown function alleles</td><td>*1/*7, *1/*10, *7/*10, *1/*57</td><td>n/a</td><td>No recommendation.</td><td>n/a</td><td></td></tr>
</tbody>
</table>
<p><sup>a</sup> See the <a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 frequency table</a> for race-specific allele and phenotype frequencies.<br />
<sup>b</sup> For a complete list of CYP2C9 diplotypes and resulting phenotypes, see the <a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials"">CYP2C9 genotype to phenotype table</a>.</p>
<p><sup>c</sup> CPIC assigned each allele functional status an activity value ranging from 0 to 1 (e.g., 0 for no function, 0.5 for decreased, and 1.0 for normal function), which are summed to calculate the activity score (AS) for each diplotype. The CYP2C9 AS has been translated into the phenotype classification system as follows: individuals with an AS of 0 or 0.5 are poor
metabolizers (PMs), those with a score of 1 or 1.5 are intermediate metabolizers (IMs), and those with a score of 2 are normal metabolizers (NMs).<br />
<sup>d</sup> Rating scheme described in Supplement.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166192341"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166192341"",""name"":""Annotation of CPIC Guideline for tenoxicam and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[{""id"":1.450986662E9,""alleles"":[{""id"":1.45098668E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816542"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816542"",""symbol"":""CYP2C9*1"",""name"":""*1""}},{""id"":1.450986681E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816543"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816543"",""symbol"":""CYP2C9*2"",""name"":""*2""}},{""id"":1.450986682E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816544"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816544"",""symbol"":""CYP2C9*3"",""name"":""*3""}},{""id"":1.450986683E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816545"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816545"",""symbol"":""CYP2C9*4"",""name"":""*4""}},{""id"":1.450986684E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816546"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816546"",""symbol"":""CYP2C9*5"",""name"":""*5""}},{""id"":1.450986685E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816547"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816547"",""symbol"":""CYP2C9*6"",""name"":""*6""}},{""id"":1.450986686E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816548"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816548"",""symbol"":""CYP2C9*7"",""name"":""*7""}},{""id"":1.450986687E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816549"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816549"",""symbol"":""CYP2C9*8"",""name"":""*8""}},{""id"":1.450986688E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816550"",""symbol"":""CYP2C9*9"",""name"":""*9""}},{""id"":1.450986689E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816551"",""symbol"":""CYP2C9*10"",""name"":""*10""}},{""id"":1.45098669E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816552"",""symbol"":""CYP2C9*11"",""name"":""*11""}},{""id"":1.450986691E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816553"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816553"",""symbol"":""CYP2C9*12"",""name"":""*12""}},{""id"":1.450986692E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816554"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816554"",""symbol"":""CYP2C9*13"",""name"":""*13""}},{""id"":1.450986693E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816555"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816555"",""symbol"":""CYP2C9*14"",""name"":""*14""}},{""id"":1.450986694E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816556"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816556"",""symbol"":""CYP2C9*15"",""name"":""*15""}},{""id"":1.450986695E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816557"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816557"",""symbol"":""CYP2C9*16"",""name"":""*16""}},{""id"":1.450986696E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816563"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816563"",""symbol"":""CYP2C9*17"",""name"":""*17""}},{""id"":1.450986697E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816558"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816558"",""symbol"":""CYP2C9*18"",""name"":""*18""}},{""id"":1.450986698E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816564"",""symbol"":""CYP2C9*19"",""name"":""*19""}},{""id"":1.450986699E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816565"",""symbol"":""CYP2C9*20"",""name"":""*20""}},{""id"":1.4509867E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816566"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816566"",""symbol"":""CYP2C9*21"",""name"":""*21""}},{""id"":1.450986701E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816567"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816567"",""symbol"":""CYP2C9*22"",""name"":""*22""}},{""id"":1.450986702E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816568"",""symbol"":""CYP2C9*23"",""name"":""*23""}},{""id"":1.450986703E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816569"",""symbol"":""CYP2C9*24"",""name"":""*24""}},{""id"":1.450986704E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816559"",""symbol"":""CYP2C9*25"",""name"":""*25""}},{""id"":1.450986705E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816570"",""symbol"":""CYP2C9*26"",""name"":""*26""}},{""id"":1.450986706E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816571"",""symbol"":""CYP2C9*27"",""name"":""*27""}},{""id"":1.450986707E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816572"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816572"",""symbol"":""CYP2C9*28"",""name"":""*28""}},{""id"":1.450986708E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816573"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816573"",""symbol"":""CYP2C9*29"",""name"":""*29""}},{""id"":1.450986709E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816574"",""symbol"":""CYP2C9*30"",""name"":""*30""}},{""id"":1.45098671E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816560"",""symbol"":""CYP2C9*31"",""name"":""*31""}},{""id"":1.450986711E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816575"",""symbol"":""CYP2C9*32"",""name"":""*32""}},{""id"":1.450986712E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816561"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816561"",""symbol"":""CYP2C9*33"",""name"":""*33""}},{""id"":1.450986713E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816562"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816562"",""symbol"":""CYP2C9*34"",""name"":""*34""}},{""id"":1.450986714E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048681"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048681"",""symbol"":""CYP2C9*35"",""name"":""*35""}},{""id"":1.450986715E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048682"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048682"",""symbol"":""CYP2C9*36"",""name"":""*36""}},{""id"":1.450986716E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048683"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048683"",""symbol"":""CYP2C9*37"",""name"":""*37""}},{""id"":1.450986717E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048684"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048684"",""symbol"":""CYP2C9*38"",""name"":""*38""}},{""id"":1.450986718E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048685"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048685"",""symbol"":""CYP2C9*39"",""name"":""*39""}},{""id"":1.450986719E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048686"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048686"",""symbol"":""CYP2C9*40"",""name"":""*40""}},{""id"":1.45098672E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048687"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048687"",""symbol"":""CYP2C9*41"",""name"":""*41""}},{""id"":1.450986721E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048688"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048688"",""symbol"":""CYP2C9*42"",""name"":""*42""}},{""id"":1.450986722E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048689"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048689"",""symbol"":""CYP2C9*43"",""name"":""*43""}},{""id"":1.450986723E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048690"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048690"",""symbol"":""CYP2C9*44"",""name"":""*44""}},{""id"":1.450986724E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048691"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048691"",""symbol"":""CYP2C9*45"",""name"":""*45""}},{""id"":1.450986725E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048692"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048692"",""symbol"":""CYP2C9*46"",""name"":""*46""}},{""id"":1.450986726E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048693"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048693"",""symbol"":""CYP2C9*47"",""name"":""*47""}},{""id"":1.450986727E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048694"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048694"",""symbol"":""CYP2C9*48"",""name"":""*48""}},{""id"":1.450986728E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048695"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048695"",""symbol"":""CYP2C9*49"",""name"":""*49""}},{""id"":1.450986729E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048696"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048696"",""symbol"":""CYP2C9*50"",""name"":""*50""}},{""id"":1.45098673E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048697"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048697"",""symbol"":""CYP2C9*51"",""name"":""*51""}},{""id"":1.450986731E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048698"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048698"",""symbol"":""CYP2C9*52"",""name"":""*52""}},{""id"":1.450986732E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048699"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048699"",""symbol"":""CYP2C9*53"",""name"":""*53""}},{""id"":1.450986733E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048700"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048700"",""symbol"":""CYP2C9*54"",""name"":""*54""}},{""id"":1.450986734E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048701"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048701"",""symbol"":""CYP2C9*55"",""name"":""*55""}},{""id"":1.450986735E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048702"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048702"",""symbol"":""CYP2C9*56"",""name"":""*56""}},{""id"":1.450986736E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166048703"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166048703"",""symbol"":""CYP2C9*57"",""name"":""*57""}},{""id"":1.450986737E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166122566"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166122566"",""symbol"":""CYP2C9*58"",""name"":""*58""}},{""id"":1.450986738E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128210"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128210"",""symbol"":""CYP2C9*59"",""name"":""*59""}},{""id"":1.450986739E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128211"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128211"",""symbol"":""CYP2C9*60"",""name"":""*60""}},{""id"":1.45098674E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166183345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166183345"",""symbol"":""CYP2C9*61"",""name"":""*61""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}}],""history"":[{""id"":1.451095141E9,""date"":""2020-03-19T00:00:00-07:00"",""description"":""Guideline published"",""type"":""Note"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15105062"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5105062E7,""resourceId"":""32189324"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/32189324"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/32189324"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.451090662E9,""resource"":""PubMed"",""resourceId"":""32189324"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/32189324""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1830"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.451090663E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1830"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1830""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA131890625"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA131890625"",""name"":""tenoxicam""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.45098656E9,""html"":""\u003cp\u003eThe CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450986561E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for Nonsteroidal Anti-inflammatory Drugs and CYP2C9\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""march-2020\""\u003eMarch 2020\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication March 2020.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1830\"" target\u003d\""_blank\""\u003eCPIC guideline regarding for \u003cem\u003eCYP2C9\u003c/em\u003e and Nonsteroidal Anti-inflammatory Drugs\u003c/a\u003e is published in Clinical Pharmacology and Therapeutics.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThese guidelines are applicable to:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003epediatric patients\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eadult patients\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExcerpts from the 2020 Nonsteroidal Anti-inflammatory Drugs dosing guideline:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Substantial evidence links CYP2C9 genotypes with phenotypic variability in CYP2C9 metabolism and plasma NSAID concentrations, with the majority of studies conducted in healthy volunteers.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;Although clinical evidence linking genetic variation in CYP2C9 to an increased rate of adverse events with NSAIDs use is scarce, several studies have established an association between CYP2C9 decreased function and no function alleles and elevated NSAID exposure (Figure 1 and Figure S2). Because most NSAID adverse events are dose-dependent, on-target adverse events involving COX inhibition (19-23) it is reasonable to assume that elevated exposure increases the risk of adverse events.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;CYP2C9 IM and PM phenotypes affect systemic plasma concentrations of NSAIDs by decreasing metabolic clearance and consequently prolonging plasma elimination half-life. Therefore, therapeutic recommendations are broadly organized according to the NSAID plasma elimination half-life in NMs. Where more than two studies reported plasma concentration areaunder-the-curve (AUC), a meta-analysis was conducted to estimate the average impact of CYP2C9 genotype on drug exposure (Figure 1 and Figures S2 to S4).\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003ePiroxicam and tenoxicam\u003c/strong\u003e\u003c/em\u003e. These drugs have extremely long half-lives (30-86 and 60 hours, respectively), thus\namplifying the potential risks in individuals with reduced CYP2C9 metabolism and hampering dose titration strategies due to lack of data. Accordingly, rather than use of a lower starting dose, IMs with an AS of 1 and PMs are recommended to receive an alternative therapy. This includes drugs that are not metabolized by CYP2C9 or significantly affected by CYP2C9 genetic variants in vivo. Selection of a NSAID with a short half-life (Table 2) could also be considered.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003eMeloxicam\u003c/strong\u003e\u003c/em\u003e. Meloxicam has a longer half-life (15-20 hours, Table S12) than celecoxib and ibuprofen; thus, impaired meloxicam metabolism is expected to cause sustained elevations in drug exposure. Recommendations for CYP2C9 NMs and IMs with an AS of 1.5 are similar to the short half-life NSAIDs and include initiation of therapy with the standard dose while using the lowest effective dosage for shortest duration capable to achieve treatment goals. For IMs with an AS of 1, reduced metabolism and increased plasma concentrations are expected that may increase probability of toxicities...The recommendations are to either initiate therapy with 50% of the lowest recommended starting dose or choose an alternative therapy, consistent with the recommendations in PMs for short half-life NSAIDs (Table 2). Upward dose titration should not occur until after steady-state is reached (at least seven days), and careful monitoring is recommended. CYP2C9 PMs should be prescribed an alternative therapy because markedly prolonged half-life is expected (i.e., \u0026gt;100 hours)\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cem\u003e\u003cstrong\u003eCelecoxib, flurbiprofen, ibuprofen, lornoxicam\u003c/strong\u003e\u003c/em\u003e: Based on current evidence, NMs and IMs with an AS of 1.5 are recommended to initiate therapy with the approved starting dose. Despitehaving mildly reduced metabolism, IMs with an AS of 1.5 do not exhibit significant increases in drug exposure relative to NMs... CYP2C9 IMs with an AS of 1 have reduced metabolism and are expected to exhibit a prolonged drug half-life and higher plasma concentrations compared to NMs, which may increase probability of toxicities.For IMs with an AS of 1, it is recommended to initiate NSAID therapy with the lowest recommended starting dose and titrate to clinical effect with close monitoring for adverse events such as elevated blood pressure and kidney dysfunction during course of therapy. Regarding ibuprofen use, it should be taken into consideration that while the CYP2C9*2 allele alone might not cause a clinically relevant reduction in clearance, its strong linkage with the\ndecreased function CYP2C8*3 allele may result in impaired R (-) ibuprofen hydroxylation and increased exposure to the parent drug...Individuals with a CYP2C9 PM phenotype (AS of 0) are expected to have markedly reduced metabolism and are expected to exhibit a pronounced prolongation of drug half-life and increase in plasma concentrations, which may increase the probability and/or severity of toxicities...It is recommended to initiate therapy with 25-50% of the lowest recommended starting dose (i.e. 50-75% dose reduction), and careful dose titration to clinical effect. Because drug half-life is significantly prolonged in these patients, upward dose titration should not occur until after steady-state is reached, taking into consideration the PM half-life for each drug; of course, dosing may be stopped or decreased due to toxicity at any time. Treatment with an alternative therapy could also be considered. This could include NSAIDs not primarily metabolized by CYP2C9 (such as aspirin, ketorolac (approved for short term use only), metamizole, naproxen, sulindac, etoricoxib, parecoxib, or valdecoxib), or with pharmacokinetic parameters apparently not impacted by CYP2C9 genetic variants in vivo despite CYP2C9 metabolism in vitro\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot; \u003cem\u003e\u003cstrong\u003eAceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen\u003c/strong\u003e\u003c/em\u003e. The pharmacokinetics of these drugs are not significantly impacted by CYP2C9 genetic variants in vivo and/or there is insufficient evidence to provide a recommendation to guide clinical practice at this time (CPIC classification of recommendation “no recommendation”; CPIC level C\u0026quot;.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cem\u003e\u003cstrong\u003ePediatrics\u003c/strong\u003e\u003c/em\u003e: Because CYP2C9 activity is fully mature by early childhood, it may be appropriate to extrapolate these recommendations to adolescents or possibly younger children with close monitoring. Ultimately, additional research\nand clinical trials in pediatric patients investigating the association between CYP2C9 genotype and NSAID systemic exposure and treatment outcomes are needed.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for \u003cem\u003eCYP2C9\u003c/em\u003e and NSAIDs Therapy\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/2020/CPIC_NSAID_PREPRINT_supplement.pdf\"" target\u003d\""_blank\""\u003e2020 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Tenoxicam_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003etenoxicam Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/NSAID/Tenoxicam_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003etenoxicam Pre and Post Test Alerts\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-tenoxicam-by-cyp2c9-phenotype\""\u003eTable 1: Recommended dosing of \u003cem\u003e\u003cstrong\u003etenoxicam\u003c/strong\u003e\u003c/em\u003e by CYP2C9 phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 4 of the 2020 guideline.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eActivity Score\u003c/th\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eExamples of genotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003csup\u003ed\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eOther considerations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Normal metabolizer\u003c/td\u003e\u003ctd\u003e2\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Intermediate metabolizer\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.5\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function and one decreased function allele.\u003c/td\u003e\u003ctd\u003e*1/*2\u003c/td\u003e\u003ctd\u003eMildly reduced metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eIMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Intermediate metabolizer\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele plus one no function allele OR two decreased function alleles.\u003c/td\u003e\u003ctd\u003e*1/*3, *2/*2\u003c/td\u003e\u003ctd\u003eModerately reduced metabolism; higher plasma concentrations may increase probability of toxicities\u003c/td\u003e\u003ctd\u003eChoose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003ctd\u003eAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Poor metabolizer\u003c/td\u003e\u003ctd\u003e0 or 0.5\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one no function allele plus one decreased function allele; OR two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eSignificantly reduced metabolism and prolonged half life; higher plasma concentrations may increase probability and/or severity of toxicities\u003c/td\u003e\u003ctd\u003eChoose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (Table 2).\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003ctd\u003eAlternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003en/a\u003csup\u003ec\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying allele combinations with uncertain and/or unknown function alleles\u003c/td\u003e\u003ctd\u003e*1/*7, *1/*10, *7/*10, *1/*57\u003c/td\u003e\u003ctd\u003en/a\u003c/td\u003e\u003ctd\u003eNo recommendation.\u003c/td\u003e\u003ctd\u003en/a\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e See the \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 frequency table\u003c/a\u003e for race-specific allele and phenotype frequencies.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e For a complete list of CYP2C9 diplotypes and resulting phenotypes, see the \u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003eCYP2C9 genotype to phenotype table\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e CPIC assigned each allele functional status an activity value ranging from 0 to 1 (e.g., 0 for no function, 0.5 for decreased, and 1.0 for normal function), which are summed to calculate the activity score (AS) for each diplotype. The CYP2C9 AS has been translated into the phenotype classification system as follows: individuals with an AS of 0 or 0.5 are poor\nmetabolizers (PMs), those with a score of 1 or 1.5 are intermediate metabolizers (IMs), and those with a score of 2 are normal metabolizers (NMs).\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003e Rating scheme described in Supplement.\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104965,Guideline Annotation,"Annotation of CPIC Guideline for thioguanine and NUDT15,TPMT",t,PA451663,Clinical Pharmacogenetics Implementation Consortium,"<p>Consider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"" target=""_blank"">CPIC&reg; guideline for thiopurines and TPMT and NUDT15</a>.</p>
<h3 id=""october-2018-update"">October 2018 Update</h3>
<p><em>Advance online publication November 2018.</em></p>
<ul>
<li>The <a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1304?af=R"" target=""_blank"">2018 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine</a>, have been published in Clinical Pharmacology and Therapeutics.  Literature published between October 2012 to June 2017 was reviewed, recommendations and supplemental information was updated.</li>
<li>These guidelines are applicable to:
<ul>
<li>pediatric patients</li>
<li>adult patients</li>
</ul>
</li>
<li>Excerpt from the 2018 thiopurine dosing guideline update:
<ul>
<li>&quot;TPMT activity exhibits a monogenic co-dominant inheritance and catabolizes
thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines.&quot;</li>
<li>&quot;Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduces the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Submitted.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on <em>TPMT</em> and <em>NUDT15</em> genotypes: 2018 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Supplemental_Material.pdf"" target=""_blank"">2018 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/tpmtRefMaterials"">TPMT Gene-Specific Information Tables</a></li>
<li><a href=""https://www.pharmgkb.org/page/nudt15RefMaterials"">NUDT15 Gene-Specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/Thioguanine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Thioguanine Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/thiopurines/Thiopurines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Thiopurines Pre and Post Test Alerts and Flow Chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-recommended-dosing-of-thioguanine-by-tpmt-phenotype"">Table 1: Recommended dosing of thioguanine by TPMT phenotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2018 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>TPMT phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations</th></tr>
</thead>
<tbody>
<tr><td>Normal Metabolizer</td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Lower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine.  Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with normal starting dose<sup>a</sup> (e.g. 40-60 mg/m<sup>2</sup>/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine.  Allow 2 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Intermediate Metabolizer</td><td>An individual carrying one normal function allele and one no function allele</td><td>*1/*2, *1/*3A, *1/*3B, *1/*3C, *1/*4</td><td>Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine.  Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced doses (50% to 80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 40-60 mg/m<sup>2</sup>/day (e.g. 20-48 mg/m<sup>2</sup>/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.</td><td>Moderate</td></tr>
<tr><td>Possible Intermediate Metabolizer</td><td>An individual carrying one uncertain/unknown function allele and one no function allele</td><td>*2/*8, *3A/*7</td><td>Moderate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine.  Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced doses (50% to 80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 40-60 mg/m<sup>2</sup>/day (e.g. 20-48 mg/m<sup>2</sup>/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.</td><td>Moderate</td></tr>
<tr><td>Poor Metabolizer</td><td>An individual carrying two no function alleles</td><td>*3A/*3A, *2/*3A, *3A/*3C, *3C/*4, *2/*3C, *3A/*4</td><td>Extremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease.  Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>Strong</td></tr>
<tr><td>Indeterminate</td><td>An individual carrying two uncertain/unknown function alleles OR one normal function allele and one uncertain/unknown function allele</td><td>*6/*8, *1/*8</td><td>None</td><td>None</td><td>None</td></tr>
</tbody>
</table>
<p><sup>a</sup>Normal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</p>
<h3 id=""table-2-recommended-dosing-of-thioguanine-by-nudt15-phenotype"">Table 2: Recommended dosing of thioguanine by NUDT15 phenotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2018 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>NUDT15 phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Dosing recommendations</th><th>Classification of recommendations</th></tr>
</thead>
<tbody>
<tr><td>Normal Metabolizer</td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression</td><td>Start with normal starting dose<sup>a</sup> (40-60 mg/day).  Adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine.  Allow 2 weeks to reach steady-state after each dose adjustment.</td><td>Strong</td></tr>
<tr><td>Intermediate Metabolizer</td><td>An individual carrying one normal function allele and one no function allele</td><td>*1/*2, *1/*3</td><td>Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced doses (50% to 80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 40-60 mg/m<sup>2</sup>/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.</td><td>Moderate</td></tr>
<tr><td>Possible Intermediate Metabolizer</td><td>An individual carrying one uncertain function allele and one no function allele</td><td>*2/*5, *3/*6</td><td>Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.</td><td>Start with reduced doses (50% to 80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 40-60 mg/m<sup>2</sup>/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.</td><td>Moderate</td></tr>
<tr><td>Poor Metabolizer</td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression</td><td>Reduce doses to 25% of normal dose<sup>a</sup> and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>Strong</td></tr>
<tr><td>Indeterminate</td><td>An individual carrying two uncertain function alleles OR one normal function allele and one uncertain function allele</td><td>*1/*4, *1/*5, *4/*5, *5/*6</td><td>None</td><td>None</td><td>None</td></tr>
</tbody>
</table>
<p><sup>a</sup>Normal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</p>
<h3 id=""table-3-recommended-dosing-of-thioguanine-by-tpmt-and-nudt15-phenotypes"">Table 3: Recommended dosing of thioguanine by TPMT and NUDT15 phenotypes</h3>
<p><em>Adapted from Figure 2 and Table 2 of the 2018 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Phenotype</th><th>TPMT Normal Metabolizer</th><th>TPMT Intermediate Metabolizer</th><th>TPMT Possible Intermediate Metabolizer</th><th>TPMT Poor Metabolizer</th><th>Indeterminate</th></tr>
</thead>
<tbody>
<tr><td>NUDT 15 Normal Metabolizer</td><td>Use standard dose</td><td>Start with reduced doses (50% to 80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 40-60 mg/m<sup>2</sup>/day (e.g. 20-48 mg/m<sup>2</sup>/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.</td><td>See TPMT Intermediate Metabolizer.</td><td>Start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>None</td></tr>
<tr><td>NUDT15 Intermediate Metabolizer</td><td>Start with reduced doses (50% to 80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 40-60 mg/m<sup>2</sup>/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.</td><td>Start with reduced doses (50% to 80% of normal dose) if normal starting dose<sup>a</sup> is &gt; or = 40-60 mg/m<sup>2</sup>/day (e.g. 20-48 mg/m<sup>2</sup>/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.</td><td>See TPMT Intermediate Metabolizer.</td><td>Start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>None</td></tr>
<tr><td>NUDT15 Possible Intermediate Metabolizer</td><td>See NUDT15 Intermediate Metabolizer.</td><td>See NUDT15 Intermediate Metabolizer.</td><td>See TPMT Intermediate Metabolizer/NUDT15 Intermediate Metabolizer.</td><td>See NUDT15 Intermediate Metabolizer.</td><td>None</td></tr>
<tr><td>NUDT15 Poor  Metabolizer</td><td>Reduce doses to 25% of normal dose<sup>a</sup> and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>Reduce doses to 25% of normal dose<sup>a</sup> and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>See TPMT Intermediate Metabolizer.</td><td>Start with drastically reduced doses (reduce daily dose<sup>a</sup> by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.</td><td>None</td></tr>
<tr><td>NUDT15 Indeterminate</td><td>None</td><td>None</td><td>None</td><td>None</td><td>None</td></tr>
</tbody>
</table>
<p><sup>a</sup>Normal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.</p>
<h3 id=""may-2016-update-on-pharmgkb"">May 2016 Update on PharmGKB</h3>
<p>Several studies have reported that individuals who carry low-function alleles for NUDT15 are unable to tolerate usual doses of thiopurines. [Articles:<a href=""/pmid/25108385"">25108385</a>, <a href=""/pmid/25624441"">25624441</a>, <a href=""/pmid/26033531"">26033531</a>, <a href=""/pmid/26076924"">26076924</a>, <a href=""/pmid/26405151"">26405151</a>, <a href=""/pmid/26503813"">26503813</a>, <a href=""/pmid/26590936"">26590936</a>, <a href=""/pmid/26735160"">26735160</a>, <a href=""/pmid/26878724"">26878724</a>] These alleles are more common among those of Asian ancestry and Hispanic ethnicity than others. [Articles:<a href=""/pmid/25624441"">25624441</a>, <a href=""/pmid/26878724"">26878724</a>] The dose tolerated by those with two low-function alleles is only ~ 10% that tolerated by those with no low-function NUDT15 or TPMT alleles. [Articles:<a href=""/pmid/25624441"">25624441</a>, <a href=""/pmid/26878724"">26878724</a>] CPIC is planning a guideline to address NUDT15 variants and possible dosing recommendations for thiopurines.</p>
<h3 id=""april-2013-update"">April 2013 Update</h3>
<p><em>Advance online publication January 2013.</em></p>
<ul>
<li>The <a rel=""noopener noreferrer"" href=""http://www.nature.com/clpt/journal/vaop/naam/index.html#17012013"" target=""_blank"">2013 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine</a>, have been published in Clinical Pharmacology and Therapeutics.  Literature published between June 2010-November 2012 was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current.</strong></li>
<li>These guidelines are applicable to:
<ul>
<li>pediatric patients</li>
<li>adult patients</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a href=""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_TPMT_update.pdf"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update</a></li>
<li><a href=""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_TPMT_update_supp.pdf"">2013 supplement</a></li>
</ul>
</li>
</ul>
<h3 id=""march-2011"">March 2011</h3>
<p><em>Advance online publication January 2011.</em></p>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for azathioprine, thioguanine and mercaptopurine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpt from the 2011 thiopurine dosing guidelines:
<ul>
<li>&quot;Thiopurines are most commonly used to treat nonmalignant conditions but are also critical anticancer agents. The approach to dosing adjustments based on TPMT status may differ depending on the clinical indication and the propensity to initiate therapy at higher vs. lower starting doses. We and others advocate testing for TPMT status prior to initiating thiopurine therapy, so that starting dosages can be adjusted accordingly.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a href=""https://api.pharmgkb.org/v1/download/file/attachment/cpic-tpmt-article.pdf"">Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing</a></li>
<li><a href=""https://api.pharmgkb.org/v1/download/file/attachment/cpic-tpmt-supplement.pdf"">2011 supplement</a></li>
</ul>
</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104965"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104965"",""name"":""Annotation of CPIC Guideline for thioguanine and NUDT15,TPMT"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.183699779E9,""date"":""2011-01-26T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.18369978E9,""date"":""2013-01-17T00:00:00-08:00"",""type"":""Update"",""version"":0.0},{""id"":1.447986823E9,""date"":""2016-05-10T21:45:35.599-07:00"",""description"":""Update guideline with information regarding the NUDT15 gene."",""type"":""Update"",""version"":0.0},{""id"":1.44971712E9,""date"":""2018-08-23T17:19:47.428-07:00"",""description"":""Updated video link"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15101542"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5101542E7,""resourceId"":""30447069"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/30447069"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/30447069"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450043138E9,""resource"":""PubMed"",""resourceId"":""30447069"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/30447069""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.1304"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450043139E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.1304"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.1304""}]},{""@id"":""https://pharmgkb.org/literature/15051187"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051187E7,""resourceId"":""23422873"",""title"":""Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604643"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3604643"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275272E9,""resource"":""PubMed Central"",""resourceId"":""PMC3604643"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604643""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23422873"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275271E9,""resource"":""PubMed"",""resourceId"":""23422873"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23422873""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.4"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275273E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.4"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.4""}]},{""@id"":""https://pharmgkb.org/literature/6690400"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":6690400.0,""resourceId"":""21270794"",""title"":""Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3098761"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449245874E9,""resource"":""PubMed Central"",""resourceId"":""PMC3098761"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/21270794"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69164748E8,""resource"":""PubMed"",""resourceId"":""21270794"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21270794""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2010.320"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449245875E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2010.320"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2010.320""}]},{""@id"":""https://pharmgkb.org/literature/15100906"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100906E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""title"":""CPIC® Guideline for Thiopurines and TPMT – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983453E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451663"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451663"",""name"":""thioguanine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134963132"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134963132"",""symbol"":""NUDT15"",""name"":""nudix hydrolase 15""},{""@id"":""https://pharmgkb.org/gene/PA356"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA356"",""symbol"":""TPMT"",""name"":""thiopurine S-methyltransferase""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.450044198E9,""html"":""\u003cp\u003eConsider an alternate agent or extreme dose reduction of thioguanine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 50-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.450044399E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for thiopurines and TPMT and NUDT15\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2018-update\""\u003eOctober 2018 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication November 2018.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1304?af\u003dR\"" target\u003d\""_blank\""\u003e2018 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine\u003c/a\u003e, have been published in Clinical Pharmacology and Therapeutics.  Literature published between October 2012 to June 2017 was reviewed, recommendations and supplemental information was updated.\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2018 thiopurine dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;TPMT activity exhibits a monogenic co-dominant inheritance and catabolizes\nthiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduces the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Submitted.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on \u003cem\u003eTPMT\u003c/em\u003e and \u003cem\u003eNUDT15\u003c/em\u003e genotypes: 2018 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/2018/CPIC_TPMT_NUDT15_Thiopurine_Supplemental_Material.pdf\"" target\u003d\""_blank\""\u003e2018 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/tpmtRefMaterials\""\u003eTPMT Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/nudt15RefMaterials\""\u003eNUDT15 Gene-Specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/Thioguanine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eThioguanine Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/thiopurines/Thiopurines_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eThiopurines Pre and Post Test Alerts and Flow Chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-recommended-dosing-of-thioguanine-by-tpmt-phenotype\""\u003eTable 1: Recommended dosing of thioguanine by TPMT phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2018 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eTPMT phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNormal Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eLower concentrations of TGN metabolites, but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine.  Normal risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with normal starting dose\u003csup\u003ea\u003c/sup\u003e (e.g. 40-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine.  Allow 2 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3A, *1/*3B, *1/*3C, *1/*4\u003c/td\u003e\u003ctd\u003eModerate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine.  Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced doses (50% to 80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 40-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day (e.g. 20-48 mg/m\u003csup\u003e2\u003c/sup\u003e/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePossible Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one uncertain/unknown function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*2/*8, *3A/*7\u003c/td\u003e\u003ctd\u003eModerate to high concentrations of TGN metabolites; but note that TGN after thioguanine are 5-10X higher than TGN after mercaptopurine or azathioprine.  Increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced doses (50% to 80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 40-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day (e.g. 20-48 mg/m\u003csup\u003e2\u003c/sup\u003e/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*3A/*3A, *2/*3A, *3A/*3C, *3C/*4, *2/*3C, *3A/*4\u003c/td\u003e\u003ctd\u003eExtremely high concentrations of TGN metabolites; fatal toxicity possible without dose decrease.  Greatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003eAn individual carrying two uncertain/unknown function alleles OR one normal function allele and one uncertain/unknown function allele\u003c/td\u003e\u003ctd\u003e*6/*8, *1/*8\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eNormal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""table-2-recommended-dosing-of-thioguanine-by-nudt15-phenotype\""\u003eTable 2: Recommended dosing of thioguanine by NUDT15 phenotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2018 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eNUDT15 phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eDosing recommendations\u003c/th\u003e\u003cth\u003eClassification of recommendations\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNormal Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal risk of thiopurine-related leukopenia, neutropenia, myelosuppression\u003c/td\u003e\u003ctd\u003eStart with normal starting dose\u003csup\u003ea\u003c/sup\u003e (40-60 mg/day).  Adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine.  Allow 2 weeks to reach steady-state after each dose adjustment.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3\u003c/td\u003e\u003ctd\u003eIncreased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced doses (50% to 80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 40-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePossible Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying one uncertain function allele and one no function allele\u003c/td\u003e\u003ctd\u003e*2/*5, *3/*6\u003c/td\u003e\u003ctd\u003eIncreased risk of thiopurine-related leukopenia, neutropenia, myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with reduced doses (50% to 80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 40-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor Metabolizer\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly increased risk of thiopurine-related leukopenia, neutropenia, myelosuppression\u003c/td\u003e\u003ctd\u003eReduce doses to 25% of normal dose\u003csup\u003ea\u003c/sup\u003e and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIndeterminate\u003c/td\u003e\u003ctd\u003eAn individual carrying two uncertain function alleles OR one normal function allele and one uncertain function allele\u003c/td\u003e\u003ctd\u003e*1/*4, *1/*5, *4/*5, *5/*6\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eNormal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""table-3-recommended-dosing-of-thioguanine-by-tpmt-and-nudt15-phenotypes\""\u003eTable 3: Recommended dosing of thioguanine by TPMT and NUDT15 phenotypes\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Figure 2 and Table 2 of the 2018 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype\u003c/th\u003e\u003cth\u003eTPMT Normal Metabolizer\u003c/th\u003e\u003cth\u003eTPMT Intermediate Metabolizer\u003c/th\u003e\u003cth\u003eTPMT Possible Intermediate Metabolizer\u003c/th\u003e\u003cth\u003eTPMT Poor Metabolizer\u003c/th\u003e\u003cth\u003eIndeterminate\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT 15 Normal Metabolizer\u003c/td\u003e\u003ctd\u003eUse standard dose\u003c/td\u003e\u003ctd\u003eStart with reduced doses (50% to 80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 40-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day (e.g. 20-48 mg/m\u003csup\u003e2\u003c/sup\u003e/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eStart with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eStart with reduced doses (50% to 80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 40-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.\u003c/td\u003e\u003ctd\u003eStart with reduced doses (50% to 80% of normal dose) if normal starting dose\u003csup\u003ea\u003c/sup\u003e is \u0026gt; or \u003d 40-60 mg/m\u003csup\u003e2\u003c/sup\u003e/day (e.g. 20-48 mg/m\u003csup\u003e2\u003c/sup\u003e/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 2-4 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eStart with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Possible Intermediate Metabolizer\u003c/td\u003e\u003ctd\u003eSee NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eSee NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer/NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eSee NUDT15 Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Poor  Metabolizer\u003c/td\u003e\u003ctd\u003eReduce doses to 25% of normal dose\u003csup\u003ea\u003c/sup\u003e and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eReduce doses to 25% of normal dose\u003csup\u003ea\u003c/sup\u003e and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eSee TPMT Intermediate Metabolizer.\u003c/td\u003e\u003ctd\u003eStart with drastically reduced doses (reduce daily dose\u003csup\u003ea\u003c/sup\u003e by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines.  Allow 4-6 weeks to reach steady-state after each dose adjustment.  If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents.  For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy.\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 Indeterminate\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003eNormal starting doses vary by race/ethnicity and treatment regimens.  If standard dose is below normal recommended dose, dose reduction might not be recommended for intermediate metabolizers.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2016-update-on-pharmgkb\""\u003eMay 2016 Update on PharmGKB\u003c/h3\u003e\n\u003cp\u003eSeveral studies have reported that individuals who carry low-function alleles for NUDT15 are unable to tolerate usual doses of thiopurines. [Articles:\u003ca href\u003d\""/pmid/25108385\""\u003e25108385\u003c/a\u003e, \u003ca href\u003d\""/pmid/25624441\""\u003e25624441\u003c/a\u003e, \u003ca href\u003d\""/pmid/26033531\""\u003e26033531\u003c/a\u003e, \u003ca href\u003d\""/pmid/26076924\""\u003e26076924\u003c/a\u003e, \u003ca href\u003d\""/pmid/26405151\""\u003e26405151\u003c/a\u003e, \u003ca href\u003d\""/pmid/26503813\""\u003e26503813\u003c/a\u003e, \u003ca href\u003d\""/pmid/26590936\""\u003e26590936\u003c/a\u003e, \u003ca href\u003d\""/pmid/26735160\""\u003e26735160\u003c/a\u003e, \u003ca href\u003d\""/pmid/26878724\""\u003e26878724\u003c/a\u003e] These alleles are more common among those of Asian ancestry and Hispanic ethnicity than others. [Articles:\u003ca href\u003d\""/pmid/25624441\""\u003e25624441\u003c/a\u003e, \u003ca href\u003d\""/pmid/26878724\""\u003e26878724\u003c/a\u003e] The dose tolerated by those with two low-function alleles is only ~ 10% that tolerated by those with no low-function NUDT15 or TPMT alleles. [Articles:\u003ca href\u003d\""/pmid/25624441\""\u003e25624441\u003c/a\u003e, \u003ca href\u003d\""/pmid/26878724\""\u003e26878724\u003c/a\u003e] CPIC is planning a guideline to address NUDT15 variants and possible dosing recommendations for thiopurines.\u003c/p\u003e\n\u003ch3 id\u003d\""april-2013-update\""\u003eApril 2013 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication January 2013.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.nature.com/clpt/journal/vaop/naam/index.html#17012013\"" target\u003d\""_blank\""\u003e2013 update of CPIC guidelines regarding azathioprine, thioguanine and mercaptopurine\u003c/a\u003e, have been published in Clinical Pharmacology and Therapeutics.  Literature published between June 2010-November 2012 was reviewed and there is \u003cstrong\u003eno new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current.\u003c/strong\u003e\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003epediatric patients\u003c/li\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_TPMT_update.pdf\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/CPIC_TPMT_update_supp.pdf\""\u003e2013 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""march-2011\""\u003eMarch 2011\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication January 2011.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for azathioprine, thioguanine and mercaptopurine were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2011 thiopurine dosing guidelines:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Thiopurines are most commonly used to treat nonmalignant conditions but are also critical anticancer agents. The approach to dosing adjustments based on TPMT status may differ depending on the clinical indication and the propensity to initiate therapy at higher vs. lower starting doses. We and others advocate testing for TPMT status prior to initiating thiopurine therapy, so that starting dosages can be adjusted accordingly.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/cpic-tpmt-article.pdf\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/cpic-tpmt-supplement.pdf\""\u003e2011 supplement\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983453E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/""}]},""status"":""success""}"
PA166104960,Guideline Annotation,Annotation of DPWG Guideline for thioguanine and TPMT,t,PA451663,Dutch Pharmacogenetics Working Group,"<p>Select an alternative drug or reduce the initial dose of thioguanine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.</p>
","<h3 id=""august-2019-update"">August 2019 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers. They updated the wording for the intermediate metabolizer recommendation, reflected in the table below.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>TPMT IM</td><td>thioguanine</td><td>Genetic variation reduces conversion of thioguanine to inactive metabolites. This increases the risk of serious adverse events such as myelosuppression.</td><td>- IMMUNOSUPPRESSION: Start with 75% of the standard dose.  Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. The frequency of monitoring should be increased.<br/>- LEUKAEMIA: Start with 75% of the standard thioguanine dose, or start with the standard dose and reduce to 75% if side effects necessitate a dose reduction.  It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity.  The initial dose should be adjusted based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>Note: more stringent dose reductions are necessary if the patient is also NUDT15 IM.</td></tr>
<tr><td>TPMT PM</td><td>thioguanine</td><td>Genetic variation reduces conversion of thioguanine to inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.</td><td>1. Choose an alternative or start with 6-7% of the standard dose.  Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased.<br/>2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) develop.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001906.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>TPMT IM</td><td>thioguanine</td><td>Genetic variation reduces conversion of thioguanine to inactive metabolites. This increases the risk of serious adverse events such as myelosuppression.</td><td>Start with 75% of the standard dose.  Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. The frequency of monitoring should be increased.</td></tr>
<tr><td>TPMT PM</td><td>thioguanine</td><td>Genetic variation reduces conversion of thioguanine to inactive metabolites. This increases the risk of serious adverse events such as myelosuppression.</td><td>1. Choose an alternative or start with 6-7% of the standard dose.  Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased.  2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) develop.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001906.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on TPMT genotype [Article:<a href=""/pmid/21412232"">21412232</a>].  They recommend selecting an alternative drug for patients carrying inactive alleles.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>IM (one inactive allele: *2, *3, *4-*18)</td><td>Select alternative drug.  Insufficient data to allow calculation of dose adjustment.</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10<sup>9</sup>/l; leucopenia 1.0-2.0x10<sup>9</sup>/l; thrombocytopenia 25-50x10<sup>9</sup>/l; severe diarrhea.</td></tr>
<tr><td>PM (two inactive alleles: *2, *3, *4-*18)</td><td>Select alternative drug.  Insufficient data to allow calculation of dose adjustment.</td><td>Published case reports, well documented, and having relevant pharmacokinetic or clinical endpoints. Well documented case series.</td><td>Clinical effect (S): death; arrhythmia; unanticipated myelosuppression.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104960"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104960"",""name"":""Annotation of DPWG Guideline for thioguanine and TPMT"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704539E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450414873E9,""date"":""2019-05-22T16:39:12.063-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450821361E9,""date"":""2019-10-08T19:31:45.621-07:00"",""description"":""Changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45095648E9,""date"":""2020-01-31T14:20:15.750-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096392E9,""date"":""2020-02-11T08:08:44.012-08:00"",""description"":""Fixed links to 2018 and 2019 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451663"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451663"",""name"":""thioguanine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA356"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA356"",""symbol"":""TPMT"",""name"":""thiopurine S-methyltransferase""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981928E9,""html"":""\u003cp\u003eSelect an alternative drug or reduce the initial dose of thioguanine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981927E9,""html"":""\u003ch3 id\u003d\""august-2019-update\""\u003eAugust 2019 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers. They updated the wording for the intermediate metabolizer recommendation, reflected in the table below.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT IM\u003c/td\u003e\u003ctd\u003ethioguanine\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of thioguanine to inactive metabolites. This increases the risk of serious adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003e- IMMUNOSUPPRESSION: Start with 75% of the standard dose.  Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. The frequency of monitoring should be increased.\u003cbr/\u003e- LEUKAEMIA: Start with 75% of the standard thioguanine dose, or start with the standard dose and reduce to 75% if side effects necessitate a dose reduction.  It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity.  The initial dose should be adjusted based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNote: more stringent dose reductions are necessary if the patient is also NUDT15 IM.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT PM\u003c/td\u003e\u003ctd\u003ethioguanine\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of thioguanine to inactive metabolites. This increases the risk of serious, life-threatening adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative or start with 6-7% of the standard dose.  Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased.\u003cbr/\u003e2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) develop.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001906.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on TPMT genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT IM\u003c/td\u003e\u003ctd\u003ethioguanine\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of thioguanine to inactive metabolites. This increases the risk of serious adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003eStart with 75% of the standard dose.  Adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. The frequency of monitoring should be increased.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eTPMT PM\u003c/td\u003e\u003ctd\u003ethioguanine\u003c/td\u003e\u003ctd\u003eGenetic variation reduces conversion of thioguanine to inactive metabolites. This increases the risk of serious adverse events such as myelosuppression.\u003c/td\u003e\u003ctd\u003e1. Choose an alternative or start with 6-7% of the standard dose.  Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and effectiveness. The frequency of monitoring should be increased.  2. If the dose is decreased: advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) develop.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001906.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on TPMT genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  They recommend selecting an alternative drug for patients carrying inactive alleles.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eIM (one inactive allele: *2, *3, *4-*18)\u003c/td\u003e\u003ctd\u003eSelect alternative drug.  Insufficient data to allow calculation of dose adjustment.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (\u0026gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR \u0026gt; 6.0; neutropenia 0.5-1.0x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 1.0-2.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 25-50x10\u003csup\u003e9\u003c/sup\u003e/l; severe diarrhea.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive alleles: *2, *3, *4-*18)\u003c/td\u003e\u003ctd\u003eSelect alternative drug.  Insufficient data to allow calculation of dose adjustment.\u003c/td\u003e\u003ctd\u003ePublished case reports, well documented, and having relevant pharmacokinetic or clinical endpoints. Well documented case series.\u003c/td\u003e\u003ctd\u003eClinical effect (S): death; arrhythmia; unanticipated myelosuppression.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166184612,Guideline Annotation,Annotation of DPWG Guideline for thioguanine and NUDT15,t,PA451663,Dutch Pharmacogenetics Working Group,"<p>Select an alternative drug or reduce the initial dose of thioguanine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.</p>
","<h3 id=""august-2019-guideline"">August 2019 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on NUDT15 genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers. They updated the wording for the intermediate metabolizer recommendation, reflected in the table below.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>NUDT15 IM</td><td>thioguanine</td><td>Grade = 2 leukopaenia occurs in an estimated 40% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of thioguanine.</td><td>- IMMUNOSUPPRESSION: start with 75% of the standard dose. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>NOTE: The percentage of 75% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15.<br/>NOTE: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.<br/>- LEUKAEMIA: start with 75% of the standard tioguanine dose or start with the standard dose and reduce to 75% if side effects necessitate a dose reduction. It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>NOTE: The percentage of 75% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15.<br/>NOTE: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.<br/>Note: more stringent dose reductions are necessary if the patient is also TPMT IM.</td></tr>
<tr><td>NUDT15 PM</td><td>thioguanine</td><td>Grade = 2 leukopaenia occurs in an estimated 95% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of thioguanine.</td><td>- avoid thioguanine<br/>- if it is not possible to avoid tioguanine: use 10% of the standard dose and advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. Monitoring should be performed at an increased frequency.<br/>NOTE: The percentage of 10% is based on the analogy with azathioprine and mercaptopurine and the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. For NUDT15 PM, a percentage of &lt; 20% was calculated for azathioprine and mercaptopurine, but there were insufficient data available to calculate the exact percentage.<br/>NOTE: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0007033.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166184612"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166184612"",""name"":""Annotation of DPWG Guideline for thioguanine and NUDT15"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450821369E9,""date"":""2019-10-08T00:00:00-07:00"",""description"":""August 2019 Guideline"",""type"":""Update"",""version"":0.0},{""id"":1.450963906E9,""date"":""2020-02-11T08:03:43.510-08:00"",""description"":""Fixed links to 2019 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451663"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451663"",""name"":""thioguanine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA134963132"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA134963132"",""symbol"":""NUDT15"",""name"":""nudix hydrolase 15""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450821366E9,""html"":""\u003cp\u003eSelect an alternative drug or reduce the initial dose of thioguanine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450821367E9,""html"":""\u003ch3 id\u003d\""august-2019-guideline\""\u003eAugust 2019 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for thioguanine based on NUDT15 genotype.  They recommend reducing the initial dose for patients that are intermediate metabolizers and selecting an alternative drug or reducing the initial dose for patients that are poor metabolizers. They updated the wording for the intermediate metabolizer recommendation, reflected in the table below.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 IM\u003c/td\u003e\u003ctd\u003ethioguanine\u003c/td\u003e\u003ctd\u003eGrade \u003d 2 leukopaenia occurs in an estimated 40% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of thioguanine.\u003c/td\u003e\u003ctd\u003e- IMMUNOSUPPRESSION: start with 75% of the standard dose. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNOTE: The percentage of 75% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15.\u003cbr/\u003eNOTE: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\u003cbr/\u003e- LEUKAEMIA: start with 75% of the standard tioguanine dose or start with the standard dose and reduce to 75% if side effects necessitate a dose reduction. It is not known whether dose reduction in advance results in the same efficacy as dose reduction based on toxicity. Adjustment of the initial dose should be performed based on toxicity (monitoring of the blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNOTE: The percentage of 75% is based on the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15.\u003cbr/\u003eNOTE: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\u003cbr/\u003eNote: more stringent dose reductions are necessary if the patient is also TPMT IM.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNUDT15 PM\u003c/td\u003e\u003ctd\u003ethioguanine\u003c/td\u003e\u003ctd\u003eGrade \u003d 2 leukopaenia occurs in an estimated 95% of these patients with standard therapy. The genetic variation increases the concentration of the fully activated metabolite of thioguanine.\u003c/td\u003e\u003ctd\u003e- avoid thioguanine\u003cbr/\u003e- if it is not possible to avoid tioguanine: use 10% of the standard dose and advise patients to seek medical attention when symptoms of myelosuppression (such as severe sore throat in combination with fever, regular nosebleeds and tendency to bruising) occur Any adjustment of the initial dose should be guided by toxicity (monitoring of blood counts) and efficacy. Monitoring should be performed at an increased frequency.\u003cbr/\u003eNOTE: The percentage of 10% is based on the analogy with azathioprine and mercaptopurine and the analogy with TPMT, for which the gene variants have a comparable effect on toxicity to those of NUDT15. For NUDT15 PM, a percentage of \u0026lt; 20% was calculated for azathioprine and mercaptopurine, but there were insufficient data available to calculate the exact percentage.\u003cbr/\u003eNOTE: Dose adjustment based on the total of 6-TGN metabolites is not possible for these patients, as they develop toxicity within the therapeutic range that applies for patients without gene variants.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0007033.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182807,Guideline Annotation,Annotation of DPWG Guideline for ticagrelor and CYP2C19,f,PA165374673,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for ticagrelor based on CYP2C19 genotypes.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for ticagrelor based on CYP2C19 genotypes. They conclude that there is not a gene-drug interaction. See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0003515.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182807"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182807"",""name"":""Annotation of DPWG Guideline for ticagrelor and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450414893E9,""date"":""2019-05-22T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.45082068E9,""date"":""2019-10-03T16:32:34.213-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450963921E9,""date"":""2020-02-11T08:09:52.232-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA165374673"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA165374673"",""name"":""ticagrelor""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.45041489E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for ticagrelor based on CYP2C19 genotypes.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450414891E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for ticagrelor based on CYP2C19 genotypes. They conclude that there is not a gene-drug interaction. See the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0003515.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104986,Guideline Annotation,Annotation of DPWG Guideline for tolbutamide and CYP2C9,f,PA451718,Dutch Pharmacogenetics Working Group,"<p>There are currently no dosing recommendations for tolbutamide based on <em>CYP2C9</em> genotype.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for tolbutamide based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction. See the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</p>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001903.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Association for the Advancement of Pharmacy - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tolbutamide based on <em>CYP2C9</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>].They concluded that there are no recommendations at this time.</p>
<table class=""table"">
<thead>
<tr><th>Genotype</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>CYP2C9 *1/*2</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *2/*2</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *1/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>CYP2C9 *2/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (NS) Kinetic effect (NS)</td></tr>
<tr><td>CYP2C9 *3/*3</td><td>None</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms females, &lt;470 ms males); INR increase &lt; 4.5</td></tr>
</tbody>
</table>
<p>Kinetic effect (S) |</p>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104986"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104986"",""name"":""Annotation of DPWG Guideline for tolbutamide and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704541E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415077E9,""date"":""2019-05-23T16:44:38.917-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820679E9,""date"":""2019-10-03T16:30:44.974-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.4509565E9,""date"":""2020-01-31T14:20:45.063-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.45096394E9,""date"":""2020-02-11T08:11:05.625-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":false,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451718"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451718"",""name"":""tolbutamide""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981982E9,""html"":""\u003cp\u003eThere are currently no dosing recommendations for tolbutamide based on \u003cem\u003eCYP2C9\u003c/em\u003e genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981981E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for tolbutamide based on CYP2C9 genotypes. They conclude that no action is needed for this gene-drug interaction. See the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001903.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Association for the Advancement of Pharmacy - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tolbutamide based on \u003cem\u003eCYP2C9\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].They concluded that there are no recommendations at this time.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eGenotype\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*2\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*2\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *1/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026gt; 3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia  \u0026gt; 75x10\u003csup\u003e9\u003c/sup\u003e/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *2/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (NS) Kinetic effect (NS)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 *3/*3\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms females, \u0026lt;470 ms males); INR increase \u0026lt; 4.5\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eKinetic effect (S) |\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104959,Guideline Annotation,Annotation of DPWG Guideline for tramadol and CYP2D6,t,PA451735,Dutch Pharmacogenetics Working Group,"<p>Be alert to a reduced efficacy of tramadol in CYP2D6 intermediate or poor metabolizers. If tramadol is not effective in these patients, try a dose increase or select an alternative to tramadol (not codeine) and be alert for symptoms of insufficient pain relief. For CYP2D6 ultrarapid metabolizers, use an alternative to tramadol (not codeine) or use 40% of the standard dose and be alert to side effects.</p>
","<p><em><strong>Note that the FDA released a <a rel=""noopener noreferrer"" href=""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery"" target=""_blank"">safety announcement</a> on 4/20/2017 stating that codeine and tramadol should not be used in children under 12 years.</strong></em></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tramadol based on CYP2D6 genotype. They recommend that an alternative analgesic (not codeine) be selected or a dose reduction be considered for CYP2D6 ultrarapid metabolizers (UMs). If tramadol is not effective in CYP2D6 intermediate metabolizers (IMs) and poor metabolizers (PMs), a dose increase or an alternative analgesic (not codeine) can be considered.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>tramadol</td><td>The genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects.</td><td>As the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.<br/>1. Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.<br/>2. If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).</td></tr>
<tr><td>CYP2D6 IM</td><td>tramadol</td><td>The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia.</td><td>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.<br/>1. be alert to a reduced effectiveness<br/>2. in the case of inadequate effectiveness:<br/>a. try a dose increase<br/>b. if this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.<br/>3. if no alternative is selected: advise the patient to report inadequate analgesia</td></tr>
<tr><td>CYP2D6 PM</td><td>tramadol</td><td>The genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia.</td><td>It is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.<br/>1. be alert to a reduced effectiveness<br/>2. in the case of inadequate effectiveness:<br/>a. try a dose increase.<br/>b. if this does not work: choose an alternative Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.<br/>3. if no alternative is selected: advise the patient to report inadequate analgesia.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001590.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tramadol based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  For PM and IM genotypes, they recommend selecting an alternative drug (not oxycodone or codeine) and/or being extra alert to symptoms of insufficient pain relief.  For UM genotypes, they recommend using a 30% decreased dose and being alert for ADEs, or using an alternative drug (not oxycodone or codeine).</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Select alternative drug-not oxycodone or codeine- or be alert to symptoms of insufficient pain relief.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc.); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Be alert to decreased efficacy. Consider dose increase.  If response is still inadequate, select alternative drug- not oxycodone or codeine-or be alert to symptoms of insufficient pain relief.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10<sup>9</sup>/l; leucopenia &gt; 3.0x10<sup>9</sup>/l; thrombocytopenia  &gt; 75x10<sup>9</sup>/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Reduce dose by 30% and be alert to ADEs (e.g., nausea, vomiting, constipation, respiratory depression, confusion, urinary retention) or select alternative drug (e.g., acetaminophen, NSAID, morphine-not oxycodone or codeine).</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good&quot; and &quot;moderate&quot; quality.</li>
<li>S: statistically significant difference.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104959"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104959"",""name"":""Annotation of DPWG Guideline for tramadol and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704543E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.448616263E9,""date"":""2017-05-02T11:43:08.837-07:00"",""description"":""added note about FDA safety announcement"",""type"":""Update"",""version"":0.0},{""id"":1.450415049E9,""date"":""2019-05-23T15:10:59.430-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820678E9,""date"":""2019-10-03T16:28:39.990-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45095652E9,""date"":""2020-01-31T14:21:07.005-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963941E9,""date"":""2020-02-11T08:13:45.147-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451735"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451735"",""name"":""tramadol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981886E9,""html"":""\u003cp\u003eBe alert to a reduced efficacy of tramadol in CYP2D6 intermediate or poor metabolizers. If tramadol is not effective in these patients, try a dose increase or select an alternative to tramadol (not codeine) and be alert for symptoms of insufficient pain relief. For CYP2D6 ultrarapid metabolizers, use an alternative to tramadol (not codeine) or use 40% of the standard dose and be alert to side effects.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981885E9,""html"":""\u003cp\u003e\u003cem\u003e\u003cstrong\u003eNote that the FDA released a \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm?source\u003dgovdelivery\u0026amp;utm_medium\u003demail\u0026amp;utm_source\u003dgovdelivery\"" target\u003d\""_blank\""\u003esafety announcement\u003c/a\u003e on 4/20/2017 stating that codeine and tramadol should not be used in children under 12 years.\u003c/strong\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tramadol based on CYP2D6 genotype. They recommend that an alternative analgesic (not codeine) be selected or a dose reduction be considered for CYP2D6 ultrarapid metabolizers (UMs). If tramadol is not effective in CYP2D6 intermediate metabolizers (IMs) and poor metabolizers (PMs), a dose increase or an alternative analgesic (not codeine) can be considered.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003etramadol\u003c/td\u003e\u003ctd\u003eThe genetic variation increases the conversion of tramadol to a metabolite with a stronger opioid effect. This can result in an increase in potentially life-threatening side effects.\u003c/td\u003e\u003ctd\u003eAs the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes, the effect of a dose reduction cannot be predicted with certainty.\u003cbr/\u003e1. Select an alternative. Do not choose codeine, as it is contra-indicated for CYP2D6 UM. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in side effects in patients.\u003cbr/\u003e2. If an alternative is not possible, use 40% of the standard dose. Advise the patient to report side effects (such as drowsiness, confusion, constipation, nausea and vomiting, respiratory depression or urine retention).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003etramadol\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia.\u003c/td\u003e\u003ctd\u003eIt is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.\u003cbr/\u003e1. be alert to a reduced effectiveness\u003cbr/\u003e2. in the case of inadequate effectiveness:\u003cbr/\u003ea. try a dose increase\u003cbr/\u003eb. if this does not work: choose an alternative. Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.\u003cbr/\u003e3. if no alternative is selected: advise the patient to report inadequate analgesia\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003etramadol\u003c/td\u003e\u003ctd\u003eThe genetic variation reduces the conversion of tramadol to a metabolite with a higher activity. This can result in reduced analgesia.\u003c/td\u003e\u003ctd\u003eIt is not possible to provide a recommendation for dose adjustment, because the total analgesic effect changes when the ratio between the mother compound and the active metabolite changes.\u003cbr/\u003e1. be alert to a reduced effectiveness\u003cbr/\u003e2. in the case of inadequate effectiveness:\u003cbr/\u003ea. try a dose increase.\u003cbr/\u003eb. if this does not work: choose an alternative Do not select codeine, as this is also metabolised by CYP2D6. Morphine is not metabolised by CYP2D6. Oxycodone is metabolised by CYP2D6 to a limited extent, but this does not result in differences in analgesia in patients.\u003cbr/\u003e3. if no alternative is selected: advise the patient to report inadequate analgesia.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001590.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tramadol based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For PM and IM genotypes, they recommend selecting an alternative drug (not oxycodone or codeine) and/or being extra alert to symptoms of insufficient pain relief.  For UM genotypes, they recommend using a 30% decreased dose and being alert for ADEs, or using an alternative drug (not oxycodone or codeine).\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eSelect alternative drug-not oxycodone or codeine- or be alert to symptoms of insufficient pain relief.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc.); neutropenia \u0026gt; 1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026gt; 3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia  \u0026gt; 75x10\u003csup\u003e9\u003c/sup\u003e/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eBe alert to decreased efficacy. Consider dose increase.  If response is still inadequate, select alternative drug- not oxycodone or codeine-or be alert to symptoms of insufficient pain relief.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): short-lived discomfort (\u0026lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia \u0026gt; 1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia \u0026gt; 3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia  \u0026gt; 75x10\u003csup\u003e9\u003c/sup\u003e/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eReduce dose by 30% and be alert to ADEs (e.g., nausea, vomiting, constipation, respiratory depression, confusion, urinary retention) or select alternative drug (e.g., acetaminophen, NSAID, morphine-not oxycodone or codeine).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good\u0026quot; and \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104992,Guideline Annotation,Annotation of DPWG Guideline for zuclopenthixol and CYP2D6,t,PA452629,Dutch Pharmacogenetics Working Group,"<p>For CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose or select an alternative drug that is not metabolized by CYP2D6. For ultrarapid metabolizers, be alert to low zuclopenthixol plasma concentrations and, if necessary, increase the dose or select an alternative drug.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for zuclopenthixol based on CYP2D6 genotype. They recommend a dose reduction or an alternative drug that is not metabolized by CYP2D6 for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs). They also recommend a dose increase or an alternative drug that is not metabolized by CYP2D6 for patients who are CYP2D6 ultrarapid metabolizers (UMs) who have low zuclopenthixol plasma concentrations.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>zuclopenthixol</td><td>The genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause decreased zuclopentixol plasma concentrations.</td><td>No data have been published from studies into the pharmacokinetics and effects of zuclopentixol for this phenotype.<br/>As a precaution, the prescriber should advised to be alert to a decreased zuclopentixol plasma concentration and - if necessary - the dose should be increased on the basis of the clinical effect, or an alternative should be prescribed according to the current guidelines. Antipsychotics that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.</td></tr>
<tr><td>CYP2D6 IM</td><td>zuclopenthixol</td><td>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause increased zuclopentixol plasma concentrations.</td><td>Advise the prescriber to start with 75% of the standard dose or to choose an alternative according to the current guidelines. Antipsychotics that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.</td></tr>
<tr><td>CYP2D6 PM</td><td>zuclopenthixol</td><td>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause increased zuclopentixol plasma concentrations.</td><td>Advise the prescriber to start with 50% of the standard dose or to choose an alternative according to the current guidelines. Antipsychotics that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001548.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for zuclopenthixol based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  For PM genotypes, they recommend reducing dose by 50% or selecting an alternative drug.  For IM genotypes, they recommend reducing dose by 25% or selecting an alternative drug.  For UM genotypes, they state that there are insufficient data to allow calculation of dose adjustment, and to be alert to low zuclopenthixol plasma concentrations or to select an alternative drug.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Reduce dose by 50% or select alternative drug (e.g., flupenthixol, quetiapine, olanzapine, clozapine).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms ); INR increase &lt; 4.5.  Kinetic effect (S).</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Reduce dose by 25% or select alternative drug (flupenthixol, quetiapine, olanzapine, clozapine).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5. Kinetic effect (S).</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Insufficient data to allow calculation of dose adjustment. Be alert to low zuclopenthixol plasma concentrations or select alternative drug (flupenthixol, quetiapine, olanzapine, clozapine).</td><td>not given.</td><td>not given.</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods</a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/zuclopenthixol_CYP2D6_271111.pdf"">Zuclopenthixol CYP2D6 </a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104992"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104992"",""name"":""Annotation of DPWG Guideline for zuclopenthixol and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704549E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.45041507E9,""date"":""2019-05-23T16:10:30.991-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820674E9,""date"":""2019-10-03T16:15:50.560-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.45095654E9,""date"":""2020-01-31T14:22:54.411-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963982E9,""date"":""2020-02-11T08:51:48.421-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA452629"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA452629"",""name"":""zuclopenthixol""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982014E9,""html"":""\u003cp\u003eFor CYP2D6 poor and intermediate metabolizers, reduce zuclopenthixol dose or select an alternative drug that is not metabolized by CYP2D6. For ultrarapid metabolizers, be alert to low zuclopenthixol plasma concentrations and, if necessary, increase the dose or select an alternative drug.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982013E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for zuclopenthixol based on CYP2D6 genotype. They recommend a dose reduction or an alternative drug that is not metabolized by CYP2D6 for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs). They also recommend a dose increase or an alternative drug that is not metabolized by CYP2D6 for patients who are CYP2D6 ultrarapid metabolizers (UMs) who have low zuclopenthixol plasma concentrations.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003ezuclopenthixol\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to increased metabolic capacity of CYP2D6, which may cause decreased zuclopentixol plasma concentrations.\u003c/td\u003e\u003ctd\u003eNo data have been published from studies into the pharmacokinetics and effects of zuclopentixol for this phenotype.\u003cbr/\u003eAs a precaution, the prescriber should advised to be alert to a decreased zuclopentixol plasma concentration and - if necessary - the dose should be increased on the basis of the clinical effect, or an alternative should be prescribed according to the current guidelines. Antipsychotics that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003ezuclopenthixol\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause increased zuclopentixol plasma concentrations.\u003c/td\u003e\u003ctd\u003eAdvise the prescriber to start with 75% of the standard dose or to choose an alternative according to the current guidelines. Antipsychotics that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003ezuclopenthixol\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to decreased metabolic capacity of CYP2D6, which may cause increased zuclopentixol plasma concentrations.\u003c/td\u003e\u003ctd\u003eAdvise the prescriber to start with 50% of the standard dose or to choose an alternative according to the current guidelines. Antipsychotics that are not metabolised via CYP2D6 - or to a lesser extent - include, for example, flupentixol, quetiapine, olanzapine and clozapine.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001548.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for zuclopenthixol based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For PM genotypes, they recommend reducing dose by 50% or selecting an alternative drug.  For IM genotypes, they recommend reducing dose by 25% or selecting an alternative drug.  For UM genotypes, they state that there are insufficient data to allow calculation of dose adjustment, and to be alert to low zuclopenthixol plasma concentrations or to select an alternative drug.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eReduce dose by 50% or select alternative drug (e.g., flupenthixol, quetiapine, olanzapine, clozapine).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms , \u0026lt;470 ms ); INR increase \u0026lt; 4.5.  Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eReduce dose by 25% or select alternative drug (flupenthixol, quetiapine, olanzapine, clozapine).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5. Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment. Be alert to low zuclopenthixol plasma concentrations or select alternative drug (flupenthixol, quetiapine, olanzapine, clozapine).\u003c/td\u003e\u003ctd\u003enot given.\u003c/td\u003e\u003ctd\u003enot given.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods\u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/zuclopenthixol_CYP2D6_271111.pdf\""\u003eZuclopenthixol CYP2D6 \u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166105001,Guideline Annotation,"Annotation of CPIC Guideline for trimipramine and CYP2C19,CYP2D6",t,PA451791,Clinical Pharmacogenetics Implementation Consortium,"<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.</li>
</ul>
</li>
</ul>
<h3 id=""december-2016-update"">December 2016 Update</h3>
<p><em>Advance online publication December 2016.</em></p>
<ul>
<li>The 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">(CPIC)</a>.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.</li>
<li>Excerpt from the 2016 dosing guideline update:
<ul>
<li>&quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.&quot;</li>
<li>&quot;There is substantial evidence linking <em>CYP2D6</em> and <em>CYP2C19</em> genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have <em>CYP2D6</em> or <em>CYP2C19</em> genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.&quot;</li>
<li>&quot; There are scarce studies focusing solely on <em>CYP2D6</em> or <em>CYP2C19</em> genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.&quot;</li>
</ul>
</li>
<li>The guideline includes dosing recommendation for TCAs based on:
<ul>
<li>CYP2D6 phenotype (<a href=""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1 below</a>)</li>
<li>CYP2C19 phenotype (<a href=""#table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype"">Table 2 below</a>)</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf"" target=""_blank"">2016 supplement</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2d6RefMaterials"">CYP2D6 Gene-specific Information Tables</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c19RefMaterials"">CYP2C19 Gene-specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2016/Trimipramine_Drug_Resource_Mappings.xlsx"" target=""_blank"">Trimipramine Drug Resource Mappings</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype"">Table 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Activity score</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic Recommendations<sup>a, b</sup></th><th>Classification of recommendation for other TCAs <sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 Ultrarapid metabolizer (~1-20% of patients)<sup>d</sup></td><td>&gt;2.0</td><td>An individual carrying more than two copies of functional alleles</td><td>*1/*1xN, *1/*2xN</td><td>Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.</td><td>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Normal metabolizer (~72-88% of patients)<sup>d</sup></td><td>1.0-2.0<sup>f</sup></td><td>An individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0</td><td>*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5</td><td>Normal metabolism of TCAs.</td><td>Initiate therapy with recommended starting dose.<sup>g</sup></td><td>Strong</td></tr>
<tr><td>CYP2D6 Intermediate metabolizer (~1-13% of patients)<sup>d</sup></td><td>0.5</td><td>An individual carrying one decreased and one no function allele</td><td>*4/*41, *5/*9, *4/*10</td><td>Reduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Consider 25% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2D6 Poor metabolizer (~1-10% of patients)<sup>d</sup></td><td>0</td><td>An individual carrying only no function alleles</td><td>*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6</td><td>Greatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.</td><td>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.<br/>If a TCA is warranted, consider 50% reduction of recommended starting dose.<sup>g</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
<p><sup>g</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<h3 id=""table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype"">Table 2: Dosing recommendations for TCAs based on CYP2C19 phenotype:</h3>
<p><em>Adapted from Tables 1 and 3 of the 2016 guideline update.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic recommendations<sup>a,b</sup></th><th>Classification of recommendations for amitriptyline<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 Ultrarapid metabolizer (~2-5% of patients)<sup>d</sup></td><td>An individual carrying two increased function alleles</td><td>*17/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Rapid metabolizer (~2-30% of patients)<sup>d</sup></td><td>An individual carrying one normal and one increased function allele</td><td>*1/*17</td><td>Increased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Normal metabolizer (~35-50% of patients)<sup>d</sup></td><td>An individual carrying two normal function alleles</td><td>*1/*1</td><td>Normal metabolism of tertiary amines.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Strong</td></tr>
<tr><td>CYP2C19 Intermediate metabolizer (~18-45% of patients)<sup>d</sup></td><td>An individual carrying one normal and one no function allele or one no and one increased function allele</td><td>*1/*2, *1/*3, *2/*17<sup>g</sup></td><td>Reduced metabolism of tertiary amines compared to normal metabolizers.</td><td>Initiate therapy with recommended starting dose.<sup>f</sup></td><td>Optional</td></tr>
<tr><td>CYP2C19 Poor metabolizer (~2-15% of patients)<sup>d</sup></td><td>An individual carrying two no function alleles</td><td>*2/*2, *2/*3, *3/*3</td><td>Greatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.</td><td>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.<br/>For tertiary amines, consider a 50% reduction of the recommended starting dose.<sup>f</sup> Utilize therapeutic drug monitoring to guide dose adjustments.<sup>e</sup></td><td>Optional</td></tr>
</tbody>
</table>
<p><sup>a</sup> For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.</p>
<p><sup>b</sup> Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>
<p><sup>c</sup> The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2C19 including clomipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).</p>
<p><sup>d</sup> CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.</p>
<p><sup>e</sup> Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>
<p><sup>f</sup> Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>
<p><sup>g</sup> The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.</p>
<h3 id=""may-2013"">May 2013</h3>
<p>Guidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</p>
<p><strong>Download:</strong> <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a> and <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">supplement</a></p>
<h5 id=""excerpt-from-the-dosing-guidelines"">Excerpt from the dosing guidelines:</h5>
<p><a href=""http://www.pharmgkb.org/drug/PA448385"">Amitriptyline</a> and nortriptyline are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">guideline</a> to other tricyclics including clomipramine (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf"" target=""_blank"">Supplementary Table S18</a>), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.</p>
<p>See <a href=""http://www.pharmgkb.org/drug/PA448385"">amitriptyline</a> for excerpts and tables that summarize <em>CYP2D6</em>-based and <em>CYP2C19</em>-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (<a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf"" target=""_blank"">article</a>).</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166105001"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166105001"",""name"":""Annotation of CPIC Guideline for trimipramine and CYP2C19,CYP2D6"",""cancerGenome"":false,""guidelineGenes"":[{""id"":1.449562521E9,""alleles"":[{""id"":1.449562522E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.449562523E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980634"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980634"",""symbol"":""CYP2C19*1"",""name"":""*1""}},{""id"":1.449562524E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980635"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980635"",""symbol"":""CYP2C19*2"",""name"":""*2""}},{""id"":1.449562525E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980636"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980636"",""symbol"":""CYP2C19*3"",""name"":""*3""}},{""id"":1.449562567E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123292"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123292"",""symbol"":""CYP2C19*29"",""name"":""*29""}},{""id"":1.449562568E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123293"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123293"",""symbol"":""CYP2C19*30"",""name"":""*30""}},{""id"":1.449562569E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123294"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123294"",""symbol"":""CYP2C19*31"",""name"":""*31""}},{""id"":1.44956257E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123295"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123295"",""symbol"":""CYP2C19*32"",""name"":""*32""}},{""id"":1.449562571E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123296"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123296"",""symbol"":""CYP2C19*33"",""name"":""*33""}},{""id"":1.449562572E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115676"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115676"",""symbol"":""CYP2C19*34"",""name"":""*34""}},{""id"":1.449562573E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128094"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128094"",""symbol"":""CYP2C19*35"",""name"":""*35""}},{""id"":1.449562602E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980638"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980638"",""symbol"":""CYP2C19*5"",""name"":""*5""}},{""id"":1.449562603E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816522"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816522"",""symbol"":""CYP2C19*6"",""name"":""*6""}},{""id"":1.449562604E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816523"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816523"",""symbol"":""CYP2C19*7"",""name"":""*7""}},{""id"":1.449562605E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816524"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816524"",""symbol"":""CYP2C19*8"",""name"":""*8""}},{""id"":1.449562606E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816525"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816525"",""symbol"":""CYP2C19*9"",""name"":""*9""}},{""id"":1.449562607E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816526"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816526"",""symbol"":""CYP2C19*10"",""name"":""*10""}},{""id"":1.449562608E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816527"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816527"",""symbol"":""CYP2C19*11"",""name"":""*11""}},{""id"":1.449562609E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816528"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816528"",""symbol"":""CYP2C19*12"",""name"":""*12""}},{""id"":1.44956261E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816529"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816529"",""symbol"":""CYP2C19*13"",""name"":""*13""}},{""id"":1.449562611E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816530"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816530"",""symbol"":""CYP2C19*14"",""name"":""*14""}},{""id"":1.449562612E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816531"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816531"",""symbol"":""CYP2C19*15"",""name"":""*15""}},{""id"":1.449562613E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816532"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816532"",""symbol"":""CYP2C19*16"",""name"":""*16""}},{""id"":1.449562614E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816533"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816533"",""symbol"":""CYP2C19*17"",""name"":""*17""}},{""id"":1.449562615E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816534"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816534"",""symbol"":""CYP2C19*18"",""name"":""*18""}},{""id"":1.449562616E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816535"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816535"",""symbol"":""CYP2C19*19"",""name"":""*19""}},{""id"":1.449562617E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816536"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816536"",""symbol"":""CYP2C19*22"",""name"":""*22""}},{""id"":1.449562618E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816537"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816537"",""symbol"":""CYP2C19*23"",""name"":""*23""}},{""id"":1.449562619E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816538"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816538"",""symbol"":""CYP2C19*24"",""name"":""*24""}},{""id"":1.44956262E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816539"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816539"",""symbol"":""CYP2C19*25"",""name"":""*25""}},{""id"":1.449562621E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816540"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816540"",""symbol"":""CYP2C19*26"",""name"":""*26""}},{""id"":1.449562624E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115675"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115675"",""symbol"":""CYP2C19*28"",""name"":""*28""}},{""id"":1.45080522E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980637"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980637"",""symbol"":""CYP2C19*4"",""name"":""*4""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}},{""id"":1.449562526E9,""alleles"":[{""id"":1.449562527E9,""_label"":""Unknown"",""allele"":""Unknown"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558512"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558512E9,""resource"":""Allele Function"",""term"":""Unknown"",""termId"":""haplotypeTags:1445558512""}},{""id"":1.449562528E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449562529E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.44956253E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.449562531E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449562532E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449562533E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449562534E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449562535E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449562536E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449562537E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449562538E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449562539E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.44956254E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.449562541E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449562542E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449562543E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.449562544E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449562545E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449562546E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.449562549E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.44956255E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.449562551E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449562552E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449562553E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449562554E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449562555E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449562556E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449562557E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449562558E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449562559E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.44956256E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.449562561E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449562562E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449562563E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449562564E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449562565E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449562574E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449562575E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449562576E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449562577E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449562578E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.449562579E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.44956258E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449562581E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449562582E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449562583E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449562584E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449562585E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449562586E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449562587E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449562588E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.449562589E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.44956259E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449562591E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449562592E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449562593E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449562594E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449562595E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449562596E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449562597E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449562598E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.449562599E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.4495626E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449562601E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449562625E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449562626E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449562627E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449562628E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449562629E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.44956263E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.449562631E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449562632E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449562633E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449562634E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449562635E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449562636E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449562637E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449562638E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449562639E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.44956264E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.449562641E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449562642E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449562643E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449562644E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449562645E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449562646E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449562647E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449562648E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449562649E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.44956265E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.449562651E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449562652E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449562653E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449562654E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449562655E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449562656E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449562657E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449562658E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449562659E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.44956266E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.449562661E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449562662E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449562663E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449562664E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449562665E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449562666E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449562667E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449562668E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449562669E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.44956267E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.449562671E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449562672E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449562673E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449562674E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449562675E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.449562676E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.450042787E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042788E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824682E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.183699781E9,""date"":""2013-01-16T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.44852614E9,""date"":""2016-12-14T14:15:07.523-08:00"",""description"":""2016 TCA CPIC guideline update"",""type"":""Update"",""version"":0.0},{""id"":1.450042789E9,""date"":""2018-11-15T20:21:56.215-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824538E9,""date"":""2019-10-24T18:37:17.171-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098242"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098242E7,""resourceId"":""27997040"",""title"":""Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5478479"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293321E9,""resource"":""PubMed Central"",""resourceId"":""PMC5478479"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478479""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/27997040"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44929332E9,""resource"":""PubMed"",""resourceId"":""27997040"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/27997040""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.597"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293322E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.597"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.597""}]},{""@id"":""https://pharmgkb.org/literature/15051926"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5051926E7,""resourceId"":""23486447"",""title"":""Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3689226"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275357E9,""resource"":""PubMed Central"",""resourceId"":""PMC3689226"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/23486447"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275356E9,""resource"":""PubMed"",""resourceId"":""23486447"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/23486447""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2013.2"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449275358E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2013.2"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2013.2""}]},{""@id"":""https://pharmgkb.org/literature/15100907"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100907E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""title"":""CPIC® Guideline for Tricyclic Antidepressants and CYP2D6 and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451791"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451791"",""name"":""trimipramine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""},{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.44798194E9,""html"":""\u003cp\u003eTricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981939E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for tricyclic antidepressants and CYP2D6 and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table and the CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The recommendation for CYP2D6 IM (reduce starting dose by 25%) should be considered for CYP2D6 AS of 1 (strength of recommendation: optional). The authors of this guideline are in the process of updating this guideline to reflect this change and evaluate new evidence since the publication of this guideline.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower activity value of 0.25 for CYP2D6*10). See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Prior to the consensus projects, the combination of a duplicated normal function allele with a CYP2D6*10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2016-update\""\u003eDecember 2016 Update\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication December 2016.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe 2016 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs) have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.  Literature up to July 2016 was reviewed, recommendations and supplemental information were updated.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2016 dosing guideline update:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Both amitriptyline and nortriptyline are used as representative TCAs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. However, the results of these studies may apply to other TCAs because these drugs have comparable pharmacokinetic properties.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;There is substantial evidence linking \u003cem\u003eCYP2D6\u003c/em\u003e and \u003cem\u003eCYP2C19\u003c/em\u003e genotypes to phenotypic variability in tricyclic side-effect and pharmacokinetic profiles. Modifying pharmacotherapy for patients who have \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genomic variants that affect drug efficacy and safety could potentially improve clinical outcomes and reduce the failure rate of initial treatment.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot; There are scarce studies focusing solely on \u003cem\u003eCYP2D6\u003c/em\u003e or \u003cem\u003eCYP2C19\u003c/em\u003e genotype and association with pharmacokinetic parameters or treatment outcomes of TCAs in pediatric patients. CYP2D6 activity is fully mature by early childhood, but CYP2C19 activity may be increased in children relative to adults. Although further genomic ontogeny studies are needed, there is a lack of evidence suggesting that this guideline cannot be extrapolated to pediatric patients.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eThe guideline includes dosing recommendation for TCAs based on:\n\u003cul\u003e\n\u003cli\u003eCYP2D6 phenotype (\u003ca href\u003d\""#table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1 below\u003c/a\u003e)\u003c/li\u003e\n\u003cli\u003eCYP2C19 phenotype (\u003ca href\u003d\""#table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype\""\u003eTable 2 below\u003c/a\u003e)\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_2016.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/TCA_Supplement_2016.pdf\"" target\u003d\""_blank\""\u003e2016 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2d6RefMaterials\""\u003eCYP2D6 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c19RefMaterials\""\u003eCYP2C19 Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2016/Trimipramine_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eTrimipramine Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-tcas-based-on-cyp2d6-phenotype\""\u003eTable 1: Dosing recommendations for TCAs based on CYP2D6 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic Recommendations\u003csup\u003ea, b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendation for other TCAs \u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Ultrarapid metabolizer (~1-20% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying more than two copies of functional alleles\u003c/td\u003e\u003ctd\u003e*1/*1xN, *1/*2xN\u003c/td\u003e\u003ctd\u003eIncreased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Normal metabolizer (~72-88% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e1.0-2.0\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles or two decreased function alleles or one normal and no function allele or one normal and decreased function allele or combinations of duplicated alleles that result in an activity score of 1.0-2.0\u003c/td\u003e\u003ctd\u003e*1/*1, *1/*2, *2/*2, *1/*9, *1/*41, *41/*41, *1/*4, *1/*5\u003c/td\u003e\u003ctd\u003eNormal metabolism of TCAs.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Intermediate metabolizer (~1-13% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased and one no function allele\u003c/td\u003e\u003ctd\u003e*4/*41, *5/*9, *4/*10\u003c/td\u003e\u003ctd\u003eReduced metabolism of TCAs to less active compounds when compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eConsider 25% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 Poor metabolizer (~1-10% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying only no function alleles\u003c/td\u003e\u003ctd\u003e*4/*4, *4/*4xN, *3/*4, *5/*5, *5/*6\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of  TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects.\u003c/td\u003e\u003ctd\u003eAvoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6.\u003cbr/\u003eIf a TCA is warranted, consider 50% reduction of recommended starting dose.\u003csup\u003eg\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2C19 genotype results are also available, see Table 2 for CYP2C19-based dosing recommendations and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2D6 including clomipramine, desipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting genotype-guided dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003ch3 id\u003d\""table-2-dosing-recommendations-for-tcas-based-on-cyp2c19-phenotype\""\u003eTable 2: Dosing recommendations for TCAs based on CYP2C19 phenotype:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3 of the 2016 guideline update.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003csup\u003ea,b\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eClassification of recommendations for amitriptyline\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Ultrarapid metabolizer (~2-5% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles\u003c/td\u003e\u003ctd\u003e*17/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Rapid metabolizer (~2-30% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*17\u003c/td\u003e\u003ctd\u003eIncreased metabolism of tertiary amines compared to normal metabolizers. Greater conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eIf a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Normal metabolizer (~35-50% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e*1/*1\u003c/td\u003e\u003ctd\u003eNormal metabolism of tertiary amines.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Intermediate metabolizer (~18-45% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal and one no function allele or one no and one increased function allele\u003c/td\u003e\u003ctd\u003e*1/*2, *1/*3, *2/*17\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eReduced metabolism of tertiary amines compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 Poor metabolizer (~2-15% of patients)\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e*2/*2, *2/*3, *3/*3\u003c/td\u003e\u003ctd\u003eGreatly reduced metabolism of tertiary amines compared to normal metabolizers. Decreased conversion of tertiary amines to secondary amines may affect response or side effects.\u003c/td\u003e\u003ctd\u003eAvoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19.  TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine.\u003cbr/\u003eFor tertiary amines, consider a 50% reduction of the recommended starting dose.\u003csup\u003ef\u003c/sup\u003e Utilize therapeutic drug monitoring to guide dose adjustments.\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eOptional\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e For tertiary amines (e.g., amitriptyline), if CYP2D6 genotype results are also available, see Table 1 for CYP2D6-based dosing recommendations above and Table 3 below for CYP2D6/CYP2C19-based dosing recommendations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations in the guideline for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e The rating scheme for the recommendation of classification is described in the Supplement. It may be reasonable to apply amitriptyline recommendation to other TCAs also metabolized by CYP2C19 including clomipramine, doxepin, imipramine, and trimipramine. There are fewer clinical and pharmacokinetic data supporting dose adjustments for these drugs when compared to amitriptyline or nortriptyline (Supplemental Tables S8-S16).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e CYP2D6 and CYP2C19 metabolizer status frequencies are based on average multi-ethnic frequencies. See the CYP2C19 and CYP2D6 Frequency Tables for population-specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e The predicted metabolizer phenotype for the*2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the CYP2C19*2 no function allele.\u003c/p\u003e\n\u003ch3 id\u003d\""may-2013\""\u003eMay 2013\u003c/h3\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDownload:\u003c/strong\u003e \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e and \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003esupplement\u003c/a\u003e\u003c/p\u003e\n\u003ch5 id\u003d\""excerpt-from-the-dosing-guidelines\""\u003eExcerpt from the dosing guidelines:\u003c/h5\u003e\n\u003cp\u003e\u003ca href\u003d\""http://www.pharmgkb.org/drug/PA448385\""\u003eAmitriptyline\u003c/a\u003e and nortriptyline are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003eguideline\u003c/a\u003e to other tricyclics including clomipramine (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447-supplement.pdf\"" target\u003d\""_blank\""\u003eSupplementary Table S18\u003c/a\u003e), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.\u003c/p\u003e\n\u003cp\u003eSee \u003ca href\u003d\""http://www.pharmgkb.org/drug/PA448385\""\u003eamitriptyline\u003c/a\u003e for excerpts and tables that summarize \u003cem\u003eCYP2D6\u003c/em\u003e-based and \u003cem\u003eCYP2C19\u003c/em\u003e-based dosing recommendations for amitriptyline when higher initial starting doses are warranted (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/TCA/2013/23486447.pdf\"" target\u003d\""_blank\""\u003earticle\u003c/a\u003e).\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983444E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/""}]},""status"":""success""}"
PA166161955,Guideline Annotation,Annotation of CPIC Guideline for tropisetron and CYP2D6,t,PA161925594,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"" target=""_blank"">CPIC&reg; guideline for ondansetron and tropisetron and CYP2D6</a>.</p>
<h3 id=""october-2019-update"">October 2019 Update</h3>
<p><a rel=""noopener noreferrer"" href=""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692"" target=""_blank"">CYP2D6 genotype to phenotype translation changes</a>: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/"" target=""_blank"">more information</a>. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (<a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>).</p>
<p>As a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):</p>
<ul>
<li>Diplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.</li>
</ul>
</li>
<li>All activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See <a rel=""noopener noreferrer"" href=""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx"" target=""_blank"">table of all previous and new phenotype groupings</a>.
<ul>
<li><strong>Impact on the recommendations in this guideline:</strong> The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.</li>
</ul>
</li>
</ul>
<h3 id=""december-2016"">December 2016</h3>
<ul>
<li>Guidelines regarding the use of pharmacogenomic tests in dosing for tropisetron were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">(CPIC)</a>.</li>
<li>Excerpt from the 2016 tropisetron dosing guidelines:
<ul>
<li>&quot;Gene duplication has been shown to be associated with higher metabolism and clearance of ondansetron resulting in lower area under the plasma concentration-time curve. This translates clinically into a decreased response to ondansetron and tropisetron, specifically increased risk of vomiting in CYP2D6 ultrarapid metabolizers. If CYP2D6 genotype is known, alternative 5-HT3 receptor antagonist antiemetics not metabolized by CYP2D6 (e.g., granisetron) should be considered in CYP2D6 ultrarapid metabolizers. &quot;</li>
</ul>
</li>
<li>Download and read:</li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/ondansetron/2016/28002639.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/ondansetron/2016/28002639-supplement.pdf"" target=""_blank"">2016 supplement</a></li>
<li><a href=""/page/cyp2d6RefMaterials"">Gene-specific Information Tables for CYP2D6</a></li>
<li><a rel=""noopener noreferrer"" href=""https://raw.githubusercontent.com/PharmGKB/cpic-guidelines/master/ondansetron/2016/Tropisetron_Drug_Resource_Mappings.xlsx"" target=""_blank"">Tropisetron Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://raw.githubusercontent.com/PharmGKB/cpic-guidelines/master/ondansetron/2016/Ondansetron_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Ondansetron Pre- and Post-Test Alerts and Flow Chart</a> (note that while the title of the file does not state tropisetron, alerts for tropisetron are found in the file)</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-tropisetron-based-on-cyp2d6-phenotype-genotype"">Table 1: Dosing recommendations for tropisetron based on CYP2D6 phenotype/genotype</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>CYP2D6 Phenotype</th><th>Activity score</th><th>CYP2D6 Genotypes<sup>a</sup></th><th>Examples of diplotypes</th><th>Implications</th><th>Therapeutic recommendations</th><th>Classification of Recommendations<sup>b</sup></th><th>Consideration for alternative 5-HT<sub>3</sub> receptor antagonists antiemetics<sup>c</sup></th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer</td><td>&gt;2.0</td><td>An individual carrying duplications of function alleles</td><td><em>*1/*1xN, *1/*2xN, *2/*2xN</em><sup>d</sup></td><td>Increased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).</td><td>Select and alternative drug not predominantly metabolized by CYP2D6 (i.e. granisetron).<sup>e</sup></td><td>Moderate</td><td>Dolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6.  Limited evidence is available regarding the utilization of <em>CYP2D6</em> genetic variation to guide use of these drugs.</td></tr>
<tr><td>Normal metabolizer</td><td>2.0-1.0<sup>f</sup></td><td>An individual carrying two normal function alleles, or two decreased function alleles, or one normal function and one no function allele, or one normal function and one decreased function allele, or combinations of duplicated alleles that result in an activity score of 1.0-2.0</td><td><em>*1/*1, *1/*2, *1/*4, *1/*5, *1/*9, *1/*41, *2/*2,*41/*41</em></td><td>Normal metabolism</td><td>Initiate therapy with recommended starting dose.</td><td>Strong</td><td></td></tr>
<tr><td>Intermediate metabolizer</td><td>0.5</td><td>An individual carrying one decreased function and one no function allele</td><td><em>*4/*10,*4/*41, *5/*9</em></td><td>Very limited data available for CYP2D6 intermediate metabolizers</td><td>Insufficient evidence demonstrating clinical impact based on <em>CYP2D6</em> genotype.  Initiate therapy with recommended starting dose.</td><td>No recommendation</td><td></td></tr>
<tr><td>Poor metabolizer</td><td>0</td><td>An individual carrying no functional alleles</td><td><em>*3/*4,*4/*4, *5/*5, *5/*6</em></td><td>Very limited data available for CYP2D6 poor metabolizers</td><td>Insufficient evidence demonstrating clinical impact based on <em>CYP2D6</em> genotype.  Initiate therapy with recommended starting dose.</td><td>No recommendation</td><td></td></tr>
</tbody>
</table>
<p><sup>a</sup> Assignment of allele function and citations for allele function can be found on PharmGKB: <a href=""/page/cyp2d6RefMaterials"">CYP2D6 Allele Definition Table and CYP2D6 Allele Functionality Table</a>.</p>
<p><sup>b</sup> Rating scheme is described in the 2016 Supplement</p>
<p><sup>c</sup> CPIC strength of recommendation: No Recommendation. See rating scheme described in the Supplement.</p>
<p><sup>d</sup> Where <em>xN</em> represents the number of <em>CYP2D6</em> gene copies.  For individuals with <em>CYP2D6</em> duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.</p>
<p><sup>e</sup> Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.</p>
<p><sup>f</sup> Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166161955"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166161955"",""name"":""Annotation of CPIC Guideline for tropisetron and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":""OHD9LFRlJ4g"",""guidelineGenes"":[{""id"":1.449562226E9,""alleles"":[{""id"":1.449562227E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816576"",""symbol"":""CYP2D6*1"",""name"":""*1""}},{""id"":1.449562228E9,""_label"":""*1xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988479"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988479"",""symbol"":""CYP2D6*1xN"",""name"":""*1xN""}},{""id"":1.449562229E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816577"",""symbol"":""CYP2D6*2"",""name"":""*2""}},{""id"":1.44956223E9,""_label"":""*2xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988480"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988480"",""symbol"":""CYP2D6*2xN"",""name"":""*2xN""}},{""id"":1.449562231E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816578"",""symbol"":""CYP2D6*3"",""name"":""*3""}},{""id"":1.449562232E9,""_label"":""*3xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128733"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128733"",""symbol"":""CYP2D6*3xN"",""name"":""*3xN""}},{""id"":1.449562233E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816579"",""symbol"":""CYP2D6*4"",""name"":""*4""}},{""id"":1.449562234E9,""_label"":""*4xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123455"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123455"",""symbol"":""CYP2D6*4xN"",""name"":""*4xN""}},{""id"":1.449562235E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948092"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948092"",""symbol"":""CYP2D6*5"",""name"":""*5""}},{""id"":1.449562236E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816581"",""symbol"":""CYP2D6*6"",""name"":""*6""}},{""id"":1.449562237E9,""_label"":""*6xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128734"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128734"",""symbol"":""CYP2D6*6xN"",""name"":""*6xN""}},{""id"":1.449562238E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971559"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971559"",""symbol"":""CYP2D6*7"",""name"":""*7""}},{""id"":1.449562239E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971560"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971560"",""symbol"":""CYP2D6*8"",""name"":""*8""}},{""id"":1.44956224E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948317"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948317"",""symbol"":""CYP2D6*9"",""name"":""*9""}},{""id"":1.449562241E9,""_label"":""*9x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123309"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123309"",""symbol"":""CYP2D6*9x2"",""name"":""*9x2""}},{""id"":1.449562242E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/alleleFunction:1450823945"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.450823945E9,""resource"":""Allele Function"",""term"":""Decreased function (0.25)"",""termId"":""alleleFunction:1450823945""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816582"",""symbol"":""CYP2D6*10"",""name"":""*10""}},{""id"":1.449562243E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971564"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971564"",""symbol"":""CYP2D6*11"",""name"":""*11""}},{""id"":1.449562244E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971565"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971565"",""symbol"":""CYP2D6*12"",""name"":""*12""}},{""id"":1.449562245E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988481"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988481"",""symbol"":""CYP2D6*13"",""name"":""*13""}},{""id"":1.449562248E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971568"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971568"",""symbol"":""CYP2D6*15"",""name"":""*15""}},{""id"":1.449562249E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816583"",""symbol"":""CYP2D6*17"",""name"":""*17""}},{""id"":1.44956225E9,""_label"":""*17x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123457"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123457"",""symbol"":""CYP2D6*17x2"",""name"":""*17x2""}},{""id"":1.449562251E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971569"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971569"",""symbol"":""CYP2D6*18"",""name"":""*18""}},{""id"":1.449562252E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971570"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971570"",""symbol"":""CYP2D6*19"",""name"":""*19""}},{""id"":1.449562253E9,""_label"":""*20"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971571"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971571"",""symbol"":""CYP2D6*20"",""name"":""*20""}},{""id"":1.449562254E9,""_label"":""*21"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988484"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988484"",""symbol"":""CYP2D6*21"",""name"":""*21""}},{""id"":1.449562255E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971574"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971574"",""symbol"":""CYP2D6*22"",""name"":""*22""}},{""id"":1.449562256E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971575"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971575"",""symbol"":""CYP2D6*23"",""name"":""*23""}},{""id"":1.449562257E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971576"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971576"",""symbol"":""CYP2D6*24"",""name"":""*24""}},{""id"":1.449562258E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971577"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971577"",""symbol"":""CYP2D6*25"",""name"":""*25""}},{""id"":1.449562259E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971578"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971578"",""symbol"":""CYP2D6*26"",""name"":""*26""}},{""id"":1.44956226E9,""_label"":""*27"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971579"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971579"",""symbol"":""CYP2D6*27"",""name"":""*27""}},{""id"":1.449562261E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971580"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971580"",""symbol"":""CYP2D6*28"",""name"":""*28""}},{""id"":1.449562262E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165948318"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165948318"",""symbol"":""CYP2D6*29"",""name"":""*29""}},{""id"":1.449562263E9,""_label"":""*29x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128735"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128735"",""symbol"":""CYP2D6*29x2"",""name"":""*29x2""}},{""id"":1.449562264E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971581"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971581"",""symbol"":""CYP2D6*30"",""name"":""*30""}},{""id"":1.449562265E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971582"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971582"",""symbol"":""CYP2D6*31"",""name"":""*31""}},{""id"":1.449562266E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971583"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971583"",""symbol"":""CYP2D6*32"",""name"":""*32""}},{""id"":1.449562267E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971584"",""symbol"":""CYP2D6*33"",""name"":""*33""}},{""id"":1.449562268E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971585"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971585"",""symbol"":""CYP2D6*34"",""name"":""*34""}},{""id"":1.449562269E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988487"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988487"",""symbol"":""CYP2D6*35"",""name"":""*35""}},{""id"":1.44956227E9,""_label"":""*35xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971588"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971588"",""symbol"":""CYP2D6*35xN"",""name"":""*35xN""}},{""id"":1.449562271E9,""_label"":""*36xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971589"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971589"",""symbol"":""CYP2D6*36xN"",""name"":""*36xN""}},{""id"":1.449562272E9,""_label"":""*36"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988488"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988488"",""symbol"":""CYP2D6*36"",""name"":""*36""}},{""id"":1.449562273E9,""_label"":""*37"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971591"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971591"",""symbol"":""CYP2D6*37"",""name"":""*37""}},{""id"":1.449562274E9,""_label"":""*38"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971592"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971592"",""symbol"":""CYP2D6*38"",""name"":""*38""}},{""id"":1.449562275E9,""_label"":""*39"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166001447"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166001447"",""symbol"":""CYP2D6*39"",""name"":""*39""}},{""id"":1.449562276E9,""_label"":""*40"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971594"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971594"",""symbol"":""CYP2D6*40"",""name"":""*40""}},{""id"":1.449562277E9,""_label"":""*41"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816584"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816584"",""symbol"":""CYP2D6*41"",""name"":""*41""}},{""id"":1.449562278E9,""_label"":""*41x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128209"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128209"",""symbol"":""CYP2D6*41x2"",""name"":""*41x2""}},{""id"":1.449562279E9,""_label"":""*42"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971595"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971595"",""symbol"":""CYP2D6*42"",""name"":""*42""}},{""id"":1.44956228E9,""_label"":""*43"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971596"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971596"",""symbol"":""CYP2D6*43"",""name"":""*43""}},{""id"":1.449562281E9,""_label"":""*44"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971597"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971597"",""symbol"":""CYP2D6*44"",""name"":""*44""}},{""id"":1.449562282E9,""_label"":""*45"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988489"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988489"",""symbol"":""CYP2D6*45"",""name"":""*45""}},{""id"":1.449562283E9,""_label"":""*45xN"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988490"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988490"",""symbol"":""CYP2D6*45xN"",""name"":""*45xN""}},{""id"":1.449562284E9,""_label"":""*46"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971600"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971600"",""symbol"":""CYP2D6*46"",""name"":""*46""}},{""id"":1.449562285E9,""_label"":""*47"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971601"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971601"",""symbol"":""CYP2D6*47"",""name"":""*47""}},{""id"":1.449562286E9,""_label"":""*48"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971602"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971602"",""symbol"":""CYP2D6*48"",""name"":""*48""}},{""id"":1.449562287E9,""_label"":""*49"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971603"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971603"",""symbol"":""CYP2D6*49"",""name"":""*49""}},{""id"":1.449562288E9,""_label"":""*50"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971604"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971604"",""symbol"":""CYP2D6*50"",""name"":""*50""}},{""id"":1.449562289E9,""_label"":""*51"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971605"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971605"",""symbol"":""CYP2D6*51"",""name"":""*51""}},{""id"":1.44956229E9,""_label"":""*52"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971606"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971606"",""symbol"":""CYP2D6*52"",""name"":""*52""}},{""id"":1.449562291E9,""_label"":""*53"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971607"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971607"",""symbol"":""CYP2D6*53"",""name"":""*53""}},{""id"":1.449562292E9,""_label"":""*54"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971608"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971608"",""symbol"":""CYP2D6*54"",""name"":""*54""}},{""id"":1.449562293E9,""_label"":""*55"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971609"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971609"",""symbol"":""CYP2D6*55"",""name"":""*55""}},{""id"":1.449562294E9,""_label"":""*56"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165988494"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165988494"",""symbol"":""CYP2D6*56"",""name"":""*56""}},{""id"":1.449562295E9,""_label"":""*57"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971612"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971612"",""symbol"":""CYP2D6*57"",""name"":""*57""}},{""id"":1.449562296E9,""_label"":""*58"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971613"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971613"",""symbol"":""CYP2D6*58"",""name"":""*58""}},{""id"":1.449562297E9,""_label"":""*59"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971614"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971614"",""symbol"":""CYP2D6*59"",""name"":""*59""}},{""id"":1.449562298E9,""_label"":""*60"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971615"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971615"",""symbol"":""CYP2D6*60"",""name"":""*60""}},{""id"":1.449562299E9,""_label"":""*61"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971616"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971616"",""symbol"":""CYP2D6*61"",""name"":""*61""}},{""id"":1.4495623E9,""_label"":""*62"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971617"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971617"",""symbol"":""CYP2D6*62"",""name"":""*62""}},{""id"":1.449562301E9,""_label"":""*63"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971618"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971618"",""symbol"":""CYP2D6*63"",""name"":""*63""}},{""id"":1.449562302E9,""_label"":""*64"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971619"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971619"",""symbol"":""CYP2D6*64"",""name"":""*64""}},{""id"":1.449562303E9,""_label"":""*65"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971620"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971620"",""symbol"":""CYP2D6*65"",""name"":""*65""}},{""id"":1.449562304E9,""_label"":""*68"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128736"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128736"",""symbol"":""CYP2D6*68"",""name"":""*68""}},{""id"":1.449562305E9,""_label"":""*69"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971621"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971621"",""symbol"":""CYP2D6*69"",""name"":""*69""}},{""id"":1.449562306E9,""_label"":""*70"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971622"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971622"",""symbol"":""CYP2D6*70"",""name"":""*70""}},{""id"":1.449562307E9,""_label"":""*71"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971623"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971623"",""symbol"":""CYP2D6*71"",""name"":""*71""}},{""id"":1.449562308E9,""_label"":""*72"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971624"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971624"",""symbol"":""CYP2D6*72"",""name"":""*72""}},{""id"":1.449562309E9,""_label"":""*73"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971625"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971625"",""symbol"":""CYP2D6*73"",""name"":""*73""}},{""id"":1.44956231E9,""_label"":""*74"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971626"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971626"",""symbol"":""CYP2D6*74"",""name"":""*74""}},{""id"":1.449562311E9,""_label"":""*75"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165971627"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165971627"",""symbol"":""CYP2D6*75"",""name"":""*75""}},{""id"":1.449562312E9,""_label"":""*81"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123321"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123321"",""symbol"":""CYP2D6*81"",""name"":""*81""}},{""id"":1.449562313E9,""_label"":""*82"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123322"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123322"",""symbol"":""CYP2D6*82"",""name"":""*82""}},{""id"":1.449562314E9,""_label"":""*83"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123323"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123323"",""symbol"":""CYP2D6*83"",""name"":""*83""}},{""id"":1.449562315E9,""_label"":""*84"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123324"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123324"",""symbol"":""CYP2D6*84"",""name"":""*84""}},{""id"":1.449562316E9,""_label"":""*85"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123325"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123325"",""symbol"":""CYP2D6*85"",""name"":""*85""}},{""id"":1.449562317E9,""_label"":""*86"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123326"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123326"",""symbol"":""CYP2D6*86"",""name"":""*86""}},{""id"":1.449562318E9,""_label"":""*87"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123327"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123327"",""symbol"":""CYP2D6*87"",""name"":""*87""}},{""id"":1.449562319E9,""_label"":""*88"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123328"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123328"",""symbol"":""CYP2D6*88"",""name"":""*88""}},{""id"":1.44956232E9,""_label"":""*89"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123329"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123329"",""symbol"":""CYP2D6*89"",""name"":""*89""}},{""id"":1.449562321E9,""_label"":""*90"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123330"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123330"",""symbol"":""CYP2D6*90"",""name"":""*90""}},{""id"":1.449562322E9,""_label"":""*91"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123331"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123331"",""symbol"":""CYP2D6*91"",""name"":""*91""}},{""id"":1.449562323E9,""_label"":""*92"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123332"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123332"",""symbol"":""CYP2D6*92"",""name"":""*92""}},{""id"":1.449562324E9,""_label"":""*93"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123333"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123333"",""symbol"":""CYP2D6*93"",""name"":""*93""}},{""id"":1.449562325E9,""_label"":""*94"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128737"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128737"",""symbol"":""CYP2D6*94"",""name"":""*94""}},{""id"":1.449562326E9,""_label"":""*95"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123336"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123336"",""symbol"":""CYP2D6*95"",""name"":""*95""}},{""id"":1.449562327E9,""_label"":""*96"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123337"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123337"",""symbol"":""CYP2D6*96"",""name"":""*96""}},{""id"":1.449562328E9,""_label"":""*97"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123338"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123338"",""symbol"":""CYP2D6*97"",""name"":""*97""}},{""id"":1.449562329E9,""_label"":""*98"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123339"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123339"",""symbol"":""CYP2D6*98"",""name"":""*98""}},{""id"":1.44956233E9,""_label"":""*99"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169821"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169821"",""symbol"":""CYP2D6*99"",""name"":""*99""}},{""id"":1.449562331E9,""_label"":""*100"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123340"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123340"",""symbol"":""CYP2D6*100"",""name"":""*100""}},{""id"":1.449562332E9,""_label"":""*101"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123341"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123341"",""symbol"":""CYP2D6*101"",""name"":""*101""}},{""id"":1.449562333E9,""_label"":""*102"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123342"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123342"",""symbol"":""CYP2D6*102"",""name"":""*102""}},{""id"":1.449562334E9,""_label"":""*103"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123343"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123343"",""symbol"":""CYP2D6*103"",""name"":""*103""}},{""id"":1.449562335E9,""_label"":""*104"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123344"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123344"",""symbol"":""CYP2D6*104"",""name"":""*104""}},{""id"":1.449562336E9,""_label"":""*105"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123345"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123345"",""symbol"":""CYP2D6*105"",""name"":""*105""}},{""id"":1.449562337E9,""_label"":""*106"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166170941"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166170941"",""symbol"":""CYP2D6*106"",""name"":""*106""}},{""id"":1.449562338E9,""_label"":""*107"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129550"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129550"",""symbol"":""CYP2D6*107"",""name"":""*107""}},{""id"":1.449562339E9,""_label"":""*108"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129551"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129551"",""symbol"":""CYP2D6*108"",""name"":""*108""}},{""id"":1.44956234E9,""_label"":""*109"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166129552"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166129552"",""symbol"":""CYP2D6*109"",""name"":""*109""}},{""id"":1.449562341E9,""_label"":""*110"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169822"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169822"",""symbol"":""CYP2D6*110"",""name"":""*110""}},{""id"":1.449562342E9,""_label"":""*111"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169823"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169823"",""symbol"":""CYP2D6*111"",""name"":""*111""}},{""id"":1.449562343E9,""_label"":""*112"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169824"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169824"",""symbol"":""CYP2D6*112"",""name"":""*112""}},{""id"":1.449562344E9,""_label"":""*113"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448589712"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448589712E9,""resource"":""Allele Function"",""term"":""Unknown function"",""termId"":""haplotypeTags:1448589712""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166169825"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166169825"",""symbol"":""CYP2D6*113"",""name"":""*113""}},{""id"":1.45004276E9,""_label"":""*114"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181184"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181184"",""symbol"":""CYP2D6*114"",""name"":""*114""}},{""id"":1.450042761E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166181185"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166181185"",""symbol"":""CYP2D6*14"",""name"":""*14""}},{""id"":1.450824321E9,""_label"":""*10x2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123456"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123456"",""symbol"":""CYP2D6*10x2"",""name"":""*10x2""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}}],""history"":[{""id"":1.448526494E9,""date"":""2016-12-23T16:11:47.746-08:00"",""type"":""Update"",""version"":0.0},{""id"":1.450042762E9,""date"":""2018-11-15T18:58:52.433-08:00"",""description"":""updated *14B to *14 and *14A to *114 based on the Nov 2018 PharmVar release"",""type"":""Update"",""version"":0.0},{""id"":1.450824545E9,""date"":""2019-10-24T20:14:04.667-07:00"",""description"":""online October 2019 guideline update (G2P project)"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098241"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098241E7,""resourceId"":""28002639"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479760"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5479760"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293318E9,""resource"":""PubMed Central"",""resourceId"":""PMC5479760"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479760""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/28002639"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293317E9,""resource"":""PubMed"",""resourceId"":""28002639"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/28002639""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.598"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293319E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.598"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.598""}]},{""@id"":""https://pharmgkb.org/literature/15100912"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100912E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""title"":""CPIC® Guideline for Ondansetron and Tropisetron based on CYP2D6 genotype – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.448526498E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA161925594"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA161925594"",""name"":""tropisetron""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.448526104E9,""html"":""\u003cp\u003eThe CPIC dosing guideline for tropisetron recommends selecting an alternate drug for CYP2D6 ultrarapid metabolizers.  It is recommended that the alternate drug not be predominantly metabolized by CYP2D6 (eg. granisetron).\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.448526146E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for ondansetron and tropisetron and CYP2D6\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2019-update\""\u003eOctober 2019 Update\u003c/h3\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12692\"" target\u003d\""_blank\""\u003eCYP2D6 genotype to phenotype translation changes\u003c/a\u003e: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype translation across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing laboratories. CPIC recently conducted a modified-Delphi project to obtain consensus for a uniform system for translating CYP2D6 genotype to phenotype among a panel of international CYP2D6 experts \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/resources/cyp2d6-genotype-to-phenotype-standardization-project/\"" target\u003d\""_blank\""\u003emore information\u003c/a\u003e. Modifications to CPIC’s prior system include downgrading the value assigned to the CYP2D6*10 allele for activity score calculation from 0.5 to 0.25 and changing the phenotype assignment for an activity score of 1 from normal metabolizer to intermediate metabolizer (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003eAs a result, the following changes have been made in the CYP2D6 allele functionality table, CYP2D6 genotype to phenotype table (access tables below):\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiplotypes giving rise to activity scores of 1 changed from CYP2D6 normal metabolizer to CYP2D6 intermediate metabolizer assignments.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e Because the recommendations in this guideline do not differ between a CYP2D6 normal and intermediate metabolizer, the current published recommendations for normal and intermediate metabolizers will remain unchanged.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eAll activity scores for diplotypes containing a CYP2D6*10 allele have been updated accordingly (activity scores changed to reflect the lower value of 0.25 for *10). Prior to the consensus projects, the combination of a duplicated normal function allele with a *10 allele resulted in an activity score of 2.5 which translates to an ultrarapid metabolizer. The lower value of 0.25 for CYP2D6*10 results in an activity score of 2.25 for these allele combinations, which based on the consensus project translates to a normal metabolizer.  See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://files.cpicpgx.org/data/gene/CYP2D6/Inferred_CYP2D6_Phenotype10242019.docx\"" target\u003d\""_blank\""\u003etable of all previous and new phenotype groupings\u003c/a\u003e.\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eImpact on the recommendations in this guideline:\u003c/strong\u003e The authors of this guideline are currently reviewing evidence for the affected activity score (AS of 2.25) and will update this webpage and relevant tables accordingly.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""december-2016\""\u003eDecember 2016\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for tropisetron were published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2016 tropisetron dosing guidelines:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Gene duplication has been shown to be associated with higher metabolism and clearance of ondansetron resulting in lower area under the plasma concentration-time curve. This translates clinically into a decreased response to ondansetron and tropisetron, specifically increased risk of vomiting in CYP2D6 ultrarapid metabolizers. If CYP2D6 genotype is known, alternative 5-HT3 receptor antagonist antiemetics not metabolized by CYP2D6 (e.g., granisetron) should be considered in CYP2D6 ultrarapid metabolizers. \u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/ondansetron/2016/28002639.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/ondansetron/2016/28002639-supplement.pdf\"" target\u003d\""_blank\""\u003e2016 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""/page/cyp2d6RefMaterials\""\u003eGene-specific Information Tables for CYP2D6\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://raw.githubusercontent.com/PharmGKB/cpic-guidelines/master/ondansetron/2016/Tropisetron_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eTropisetron Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://raw.githubusercontent.com/PharmGKB/cpic-guidelines/master/ondansetron/2016/Ondansetron_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eOndansetron Pre- and Post-Test Alerts and Flow Chart\u003c/a\u003e (note that while the title of the file does not state tropisetron, alerts for tropisetron are found in the file)\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-tropisetron-based-on-cyp2d6-phenotype-genotype\""\u003eTable 1: Dosing recommendations for tropisetron based on CYP2D6 phenotype/genotype\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eCYP2D6 Phenotype\u003c/th\u003e\u003cth\u003eActivity score\u003c/th\u003e\u003cth\u003eCYP2D6 Genotypes\u003csup\u003ea\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003c/th\u003e\u003cth\u003eClassification of Recommendations\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eConsideration for alternative 5-HT\u003csub\u003e3\u003c/sub\u003e receptor antagonists antiemetics\u003csup\u003ec\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer\u003c/td\u003e\u003ctd\u003e\u0026gt;2.0\u003c/td\u003e\u003ctd\u003eAn individual carrying duplications of function alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*1xN, *1/*2xN, *2/*2xN\u003c/em\u003e\u003csup\u003ed\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eIncreased metabolism to less active compounds when compared to normal metabolizers and is associated with decreased response to ondansetron and tropisetron (i.e. vomiting).\u003c/td\u003e\u003ctd\u003eSelect and alternative drug not predominantly metabolized by CYP2D6 (i.e. granisetron).\u003csup\u003ee\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003ctd\u003eDolasetron, palonosetron, and ramosetron are also metabolized by CYP2D6.  Limited evidence is available regarding the utilization of \u003cem\u003eCYP2D6\u003c/em\u003e genetic variation to guide use of these drugs.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNormal metabolizer\u003c/td\u003e\u003ctd\u003e2.0-1.0\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles, or two decreased function alleles, or one normal function and one no function allele, or one normal function and one decreased function allele, or combinations of duplicated alleles that result in an activity score of 1.0-2.0\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*1, *1/*2, *1/*4, *1/*5, *1/*9, *1/*41, *2/*2,*41/*41\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eNormal metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer\u003c/td\u003e\u003ctd\u003e0.5\u003c/td\u003e\u003ctd\u003eAn individual carrying one decreased function and one no function allele\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*4/*10,*4/*41, *5/*9\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eVery limited data available for CYP2D6 intermediate metabolizers\u003c/td\u003e\u003ctd\u003eInsufficient evidence demonstrating clinical impact based on \u003cem\u003eCYP2D6\u003c/em\u003e genotype.  Initiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eNo recommendation\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizer\u003c/td\u003e\u003ctd\u003e0\u003c/td\u003e\u003ctd\u003eAn individual carrying no functional alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*3/*4,*4/*4, *5/*5, *5/*6\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eVery limited data available for CYP2D6 poor metabolizers\u003c/td\u003e\u003ctd\u003eInsufficient evidence demonstrating clinical impact based on \u003cem\u003eCYP2D6\u003c/em\u003e genotype.  Initiate therapy with recommended starting dose.\u003c/td\u003e\u003ctd\u003eNo recommendation\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e Assignment of allele function and citations for allele function can be found on PharmGKB: \u003ca href\u003d\""/page/cyp2d6RefMaterials\""\u003eCYP2D6 Allele Definition Table and CYP2D6 Allele Functionality Table\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Rating scheme is described in the 2016 Supplement\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e CPIC strength of recommendation: No Recommendation. See rating scheme described in the Supplement.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e Where \u003cem\u003exN\u003c/em\u003e represents the number of \u003cem\u003eCYP2D6\u003c/em\u003e gene copies.  For individuals with \u003cem\u003eCYP2D6\u003c/em\u003e duplications or multiplications, see supplemental data for additional information on how to translate diplotypes into phenotypes.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Drug-drug interactions and other patient characteristics (e.g., age, renal function, and liver function) should be considered when selecting alternative therapy.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Patients with an activity score of 1.0 may be classified as intermediate metabolizers by some reference laboratories.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.448526498E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/""}]},""status"":""success""}"
PA166104968,Guideline Annotation,Annotation of DPWG Guideline for venlafaxine and CYP2D6,t,PA451866,Dutch Pharmacogenetics Working Group,"<p>For CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient's plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine.</p>
","<h3 id=""august-2019-update"">August 2019 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for venlafaxine based on CYP2D6 genotype. They recommend that an alternative drug that is not metabolized by CYP2D6 or a dose reduction be considered for CYP2D6 intermediate metabolizers (IMs) and poor metabolizers (PMs). Clinicians should be alert to possible decreases in venlafaxine plasma concentrations in CYP2D6 ultrarapid metabolizers (UMs) and, if necessary, increase the dose to 150% of the standard dose. If a dose increase is not possible, an alternative drug that is not metabolized by CYP2D6 should be selected.</p>
<p><em>Wording in table taken from <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf"">Dutch guidelines August 2019 update</a></em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>venlafaxine</td><td>It may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine.</td><td>1. be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine<br/>2. if necessary, increase the dose to 150% of the standard dose<br/>3. if dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided<br/>Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.</td></tr>
<tr><td>CYP2D6 IM</td><td>venlafaxine</td><td>There are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found.</td><td>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.<br/>- avoid venlafaxine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.<br/>- if it is not possible to avoid venlafaxine and side effects occur:<br/>1. reduce the dose<br/>2. monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine.<br/>It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.</td></tr>
<tr><td>CYP2D6 PM</td><td>venlafaxine</td><td>There are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found.</td><td>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.<br/>- avoid venlafaxine.  Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.<br/>- If it is not possible to avoid venlafaxine and side effects occur:<br/>1. reduce the dose<br/>2. monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine<br/>It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum. Furthermore, a reduced effectiveness of venlafaxine has been observed in depression patients with this gene variation.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001539.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for venlafaxine based on CYP2D6 genotype. They recommend that an alternative drug that is not metabolized by CYP2D6 or a dose reduction be considered for CYP2D6 intermediate metabolizers (IMs) and poor metabolizers (PMs). Clinicians should be alert to possible decreases in venlafaxine plasma concentrations in CYP2D6 ultrarapid metabolizers (UMs) and, if necessary, increase the dose to 150% of the standard dose. If a dose increase is not possible, an alternative drug that is not metabolized by CYP2D6 should be selected.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2D6 UM</td><td>venlafaxine</td><td>The genetic polymorphism leads to increased metabolic capacity of CYP2D6. This can cause a decrease in the plasma concentration of venlafaxine and an increase in the plasma concentration of the active metabolite O-desmethylvenlafaxine.</td><td>Recommendation:<br/>1. be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O-desmethylvenlafaxine<br/>2. if necessary, increase the dose to 150% of the standard dose<br/>3. if dose adjustment based on therapeutic drug monitoring is not possible, an alternative should be selected. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.</td></tr>
<tr><td>CYP2D6 IM</td><td>venlafaxine</td><td>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6. This can cause an increase in the plasma concentration of venlafaxine and a decrease in the plasma concentration of the active metabolite O-desmethylvenlafaxine.</td><td>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.<br/>1. Choose an alternative. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.<br/>2. If an alternative is not an option and side effects occur:<br/>a. reduce the dose<br/>b. check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.</td></tr>
<tr><td>CYP2D6 PM</td><td>venlafaxine</td><td>The genetic polymorphism leads to decreased metabolic capacity of CYP2D6. This can cause an increase in the plasma concentration of venlafaxine and a decrease in the plasma concentration of the active metabolite O-desmethylvenlafaxine. There are indications that the effectiveness of venlafaxine is reduced in depression patients with this genetic polymorphism.</td><td>It is not possible to offer adequately substantiated advice for dose reduction based on the literature.<br/>1. Choose an alternative. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.<br/>2. If an alternative is not an option and side effects occur:<br/>a. reduce the dose<br/>b. check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum. Furthermore, a reduced effectiveness of venlafaxine has been observed in depression patients with this genetic polymorphism.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001539.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for venlafaxine based on CYP2D6 genotypes [Article:<a href=""/pmid/21412232"">21412232</a>].  For PM and IM genotypes, they state that there are not sufficient data to allow calculation of dose adjustment, and they recommend selecting an alternative drug or adjusting dose to clinical response and monitoring (O-desmethyl)venlafaxine plasma concentration.  For UM genotypes, they recommend titrating dose to a maximum of 150% of the normal dose(based on venlafaxine and (O-desmethyl)venlafaxine plasma concentration) or selecting an alternative drug.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td>PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)</td><td>Insufficient data to allow calculation of dose adjustment.  Select alternative drug (e.g., citalopram, sertraline) or adjust dose to clinical response and monitor (O-desmethyl)venlafaxine plasma concentration.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
<tr><td>IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)</td><td>Insufficient data to allow calculation of dose adjustment.  Select alternative drug (e.g., citalopram, sertraline) or adjust dose to clinical response and monitor (O-desmethyl)venlafaxine plasma concentration.</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td></tr>
<tr><td>UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)</td><td>Be alert to decreased venlafaxine and increased (O-desmethyl)venlafaxine plasma concentration. Titrate dose to a maximum of 150% of the normal dose or select alternative drug (e.g., citalopram, sertraline).</td><td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td><td>Minor clinical effect (S): QTc prolongation (&lt;450 ms female, &lt;470 ms male); INR increase &lt; 4.5.  Kinetic effect (S).</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""http://www.pharmgkb.org/page/dpwg"">Methods </a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;good quality.&quot;</li>
<li>S: statistically significant difference.</li>
<li>Please see attached PDF for detailed information about the evaluated studies: <a href=""https://api.pharmgkb.org/v1/download/file/attachment/venlafaxine_CYP2D6_271111.pdf"">Venlafaxine CYP2D6</a></li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104968"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104968"",""name"":""Annotation of DPWG Guideline for venlafaxine and CYP2D6"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704545E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415065E9,""date"":""2019-05-23T15:45:11.757-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820684E9,""date"":""2019-10-03T17:08:14.139-07:00"",""description"":""Slight wording changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450956521E9,""date"":""2020-01-31T14:21:32.927-08:00"",""description"":""Updated link to 2011 DPWG methods"",""type"":""Update"",""version"":0.0},{""id"":1.450963942E9,""date"":""2020-02-11T08:19:44.307-08:00"",""description"":""Fixed links to 2019 guideline pdfs. 2018 link already went to attachment."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451866"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451866"",""name"":""venlafaxine""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA128"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA128"",""symbol"":""CYP2D6"",""name"":""cytochrome P450 family 2 subfamily D member 6""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447981908E9,""html"":""\u003cp\u003eFor CYP2D6 poor (PM) and intermediate metabolizers (IM), select an alternative to venlafaxine or reduce the dose and monitor patient\u0027s plasma metabolite level. For CYP2D6 ultrarapid metabolizers (UM), increase dose to 150% of the normal dose or select an alternative to venlafaxine.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447981907E9,""html"":""\u003ch3 id\u003d\""august-2019-update\""\u003eAugust 2019 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for venlafaxine based on CYP2D6 genotype. They recommend that an alternative drug that is not metabolized by CYP2D6 or a dose reduction be considered for CYP2D6 intermediate metabolizers (IMs) and poor metabolizers (PMs). Clinicians should be alert to possible decreases in venlafaxine plasma concentrations in CYP2D6 ultrarapid metabolizers (UMs) and, if necessary, increase the dose to 150% of the standard dose. If a dose increase is not possible, an alternative drug that is not metabolized by CYP2D6 should be selected.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\""\u003eDutch guidelines August 2019 update\u003c/a\u003e\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003evenlafaxine\u003c/td\u003e\u003ctd\u003eIt may be difficult to adjust the dose for patients due to altered metabolism between venlafaxine and the active metabolite O- desmethylvenlafaxine. The gene variation increases the conversion of venlafaxine to O-desmethylvenlafaxine and reduces the sum of venlafaxine plus O-desmethylvenlafaxine.\u003c/td\u003e\u003ctd\u003e1. be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O- desmethylvenlafaxine\u003cbr/\u003e2. if necessary, increase the dose to 150% of the standard dose\u003cbr/\u003e3. if dose adjustment does not result in efficacy without unacceptable side effects or if dose adjustment based on therapeutic drug monitoring is not possible, then venlafaxine should be avoided\u003cbr/\u003eAntidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003evenlafaxine\u003c/td\u003e\u003ctd\u003eThere are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found.\u003c/td\u003e\u003ctd\u003eIt is not possible to offer adequately substantiated advice for dose reduction based on the literature.\u003cbr/\u003e- avoid venlafaxine. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.\u003cbr/\u003e- if it is not possible to avoid venlafaxine and side effects occur:\u003cbr/\u003e1. reduce the dose\u003cbr/\u003e2. monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine.\u003cbr/\u003eIt is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003evenlafaxine\u003c/td\u003e\u003ctd\u003eThere are indications of an increased risk of side effects and a reduced chance of efficacy. The gene variation reduces the conversion of venlafaxine to the active metabolite O-desmethylvenlafaxine, whilst an association between high O-desmethylvenlafaxine/venlafaxine ratios and response without side effects was found.\u003c/td\u003e\u003ctd\u003eIt is not possible to offer adequately substantiated advice for dose reduction based on the literature.\u003cbr/\u003e- avoid venlafaxine.  Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, duloxetine, mirtazapine, citalopram and sertraline.\u003cbr/\u003e- If it is not possible to avoid venlafaxine and side effects occur:\u003cbr/\u003e1. reduce the dose\u003cbr/\u003e2. monitor the effect and side effects or check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine\u003cbr/\u003eIt is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum. Furthermore, a reduced effectiveness of venlafaxine has been observed in depression patients with this gene variation.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001539.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for venlafaxine based on CYP2D6 genotype. They recommend that an alternative drug that is not metabolized by CYP2D6 or a dose reduction be considered for CYP2D6 intermediate metabolizers (IMs) and poor metabolizers (PMs). Clinicians should be alert to possible decreases in venlafaxine plasma concentrations in CYP2D6 ultrarapid metabolizers (UMs) and, if necessary, increase the dose to 150% of the standard dose. If a dose increase is not possible, an alternative drug that is not metabolized by CYP2D6 should be selected.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 UM\u003c/td\u003e\u003ctd\u003evenlafaxine\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to increased metabolic capacity of CYP2D6. This can cause a decrease in the plasma concentration of venlafaxine and an increase in the plasma concentration of the active metabolite O-desmethylvenlafaxine.\u003c/td\u003e\u003ctd\u003eRecommendation:\u003cbr/\u003e1. be alert to a possible decrease in the sum of the plasma concentrations of venlafaxine and the active metabolite O-desmethylvenlafaxine\u003cbr/\u003e2. if necessary, increase the dose to 150% of the standard dose\u003cbr/\u003e3. if dose adjustment based on therapeutic drug monitoring is not possible, an alternative should be selected. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 IM\u003c/td\u003e\u003ctd\u003evenlafaxine\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to decreased metabolic capacity of CYP2D6. This can cause an increase in the plasma concentration of venlafaxine and a decrease in the plasma concentration of the active metabolite O-desmethylvenlafaxine.\u003c/td\u003e\u003ctd\u003eIt is not possible to offer adequately substantiated advice for dose reduction based on the literature.\u003cbr/\u003e1. Choose an alternative. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\u003cbr/\u003e2. If an alternative is not an option and side effects occur:\u003cbr/\u003ea. reduce the dose\u003cbr/\u003eb. check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2D6 PM\u003c/td\u003e\u003ctd\u003evenlafaxine\u003c/td\u003e\u003ctd\u003eThe genetic polymorphism leads to decreased metabolic capacity of CYP2D6. This can cause an increase in the plasma concentration of venlafaxine and a decrease in the plasma concentration of the active metabolite O-desmethylvenlafaxine. There are indications that the effectiveness of venlafaxine is reduced in depression patients with this genetic polymorphism.\u003c/td\u003e\u003ctd\u003eIt is not possible to offer adequately substantiated advice for dose reduction based on the literature.\u003cbr/\u003e1. Choose an alternative. Antidepressants that are not metabolised by CYP2D6 - or to a lesser extent - include, for example, citalopram and sertraline.\u003cbr/\u003e2. If an alternative is not an option and side effects occur:\u003cbr/\u003ea. reduce the dose\u003cbr/\u003eb. check the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. It is not known whether it is possible to reduce the dose to such an extent that the side effects disappear, while the effectiveness is maintained. In general, it is assumed that the effectiveness is determined by the sum of the plasma concentrations of venlafaxine and O-desmethylvenlafaxine. However, the side effects do not appear to be related to this sum. Furthermore, a reduced effectiveness of venlafaxine has been observed in depression patients with this genetic polymorphism.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001539.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for venlafaxine based on CYP2D6 genotypes [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e].  For PM and IM genotypes, they state that there are not sufficient data to allow calculation of dose adjustment, and they recommend selecting an alternative drug or adjusting dose to clinical response and monitoring (O-desmethyl)venlafaxine plasma concentration.  For UM genotypes, they recommend titrating dose to a maximum of 150% of the normal dose(based on venlafaxine and (O-desmethyl)venlafaxine plasma concentration) or selecting an alternative drug.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003ePM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment.  Select alternative drug (e.g., citalopram, sertraline) or adjust dose to clinical response and monitor (O-desmethyl)venlafaxine plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele)\u003c/td\u003e\u003ctd\u003eInsufficient data to allow calculation of dose adjustment.  Select alternative drug (e.g., citalopram, sertraline) or adjust dose to clinical response and monitor (O-desmethyl)venlafaxine plasma concentration.\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eClinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10\u003csup\u003e9\u003c/sup\u003e/l; leucopenia 2.0-3.0x10\u003csup\u003e9\u003c/sup\u003e/l; thrombocytopenia 50-75x10\u003csup\u003e9\u003c/sup\u003e/l.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eUM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles)\u003c/td\u003e\u003ctd\u003eBe alert to decreased venlafaxine and increased (O-desmethyl)venlafaxine plasma concentration. Titrate dose to a maximum of 150% of the normal dose or select alternative drug (e.g., citalopram, sertraline).\u003c/td\u003e\u003ctd\u003ePublished controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.\u003c/td\u003e\u003ctd\u003eMinor clinical effect (S): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); INR increase \u0026lt; 4.5.  Kinetic effect (S).\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""http://www.pharmgkb.org/page/dpwg\""\u003eMethods \u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;good quality.\u0026quot;\u003c/li\u003e\n\u003cli\u003eS: statistically significant difference.\u003c/li\u003e\n\u003cli\u003ePlease see attached PDF for detailed information about the evaluated studies: \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/venlafaxine_CYP2D6_271111.pdf\""\u003eVenlafaxine CYP2D6\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166161537,Guideline Annotation,Annotation of CPIC Guideline for voriconazole and CYP2C19,t,PA10233,Clinical Pharmacogenetics Implementation Consortium,"<p>The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guideline-for-voriconazole-and-cyp2c19/"" target=""_blank"">CPIC&reg; guideline for voriconazole and CYP2C19</a>.</p>
<h3 id=""december-2016"">December 2016</h3>
<ul>
<li>
<p>Guidelines regarding the use of pharmacogenomic tests in dosing for voriconazole have been published in Clinical Pharmacology and Therapeutics by the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</p>
</li>
<li>
<p>These guidelines are applicable to:</p>
<ul>
<li>Adult patients (see Table 1 below)</li>
<li>Pediatric patients (see Table 2 below)</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/voriconazole/2016/27981572.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/voriconazole/2016/27981572-supplement.pdf"" target=""_blank"">2016 Supplement</a></li>
<li><a href=""/page/cyp2c19RefMaterials"">Gene-specific Information Tables for CYP2C19</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/voriconazole/2016/Voriconazole_Drug_Resource_Mappings.xlsx"" target=""_blank"">Voriconazole Drug Resource Mappings</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/voriconazole/2016/Voriconazole_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx"" target=""_blank"">Voriconazole Pre- and Post-Test Alerts and Flow Chart</a></li>
</ul>
</li>
</ul>
<h3 id=""table-1-dosing-recommendations-for-voriconazole-treatment-based-on-cyp2c19-phenotype-for-adult-patients"">Table 1: Dosing recommendations for voriconazole treatment based on CYP2C19 phenotype for adult patients</h3>
<p><em>Adapted from Tables 1 and 2 of the 2016 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely Phenotype</th><th>Genotypes<sup>b</sup></th><th>Examples of diplotypes</th><th>Implications for pharmacologic measures</th><th>Therapeutic recommendations</th><th>Classification of Recommendations<sup>e</sup></th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer (~2-5% of patients)<sup>a</sup></td><td>An individual carrying two increased function alleles</td><td><em>*17/*17</em></td><td>In patients for whom an ultrarapid metabolizer genotype is identified, the probability of attainment of therapeutic voriconazole concentrations is small with standard dosing.</td><td>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.<sup>f</sup></td><td>Moderate<sup>g</sup></td></tr>
<tr><td>Rapid metabolizer (~2-30% of patients)<sup>a</sup></td><td>An individual carrying one normal function allele and one increased function allele</td><td><em>*1/*17</em></td><td>In patients for whom a rapid metabolizer genotype is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing.</td><td>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.<sup>f</sup></td><td>Moderate</td></tr>
<tr><td>Normal metabolizer<sup>c</sup> (~35-50% of patients)<sup>a</sup></td><td>An individual carrying two normal function alleles</td><td><em>*1/*1</em></td><td>Normal voriconazole metabolism</td><td>Initiate therapy with recommended standard of care dosing.<sup>f</sup></td><td>Strong</td></tr>
<tr><td>Intermediate metabolizer (~18-45% of patients)<sup>a</sup></td><td>An individual carrying one normal function allele and one no function allele or one no function allele and one increased function allele</td><td><em>*1/*2, *1/*3, *2/*17<sup>d</sup></em></td><td>Higher dose-adjusted trough concentrations of voriconazole compared to normal metabolizers.</td><td>Initiate therapy with recommended standard of care dosing.<sup>f</sup></td><td>Moderate</td></tr>
<tr><td>Poor metabolizer (~2-15% of patients)<sup>a</sup></td><td>An individual carrying two no function alleles</td><td><em>*2/*2, *2/*3, *3/*3</em></td><td>Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events.</td><td>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.<sup>f</sup> In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.</td><td>Moderate</td></tr>
</tbody>
</table>
<p><sup>a</sup> See the <a href=""/page/cyp2c19RefMaterials"">CYP2C19 Frequency Table</a> for race specific allele and phenotype frequencies.</p>
<p><sup>b</sup> Assignment of allele function can be found on PharmGKB (<a href=""/page/cyp2c19RefMaterials"">CYP2C19 Allele Definition Table</a>) and citations for allele function can be on PharmGKB (<a href=""/page/cyp2c19RefMaterials"">CYP2C19 Allele Functionality Table</a>).</p>
<p><sup>c</sup> Based on the <a rel=""noopener noreferrer"" href=""https://www.ncbi.nlm.nih.gov/pubmed/27441996"" target=""_blank"">CPIC term standardization project</a>, the term &quot;Normal Metabolizer&quot; will be used instead of the term &quot;Extensive Metabolizer&quot; in all new and updated CPIC guidelines.</p>
<p><sup>d</sup> The predicted metabolizer phenotype for the <em>*2/*17</em> genotype is a provisional classification. The currently available evidence indicates that the <em>CYP2C19*17</em> increased function allele is unable to completely compensate for the no function <em>CYP2C19*2</em> (<a rel=""noopener noreferrer"" href=""https://www.ncbi.nlm.nih.gov/pubmed/20083681"" target=""_blank"">Sibbing <em>et al.</em>, 2010</a>). See the 2016 Supplement for a more comprehensive list of predicted metabolizer phenotypes.</p>
<p><sup>e</sup> Rating scheme is described in the 2016 Supplement</p>
<p><sup>f</sup> Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, TDM, and comorbidities.</p>
<p><sup>g</sup> Recommendations based upon data extrapolated from patients with CYP2C19*1/*17 genotype</p>
<hr />
<h3 id=""table-2-dosing-recommendations-for-voriconazole-treatment-based-on-cyp2c19-phenotype-for-pediatric-patients"">Table 2: Dosing recommendations for voriconazole treatment based on CYP2C19 phenotype for pediatric patients</h3>
<p><em>Adapted from Tables 1 and 3 of the 2016 guideline manuscript.</em></p>
<table class=""table"">
<thead>
<tr><th>Likely Phenotype</th><th>Genotypes<sup>b</sup></th><th>Examples of diplotypes</th><th>Implications for pharmacologic measures</th><th>Therapeutic recommendations</th><th>Classification of Recommendations<sup>e</sup></th></tr>
</thead>
<tbody>
<tr><td>Ultrarapid metabolizer (~2-5% of patients)<sup>a</sup></td><td>An individual carrying two increased function alleles</td><td><em>*17/*17</em></td><td>In patients for whom an ultrarapid metabolizer genotype is identified, the probability of attainment of therapeutic voriconazole concentrations is small.</td><td>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.<sup>f,g</sup></td><td>Moderate</td></tr>
<tr><td>Rapid metabolizer (~2-30% of patients)<sup>a</sup></td><td>An individual carrying one normal function allele and one increased function allele</td><td><em>*1/*17</em></td><td>In patients for whom a rapid metabolizer genotype is identified, the probability of attainment of therapeutic concentrations is variable.</td><td>Initiate therapy with recommended standard case dosing.<sup>f</sup> Use therapeutic dose monitoring to titrate dose to therapeutic trough concentrations.<sup>g,h</sup></td><td>Moderate</td></tr>
<tr><td>Normal metabolizer<sup>c</sup> (~35-50% of patients)<sup>a</sup></td><td>An individual carrying two normal function alleles</td><td><em>*1/*1</em></td><td>Normal voriconazole metabolism</td><td>Initiate therapy with recommended standard of care dosing.<sup>f</sup></td><td>Strong</td></tr>
<tr><td>Intermediate metabolizer (~18-45% of patients)<sup>a</sup></td><td>An individual carrying one normal function allele and one no function allele or one no function allele and one increased function allele</td><td><em>*1/*2, *1/*3, *2/*17<sup>d</sup></em></td><td>Higher dose-adjusted trough concentrations of voriconazole compared to normal metabolizers.</td><td>Initiate therapy with recommended standard of care dosing.<sup>f</sup></td><td>Moderate</td></tr>
<tr><td>Poor metabolizer (~2-15% of patients)<sup>a</sup></td><td>An individual carrying two no function alleles</td><td><em>*2/*2, *2/*3, *3/*3</em></td><td>Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events.</td><td>Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole<sup>f,i</sup>. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.</td><td>Moderate<sup>i</sup></td></tr>
</tbody>
</table>
<p><sup>a</sup> See the <a href=""/page/cyp2c19RefMaterials"">CYP2C19 frequency table</a> for race specific allele and phenotype frequencies.</p>
<p><sup>b</sup> Assignment of allele function can be found on PharmGKB (<a href=""/page/cyp2c19RefMaterials"">CYP2C19 Allele Definition Table</a>) and citations for allele function can be on PharmGKB (<a href=""/page/cyp2c19RefMaterials"">CYP2C19 Allele Functionality Table</a>).</p>
<p><sup>c</sup> Based on the <a rel=""noopener noreferrer"" href=""https://www.ncbi.nlm.nih.gov/pubmed/27441996"" target=""_blank"">CPIC term standardization project</a>, the term &quot;Normal Metabolizer&quot; will be used instead of the term &quot;Extensive Metabolizer&quot; in all new and updated CPIC guidelines.</p>
<p><sup>d</sup> The predicted metabolizer phenotype for the <em>*2/*17</em> genotype is a provisional classification. The currently available evidence indicates that the <em>CYP2C19*17</em> increased function allele is unable to completely compensate for the no function <em>CYP2C19*2</em> (<a rel=""noopener noreferrer"" href=""https://www.ncbi.nlm.nih.gov/pubmed/20083681"" target=""_blank"">Sibbing <em>et al.</em>, 2010</a>). See the 2016 Supplement for a more comprehensive list of predicted metabolizer phenotypes.</p>
<p><sup>e</sup> Rating scheme is described in the 2016 Supplement</p>
<p><sup>f</sup> Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, TDM, and comorbidities.</p>
<p><sup>g</sup> Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible.</p>
<p><sup>h</sup> Meticulous therapeutic drug monitoring is critical for rapid metabolizers. There is insufficient evidence to distinguish a CYP2C19*1/*17 and *1/*1 pediatric patient due to large variability in trough concentrations.</p>
<p><sup>i</sup> Recommendation based upon data extrapolated from adults.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166161537"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166161537"",""name"":""Annotation of CPIC Guideline for voriconazole and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":""U1PKEF6M9oM"",""guidelineGenes"":[{""id"":1.449562677E9,""alleles"":[{""id"":1.449562678E9,""_label"":""*1"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980634"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980634"",""symbol"":""CYP2C19*1"",""name"":""*1""}},{""id"":1.449562679E9,""_label"":""*2"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980635"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980635"",""symbol"":""CYP2C19*2"",""name"":""*2""}},{""id"":1.44956268E9,""_label"":""*3"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980636"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980636"",""symbol"":""CYP2C19*3"",""name"":""*3""}},{""id"":1.449562683E9,""_label"":""*5"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980638"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980638"",""symbol"":""CYP2C19*5"",""name"":""*5""}},{""id"":1.449562684E9,""_label"":""*6"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816522"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816522"",""symbol"":""CYP2C19*6"",""name"":""*6""}},{""id"":1.449562685E9,""_label"":""*7"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816523"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816523"",""symbol"":""CYP2C19*7"",""name"":""*7""}},{""id"":1.449562686E9,""_label"":""*8"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816524"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816524"",""symbol"":""CYP2C19*8"",""name"":""*8""}},{""id"":1.449562687E9,""_label"":""*9"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816525"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816525"",""symbol"":""CYP2C19*9"",""name"":""*9""}},{""id"":1.449562688E9,""_label"":""*10"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816526"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816526"",""symbol"":""CYP2C19*10"",""name"":""*10""}},{""id"":1.449562689E9,""_label"":""*11"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816527"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816527"",""symbol"":""CYP2C19*11"",""name"":""*11""}},{""id"":1.44956269E9,""_label"":""*12"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816528"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816528"",""symbol"":""CYP2C19*12"",""name"":""*12""}},{""id"":1.449562691E9,""_label"":""*13"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816529"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816529"",""symbol"":""CYP2C19*13"",""name"":""*13""}},{""id"":1.449562692E9,""_label"":""*14"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816530"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816530"",""symbol"":""CYP2C19*14"",""name"":""*14""}},{""id"":1.449562693E9,""_label"":""*15"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816531"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816531"",""symbol"":""CYP2C19*15"",""name"":""*15""}},{""id"":1.449562694E9,""_label"":""*16"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816532"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816532"",""symbol"":""CYP2C19*16"",""name"":""*16""}},{""id"":1.449562695E9,""_label"":""*17"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558332"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558332E9,""resource"":""Allele Function"",""term"":""Increased function"",""termId"":""haplotypeTags:1445558332""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816533"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816533"",""symbol"":""CYP2C19*17"",""name"":""*17""}},{""id"":1.449562696E9,""_label"":""*18"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816534"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816534"",""symbol"":""CYP2C19*18"",""name"":""*18""}},{""id"":1.449562697E9,""_label"":""*19"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816535"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816535"",""symbol"":""CYP2C19*19"",""name"":""*19""}},{""id"":1.449562698E9,""_label"":""*22"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816536"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816536"",""symbol"":""CYP2C19*22"",""name"":""*22""}},{""id"":1.449562699E9,""_label"":""*23"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816537"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816537"",""symbol"":""CYP2C19*23"",""name"":""*23""}},{""id"":1.4495627E9,""_label"":""*24"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816538"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816538"",""symbol"":""CYP2C19*24"",""name"":""*24""}},{""id"":1.449562701E9,""_label"":""*25"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816539"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816539"",""symbol"":""CYP2C19*25"",""name"":""*25""}},{""id"":1.449562702E9,""_label"":""*26"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558331"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558331E9,""resource"":""Allele Function"",""term"":""Decreased function"",""termId"":""haplotypeTags:1445558331""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165816540"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816540"",""symbol"":""CYP2C19*26"",""name"":""*26""}},{""id"":1.449562704E9,""_label"":""*28"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558335"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558335E9,""resource"":""Allele Function"",""term"":""Normal function"",""termId"":""haplotypeTags:1445558335""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115675"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115675"",""symbol"":""CYP2C19*28"",""name"":""*28""}},{""id"":1.449562705E9,""_label"":""*29"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123292"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123292"",""symbol"":""CYP2C19*29"",""name"":""*29""}},{""id"":1.449562706E9,""_label"":""*30"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123293"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123293"",""symbol"":""CYP2C19*30"",""name"":""*30""}},{""id"":1.449562707E9,""_label"":""*31"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123294"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123294"",""symbol"":""CYP2C19*31"",""name"":""*31""}},{""id"":1.449562708E9,""_label"":""*32"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123295"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123295"",""symbol"":""CYP2C19*32"",""name"":""*32""}},{""id"":1.449562709E9,""_label"":""*33"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166123296"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166123296"",""symbol"":""CYP2C19*33"",""name"":""*33""}},{""id"":1.44956271E9,""_label"":""*34"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1448531118"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.448531118E9,""resource"":""Allele Function"",""term"":""Uncertain function"",""termId"":""haplotypeTags:1448531118""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166115676"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166115676"",""symbol"":""CYP2C19*34"",""name"":""*34""}},{""id"":1.449562711E9,""_label"":""*35"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA166128094"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA166128094"",""symbol"":""CYP2C19*35"",""name"":""*35""}},{""id"":1.450805215E9,""_label"":""*4"",""function"":{""@id"":""https://pharmgkb.org/ontologyTerm/alleleFunction/haplotypeTags:1445558515"",""@context"":""https://api.pharmgkb.org/jsonld/ontologyTerm.jsonld"",""id"":1.445558515E9,""resource"":""Allele Function"",""term"":""No function"",""termId"":""haplotypeTags:1445558515""},""haplotype"":{""@id"":""https://pharmgkb.org/haplotype/PA165980637"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165980637"",""symbol"":""CYP2C19*4"",""name"":""*4""}}],""gene"":{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}}],""history"":[{""id"":1.448530671E9,""date"":""2016-12-02T00:00:00-08:00"",""type"":""Create"",""version"":0.0},{""id"":1.449717119E9,""date"":""2018-08-23T17:04:13.204-07:00"",""description"":""Updated video link"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098243"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098243E7,""resourceId"":""27981572"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474211"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5474211"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293324E9,""resource"":""PubMed Central"",""resourceId"":""PMC5474211"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474211""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/27981572"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293323E9,""resource"":""PubMed"",""resourceId"":""27981572"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/27981572""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.583"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293325E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.583"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.583""}]},{""@id"":""https://pharmgkb.org/literature/15100925"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100925E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"",""title"":""CPIC® Guideline for Voriconazole and CYP2C19 – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44843252E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10233"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10233"",""name"":""voriconazole""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.448432518E9,""html"":""\u003cp\u003eThe CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.448432597E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guideline-for-voriconazole-and-cyp2c19/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for voriconazole and CYP2C19\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""december-2016\""\u003eDecember 2016\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGuidelines regarding the use of pharmacogenomic tests in dosing for voriconazole have been published in Clinical Pharmacology and Therapeutics by the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC)\u003c/a\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThese guidelines are applicable to:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdult patients (see Table 1 below)\u003c/li\u003e\n\u003cli\u003ePediatric patients (see Table 2 below)\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/voriconazole/2016/27981572.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/voriconazole/2016/27981572-supplement.pdf\"" target\u003d\""_blank\""\u003e2016 Supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""/page/cyp2c19RefMaterials\""\u003eGene-specific Information Tables for CYP2C19\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/voriconazole/2016/Voriconazole_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eVoriconazole Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/voriconazole/2016/Voriconazole_Pre_and_Post_Test_Alerts_and_Flow_Chart.xlsx\"" target\u003d\""_blank\""\u003eVoriconazole Pre- and Post-Test Alerts and Flow Chart\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""table-1-dosing-recommendations-for-voriconazole-treatment-based-on-cyp2c19-phenotype-for-adult-patients\""\u003eTable 1: Dosing recommendations for voriconazole treatment based on CYP2C19 phenotype for adult patients\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 2 of the 2016 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely Phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications for pharmacologic measures\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003c/th\u003e\u003cth\u003eClassification of Recommendations\u003csup\u003ee\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer (~2-5% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*17/*17\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eIn patients for whom an ultrarapid metabolizer genotype is identified, the probability of attainment of therapeutic voriconazole concentrations is small with standard dosing.\u003c/td\u003e\u003ctd\u003eChoose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003csup\u003eg\u003c/sup\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eRapid metabolizer (~2-30% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one increased function allele\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*17\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eIn patients for whom a rapid metabolizer genotype is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing.\u003c/td\u003e\u003ctd\u003eChoose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNormal metabolizer\u003csup\u003ec\u003c/sup\u003e (~35-50% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*1\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eNormal voriconazole metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended standard of care dosing.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer (~18-45% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one no function allele or one no function allele and one increased function allele\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*2, *1/*3, *2/*17\u003csup\u003ed\u003c/sup\u003e\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eHigher dose-adjusted trough concentrations of voriconazole compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended standard of care dosing.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizer (~2-15% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*2/*2, *2/*3, *3/*3\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eHigher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events.\u003c/td\u003e\u003ctd\u003eChoose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.\u003csup\u003ef\u003c/sup\u003e In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e See the \u003ca href\u003d\""/page/cyp2c19RefMaterials\""\u003eCYP2C19 Frequency Table\u003c/a\u003e for race specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Assignment of allele function can be found on PharmGKB (\u003ca href\u003d\""/page/cyp2c19RefMaterials\""\u003eCYP2C19 Allele Definition Table\u003c/a\u003e) and citations for allele function can be on PharmGKB (\u003ca href\u003d\""/page/cyp2c19RefMaterials\""\u003eCYP2C19 Allele Functionality Table\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.ncbi.nlm.nih.gov/pubmed/27441996\"" target\u003d\""_blank\""\u003eCPIC term standardization project\u003c/a\u003e, the term \u0026quot;Normal Metabolizer\u0026quot; will be used instead of the term \u0026quot;Extensive Metabolizer\u0026quot; in all new and updated CPIC guidelines.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e The predicted metabolizer phenotype for the \u003cem\u003e*2/*17\u003c/em\u003e genotype is a provisional classification. The currently available evidence indicates that the \u003cem\u003eCYP2C19*17\u003c/em\u003e increased function allele is unable to completely compensate for the no function \u003cem\u003eCYP2C19*2\u003c/em\u003e (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.ncbi.nlm.nih.gov/pubmed/20083681\"" target\u003d\""_blank\""\u003eSibbing \u003cem\u003eet al.\u003c/em\u003e, 2010\u003c/a\u003e). See the 2016 Supplement for a more comprehensive list of predicted metabolizer phenotypes.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Rating scheme is described in the 2016 Supplement\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, TDM, and comorbidities.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Recommendations based upon data extrapolated from patients with CYP2C19*1/*17 genotype\u003c/p\u003e\n\u003chr /\u003e\n\u003ch3 id\u003d\""table-2-dosing-recommendations-for-voriconazole-treatment-based-on-cyp2c19-phenotype-for-pediatric-patients\""\u003eTable 2: Dosing recommendations for voriconazole treatment based on CYP2C19 phenotype for pediatric patients\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Tables 1 and 3 of the 2016 guideline manuscript.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eLikely Phenotype\u003c/th\u003e\u003cth\u003eGenotypes\u003csup\u003eb\u003c/sup\u003e\u003c/th\u003e\u003cth\u003eExamples of diplotypes\u003c/th\u003e\u003cth\u003eImplications for pharmacologic measures\u003c/th\u003e\u003cth\u003eTherapeutic recommendations\u003c/th\u003e\u003cth\u003eClassification of Recommendations\u003csup\u003ee\u003c/sup\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eUltrarapid metabolizer (~2-5% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two increased function alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*17/*17\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eIn patients for whom an ultrarapid metabolizer genotype is identified, the probability of attainment of therapeutic voriconazole concentrations is small.\u003c/td\u003e\u003ctd\u003eChoose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.\u003csup\u003ef,g\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eRapid metabolizer (~2-30% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one increased function allele\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*17\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eIn patients for whom a rapid metabolizer genotype is identified, the probability of attainment of therapeutic concentrations is variable.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended standard case dosing.\u003csup\u003ef\u003c/sup\u003e Use therapeutic dose monitoring to titrate dose to therapeutic trough concentrations.\u003csup\u003eg,h\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eNormal metabolizer\u003csup\u003ec\u003c/sup\u003e (~35-50% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two normal function alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*1\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eNormal voriconazole metabolism\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended standard of care dosing.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eStrong\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eIntermediate metabolizer (~18-45% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying one normal function allele and one no function allele or one no function allele and one increased function allele\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*1/*2, *1/*3, *2/*17\u003csup\u003ed\u003c/sup\u003e\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eHigher dose-adjusted trough concentrations of voriconazole compared to normal metabolizers.\u003c/td\u003e\u003ctd\u003eInitiate therapy with recommended standard of care dosing.\u003csup\u003ef\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eModerate\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003ePoor metabolizer (~2-15% of patients)\u003csup\u003ea\u003c/sup\u003e\u003c/td\u003e\u003ctd\u003eAn individual carrying two no function alleles\u003c/td\u003e\u003ctd\u003e\u003cem\u003e*2/*2, *2/*3, *3/*3\u003c/em\u003e\u003c/td\u003e\u003ctd\u003eHigher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events.\u003c/td\u003e\u003ctd\u003eChoose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole\u003csup\u003ef,i\u003c/sup\u003e. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.\u003c/td\u003e\u003ctd\u003eModerate\u003csup\u003ei\u003c/sup\u003e\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003csup\u003ea\u003c/sup\u003e See the \u003ca href\u003d\""/page/cyp2c19RefMaterials\""\u003eCYP2C19 frequency table\u003c/a\u003e for race specific allele and phenotype frequencies.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Assignment of allele function can be found on PharmGKB (\u003ca href\u003d\""/page/cyp2c19RefMaterials\""\u003eCYP2C19 Allele Definition Table\u003c/a\u003e) and citations for allele function can be on PharmGKB (\u003ca href\u003d\""/page/cyp2c19RefMaterials\""\u003eCYP2C19 Allele Functionality Table\u003c/a\u003e).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ec\u003c/sup\u003e Based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.ncbi.nlm.nih.gov/pubmed/27441996\"" target\u003d\""_blank\""\u003eCPIC term standardization project\u003c/a\u003e, the term \u0026quot;Normal Metabolizer\u0026quot; will be used instead of the term \u0026quot;Extensive Metabolizer\u0026quot; in all new and updated CPIC guidelines.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ed\u003c/sup\u003e The predicted metabolizer phenotype for the \u003cem\u003e*2/*17\u003c/em\u003e genotype is a provisional classification. The currently available evidence indicates that the \u003cem\u003eCYP2C19*17\u003c/em\u003e increased function allele is unable to completely compensate for the no function \u003cem\u003eCYP2C19*2\u003c/em\u003e (\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.ncbi.nlm.nih.gov/pubmed/20083681\"" target\u003d\""_blank\""\u003eSibbing \u003cem\u003eet al.\u003c/em\u003e, 2010\u003c/a\u003e). See the 2016 Supplement for a more comprehensive list of predicted metabolizer phenotypes.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ee\u003c/sup\u003e Rating scheme is described in the 2016 Supplement\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ef\u003c/sup\u003e Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, TDM, and comorbidities.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eg\u003c/sup\u003e Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003eh\u003c/sup\u003e Meticulous therapeutic drug monitoring is critical for rapid metabolizers. There is insufficient evidence to distinguish a CYP2C19*1/*17 and *1/*1 pediatric patient due to large variability in trough concentrations.\u003c/p\u003e\n\u003cp\u003e\u003csup\u003ei\u003c/sup\u003e Recommendation based upon data extrapolated from adults.\u003c/p\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.44843252E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/""}]},""status"":""success""}"
PA166104990,Guideline Annotation,Annotation of DPWG Guideline for voriconazole and CYP2C19,t,PA10233,Dutch Pharmacogenetics Working Group,"<p>Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers.</p>
","<h3 id=""november-2018-update"">November 2018 Update</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for voriconazole based on CYP2C19 genotype. Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C19 PM</td><td>voriconazole</td><td>The gene variation can reduce the conversion of voriconazole and consequently increase the plasma concentration. This could result in improved efficacy or an increase in the risk of side effects. Initially, the risk of side effects is of particular interest.</td><td>Use 50% of the standard dose and monitor the plasma concentration.</td></tr>
<tr><td>CYP2C19 IM</td><td>voriconazole</td><td>The gene variation can reduce the conversion of voriconazole and consequently increase the plasma concentration. This could result in improved efficacy or an increase in the risk of side effects.</td><td>Monitor the plasma concentration.</td></tr>
<tr><td>CYP2C19 UM</td><td>voriconazole</td><td>The gene variation increases the conversion of voriconazole, which increases the risk of ineffectiveness.</td><td>Use an initial dose that is 1.5x higher and monitor the plasma concentration.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0001683.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
<h3 id=""2011-guideline"">2011 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for voriconazole based on <em>CYP2C19</em> genotype [Article:<a href=""/pmid/21412232"">21412232</a>]. They conclude to monitor serum concentration for patients carrying the <em>CYP2C19</em> PM or IM phenotype.</p>
<table class=""table"">
<thead>
<tr><th>Phenotype (Genotype)</th><th>Therapeutic Dose Recommendation</th><th>Level of Evidence</th><th>Clinical Relevance</th></tr>
</thead>
<tbody>
<tr><td><em>CYP2C19</em> PM (*2/*2, *2/*3, *3/*3)</td><td>Monitor serum concentration</td><td>Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 ; Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> IM (*1/*2, *1/*3, *17/*2, *17/*3)</td><td>Monitor serum concentration</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 ; Kinetic effect (statistically significant difference)</td></tr>
<tr><td><em>CYP2C19</em> UM (*17/*17)</td><td>None</td><td>Published controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints</td><td>Minor clinical effect (statistically significant difference): QTc prolongation (&lt;450 ms female, &lt;470 ms male); international normalized ratio increase &lt; 4.5 ; Kinetic effect (statistically significant difference)</td></tr>
</tbody>
</table>
<ul>
<li>*See <a href=""/page/dpwg"">Methods</a> or [Article:<a href=""/pmid/18253145"">18253145</a>] for definition of &quot;moderate&quot; quality.</li>
</ul>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104990"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104990"",""name"":""Annotation of DPWG Guideline for voriconazole and CYP2C19"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.183704547E9,""date"":""2011-08-10T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.450415066E9,""date"":""2019-05-23T15:52:49.169-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820677E9,""date"":""2019-10-03T16:26:04.491-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450963943E9,""date"":""2020-02-11T08:22:09.164-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/7283333"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":7283333.0,""resourceId"":""21412232"",""title"":""Pharmacogenetics: from bench to byte--an update of guidelines."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/21412232"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":7.69250885E8,""resource"":""PubMed"",""resourceId"":""21412232"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21412232""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.34"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449247827E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.34"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.34""}]},{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA10233"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA10233"",""name"":""voriconazole""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA124"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA124"",""symbol"":""CYP2C19"",""name"":""cytochrome P450 family 2 subfamily C member 19""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.447982004E9,""html"":""\u003cp\u003ePatients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.447982003E9,""html"":""\u003ch3 id\u003d\""november-2018-update\""\u003eNovember 2018 Update\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for voriconazole based on CYP2C19 genotype. Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 PM\u003c/td\u003e\u003ctd\u003evoriconazole\u003c/td\u003e\u003ctd\u003eThe gene variation can reduce the conversion of voriconazole and consequently increase the plasma concentration. This could result in improved efficacy or an increase in the risk of side effects. Initially, the risk of side effects is of particular interest.\u003c/td\u003e\u003ctd\u003eUse 50% of the standard dose and monitor the plasma concentration.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 IM\u003c/td\u003e\u003ctd\u003evoriconazole\u003c/td\u003e\u003ctd\u003eThe gene variation can reduce the conversion of voriconazole and consequently increase the plasma concentration. This could result in improved efficacy or an increase in the risk of side effects.\u003c/td\u003e\u003ctd\u003eMonitor the plasma concentration.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C19 UM\u003c/td\u003e\u003ctd\u003evoriconazole\u003c/td\u003e\u003ctd\u003eThe gene variation increases the conversion of voriconazole, which increases the risk of ineffectiveness.\u003c/td\u003e\u003ctd\u003eUse an initial dose that is 1.5x higher and monitor the plasma concentration.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0001683.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""2011-guideline\""\u003e2011 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for voriconazole based on \u003cem\u003eCYP2C19\u003c/em\u003e genotype [Article:\u003ca href\u003d\""/pmid/21412232\""\u003e21412232\u003c/a\u003e]. They conclude to monitor serum concentration for patients carrying the \u003cem\u003eCYP2C19\u003c/em\u003e PM or IM phenotype.\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003ePhenotype (Genotype)\u003c/th\u003e\u003cth\u003eTherapeutic Dose Recommendation\u003c/th\u003e\u003cth\u003eLevel of Evidence\u003c/th\u003e\u003cth\u003eClinical Relevance\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e PM (*2/*2, *2/*3, *3/*3)\u003c/td\u003e\u003ctd\u003eMonitor serum concentration\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio increase \u0026lt; 4.5 ; Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e IM (*1/*2, *1/*3, *17/*2, *17/*3)\u003c/td\u003e\u003ctd\u003eMonitor serum concentration\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio increase \u0026lt; 4.5 ; Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e\u003cem\u003eCYP2C19\u003c/em\u003e UM (*17/*17)\u003c/td\u003e\u003ctd\u003eNone\u003c/td\u003e\u003ctd\u003ePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints\u003c/td\u003e\u003ctd\u003eMinor clinical effect (statistically significant difference): QTc prolongation (\u0026lt;450 ms female, \u0026lt;470 ms male); international normalized ratio increase \u0026lt; 4.5 ; Kinetic effect (statistically significant difference)\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cul\u003e\n\u003cli\u003e*See \u003ca href\u003d\""/page/dpwg\""\u003eMethods\u003c/a\u003e or [Article:\u003ca href\u003d\""/pmid/18253145\""\u003e18253145\u003c/a\u003e] for definition of \u0026quot;moderate\u0026quot; quality.\u003c/li\u003e\n\u003c/ul\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166104949,Guideline Annotation,"Annotation of CPIC Guideline for warfarin and CYP2C9,CYP4F2,VKORC1",t,PA451906,Clinical Pharmacogenetics Implementation Consortium,"<p>The updated guideline for pharmacogenetics-guided warfarin dosing is published by the <em>Clinical Pharmacogenetics Implementation Consortium</em>.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from <em>CYP2C9</em>, <em>VKORC1</em>, <em>CYP4F2</em>, and rs12777823.</p>
","<p>This annotation is based on the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"" target=""_blank"">CPIC&reg; guideline for pharmacogenetics-guided warfarin dosing</a>.</p>
<h3 id=""february-2017-update"">February 2017 Update</h3>
<ul>
<li>
<p>The 2017 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of warfarin is published in <a rel=""noopener noreferrer"" href=""http://onlinelibrary.wiley.com/doi/10.1002/cpt.668/abstract"" target=""_blank""><em>Clinical Pharmacology and Therapeutics</em></a> by the <em>Clinical Pharmacogenetics Implementation Consortium</em> <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">(CPIC)</a>.  Literature up to Dec 2016 was reviewed, recommendations and supplemental information were updated.</p>
</li>
<li>
<p>Excerpt from the 2017 dosing guideline update:</p>
<ul>
<li>
<p>&quot;<strong><em>Therapeutic Recommendations: Adults</em></strong><br />
Numerous studies have derived warfarin dosing algorithms that use both genetic and non-genetic factors to predict warfarin dose [Articles:<a href=""/pmid/18305455"">18305455</a>, <a href=""/pmid/19228618"">19228618</a>, <a href=""/pmid/20375999"">20375999</a>, <a href=""/pmid/22012312"">22012312</a>]. Two algorithms perform well in estimating stable warfarin dose [Articles:<a href=""/pmid/18305455"">18305455</a>, <a href=""/pmid/19228618"">19228618</a>] and were created using more than 5,000 subjects, though as noted above, more recent data suggest they do not perform acceptably in African Americans when used without modification for CYP2C9 alleles frequently found in the African population [Article:<a href=""/pmid/24251361"">24251361</a>].  The Gage and IWPC algorithms or minor adjustments to them have also been the algorithms used in both randomized controlled trials and most of the prospective dosing studies.  Dosing algorithms using genetic information outperform non-genetic clinical algorithms and fixed-dose approaches in dose prediction, except in African Americans when the algorithm only includes CYP2C9*2 and *3 [Articles:<a href=""/pmid/18305455"">18305455</a>, <a href=""/pmid/19228618"">19228618</a>, <a href=""/pmid/24251361"">24251361</a>]. Genetics-based algorithms also better predict warfarin dose than the FDA-approved warfarin label table [Article:<a href=""/pmid/21272753"">21272753</a>].</p>
<p><strong><em>Pharmacogenetic algorithm-based warfarin dosing</em></strong>:  This guideline recommends that pharmacogenetic warfarin dosing be accomplished through the use of one of the pharmacogenetic dosing algorithms described above, as summarized in <a href=""#figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients"">Figure 2</a>.  The two algorithms provide very similar dose recommendations...It is important to note that these algorithms do not include CYP4F2, CYP2C9*5, *6, *8, or *11 or rs12777823, and incorporation of these should be added when results are available, as described in <a href=""#figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients"">Figure 2</a>.  The warfarindosing.org website contains both algorithms, the Gage algorithm [Article:<a href=""/pmid/18305455"">18305455</a>] as the primary algorithm and the IWPC algorithm [Article:<a href=""/pmid/19228618"">19228618</a>] as the secondary algorithm and can adjust for CYP4F2, CYP2C9*5 and *6.  If utilizing warfarindosing.org, the user should be clear on whether the algorithm is or is not incorporating genotypes beyond CYP2C9 *2 and *3 and VKORC1, which are the only three genotypes in the original version of both algorithms.</p>
<p><strong><em>Non-African ancestry recommendation</em></strong>. In patients who self-identify as non-African ancestry, the recommendation, as summarized in <a href=""#figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients"">Figure 2</a>, is to:  1) calculate warfarin dosing using a published pharmacogenetic algorithm [Articles:<a href=""/pmid/18305455"">18305455</a>, <a href=""/pmid/19228618"">19228618</a>], including genotype information for VKORC1-1639G&gt;A and CYP2C9*2 and *3. In individuals with genotypes associated with CYP2C9 poor metabolism (e.g., CYP2C9 *2/*3, *3/*3) or both increased sensitivity (VKORC1-1639 A/A) and CYP2C9 poor metabolism, an alternative oral anticoagulant might be considered. These recommendations are graded as STRONG.  2) If a loading dose is to be utilized, the EU-PACT loading dose algorithm that incorporates genetic information could be used [Article:<a href=""/pmid/24251363"">24251363</a>].  This recommendation is OPTIONAL. 3) While CYP2C9*5, *6, *8, or*11 variant alleles are commonly referred to as African specific alleles, they can occur among individuals who do not identify as, or know of their, African ancestry.  If these variant alleles are detected, decrease calculated dose by 15-30% per variant allele or consider an alternative agent. Larger dose reductions might be needed in patients homozygous for variant alleles (i.e. 20-40%, e.g. CYP2C9*2/*5). This recommendation is graded as OPTIONAL.  4) If the CYP4F2*3 (i.e., c.1297A, p.433Met) allele is also detected, increase the dose by 5-10%.  This recommendation is also considered OPTIONAL.   5) The data do not suggest an association between rs12777823 genotype and warfarin dose in non-African Americans, thus rs12777823 should not be considered in these individuals (even if available).</p>
<p><strong><em>African ancestry recommendation</em></strong>. In patients of African ancestry, CYP2C9*5, *6, *8, *11 are important for warfarin dosing. If these genotypes are not available, warfarin should be dosed clinically without consideration for genotype. If CYP2C9*5, *6, *8, and *11 are known, then the recommendation, as shown in  <a href=""#figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients"">Figure 2</a>, is to: 1) calculate warfarin dose using a validated pharmacogenetic algorithm, including genotype information for VKORC1 c.-1639G&gt;A and CYP2C9*2 and *3 [Articles:<a href=""/pmid/18305455"">18305455</a>, <a href=""/pmid/19228618"">19228618</a>]; 2) if the individual carriers a CYP2C9*5, *6, *8, or *11 variant allele(s), decrease calculated dose by 15-30%. Larger dose reductions might be needed in patients who carry two variant alleles (e.g., CYP2C9*5/*6) (i.e. 20-40% dose reduction). 3) In addition, rs12777823 is associated with warfarin dosing in African Americans (mainly originating from West Africa). Thus, in African Americans a dose reductions of 10-25% in those with rs12777823 A/G or A/A genotype is recommended.  These recommendations are considered MODERATE.   In individuals with genotypes that predict CYP2C9 poor metabolism or who have increased warfarin sensitivity (VKORC1 c.-1639 A/A) and CYP2C9 poor metabolism, an alternative oral anticoagulant should be considered.&quot;</p>
</li>
<li>
<p>&quot;<strong><em>Therapeutic Recommendations: Pediatric</em></strong><br />
In children of European ancestry and if CYP2C9*2 and *3 and VKORC1-1639 genotype are available, calculate warfarin dosing based on a validated published pediatric pharmacogenetic algorithm (<a href=""#figure-3-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-pediatric-patients"">Figure 3</a>) [Articles:<a href=""/pmid/22010099"">22010099</a>, <a href=""/pmid/23307232"">23307232</a>].  A dosing tool that can be used in children of European ancestry is available at http://www.warfarindoserevision.com [Article:<a href=""/pmid/24330000"">24330000</a>].&quot;</p>
</li>
</ul>
</li>
<li>
<p>Download and read:</p>
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/warfarin/2017/28198005.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for pharmacogenetics-guided warfarin dosing: 2017 update</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/warfarin/2017/28198005-supplement.pdf"" target=""_blank"">2017 supplement</a></li>
<li>Look up your warfarin dosing guideline using the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/warfarin/2011/IWPC_dose_calculator.xls"" target=""_blank"">IWPC Pharmacogenetic Dosing Algorithm</a>.</li>
<li><a href=""https://www.pharmgkb.org/page/cyp2c9RefMaterials""><em>CYP2C9</em> Gene-specific Information Tables</a> (Note: allele functionality and diplotype-phenotype mappings are not applicable to the warfarin guideline)</li>
<li><a href=""https://www.pharmgkb.org/page/vkorc1RefMaterials""><em>VKORC1</em> Gene-specific Information Tables</a></li>
<li><a href=""https://www.pharmgkb.org/page/cyp4f2RefMaterials""><em>CYP4F2</em> Gene-specific Information Tables</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/warfarin/2017/Warfarin_Drug_Resource_Mappings.xlsx"" target=""_blank"">Warfarin Drug Resource Mappings</a></li>
</ul>
</li>
</ul>
<h3 id=""figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients"">Figure 2. Dosing recommendations for Warfarin dosing based on genotype for adult patients</h3>
<p><em>Adapted from Figure 2 of the 2017 guideline manuscript</em></p>
<p><img src=""https://s3.pgkb.org/attachment/CPIC_warfarin_2017_Fig_2.png"" alt=""Fig2"" /></p>
<p><strong>Figure 2 Legend:</strong> <sup>a</sup>“Dose clinically” means to dose without genetic information, which may include use of a clinical dosing algorithm or standard dose approach<br />
<sup>b</sup>Data strongest for European and East Asian ancestry populations and consistent in other populations.<br />
<sup>c</sup>45-50% of individuals with self-reported African ancestry carry CYP2C9*5,*6,*8,*11, or rs12777823. IF CYP2C9*5, *6, *8, and *11 WERE NOT TESTED, DOSE WARFARIN CLINICALLY.  Note: these data derive primarily from African Americans, who are largely from West Africa.  It is unknown if the same associations are present for those from other parts of Africa.<br />
<sup>d</sup>Most algorithms are developed for the target INR 2-3.<br />
<sup>e</sup>Consider an alternative agent in individuals with genotypes associated with CYP2C9 poor metabolism (e.g., CYP2C9*3/*3, *2/*3, *3/*3) or both increased sensitivity (VKORC1 A/G or A/A) and CYP2C9 poor metabolism.<br />
<sup>f</sup>See the EU-PACT trial for pharmacogenetics-based warfarin initiation (loading) dose algorithm [Article:<a href=""/pmid/24251363"">24251363</a>] with the caveat that the loading dose PG algorithm has not been specifically tested or validated in populations of African ancestry.<br />
<sup>g</sup>Larger dose reduction might be needed in variant homozygotes (i.e. 20-40%).<br />
<sup>h</sup>African American refers to individuals mainly originating from West Africa.</p>
<h3 id=""figure-3-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-pediatric-patients"">Figure 3. Dosing recommendations for Warfarin dosing based on genotype for pediatric patients</h3>
<p><em>Adapted from Figure 3 of the 2017 guideline manuscript</em></p>
<p><img src=""https://s3.pgkb.org/attachment/CPIC_warfarin_2017_Fig_3.png"" alt=""Fig3"" /></p>
<p><strong>Figure 3 Legend:</strong> <sup>a</sup>Data strongest for European ancestry populations and consistent in most Japanese studies.<br />
<sup>b</sup>“Dose clinically” means to dose without genetic information, which may include use of a clinical dosing algorithm or standard dose approach<br />
<sup>c</sup>Validated published pediatric pharmacogenetic algorithms include Hamberg et al.[Article:<a href=""/pmid/24330000"">24330000</a>] and Biss et al.[Article:<a href=""/pmid/22010099"">22010099</a>]<br />
<sup>d</sup>No studies in children included CYP2C9*5, *6, *8, or *11 genotyping.</p>
<h3 id=""november-2013-update"">November 2013 Update</h3>
<p>CPIC guideline authors are aware of several recently published studies on warfarin pharmacogenetics [Articles:<a href=""/pmid/24251361"">24251361</a>, <a href=""/pmid/24251363"">24251363</a>, <a href=""/pmid/24251360"">24251360</a>]. These papers have prompted several opinion pieces [Articles:<a href=""/pmid/24328463"">24328463</a>, <a href=""/pmid/24251364"">24251364</a>]. The authors are evaluating the information, which will be incorporated into the next update of the CPIC guideline on warfarin.</p>
<h3 id=""october-2011"">October 2011</h3>
<p><em>Advance online publication September 2011.</em></p>
<ul>
<li>Guideline regarding the use of pharmacogenomic tests in dosing for warfarin was published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a rel=""noopener noreferrer"" href=""https://cpicpgx.org"" target=""_blank"">(CPIC)</a>.</li>
<li>These guidelines are applicable to:
<ul>
<li>adult patients</li>
</ul>
</li>
<li>Excerpt from the 2011 warfarin dosing guideline:
<ul>
<li>&quot;Pharmacogenetic algorithm-based warfarin dosing: Numerous studies have derived warfarin dosing algorithms that use both genetic and non-genetic factors to predict warfarin dose [Articles:<a href=""/pmid/18305455"">18305455</a>, <a href=""/pmid/19228618"">19228618</a>, <a href=""/pmid/18574025"">18574025</a>]. Two algorithms perform well in estimating stable warfarin dose across different ethnic populations; [Articles:<a href=""/pmid/18305455"">18305455</a>, <a href=""/pmid/19228618"">19228618</a>] these were created using more than 5,000 subjects. Dosing algorithms using genetics outperform nongenetic clinical algorithms and fixed-dose approaches in dose prediction [Articles:<a href=""/pmid/18305455"">18305455</a>, <a href=""/pmid/19228618"">19228618</a>]. The best way to estimate the anticipated stable dose of warfarin is to use the algorithms available on <a rel=""noopener noreferrer"" href=""http://www.warfarindosing.org"" target=""_blank"">http://www.warfarindosing.org</a> (offering both high-performing algorithms [Articles:<a href=""/pmid/18305455"">18305455</a>, <a href=""/pmid/19228618"">19228618</a>]). The dosing algorithm published by the International Warfarin Pharmacogenetics Consortium is also online, at <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/warfarin/2011/IWPC_dose_calculator.xls"" target=""_blank"">IWPC Pharmacogenetic Dosing Algorithm</a>. The two algorithms provide very similar dose recommendations.&quot;</li>
<li>&quot;Approach to pharmacogenetic-based warfarin dosing without access to dosing algorithms:     In 2007, the FDA modified the warfarin label, stating that CYP2C9 and VKORC1 genotypes may be useful in determining the optimal initial dose of warfarin [Article:<a href=""/pmid/17906972"">17906972</a>]. The label was further updated in 2010 to include a table (Table 1) describing recommendations for initial dosing ranges for patients with different combinations of CYP2C9 and VKORC1 genotypes. Genetics-based algorithms also better predict warfarin dose than the FDA-approved warfarin label table [Article:<a href=""/pmid/21272753"">21272753</a>]. Therefore, the use of pharmacogenetic algorithm-based dosing is recommended when possible, although if electronic means for such dosing are not available, the table-based dosing approaches (Table 1) are suggested. The range of doses by VKORC1 genotype and the range of dose recommendations/predictions by the FDA table and algorithm are shown in Figure 2.&quot;</li>
</ul>
</li>
<li>Download and read:
<ul>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/warfarin/2011/21900891.pdf"" target=""_blank"">Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing</a></li>
<li><a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/warfarin/2011/21900891-supplement.pdf"" target=""_blank"">2011 supplement</a></li>
<li>Look up your warfarin dosing guideline using the <a rel=""noopener noreferrer"" href=""https://cpicpgx.org/content/guideline/publication/warfarin/2011/IWPC_dose_calculator.xls"" target=""_blank"">IWPC Pharmacogenetic Dosing Algorithm</a>.</li>
</ul>
</li>
</ul>
<h3 id=""figure-2-frequency-histograms-of-stable-therapeutic-warfarin-doses-in-mg-week-stratified-by-vkorc1-1639g-a-genotype"">Figure 2. Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by VKORC1 -1639G&gt;A genotype.</h3>
<p><em>Adapted from Figure 2 of the 2011 guideline manuscript</em></p>
<p><img src=""https://s3.pgkb.org/attachment/Figure_2-CPIC_Warfarin_dosing_guidelines.png"" alt=""CPIC warfarin dosing guideline"" /></p>
<p><strong>Figure 2 Legend:</strong> Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by <em>VKORC1</em> -1639G&gt;A genotype in 3,616 patients recruited by the International Warfarin Pharmacogenetics Consortium (IWPC) who did not carry the <em>CYP2C9*2</em> or <em>*3</em> allele (i.e., coded as <em>*1/*1</em> for US Food and Drug Administration (FDA) table and algorithm dosing). The range of doses within each genotype group recommended on the FDA table is shown via the shaded rectangle. The range of doses predicted using the IWPC dosing algorithm in these 3,616 patients is shown by the solid lines.</p>
<p>Figure 2 demonstrates that the range of individuals covered by the FDA table is much narrower than that of the algorithm. The article and supplement detail important variables that are not covered by the table that should also be taken into consideration.</p>
<h3 id=""table-1-recommended-daily-warfarin-doses-mg-day-to-achieve-a-therapeutic-inr-based-on-cyp2c9-and-vkorc1-genotype-using-the-warfarin-product-insert-approved-by-the-united-states-food-and-drug-administration"">Table 1: Recommended daily warfarin doses (mg/day) to achieve a therapeutic INR based on <em>CYP2C9</em> and <em>VKORC1</em> genotype using the warfarin product insert approved by the United States Food and Drug Administration:</h3>
<p><em>Adapted from Table 1 of the 2011 guideline manuscript</em></p>
<table class=""table"">
<thead>
<tr><th><em>VKORC1</em> Genotype (-1639G&gt;A, <a href=""/variant/PA166155091"">rs9923231</a>)</th><th><em>CYP2C9*1/*1</em></th><th><em>CYP2C9*1/*2</em></th><th><em>CYP2C9*1/*3</em></th><th><em>CYP2C9*2/*2</em></th><th><em>CYP2C9*2/*3</em></th><th><em>CYP2C9*3/*3</em></th></tr>
</thead>
<tbody>
<tr><td>GG</td><td>5-7</td><td>5-7</td><td>3-4</td><td>3-4</td><td>3-4</td><td>0.5-2</td></tr>
<tr><td>GA</td><td>5-7</td><td>3-4</td><td>3-4</td><td>3-4</td><td>0.5-2</td><td>0.5-2</td></tr>
<tr><td>AA</td><td>3-4</td><td>3-4</td><td>0.5-2</td><td>0.5-2</td><td>0.5-2</td><td>0.5-2</td></tr>
</tbody>
</table>
<p><em>Reproduced from updated warfarin (Coumadin) product label.</em></p>
<h3 id=""supplemental-table-s1-genotypes-that-constitute-the-alleles-for-cyp2c9"">Supplemental Table S1. Genotypes that constitute the * alleles for <em>CYP2C9</em></h3>
<p><em>Adapted from Table S1 of the 2011 guideline supplement</em></p>
<table class=""table"">
<thead>
<tr><th>Allele</th><th>Constituted by genotypes at:</th><th>Amino acid changes</th><th>Enzymatic Activity</th></tr>
</thead>
<tbody>
<tr><td>*1</td><td>reference allele at all positions</td><td></td><td>Normal</td></tr>
<tr><td>*2</td><td>C&gt;T at <a href=""/variant/PA166153972"">rs1799853</a></td><td>R144C</td><td>Decreased</td></tr>
<tr><td>*3</td><td>A&gt;C at <a href=""/variant/PA166153959"">rs1057910</a></td><td>I359L</td><td>Decreased</td></tr>
</tbody>
</table>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166104949"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166104949"",""name"":""Annotation of CPIC Guideline for warfarin and CYP2C9,CYP4F2,VKORC1"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.183699782E9,""date"":""2011-09-07T00:00:00-07:00"",""type"":""Create"",""version"":0.0},{""id"":1.183701832E9,""date"":""2013-12-18T00:00:00-08:00"",""description"":""Added note about recent publications"",""type"":""Update"",""version"":0.0},{""id"":1.183846974E9,""date"":""2014-02-27T00:00:00-08:00"",""description"":""changed URL of dosing algorithm"",""type"":""Correction"",""version"":1.0},{""id"":1.184470001E9,""date"":""2014-06-19T00:00:00-07:00"",""type"":""Update"",""version"":0.0},{""id"":1.4485943E9,""date"":""2017-02-08T17:14:38.661-08:00"",""description"":""warfarin 2017 update based on accepted manuscript"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15098503"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5098503E7,""resourceId"":""28198005"",""title"":""Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546947"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC5546947"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293783E9,""resource"":""PubMed Central"",""resourceId"":""PMC5546947"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546947""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/28198005"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293782E9,""resource"":""PubMed"",""resourceId"":""28198005"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/28198005""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1002/cpt.668"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449293784E9,""resource"":""DOI"",""resourceId"":""10.1002/cpt.668"",""_url"":""http://dx.doi.org/10.1002%2Fcpt.668""}]},{""@id"":""https://pharmgkb.org/literature/8560040"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":8560040.0,""resourceId"":""21900891"",""title"":""Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187550"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pmc/PMC3187550"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449251343E9,""resource"":""PubMed Central"",""resourceId"":""PMC3187550"",""_url"":""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3187550""},{""@id"":""https://pharmgkb.org/crossReference/pubMed/21900891"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":8.277078E8,""resource"":""PubMed"",""resourceId"":""21900891"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/21900891""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1038/clpt.2011.185"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449251344E9,""resource"":""DOI"",""resourceId"":""10.1038/clpt.2011.185"",""_url"":""http://dx.doi.org/10.1038%2Fclpt.2011.185""}]},{""@id"":""https://pharmgkb.org/literature/15100922"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5100922E7,""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"",""title"":""CPIC® Guideline for Pharmacogenetics-Guided Warfarin Dosing – CPIC"",""_sameAs"":""https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983518E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451906"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451906"",""name"":""warfarin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""},{""@id"":""https://pharmgkb.org/gene/PA27121"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA27121"",""symbol"":""CYP4F2"",""name"":""cytochrome P450 family 4 subfamily F member 2""},{""@id"":""https://pharmgkb.org/gene/PA133787052"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA133787052"",""symbol"":""VKORC1"",""name"":""vitamin K epoxide reductase complex subunit 1""}],""source"":""Clinical Pharmacogenetics Implementation Consortium"",""summaryMarkdown"":{""id"":1.447981868E9,""html"":""\u003cp\u003eThe updated guideline for pharmacogenetics-guided warfarin dosing is published by the \u003cem\u003eClinical Pharmacogenetics Implementation Consortium\u003c/em\u003e.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from \u003cem\u003eCYP2C9\u003c/em\u003e, \u003cem\u003eVKORC1\u003c/em\u003e, \u003cem\u003eCYP4F2\u003c/em\u003e, and rs12777823.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.447981867E9,""html"":""\u003cp\u003eThis annotation is based on the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/\"" target\u003d\""_blank\""\u003eCPIC\u0026reg; guideline for pharmacogenetics-guided warfarin dosing\u003c/a\u003e.\u003c/p\u003e\n\u003ch3 id\u003d\""february-2017-update\""\u003eFebruary 2017 Update\u003c/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe 2017 update of CPIC guidelines regarding the use of pharmacogenomic tests in dosing of warfarin is published in \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://onlinelibrary.wiley.com/doi/10.1002/cpt.668/abstract\"" target\u003d\""_blank\""\u003e\u003cem\u003eClinical Pharmacology and Therapeutics\u003c/em\u003e\u003c/a\u003e by the \u003cem\u003eClinical Pharmacogenetics Implementation Consortium\u003c/em\u003e \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.  Literature up to Dec 2016 was reviewed, recommendations and supplemental information were updated.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExcerpt from the 2017 dosing guideline update:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cstrong\u003e\u003cem\u003eTherapeutic Recommendations: Adults\u003c/em\u003e\u003c/strong\u003e\u003cbr /\u003e\nNumerous studies have derived warfarin dosing algorithms that use both genetic and non-genetic factors to predict warfarin dose [Articles:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e, \u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e, \u003ca href\u003d\""/pmid/20375999\""\u003e20375999\u003c/a\u003e, \u003ca href\u003d\""/pmid/22012312\""\u003e22012312\u003c/a\u003e]. Two algorithms perform well in estimating stable warfarin dose [Articles:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e, \u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e] and were created using more than 5,000 subjects, though as noted above, more recent data suggest they do not perform acceptably in African Americans when used without modification for CYP2C9 alleles frequently found in the African population [Article:\u003ca href\u003d\""/pmid/24251361\""\u003e24251361\u003c/a\u003e].  The Gage and IWPC algorithms or minor adjustments to them have also been the algorithms used in both randomized controlled trials and most of the prospective dosing studies.  Dosing algorithms using genetic information outperform non-genetic clinical algorithms and fixed-dose approaches in dose prediction, except in African Americans when the algorithm only includes CYP2C9*2 and *3 [Articles:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e, \u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e, \u003ca href\u003d\""/pmid/24251361\""\u003e24251361\u003c/a\u003e]. Genetics-based algorithms also better predict warfarin dose than the FDA-approved warfarin label table [Article:\u003ca href\u003d\""/pmid/21272753\""\u003e21272753\u003c/a\u003e].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003ePharmacogenetic algorithm-based warfarin dosing\u003c/em\u003e\u003c/strong\u003e:  This guideline recommends that pharmacogenetic warfarin dosing be accomplished through the use of one of the pharmacogenetic dosing algorithms described above, as summarized in \u003ca href\u003d\""#figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients\""\u003eFigure 2\u003c/a\u003e.  The two algorithms provide very similar dose recommendations...It is important to note that these algorithms do not include CYP4F2, CYP2C9*5, *6, *8, or *11 or rs12777823, and incorporation of these should be added when results are available, as described in \u003ca href\u003d\""#figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients\""\u003eFigure 2\u003c/a\u003e.  The warfarindosing.org website contains both algorithms, the Gage algorithm [Article:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e] as the primary algorithm and the IWPC algorithm [Article:\u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e] as the secondary algorithm and can adjust for CYP4F2, CYP2C9*5 and *6.  If utilizing warfarindosing.org, the user should be clear on whether the algorithm is or is not incorporating genotypes beyond CYP2C9 *2 and *3 and VKORC1, which are the only three genotypes in the original version of both algorithms.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eNon-African ancestry recommendation\u003c/em\u003e\u003c/strong\u003e. In patients who self-identify as non-African ancestry, the recommendation, as summarized in \u003ca href\u003d\""#figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients\""\u003eFigure 2\u003c/a\u003e, is to:  1) calculate warfarin dosing using a published pharmacogenetic algorithm [Articles:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e, \u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e], including genotype information for VKORC1-1639G\u0026gt;A and CYP2C9*2 and *3. In individuals with genotypes associated with CYP2C9 poor metabolism (e.g., CYP2C9 *2/*3, *3/*3) or both increased sensitivity (VKORC1-1639 A/A) and CYP2C9 poor metabolism, an alternative oral anticoagulant might be considered. These recommendations are graded as STRONG.  2) If a loading dose is to be utilized, the EU-PACT loading dose algorithm that incorporates genetic information could be used [Article:\u003ca href\u003d\""/pmid/24251363\""\u003e24251363\u003c/a\u003e].  This recommendation is OPTIONAL. 3) While CYP2C9*5, *6, *8, or*11 variant alleles are commonly referred to as African specific alleles, they can occur among individuals who do not identify as, or know of their, African ancestry.  If these variant alleles are detected, decrease calculated dose by 15-30% per variant allele or consider an alternative agent. Larger dose reductions might be needed in patients homozygous for variant alleles (i.e. 20-40%, e.g. CYP2C9*2/*5). This recommendation is graded as OPTIONAL.  4) If the CYP4F2*3 (i.e., c.1297A, p.433Met) allele is also detected, increase the dose by 5-10%.  This recommendation is also considered OPTIONAL.   5) The data do not suggest an association between rs12777823 genotype and warfarin dose in non-African Americans, thus rs12777823 should not be considered in these individuals (even if available).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eAfrican ancestry recommendation\u003c/em\u003e\u003c/strong\u003e. In patients of African ancestry, CYP2C9*5, *6, *8, *11 are important for warfarin dosing. If these genotypes are not available, warfarin should be dosed clinically without consideration for genotype. If CYP2C9*5, *6, *8, and *11 are known, then the recommendation, as shown in  \u003ca href\u003d\""#figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients\""\u003eFigure 2\u003c/a\u003e, is to: 1) calculate warfarin dose using a validated pharmacogenetic algorithm, including genotype information for VKORC1 c.-1639G\u0026gt;A and CYP2C9*2 and *3 [Articles:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e, \u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e]; 2) if the individual carriers a CYP2C9*5, *6, *8, or *11 variant allele(s), decrease calculated dose by 15-30%. Larger dose reductions might be needed in patients who carry two variant alleles (e.g., CYP2C9*5/*6) (i.e. 20-40% dose reduction). 3) In addition, rs12777823 is associated with warfarin dosing in African Americans (mainly originating from West Africa). Thus, in African Americans a dose reductions of 10-25% in those with rs12777823 A/G or A/A genotype is recommended.  These recommendations are considered MODERATE.   In individuals with genotypes that predict CYP2C9 poor metabolism or who have increased warfarin sensitivity (VKORC1 c.-1639 A/A) and CYP2C9 poor metabolism, an alternative oral anticoagulant should be considered.\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026quot;\u003cstrong\u003e\u003cem\u003eTherapeutic Recommendations: Pediatric\u003c/em\u003e\u003c/strong\u003e\u003cbr /\u003e\nIn children of European ancestry and if CYP2C9*2 and *3 and VKORC1-1639 genotype are available, calculate warfarin dosing based on a validated published pediatric pharmacogenetic algorithm (\u003ca href\u003d\""#figure-3-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-pediatric-patients\""\u003eFigure 3\u003c/a\u003e) [Articles:\u003ca href\u003d\""/pmid/22010099\""\u003e22010099\u003c/a\u003e, \u003ca href\u003d\""/pmid/23307232\""\u003e23307232\u003c/a\u003e].  A dosing tool that can be used in children of European ancestry is available at http://www.warfarindoserevision.com [Article:\u003ca href\u003d\""/pmid/24330000\""\u003e24330000\u003c/a\u003e].\u0026quot;\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDownload and read:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/warfarin/2017/28198005.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for pharmacogenetics-guided warfarin dosing: 2017 update\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/warfarin/2017/28198005-supplement.pdf\"" target\u003d\""_blank\""\u003e2017 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003eLook up your warfarin dosing guideline using the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/warfarin/2011/IWPC_dose_calculator.xls\"" target\u003d\""_blank\""\u003eIWPC Pharmacogenetic Dosing Algorithm\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp2c9RefMaterials\""\u003e\u003cem\u003eCYP2C9\u003c/em\u003e Gene-specific Information Tables\u003c/a\u003e (Note: allele functionality and diplotype-phenotype mappings are not applicable to the warfarin guideline)\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/vkorc1RefMaterials\""\u003e\u003cem\u003eVKORC1\u003c/em\u003e Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca href\u003d\""https://www.pharmgkb.org/page/cyp4f2RefMaterials\""\u003e\u003cem\u003eCYP4F2\u003c/em\u003e Gene-specific Information Tables\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/warfarin/2017/Warfarin_Drug_Resource_Mappings.xlsx\"" target\u003d\""_blank\""\u003eWarfarin Drug Resource Mappings\u003c/a\u003e\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""figure-2-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-adult-patients\""\u003eFigure 2. Dosing recommendations for Warfarin dosing based on genotype for adult patients\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Figure 2 of the 2017 guideline manuscript\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cimg src\u003d\""https://s3.pgkb.org/attachment/CPIC_warfarin_2017_Fig_2.png\"" alt\u003d\""Fig2\"" /\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 2 Legend:\u003c/strong\u003e \u003csup\u003ea\u003c/sup\u003e“Dose clinically” means to dose without genetic information, which may include use of a clinical dosing algorithm or standard dose approach\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003eData strongest for European and East Asian ancestry populations and consistent in other populations.\u003cbr /\u003e\n\u003csup\u003ec\u003c/sup\u003e45-50% of individuals with self-reported African ancestry carry CYP2C9*5,*6,*8,*11, or rs12777823. IF CYP2C9*5, *6, *8, and *11 WERE NOT TESTED, DOSE WARFARIN CLINICALLY.  Note: these data derive primarily from African Americans, who are largely from West Africa.  It is unknown if the same associations are present for those from other parts of Africa.\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003eMost algorithms are developed for the target INR 2-3.\u003cbr /\u003e\n\u003csup\u003ee\u003c/sup\u003eConsider an alternative agent in individuals with genotypes associated with CYP2C9 poor metabolism (e.g., CYP2C9*3/*3, *2/*3, *3/*3) or both increased sensitivity (VKORC1 A/G or A/A) and CYP2C9 poor metabolism.\u003cbr /\u003e\n\u003csup\u003ef\u003c/sup\u003eSee the EU-PACT trial for pharmacogenetics-based warfarin initiation (loading) dose algorithm [Article:\u003ca href\u003d\""/pmid/24251363\""\u003e24251363\u003c/a\u003e] with the caveat that the loading dose PG algorithm has not been specifically tested or validated in populations of African ancestry.\u003cbr /\u003e\n\u003csup\u003eg\u003c/sup\u003eLarger dose reduction might be needed in variant homozygotes (i.e. 20-40%).\u003cbr /\u003e\n\u003csup\u003eh\u003c/sup\u003eAfrican American refers to individuals mainly originating from West Africa.\u003c/p\u003e\n\u003ch3 id\u003d\""figure-3-dosing-recommendations-for-warfarin-dosing-based-on-genotype-for-pediatric-patients\""\u003eFigure 3. Dosing recommendations for Warfarin dosing based on genotype for pediatric patients\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Figure 3 of the 2017 guideline manuscript\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cimg src\u003d\""https://s3.pgkb.org/attachment/CPIC_warfarin_2017_Fig_3.png\"" alt\u003d\""Fig3\"" /\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 3 Legend:\u003c/strong\u003e \u003csup\u003ea\u003c/sup\u003eData strongest for European ancestry populations and consistent in most Japanese studies.\u003cbr /\u003e\n\u003csup\u003eb\u003c/sup\u003e“Dose clinically” means to dose without genetic information, which may include use of a clinical dosing algorithm or standard dose approach\u003cbr /\u003e\n\u003csup\u003ec\u003c/sup\u003eValidated published pediatric pharmacogenetic algorithms include Hamberg et al.[Article:\u003ca href\u003d\""/pmid/24330000\""\u003e24330000\u003c/a\u003e] and Biss et al.[Article:\u003ca href\u003d\""/pmid/22010099\""\u003e22010099\u003c/a\u003e]\u003cbr /\u003e\n\u003csup\u003ed\u003c/sup\u003eNo studies in children included CYP2C9*5, *6, *8, or *11 genotyping.\u003c/p\u003e\n\u003ch3 id\u003d\""november-2013-update\""\u003eNovember 2013 Update\u003c/h3\u003e\n\u003cp\u003eCPIC guideline authors are aware of several recently published studies on warfarin pharmacogenetics [Articles:\u003ca href\u003d\""/pmid/24251361\""\u003e24251361\u003c/a\u003e, \u003ca href\u003d\""/pmid/24251363\""\u003e24251363\u003c/a\u003e, \u003ca href\u003d\""/pmid/24251360\""\u003e24251360\u003c/a\u003e]. These papers have prompted several opinion pieces [Articles:\u003ca href\u003d\""/pmid/24328463\""\u003e24328463\u003c/a\u003e, \u003ca href\u003d\""/pmid/24251364\""\u003e24251364\u003c/a\u003e]. The authors are evaluating the information, which will be incorporated into the next update of the CPIC guideline on warfarin.\u003c/p\u003e\n\u003ch3 id\u003d\""october-2011\""\u003eOctober 2011\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdvance online publication September 2011.\u003c/em\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eGuideline regarding the use of pharmacogenomic tests in dosing for warfarin was published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org\"" target\u003d\""_blank\""\u003e(CPIC)\u003c/a\u003e.\u003c/li\u003e\n\u003cli\u003eThese guidelines are applicable to:\n\u003cul\u003e\n\u003cli\u003eadult patients\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eExcerpt from the 2011 warfarin dosing guideline:\n\u003cul\u003e\n\u003cli\u003e\u0026quot;Pharmacogenetic algorithm-based warfarin dosing: Numerous studies have derived warfarin dosing algorithms that use both genetic and non-genetic factors to predict warfarin dose [Articles:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e, \u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e, \u003ca href\u003d\""/pmid/18574025\""\u003e18574025\u003c/a\u003e]. Two algorithms perform well in estimating stable warfarin dose across different ethnic populations; [Articles:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e, \u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e] these were created using more than 5,000 subjects. Dosing algorithms using genetics outperform nongenetic clinical algorithms and fixed-dose approaches in dose prediction [Articles:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e, \u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e]. The best way to estimate the anticipated stable dose of warfarin is to use the algorithms available on \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""http://www.warfarindosing.org\"" target\u003d\""_blank\""\u003ehttp://www.warfarindosing.org\u003c/a\u003e (offering both high-performing algorithms [Articles:\u003ca href\u003d\""/pmid/18305455\""\u003e18305455\u003c/a\u003e, \u003ca href\u003d\""/pmid/19228618\""\u003e19228618\u003c/a\u003e]). The dosing algorithm published by the International Warfarin Pharmacogenetics Consortium is also online, at \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/warfarin/2011/IWPC_dose_calculator.xls\"" target\u003d\""_blank\""\u003eIWPC Pharmacogenetic Dosing Algorithm\u003c/a\u003e. The two algorithms provide very similar dose recommendations.\u0026quot;\u003c/li\u003e\n\u003cli\u003e\u0026quot;Approach to pharmacogenetic-based warfarin dosing without access to dosing algorithms:     In 2007, the FDA modified the warfarin label, stating that CYP2C9 and VKORC1 genotypes may be useful in determining the optimal initial dose of warfarin [Article:\u003ca href\u003d\""/pmid/17906972\""\u003e17906972\u003c/a\u003e]. The label was further updated in 2010 to include a table (Table 1) describing recommendations for initial dosing ranges for patients with different combinations of CYP2C9 and VKORC1 genotypes. Genetics-based algorithms also better predict warfarin dose than the FDA-approved warfarin label table [Article:\u003ca href\u003d\""/pmid/21272753\""\u003e21272753\u003c/a\u003e]. Therefore, the use of pharmacogenetic algorithm-based dosing is recommended when possible, although if electronic means for such dosing are not available, the table-based dosing approaches (Table 1) are suggested. The range of doses by VKORC1 genotype and the range of dose recommendations/predictions by the FDA table and algorithm are shown in Figure 2.\u0026quot;\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003eDownload and read:\n\u003cul\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/warfarin/2011/21900891.pdf\"" target\u003d\""_blank\""\u003eClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/warfarin/2011/21900891-supplement.pdf\"" target\u003d\""_blank\""\u003e2011 supplement\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003eLook up your warfarin dosing guideline using the \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://cpicpgx.org/content/guideline/publication/warfarin/2011/IWPC_dose_calculator.xls\"" target\u003d\""_blank\""\u003eIWPC Pharmacogenetic Dosing Algorithm\u003c/a\u003e.\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003ch3 id\u003d\""figure-2-frequency-histograms-of-stable-therapeutic-warfarin-doses-in-mg-week-stratified-by-vkorc1-1639g-a-genotype\""\u003eFigure 2. Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by VKORC1 -1639G\u0026gt;A genotype.\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Figure 2 of the 2011 guideline manuscript\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cimg src\u003d\""https://s3.pgkb.org/attachment/Figure_2-CPIC_Warfarin_dosing_guidelines.png\"" alt\u003d\""CPIC warfarin dosing guideline\"" /\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFigure 2 Legend:\u003c/strong\u003e Frequency histograms of stable therapeutic warfarin doses in mg/week, stratified by \u003cem\u003eVKORC1\u003c/em\u003e -1639G\u0026gt;A genotype in 3,616 patients recruited by the International Warfarin Pharmacogenetics Consortium (IWPC) who did not carry the \u003cem\u003eCYP2C9*2\u003c/em\u003e or \u003cem\u003e*3\u003c/em\u003e allele (i.e., coded as \u003cem\u003e*1/*1\u003c/em\u003e for US Food and Drug Administration (FDA) table and algorithm dosing). The range of doses within each genotype group recommended on the FDA table is shown via the shaded rectangle. The range of doses predicted using the IWPC dosing algorithm in these 3,616 patients is shown by the solid lines.\u003c/p\u003e\n\u003cp\u003eFigure 2 demonstrates that the range of individuals covered by the FDA table is much narrower than that of the algorithm. The article and supplement detail important variables that are not covered by the table that should also be taken into consideration.\u003c/p\u003e\n\u003ch3 id\u003d\""table-1-recommended-daily-warfarin-doses-mg-day-to-achieve-a-therapeutic-inr-based-on-cyp2c9-and-vkorc1-genotype-using-the-warfarin-product-insert-approved-by-the-united-states-food-and-drug-administration\""\u003eTable 1: Recommended daily warfarin doses (mg/day) to achieve a therapeutic INR based on \u003cem\u003eCYP2C9\u003c/em\u003e and \u003cem\u003eVKORC1\u003c/em\u003e genotype using the warfarin product insert approved by the United States Food and Drug Administration:\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Table 1 of the 2011 guideline manuscript\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003e\u003cem\u003eVKORC1\u003c/em\u003e Genotype (-1639G\u0026gt;A, \u003ca href\u003d\""/variant/PA166155091\""\u003ers9923231\u003c/a\u003e)\u003c/th\u003e\u003cth\u003e\u003cem\u003eCYP2C9*1/*1\u003c/em\u003e\u003c/th\u003e\u003cth\u003e\u003cem\u003eCYP2C9*1/*2\u003c/em\u003e\u003c/th\u003e\u003cth\u003e\u003cem\u003eCYP2C9*1/*3\u003c/em\u003e\u003c/th\u003e\u003cth\u003e\u003cem\u003eCYP2C9*2/*2\u003c/em\u003e\u003c/th\u003e\u003cth\u003e\u003cem\u003eCYP2C9*2/*3\u003c/em\u003e\u003c/th\u003e\u003cth\u003e\u003cem\u003eCYP2C9*3/*3\u003c/em\u003e\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eGG\u003c/td\u003e\u003ctd\u003e5-7\u003c/td\u003e\u003ctd\u003e5-7\u003c/td\u003e\u003ctd\u003e3-4\u003c/td\u003e\u003ctd\u003e3-4\u003c/td\u003e\u003ctd\u003e3-4\u003c/td\u003e\u003ctd\u003e0.5-2\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eGA\u003c/td\u003e\u003ctd\u003e5-7\u003c/td\u003e\u003ctd\u003e3-4\u003c/td\u003e\u003ctd\u003e3-4\u003c/td\u003e\u003ctd\u003e3-4\u003c/td\u003e\u003ctd\u003e0.5-2\u003c/td\u003e\u003ctd\u003e0.5-2\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eAA\u003c/td\u003e\u003ctd\u003e3-4\u003c/td\u003e\u003ctd\u003e3-4\u003c/td\u003e\u003ctd\u003e0.5-2\u003c/td\u003e\u003ctd\u003e0.5-2\u003c/td\u003e\u003ctd\u003e0.5-2\u003c/td\u003e\u003ctd\u003e0.5-2\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cem\u003eReproduced from updated warfarin (Coumadin) product label.\u003c/em\u003e\u003c/p\u003e\n\u003ch3 id\u003d\""supplemental-table-s1-genotypes-that-constitute-the-alleles-for-cyp2c9\""\u003eSupplemental Table S1. Genotypes that constitute the * alleles for \u003cem\u003eCYP2C9\u003c/em\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cem\u003eAdapted from Table S1 of the 2011 guideline supplement\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele\u003c/th\u003e\u003cth\u003eConstituted by genotypes at:\u003c/th\u003e\u003cth\u003eAmino acid changes\u003c/th\u003e\u003cth\u003eEnzymatic Activity\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003e*1\u003c/td\u003e\u003ctd\u003ereference allele at all positions\u003c/td\u003e\u003ctd\u003e\u003c/td\u003e\u003ctd\u003eNormal\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e*2\u003c/td\u003e\u003ctd\u003eC\u0026gt;T at \u003ca href\u003d\""/variant/PA166153972\""\u003ers1799853\u003c/a\u003e\u003c/td\u003e\u003ctd\u003eR144C\u003c/td\u003e\u003ctd\u003eDecreased\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003e*3\u003c/td\u003e\u003ctd\u003eA\u0026gt;C at \u003ca href\u003d\""/variant/PA166153959\""\u003ers1057910\u003c/a\u003e\u003c/td\u003e\u003ctd\u003eI359L\u003c/td\u003e\u003ctd\u003eDecreased\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n""},""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.447983518E9,""resource"":""URL"",""resourceId"":""https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/"",""_url"":""https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/""}]},""status"":""success""}"
PA166170752,Guideline Annotation,"Annotation of CPNDS Guideline for warfarin and CYP2C9,VKORC1",t,PA451906,Canadian Pharmacogenomics Network for Drug Safety,"<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for variants in VKORC1 and CYP2C9 in adult and pediatric patients with an indication for warfarin. They recommend testing for the VKORC1 SNP -1639G&gt;A (rs9923231) and the CYP2C9 alleles *2 and *3 in order to better guide warfarin dosage.</p>
","<p>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines in the journal Therapeutic Drug Monitoring. Excerpts from “Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy” [Article:<a href=""/pmid/26186657"">26186657</a>] follow:</p>
<blockquote class=""blockquote"">
<ul>
<li>
<p>Testing of all warfarin-naive patients for VKORC1 (-1639G&gt;A), CYP2C9*2, and CYP2C9*3 should be considered before initiation of therapy and within the first 2 weeks of therapy (level B - moderate recommendation). Genetic testing for CYP2C9*5, *6, *8 or *11 and CYP4F2 V433M is currently not recommended (level C - optional recommendation).
<strong>Management of patients with VKORC1 and CYP2C9 variants</strong></p>
</li>
<li>
<p>Genotyping results should be interpreted using a pharmacogenetic dosing algorithm to estimate the required dose (level A – strong recommendation).</p>
</li>
<li>
<p>After testing for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G&gt;A), pharmacogenetic dosing algorithms that incorporate both clinical variables and genetic information should be used to predict a stable warfarin dose.</p>
</li>
<li>
<p>Of importance, pharmacogenetic-guided dosing should not replace regular INR monitoring. Rather, test results should be used to help physicians estimate an appropriate warfarin dose, while still using regular INR monitoring to ensure that stable anticoagulation is achieved.</p>
</li>
</ul>
</blockquote>
<p>See full guideline [Article:<a href=""/pmid/26186657"">26186657</a>] for further details and grading scheme.</p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166170752"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166170752"",""name"":""Annotation of CPNDS Guideline for warfarin and CYP2C9,VKORC1"",""cancerGenome"":false,""guidelineGenes"":[],""history"":[{""id"":1.449003697E9,""date"":""2017-10-31T00:00:00-07:00"",""description"":""initial save"",""type"":""Create"",""version"":1.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15096965"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5096965E7,""resourceId"":""26186657"",""title"":""Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy."",""_sameAs"":""https://www.ncbi.nlm.nih.gov/pubmed/26186657"",""objCls"":""Literature"",""type"":""Article"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/pubMed/26186657"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449287318E9,""resource"":""PubMed"",""resourceId"":""26186657"",""_url"":""https://www.ncbi.nlm.nih.gov/pubmed/26186657""},{""@id"":""https://pharmgkb.org/crossReference/doi/10.1097/FTD.0000000000000192"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.449287319E9,""resource"":""DOI"",""resourceId"":""10.1097/FTD.0000000000000192"",""_url"":""http://dx.doi.org/10.1097%2FFTD.0000000000000192""}]}],""recommendation"":true,""relatedAlleles"":[],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451906"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451906"",""name"":""warfarin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""},{""@id"":""https://pharmgkb.org/gene/PA133787052"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA133787052"",""symbol"":""VKORC1"",""name"":""vitamin K epoxide reductase complex subunit 1""}],""source"":""Canadian Pharmacogenomics Network for Drug Safety"",""summaryMarkdown"":{""id"":1.449003696E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for variants in VKORC1 and CYP2C9 in adult and pediatric patients with an indication for warfarin. They recommend testing for the VKORC1 SNP -1639G\u0026gt;A (rs9923231) and the CYP2C9 alleles *2 and *3 in order to better guide warfarin dosage.\u003c/p\u003e\n""},""textMarkdown"":{""id"":1.449003695E9,""html"":""\u003cp\u003eThe Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines in the journal Therapeutic Drug Monitoring. Excerpts from “Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy” [Article:\u003ca href\u003d\""/pmid/26186657\""\u003e26186657\u003c/a\u003e] follow:\u003c/p\u003e\n\u003cblockquote class\u003d\""blockquote\""\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eTesting of all warfarin-naive patients for VKORC1 (-1639G\u0026gt;A), CYP2C9*2, and CYP2C9*3 should be considered before initiation of therapy and within the first 2 weeks of therapy (level B - moderate recommendation). Genetic testing for CYP2C9*5, *6, *8 or *11 and CYP4F2 V433M is currently not recommended (level C - optional recommendation).\n\u003cstrong\u003eManagement of patients with VKORC1 and CYP2C9 variants\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eGenotyping results should be interpreted using a pharmacogenetic dosing algorithm to estimate the required dose (level A – strong recommendation).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAfter testing for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G\u0026gt;A), pharmacogenetic dosing algorithms that incorporate both clinical variables and genetic information should be used to predict a stable warfarin dose.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eOf importance, pharmacogenetic-guided dosing should not replace regular INR monitoring. Rather, test results should be used to help physicians estimate an appropriate warfarin dose, while still using regular INR monitoring to ensure that stable anticoagulation is achieved.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/blockquote\u003e\n\u003cp\u003eSee full guideline [Article:\u003ca href\u003d\""/pmid/26186657\""\u003e26186657\u003c/a\u003e] for further details and grading scheme.\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182842,Guideline Annotation,Annotation of DPWG Guideline for warfarin and CYP2C9,t,PA451906,Dutch Pharmacogenetics Working Group,"<p>Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. &quot;The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a>&quot;</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for warfarin based on CYP2C9 genotype/phenotype.  They recommend reducing warfarin dose for CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype.The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a>.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>CYP2C9 IM</td><td>warfarin</td><td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td><td>1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *1/*2 or *1/*3 is present. See <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</td></tr>
<tr><td>CYP2C9 PM</td><td>warfarin</td><td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td><td>1. use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *2 or *3 is present. See <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</td></tr>
<tr><td>CYP2C9*1/*2</td><td>warfarin</td><td>Genetic variation may lead to a decrease in the required maintenance dose. However, there is insufficient evidence that this causes problems when therapy is initiated as usual.</td><td>NO action is required for this gene-drug interaction.</td></tr>
<tr><td>CYP2C9*1/*3</td><td>warfarin</td><td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td><td>1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</td></tr>
<tr><td>CYP2C9*2/*2</td><td>warfarin</td><td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td><td>1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</td></tr>
<tr><td>CYP2C9*2/*3</td><td>warfarin</td><td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td><td>1. use 45% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</td></tr>
<tr><td>CYP2C9*3/*3</td><td>warfarin</td><td>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</td><td>1. use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0006232.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182842"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182842"",""name"":""Annotation of DPWG Guideline for warfarin and CYP2C9"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.45041524E9,""date"":""2019-05-27T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Create"",""version"":0.0},{""id"":1.450820676E9,""date"":""2019-10-03T16:23:52.557-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450963944E9,""date"":""2020-02-11T08:29:07-08:00"",""description"":""Fixed links to 2018 guideline pdfs."",""type"":""Update"",""version"":0.0},{""id"":1.45096398E9,""date"":""2020-02-11T08:45:28.833-08:00"",""description"":""Fixed links to the algorithms."",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/haplotype/PA165816543"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816543"",""symbol"":""CYP2C9*2"",""name"":""*2""},{""@id"":""https://pharmgkb.org/haplotype/PA165816544"",""@context"":""https://api.pharmgkb.org/jsonld/haplotype.jsonld"",""objCls"":""Haplotype"",""id"":""PA165816544"",""symbol"":""CYP2C9*3"",""name"":""*3""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451906"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451906"",""name"":""warfarin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA126"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA126"",""symbol"":""CYP2C9"",""name"":""cytochrome P450 family 2 subfamily C member 9""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415238E9,""html"":""\u003cp\u003eReduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. \u0026quot;The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e\u0026quot;\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415239E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for warfarin based on CYP2C9 genotype/phenotype.  They recommend reducing warfarin dose for CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype.The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 IM\u003c/td\u003e\u003ctd\u003ewarfarin\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.\u003c/td\u003e\u003ctd\u003e1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *1/*2 or *1/*3 is present. See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9 PM\u003c/td\u003e\u003ctd\u003ewarfarin\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.\u003c/td\u003e\u003ctd\u003e1. use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *2 or *3 is present. See \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9*1/*2\u003c/td\u003e\u003ctd\u003ewarfarin\u003c/td\u003e\u003ctd\u003eGenetic variation may lead to a decrease in the required maintenance dose. However, there is insufficient evidence that this causes problems when therapy is initiated as usual.\u003c/td\u003e\u003ctd\u003eNO action is required for this gene-drug interaction.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9*1/*3\u003c/td\u003e\u003ctd\u003ewarfarin\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.\u003c/td\u003e\u003ctd\u003e1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9*2/*2\u003c/td\u003e\u003ctd\u003ewarfarin\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.\u003c/td\u003e\u003ctd\u003e1. use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9*2/*3\u003c/td\u003e\u003ctd\u003ewarfarin\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.\u003c/td\u003e\u003ctd\u003e1. use 45% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eCYP2C9*3/*3\u003c/td\u003e\u003ctd\u003ewarfarin\u003c/td\u003e\u003ctd\u003eThis gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.\u003c/td\u003e\u003ctd\u003e1. use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0006232.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
PA166182841,Guideline Annotation,Annotation of DPWG Guideline for warfarin and VKORC1,t,PA451906,Dutch Pharmacogenetics Working Group,"<p>Patients with the VKORC1 -1639 (rs9923231) AA genotype should be given 60% of the standard initial dose of warfarin. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There are no recommendation for patients with the VKORC1 -1639 AG genotype.</p>
","<h3 id=""november-2018-guideline"">November 2018 Guideline</h3>
<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for warfarin based on VKORC1 genotype. They recommend that patients with the VKORC1 -1639 (<a href=""/variant/PA166155091"">rs9923231</a>) AA genotype receive 60% of the standard initial dose.The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. No action is needed for patients with the VKORC1 -1639 AG genotype.</p>
<p><em>Wording in table taken from the <a href=""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf"">Dutch guidelines November 2018 update</a>.</em></p>
<table class=""table"">
<thead>
<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>
</thead>
<tbody>
<tr><td>VKORC1 -1639 AA</td><td>warfarin</td><td>The genetic variation results in increased sensitivity to warfarin. This results in an increase in the risk of excessively severe inhibition of blood clotting (INR &gt; 4) during the first month of the treatment.</td><td>1. use 60% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</td></tr>
<tr><td>VKORC1 -1639 AG</td><td>warfarin</td><td>The genetic variation results in a reduction in the required dose and an increase in the risk of excessively severe inhibition of blood clotting during the first month of the treatment. However, the effect is small and GA is also the most common genotype, meaning that the standard treatment will primarily be based on patients with this genotype.</td><td>NO action is needed for this gene-drug interaction</td></tr>
</tbody>
</table>
<p><a rel=""noopener noreferrer"" href=""https://www.g-standaard.nl/risicoanalyse/B0006236.PDF"" target=""_blank"">Read for more information about this recommendation</a>, <a rel=""noopener noreferrer"" href=""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics"" target=""_blank"">Read about gene information from DPWG</a></p>
","{""data"":{""@id"":""https://pharmgkb.org/guidelineAnnotation/PA166182841"",""@context"":""https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld"",""objCls"":""Guideline Annotation"",""id"":""PA166182841"",""name"":""Annotation of DPWG Guideline for warfarin and VKORC1"",""cancerGenome"":false,""descriptiveVideoId"":"""",""guidelineGenes"":[],""history"":[{""id"":1.450415237E9,""date"":""2019-05-27T00:00:00-07:00"",""description"":""Annotation current with November 2018 DPWG Guideline release"",""type"":""Update"",""version"":0.0},{""id"":1.450820675E9,""date"":""2019-10-03T16:20:39.794-07:00"",""description"":""No changes based on August 2019 guidelines"",""type"":""Update"",""version"":0.0},{""id"":1.450963981E9,""date"":""2020-02-11T08:50:11.941-08:00"",""description"":""Fixed links to 2018 guideline pdfs and links to algorithms"",""type"":""Update"",""version"":0.0}],""literature"":[{""@id"":""https://pharmgkb.org/literature/15103288"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5103288E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines August 2019"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450815695E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf""}]},{""@id"":""https://pharmgkb.org/literature/15102465"",""@context"":""https://api.pharmgkb.org/jsonld/literature.jsonld"",""id"":1.5102465E7,""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""title"":""Dutch Pharmacogenetics Working Group Guidelines November 2018"",""_sameAs"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""objCls"":""Literature"",""type"":""Web Page"",""xrefs"":[{""@id"":""https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""@context"":""https://api.pharmgkb.org/jsonld/crossReference.jsonld"",""id"":1.450415575E9,""resource"":""URL"",""resourceId"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"",""_url"":""https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf""}]}],""recommendation"":true,""relatedAlleles"":[{""@id"":""https://pharmgkb.org/variant/PA166155091"",""@context"":""https://api.pharmgkb.org/jsonld/variant.jsonld"",""objCls"":""Variant"",""id"":""PA166155091"",""symbol"":""rs9923231"",""name"":""rs9923231""}],""relatedChemicals"":[{""@id"":""https://pharmgkb.org/chemical/PA451906"",""@context"":""https://api.pharmgkb.org/jsonld/chemical.jsonld"",""objCls"":""Chemical"",""id"":""PA451906"",""name"":""warfarin""}],""relatedGenes"":[{""@id"":""https://pharmgkb.org/gene/PA133787052"",""@context"":""https://api.pharmgkb.org/jsonld/gene.jsonld"",""objCls"":""Gene"",""id"":""PA133787052"",""symbol"":""VKORC1"",""name"":""vitamin K epoxide reductase complex subunit 1""}],""source"":""Dutch Pharmacogenetics Working Group"",""summaryMarkdown"":{""id"":1.450415234E9,""html"":""\u003cp\u003ePatients with the VKORC1 -1639 (rs9923231) AA genotype should be given 60% of the standard initial dose of warfarin. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There are no recommendation for patients with the VKORC1 -1639 AG genotype.\u003c/p\u003e\n""},""summaryVideoId"":"""",""textMarkdown"":{""id"":1.450415235E9,""html"":""\u003ch3 id\u003d\""november-2018-guideline\""\u003eNovember 2018 Guideline\u003c/h3\u003e\n\u003cp\u003eThe Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for warfarin based on VKORC1 genotype. They recommend that patients with the VKORC1 -1639 (\u003ca href\u003d\""/variant/PA166155091\""\u003ers9923231\u003c/a\u003e) AA genotype receive 60% of the standard initial dose.The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. No action is needed for patients with the VKORC1 -1639 AG genotype.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWording in table taken from the \u003ca href\u003d\""https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\""\u003eDutch guidelines November 2018 update\u003c/a\u003e.\u003c/em\u003e\u003c/p\u003e\n\u003ctable class\u003d\""table\""\u003e\n\u003cthead\u003e\n\u003ctr\u003e\u003cth\u003eAllele/Genotype/Phenotype\u003c/th\u003e\u003cth\u003eDrug\u003c/th\u003e\u003cth\u003eDescription\u003c/th\u003e\u003cth\u003eRecommendation\u003c/th\u003e\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 -1639 AA\u003c/td\u003e\u003ctd\u003ewarfarin\u003c/td\u003e\u003ctd\u003eThe genetic variation results in increased sensitivity to warfarin. This results in an increase in the risk of excessively severe inhibition of blood clotting (INR \u0026gt; 4) during the first month of the treatment.\u003c/td\u003e\u003ctd\u003e1. use 60% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eAlgorithms coumarins\u003c/a\u003e. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.\u003c/td\u003e\u003c/tr\u003e\n\u003ctr\u003e\u003ctd\u003eVKORC1 -1639 AG\u003c/td\u003e\u003ctd\u003ewarfarin\u003c/td\u003e\u003ctd\u003eThe genetic variation results in a reduction in the required dose and an increase in the risk of excessively severe inhibition of blood clotting during the first month of the treatment. However, the effect is small and GA is also the most common genotype, meaning that the standard treatment will primarily be based on patients with this genotype.\u003c/td\u003e\u003ctd\u003eNO action is needed for this gene-drug interaction\u003c/td\u003e\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.g-standaard.nl/risicoanalyse/B0006236.PDF\"" target\u003d\""_blank\""\u003eRead for more information about this recommendation\u003c/a\u003e, \u003ca rel\u003d\""noopener noreferrer\"" href\u003d\""https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\"" target\u003d\""_blank\""\u003eRead about gene information from DPWG\u003c/a\u003e\u003c/p\u003e\n""},""xrefs"":[]},""status"":""success""}"
